Clustering O 0 2.2667834855383262e-05
of O 0 3.0282888019428356e-07
missense O 0 6.550423131557181e-05
mutations O 0 3.0459150366368704e-05
in O 0 4.329293190608041e-08
the O 0 6.04614001531445e-07
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999990463256836
telangiectasia I-Disease 1 1.0
gene O 0 0.00013641822442878038
in O 0 2.8682856978434756e-08
a O 0 8.979395005326296e-08
sporadic B-Disease 0 0.37053340673446655
T I-Disease 1 0.9954448938369751
- I-Disease 0 0.443112313747406
cell I-Disease 0 0.014591159299015999
leukaemia I-Disease 0 0.01472835149616003
. O 0 2.3420741968038783e-07

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 1 0.7001716494560242
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 7.500373655489057e-09
is O 0 5.085469267918086e-10
a O 0 5.589070095624038e-09
recessive B-Disease 0 0.00019890205294359475
multi I-Disease 0 0.0013988834107294679
- I-Disease 1 0.9938879609107971
system I-Disease 0 0.0035939952358603477
disorder I-Disease 1 0.8927546143531799
caused O 0 2.1052380816399818e-07
by O 0 2.9846718430093233e-09
mutations O 0 4.951030518896005e-07
in O 0 7.32676308512481e-10
the O 0 3.848891427793433e-09
ATM O 0 1.099355813494185e-06
gene O 0 6.391833267116453e-07
at O 0 1.299430039125582e-07
11q22 O 0 2.274502776344889e-06
- O 0 5.206224614084931e-06
q23 O 0 1.5385650158350472e-06
( O 0 1.6686231063545165e-08
ref O 0 4.2481469790800475e-06
. O 0 3.824303984600874e-09
3 O 0 2.391651676703077e-08
) O 0 1.332589949498697e-08
. O 0 6.762159188156147e-08

The O 0 1.263110220861563e-06
risk O 0 5.214885732129915e-06
of O 0 1.077448885666854e-08
cancer B-Disease 0 9.574357136443723e-06
, O 0 2.598707693479696e-09
especially O 0 2.463014325826407e-08
lymphoid B-Disease 0 7.827001354598906e-06
neoplasias I-Disease 0 2.6038154828711413e-05
, O 0 1.7691565545874255e-08
is O 0 6.883307257510296e-09
substantially O 0 5.261405817691411e-07
elevated O 0 2.3035249796521384e-06
in O 0 7.328363693659412e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.7124884582008235e-05
and O 0 1.0912458492384758e-08
has O 0 1.5771201233860666e-08
long O 0 5.584117275247991e-07
been O 0 2.0871347317097388e-07
associated O 0 1.0344786005589413e-07
with O 0 8.304905918521399e-07
chromosomal O 1 1.0
instability O 1 1.0
. O 0 1.3911103451391682e-06

By O 0 1.366958372273075e-06
analysing O 0 4.582609108183533e-05
tumour B-Disease 1 0.9999951124191284
DNA O 0 1.1822889973700512e-06
from O 0 2.0505515507807104e-08
patients O 0 1.7682599207091698e-07
with O 0 7.232738852280818e-09
sporadic B-Disease 0 0.03886451944708824
T I-Disease 1 0.9925761222839355
- I-Disease 0 0.03589935228228569
cell I-Disease 0 0.0006955690914765
prolymphocytic I-Disease 0 0.0003559243050403893
leukaemia I-Disease 0 0.03299130126833916
( O 0 3.1443610737369454e-07
T B-Disease 0 0.0004651937633752823
- I-Disease 0 3.320425093988888e-05
PLL I-Disease 0 2.0763713109772652e-05
) O 0 9.081495555562924e-09
, O 0 6.415479258947698e-10
a O 0 2.097797047184713e-09
rare O 0 1.6991922535680715e-08
clonal B-Disease 0 6.4472228586964775e-06
malignancy I-Disease 0 0.0001022343203658238
with O 0 2.3931516768271877e-09
similarities O 0 1.2964033402340647e-08
to O 0 2.626308504005692e-09
a O 0 4.452837032431489e-08
mature B-Disease 0 1.4377706065715756e-06
T I-Disease 0 9.82646452030167e-05
- I-Disease 0 6.102671250118874e-05
cell I-Disease 0 6.42537052044645e-05
leukaemia I-Disease 0 0.0003364419681020081
seen O 0 6.440118795580929e-06
in O 0 5.8937761338029304e-08
A B-Disease 1 0.9999998807907104
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
, O 0 3.686873384367573e-08
we O 0 1.1307903946544684e-08
demonstrate O 0 4.901875794161015e-09
a O 0 1.3971304113624683e-09
high O 0 5.614692266675547e-09
frequency O 0 5.953419446314001e-08
of O 0 2.5839443917874405e-09
ATM O 0 1.3726586985285394e-05
mutations O 0 6.285848940024152e-06
in O 0 1.1149128198439939e-07
T B-Disease 0 0.0003750972682610154
- I-Disease 0 3.216483673895709e-05
PLL I-Disease 0 8.612580131739378e-05
. O 0 3.7654433526768116e-07

In O 0 4.607743733231473e-07
marked O 0 4.612487600752502e-07
contrast O 0 9.853832949602293e-08
to O 0 5.965875349289718e-09
the O 0 9.129307976252221e-09
ATM O 0 1.8827273379429244e-05
mutation O 0 3.6982237361371517e-06
pattern O 0 2.6244326818414265e-06
in O 0 9.708430326327289e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
, O 0 6.53379972348489e-09
the O 0 9.913110332604447e-10
most O 0 9.919919330414473e-10
frequent O 0 4.102207995515528e-08
nucleotide O 0 2.2976180957812176e-07
changes O 0 1.2152499451190124e-08
in O 0 1.4350881594182852e-09
this O 0 2.8565132481617184e-09
leukaemia B-Disease 0 9.608940308680758e-05
were O 0 3.128600667423598e-07
missense O 0 2.303065593878273e-05
mutations O 0 3.109636963927187e-05
. O 0 3.469987746029801e-07

These O 0 7.796694490025402e-07
clustered O 0 3.321399844935513e-06
in O 0 4.689103771937653e-09
the O 0 2.6207840342351574e-09
region O 0 4.397089803376275e-09
corresponding O 0 7.405388302572646e-09
to O 0 1.708684638224156e-09
the O 0 1.269437888140601e-09
kinase O 0 1.8758245801109297e-07
domain O 0 7.183769668017703e-08
, O 0 1.8233243803678079e-09
which O 0 5.731974339617807e-10
is O 0 2.485873451529841e-10
highly O 0 2.2354755824238737e-09
conserved O 0 4.150466637042882e-09
in O 0 7.052479711333604e-10
ATM O 0 1.6079459328466328e-06
- O 0 9.407711445419409e-07
related O 0 7.941337365480194e-09
proteins O 0 5.732392782675788e-09
in O 0 1.1539199595844707e-09
mouse O 0 2.84623666857442e-07
, O 0 2.8702105137057288e-09
yeast O 0 1.341723390169136e-07
and O 0 1.6171339822790287e-08
Drosophila O 0 4.5488141608984733e-07
. O 0 1.079108997714684e-07

The O 0 1.5488114968320588e-06
resulting O 0 2.340339960937854e-06
amino O 0 2.442986215100973e-06
- O 0 5.2773734751099255e-06
acid O 0 2.2527999021804135e-07
substitutions O 0 1.5015588417099934e-07
are O 0 8.709219123659295e-09
predicted O 0 2.0337715511686838e-08
to O 0 2.261930198699247e-09
interfere O 0 2.74175022241252e-07
with O 0 2.134555820987316e-08
ATP O 0 9.748694083100418e-07
binding O 0 6.618326438001532e-07
or O 0 1.514974741212427e-07
substrate O 0 4.360263119451702e-06
recognition O 0 1.1104449413323891e-06
. O 0 5.072696467323112e-07

Two O 0 8.545518994651502e-07
of O 0 3.366926648595836e-08
seventeen O 0 1.7730992567521753e-06
mutated O 0 6.563844181073364e-06
T B-Disease 0 6.369300535880029e-05
- I-Disease 0 4.890661784884287e-06
PLL I-Disease 0 7.587422260257881e-06
samples O 0 1.0850484386537573e-06
had O 0 4.5665046854992397e-07
a O 0 4.52308839271609e-08
previously O 0 1.4325217307487037e-05
reported O 0 1.915052780532278e-05
A B-Disease 1 0.9999988079071045
- I-Disease 1 0.9999932050704956
T I-Disease 1 1.0
allele O 0 2.379810575803276e-05
. O 0 2.1677489314697596e-07

In O 0 2.1060172628040164e-07
contrast O 0 1.8413066982247983e-07
, O 0 4.862189317833554e-09
no O 0 2.5930400937568265e-08
mutations O 0 2.1083594674564665e-06
were O 0 1.4189937758146698e-07
detected O 0 2.6381766815575247e-07
in O 0 5.713037265486776e-10
the O 0 1.8719112926390835e-09
p53 O 0 4.268095921133863e-08
gene O 0 5.6843479256940554e-08
, O 0 1.6817608416985763e-09
suggesting O 0 2.813365895804054e-08
that O 0 2.0411230483574627e-09
this O 0 8.71548344605344e-09
tumour B-Disease 1 0.9999997615814209
suppressor O 0 1.3370550959734828e-06
is O 0 8.277080354446298e-09
not O 0 1.069614796733731e-08
frequently O 0 2.9374990617725416e-07
altered O 0 5.27706390585081e-07
in O 0 4.474374204477272e-09
this O 0 2.630129536385084e-08
leukaemia B-Disease 0 0.0009009375935420394
. O 0 3.2496731705577986e-07

Occasional O 0 0.00019106749095954
missense O 0 0.0006415107636712492
mutations O 0 6.725302955601364e-05
in O 0 1.924236592287798e-08
ATM O 0 5.063415301265195e-06
were O 0 1.2189897233838565e-06
also O 0 1.6139262370984397e-08
found O 0 3.8106900746015526e-08
in O 0 2.0697505931366322e-08
tumour B-Disease 1 0.9999995231628418
DNA O 0 4.78119886793138e-07
from O 0 1.2443963193220497e-08
patients O 0 8.884317992396973e-08
with O 0 2.4349882110641374e-08
B B-Disease 0 0.01735582761466503
- I-Disease 0 0.0001427255047019571
cell I-Disease 0 0.0004220368864480406
non I-Disease 0 0.0030627117957919836
- I-Disease 1 0.7570712566375732
Hodgkins I-Disease 1 0.9999954700469971
lymphomas I-Disease 1 0.6669116616249084
( O 0 9.995996208544966e-08
B B-Disease 0 8.258807065431029e-05
- I-Disease 0 1.7296451915171929e-06
NHL I-Disease 0 2.4462073611175583e-07
) O 0 2.5385717972170596e-09
and O 0 2.903329132664112e-09
a O 0 8.449161725820886e-08
B B-Disease 0 0.00033643265487626195
- I-Disease 0 7.149826615204802e-06
NHL I-Disease 0 2.5994042971433373e-06
cell O 0 5.082602456241148e-06
line O 0 3.3500495192129165e-05
. O 0 2.8113578309785225e-07

The O 0 1.6835917904245434e-07
evidence O 0 2.5001888559472718e-08
of O 0 5.809460690286983e-10
a O 0 2.727909231836634e-09
significant O 0 4.441476963989999e-09
proportion O 0 4.992346802623615e-08
of O 0 1.4997456609933124e-09
loss O 0 7.590263635393057e-07
- O 0 6.363481134030735e-06
of O 0 1.1346275030632569e-08
- O 0 0.00013494181621354073
function O 0 1.27849193631846e-06
mutations O 0 6.657100584561704e-06
and O 0 1.8826899150781173e-08
a O 0 1.0340658107566014e-08
complete O 0 3.2781852610241913e-07
absence O 0 1.330879655370154e-07
of O 0 8.220922831370103e-10
the O 0 7.472899632432473e-09
normal O 0 4.082584581510673e-08
copy O 0 2.3431796947193106e-08
of O 0 2.6415794551759575e-10
ATM O 0 9.36001185891655e-07
in O 0 1.4410869164649398e-09
the O 0 6.243528472005266e-10
majority O 0 3.0625226798974836e-09
of O 0 1.6326102691976985e-09
mutated O 0 0.00019011816766578704
tumours B-Disease 1 1.0
establishes O 0 2.9820421332260594e-07
somatic O 0 5.546090733332676e-07
inactivation O 0 4.809369329450419e-07
of O 0 1.3095118323036559e-09
this O 0 1.1237268893182772e-09
gene O 0 1.0690401097690483e-07
in O 0 1.6269807723290342e-09
the O 0 4.194971925386426e-09
pathogenesis O 0 4.430792444054532e-08
of O 0 3.163747930301497e-09
sporadic B-Disease 0 0.03890221565961838
T I-Disease 1 0.839533269405365
- I-Disease 0 4.387196895550005e-05
PLL I-Disease 0 1.187238194688689e-05
and O 0 4.5394664027753606e-08
suggests O 0 3.407927806620137e-08
that O 0 1.2171956775830495e-09
ATM O 0 1.5460414033441339e-06
acts O 0 1.655818522294794e-07
as O 0 2.517482755592937e-08
a O 0 1.166763240689761e-06
tumour B-Disease 1 1.0
suppressor O 0 2.3296639483305626e-05
. O 0 1.965746179166672e-07

As O 0 8.831838727019203e-07
constitutional O 0 2.642651111273153e-07
DNA O 0 6.180783884701668e-07
was O 0 1.1354981666045205e-07
not O 0 3.885876953546585e-09
available O 0 2.054159953246426e-09
, O 0 7.390695833109362e-10
a O 0 4.798984321041644e-09
putative O 0 6.688441317237448e-06
hereditary O 0 0.11006574332714081
predisposition O 0 6.796764500904828e-05
to O 0 5.941315066593233e-07
T B-Disease 1 0.5644760727882385
- I-Disease 0 6.785483856219798e-05
PLL I-Disease 0 1.657673237787094e-05
will O 0 2.9002864110339033e-08
require O 0 2.061052484236825e-08
further O 0 1.829878648607064e-08
investigation O 0 9.33620256660106e-08
. O 0 1.8482698038724266e-08
. O 0 5.152255511120529e-08

Myotonic B-Disease 1 0.9999997615814209
dystrophy I-Disease 1 1.0
protein O 0 0.00012862941366620362
kinase O 0 1.776198041625321e-05
is O 0 3.9963882869642475e-08
involved O 0 1.3006136612148111e-08
in O 0 2.9546617930087393e-10
the O 0 1.9990373245626358e-10
modulation O 0 5.798493241115921e-09
of O 0 4.142350629177116e-10
the O 0 4.046950774494462e-09
Ca2 O 0 3.626108764365199e-07
+ O 0 8.396545467803662e-07
homeostasis O 0 2.7535518256627256e-06
in O 0 2.034182955412689e-08
skeletal O 0 2.159587347705383e-05
muscle O 0 2.5797886337386444e-05
cells O 0 2.448046870995313e-06
. O 0 1.2371197044558357e-07

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9992461204528809
DM B-Disease 1 1.0
) O 0 7.356385935963772e-07
, O 0 1.5439152178942095e-09
the O 0 2.543708299551639e-10
most O 0 1.3593388636934378e-09
prevalent O 0 1.0174885574087966e-06
muscular B-Disease 0 0.00032686491613276303
disorder I-Disease 0 0.002362611470744014
in O 0 4.449947965667889e-09
adults O 0 2.7056087219534675e-06
, O 0 4.597882075074722e-09
is O 0 2.6156901089535722e-09
caused O 0 8.848127919236504e-08
by O 0 4.935857056409532e-09
( O 0 8.431481290926968e-09
CTG O 0 5.684227630808891e-07
) O 0 8.772940596202261e-09
n O 0 9.987484190787654e-07
- O 0 3.902776825270848e-06
repeat O 0 8.498990382577176e-07
expansion O 0 1.3037928958681277e-08
in O 0 1.1921672538051098e-09
a O 0 2.988197911335533e-09
gene O 0 2.1816562778553816e-08
encoding O 0 1.6630787413873804e-08
a O 0 1.1708498171003612e-08
protein O 0 2.0336675277121685e-07
kinase O 0 4.915219051326858e-06
( O 0 1.9987292887435615e-07
DM B-Disease 1 0.9999980926513672
protein O 0 5.264271862870373e-07
kinase O 0 3.980344445153605e-06
; O 0 3.684124649794285e-08
DMPK O 0 1.2847890502598602e-06
) O 0 3.323994857140633e-09
and O 0 1.2519448810976996e-09
involves O 0 6.2204246198405144e-09
changes O 0 1.7547362674008582e-08
in O 0 3.221222399929502e-09
cytoarchitecture O 0 1.1254691116846516e-06
and O 0 5.18670582039249e-08
ion O 0 5.57452540306258e-06
homeostasis O 0 9.936284186551347e-05
. O 0 5.337537345440069e-07

To O 0 3.023354508968623e-07
obtain O 0 3.816673483925115e-07
clues O 0 3.571866784568556e-07
to O 0 6.298900512291539e-09
the O 0 6.4673790767244554e-09
normal O 0 1.4950374804811872e-07
biological O 0 1.78591932353811e-07
role O 0 1.0937172056912914e-08
of O 0 9.18414289063918e-10
DMPK O 0 7.089094538059726e-07
in O 0 1.737599841789006e-09
cellular O 0 2.1225513080480596e-07
ion O 0 3.8330003349074104e-07
homeostasis O 0 9.356056580145378e-06
, O 0 7.606203666910005e-09
we O 0 1.3852673674819016e-08
have O 0 2.705049517714997e-09
compared O 0 3.3085230111140618e-09
the O 0 1.5244211448717238e-09
resting O 0 1.3996387338011118e-07
[ O 0 1.519736336774713e-08
Ca2 O 0 2.8900320359070975e-08
+ O 0 9.943910583842808e-08
] O 0 1.332211780891157e-07
i O 0 6.785543860132748e-07
, O 0 6.136235963793979e-10
the O 0 2.989250791340936e-10
amplitude O 0 7.2459118705126e-09
and O 0 9.056431160558986e-09
shape O 0 1.5922910279186908e-07
of O 0 1.334158450383427e-09
depolarization O 0 1.1358989127074892e-07
- O 0 4.884685949946288e-06
induced O 0 2.624813078000443e-06
Ca2 O 0 2.6528854846219474e-07
+ O 0 2.7941200642089825e-07
transients O 0 5.181668711884413e-07
, O 0 2.5572233219861573e-09
and O 0 1.1767508079074673e-09
the O 0 3.0062899392113707e-10
content O 0 2.7944007108260394e-09
of O 0 3.7111044792759174e-10
ATP O 0 1.1044128456205726e-07
- O 0 8.085467015916947e-07
driven O 0 3.705680171606218e-07
ion O 0 9.034040715505398e-08
pumps O 0 3.7405717989713594e-07
in O 0 4.163740019436091e-09
cultured O 0 2.16033157585116e-07
skeletal O 0 1.3550884432333987e-06
muscle O 0 3.930665002371825e-07
cells O 0 3.7477342118563683e-08
of O 0 5.542464265317903e-10
wild O 0 2.6261593788490245e-08
- O 0 7.400449248962104e-07
type O 0 9.596285235602409e-05
and O 0 1.410640493304527e-07
DMPK O 0 4.6189106797100976e-05
[ O 0 6.022062848387577e-07
- O 0 6.3396637415280566e-06
/ O 0 3.458623177721165e-05
- O 0 0.00016511046851519495
] O 0 1.8323605672776466e-06
knockout O 0 0.0007321442826651037
mice O 0 0.0001576091453898698
. O 0 2.085899097892252e-07

In O 0 2.4471505639667157e-06
vitro O 0 4.844214709009975e-05
- O 0 1.7597605619812384e-05
differentiated O 0 6.368477897922276e-06
DMPK O 0 1.367243385175243e-05
[ O 0 4.736039613817411e-07
- O 0 6.178501280373894e-06
/ O 0 2.4739885702729225e-05
- O 0 3.207628469681367e-05
] O 0 4.3336183352948865e-07
myotubes O 0 1.6466864281028393e-06
exhibit O 0 7.736545626357838e-08
a O 0 2.060549242344223e-08
higher O 0 3.052564068184438e-07
resting O 0 1.7416706441508722e-06
[ O 0 5.373954792275981e-08
Ca2 O 0 1.4406442971903743e-07
+ O 0 2.5768471800802217e-07
] O 0 2.1498006219644594e-07
i O 0 1.6149969894740934e-07
than O 0 2.9812354807035035e-09
do O 0 4.5861305864036694e-08
wild O 0 1.888069611766241e-08
- O 0 1.0230600082650199e-06
type O 0 7.360972813330591e-05
myotubes O 0 1.1454207196948119e-05
because O 0 1.807990912539026e-08
of O 0 4.077561621684822e-10
an O 0 1.5920678109182518e-09
altered O 0 5.406621994552552e-07
open O 0 6.42175379539367e-08
probability O 0 1.3368005369329694e-08
of O 0 2.2818198441854065e-09
voltage O 0 1.4271819054556545e-05
- O 0 7.268183253472671e-05
dependent O 0 3.6659148463513702e-06
l O 0 1.05411004369671e-06
- O 0 3.402875279334694e-07
type O 0 6.921026169948163e-07
Ca2 O 0 5.504668365574616e-07
+ O 0 3.206365875030315e-07
and O 0 3.349466126678635e-08
Na O 0 4.3272557377349585e-06
+ O 0 1.126551524066599e-06
channels O 0 4.821161837753607e-06
. O 0 5.683610311280063e-07

The O 0 9.456176144340134e-07
mutant O 0 5.587624400504865e-06
myotubes O 0 5.248303295957157e-06
exhibit O 0 1.1240602049156223e-07
smaller O 0 9.287980873295965e-08
and O 0 1.6619496889802576e-08
slower O 0 7.526701892857091e-07
Ca2 O 0 6.402271424121864e-07
+ O 0 3.9360668324661674e-07
responses O 0 2.280729347603483e-07
upon O 0 1.5924086937957327e-08
triggering O 0 1.5762337568503426e-07
by O 0 2.319433756170497e-09
acetylcholine O 0 1.2654888337237935e-07
or O 0 8.990928535013154e-08
high O 0 2.413206914297916e-07
external O 0 2.6267283828929067e-05
K O 0 1.5180918126134202e-05
+ O 0 3.11054395751853e-06
. O 0 2.66134406956553e-07

In O 0 2.0850498572144716e-07
addition O 0 7.272943491898332e-08
, O 0 8.968044085122528e-09
we O 0 6.588373402394154e-09
observed O 0 3.6233345213076973e-09
that O 0 1.863908472010678e-10
these O 0 1.3413180566246297e-09
Ca2 O 0 1.5800142705302278e-07
+ O 0 6.946411872377212e-07
transients O 0 8.347798029717524e-06
partially O 0 3.874543835991062e-05
result O 0 3.632248279927808e-08
from O 0 1.9416446228603945e-09
an O 0 3.6100603062472203e-10
influx O 0 2.9201512319332323e-09
of O 0 9.149069835068246e-10
extracellular O 0 5.59556916357451e-08
Ca2 O 0 1.6757986998072738e-07
+ O 0 1.5330009262015665e-07
through O 0 1.5053636559514416e-08
the O 0 1.4884330212794339e-08
l O 0 6.716571192555421e-07
- O 0 2.856313869870064e-07
type O 0 1.0987331506839837e-06
Ca2 O 0 1.5561756754323142e-06
+ O 0 1.2286511719139526e-06
channel O 0 5.02975535709993e-06
. O 0 3.360223388426675e-07

Neither O 0 6.9953066486050375e-06
the O 0 3.0563153785578834e-08
content O 0 6.073538116879718e-08
nor O 0 3.301817130818563e-08
the O 0 7.107819888219069e-10
activity O 0 5.699696270511367e-09
of O 0 1.334048982393199e-09
Na O 0 4.7453983142986544e-07
+ O 0 2.4698456968508253e-07
/ O 0 2.3652724223666155e-07
K O 0 6.720069336552115e-07
+ O 0 2.7977893068964477e-07
ATPase O 0 1.0895778359554242e-06
and O 0 4.8957954135175896e-08
sarcoplasmic O 0 4.469840405363357e-06
reticulum O 0 2.657602863109787e-06
Ca2 O 0 1.5021777244328405e-06
+ O 0 2.018081204369082e-06
- O 0 1.992828174479655e-06
ATPase O 0 9.64928312896518e-06
are O 0 5.0887052793768817e-08
affected O 0 8.580285282278055e-08
by O 0 9.814701051880093e-09
DMPK O 0 1.6921834685490467e-05
absence O 0 1.1921289342353703e-06
. O 0 1.809095095950397e-07

In O 0 7.69196162764274e-07
conclusion O 0 8.223094738468717e-08
, O 0 3.1898816921227535e-09
our O 0 6.799508511790009e-09
data O 0 1.5733045088950348e-08
suggest O 0 2.6988873358391174e-08
that O 0 1.9719650357075125e-09
DMPK O 0 4.6362538341782056e-07
is O 0 8.70380101325452e-10
involved O 0 1.5282437537678106e-09
in O 0 3.834673689695478e-10
modulating O 0 7.762842102465584e-08
the O 0 1.7520765949186057e-09
initial O 0 5.263721458703685e-09
events O 0 2.9893323372220948e-09
of O 0 1.5294684407862746e-09
excitation O 0 1.2004663858533604e-06
- O 0 0.004039769526571035
contraction O 0 1.5875355529715307e-05
coupling O 0 2.910372131736949e-06
in O 0 1.7618761560811436e-08
skeletal O 0 2.057176061498467e-05
muscle O 0 5.7428637774137314e-06
. O 0 3.4123246450690203e-08
. O 0 1.005673340159774e-07

Constitutional O 0 4.545986303128302e-05
RB1 O 0 0.0010635502403602004
- O 0 5.119019260746427e-05
gene O 0 5.419814897322794e-06
mutations O 0 5.265087565931026e-06
in O 0 1.476241617837104e-08
patients O 0 9.478197284806811e-07
with O 0 2.0000424427735197e-08
isolated O 0 1.4410388757823966e-05
unilateral B-Disease 0 0.00011155304673593491
retinoblastoma I-Disease 0 0.0006249769357964396
. O 0 6.805219072703039e-07

In O 0 2.972669506107195e-07
most O 0 5.453711793279581e-08
patients O 0 7.81254072990123e-07
with O 0 5.084016763134969e-09
isolated O 0 3.984446266258601e-06
unilateral B-Disease 0 1.4624562027165666e-05
retinoblastoma I-Disease 0 4.764864206663333e-05
, O 0 4.7193982055659944e-08
tumor B-Disease 0 7.700858191128646e-07
development O 0 2.8966362641824617e-09
is O 0 6.910323424591525e-10
initiated O 0 5.109700662586647e-09
by O 0 1.0966264563094796e-09
somatic O 0 1.7370943794503546e-07
inactivation O 0 3.0870802447680035e-07
of O 0 6.62122523475972e-10
both O 0 6.558183329730127e-09
alleles O 0 2.983330205097445e-08
of O 0 1.515928604867156e-09
the O 0 6.623403692174179e-08
RB1 O 0 2.7677144316839986e-05
gene O 0 2.3947957288328325e-06
. O 0 3.047241534659406e-07

However O 0 6.177861564538034e-07
, O 0 2.223704331782983e-09
some O 0 1.773239194369225e-10
of O 0 1.1065768440454704e-10
these O 0 2.985161451363183e-09
patients O 0 2.681707478302542e-08
can O 0 8.012084329322988e-09
transmit O 0 0.0008061654516495764
retinoblastoma B-Disease 0 0.00029585498850792646
predisposition O 0 0.00019237784727010876
to O 0 6.511010752774382e-08
their O 0 2.8657702841883292e-06
offspring O 0 3.1558498449157923e-05
. O 0 1.8300816861938074e-07

To O 0 4.453983990515553e-07
determine O 0 1.3637249196563062e-07
the O 0 2.7884161646341e-09
frequency O 0 9.858042915311671e-08
and O 0 3.2615312672845675e-09
nature O 0 4.73102179654461e-09
of O 0 4.294631039680752e-10
constitutional O 0 2.19073243101775e-07
RB1 O 0 3.9069203921826556e-05
- O 0 2.2438125597545877e-06
gene O 0 1.942725475601037e-06
mutations O 0 2.6435209292685613e-06
in O 0 5.325524465860099e-09
patients O 0 2.263390683765465e-07
with O 0 3.897656863927068e-09
isolated O 0 1.6749819451433723e-06
unilateral B-Disease 0 1.433561692465446e-06
retinoblastoma I-Disease 0 3.2704617751733167e-06
, O 0 9.812155532529232e-09
we O 0 6.050007606006602e-09
analyzed O 0 3.384439750675483e-08
DNA O 0 6.82042298194574e-08
from O 0 2.738204551988588e-09
peripheral O 0 4.469934083317639e-06
blood O 0 1.4696846847073175e-05
and O 0 1.261312689848637e-07
from O 0 1.6201261132664513e-07
tumor B-Disease 0 0.0001521146623417735
tissue O 0 3.3827494917204604e-05
. O 0 4.154746591211733e-07

The O 0 2.2392839582607849e-07
analysis O 0 6.489450044000478e-08
of O 0 1.6396983326671943e-08
tumors B-Disease 1 1.0
from O 0 4.563878874819238e-08
54 O 0 1.8945652868751495e-07
( O 0 7.71388020126551e-09
71 O 0 1.2790245307314763e-07
% O 0 2.791087361231348e-09
) O 0 2.506995999684847e-10
of O 0 1.6592464902043247e-10
76 O 0 1.3500381612630008e-07
informative O 0 6.836978172941599e-06
patients O 0 4.896571772405878e-05
showed O 0 9.092545951716602e-06
loss O 0 8.31948554491646e-08
of O 0 2.5610111809015734e-09
constitutional O 0 5.859968723598286e-07
heterozygosity O 0 0.000145114550832659
( O 0 1.94891617866233e-06
LOH O 1 0.9999967813491821
) O 0 2.3529165105173888e-07
at O 0 6.459270025516162e-07
intragenic O 0 2.290445081598591e-05
loci O 0 6.808621947129723e-06
. O 0 2.879188230053842e-07

Three O 0 5.427042992778297e-07
of O 0 2.9651882726966505e-08
13 O 0 2.6576688583190844e-07
uninformative O 0 0.005236185155808926
patients O 0 0.0008330909186042845
had O 0 5.18503497914935e-07
constitutional O 0 3.5825445365844644e-07
deletions O 0 2.5063203793251887e-05
. O 0 6.757052233297145e-07

For O 0 5.998098799864238e-07
39 O 0 3.3426040317863226e-06
randomly O 0 3.4196432352473494e-06
selected O 0 4.951000846631359e-06
tumors B-Disease 1 1.0
, O 0 5.6812261561844934e-08
SSCP O 0 5.955457254458452e-06
, O 0 1.6211487263717572e-08
hetero O 0 4.498075668379897e-06
- O 0 4.3411753836153366e-07
duplex O 0 1.167355435427453e-06
analysis O 0 4.444369139378068e-08
, O 0 2.0999748606698176e-09
sequencing O 0 1.916917469202417e-08
, O 0 3.5883553906046473e-09
and O 0 8.190953693087977e-09
Southern O 0 1.5572217293424728e-08
blot O 0 1.3611366739496589e-05
analysis O 0 3.0907625614418066e-07
were O 0 3.704121809278149e-07
used O 0 5.3621594275909956e-08
to O 0 6.479692160610284e-08
identify O 0 0.00010285741154802963
mutations O 0 3.479597216937691e-05
. O 0 2.3251450897987525e-07

Mutations O 0 0.002570448676124215
were O 0 3.3145461202366278e-06
detected O 0 8.165451959030179e-07
in O 0 3.3578826386104765e-09
21 O 0 2.0241431641920826e-08
( O 0 2.519825681446264e-09
91 O 0 3.680009186268762e-08
% O 0 6.0874412177724935e-09
) O 0 1.1937872912426428e-09
of O 0 6.323879198077975e-09
23 O 0 0.004293354228138924
tumors B-Disease 1 1.0
with O 0 2.0202522136969492e-05
LOH O 1 0.9999997615814209
. O 0 2.4580667741247453e-06

In O 0 9.637644780013943e-07
6 O 0 4.0656453847986995e-07
( O 0 1.608833599675563e-08
38 O 0 2.3480204447423603e-08
% O 0 2.967908363515903e-09
) O 0 9.235154307951632e-10
of O 0 2.7285596004844592e-09
16 O 0 0.0003817092510871589
tumors B-Disease 1 1.0
without O 0 0.002267534378916025
LOH O 1 0.9999719858169556
, O 0 5.152785931272774e-08
one O 0 2.638908114249716e-08
mutation O 0 1.0201381428487366e-06
was O 0 4.6383721041820536e-07
detected O 0 1.1951182159464224e-06
, O 0 2.998977954860038e-09
and O 0 4.859259217226963e-09
in O 0 1.4237979684139646e-09
9 O 0 2.839279211741541e-08
( O 0 3.8650314060362234e-09
56 O 0 3.720768404491537e-08
% O 0 3.5898064520978323e-09
) O 0 3.771998269286314e-10
of O 0 1.149307204961758e-09
the O 0 5.367344419937581e-05
tumors B-Disease 1 1.0
without O 0 0.002429733518511057
LOH O 1 0.9999170303344727
, O 0 2.8343444924416872e-08
both O 0 3.277947158153438e-08
mutations O 0 6.324114565359196e-06
were O 0 2.1807913697102776e-07
found O 0 9.664052669222656e-08
. O 0 6.51058869038934e-08

Thus O 0 7.897490831965115e-06
, O 0 1.480589784108588e-08
a O 0 2.953153499518635e-09
total O 0 1.545064187702394e-09
of O 0 4.1336528644464465e-10
45 O 0 2.912809904387359e-08
mutations O 0 2.5597757939976873e-06
were O 0 5.279238735056424e-07
identified O 0 3.6464513186729164e-07
in O 0 1.6080113240946048e-08
tumors B-Disease 1 1.0
of O 0 1.5939312092427826e-08
36 O 0 6.106636192271253e-06
patients O 0 2.5447843654546887e-06
. O 0 1.68387288113081e-07

Thirty O 0 0.00013454376312438399
- O 0 3.768169699469581e-05
nine O 0 8.77630839113408e-08
of O 0 7.608347285525952e-10
the O 0 4.470330772221587e-09
mutations O 0 1.447326212655753e-06
- O 0 3.556052092790196e-07
including O 0 7.00011026921743e-09
34 O 0 6.40910116089799e-08
small O 0 1.1633191299154078e-08
mutations O 0 1.0138766810996458e-05
, O 0 1.5133256869859224e-09
2 O 0 1.9807937512439366e-09
large O 0 2.5245980861399175e-09
structural O 0 4.569385055219755e-06
alterations O 0 4.678409368352732e-06
, O 0 1.4596273523181935e-08
and O 0 4.684009180522253e-09
hypermethylation O 0 7.727526281087194e-07
in O 0 1.2336812460489455e-08
3 O 0 9.029369721247349e-06
tumors O 1 1.0
- O 0 0.17573362588882446
were O 0 3.1734296499053016e-05
not O 0 3.600532849645788e-08
detected O 0 1.1912727160279246e-07
in O 0 7.737054885659234e-10
the O 0 3.4552343208815728e-09
corresponding O 0 2.2075586514347378e-07
peripheral O 0 4.477717448025942e-05
blood O 0 1.2595721273100935e-05
DNA O 0 4.524561063590227e-06
. O 0 2.1543034733895183e-07

In O 0 5.916612053624704e-07
6 O 0 3.205962286756403e-07
( O 0 1.3741882298745622e-08
17 O 0 3.658767866454582e-08
% O 0 4.198286163159537e-09
) O 0 2.226912126923608e-10
of O 0 6.035456162623021e-11
the O 0 4.4174242042061e-09
36 O 0 1.100608301385364e-06
patients O 0 6.460230395077815e-08
, O 0 4.5053125119487447e-10
a O 0 5.939885028283243e-09
mutation O 0 6.280539764702553e-06
was O 0 1.564396825415315e-07
detected O 0 2.382878108164732e-07
in O 0 1.011397188221963e-09
constitutional O 0 1.8200557505565484e-08
DNA O 0 4.54078275424763e-07
, O 0 6.930628071444289e-09
and O 0 3.2264242388890807e-09
1 O 0 9.251991950343097e-10
of O 0 1.8646764687879624e-10
these O 0 6.290147958054604e-09
mutations O 0 9.954972028936027e-07
is O 0 1.5972201339309322e-09
known O 0 3.6241361023314766e-09
to O 0 5.684865467259215e-09
be O 0 5.234849353996651e-08
associated O 0 3.5403672882239334e-08
with O 0 8.976840604191239e-09
reduced O 0 2.4320304419234162e-06
expressivity O 0 0.00015595724107697606
. O 0 6.449193392654706e-07

The O 0 3.9161773202067707e-07
presence O 0 5.543146386344233e-08
of O 0 7.517699796011357e-10
a O 0 6.872733049334556e-09
constitutional O 0 4.843938228304978e-08
mutation O 0 4.464728135644691e-06
was O 0 2.1951639439521387e-07
not O 0 4.092226557617096e-09
associated O 0 3.900847200810631e-09
with O 0 5.880418929571363e-10
an O 0 2.317227076886752e-09
early O 0 2.924255966263445e-07
age O 0 1.6828098523546942e-06
at O 0 1.533313707113848e-07
treatment O 0 2.7907489652534423e-07
. O 0 8.248778726738237e-08

In O 0 7.018454653007211e-07
1 O 0 5.167461267774343e-07
patient O 0 1.0108577725986834e-06
, O 0 3.3700797708036134e-09
somatic O 0 1.0458420547365677e-06
mosaicism O 0 1.6096972103696316e-05
was O 0 7.97809434516239e-07
demonstrated O 0 2.869620807643969e-08
by O 0 7.142338387389202e-10
molecular O 0 1.1086568107998573e-08
analysis O 0 1.697057783189848e-08
of O 0 1.2271144100850506e-09
DNA O 0 2.785770902846707e-07
and O 0 2.0460822369727794e-08
RNA O 0 1.4946981252705882e-07
from O 0 1.8263429879539217e-08
peripheral O 0 6.95443304721266e-05
blood O 0 3.5046406992478296e-05
. O 0 9.408405077238058e-08

In O 0 1.0557972700553364e-06
2 O 0 2.1679693418263923e-06
patients O 0 1.6028865502448753e-05
without O 0 4.119960905768494e-08
a O 0 3.1823113033624395e-08
detectable O 0 0.008819046430289745
mutation O 0 5.686468284693547e-06
in O 0 1.2309265606802455e-08
peripheral O 0 9.989753743866459e-05
blood O 0 8.391644951188937e-05
, O 0 7.783075517409088e-09
mosaicism O 0 3.0498101750708884e-06
was O 0 5.558475777434069e-07
suggested O 0 3.148801752672625e-08
because O 0 1.2981221653163288e-09
1 O 0 5.749076770200645e-10
of O 0 1.4052943531073225e-10
the O 0 7.309194582916234e-09
patients O 0 5.995634069222433e-07
showed O 0 5.975642125122249e-06
multifocal O 1 0.9996626377105713
tumors B-Disease 1 1.0
and O 0 2.9710881221944874e-07
the O 0 7.177603844610303e-09
other O 0 4.047954416108723e-09
later O 0 2.9358345088326132e-08
developed O 0 8.409770657635818e-08
bilateral B-Disease 0 2.753772605501581e-06
retinoblastoma I-Disease 0 5.846701969858259e-05
. O 0 3.894549251981516e-07

In O 0 6.658184474872542e-07
conclusion O 0 1.2691123174590757e-07
, O 0 6.137983010745529e-09
our O 0 1.9888316771243808e-08
results O 0 1.4309152085445476e-08
emphasize O 0 4.608824610841111e-08
that O 0 6.172307664975563e-10
the O 0 8.270479856520296e-10
manifestation O 0 1.2032105978221352e-08
and O 0 4.316131896331399e-09
transmissibility O 0 8.844095589211065e-08
of O 0 1.3544552146527167e-09
retinoblastoma B-Disease 0 3.9871761714493914e-07
depend O 0 4.722171098592298e-08
on O 0 1.7889425052430852e-08
the O 0 1.9632211412101697e-09
nature O 0 4.633652128660515e-09
of O 0 4.1990844135142424e-10
the O 0 2.6375834849545754e-09
first O 0 2.43996254312151e-08
mutation O 0 2.225292945468027e-07
, O 0 6.897760695956379e-10
its O 0 3.8549141656574193e-10
time O 0 1.1659203380531835e-08
in O 0 3.1114252840858114e-10
development O 0 5.844882355887648e-10
, O 0 8.056244005238966e-10
and O 0 4.797792718669314e-10
the O 0 3.7137029562650525e-10
number O 0 1.5734776814824158e-09
and O 0 1.4329656350398068e-09
types O 0 6.360787452308614e-09
of O 0 6.737203572804162e-10
cells O 0 1.1976833746984994e-08
that O 0 8.067622125906837e-10
are O 0 6.5452869790760815e-09
affected O 0 8.381714167171594e-08
. O 0 4.82076423224953e-09
. O 0 3.5952350430079605e-08

Hereditary B-Disease 1 0.9999991655349731
deficiency I-Disease 1 0.999711811542511
of I-Disease 0 1.8801635803811223e-08
the I-Disease 0 1.49817118710871e-08
fifth I-Disease 0 5.467073265208455e-07
component I-Disease 0 1.393300834706679e-07
of I-Disease 0 1.803870386396511e-09
complement I-Disease 0 1.9400987127937697e-07
in O 0 4.123262797861571e-08
man O 0 7.178213763836538e-06
. O 0 1.379485610186748e-07

I O 0 0.003284885548055172
. O 0 2.533374527047272e-06

Clinical O 0 0.0027018107939511538
, O 0 3.882934151988593e-07
immunochemical O 0 3.425845079618739e-06
, O 0 1.5541536058094607e-08
and O 0 6.6559735500959505e-09
family O 0 2.4082314808993033e-08
studies O 0 1.0889488066823105e-07
. O 0 9.465788508578044e-08

The O 0 3.9062254586497147e-07
first O 0 6.746622460696017e-08
recognized O 0 4.44210641603604e-08
human O 0 1.636480106981253e-08
kindred O 0 4.751008759740216e-07
with O 0 5.52178818225002e-08
hereditary B-Disease 1 0.9999995231628418
deficiency I-Disease 1 0.7257809638977051
of I-Disease 0 1.1654349707512779e-09
the I-Disease 0 1.1486459783327518e-08
fifth I-Disease 0 1.1486786206660327e-06
component I-Disease 0 1.0814786577384439e-07
of I-Disease 0 2.638594676085404e-09
complement I-Disease 0 5.242762881607632e-07
( O 0 3.244043256245277e-08
C5 O 0 2.526098342059413e-06
) O 0 5.392011726002011e-09
is O 0 4.5780179647181285e-09
described O 0 3.098075183061155e-07
. O 0 1.3773666296401643e-07

The O 0 9.487040983913175e-07
proband O 0 1.0228561222902499e-05
, O 0 1.723039666501336e-08
a O 0 1.3836829459989985e-08
20 O 0 2.3956008732284317e-08
- O 0 4.2257639165654837e-07
year O 0 9.820992907805248e-09
- O 0 7.741305125819054e-07
old O 0 1.3554102906709886e-06
black O 0 8.696939346464205e-08
female O 0 2.5977809059440915e-07
with O 0 7.57419684305205e-07
systemic B-Disease 1 1.0
lupus I-Disease 1 0.9997718930244446
erythematosus I-Disease 1 0.9999998807907104
since O 0 8.875246066963882e-07
age O 0 7.625794751220383e-07
11 O 0 3.234189449585756e-08
, O 0 3.817365978875387e-09
lacked O 0 1.7748163827491226e-06
serum O 0 4.38947699876735e-06
hemolytic O 0 2.550772114773281e-05
complement O 0 4.26532125175072e-07
activity O 0 9.47498790537793e-07
, O 0 1.2260574777656075e-08
even O 0 4.7253244872536015e-08
during O 0 4.3209777800257143e-07
remission O 0 1.1719595022441354e-05
. O 0 3.046546908080927e-07

C5 O 0 0.001306865713559091
was O 0 2.209962622146122e-05
undetectable O 0 2.551949910412077e-05
in O 0 2.3254681735807026e-08
her O 0 1.1758410067841396e-07
serum O 0 3.3718629310897086e-07
by O 0 2.8934170615002586e-09
both O 0 2.4188700820104714e-08
immunodiffusion O 0 1.0036122148449067e-05
and O 0 1.5880357295827707e-07
hemolytic O 0 0.00018539624579716474
assays O 0 3.4630520531209186e-05
. O 0 6.451414265029598e-07

Other O 0 3.773268986151379e-07
complement O 0 6.857383141323226e-07
components O 0 1.3058170225122012e-06
were O 0 2.2456913484347751e-07
normal O 0 1.226600687687096e-07
during O 0 7.572883475859271e-08
remission O 0 1.3413090016456408e-07
of O 0 1.067476329552619e-09
lupus O 0 1.3746883951171185e-06
, O 0 1.5314564061341684e-09
but O 0 6.404504038215464e-09
C1 O 0 3.740551255759783e-05
, O 0 6.177987899036452e-09
C4 O 0 5.19600405368692e-07
, O 0 1.0259599392270502e-08
C2 O 0 3.922515588783426e-06
, O 0 9.847177295796428e-09
and O 0 1.7799605345203418e-08
C3 O 0 4.4961598177906126e-05
levels O 0 1.426213111699326e-05
fell O 0 0.0005446242867037654
during O 0 3.7699743415942066e-07
exacerbations O 0 0.0006298179505392909
. O 0 4.936707114211458e-07

A O 0 2.4109810965455836e-06
younger O 0 2.5309161628683796e-06
half O 0 3.259176537540043e-07
- O 0 2.1248065422696527e-06
sister O 0 4.238964265823597e-06
, O 0 3.416960492330645e-09
who O 0 2.4148734567575048e-08
had O 0 5.145921022631228e-07
no O 0 2.170088322372976e-07
underlying O 0 0.0001828977110562846
disease O 0 0.00034571182914078236
, O 0 1.6465955265942966e-09
was O 0 6.355587345296954e-08
also O 0 4.8775894434527345e-09
found O 0 8.143877572308611e-09
to O 0 1.0498232505540273e-08
lack O 0 5.945639713900164e-06
immunochemically O 0 0.0024961933959275484
detectable O 0 0.02759179286658764
C5 O 0 5.575610339292325e-05
. O 0 6.438138484554656e-07

By O 0 1.8948793467643554e-06
hemolytic O 0 0.0005921707488596439
assay O 0 7.064750207064208e-06
, O 0 7.737313012512459e-08
she O 0 1.5033987210699706e-07
exhibited O 0 9.684627855222061e-08
1 O 0 6.270623131854336e-09
- O 0 3.3365611784574867e-07
2 O 0 1.778860969636753e-08
% O 0 2.289352929452093e-09
of O 0 2.3186098874194982e-10
the O 0 5.63355051497183e-09
normal O 0 1.7493401571755385e-07
serum O 0 2.555835862949607e-07
C5 O 0 4.476322885693662e-07
level O 0 1.925085086895706e-07
and O 0 3.8253489265116514e-08
normal O 0 9.273147583144237e-08
concentrations O 0 7.072719654388493e-08
of O 0 4.767579664388677e-10
other O 0 2.3440722696221883e-09
complement O 0 1.8833729598100035e-07
components O 0 3.6416486182133667e-06
. O 0 8.638068749178274e-08

C5 O 0 0.00028410457889549434
levels O 0 1.9558499388949713e-06
of O 0 4.603305292505411e-09
other O 0 3.5665406183937876e-09
family O 0 1.3829177802904269e-08
members O 0 4.065216163695595e-09
were O 0 1.6266875491055544e-07
either O 0 2.7647610423287006e-08
normal O 0 9.244784848760901e-08
or O 0 6.286744280714629e-08
approximately O 0 1.8638248278080027e-08
half O 0 6.028475922903453e-07
- O 0 0.0005270552355796099
normal O 0 3.3014446216839133e-06
, O 0 5.045251327828737e-09
consistent O 0 1.991014784152867e-07
with O 0 1.142005068288654e-08
autosomal O 0 0.00029431129223667085
codominant O 0 1.871771246442222e-06
inheritance O 0 1.2005324379060767e-07
of O 0 1.0685662354958936e-09
the O 0 2.1528324012365374e-08
gene O 0 4.840700057684444e-05
determining O 0 0.05354316160082817
C5 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 1.1303957307973178e-06

Normal O 0 0.0018449366325512528
hemolytic O 0 0.02636461704969406
titers O 0 0.0012665505055338144
were O 0 2.203592157457024e-05
restored O 0 7.838062856535544e-07
to O 0 2.7681378966804004e-08
both O 0 2.3150123524828814e-06
homozygous O 1 0.9992926120758057
C5 B-Disease 1 1.0
- I-Disease 1 0.9999997615814209
deficient I-Disease 1 1.0
( O 0 7.797573744028341e-06
C5D B-Disease 1 1.0
) O 0 4.7582457085582064e-08
sera O 0 2.6866001689995755e-07
by O 0 6.038706201749733e-10
addition O 0 1.073808819640476e-09
of O 0 5.778374445597478e-10
highly O 0 1.3358707917632273e-07
purified O 0 4.747421655793005e-07
human O 0 8.378277982501459e-08
C5 O 0 1.5070410881889984e-05
. O 0 3.456100330367917e-07

In O 0 7.986468517628964e-07
specific O 0 5.777299634246447e-07
C5 O 0 1.525539846625179e-05
titrations O 0 1.4159756574372295e-05
, O 0 2.527904818805382e-08
however O 0 1.7225927351205428e-08
, O 0 1.0714479303786106e-09
it O 0 9.422906899203554e-10
was O 0 4.6573564560503655e-08
noted O 0 2.771480600571863e-09
that O 0 5.235263333958073e-10
when O 0 3.635088230424799e-09
limited O 0 2.450674774223671e-09
amounts O 0 2.147090283344255e-09
of O 0 1.0253706772545002e-09
C5 O 0 1.8498604958949727e-06
were O 0 2.404390500032605e-07
assayed O 0 6.9040839889567e-07
in O 0 1.1455801862680914e-09
the O 0 1.5902438255110951e-09
presence O 0 3.982825624859743e-09
of O 0 9.649475662953932e-10
low O 0 9.045124897966161e-07
dilutions O 0 1.668459844950121e-06
of O 0 1.0771427305655834e-08
either O 0 2.10546550079016e-05
C5D B-Disease 1 1.0
serum O 0 1.2680402505793609e-05
, O 0 1.4716086127464223e-08
curving O 0 3.0971386877354234e-07
rather O 0 2.758682171588589e-08
than O 0 1.7355527015538996e-09
linear O 0 1.7313480427105787e-08
dose O 0 6.140609229987604e-07
- O 0 1.5467832099602674e-06
response O 0 4.0923460176145454e-08
plots O 0 6.148003990347206e-07
were O 0 3.535054474923527e-06
consistently O 0 1.4838340575806797e-05
obtained O 0 3.087320976646879e-08
, O 0 1.588458364842893e-09
suggesting O 0 1.5763021110615227e-08
some O 0 2.132959142642221e-09
inhibitory O 0 1.5978889678081032e-07
effect O 0 1.87673720120074e-07
. O 0 6.835347221567645e-08

Further O 0 2.2442213776230346e-06
studies O 0 4.326395810494432e-07
suggested O 0 2.0193044747429667e-07
that O 0 7.914361610517062e-09
low O 0 2.13679368243902e-06
dilutions O 0 1.1366913895471953e-05
of O 0 1.4210277754500567e-07
C5D B-Disease 1 1.0
serum O 0 3.2927833672147244e-05
contain O 0 2.4206613602473226e-07
a O 0 2.0529778765876472e-08
factor O 0 6.019507026167048e-08
( O 0 3.4648697244676896e-09
or O 0 2.9128765177688365e-08
factors O 0 2.6895756732869813e-08
) O 0 9.944641776726826e-10
interfering O 0 3.723963359902882e-08
at O 0 2.3111592639679657e-08
some O 0 1.339020005985958e-09
step O 0 1.7571073485100897e-08
in O 0 6.896945237144791e-10
the O 0 7.238162513800717e-09
hemolytic O 0 2.3498807877331274e-06
assay O 0 2.1982897635552945e-07
of O 0 4.812000131693139e-09
C5 O 0 3.413449121580925e-06
, O 0 1.3754469563309613e-08
rather O 0 1.829742579673166e-08
than O 0 2.147241939809419e-09
a O 0 1.4694853334162872e-08
true O 0 1.065770405261901e-07
C5 O 0 3.2631935482640984e-06
inhibitor O 0 6.193865829118295e-07
or O 0 4.169982048551901e-07
inactivator O 0 4.109552173758857e-05
. O 0 6.115858468547231e-07

Of O 0 2.1618195944483887e-07
clinical O 0 8.797189366305247e-06
interest O 0 1.0120270843572143e-07
are O 0 2.0039372827795887e-08
( O 0 2.185082559336138e-09
a O 0 5.3150932544099305e-09
) O 0 1.0000011929633956e-09
the O 0 8.65806870642416e-10
documentation O 0 7.1334277151891e-08
of O 0 1.8647707378249834e-08
membranous O 1 0.9855741858482361
glomerulonephritis B-Disease 1 1.0
, O 0 8.620771041023545e-06
vasculitis B-Disease 1 1.0
, O 0 6.130790097813588e-07
and O 0 0.0005303841317072511
arthritis B-Disease 1 1.0
in O 0 6.929834928115497e-09
an O 0 1.7720465095294458e-09
individual O 0 4.432060762837864e-08
lacking O 0 5.735068953072187e-07
C5 O 0 8.728861189410964e-07
( O 0 5.3280748701922676e-09
and O 0 1.1564141866315936e-09
its O 0 8.141263774241736e-10
biologic O 0 1.6588748152912558e-08
functions O 0 7.734977991447067e-09
) O 0 1.9079360313867255e-09
, O 0 1.17248499797995e-09
and O 0 1.6592544227478356e-08
( O 0 2.237127461057753e-08
b O 0 3.7597199025185546e-06
) O 0 5.146435499980839e-10
a O 0 8.456956801516924e-10
remarkable O 0 2.7097810217924234e-08
propensity O 0 1.3462984043144388e-06
to O 0 2.883166644096491e-06
bacterial B-Disease 1 1.0
infections I-Disease 1 1.0
in O 0 8.368165715921805e-09
the O 0 8.469067225291838e-09
proband O 0 2.120650378856226e-06
, O 0 1.6131898039617454e-09
even O 0 4.592982438822446e-09
during O 0 5.835439242929397e-09
periods O 0 3.384491265023826e-08
of O 0 2.072206628511708e-09
low O 0 0.00030544149922207
- O 0 7.727260526735336e-05
dose O 0 1.0722252454797854e-06
or O 0 3.4894299005827634e-08
alternate O 0 1.196458896401964e-07
- O 0 6.646886504313443e-06
day O 0 2.5515373636153527e-07
corticosteroid O 0 4.1556810174370185e-05
therapy O 0 2.9451524824253283e-05
. O 0 2.8406068963704456e-07

Other O 0 2.0312793935772788e-07
observations O 0 9.068332929018652e-07
indicate O 0 1.9762792362598702e-06
that O 0 3.8022371917634246e-09
the O 0 2.1552400752966605e-08
C5D B-Disease 1 1.0
state O 0 3.2421549889249945e-09
is O 0 4.854801005649279e-10
compatible O 0 2.831507650569165e-08
with O 0 2.018913924928256e-09
normal O 0 8.678016172325442e-08
coagulation O 0 1.1765947505182339e-07
function O 0 7.005856161867996e-08
and O 0 1.560209561546344e-08
the O 0 1.255342718664565e-09
capacity O 0 2.6227942040435437e-09
to O 0 1.897035417641746e-09
mount O 0 7.239946171466727e-07
a O 0 3.890473294632102e-07
neutrophilic O 0 0.0556582510471344
leukocytosis O 0 0.0006507073412649333
during O 0 4.229709247738356e-06
pyogenic B-Disease 1 0.6763517260551453
infection I-Disease 1 0.8583763241767883
. O 0 6.793560203277593e-08
. O 0 1.2350542988315283e-07

Susceptibility O 0 0.0035158542450517416
to O 0 1.3009262147534173e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
in O 0 5.576343755819835e-05
twins O 0 0.0007286438485607505
: O 0 4.847567236510031e-09
the O 0 5.011814296906891e-10
role O 0 2.6878357317627888e-09
of O 0 2.991703551558089e-10
genes O 0 2.7682803604989203e-08
, O 0 1.1051684012386431e-09
HLA O 0 9.568275061155873e-08
, O 0 2.4952235833097802e-09
and O 0 3.9166678789115394e-09
the O 0 6.493732218615378e-09
environment O 0 2.038949702409809e-07
. O 0 6.646435934953843e-08

OBJECTIVE O 0 1.177901322080288e-05
To O 0 5.07015229800345e-08
determine O 0 5.122526047784959e-08
the O 0 4.265586994733894e-09
relative O 0 7.538915269833524e-08
effects O 0 1.6728398577470216e-07
of O 0 5.666826452532803e-10
genetic O 0 4.859753062191885e-07
and O 0 8.816150476320672e-09
environmental O 0 2.1432208896499105e-08
factors O 0 2.617168703977768e-08
in O 0 3.1079807616407606e-09
susceptibility O 0 1.8326929421164095e-05
to O 0 1.772235191310756e-05
ankylosing B-Disease 1 1.0
spondylitis I-Disease 1 1.0
( O 0 0.002340062288567424
AS B-Disease 1 0.9999991655349731
) O 0 4.958694788115281e-08
. O 0 6.297893406781441e-08

METHODS O 0 0.00031904783099889755
Twins O 0 0.01256300788372755
with O 0 4.814311296286178e-07
AS B-Disease 1 0.9999991655349731
were O 0 2.6904842798103346e-06
identified O 0 1.32357129700722e-07
from O 0 8.226082592877049e-10
the O 0 1.466421539753071e-09
Royal O 0 4.2944552802737235e-08
National O 0 1.1451572845544433e-07
Hospital O 0 8.400886599702062e-07
for O 0 3.223049205303141e-08
Rheumatic B-Disease 1 0.9545730948448181
Diseases I-Disease 0 0.00014125867164693773
database O 0 7.518028724007308e-07
. O 0 1.1648072018033417e-07

Clinical O 0 0.0019089070847257972
and O 0 1.3225471775513142e-06
radiographic O 0 0.0002647142100613564
examinations O 0 0.1018025353550911
were O 0 5.314692316460423e-06
performed O 0 5.17946034506167e-07
to O 0 3.1240814379884796e-09
establish O 0 8.122812005240121e-07
diagnoses O 0 0.18631087243556976
, O 0 7.768247911599246e-08
and O 0 4.231052571412874e-06
disease O 0 0.3726828396320343
severity O 0 0.00010297477274434641
was O 0 2.4358673726965208e-06
assessed O 0 9.554561586355703e-08
using O 0 3.358985978252349e-08
a O 0 1.1795558307881038e-08
combination O 0 6.822791220884028e-08
of O 0 2.340462712524527e-09
validated O 0 1.214714529851335e-06
scoring O 0 3.378629480721429e-05
systems O 0 1.3655909242515918e-05
. O 0 2.2659392584500893e-07

HLA O 0 0.00021785785793326795
typing O 0 3.6804198316531256e-05
for O 0 1.0947340456368693e-07
HLA O 0 5.699155735783279e-06
- O 0 2.1395178464445053e-06
B27 O 0 1.4186043699737638e-06
, O 0 7.761046916243686e-09
HLA O 0 3.120084670626966e-07
- O 0 2.806897327900515e-07
B60 O 0 2.9273169843690994e-07
, O 0 1.7342456359870084e-09
and O 0 5.7296927202799e-09
HLA O 0 8.687652552907821e-07
- O 0 5.877369403606281e-06
DR1 O 0 0.00019213222549296916
was O 0 2.8289824172134104e-07
performed O 0 5.778247924581592e-08
by O 0 6.239742611491295e-10
polymerase O 0 6.529926821485788e-08
chain O 0 1.0156954743933966e-07
reaction O 0 8.445805832479891e-09
with O 0 2.3957640316041307e-09
sequence O 0 8.076498403397636e-08
- O 0 1.89747481726954e-07
specific O 0 3.6395437774672246e-08
primers O 0 7.631085281900596e-06
, O 0 1.9701765552326833e-08
and O 0 3.7830183430287434e-08
zygosity O 0 1.1671389074763283e-05
was O 0 1.6196844399019028e-07
assessed O 0 8.650302874002591e-08
using O 0 1.7007900510179752e-07
microsatellite O 0 0.00011074299254687503
markers O 0 0.00028278579702600837
. O 0 9.535806384519674e-07

Genetic O 0 0.00010558842768659815
and O 0 1.98155845509973e-07
environmental O 0 3.85452061379965e-08
variance O 0 1.9620465252501162e-08
components O 0 2.3450900243915385e-06
were O 0 6.254213076317683e-07
assessed O 0 2.8490166670280814e-08
with O 0 8.129222850428164e-10
the O 0 2.5265824987741325e-09
program O 0 2.4459408720645115e-08
Mx O 0 9.81211883299693e-07
, O 0 7.593443651643383e-10
using O 0 1.8344381569335155e-09
data O 0 5.6677730952969796e-08
from O 0 9.900961162045974e-10
this O 0 3.062743392234779e-10
and O 0 1.0574619402348162e-08
previous O 0 1.4499384803912108e-07
studies O 0 1.8710197835503095e-08
of O 0 4.325757974044109e-09
twins O 0 0.00013689672050531954
with O 0 6.386050444007196e-08
AS B-Disease 1 0.9999998807907104
. O 0 2.6732053015621204e-07

RESULTS O 0 0.00014846738486085087
Six O 0 4.93636321152735e-07
of O 0 1.1121130683022784e-08
8 O 0 2.4808466037029575e-07
monozygotic O 0 9.025771760207135e-06
( O 0 1.256460109289037e-07
MZ O 1 0.8097532391548157
) O 0 5.1206697548877855e-08
twin O 0 3.399650449864566e-05
pairs O 0 4.5443839553627186e-06
were O 0 1.1418390386097599e-05
disease O 0 1.4906916476320475e-05
concordant O 0 4.179476604804222e-07
, O 0 4.837887424002929e-09
compared O 0 2.322321179804021e-08
with O 0 2.4836663836680373e-09
4 O 0 1.0507989145480678e-08
of O 0 2.300830637125273e-09
15 O 0 1.4281155813478108e-07
B27 O 0 5.0382236622681376e-06
- O 0 2.6069084924529307e-05
positive O 0 2.8155514542049787e-07
dizygotic O 0 8.409964721067809e-06
( O 0 5.4760803891440446e-08
DZ O 0 8.684262866154313e-05
) O 0 1.667614668576789e-08
twin O 0 3.945047410525149e-06
pairs O 0 5.285328938953171e-07
( O 0 9.694215208355672e-09
27 O 0 5.451007822898646e-08
% O 0 6.456261747445069e-09
) O 0 9.960398061892306e-10
and O 0 3.7498990579365454e-09
4 O 0 7.81049802611733e-09
of O 0 2.1356867385691203e-09
32 O 0 1.1923790452783578e-06
DZ O 0 0.2309732884168625
twin O 0 0.00015426450408995152
pairs O 0 2.780297791105113e-06
overall O 0 1.9306739886815194e-06
( O 0 1.1939428112839323e-08
12 O 0 2.3422412454010555e-08
. O 0 1.1288633361417055e-09
5 O 0 9.453227534095276e-09
% O 0 1.5473741399318897e-08
) O 0 1.3876578996985245e-08
. O 0 4.3346801703592064e-08

Nonsignificant O 0 0.00021510437363758683
increases O 0 2.0215138647472486e-06
in O 0 4.0089140895815945e-09
similarity O 0 1.4604489173564161e-08
with O 0 1.222435153103163e-09
regard O 0 5.935207880725102e-09
to O 0 7.460181805640786e-09
age O 0 5.80126697968808e-06
at O 0 1.9896453977708006e-06
disease O 0 0.000560679764021188
onset O 0 4.693885784945451e-06
and O 0 6.072851999050499e-09
all O 0 9.82930847825969e-10
of O 0 4.768598294013771e-10
the O 0 1.9632636849564733e-07
disease O 0 0.0028931195847690105
severity O 0 6.89525450070505e-06
scores O 0 2.5549112251610495e-05
assessed O 0 1.5764532008688548e-06
were O 0 7.991900474735303e-07
noted O 0 5.149033199813857e-08
in O 0 5.449438233995352e-08
disease O 0 0.009801482781767845
- O 0 0.0007354672998189926
concordant O 0 0.0015215876046568155
MZ O 1 0.999966025352478
twins O 0 0.0004278826236259192
compared O 0 8.365972234969377e-07
with O 0 1.8137318136268732e-07
concordant O 0 0.00037609125138260424
DZ O 1 0.9959696531295776
twins O 0 0.000518878863658756
. O 0 4.646762192805909e-07

HLA O 0 0.0046998863108456135
- O 0 0.0002530810597818345
B27 O 0 1.3058596778137144e-05
and O 0 1.369174640331039e-07
B60 O 0 1.8640029111338663e-06
were O 0 1.2002817584289005e-07
associated O 0 8.906710036171717e-09
with O 0 2.155313039153839e-09
the O 0 3.316049301815838e-08
disease O 0 7.356733476626687e-06
in O 0 8.738699763810587e-10
probands O 0 1.2170497711849748e-06
, O 0 2.203871751760289e-09
and O 0 1.9386212635197353e-09
the O 0 3.3937916921189526e-09
rate O 0 1.1633899248408852e-06
of O 0 3.499592837741261e-09
disease O 0 7.098132641658594e-07
concordance O 0 4.9068731300394575e-08
was O 0 6.534936147772896e-08
significantly O 0 4.337119818842439e-08
increased O 0 4.116033736067948e-08
among O 0 3.7902772476172686e-08
DZ O 0 0.0015497803688049316
twin O 0 1.682137190073263e-05
pairs O 0 1.5341299786086893e-07
in O 0 1.5925173402209225e-09
which O 0 3.999207631721902e-09
the O 0 3.008897309086933e-08
co O 0 3.936022039852105e-05
- O 0 3.646302502602339e-05
twin O 0 0.0013674189103767276
was O 0 2.771477625174157e-07
positive O 0 6.314671008311734e-09
for O 0 1.0627611013447336e-09
both O 0 2.098146367757181e-08
B27 O 0 1.3729577403864823e-06
and O 0 9.2851998090282e-08
DR1 O 0 0.0007276394753716886
. O 0 3.961788479500683e-07

Additive O 0 3.4489232348278165e-05
genetic O 0 1.2344517017481849e-05
effects O 0 7.146546977310209e-06
were O 0 2.7469872065921663e-07
estimated O 0 7.89271492607213e-09
to O 0 2.2781450059738972e-09
contribute O 0 1.9601088752096985e-08
97 O 0 7.055150064161353e-08
% O 0 1.139765881674748e-08
of O 0 1.0253784488156725e-09
the O 0 1.095824053720662e-08
population O 0 1.8369741283663643e-08
variance O 0 1.4155040162222576e-07
. O 0 1.442559494080342e-07

CONCLUSION O 0 9.473820682615042e-06
Susceptibility O 0 1.1281544175290037e-05
to O 0 3.588152139855083e-07
AS B-Disease 1 0.9999963045120239
is O 0 8.884619262516935e-09
largely O 0 2.4429709810647182e-08
genetically O 0 2.0910947640118138e-08
determined O 0 5.74955443255476e-08
, O 0 5.2898668778667e-10
and O 0 1.0597228650155444e-09
the O 0 9.39738509231347e-10
environmental O 0 9.898283970244393e-09
trigger O 0 8.235005566348264e-07
for O 0 3.32770566657814e-09
the O 0 1.5244560813698627e-07
disease O 0 3.78422046196647e-05
is O 0 3.1025377822402334e-09
probably O 0 5.863826402219274e-08
ubiquitous O 0 9.490715342508338e-07
. O 0 8.30165305387709e-08

HLA O 0 0.0010077538900077343
- O 0 0.00012341458932496607
B27 O 0 5.215378223510925e-06
accounts O 0 1.3023368694575765e-07
for O 0 5.870489649950628e-10
a O 0 2.0310646497989637e-09
minority O 0 7.239170596307076e-09
of O 0 2.6420732268661595e-10
the O 0 1.905408497648864e-09
overall O 0 6.251476634133724e-07
genetic O 0 5.800934559374582e-06
susceptibility O 0 2.536836746003246e-06
to O 0 8.719642323740118e-07
AS B-Disease 1 0.9999998807907104
. O 0 5.507225750989164e-07

Cell O 0 0.0013053094735369086
cycle O 0 8.490102482028306e-05
- O 0 1.1617342352110427e-05
dependent O 0 1.4713469909111154e-06
colocalization O 0 6.616369887524343e-07
of O 0 3.310581142557112e-09
BARD1 O 0 2.205547843914246e-06
and O 0 1.9438354925682688e-08
BRCA1 O 0 2.659400479387841e-06
proteins O 0 1.5418031296121626e-08
in O 0 2.5901816247397846e-09
discrete O 0 3.8576473571083625e-07
nuclear O 0 1.16581622933154e-05
domains O 0 6.458206826209789e-06
. O 0 4.944434408571396e-07

Germ O 0 0.005858161486685276
- O 0 0.0011510963086038828
line O 0 9.746195246407297e-06
mutations O 0 5.837039225298213e-07
of O 0 5.622855514531011e-10
the O 0 2.8663809104045868e-09
BRCA1 O 0 6.873011443531141e-06
gene O 0 3.4495212730689673e-07
predispose O 0 5.742950293097238e-07
women O 0 9.386430122049205e-08
to O 0 6.496308824210928e-09
early O 0 2.151457010768354e-06
- O 1 0.9927592277526855
onset O 1 0.999963641166687
breast B-Disease 1 1.0
and I-Disease 1 0.9999958276748657
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
by O 0 8.402391671324949e-09
compromising O 0 2.166311787732411e-06
the O 0 5.403738789766521e-09
genes O 0 5.429600378192845e-07
presumptive O 0 1.0580959497019649e-05
function O 0 1.1448646830558573e-07
as O 0 2.7460041351901054e-08
a O 0 1.3263070286484435e-07
tumor B-Disease 0 3.0050405257497914e-05
suppressor O 0 7.769278454361483e-06
. O 0 1.586479640991456e-07

Although O 0 1.524437152511382e-06
the O 0 1.4728272823560928e-08
biochemical O 0 1.5950418230659125e-07
properties O 0 3.771498313653865e-08
of O 0 1.9915373794532343e-09
BRCA1 O 0 1.2412278010742739e-05
polypeptides O 0 2.637791567394743e-07
are O 0 1.3850718794117256e-08
not O 0 1.3344721772057255e-08
understood O 0 1.4861238462060555e-08
, O 0 1.783894559848065e-10
their O 0 1.920975600810948e-09
expression O 0 1.7624206094524197e-08
pattern O 0 5.137369498697808e-07
and O 0 1.2174168340095548e-08
subcellular O 0 4.761177933687577e-06
localization O 0 1.0183000540564535e-06
suggest O 0 2.1202691868893453e-07
a O 0 2.4947583554535413e-08
role O 0 9.39151547640904e-08
in O 0 1.1649955666825917e-08
cell O 0 4.530139449343551e-06
- O 0 7.118735811673105e-05
cycle O 0 6.9952266130712815e-06
regulation O 0 1.155752897830098e-06
. O 0 1.1787770404225739e-07

When O 0 7.354172794293845e-06
resting O 0 1.840408003772609e-05
cells O 0 4.483038651414972e-07
are O 0 5.077291476140999e-09
induced O 0 1.2230543688929174e-07
to O 0 4.814322718260655e-09
proliferate O 0 4.377921868581325e-06
, O 0 2.4891153582728975e-09
the O 0 2.2818109624012095e-09
steady O 0 1.8947201851915452e-06
- O 0 1.408769065847082e-07
state O 0 2.7170823369004893e-09
levels O 0 1.977155861254687e-08
of O 0 4.6448259127807034e-10
BRCA1 O 0 2.1205158873272012e-07
increase O 0 5.975623551535136e-09
in O 0 2.9145255098228517e-09
late O 0 1.1638388741630479e-07
G1 O 0 1.3651982726514689e-06
and O 0 2.035219104357111e-08
reach O 0 5.50840830726429e-08
a O 0 9.064865302832459e-09
maximum O 0 3.373599355427359e-08
during O 0 3.5502745276971837e-07
S O 0 4.2234361899318174e-05
phase O 0 1.0512438848309102e-06
. O 0 1.1562375590301599e-07

Moreover O 0 3.122730413451791e-05
, O 0 2.5379833346050873e-07
in O 0 2.1541056938190195e-08
S O 0 3.138320380458026e-06
phase O 0 4.051610744681966e-07
cells O 0 2.0133568057190132e-07
, O 0 2.9571438631137426e-09
BRCA1 O 0 1.3465885331243044e-06
polypeptides O 0 3.220272333237517e-07
are O 0 2.6016405030304668e-08
hyperphosphorylated O 0 9.72022917267168e-07
and O 0 3.63171501760462e-08
accumulate O 0 1.511306436441373e-06
into O 0 1.7713682964881627e-08
discrete O 0 5.587911005022761e-07
subnuclear O 0 1.4209455912350677e-05
foci O 0 1.1261218787694816e-05
termed O 0 5.320904620020883e-06
" O 0 7.670571449125418e-07
BRCA1 O 0 3.227612978662364e-05
nuclear O 0 9.263976608053781e-06
dots O 0 0.00011371936125215143
. O 0 8.221163625421468e-07

" O 0 9.684544238552917e-06
BRCA1 O 0 0.000163215197972022
associates O 0 6.611364369746298e-06
in O 0 1.8517523514560708e-08
vivo O 0 3.2425637073174585e-06
with O 0 5.740872222048665e-09
a O 0 5.8777786193786596e-08
structurally O 0 1.697543302725535e-05
related O 0 1.0183122611806539e-07
protein O 0 5.424424784905568e-07
termed O 0 6.654618573520565e-06
BARD1 O 0 0.0001582435506861657
. O 0 2.976346138439112e-07

Here O 0 2.335735871383804e-06
we O 0 8.595780798259511e-08
show O 0 2.7447265793512088e-08
that O 0 4.970602263121293e-10
the O 0 8.632906056682543e-10
steady O 0 8.822494237392675e-07
- O 0 2.166686527971251e-07
state O 0 3.1997715588261144e-09
levels O 0 1.1905499697206778e-08
of O 0 3.8275421720967984e-10
BARD1 O 0 2.764592750281736e-07
, O 0 5.656201063075628e-10
unlike O 0 1.7288525056002868e-09
those O 0 8.737700007976912e-10
of O 0 3.573395745970487e-10
BRCA1 O 0 2.3722309379081707e-06
, O 0 1.1807061106594574e-08
remain O 0 4.4706570889729846e-08
relatively O 0 3.182165642101609e-08
constant O 0 9.877033591010331e-08
during O 0 4.0651414678904985e-07
cell O 0 6.902619497850537e-05
cycle O 0 8.657019498059526e-05
progression O 0 1.8837799871107563e-05
. O 0 4.3726461740334344e-07

However O 0 4.163006451562978e-06
, O 0 6.903822225012846e-08
immunostaining O 0 2.5656236175564118e-06
revealed O 0 3.5415601473687275e-07
that O 0 7.656902667463328e-09
BARD1 O 0 5.093063919048291e-06
resides O 0 1.587743412301279e-07
within O 0 2.1649551484870244e-08
BRCA1 O 0 5.681188667949755e-06
nuclear O 0 6.977031716814963e-07
dots O 0 1.8588033299238305e-06
during O 0 2.4747168936301023e-07
S O 0 9.338515383205959e-07
phase O 0 1.9177512911028316e-08
of O 0 4.827681032715248e-10
the O 0 4.1581369458754125e-09
cell O 0 6.339787432807498e-07
cycle O 0 4.1385803228877194e-07
, O 0 2.228383477742568e-09
but O 0 1.2501718549273733e-09
not O 0 1.4945200632610067e-09
during O 0 3.3028231261056362e-09
the O 0 5.72711433832751e-09
G1 O 0 8.168931344698649e-06
phase O 0 7.079142960719764e-07
. O 0 2.3725809228380967e-07

Nevertheless O 0 2.925716580648441e-05
, O 0 6.953670350640095e-08
BARD1 O 0 2.9648374493262963e-06
polypeptides O 0 3.653500186828751e-07
are O 0 1.5177954892919843e-08
found O 0 5.175309070182266e-09
exclusively O 0 3.2199198862770118e-09
in O 0 3.669834991448795e-10
the O 0 1.0055938304276424e-09
nuclear O 0 3.861157793494385e-08
fractions O 0 1.3574351420686526e-08
of O 0 6.118191508974746e-10
both O 0 7.69140218181974e-09
G1 O 0 2.6190621156274574e-06
- O 0 4.038859060528921e-06
and O 0 1.4920463797807315e-07
S O 0 1.8732156604528427e-05
- O 0 1.947416649272782e-06
phase O 0 8.834500704324455e-07
cells O 0 9.720525895318133e-07
. O 0 1.6797844182292465e-07

Therefore O 0 7.141798505472252e-06
, O 0 5.602350583444604e-08
progression O 0 3.689427501285536e-07
to O 0 2.241984375928041e-08
S O 0 1.834436261560768e-05
phase O 0 2.7188599460714613e-07
is O 0 3.50420181760569e-09
accompanied O 0 1.623574696907326e-08
by O 0 5.31340749176934e-10
the O 0 8.424115294225487e-10
aggregation O 0 2.312239466562005e-08
of O 0 2.75712364050662e-09
nuclear O 0 2.132008148691966e-06
BARD1 O 0 3.364729991517379e-06
polypeptides O 0 3.9880430335870187e-07
into O 0 6.277829101009047e-08
BRCA1 O 0 3.149470649077557e-05
nuclear O 0 6.301122994045727e-06
dots O 0 3.0086679544183426e-05
. O 0 5.163313403500069e-07

This O 0 4.760960337080178e-07
cell O 0 4.690323748945957e-06
cycle O 0 7.3964311013696715e-06
- O 0 1.9195426830265205e-06
dependent O 0 4.304731362481107e-07
colocalization O 0 5.515682914847275e-07
of O 0 3.1393851962491226e-09
BARD1 O 0 7.614344212925062e-06
and O 0 4.2318450965694865e-08
BRCA1 O 0 6.606525130337104e-05
indicates O 0 1.3464675419072591e-07
a O 0 6.515493033987241e-09
role O 0 2.157247180889499e-08
for O 0 4.42482805951272e-09
BARD1 O 0 3.421701649131137e-06
in O 0 2.026360412799022e-08
BRCA1 O 0 0.0012748215813189745
- O 0 0.0006025806069374084
mediated O 0 0.0010208323365077376
tumor B-Disease 0 0.00019877862359862775
suppression O 0 2.308961938979337e-06
. O 0 2.601703101845487e-07

Ethnic O 0 9.57191878114827e-06
differences O 0 4.830605575989466e-06
in O 0 4.299782574435085e-08
the O 0 7.38538972200331e-08
HFE O 0 0.00012732853065244853
codon O 0 6.023009063937934e-06
282 O 0 1.6287035577988718e-06
( O 0 3.5455983038445993e-07
Cys O 0 0.00047290310612879694
/ O 0 3.612311775214039e-05
Tyr O 0 2.44906623265706e-05
) O 0 1.2711072372439958e-07
polymorphism O 0 1.7922260667546652e-05
. O 0 8.563590085941541e-07

Recent O 0 8.089839980129909e-07
studies O 0 1.9539001527846267e-07
have O 0 5.343842701677204e-08
shown O 0 1.6905133293221297e-07
that O 0 6.760275255146553e-07
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
( O 0 0.0013035614974796772
HH B-Disease 1 0.9768596291542053
) O 0 1.2857602094129561e-08
is O 0 2.4096131756579098e-09
likely O 0 2.0717173754292162e-08
to O 0 7.948004920876883e-09
be O 0 2.912405534516438e-07
caused O 0 1.0572969699751411e-07
by O 0 1.6323239426796476e-09
homozygosity O 0 5.35534240952984e-07
for O 0 9.341841744614499e-10
a O 0 1.6505204314398725e-08
Cys282Tyr O 0 5.066342509962851e-06
mutation O 0 8.092317216323863e-07
in O 0 2.6745445858011863e-09
the O 0 1.4996349051443758e-08
HFE O 0 1.6159370716195554e-05
gene O 0 4.671248632348579e-07
located O 0 2.6677068376557145e-07
4 O 0 2.280777238183873e-07
. O 0 2.2748599803890102e-07

5 O 0 2.1826877855346538e-05
Mb O 0 5.073994543636218e-05
telomeric O 0 0.00017483199189882725
to O 0 8.47651961066731e-07
HLA O 0 0.00012503551261033863
- O 0 0.0001236520620295778
A O 0 9.692478215583833e-07
. O 0 1.6585052264872502e-07

Population O 0 2.515143933123909e-06
studies O 0 4.330093972271243e-08
of O 0 7.380285826918964e-10
this O 0 3.9970393661548087e-10
polymorphism O 0 6.122376703387999e-07
are O 0 1.0202092504130178e-08
facilitated O 0 6.738568814057544e-09
by O 0 1.2282570516219948e-09
the O 0 1.8142700675127799e-09
fact O 0 3.372542689561442e-09
that O 0 5.025838079042444e-10
the O 0 5.9294600340820125e-09
Cys282Tyr O 0 3.5290149753564037e-06
mutation O 0 6.43111263798346e-07
creates O 0 4.8633047811108554e-08
a O 0 1.745223343618818e-08
Rsal O 0 1.6525324326721602e-06
restriction O 0 2.2831538615264435e-07
site O 0 5.743119686485443e-07
. O 0 1.716175717092483e-07

We O 0 1.3304231288202573e-05
have O 0 5.4232149437893895e-08
studied O 0 7.75871171754261e-08
the O 0 1.3601226811488232e-08
codon O 0 1.9814235656667734e-06
282 O 0 7.330334028665675e-07
( O 0 9.53593684016596e-08
Cys O 0 0.0001560046657687053
/ O 0 1.7019763618009165e-05
Tyr O 0 5.016997874918161e-06
) O 0 8.07513877987276e-09
polymorphism O 0 2.6638349481800105e-07
in O 0 2.673932630870013e-09
different O 0 9.142376633519689e-09
ethnic O 0 5.819647697080654e-08
groups O 0 1.4884705024087452e-07
. O 0 1.1856781867436439e-07

In O 0 5.645642886520363e-07
agreement O 0 8.226373182651514e-08
with O 0 4.393778230138423e-09
previous O 0 6.592323131826561e-08
observations O 0 2.223038251258913e-07
the O 0 1.4338740861319366e-08
Tyr O 0 2.231197186119971e-06
allele O 0 5.9628177950799e-07
appeared O 0 1.4461987518643582e-07
to O 0 1.928166515341445e-09
be O 0 3.6872089825834564e-09
rare O 0 2.9991780170490756e-09
or O 0 6.720684382344189e-07
absent O 0 1.1178143495271797e-06
in O 0 1.4529547565089729e-09
Asiatic O 0 2.134905940920362e-08
( O 0 9.2443186439084e-10
Indian O 0 1.9201293888215787e-09
, O 0 7.178941330288069e-10
Chinese O 0 1.1720937553860722e-09
) O 0 3.466449571831731e-09
populations O 0 6.544715347445162e-08
. O 0 2.041513269546158e-08

The O 0 4.702752107732522e-07
highest O 0 5.697796154890966e-07
allele O 0 4.870601060247282e-07
frequency O 0 2.548903239585343e-07
( O 0 4.973649048167772e-09
7 O 0 8.30453217304239e-09
. O 0 4.925810315192791e-10
5 O 0 4.555927191063347e-09
% O 0 7.312512817492234e-09
) O 0 3.021870975672414e-09
was O 0 2.415297615243617e-07
found O 0 2.990052294649104e-08
in O 0 7.117537670353613e-09
Swedes O 0 7.454149454133585e-06
. O 0 1.7504481775176828e-07

Saamis O 0 0.00019784907635767013
( O 0 3.94962597738413e-07
2 O 0 1.3692935851850052e-07
% O 0 2.8448571498529418e-08
) O 0 2.5374196077621036e-09
and O 0 5.381685763694577e-09
Mordvinians O 0 5.735370223192149e-07
( O 0 1.1399283739166322e-09
1 O 0 1.7610052305272461e-09
. O 0 2.4758139982594685e-10
8 O 0 4.96897412105568e-09
% O 0 2.028780254903495e-09
) O 0 1.163482754584777e-09
had O 0 5.600897168278607e-08
significantly O 0 4.2601900673844284e-08
lower O 0 2.938658205664524e-08
frequencies O 0 1.026097393719283e-07
of O 0 2.228315310048856e-09
the O 0 3.8068904473220755e-08
Tyr O 0 6.6949960455531254e-06
allele O 0 3.4365159535809653e-06
. O 0 1.412457777405507e-07

Comparisons O 0 4.285702289053006e-06
with O 0 1.131900049244905e-07
allele O 0 8.98043765573675e-07
frequencies O 0 4.4102372953602753e-07
based O 0 1.1064301475016691e-08
on O 0 1.623104139980569e-08
prevalence O 0 6.377387308020843e-06
estimates O 0 8.784832772334994e-08
of O 0 7.16798620459258e-09
HH B-Disease 1 0.9862197637557983
showed O 0 9.183454494632315e-06
some O 0 1.4426765337915981e-09
disagreements O 0 2.1269036665216845e-07
with O 0 2.4575510515489896e-09
the O 0 4.402947340054197e-09
RFLP O 0 4.0495351640856825e-06
data O 0 3.701427431224147e-07
, O 0 6.490190607166824e-09
particularly O 0 1.5879139780849982e-08
in O 0 7.036655702563621e-09
Finns O 0 7.236057172121946e-06
. O 0 1.66034098469936e-07

The O 0 3.9478220514865825e-07
newly O 0 1.3216115348768653e-06
described O 0 2.700484174056328e-07
HFE O 0 2.5576706320862286e-05
marker O 0 8.941280498220294e-07
provides O 0 9.85958159560596e-09
a O 0 3.001662030044372e-09
new O 0 1.2787184644480476e-09
approach O 0 9.361109221117658e-09
to O 0 1.1872249849886884e-09
the O 0 4.2058095894859093e-10
screening O 0 2.1719447573786965e-08
of O 0 3.993711583660797e-09
HH B-Disease 0 0.0014422578969970345
as O 0 1.8135722257284215e-08
well O 0 2.1335301525482464e-08
as O 0 1.7692028952964733e-09
studies O 0 1.4060028696860627e-09
of O 0 1.1263292382102108e-10
the O 0 1.621290102171713e-09
relationship O 0 2.8936062435036547e-08
between O 0 1.0270113648402912e-08
the O 0 3.2748978640029236e-08
HFE O 0 0.0001574613415868953
Tyr O 0 1.8908465335698565e-06
allele O 0 4.7184258278321067e-07
and O 0 1.1193955984367676e-08
different O 0 1.0350272816594952e-07
disorders O 0 0.14443166553974152
including O 0 2.0186432720947778e-06
cancer B-Disease 0 0.016519838944077492

Autosomal B-Disease 1 0.9999716281890869
dominant I-Disease 1 0.995306670665741
neurohypophyseal I-Disease 1 0.9990977048873901
diabetes I-Disease 1 0.9999997615814209
insipidus I-Disease 1 0.9998387098312378
associated O 0 3.0092649467405863e-05
with O 0 2.9017195757319314e-08
a O 0 5.6810307569321594e-08
missense O 0 2.4018379917833954e-05
mutation O 0 2.178767545046867e-06
encoding O 0 6.487365453722305e-07
Gly23 O 0 5.6285731261596084e-05
- O 0 0.00022307153267320246
- O 0 9.488467912888154e-05
> O 0 2.094487399517675e-06
Val O 0 5.916671943850815e-05
in O 0 1.384926946457199e-07
neurophysin O 0 8.087795868050307e-05
II O 0 2.8864880732726306e-05
. O 0 1.7753229997197195e-07

Autosomal B-Disease 1 0.9999843835830688
dominant I-Disease 1 0.998961329460144
neurohypophyseal I-Disease 1 0.9996428489685059
diabetes I-Disease 1 0.9999998807907104
insipidus I-Disease 1 0.9999018907546997
( O 0 2.6779821382660884e-06
ADNDI B-Disease 0 0.00020764379587490112
) O 0 2.1199289435003266e-08
is O 0 5.841073846823974e-09
an O 0 1.947762484633131e-07
inherited B-Disease 1 1.0
disease I-Disease 1 1.0
caused O 0 1.9952128695877036e-06
by O 0 5.58669377426213e-09
progressive O 0 1.1241410902584903e-05
degeneration O 0 1.54391054820735e-05
of O 0 1.690485973426803e-09
the O 0 9.319529148399397e-09
magnocellular O 0 2.2364911274053156e-06
neurons O 0 9.105868770120651e-08
of O 0 5.84885306853522e-10
the O 0 1.792982873283222e-09
hypothalamus O 0 8.843842635997134e-08
leading O 0 4.4782012764699175e-08
to O 0 6.4739453797812985e-09
decreased O 0 1.3085733598927618e-06
ability O 0 5.322217333514345e-08
to O 0 4.555805510619848e-09
produce O 0 6.13138624316889e-08
the O 0 2.9965036674184375e-08
hormone O 0 1.2834848348575179e-06
arginine O 0 2.9453926231326477e-07
vasopressin O 0 2.5797288571993704e-07
( O 0 2.0950711387968113e-08
AVP O 0 2.125363835148164e-06
) O 0 4.9936989654497665e-08
. O 0 1.4482247934211046e-07

Affected O 0 7.125193951651454e-05
individuals O 0 3.125329044451064e-07
are O 0 1.314339392877173e-08
not O 0 9.405387579874969e-09
symptomatic O 0 3.135868098524952e-07
at O 0 7.079778185925534e-08
birth O 0 7.577168162242742e-06
, O 0 2.0627188845878663e-09
but O 0 7.367841892147453e-09
usually O 0 3.03955005165335e-07
develop O 0 3.1219351512845606e-05
diabetes B-Disease 1 0.9221016764640808
insipidus I-Disease 0 0.0031963016372174025
at O 0 1.1289595249763806e-06
1 O 0 4.3207219846408407e-07
- O 0 0.00011922282283194363
6 O 0 5.323953473634901e-07
yr O 0 6.440608558477834e-05
of O 0 1.2850148500831438e-08
age O 0 4.193414611108892e-07
. O 0 6.105560146352218e-08

The O 0 3.9884045577309735e-07
genetic O 0 1.8419372054268024e-06
locus O 0 1.0815338100655936e-06
of O 0 1.1374312158807243e-08
the O 0 1.0023489238619732e-07
disease O 0 0.00019117610645480454
is O 0 3.097157419418295e-09
the O 0 6.839361521571163e-09
AVP O 0 7.118749635992572e-05
- O 0 0.00016928400145843625
neurophysin O 0 5.362892261473462e-05
II O 0 9.469421456742566e-06
( O 0 1.958300366311505e-08
NPII O 0 7.29976477487071e-07
) O 0 2.097441109683018e-09
gene O 0 3.9781966165719496e-08
, O 0 9.745489970569565e-10
and O 0 7.2628201230884315e-09
mutations O 0 2.5122888018813683e-06
that O 0 6.053654910687101e-09
cause O 0 2.1340679268178064e-07
ADNDI B-Disease 0 3.298758383607492e-05
have O 0 7.939218562569295e-07
been O 0 1.6555375736970745e-07
found O 0 1.7789490769359873e-08
in O 0 3.547792892799606e-10
both O 0 2.797728271275446e-09
the O 0 1.084623835190257e-09
signal O 0 4.892388005828252e-08
peptide O 0 8.428731490539576e-09
of O 0 4.745995263455427e-10
the O 0 5.6732321063179825e-09
prepro O 0 1.8705079583014594e-06
- O 0 3.0175638130458537e-06
AVP O 0 1.5239432286762167e-05
- O 0 9.030420187627897e-06
NPII O 0 5.904948466195492e-06
precursor O 0 2.8325106882221007e-07
and O 0 4.8933493701497355e-08
within O 0 1.1527738053018766e-07
NPII O 0 2.0936962755513377e-05
itself O 0 4.785669602824782e-07
. O 0 1.1002225619449746e-07

An O 0 5.267726805868733e-07
affected O 0 4.431952220329549e-06
girl O 0 2.9983077183715068e-05
who O 0 4.0562881054029276e-08
presented O 0 4.879487480735634e-09
at O 0 2.990742231645527e-08
9 O 0 2.290620670919452e-08
months O 0 2.556794331809442e-09
of O 0 2.658000208821676e-10
age O 0 2.8112557970416674e-07
and O 0 1.1021964674284845e-08
her O 0 2.473900337918167e-07
similarly O 0 3.447827339186915e-07
affected O 0 8.645007909535707e-08
younger O 0 1.0183394039131599e-07
brother O 0 9.60913268954755e-08
and O 0 3.2827088602971344e-08
father O 0 8.155186606018106e-07
were O 0 7.018789460744301e-07
all O 0 1.3712498914131288e-09
found O 0 4.023192445856694e-09
to O 0 2.6075506198708354e-09
have O 0 7.039879790227133e-08
a O 0 1.4595772590553224e-08
novel O 0 8.625737990541893e-08
missense O 0 1.5555792742816266e-06
mutation O 0 4.940234248351771e-07
( O 0 8.193891787300345e-09
G1758 O 0 3.852242969060171e-07
- O 0 9.757681254995987e-06
- O 0 3.726153590832837e-05
> O 0 1.1355582500982564e-06
T O 0 2.9011441711190855e-06
) O 0 1.589755549424865e-09
encoding O 0 1.5141809583951726e-08
the O 0 8.139124929584796e-09
amino O 0 1.2525288184406236e-07
acid O 0 4.875592551911723e-08
substitution O 0 7.729436646286558e-08
Gly23 O 0 4.064884251420153e-06
- O 0 2.7115474949823692e-05
- O 0 2.6617613912094384e-05
> O 0 1.7686998035060242e-06
Val O 0 4.054891905980185e-05
within O 0 4.493062988331076e-07
NPII O 0 5.3581494285026565e-05
. O 0 3.1139995826379163e-07

The O 0 1.2284893955438747e-06
mutation O 0 1.8263857782585546e-05
was O 0 3.531411607582413e-07
confirmed O 0 3.521745028933765e-08
by O 0 2.544757737865666e-09
restriction O 0 5.1059821259968885e-08
endonuclease O 0 8.214641638915055e-06
analysis O 0 1.0719891179178376e-06
. O 0 4.512730527039821e-07

A O 0 7.184356491052313e-06
T1 O 0 0.00010616055806167424
- O 0 3.419842187213362e-06
weighted O 0 4.4089586026530014e-07
magnetic O 0 2.1000965944040217e-07
resonance O 0 2.39629628140392e-07
imaging O 0 7.481097327399766e-06
of O 0 1.529501325592264e-08
the O 0 1.9067587686549814e-07
fathers O 0 0.0028364527970552444
pituitary O 0 5.390719525166787e-05
gland O 0 3.34462902173982e-06
demonstrates O 0 1.3890857530896028e-07
an O 0 3.119748015478763e-08
attenuated O 0 0.0001853646244853735
posterior O 0 0.2481440007686615
pituitary O 0 0.06380670517683029
bright O 0 9.507604409009218e-05
spot O 0 0.0002011671313084662
. O 0 6.815786264269263e-07

This O 0 2.8375771421451645e-07
mutation O 0 6.086438588681631e-06
may O 0 9.208690698869759e-08
be O 0 1.2635581470021862e-09
valuable O 0 1.8513065525027628e-09
for O 0 2.845929047978757e-10
developing O 0 1.641929614493165e-08
models O 0 9.087893459991392e-08
of O 0 5.533150826408928e-09
dominantly B-Disease 0 0.17266522347927094
inherited I-Disease 1 0.8823968768119812
neurodegeneration I-Disease 1 1.0
, O 0 7.823946823748429e-09
as O 0 6.566190369206026e-10
the O 0 3.0328517475197714e-10
early O 0 5.016723036987969e-09
age O 0 1.250129688656898e-08
of O 0 1.9340221091290744e-10
onset O 0 3.1719055186840706e-06
of O 0 4.817307885929267e-09
symptoms O 0 6.632519944105297e-05
suggests O 0 1.4111996016197281e-08
that O 0 6.272940500373636e-10
this O 0 1.8294136205909695e-09
mutation O 0 4.547397111309692e-06
may O 0 1.504374012029075e-07
be O 0 3.94231536304801e-09
particularly O 0 6.7452816665536375e-09
deleterious O 0 4.296126689951052e-07
to O 0 7.97976706934378e-09
the O 0 2.9122489308974764e-08
magnocellular O 0 8.101064850052353e-06
neuron O 0 1.6578773056608043e-06
. O 0 2.970702084326149e-08
. O 0 1.0358250790432066e-07

Frequent O 0 0.00010483078949619085
inactivation O 0 9.395334200235084e-05
of O 0 2.482481988863583e-07
PTEN O 0 0.0001086312040570192
/ O 0 5.1418184739304706e-05
MMAC1 O 0 0.0001254133094334975
in O 0 5.852830895491934e-07
primary O 1 0.9999967813491821
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 9.336823723060661e-07

Sporadic B-Disease 1 0.9999996423721313
prostate I-Disease 1 1.0
carcinoma I-Disease 1 1.0
is O 0 6.192719865794061e-07
the O 0 2.0885786433666453e-09
most O 0 1.2353194023262404e-09
common O 0 4.0664204448148666e-08
male B-Disease 0 1.5231745237542782e-05
cancer I-Disease 0 1.1867431339851464e-06
in O 0 5.904504107867581e-10
the O 0 1.3312427826761564e-09
Western O 0 8.43123970639681e-09
world O 0 6.765551461285213e-07
, O 0 2.6853812506999475e-09
yet O 0 2.6519297868787817e-09
many O 0 1.7676707320113394e-10
of O 0 6.916016370706046e-11
the O 0 5.095673327737416e-10
major O 0 1.0263984329128562e-08
genetic O 0 1.2342512434315722e-07
events O 0 3.379395607794322e-08
involved O 0 3.219368949203272e-08
in O 0 1.6753671783220625e-09
the O 0 7.796908008117498e-09
progression O 0 3.6162356309432653e-07
of O 0 4.1979636433708833e-10
this O 0 1.7215672221126965e-09
often O 0 9.573123861628119e-06
fatal O 1 0.9772475361824036
cancer B-Disease 0 0.10189174115657806
remain O 0 5.77773505483492e-07
to O 0 1.7537056251626382e-08
be O 0 2.702965389289602e-07
elucidated O 0 1.150722073361976e-05
. O 0 1.7250167161364516e-07

Numerous O 0 1.6023270291043445e-05
cytogenetic O 0 0.0006804365548305213
and O 0 1.1562611916815513e-06
allelotype O 0 1.077323940990027e-05
studies O 0 4.1335550804433296e-07
have O 0 3.287176753019594e-07
reported O 0 1.95189258533901e-07
frequent O 0 2.836383600879344e-06
loss O 0 1.3441546116155223e-06
of O 0 4.045638934968565e-09
heterozygosity O 0 2.927262812590925e-06
on O 0 1.6354667309315118e-07
chromosomal O 0 0.40664976835250854
arm O 0 0.21144427359104156
10q O 0 1.1456894753791858e-05
in O 0 2.2065084692712844e-07
sporadic B-Disease 1 0.9999988079071045
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.0124805385203217e-06

Deletion O 0 0.00019286897440906614
mapping O 0 1.8090544472215697e-05
studies O 0 1.6523338217666605e-06
have O 0 5.054809548710182e-07
unambiguously O 0 6.987230881350115e-05
identified O 0 7.299486242118292e-07
a O 0 8.886686941877997e-09
region O 0 2.2590944226408283e-08
of O 0 1.2954607386816974e-09
chromosome O 0 1.133645127993077e-05
10q23 O 0 1.6692351323399635e-07
to O 0 1.558012030500322e-08
be O 0 3.0386683391725455e-08
the O 0 2.519431552272522e-09
minimal O 0 3.81148282713184e-07
area O 0 8.28166335509195e-08
of O 0 8.122624350903607e-09
loss O 0 8.245284561780863e-07
. O 0 6.23715408210046e-08

A O 0 3.704316213770653e-06
new O 0 2.701906112179131e-07
tumor B-Disease 0 7.53573294787202e-06
suppressor O 0 6.24459835307789e-06
gene O 0 1.2443439345588558e-06
, O 0 2.5833053030055453e-08
PTEN O 0 7.825688044249546e-06
/ O 0 5.815547410747968e-06
MMAC1 O 0 3.8164129364304245e-05
, O 0 2.6470898362163098e-08
was O 0 1.0198672839578649e-07
isolated O 0 4.188346736100357e-07
recently O 0 1.3555766997797036e-07
at O 0 1.757382150913145e-08
this O 0 6.056168899704062e-10
region O 0 5.395931701457357e-09
of O 0 8.383082006346854e-10
chromosome O 0 1.4836188711342402e-05
10q23 O 0 3.7291383137016965e-07
and O 0 1.9820493690758667e-08
found O 0 2.1724710919102108e-08
to O 0 4.735372982622721e-09
be O 0 2.084377115352254e-08
inactivated O 0 8.749950097808323e-08
by O 0 8.179646404649077e-10
mutation O 0 8.138849239003321e-08
in O 0 6.627900006606069e-09
three O 0 0.006340261083096266
prostate B-Disease 1 1.0
cancer I-Disease 1 1.0
cell O 0 9.731137834023684e-05
lines O 0 0.00020827433036174625
. O 0 4.5906466539236135e-07

We O 0 2.107110594806727e-05
screened O 0 7.461369386874139e-05
80 O 0 3.505636777845211e-05
prostate B-Disease 1 0.9999914169311523
tumors I-Disease 1 1.0
by O 0 2.465289128394943e-08
microsatellite O 0 1.455759274904267e-06
analysis O 0 1.1287318812946978e-07
and O 0 4.983517953860428e-08
found O 0 1.3213377769716317e-07
chromosome O 0 1.0707603905757423e-05
10q23 O 0 3.518335347507673e-07
to O 0 1.2873503152377452e-08
be O 0 3.103178869423573e-08
deleted O 0 4.251518930686871e-06
in O 0 1.0423331531228541e-08
23 O 0 1.157233668891422e-07
cases O 0 2.1453189447129262e-08
. O 0 5.7085337346052256e-08

We O 0 1.7482807379565202e-05
then O 0 1.5574599387946364e-07
proceeded O 0 4.2151377499521914e-08
with O 0 1.2733955001564823e-09
sequence O 0 1.5329943536812607e-08
analysis O 0 6.935864771406841e-09
of O 0 1.418068551473084e-09
the O 0 1.7349977454728105e-08
entire O 0 6.38589256141131e-07
PTEN O 0 1.23048375826329e-05
/ O 0 3.175810206812457e-06
MMAC1 O 0 3.582767249099561e-06
coding O 0 2.4398568712058477e-06
region O 0 7.294573265426152e-07
and O 0 4.2342836081843416e-07
tested O 0 8.64237063069595e-06
for O 0 3.249609026312328e-09
homozygous O 0 1.0655503501766361e-06
deletion O 0 2.1862138055439573e-07
with O 0 4.065130898567304e-09
new O 0 1.0829912966414668e-08
intragenic O 0 2.3682437131355982e-06
markers O 0 9.263667379855178e-06
in O 0 1.568736918144964e-09
these O 0 5.710011574677765e-09
23 O 0 4.2712965608870945e-08
cases O 0 2.6612125836322775e-09
with O 0 1.2966356877086582e-08
10q23 O 0 1.7259679225389846e-05
loss O 0 3.972544391217525e-07
of O 0 2.4009619181697417e-08
heterozygosity O 0 1.8505188563722186e-05
. O 0 3.699278465774114e-07

The O 0 1.4493841149487707e-07
identification O 0 1.5668126707168994e-07
of O 0 3.5738065840007494e-09
the O 0 7.001846213938734e-09
second O 0 1.0432843566832162e-07
mutational O 0 2.926874913100619e-06
event O 0 2.14772683193587e-07
in O 0 6.079852177265366e-09
10 O 0 1.3193679038181472e-08
( O 0 3.0938629436150222e-09
43 O 0 6.807478314385662e-08
% O 0 9.092124031440108e-08
) O 0 4.3448369524412556e-07
tumors B-Disease 1 1.0
establishes O 0 3.302855247966363e-06
PTEN O 0 1.336951845587464e-05
/ O 0 1.4382778317667544e-05
MMAC1 O 0 2.678730925254058e-05
as O 0 1.1231017893464923e-08
a O 0 7.818129255099393e-09
main O 0 9.008316936842675e-08
inactivation O 0 1.0078467767016264e-06
target O 0 1.1660431198379229e-07
of O 0 3.4986118446767023e-09
10q O 0 1.7517318156023975e-06
loss O 0 3.3703585700095573e-07
in O 0 9.939682854565035e-08
sporadic B-Disease 1 0.9999996423721313
prostate I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.0943600509990574e-08
. O 0 8.74621193247549e-08

Risk O 0 0.00025182944955304265
reversals O 0 2.892265683840378e-06
in O 0 1.971101326603275e-08
predictive O 0 1.9839799278997816e-06
testing O 0 6.474938345490955e-06
for O 0 4.801028694600973e-07
Huntington B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 3.714791318998323e-07

The O 0 2.0263071576209768e-07
first O 0 5.936819036378438e-08
predictive O 0 7.853506645005837e-07
testing O 0 1.4303851685326663e-06
for O 0 1.9115144311854237e-07
Huntington B-Disease 1 0.9999998807907104
disease I-Disease 1 1.0
( O 0 1.0216502310811393e-08
HD B-Disease 0 1.7326188753941096e-05
) O 0 1.1964366386507663e-08
was O 0 5.5551911515294705e-08
based O 0 1.2266042626052354e-09
on O 0 1.1679630596006518e-09
analysis O 0 6.620294090708967e-09
of O 0 1.3766168205364693e-09
linked O 0 1.0188867918259348e-06
polymorphic O 0 6.070052904760814e-07
DNA O 0 4.719294679489394e-07
markers O 0 1.9617677935457323e-06
to O 0 9.515202847865112e-09
estimate O 0 1.3085093542031245e-07
the O 0 3.51197670944714e-09
likelihood O 0 4.7026489369272895e-08
of O 0 9.68637392517735e-10
inheriting O 0 3.349188943957415e-07
the O 0 6.130401519754969e-09
mutation O 0 1.9740816981084208e-07
for O 0 7.748548469521666e-09
HD B-Disease 0 8.985096064861864e-05
. O 0 5.391664217313519e-07

Limits O 0 1.892744535325619e-06
to O 0 2.302421009403588e-08
accuracy O 0 4.77494666029088e-07
included O 0 1.4864130370995099e-08
recombination O 0 4.647754892062039e-08
between O 0 1.2931187676201716e-08
the O 0 9.596967665004286e-09
DNA O 0 9.898529924612376e-07
markers O 0 1.2352536941762082e-05
and O 0 8.245380911375833e-08
the O 0 1.3471182391810999e-08
mutation O 0 3.69626332030748e-06
, O 0 5.471338049289898e-09
pedigree O 0 1.1361821634636726e-06
structure O 0 2.456465608702274e-07
, O 0 3.2708760144828375e-09
and O 0 1.475970567987872e-09
whether O 0 2.912925012310552e-09
DNA O 0 6.816040354351571e-08
samples O 0 1.1741398964204564e-07
were O 0 1.9295920594686322e-07
available O 0 2.901474616123778e-09
from O 0 5.481239906401925e-09
family O 0 4.253410779142541e-08
members O 0 2.60475871982635e-08
. O 0 3.9554148401066413e-08

With O 0 1.2786048841917363e-07
direct O 0 1.7604661195491644e-07
tests O 0 4.650642040360253e-06
for O 0 1.922562775646952e-09
the O 0 4.5043955232415556e-09
HD B-Disease 0 4.457914110389538e-05
mutation O 0 9.058461500899284e-07
, O 0 3.0576317033848e-09
we O 0 7.960718306776471e-09
have O 0 3.1523816890199896e-09
assessed O 0 1.6661998003542067e-08
the O 0 8.526602757186197e-10
accuracy O 0 2.609687498988933e-06
of O 0 4.274660181380341e-09
results O 0 8.735406140658597e-07
obtained O 0 3.887731736540445e-08
by O 0 2.4255955022312037e-09
linkage O 0 3.7203997749202244e-07
approaches O 0 7.316590000527867e-08
when O 0 1.3305607282632081e-08
requested O 0 1.521365478041048e-09
to O 0 3.3881326633178332e-09
do O 0 1.6244811149590532e-06
so O 0 7.269278512467281e-09
by O 0 4.908609629872274e-10
the O 0 2.5594388830540993e-09
test O 0 6.619437158406072e-07
individuals O 0 2.2950288780521078e-08
. O 0 1.613996936100648e-08

For O 0 2.6737663461062766e-07
six O 0 8.883317548225023e-08
such O 0 5.0331121492774855e-09
individuals O 0 1.4843646312101555e-08
, O 0 2.8033477761368886e-09
there O 0 2.582446700927221e-09
was O 0 8.903992210207434e-09
significant O 0 1.5807632980369135e-09
disparity O 0 2.9247567923107454e-08
between O 0 1.0799054983579026e-08
the O 0 3.9045563227091407e-08
tests O 0 2.5179226213367656e-05
. O 0 1.739423396429629e-07

Three O 0 1.2361409972072579e-05
went O 0 2.6715081276051933e-06
from O 0 1.9118930438821735e-08
a O 0 3.470387355264393e-08
decreased O 0 5.4856582210049964e-06
risk O 0 2.3015458339159522e-07
to O 0 1.3511910479380163e-09
an O 0 3.0296678499297514e-09
increased O 0 8.382975238419021e-07
risk O 0 5.290364242682699e-06
, O 0 1.932363824508343e-09
while O 0 4.600873459992272e-09
in O 0 5.508339895321512e-10
another O 0 5.5828692779869016e-09
three O 0 1.7602033608454803e-08
the O 0 1.7303444010963176e-08
risk O 0 3.0075316317379475e-06
was O 0 2.856858714039845e-07
decreased O 0 1.429359826943255e-06
. O 0 5.1504869702512224e-08

Knowledge O 0 1.1870420166815165e-06
of O 0 1.4123952674083284e-08
the O 0 6.396775997785653e-09
potential O 0 1.3460420333899492e-08
reasons O 0 3.749848875855832e-09
for O 0 1.6143586467620707e-10
these O 0 1.5528608399151267e-09
changes O 0 1.1287131229664737e-08
in O 0 2.7942728131336025e-09
results O 0 1.2268152431715862e-06
and O 0 2.987213676419742e-08
impact O 0 3.151842165038943e-08
of O 0 2.5283170002055044e-10
these O 0 4.454686841626199e-09
risk O 0 3.7304396016679675e-08
reversals O 0 1.553157957800977e-08
on O 0 6.648969375078195e-09
both O 0 1.1051862003341739e-07
patients O 0 5.650039014426511e-08
and O 0 1.4013817883906654e-09
the O 0 1.5526416818900657e-09
counseling O 0 1.2047530617564917e-07
team O 0 4.674193831988305e-08
can O 0 6.47962750122133e-09
assist O 0 5.894773558168254e-09
in O 0 5.883975529030749e-10
the O 0 2.3399884807595583e-10
development O 0 1.7371150351497278e-10
of O 0 9.394960504005567e-11
strategies O 0 1.205213440158559e-08
for O 0 2.600328008472985e-10
the O 0 1.432569396442318e-09
prevention O 0 5.617716070105416e-08
and O 0 2.258784093100985e-08
, O 0 1.2262908466453837e-09
where O 0 1.665649285165216e-09
necessary O 0 4.415924514944436e-09
, O 0 9.218541485722653e-10
management O 0 4.807337306012016e-10
of O 0 8.366369402823537e-11
a O 0 1.1713278347258438e-08
risk O 0 2.499715208159614e-07
reversal O 0 1.2443465813305465e-08
in O 0 7.103564403365681e-10
any O 0 4.310636292359504e-09
predictive O 0 1.0770399967441335e-06
testing O 0 1.7279950270676636e-06
program O 0 1.0873672806610557e-07
. O 0 1.6644845501900818e-08
. O 0 6.45345750172055e-08

A O 0 4.0039062696450856e-06
novel O 0 1.972547124751145e-06
common O 0 3.407112956210767e-07
missense O 0 1.7790085621527396e-05
mutation O 0 2.7607222818915034e-06
G301C O 0 9.700578402771498e-07
in O 0 1.0518014903482253e-08
the O 0 1.9646755333724286e-08
N O 0 4.2336185288149863e-05
- O 0 2.9690942028537393e-05
acetylgalactosamine O 0 0.00020253167895134538
- O 0 9.328511805506423e-05
6 O 0 1.4273954320742632e-06
- O 0 1.5655024981242605e-05
sulfate O 0 5.624600817100145e-06
sulfatase O 0 1.6662364942021668e-05
gene O 0 1.1739701903934474e-06
in O 0 1.1639065888857658e-07
mucopolysaccharidosis B-Disease 0 9.45024294196628e-05
IVA I-Disease 0 0.0001709544303594157
. O 0 7.993051553967234e-07

Mucopolysaccharidosis B-Disease 0 0.27723562717437744
IVA I-Disease 1 0.9969332218170166
( O 0 0.008233352564275265
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 8.725784539365122e-08
is O 0 5.158979021757659e-09
an O 0 7.906365340204502e-09
autosomal B-Disease 1 0.9999730587005615
recessive I-Disease 1 0.9999966621398926
lysosomal I-Disease 1 0.9999551773071289
storage I-Disease 1 0.999786913394928
disorder I-Disease 1 0.9999997615814209
caused O 0 6.3808793129283e-06
by O 0 3.006749960121624e-09
a O 0 2.4194542902478133e-07
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 1.7471293745074945e-07
N O 0 0.00036158005241304636
- O 0 0.0016718091210350394
acetylgalactosamine O 0 0.0064225769601762295
- O 0 0.0033550504595041275
6 O 0 4.892140168522019e-06
- O 0 0.00017472467152401805
sulfate O 0 1.1484593414934352e-05
sulfatase O 0 2.5227102014468983e-05
( O 0 9.122487654167344e-08
GALNS O 0 4.490138053370174e-06
) O 0 2.497472273432777e-08
. O 0 5.102788236399647e-08

In O 0 2.2984090719546657e-07
previous O 0 2.400784069322981e-07
studies O 0 4.837742650920518e-08
, O 0 1.2121849302104692e-08
we O 0 4.023217314852445e-08
have O 0 4.901249184285916e-09
found O 0 1.9441646070816887e-09
two O 0 2.11092610058472e-09
common O 0 1.9327554667825098e-08
mutations O 0 3.08811081595195e-07
in O 0 6.704873323215566e-10
Caucasians O 0 7.563947690414352e-08
and O 0 1.3259295883472078e-08
Japanese O 0 6.226932214303815e-07
, O 0 5.81792436449291e-09
respectively O 0 1.2346067990165466e-07
. O 0 5.0946585616884477e-08

To O 0 5.31619093635527e-07
characterize O 0 2.7732012313208543e-06
the O 0 1.3862716308210565e-08
mutational O 0 1.2192745089123491e-06
spectrum O 0 6.83645566823543e-08
in O 0 1.492454826390599e-09
various O 0 2.9717317495681073e-09
ethnic O 0 1.6906769317870385e-08
groups O 0 2.215885430700837e-08
, O 0 5.188256491095444e-09
mutations O 0 2.0451541615784663e-07
in O 0 9.119661137368951e-10
the O 0 4.627760841202644e-09
GALNS O 0 1.8813205997503246e-06
gene O 0 1.677882437434164e-07
in O 0 1.5059839597597602e-08
Colombian O 0 8.073630851868074e-06
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 0.001102276029996574
were O 0 5.633015689454623e-07
investigated O 0 1.4762407829493895e-07
, O 0 1.3360402784101666e-09
and O 0 6.057882639964873e-09
genetic O 0 8.356276453014289e-07
backgrounds O 0 6.481879495368048e-07
were O 0 1.8194801043591724e-07
extensively O 0 6.680713937612381e-08
analyzed O 0 7.355193787361713e-08
to O 0 7.080031672046516e-09
identify O 0 1.5014786640676903e-06
racial O 0 1.226629137818236e-06
origin O 0 7.435878757178216e-08
, O 0 2.2071824368197213e-09
based O 0 2.678342880813034e-09
on O 0 4.649543861034999e-09
mitochondrial O 0 3.4218280120512645e-07
DNA O 0 6.718960889884329e-07
( O 0 1.2571476304401585e-08
mtDNA O 0 3.611848171658494e-07
) O 0 2.44113564917825e-08
lineages O 0 8.509955478075426e-07
. O 0 1.9540026130471233e-07

Three O 0 5.346761099644937e-06
novel O 0 2.618737198645249e-06
missense O 0 8.991319191409275e-05
mutations O 0 0.00030592703842557967
never O 0 1.6516833056812175e-05
identified O 0 6.018944986863062e-07
previously O 0 1.4970063944019785e-07
in O 0 1.2469189014652216e-09
other O 0 2.3958417472158544e-09
populations O 0 5.238344868985223e-08
and O 0 5.0306098842156644e-08
found O 0 6.572398802973112e-08
in O 0 2.8062794310557138e-09
16 O 0 3.72541997251119e-08
out O 0 1.1701621893678293e-08
of O 0 1.3877842208742663e-09
19 O 0 3.1800789201952284e-07
Colombian O 0 3.6832648220297415e-06
MPS B-Disease 1 0.9999998807907104
IVA I-Disease 1 0.9999915361404419
unrelated O 0 5.010405175198684e-07
alleles O 0 3.032652955425874e-07
account O 0 1.5868820923969906e-07
for O 0 1.4250620239408818e-08
84 O 0 1.9771159713855013e-06
. O 0 2.2854150927287264e-07

2 O 0 3.4293786939088022e-06
% O 0 2.153707754359857e-07
of O 0 1.842482277858437e-09
the O 0 3.219226218931226e-09
alleles O 0 4.475255721558824e-08
in O 0 2.1690624851800067e-09
this O 0 9.480668472505727e-10
study O 0 5.3632437158057655e-08
. O 0 7.002623192420288e-08

The O 0 1.301938709730166e-06
G301C O 0 8.057822924456559e-06
and O 0 1.5903651728876866e-07
S162F O 0 2.717934194151894e-06
mutations O 0 1.3435947039397433e-06
account O 0 8.801067252761641e-08
for O 0 2.6306111067242455e-08
68 O 0 2.0502170627878513e-06
. O 0 3.406420887586137e-07

4 O 0 2.5777055270737037e-05
% O 0 1.285227767766628e-06
and O 0 1.1599429683428752e-07
10 O 0 9.964453795419104e-08
. O 0 5.466000274623184e-08

5 O 0 4.038928182126256e-06
% O 0 1.6495377508363163e-07
of O 0 8.781411153790941e-09
mutations O 0 1.1042260439353413e-06
, O 0 4.296026201444647e-09
respectively O 0 1.7088966330902622e-07
, O 0 3.1089708585341214e-09
whereas O 0 1.9053512545497142e-08
the O 0 8.881094082369145e-09
remaining O 0 2.3372926705178543e-07
F69V O 0 3.582811814339948e-06
is O 0 3.7362268834328916e-09
limited O 0 7.66720553713185e-09
to O 0 5.39153877099352e-09
a O 0 7.056334538901865e-08
single O 0 1.3230733202362899e-05
allele O 0 7.2895495577540714e-06
. O 0 1.3692283573618624e-07

The O 0 9.099416047320119e-07
skewed O 0 6.884149570396403e-06
prevalence O 0 1.1777721738326363e-05
of O 0 6.515866068923515e-09
G301C O 0 2.816789503867767e-07
in O 0 1.6342552866532856e-09
only O 0 4.482813675821262e-09
Colombian O 0 1.3714708302359213e-07
patients O 0 9.818823798468657e-08
and O 0 1.6062999819155266e-09
haplotype O 0 7.574009686095451e-08
analysis O 0 2.3542806815157746e-08
by O 0 1.977611407966151e-09
restriction O 0 5.4129014159798317e-08
fragment O 0 3.4611335308909474e-07
length O 0 1.1127601737825898e-06
polymorphisms O 0 3.0037770557100885e-05
in O 0 1.0923391080552847e-08
the O 0 1.2602012766649295e-08
GALNS O 0 2.3901116037450265e-06
gene O 0 3.016416485479567e-07
suggest O 0 5.139593994840652e-08
that O 0 2.255769127046392e-09
G301C O 0 2.1576364872544218e-07
originated O 0 2.9721867633725196e-08
from O 0 3.746117638314672e-09
a O 0 8.551460872752159e-09
common O 0 4.274792786418402e-08
ancestor O 0 4.4087400397074816e-07
. O 0 1.3020910216710035e-07

Investigation O 0 7.936084784887498e-07
of O 0 1.3389032105237675e-08
the O 0 1.3634734230549839e-08
genetic O 0 4.95592473725992e-07
background O 0 2.2061003335238638e-07
by O 0 1.7894193904410827e-09
means O 0 5.163231620031183e-09
of O 0 2.6686833298761314e-10
mtDNA O 0 4.62929932609768e-07
lineages O 0 2.449679072924482e-07
indicate O 0 4.0796123812469887e-07
that O 0 1.379636960230357e-09
all O 0 4.760494221045519e-09
our O 0 2.6714442924458126e-07
patients O 0 9.196333650152155e-08
are O 0 2.1723498555559217e-09
probably O 0 1.077040057140266e-08
of O 0 6.068865965325188e-10
native O 0 2.5949896453880683e-08
American O 0 6.228161169019586e-07
descent O 0 0.0003449680807534605

Low O 0 9.448792116018012e-05
frequency O 0 2.38665847973607e-06
of O 0 2.571139212648177e-08
BRCA1 O 0 7.986842683749273e-05
germline O 0 9.561391379975248e-06
mutations O 0 1.4187343140292796e-06
in O 0 9.331019512615057e-09
45 O 0 2.1604573419153894e-07
German O 1 0.9999988079071045
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.930660113837803e-06
. O 0 3.109877582119225e-07

In O 0 1.1421590073723564e-07
this O 0 4.068140491142458e-09
study O 0 9.333653849807888e-09
we O 0 2.0201088801741207e-08
investigated O 0 1.1272754107949368e-07
45 O 0 1.2992083497920248e-07
German O 1 0.9999867677688599
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 2.14090476902129e-07
for O 0 8.588172839552044e-09
germline O 0 1.0783014658954926e-05
mutations O 0 1.2490361768868752e-05
in O 0 4.301158540442884e-09
the O 0 4.3405378846728127e-08
BRCA1 O 0 7.731445657555014e-05
gene O 0 9.527475413051434e-06
. O 0 6.127102096797898e-07

We O 0 1.7936008589458652e-05
identified O 0 2.0828172182518756e-06
four O 0 7.701829218831335e-08
germline O 0 3.554191152943531e-06
mutations O 0 3.243581204515067e-06
in O 0 1.3097498197112145e-08
three O 0 2.1439605006889906e-06
breast B-Disease 1 0.9999959468841553
cancer I-Disease 0 0.0011842556996271014
families O 0 2.5137017800602734e-08
and O 0 1.4703067208188259e-08
in O 0 2.532344467454095e-08
one O 0 0.0860196053981781
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 9.34491524162695e-08
. O 0 7.182365813207525e-10
among O 0 6.342986691443286e-10
these O 0 1.6401635605234333e-09
were O 0 1.3135128540398e-07
one O 0 1.0753978152422405e-08
frameshift O 0 1.9309156414237805e-05
mutation O 0 3.417263314986485e-06
, O 0 6.3239520287083906e-09
one O 0 1.0974598119162238e-08
nonsense O 0 4.4257185436435975e-06
mutation O 0 9.537451433061506e-07
, O 0 2.581525659905992e-09
one O 0 3.927514757862127e-09
novel O 0 1.7303971588944478e-08
splice O 0 0.00010183792619500309
site O 0 2.850098326234729e-06
mutation O 0 1.2973716366104782e-05
, O 0 9.956300672797624e-09
and O 0 8.101921800118816e-09
one O 0 9.362541675272951e-08
missense O 0 8.202961907954887e-05
mutation O 0 3.665907570393756e-05
. O 0 3.6305382877799275e-07

The O 0 1.4005429420649307e-06
missense O 0 8.209441148210317e-05
mutation O 0 2.5331824872409925e-05
was O 0 1.4888198620610638e-06
also O 0 2.064766668752327e-08
found O 0 1.9333896261741756e-08
in O 0 5.4033053586977076e-09
2 O 0 1.9466334322260082e-07
. O 0 9.040418547101581e-08

8 O 0 8.315586455864832e-06
% O 0 9.855598648300656e-08
of O 0 5.754332010887708e-10
the O 0 9.408038792457774e-10
general O 0 7.737054885659234e-10
population O 0 1.9586392507875416e-09
, O 0 2.2488258477615375e-10
suggesting O 0 1.508387015292101e-08
that O 0 4.659431174225404e-10
it O 0 9.072194662174127e-10
is O 0 3.533545012146533e-09
not O 0 6.770643494746764e-07
disease O 0 9.925860467774328e-06
associated O 0 1.8447042293701088e-07
. O 0 1.973419188061598e-07

The O 0 3.633780636391748e-07
average O 0 1.0367535878685885e-06
age O 0 1.2299260276904533e-07
of O 0 3.987355778889423e-09
disease O 0 0.000255207356531173
onset O 0 1.3173270417610183e-05
in O 0 9.263261269154555e-09
those O 0 9.66058806284309e-08
families O 0 2.0515851417712838e-07
harbouring O 0 0.00027831635088659823
causative O 0 4.649168477044441e-05
mutations O 0 3.931903120246716e-05
was O 0 2.1507152325739298e-07
between O 0 5.436637451339266e-08
32 O 0 1.3893974255552166e-06
. O 0 2.2397217946945602e-07

3 O 0 1.818609598558396e-05
and O 0 3.506912094053405e-07
37 O 0 2.577100303824409e-06
. O 0 3.083278841131687e-07

4 O 0 6.223082891665399e-06
years O 0 1.300505090284787e-07
, O 0 5.921096501992906e-09
whereas O 0 1.4850669138866124e-08
the O 0 1.860094966943393e-09
family O 0 1.6494190901994443e-08
harbouring O 0 2.666285126906587e-06
the O 0 4.316559998329694e-09
missense O 0 1.3761024320047e-06
mutation O 0 7.314970957850164e-07
had O 0 4.183739577001688e-08
an O 0 1.0496326030562386e-09
average O 0 1.4037415212442284e-06
age O 0 1.5536191710907588e-07
of O 0 1.6319130491382339e-09
onset O 0 8.268630153906997e-06
of O 0 1.7902772597722105e-08
51 O 0 4.459094270714559e-06
. O 0 2.155563265660021e-07

2 O 0 2.619721090013627e-05
years O 0 1.1115066627098713e-06
. O 0 3.649707593922358e-07

These O 0 5.047265858593164e-07
findings O 0 1.290518554242226e-07
show O 0 8.927123218427369e-08
that O 0 2.7741620112209375e-09
BRCA1 O 0 3.00642495858483e-05
is O 0 7.324866935221053e-09
implicated O 0 1.7638288341004227e-07
in O 0 6.848731026742882e-10
a O 0 1.6915664424743682e-09
small O 0 3.6803373681948415e-09
fraction O 0 5.7286683841084596e-08
of O 0 3.58218898099949e-07
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.5942086406539602e-07
suggesting O 0 1.0013570772571256e-07
the O 0 1.92520466235635e-09
involvement O 0 1.9127320172174223e-08
of O 0 1.4926284652716504e-09
another O 0 6.810283537106443e-08
susceptibility O 0 6.124880201241467e-06
gene O 0 9.455623512621969e-06
( O 0 2.8486806513683405e-07
s O 0 3.0651117413071916e-05
) O 0 4.5024694372841623e-07

Paternal O 0 0.044997163116931915
transmission O 0 0.1373823881149292
of O 0 4.238620931573678e-06
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 1.4335946616483852e-05

We O 0 2.2601285309065133e-05
report O 0 5.315319029364218e-08
a O 0 4.151385013528852e-09
rare O 0 4.343815085405822e-09
case O 0 6.7165752959397196e-09
of O 0 2.3720396313819947e-08
paternally O 1 0.9964738488197327
transmitted O 1 0.9999991655349731
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.008775240741670132
DM B-Disease 1 1.0
) O 0 9.734460491017671e-07
. O 0 2.0111595233629487e-07

The O 0 6.560669021382637e-07
proband O 0 5.95028541283682e-06
is O 0 1.3824825728647738e-08
a O 0 9.588879912314496e-09
23 O 0 3.217938626676187e-08
year O 0 2.7769306853997477e-09
old O 0 3.0879391488269903e-06
, O 0 7.775274468713178e-08
mentally B-Disease 1 0.9999998807907104
retarded I-Disease 1 0.9999760389328003
male O 0 2.910219700424932e-05
who O 0 3.3263227123825345e-06
suffers O 0 0.09045373648405075
severe O 0 0.24428945779800415
muscular B-Disease 1 0.9822996258735657
weakness I-Disease 1 0.7310368418693542
. O 0 1.5483358311030315e-06

He O 0 4.888740022579441e-06
presented O 0 1.8280094593592366e-07
with O 0 6.13082491440764e-08
respiratory O 0 0.04843383654952049
and O 0 2.8541737151499547e-07
feeding O 0 4.940224243910052e-05
difficulties O 0 1.4908850062056445e-05
at O 0 3.0710242526765796e-07
birth O 0 1.1414274922572076e-05
. O 0 1.1206414285425126e-07

His O 0 1.0354185178584885e-05
two O 0 2.492571866241633e-06
sibs O 1 0.9110603332519531
suffer O 0 0.014553731307387352
from O 0 2.4215435701080423e-07
childhood O 0 0.1918380707502365
onset O 1 0.9999812841415405
DM B-Disease 1 1.0
. O 0 7.854174327803776e-06

Their O 0 4.74400439998135e-06
late O 0 1.2483923228501226e-06
father O 0 3.802427954724408e-07
had O 0 2.4903037854073773e-08
the O 0 6.281692943588268e-10
adult O 0 1.1568691782315454e-08
type O 0 3.479763677205483e-07
of O 0 9.569257386488061e-09
DM B-Disease 1 1.0
, O 0 1.2156770878846146e-07
with O 0 2.6795497376497224e-08
onset O 0 0.0002531742211431265
around O 0 8.642582542961463e-07
30 O 0 1.625642198632704e-07
years O 0 4.4637385343548885e-08
. O 0 6.540335562021937e-08

Only O 0 1.2560363984448486e-06
six O 0 3.711936358286039e-08
other O 0 5.586978102378737e-10
cases O 0 2.003741395029124e-09
of O 0 6.37347508103403e-10
paternal O 0 0.035950347781181335
transmission O 1 0.8671791553497314
of O 0 1.0960048939523404e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
have O 0 0.0019283804576843977
been O 0 1.4025990822119638e-05
reported O 0 5.406723175838124e-06
recently O 0 1.5362014664788148e-06
. O 0 2.3490065359510481e-07

We O 0 1.649839646233886e-06
review O 0 2.5904004274934778e-08
the O 0 2.6196345093154605e-09
sex O 0 8.257798356225976e-08
related O 0 3.15871524492195e-08
effects O 0 1.4606433751396253e-06
on O 0 9.407651191395416e-08
transmission O 0 0.02112787961959839
of O 0 6.593637067453528e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 6.890389613545267e-06

Decreased O 0 0.0003883951576426625
fertility O 0 1.495081050961744e-05
of O 0 1.2201599730587986e-08
males O 0 1.7165456256407197e-07
with O 0 3.2756208856454805e-09
adult O 0 1.1211690434720367e-05
onset O 1 0.9929829835891724
DM B-Disease 1 1.0
and O 0 1.802798465178057e-06
contraction O 0 6.103701707615983e-06
of O 0 1.564284923816217e-09
the O 0 3.5641267714936475e-09
repeat O 0 6.562978001056763e-07
upon O 0 6.1781650906311825e-09
male O 0 2.0005961687274976e-07
transmission O 0 1.0991241197189083e-06
contribute O 0 1.1261714227828179e-08
to O 0 3.532466763545017e-09
the O 0 1.5516446794094918e-08
almost O 0 1.4168693951432942e-07
absent O 0 7.466690732371717e-08
occurrence O 0 2.7984876638242895e-08
of O 0 2.0505270814652476e-09
paternal O 0 0.0005828072316944599
transmission O 1 0.6115696430206299
of O 0 4.519536560110282e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 6.290892088145483e-06

Also O 0 2.0505399334069807e-06
the O 0 3.399766868028564e-08
fathers O 0 2.659955953276949e-07
of O 0 9.645518828094168e-10
the O 0 4.089643734772608e-09
reported O 0 3.588193067116663e-07
congenitally O 0 1.0239248695143033e-05
affected O 0 2.0782921694717515e-07
children O 0 1.413717853893104e-07
showed O 0 4.2630435359569674e-07
, O 0 9.688886359882076e-10
on O 0 9.2024707853966e-09
average O 0 8.193346161533555e-07
, O 0 4.322285640512291e-09
shorter O 0 1.046527086145943e-05
CTG O 0 1.6149897419381887e-05
repeat O 0 1.0303732778993435e-05
lengths O 0 2.8924285288667306e-05
and O 0 6.027170229572221e-08
hence O 0 3.80884472406251e-07
less O 0 1.206165904932277e-07
severe O 0 0.14236728847026825
clinical O 0 0.21547085046768188
symptoms O 0 0.011736534535884857
than O 0 4.559004729287608e-09
the O 0 1.019337947383292e-08
mothers O 0 2.1826547254022444e-06
of O 0 1.4298476846974495e-09
children O 0 6.95227697633527e-07
with O 0 3.0548230824933853e-06
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
. O 0 3.143442427244736e-06

We O 0 4.923570031678537e-06
conclude O 0 5.085891530143272e-07
that O 0 5.344349851554853e-09
paternal O 0 3.439525971771218e-05
transmission O 0 0.0067964824847877026
of O 0 4.0236437826024485e-07
congenital B-Disease 1 1.0
DM I-Disease 1 1.0
is O 0 5.548942993982564e-08
rare O 0 1.314896103110641e-08
and O 0 9.614373297495149e-09
preferentially O 0 1.0922811810587518e-07
occurs O 0 1.1434130087195626e-08
with O 0 3.3307345770339225e-09
onset O 0 8.958369107858744e-06
of O 0 4.081214655116128e-08
DM B-Disease 1 1.0
past O 0 0.00014808338892180473
30 O 0 1.7501827187516028e-07
years O 0 3.929920389111885e-09
in O 0 5.01130748009615e-10
the O 0 3.0480300505786317e-09
father O 0 1.4148197635677207e-07
. O 0 2.613774974236094e-09
. O 0 2.188562397975602e-08

The O 0 4.047237780469004e-06
RB1 O 0 0.0003456900594756007
gene O 0 6.946736903046258e-06
mutation O 0 2.898754928537528e-06
in O 0 1.3152874345223609e-08
a O 0 3.4622551936536183e-08
child O 0 1.3869541362510063e-05
with O 0 1.136533228418557e-06
ectopic B-Disease 1 0.9999998807907104
intracranial I-Disease 1 0.9999978542327881
retinoblastoma I-Disease 1 0.9500271677970886
. O 0 3.411138777664746e-06

The O 0 3.0463861548923887e-06
RB1 O 0 0.0001567375147715211
gene O 0 9.49096374824876e-06
mutation O 0 6.757930350431707e-06
was O 0 9.439644799158486e-08
investigated O 0 1.084041514332057e-07
in O 0 2.2778279262780643e-09
a O 0 2.2783417819027818e-08
child O 0 6.042656423232984e-06
with O 0 1.5240055972753908e-07
ectopic B-Disease 1 0.9999984502792358
intracranial I-Disease 1 0.9745184183120728
retinoblastoma I-Disease 0 9.908458014251664e-05
using O 0 8.314843853440834e-07
DNA O 0 1.301442125622998e-06
obtained O 0 4.829067634659623e-08
from O 0 3.7752965198478705e-09
both O 0 6.902278304465881e-09
the O 0 4.465132708020292e-09
pineal B-Disease 0 9.66101765698113e-07
and I-Disease 0 2.83398321698769e-07
retinal I-Disease 0 3.2710813684388995e-05
tumours I-Disease 1 1.0
of O 0 1.037277819193605e-08
the O 0 5.825833682138182e-08
patient O 0 1.3245515219750814e-05
. O 0 4.9739647067781334e-08

A O 0 7.232511052279733e-06
nonsense O 0 2.112988477165345e-05
mutation O 0 2.4249968646472553e-06
in O 0 2.1668265404173326e-08
exon O 0 1.1203661642866791e-06
17 O 0 2.2975852687068254e-07
( O 0 1.2749661770783405e-08
codon O 0 2.926387310253631e-07
556 O 0 8.774115656251524e-08
) O 0 1.411540884177498e-09
of O 0 2.579245705902622e-10
the O 0 5.935366420573018e-09
RB1 O 0 2.3587001578562194e-06
gene O 0 1.7078228609079815e-07
was O 0 1.1782947950678135e-07
found O 0 1.275435579373152e-08
to O 0 3.2398184135473684e-09
be O 0 8.974597953681496e-09
present O 0 2.6367181771291825e-09
homozygously O 0 3.5758748140324315e-07
in O 0 1.0804035444067495e-09
both O 0 5.400369484931389e-09
the O 0 3.0653746208031407e-09
retinal B-Disease 0 7.17760642032772e-08
and I-Disease 0 1.0653598536691788e-07
the I-Disease 0 3.2949668593573733e-07
pineal I-Disease 0 0.0008651826065033674
tumours I-Disease 1 1.0
. O 0 6.741078095728881e-07

The O 0 4.7167074512799445e-07
same O 0 8.611468871322359e-08
mutation O 0 4.875648187407933e-07
was O 0 3.1836712821586843e-08
present O 0 6.568498189807315e-09
heterozygously O 0 2.729113361965574e-07
in O 0 1.1300740343500593e-09
the O 0 1.0364328284495627e-09
DNA O 0 2.60068304669403e-08
from O 0 6.910033656382097e-10
the O 0 6.878998481951726e-10
constitutional O 0 1.2400366955489517e-08
cells O 0 8.175564225609833e-09
of O 0 3.549762428445291e-10
the O 0 1.2270962024274468e-08
patient O 0 1.0804204748637858e-06
, O 0 3.0004483342338517e-09
proving O 0 1.9321589661558392e-07
it O 0 2.3827670947440538e-09
to O 0 2.7101829669362587e-09
be O 0 1.4758305688644668e-08
of O 0 3.934682801798317e-09
germline O 0 3.876265964208869e-06
origin O 0 3.481300439034385e-07
. O 0 1.1890696782757004e-07

The O 0 1.81244359964694e-07
initial O 0 1.9559938380098174e-07
mutation O 0 4.432864102454914e-07
was O 0 3.709827112174935e-08
shown O 0 6.060032031740548e-09
to O 0 2.0300576775156287e-09
have O 0 6.85519339072016e-08
occurred O 0 9.181419358128551e-08
in O 0 1.1134794197786846e-09
the O 0 1.6390041324143567e-08
paternally O 0 5.49632522961474e-06
derived O 0 4.36039442774927e-07
RB1 O 0 1.2293753570702393e-05
allele O 0 4.686094143835362e-06
. O 0 2.9761528708149854e-07

The O 0 4.2276099065929884e-07
mutation O 0 1.5350125295299222e-06
is O 0 3.956809102589887e-09
in O 0 3.7817668441242347e-10
an O 0 2.9821323188627957e-10
area O 0 7.89099807718685e-09
of O 0 1.5735548974937785e-10
the O 0 9.798011291195508e-10
gene O 0 2.372799734473574e-08
that O 0 3.040265539322462e-10
encodes O 0 8.825707276116646e-09
the O 0 3.16912940334646e-09
protein O 0 3.626267286449547e-08
- O 0 7.97454958956223e-07
binding O 0 7.396809564852447e-08
region O 0 2.1012700912592663e-08
known O 0 1.4039241769125965e-08
as O 0 4.9831254678167625e-09
the O 0 3.977048468328803e-09
pocket O 0 9.358589522889815e-06
region O 0 2.0634641373362683e-07
and O 0 1.545986805240318e-07
has O 0 5.890326093549447e-08
been O 0 4.364113692645333e-08
detected O 0 6.74273721301688e-08
in O 0 1.3839296375550703e-10
other O 0 5.28083410333835e-10
cases O 0 2.225715611814394e-09
of O 0 1.2227686640997604e-09
retinoblastoma B-Disease 0 1.5132318367250264e-06
. O 0 3.9963882869642475e-08
. O 0 1.6640630917663657e-07

Low O 0 0.0018667555414140224
levels O 0 3.6721046399179613e-06
of O 0 6.506650773729916e-09
beta O 0 4.633645644958051e-08
hexosaminidase O 0 3.1426222335539933e-07
A O 0 1.0699658936630385e-08
in O 0 8.03206334776263e-10
healthy O 0 4.282268051269966e-08
individuals O 0 1.1327500049063133e-09
with O 0 4.738535341886063e-09
apparent O 0 2.7519203285919502e-05
deficiency O 0 4.432800778886303e-05
of O 0 5.157874127803552e-10
this O 0 1.800477655855559e-09
enzyme O 0 9.102141689254495e-07
. O 0 9.354330643418507e-08

Appreciable O 0 0.000557822932023555
beta O 0 3.240106161683798e-05
hexosaminidase O 0 4.098374483874068e-05
A O 0 5.973632255518169e-07
( O 0 1.8690153424927303e-08
hex O 0 2.667027843017422e-07
A O 0 2.245159436142785e-08
) O 0 1.6879534436853305e-09
activity O 0 2.975538926364152e-08
has O 0 2.8244400152033222e-09
been O 0 5.817169856925375e-09
detected O 0 6.102695948584369e-08
in O 0 6.429297649823695e-10
cultured O 0 2.505794327589683e-07
skin O 0 6.40859070699662e-05
fibroblasts O 0 3.240243984237168e-07
and O 0 1.3073895388515666e-06
melanoma B-Disease 0 0.3653015196323395
tissue O 0 1.7888349248096347e-05
from O 0 2.0491048857707028e-08
healthy O 0 9.454057590119191e-07
individuals O 0 1.2469005383763943e-08
previously O 0 1.8070724081553635e-06
reported O 0 6.06914397849323e-07
as O 0 1.0383491400034472e-07
having O 0 0.05416911095380783
deficiency B-Disease 0 2.2269658074947074e-05
of I-Disease 0 5.045701634287525e-10
hex I-Disease 0 1.9335857359692454e-07
A I-Disease 0 1.705709351540463e-08
activity O 0 1.3875420279418904e-07
indistinguishable O 0 1.1583632186784598e-07
from O 0 5.630325095040689e-10
that O 0 2.150728761751708e-10
of O 0 1.170183949739112e-09
patients O 0 1.047419118549442e-06
with O 0 3.306887811049819e-05
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9888762831687927
( O 0 1.1887237860719324e-07
TSD B-Disease 0 3.155820013489574e-05
) O 0 8.860287437073566e-08
. O 0 8.550485830483012e-08

Identification O 0 5.230814622336766e-06
and O 0 1.8086673492234695e-07
quantitation O 0 9.86343093245523e-06
of O 0 1.0620341939215905e-08
hex O 0 2.149412239305093e-06
A O 0 9.25530088125015e-08
, O 0 6.13481132560878e-09
amounting O 0 2.6133079700230155e-08
to O 0 1.586007059017902e-08
3 O 0 2.602266420126398e-07
. O 0 1.2411730665462528e-07

5 O 0 2.8829446819145232e-05
% O 0 3.7548684304056223e-06
- O 0 3.853790258290246e-05
6 O 0 1.6037529348977841e-06
. O 0 1.736438548505248e-07

9 O 0 8.372274351131637e-06
% O 0 1.5143289999741683e-07
of O 0 3.2691855889055432e-09
total O 0 1.8308004001710287e-08
beta O 0 8.306135867997e-08
hexosaminidase O 0 9.395687925461971e-07
activity O 0 7.944807975945878e-07
, O 0 6.577374644933798e-09
has O 0 2.9141198343296537e-09
been O 0 4.117476581910751e-09
obtained O 0 1.2966506091061092e-08
by O 0 3.4339013854634004e-09
cellulose O 0 6.811609182477696e-06
acetate O 0 1.6720961866667494e-05
gel O 0 3.866269253194332e-05
electrophoresis O 0 2.2586348222830566e-06
, O 0 2.84759327229267e-08
DEAE O 0 2.4403620955126826e-06
- O 0 3.921409472695814e-07
cellulose O 0 1.6036688066378701e-06
ion O 0 5.410614107859146e-07
- O 0 2.8676895453827456e-06
exchange O 0 1.8724769290656695e-07
chromatography O 0 5.136017193763109e-07
, O 0 8.565859133113918e-09
radial O 0 8.522300163349428e-07
immunodiffusion O 0 2.1528301203943556e-06
, O 0 6.316839495923432e-09
and O 0 2.449849034746876e-08
radioimmunoassay O 0 7.60888497097767e-06
. O 0 9.167175107904768e-08

Previous O 0 1.187041198136285e-05
family O 0 2.5789810820242565e-07
studies O 0 3.3390687548262576e-08
suggested O 0 2.5394836455916447e-08
that O 0 6.685857978361298e-10
these O 0 1.288691042766743e-09
individuals O 0 4.4005714627814996e-09
may O 0 4.762213379194691e-08
be O 0 3.6055751717611884e-09
compound O 0 1.3740939053263901e-08
heterozygotes O 0 3.7632208460536276e-08
for O 0 1.846886393819247e-10
the O 0 6.704489741160558e-10
common O 0 7.134908219796898e-09
mutant O 0 3.2769008839750313e-07
TSD B-Disease 0 1.3255397561806603e-06
gene O 0 1.579152524300298e-07
and O 0 9.682795010235168e-09
a O 0 9.682240786901275e-09
rare O 0 2.1048080611762998e-08
( O 0 1.3148258481976427e-08
allelic O 0 8.377525091418647e-07
) O 0 2.21441940340128e-08
mutant O 0 2.243093604192836e-06
gene O 0 3.8646617213089485e-06
. O 0 3.1773353725839115e-07

Thus O 0 5.7132883739541285e-06
, O 0 2.8496145887402236e-08
the O 0 5.102075206764312e-09
postulated O 0 1.7233823257356562e-07
rate O 0 8.098402304312913e-08
mutant O 0 2.3657779024688352e-07
gene O 0 1.9006478169103502e-07
appears O 0 4.180461132818891e-08
to O 0 1.7187913314842262e-09
code O 0 6.1545830654097244e-09
for O 0 4.0895639652482885e-10
the O 0 1.0771401548481663e-09
expression O 0 7.176809813103091e-09
of O 0 1.2462578746763597e-09
low O 0 1.6134963516378775e-05
amounts O 0 2.0826366409210095e-08
of O 0 4.587247914855652e-09
hex O 0 6.472271252278006e-06
A O 0 8.313686521432828e-07
. O 0 1.98984352550724e-07

Heterozygotes O 0 0.00019150595471728593
for O 0 4.865744429594088e-08
the O 0 8.196486156464289e-09
rare O 0 5.84274539860985e-09
mutant O 0 4.2601419636412174e-07
may O 0 4.1417075635763467e-07
be O 0 7.258831313805558e-09
indistinguishable O 0 1.2704164475962898e-07
from O 0 1.7377521643879845e-09
heterozygotes O 0 1.2626655632175243e-07
for O 0 6.336602353940179e-10
the O 0 3.7439957800700085e-09
common O 0 7.442448435313054e-08
TSD B-Disease 0 1.3724740711040795e-05
mutant O 0 6.504371867777081e-06
. O 0 2.199338240416182e-07

However O 0 7.853723786865885e-07
, O 0 6.523800166746696e-09
direct O 0 1.064810906115099e-08
visualization O 0 3.7449552792168106e-07
and O 0 1.4389404157100216e-07
quantitation O 0 2.349572787352372e-05
of O 0 5.8141083059126686e-09
hex O 0 1.6743638298066799e-06
A O 0 3.1801995703517605e-08
by O 0 9.194133232526269e-10
the O 0 6.435898480816604e-10
methods O 0 1.5305320744118944e-07
described O 0 1.9777297666223603e-07
may O 0 6.438298072453108e-08
prevent O 0 1.8141452073905384e-07
false O 0 5.666918241331587e-07
- O 0 1.3363068319449667e-05
positive O 0 3.5549771837395383e-07
prenatal O 1 0.9991724491119385
diagnosis O 1 0.6705228090286255
of O 0 5.84031623063197e-09
TSD B-Disease 0 4.3490275857038796e-05
in O 0 1.716879580726527e-07
fetuses O 0 0.019298776984214783
having O 0 3.0573789899790427e-06
the O 0 8.695177022843836e-09
incomplete O 0 3.0744486139155924e-06
hex B-Disease 0 6.411322829080746e-06
A I-Disease 0 1.8865416677726898e-06
deficiency I-Disease 0 2.1296476916177198e-05
of O 0 2.8461785706035414e-10
the O 0 2.058081483014007e-09
type O 0 6.426620529964566e-06
described O 0 1.8724321648733167e-07
in O 0 2.790214281844783e-09
the O 0 1.2470598775848885e-08
four O 0 1.5650789464416448e-06
healthy O 0 2.4297078198287636e-06
individuals O 0 2.265606298124112e-07

The O 0 2.4866692456271267e-06
tumor B-Disease 0 7.437138992827386e-05
suppressor O 0 2.4647199097671546e-05
gene O 0 8.037171937758103e-06
Smad4 O 0 2.3805278033250943e-05
/ O 0 1.7719174138619564e-05
Dpc4 O 0 5.542740836972371e-06
is O 0 4.556258037524685e-09
required O 0 8.085604186192086e-09
for O 0 9.086913999034607e-10
gastrulation O 0 1.8804834667207615e-07
and O 0 2.8831278697794005e-08
later O 0 2.1667148075721343e-08
for O 0 2.994182679572077e-09
anterior O 0 7.976139386300929e-06
development O 0 4.382345597520043e-09
of O 0 7.510849164837907e-10
the O 0 8.135152107513477e-09
mouse O 0 1.9386129679332953e-06
embryo O 0 2.8676786314463243e-06
. O 0 2.2157044554660388e-07

Mutations O 0 0.00012085770140402019
in O 0 1.0232595570869307e-07
the O 0 6.812297215219587e-08
SMAD4 O 0 0.00011253191769355908
/ O 0 8.455804345430806e-05
DPC4 O 0 0.00017216920969076455
tumor B-Disease 0 1.5591285773552954e-05
suppressor O 0 9.74100771600206e-07
gene O 0 4.352783093963808e-07
, O 0 1.9178856280888112e-09
a O 0 5.594019025778607e-09
key O 0 2.235061629107804e-07
signal O 0 4.6479678417199466e-07
transducer O 0 4.83468454604008e-07
in O 0 3.162125228328705e-09
most O 0 2.9007443114181797e-09
TGFbeta O 0 2.2872211502544815e-06
- O 0 1.732213831928675e-06
related O 0 2.5276733595092082e-08
pathways O 0 9.678994672412955e-08
, O 0 1.657131432075687e-09
are O 0 7.670770685308526e-10
involved O 0 1.77330772288542e-09
in O 0 2.8157409737161743e-10
50 O 0 5.151073345643908e-09
% O 0 4.9023056725161496e-09
of O 0 9.886584884100102e-09
pancreatic B-Disease 1 0.9729060530662537
cancers I-Disease 1 0.9978739023208618
. O 0 2.7942854785578675e-07

Homozygous O 0 0.0057465205900371075
Smad4 O 0 0.0006044969777576625
mutant O 0 0.00020024034893140197
mice O 0 0.26520398259162903
die O 0 0.023554090410470963
before O 0 1.1015706036232586e-07
day O 0 2.5440311191005094e-08
7 O 0 1.4567548589639046e-07
. O 0 5.403298075634666e-08

5 O 0 4.676045136875473e-06
of O 0 7.74951303128546e-08
embryogenesis O 0 1.3070407476334367e-05
. O 0 9.18327259569196e-07

Mutant O 0 5.932230851612985e-05
embryos O 0 1.4508346794173121e-05
have O 0 1.0966817853841349e-07
reduced O 0 7.005001378956877e-08
size O 0 4.083387139530714e-08
, O 0 7.17171921849058e-09
fail O 0 2.5754097805474885e-06
to O 0 7.820723624263337e-09
gastrulate O 0 0.00013343819591682404
or O 0 5.239404003987147e-07
express O 0 4.63431781838608e-08
a O 0 1.4167255812935764e-08
mesodermal O 0 1.5424244566020207e-06
marker O 0 4.95921403853572e-06
, O 0 6.625599624499046e-09
and O 0 7.61572671592603e-09
show O 0 7.684168394916924e-07
abnormal O 0 9.828576366999187e-06
visceral O 0 2.603202347017941e-06
endoderm O 0 6.616776227019727e-05
development O 0 8.493772156725754e-07
. O 0 5.020593221161107e-07

Growth B-Disease 1 0.9999995231628418
retardation I-Disease 1 0.9999998807907104
of O 0 4.4163311230249747e-08
the O 0 4.9598870788258864e-08
Smad4 O 0 7.283405284397304e-05
- O 0 0.00033454224467277527
deficient O 0 5.36023399035912e-05
embryos O 0 4.667842006256251e-07
results O 0 8.110072968747772e-08
from O 0 5.0274993057541906e-09
reduced O 0 1.3552327970955957e-07
cell O 0 6.121728688412986e-07
proliferation O 0 5.397945983531827e-07
rather O 0 3.283234661921597e-08
than O 0 1.1585738590724759e-08
increased O 0 1.316665958484009e-07
apoptosis O 0 1.061576426764077e-06
. O 0 1.2750845712616865e-07

Aggregation O 0 1.3646434126712848e-05
of O 0 1.786242904699975e-07
mutant O 0 1.0122853382199537e-05
Smad4 O 0 3.336727968417108e-05
ES O 0 9.943369150278158e-06
cells O 0 2.722474334859726e-07
with O 0 7.85065967789933e-09
wild O 0 1.1104263819561311e-07
- O 0 5.0942103371198755e-06
type O 0 9.6157229563687e-05
tetraploid O 0 6.123114872025326e-05
morulae O 0 2.3392056391458027e-05
rescues O 0 8.970851013145875e-06
the O 0 1.523204815612189e-07
gastrulation B-Disease 0 6.174932786962017e-05
defect I-Disease 0 0.00022290399647317827
. O 0 1.1471219067971106e-06

These O 0 5.2316727305878885e-06
results O 0 2.1093710529385135e-06
indicate O 0 5.359843839869427e-07
that O 0 4.63692328978027e-09
Smad4 O 0 3.827283592272579e-07
is O 0 1.5222217930599413e-09
initially O 0 1.3478043570103182e-08
required O 0 2.679855448661783e-09
for O 0 2.0654500332284442e-10
the O 0 5.827383575685019e-10
differentiation O 0 5.103330646960558e-09
of O 0 1.3922270281074844e-10
the O 0 1.8132322310293603e-09
visceral O 0 6.126125384753323e-08
endoderm O 0 5.3402532103064004e-06
and O 0 3.605611453849633e-08
that O 0 1.5031421662925482e-09
the O 0 3.0698330544254304e-09
gastrulation B-Disease 0 8.675035019223287e-07
defect I-Disease 0 1.8759744762064656e-06
in O 0 2.336707050076825e-09
the O 0 5.246641787692852e-09
epiblast O 0 1.0249427759845275e-06
is O 0 2.0685497759131977e-09
secondary O 0 1.41744791903875e-07
and O 0 8.085067548790903e-08
non O 0 3.2681567972758785e-05
- O 0 0.0014871724415570498
cell O 0 1.2985834473511204e-05
autonomous O 0 9.524881079414627e-07
. O 0 1.7402713581304852e-07

Rescued O 0 0.0010485772509127855
embryos O 0 0.00023209257051348686
show O 0 4.142280522501096e-05
severe O 0 0.16016511619091034
anterior O 1 0.5079435110092163
truncations O 0 0.0008266793447546661
, O 0 2.0212021922816348e-07
indicating O 0 2.1558419120992767e-06
a O 0 1.9893212410693195e-08
second O 0 2.0615189555428515e-07
important O 0 1.2121017078925433e-08
role O 0 5.200088892820531e-08
for O 0 8.030963449812134e-09
Smad4 O 0 3.1643342026654864e-06
in O 0 1.4358856326168734e-08
anterior O 0 6.710881280014291e-05
patterning O 0 4.21105414716294e-06
during O 0 7.061901214910904e-07
embryogenesis O 0 6.0417924032662995e-06
. O 0 6.583891263289843e-07

Prevalence O 0 0.0028360306750983
of O 0 2.391593056927377e-07
p16 O 0 7.45380839362042e-06
and O 0 9.479411033908036e-08
CDK4 O 0 2.4569120796513744e-05
germline O 0 1.355717540718615e-05
mutations O 0 3.239210627725697e-06
in O 0 1.368961388692469e-08
48 O 0 2.8288411613175413e-06
melanoma B-Disease 1 0.7858108878135681
- O 0 0.10193514078855515
prone O 1 0.9758375287055969
families O 0 1.3545122783398256e-06
in O 0 4.926999253029862e-08
France O 0 7.278579869307578e-05
. O 0 3.270909303410008e-07

The O 0 2.435458554828074e-06
French O 0 7.512553565902635e-05
Familial B-Disease 0 0.4562762975692749
Melanoma I-Disease 1 0.9856492877006531
Study O 0 1.1639859849310596e-06
Group O 0 9.156041187452502e-07
. O 0 1.1055383453140166e-07

Germline O 0 0.0021491488441824913
mutations O 0 0.00042220792965963483
in O 0 5.7997791458319625e-08
the O 0 1.0279167739213335e-08
p16 O 0 3.499121419281437e-07
and O 0 9.348655183316623e-09
CDK4 O 0 1.5504843986491323e-06
genes O 0 6.984341780480463e-07
have O 0 1.8448467642429023e-07
been O 0 2.8403496799001005e-07
reported O 0 7.96612980025202e-08
in O 0 7.918705691167816e-10
a O 0 2.0019266244730716e-09
subset O 0 1.5662802610449944e-08
of O 0 3.6951082194036644e-09
melanoma B-Disease 0 9.478130959905684e-05
pedigrees O 0 7.153127171477536e-06
, O 0 1.4378423784933148e-08
but O 0 9.887641816419546e-09
their O 0 1.515305569910197e-07
prevalence O 0 3.975844447268173e-05
is O 0 5.458381302503312e-09
not O 0 1.433144092288785e-08
well O 0 5.3637144503682066e-08
known O 0 1.7207200642133103e-07
. O 0 8.356349923133166e-08

We O 0 4.169625754002482e-06
searched O 0 7.978977123457298e-07
for O 0 3.302583984066132e-09
such O 0 1.015964468109587e-08
germline O 0 6.223005584615748e-06
mutations O 0 3.3174458167195553e-06
in O 0 6.618930736834727e-09
48 O 0 2.9771578624604444e-07
French O 0 0.000497593020554632
melanoma B-Disease 1 0.9962357878684998
- O 0 0.030541030690073967
prone O 0 0.1774330586194992
families O 0 7.981581973126595e-08
selected O 0 1.1145509404286713e-08
according O 0 1.0865079946853484e-09
to O 0 1.5102518124976427e-09
two O 0 1.1480721262557836e-08
major O 0 4.8601144442272926e-08
criteria O 0 1.0614144230203237e-06
families O 0 8.207045709696104e-09
with O 0 3.0197275791010725e-09
at O 0 4.136232689688768e-07
least O 0 1.4856534669149823e-08
three O 0 1.4530107783627955e-08
affected O 0 1.6605365971145147e-08
members O 0 2.7163258309315097e-09
( O 0 2.883054905922222e-09
n O 0 2.387006816206849e-06
= O 0 1.3770062651019543e-05
20 O 0 2.3312324515245564e-08
) O 0 1.8897332587641813e-09
or O 0 1.0680943773877516e-07
families O 0 2.1388839144265148e-08
with O 0 2.11357709112292e-09
two O 0 1.8654182198929448e-08
affected O 0 2.5922192392613397e-08
members O 0 7.583485506224008e-10
, O 0 3.2349878331672244e-10
one O 0 2.7665095214679525e-10
of O 0 2.2728187387688337e-10
them O 0 9.431525782588324e-09
affected O 0 2.7092125876038153e-08
before O 0 7.352091380141701e-09
the O 0 1.42386313850551e-09
age O 0 1.8555850189727607e-08
of O 0 6.941565655615989e-10
50 O 0 1.9488322067218178e-08
( O 0 1.2322209919091165e-08
n O 0 1.6366855561500415e-05
= O 0 4.610482938005589e-05
28 O 0 5.749345177719078e-07
) O 0 4.210547466243497e-09
, O 0 1.7046222211547502e-09
and O 0 4.454754787275306e-09
one O 0 2.1721136000962815e-09
additional O 0 2.1461293187030606e-08
minor O 0 4.69543465442257e-06
criterion O 0 1.4957206531107659e-06
. O 0 1.5856778645684244e-07

Sixteen O 0 2.035943543887697e-05
different O 0 4.4115705577496556e-07
p16 O 0 1.2478622011258267e-05
germline O 0 2.3117108867154457e-05
mutations O 0 3.8912516174605116e-05
were O 0 4.410464384818624e-07
found O 0 1.723394582597848e-08
in O 0 1.903639468281426e-09
21 O 0 4.46179768687216e-08
families O 0 1.0178710319053152e-08
, O 0 1.5325258839737899e-09
while O 0 5.341170172812326e-09
one O 0 7.610702290605786e-09
germline O 0 7.964304700180946e-07
mutation O 0 3.194395219452417e-07
, O 0 3.4723455222263055e-09
Arg24His O 0 3.4277005056537746e-07
, O 0 6.618475989483841e-09
was O 0 6.13312920449971e-08
detected O 0 1.2178853125988098e-07
in O 0 2.3473205601476366e-09
the O 0 2.5898767574972226e-08
CDK4 O 0 1.388893088005716e-05
gene O 0 2.3915981728350744e-06
. O 0 2.9620068175972847e-07

The O 0 2.5358735911140684e-07
frequency O 0 5.900929522795195e-07
of O 0 1.4091877886812654e-08
p16 O 0 1.0465084869792918e-06
gene O 0 4.010454119907081e-07
mutation O 0 4.828592636840767e-07
in O 0 3.8879082175924395e-09
our O 0 1.691964079952868e-08
sample O 0 2.4655149033492307e-08
( O 0 6.029065247048493e-09
44 O 0 1.9665799655399496e-08
% O 0 2.7998210416768643e-09
) O 0 3.701370043796004e-10
is O 0 1.894539386482208e-10
among O 0 3.1955554868901004e-10
the O 0 1.806438776341679e-09
highest O 0 4.7226217247953173e-07
rates O 0 4.058385457028635e-05
yet O 0 7.764558063172444e-07
reported O 0 2.54413862421643e-07
and O 0 8.028880671417937e-09
the O 0 1.5750819315485387e-08
CDK4 O 0 9.827394933381584e-06
mutation O 0 1.757223770937344e-07
is O 0 2.775818686018283e-09
the O 0 3.239361223705828e-09
second O 0 2.580393356765853e-07
mutation O 0 1.75212289832416e-06
detected O 0 3.924387215192837e-07
in O 0 7.870701312917561e-10
this O 0 5.02507147004394e-10
gene O 0 2.608637146295223e-07
worldwide O 0 2.9735400630670483e-07
. O 0 1.4685080884646595e-07

In O 0 3.4345396215940127e-07
summary O 0 9.076820788322948e-07
, O 0 1.9086467517581696e-08
our O 0 3.697676476122069e-08
results O 0 6.188120238448391e-08
show O 0 9.854583993273991e-08
frequent O 0 2.8197811730024114e-07
involvement O 0 4.2235072328367096e-08
of O 0 5.045374118495261e-10
the O 0 1.9407855322839396e-09
p16 O 0 1.0078969836513352e-07
gene O 0 3.985472218914765e-08
in O 0 2.7456990014940175e-09
familial B-Disease 0 0.0006966205546632409
melanoma I-Disease 1 0.5884259939193726
and O 0 2.357129886831899e-07
confirm O 0 1.8148458593714167e-06
the O 0 3.419842187213362e-09
role O 0 2.0520461774253818e-08
of O 0 4.139207310238646e-10
the O 0 3.2900095980892274e-09
CDK4 O 0 8.686393471180054e-07
gene O 0 4.753673721324958e-08
as O 0 5.396816771252588e-09
a O 0 1.1636746677368137e-07
melanoma B-Disease 0 0.0063238139264285564
- O 0 1.685072129475884e-05
predisposing O 0 1.5852192518650554e-05
gene O 0 1.0677323416530271e-06
. O 0 2.503271367970683e-08
. O 0 5.055792584585106e-08

Progression O 0 0.00011348148109391332
of O 0 3.384330682365544e-07
somatic O 0 8.287689706776291e-05
CTG O 0 0.00023024181427899748
repeat O 0 1.5401417840621434e-05
length O 0 4.6990984969852434e-07
heterogeneity O 0 2.5437213935219916e-07
in O 0 6.739314439840882e-09
the O 0 1.2215943812066143e-08
blood O 0 2.0706904706457863e-06
cells O 0 2.3312308883305377e-07
of O 0 5.4341910527000437e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9953656196594238
. O 0 9.785755992197664e-07

The O 0 2.653019635090459e-07
genetic O 0 1.6837954035509028e-06
basis O 0 2.6725629709289933e-07
of O 0 1.949126442468696e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.0008532038191333413
DM B-Disease 1 1.0
) O 0 5.418045745386735e-08
is O 0 1.9727852684781055e-09
the O 0 3.618401411831229e-10
expansion O 0 1.255062609395452e-09
of O 0 1.1226150009591152e-09
an O 0 9.653327914804777e-09
unstable O 0 6.016663974151015e-05
CTG O 0 3.88775742976577e-06
repeat O 0 1.0537492016737815e-06
in O 0 2.2225681295395816e-09
the O 0 3.74967745742083e-09
34 O 0 3.5086575422837996e-08
UTR O 0 1.1901575902584227e-07
of O 0 1.2536844895549848e-09
the O 0 5.356639576348243e-08
DM B-Disease 1 0.9999997615814209
protein O 0 5.306683306116611e-07
kinase O 0 2.9422894840536173e-06
gene O 0 1.8146606635127682e-06
on O 0 1.6662878010720306e-07
chromosome O 0 8.603427704656497e-05
19 O 0 1.2352149951766478e-06
. O 0 2.592581154203799e-07

One O 0 2.6488481807973585e-07
of O 0 3.444088347848151e-09
the O 0 5.442880368633496e-09
principal O 0 1.513303260480825e-08
features O 0 8.114803939918147e-09
of O 0 1.7108957583999995e-09
the O 0 8.23794323423499e-07
DM B-Disease 1 1.0
mutation O 0 9.862767910817638e-05
is O 0 3.4411729021854853e-09
an O 0 8.075982105282264e-10
extraordinarily O 0 1.41427889843726e-07
high O 0 1.1898001162080618e-07
level O 0 1.4179941842940025e-07
of O 0 1.1925265219758785e-09
somatic O 0 8.933252502174582e-07
mosaicism O 0 4.509509381023236e-06
, O 0 5.1862478755992925e-09
due O 0 8.511787719100994e-09
to O 0 2.193860648702639e-09
an O 0 1.0345604373185324e-09
extremely O 0 1.8136384483113943e-07
high O 0 2.340142479795304e-08
degree O 0 7.78001840728848e-09
of O 0 1.4615209043000732e-09
somatic O 0 2.4487264909112127e-06
instability O 0 1.295681045121455e-06
both O 0 6.904716798317168e-08
within O 0 2.9021791192462842e-08
and O 0 9.025598934897516e-09
between O 0 7.563583537262275e-09
different O 0 7.853254402334642e-08
tissues O 0 5.883066478418186e-06
. O 0 9.531989775268812e-08

This O 0 3.4746534538498963e-07
instability O 0 1.1597078355407575e-06
appears O 0 4.6344677429033254e-08
to O 0 3.251586999653e-09
be O 0 6.421995824013038e-09
biased O 0 6.613203140659607e-08
towards O 0 4.916332674298474e-09
further O 0 3.2945683958729433e-09
expansion O 0 4.732321201572631e-09
and O 0 7.821857828105294e-09
continuous O 0 2.0318334748026246e-07
throughout O 0 3.8227742749086246e-08
the O 0 5.956438009491194e-09
life O 0 1.4700703987458041e-09
of O 0 6.272913438687411e-11
an O 0 3.5906125295248614e-10
individual O 0 1.9562236275305622e-09
, O 0 3.813165339039415e-10
features O 0 4.414032162003423e-08
that O 0 1.8749137353779588e-08
could O 0 1.3768192275165347e-06
be O 0 2.396313725228083e-08
associated O 0 4.302553424651023e-09
with O 0 1.2811548488755875e-09
the O 0 5.01775643257929e-09
progressive O 0 2.496015838460153e-07
nature O 0 2.5546704307544132e-08
of O 0 4.5031756101820974e-09
the O 0 2.900782476444874e-07
disease O 0 0.00031041214242577553
. O 0 5.561106775076041e-08

Although O 0 1.8886333918999298e-06
increasing O 0 3.3572698043826676e-07
measured O 0 8.774623552199046e-07
allele O 0 2.831287133631122e-07
size O 0 5.307720485348e-08
between O 0 5.5000299425955745e-08
patients O 0 4.053159045724897e-06
clearly O 0 4.4150340272608446e-08
correlates O 0 3.6960759786097697e-08
with O 0 1.5170537048803112e-09
an O 0 8.546890417626685e-10
increased O 0 1.1103077213192591e-07
severity O 0 1.078169862012146e-05
of O 0 1.4029684969329992e-08
symptoms O 0 0.00980203878134489
and O 0 4.545234411068577e-09
an O 0 1.4592368424715119e-09
earlier O 0 1.1970055879828578e-07
age O 0 2.1952392614821292e-07
of O 0 1.535164662058719e-09
onset O 0 1.7612330339034088e-05
, O 0 3.774821344393331e-09
this O 0 8.709380994176286e-10
correlation O 0 1.9444274812485673e-07
is O 0 9.97793403456626e-09
not O 0 1.877024935481586e-08
precise O 0 1.550998968014028e-05
and O 0 3.2189367971113825e-07
measured O 0 3.843953527393751e-05
allele O 0 1.0969679351546802e-06
length O 0 1.4583258689526701e-06
cannot O 0 5.953957952442579e-06
be O 0 1.67428186870211e-08
used O 0 8.902281223299724e-08
as O 0 5.8195670504801456e-09
an O 0 1.2503913460193417e-09
accurate O 0 0.000728459155652672
predictor O 0 0.000571983924601227
of O 0 4.796367747417207e-09
age O 0 6.492755915132875e-07
of O 0 1.7258223294902564e-08
onset O 0 0.0005338357877917588
. O 0 2.8371255211823154e-07

In O 0 1.7272604679874348e-07
order O 0 1.694916385019951e-08
to O 0 2.237390717141352e-09
further O 0 6.458749979287859e-09
characterize O 0 2.276392052635856e-07
the O 0 7.982065675093963e-09
dynamics O 0 3.365181271419715e-07
of O 0 3.4983532515298066e-08
DM B-Disease 1 1.0
CTG O 0 0.00021694290626328439
repeat O 0 6.39200061414158e-06
somatic O 0 4.018603704025736e-06
instability O 0 2.9411280593194533e-06
, O 0 3.8662868462324695e-08
we O 0 1.0391297422529533e-07
have O 0 6.814152797574025e-09
studied O 0 8.11850782156398e-08
repeat O 0 5.215196097196895e-07
length O 0 1.4202028353338392e-07
changes O 0 1.7100092009059153e-08
over O 0 5.649195777834848e-09
time O 0 4.248513718607683e-08
in O 0 4.8469668278983136e-09
111 O 0 3.664736823338899e-06
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 0 0.0022125914692878723
with O 0 4.6003472142785995e-09
varying O 0 9.086521686185733e-07
clinical O 0 0.00012744976265821606
severity O 0 0.00011751666897907853
and O 0 5.056969598626893e-07
CTG O 0 9.474976650380995e-06
repeat O 0 1.4737918263563188e-06
size O 0 5.1771781528486827e-08
over O 0 3.46752209168244e-08
time O 0 1.2154509931860957e-07
intervals O 0 4.181620170129463e-06
of O 0 3.262676129267561e-09
1 O 0 1.74674937625241e-07
- O 0 3.788245885516517e-05
7 O 0 4.398182795739558e-07
years O 0 5.346513987092294e-08
. O 0 7.47504103060237e-08

We O 0 1.80146744241938e-05
have O 0 3.708348472741818e-08
found O 0 6.170015609541224e-09
a O 0 1.3314230828953555e-09
direct O 0 2.9700164105861404e-08
progression O 0 1.0111942856383394e-06
of O 0 7.047705752327715e-10
the O 0 1.7094865523148428e-09
size O 0 6.797900020671932e-09
heterogeneity O 0 3.585086716384467e-08
over O 0 7.772216648049834e-09
time O 0 1.405566596446306e-08
related O 0 1.1062318172605501e-08
to O 0 4.351410787251098e-09
initial O 0 4.844399654757581e-07
CTG O 0 6.901596407260513e-06
repeat O 0 6.411161734831694e-07
size O 0 5.313555107022694e-08
and O 0 3.173256146737913e-08
the O 0 3.120401048661847e-09
time O 0 3.2702036634191245e-08
interval O 0 9.26730933770159e-07
and O 0 1.6934492919062905e-08
always O 0 7.863926043683023e-08
biased O 0 1.2322331599534664e-07
towards O 0 4.167603506743944e-08
further O 0 2.776603835741298e-08
expansion O 0 2.496817899100279e-07
. O 0 2.747152336723957e-07

Attempts O 0 8.197189345082734e-06
to O 0 1.0461537414130362e-07
mathematically O 0 4.6142739051902026e-07
model O 0 5.365576782878634e-08
the O 0 4.426626176723403e-09
dynamics O 0 3.020639667283831e-07
have O 0 2.793720454974391e-07
proved O 0 3.826396550721256e-06
only O 0 3.240672796778199e-08
partially O 0 4.367042492958717e-06
successful O 0 4.2019813406568574e-08
suggesting O 0 3.586317731674171e-08
that O 0 2.387602060505145e-10
individual O 0 1.1873608762869026e-09
specific O 0 4.772804818031773e-09
genetic O 0 3.6220822607901937e-07
and O 0 4.822017274364043e-08
/ O 0 1.8282888049725443e-05
or O 0 7.32962121219316e-07
environmental O 0 5.303005323753496e-08
factors O 0 2.57314383134144e-07
also O 0 4.8550560904914164e-08
play O 0 5.271008163276747e-08
a O 0 3.829661920917715e-09
role O 0 3.2272566841129446e-08
in O 0 2.1359800594922262e-09
somatic O 0 5.028336431678326e-07
mosaicism O 0 3.2667774121364346e-06
. O 0 1.751425848794952e-08
. O 0 7.122184797481168e-08

Aspartylglucosaminuria B-Disease 1 0.9999890327453613
among O 0 5.659628641296877e-06
Palestinian O 0 6.477516581071541e-05
Arabs O 0 4.370742317405529e-06
. O 0 1.9674058648888604e-07

Aspartylglucosaminuria B-Disease 1 1.0
( O 0 0.02416602335870266
AGU B-Disease 1 0.9999997615814209
) O 0 2.0447349413643678e-07
is O 0 2.341177030018571e-09
a O 0 1.9328652012262637e-09
rare O 0 4.2014363543785294e-08
disorder B-Disease 0 0.004825827665627003
of I-Disease 0 1.4675239912165239e-09
glycoprotein I-Disease 0 1.4399124665942509e-05
metabolism I-Disease 0 0.004430255852639675
caused O 0 1.7788153172659804e-06
by O 0 2.8866316004183545e-09
the O 0 1.1041201020134395e-07
deficiency B-Disease 0 8.778130722930655e-05
of I-Disease 0 4.058110236737633e-10
the I-Disease 0 1.3765649065078378e-08
lysosomal I-Disease 0 1.7422373275621794e-05
enzyme I-Disease 0 5.640274594043149e-06
aspartylglucosaminidase I-Disease 0 1.0388962436991278e-05
( O 0 4.5092889422448934e-08
AGA O 0 7.048215593385976e-07
) O 0 4.6639257789138355e-08
. O 0 4.941643538813878e-08

AGU B-Disease 1 0.9999996423721313
is O 0 4.328708655521041e-06
inherited O 0 8.94193144631572e-05
as O 0 9.145272095167911e-09
an O 0 8.53487236440742e-09
autosomal O 0 0.32403838634490967
recessive O 1 0.813389241695404
trait O 0 2.764646524155978e-05
and O 0 2.1790571125279712e-08
occurs O 0 7.039017813070814e-09
with O 0 4.032540135145979e-10
a O 0 6.227677484815786e-09
high O 0 2.2991349624135182e-07
frequency O 0 2.5346203983644955e-05
in O 0 2.0942440670523865e-08
Finland O 0 5.585988674283726e-06
because O 0 1.0262281691097996e-08
of O 0 6.425472376392349e-10
a O 0 2.0641484965722157e-08
founder O 0 2.947180064438726e-07
effect O 0 1.5703969324931677e-07
. O 0 8.583755572999507e-08

While O 0 6.121084879850969e-06
very O 0 1.491815879717251e-07
few O 0 7.258474710170049e-08
patients O 0 4.1808641526586143e-07
with O 0 3.615797083966754e-08
AGU B-Disease 1 1.0
have O 0 1.6245236110989936e-05
been O 0 6.152872629172634e-07
reported O 0 1.1208616967905982e-07
from O 0 4.05767863753681e-09
non O 0 5.077253717900021e-06
- O 0 5.6613234846736304e-06
Finnish O 0 5.957269422651734e-06
origin O 0 8.113585181490635e-08
, O 0 6.062089941138993e-09
we O 0 4.929146939502971e-07
diagnosed O 0 2.841990499291569e-05
the O 0 5.006046244204754e-09
disorder O 0 5.33832935616374e-05
in O 0 1.769513424676461e-09
8 O 0 1.2922512837576505e-07
patients O 0 3.223417976983001e-08
originating O 0 4.498831529531344e-09
from O 0 2.191819614694168e-09
3 O 0 1.2278267291776501e-08
unrelated O 0 2.0630503527740984e-08
families O 0 2.0621417462507452e-08
, O 0 1.7240119332129211e-09
all O 0 5.8471152364347745e-09
Palestinian O 0 2.449160547257634e-06
Arabs O 0 9.165566439151007e-08
from O 0 2.751481487095475e-09
the O 0 2.47616438464604e-09
region O 0 6.911711203372306e-09
of O 0 5.421805671090851e-09
Jerusalem O 0 1.0513498637010343e-05
. O 0 1.7986442912842904e-07

The O 0 1.1279995533186593e-06
clinical O 0 0.00037869601510465145
diagnosis O 1 0.9720903635025024
of O 0 1.8399376244815357e-07
AGU B-Disease 1 1.0
is O 0 2.8543942676151346e-07
often O 0 1.3275398487166967e-06
difficult O 0 1.9027900634682737e-05
, O 0 7.339201246736593e-09
in O 0 7.928166456672159e-10
particular O 0 8.271745954857579e-09
early O 0 3.898528788681688e-08
in O 0 7.825255998739067e-10
the O 0 1.498190349558115e-09
course O 0 8.866610556879095e-08
of O 0 3.4631500445136965e-10
the O 0 3.626724165428641e-08
disease O 0 6.49863068247214e-06
, O 0 4.885408189103657e-10
and O 0 6.523933060442744e-10
most O 0 1.7549586783793814e-10
of O 0 7.424445780390698e-11
the O 0 1.675451244409487e-08
patients O 0 3.669398438432836e-07
are O 0 2.5822248517215485e-07
diagnosed O 0 5.1460956456139684e-05
after O 0 6.618173120642723e-09
the O 0 2.1846449094198306e-09
age O 0 2.621665196045342e-08
of O 0 7.633974563603374e-10
5 O 0 2.4257818864725778e-08
years O 0 4.51446950933132e-08
. O 0 9.572728743023617e-08

However O 0 3.412993692109012e-06
, O 0 3.7870254487870625e-08
since O 0 1.1713546577141187e-08
these O 0 1.0493447888393348e-08
patients O 0 9.964815461671606e-08
excrete O 0 6.269381458423595e-08
early O 0 1.3295433198834417e-08
large O 0 2.9457498662566195e-09
amounts O 0 6.535095575799232e-09
of O 0 2.034111989956955e-09
aspartylglucosamine O 0 3.986396222899202e-06
in O 0 1.0930978788792345e-08
urine O 0 1.6754532907725661e-06
, O 0 5.2735091848887805e-09
biochemical O 0 1.0831527674781682e-07
screening O 0 4.1060289390770777e-07
is O 0 8.629913672564271e-09
easy O 0 3.6967884398109163e-07
by O 0 1.3317565716874924e-08
urine O 0 1.3246778962638928e-06
chromatography O 0 1.6569194940529997e-06
. O 0 3.545036619811981e-08
. O 0 1.329429721863562e-07

Detection O 0 1.6288997358060442e-05
of O 0 6.79582825569014e-08
heterozygous O 0 4.370638180262176e-06
carriers O 0 5.192714525037445e-07
of O 0 5.5186482050828545e-09
the O 0 3.363564076153125e-07
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 3.5568524481277564e-07
ATM O 0 2.609052899060771e-06
) O 0 6.4109322295280435e-09
gene O 0 3.5255219188456977e-08
by O 0 3.1308340364688547e-09
G2 O 0 8.064981216193701e-07
phase O 0 2.3182057873327722e-07
chromosomal O 0 4.6765821025474e-05
radiosensitivity O 0 5.128204065840691e-06
of O 0 3.956871097443582e-08
peripheral O 0 0.0004149249871261418
blood O 0 0.0012474290560930967
lymphocytes O 0 2.3742228222545236e-05
. O 0 3.486922537376813e-07

In O 0 5.9570094890659675e-05
ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
( O 0 0.005679421592503786
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 8.92102960392549e-08
patients O 0 2.2962467483012006e-07
, O 0 1.220019640868486e-09
mutations O 0 1.3480516258823627e-07
in O 0 1.9595013112105875e-10
a O 0 1.9334256418090945e-09
single O 0 6.693812792946119e-07
gene O 0 2.3381666380828392e-07
, O 0 3.3757991957372724e-09
ATM O 0 3.053430646104971e-06
, O 0 9.212815399450847e-09
result O 0 3.954442107101386e-08
in O 0 4.53885817819355e-09
an O 0 2.00051272258861e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
syndrome I-Disease 1 1.0
that O 0 1.7047790734636692e-08
embraces O 0 5.411910919406182e-08
a O 0 2.9173008453398097e-09
variety O 0 7.16709713799446e-09
of O 0 1.2606742316734199e-09
clinical O 0 9.137704637396382e-07
features O 0 7.560629455838352e-07
and O 0 3.1309522796618694e-07
manifests O 0 1.8330878504002612e-07
extreme O 0 1.637715627111902e-06
radiosensitivity O 0 2.2235217329580337e-05
and O 0 2.530712528425738e-08
a O 0 1.9220944835751652e-08
strong O 0 5.370823146222392e-07
pre O 0 0.015446639619767666
- O 0 0.0006092654657550156
disposition O 0 1.4708025446452666e-06
to O 0 8.10844937859656e-08
malignancy B-Disease 0 0.0004580630920827389
. O 0 1.9199514156298392e-07

Heterozygotes O 0 0.00012123595661250874
for O 0 6.345872805013641e-08
the O 0 1.0791930016296192e-08
ATM O 0 1.185831365546619e-06
gene O 0 5.367602966543927e-07
have O 0 2.983910718512561e-08
no O 0 1.9109961613139603e-08
clinical O 0 1.691468014541897e-07
expression O 0 7.494971043797705e-08
of O 0 1.9398315842522607e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
but O 0 3.983063834311906e-07
may O 0 7.973849847076053e-07
be O 0 4.63663383243329e-07
cancer B-Disease 0 1.341118831987842e-06
prone O 0 3.3654166600172175e-06
with O 0 1.7352549397386952e-09
a O 0 1.4186888108724816e-08
moderate O 0 3.1363726975541795e-06
increase O 0 9.269857770277667e-08
in O 0 1.1732776528106115e-08
in O 0 1.262128090928627e-08
vitro O 0 4.5509783376473933e-05
radiosensitivity O 0 3.5299013688927516e-05
. O 0 1.1681177625177952e-07

We O 0 2.9802118660882115e-05
performed O 0 2.110268496835488e-06
a O 0 3.346031007822603e-08
blind O 0 6.322971444205905e-07
chromosomal O 0 3.7355775930336677e-06
analysis O 0 1.158591942385101e-07
on O 0 9.397841438385512e-08
G2 O 0 2.591139946162002e-06
- O 0 2.049335535048158e-06
phase O 0 5.216808176555787e-07
lymphocytes O 0 5.304785872795037e-07
from O 0 7.911283184114382e-09
7 O 0 7.847174998687478e-08
unrelated O 0 5.675907459590235e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 0.00033978442661464214
, O 0 2.51922993577125e-09
13 O 0 8.064426459952756e-09
obligate O 0 1.811522594152848e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 6.6639986471273005e-06
( O 0 3.4428928596952346e-09
parents O 0 6.867649116060193e-09
of O 0 1.5999268576649683e-10
the O 0 4.456649715933736e-09
patients O 0 3.251743763144077e-08
) O 0 2.315277691788964e-10
, O 0 3.9491315773076963e-10
and O 0 3.951559968129459e-09
14 O 0 1.5635102101896337e-08
normal O 0 2.2946087696595896e-08
controls O 0 4.371278237158549e-07
following O 0 4.777670525868416e-08
X O 0 2.869821764761582e-05
- O 0 3.3332198654534295e-06
irradiation O 0 1.4853932839287154e-07
with O 0 6.615623604488974e-09
1 O 0 1.5890773141791215e-08
Gy O 0 2.14177998714149e-06
in O 0 2.148405453539226e-09
order O 0 2.4985096214180658e-09
to O 0 9.618953411560938e-10
evaluate O 0 4.801193398407122e-08
this O 0 6.69669375508164e-10
cytogenetic O 0 9.546124601911288e-07
method O 0 8.141799412442197e-08
as O 0 4.948808918214809e-09
a O 0 3.837324680233678e-09
tool O 0 4.5369301915343385e-07
for O 0 3.184386310195464e-09
detection O 0 2.0625473950985906e-07
of O 0 1.0449568321746483e-08
ATM O 0 6.929117807885632e-05
carriers O 0 1.5095783965080045e-05
. O 0 2.3580990671234758e-07

Both O 0 5.6416800362057984e-05
A B-Disease 1 0.9999990463256836
- I-Disease 1 0.9999967813491821
T I-Disease 1 1.0
homozygotes O 0 6.236515037016943e-05
and O 0 4.239730699850952e-08
heterozygotes O 0 1.3338559483599965e-06
showed O 0 1.5589250779157737e-07
significantly O 0 5.639014588609825e-08
increased O 0 1.6574071892705433e-08
levels O 0 5.906728972604469e-08
of O 0 2.0598722727527274e-09
radiation O 0 0.0017457029316574335
- O 0 0.008255836553871632
induced O 0 0.00013423507334664464
chromatid O 0 0.00024004867009352893
damage O 0 3.230630909456522e-06
relative O 0 8.94542822038602e-08
to O 0 1.8143047064711482e-09
that O 0 6.519666473359109e-10
of O 0 1.1217247131156682e-09
normal O 0 6.097042728470115e-07
controls O 0 3.99240234401077e-05
. O 0 2.0600627692601847e-07

These O 0 5.388106956161209e-07
results O 0 8.841784904234373e-08
show O 0 8.448484578593707e-08
that O 0 1.3565156775641185e-09
the O 0 5.2723927446152175e-09
G2 O 0 1.8135049231204903e-06
- O 0 3.355987701070262e-06
phase O 0 6.266548098210478e-07
chromosomal O 0 7.794398698024452e-05
radiosensitivity O 0 2.966254214697983e-06
assay O 0 1.3694924518858897e-06
can O 0 4.191607274606213e-07
be O 0 1.0207543255091878e-08
used O 0 2.1997319521460668e-08
for O 0 8.343807866850739e-10
the O 0 2.927607489766615e-09
detection O 0 8.748261848268157e-07
of O 0 4.2566981051095354e-08
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 0.00010502258373890072
. O 0 2.3183341113508504e-07

In O 0 4.69583682161101e-07
combination O 0 2.7878175501427904e-07
with O 0 8.742105706005532e-09
molecular O 0 6.041799451850238e-07
genetic O 0 6.545634732901817e-06
analyses O 0 8.937769052863587e-06
, O 0 9.334828909857151e-09
this O 0 1.7992898282415126e-09
test O 0 0.00030586228240281343
may O 0 1.0096910045831464e-06
be O 0 1.5678306430899625e-09
of O 0 5.662156160601839e-11
value O 0 1.2442177288463085e-09
in O 0 2.5704255390834874e-10
studies O 0 1.8900827569723333e-09
of O 0 6.59874543895711e-10
familial B-Disease 0 1.3979333743918687e-05
and I-Disease 0 7.594086923745635e-07
sporadic I-Disease 1 0.5557001233100891
cancers I-Disease 1 0.9997896552085876
aimed O 0 1.2270736988284625e-05
at O 0 4.836044809053419e-07
determination O 0 2.604867965771973e-08
of O 0 5.019342719236874e-10
the O 0 2.4456363600933173e-09
potential O 0 7.080869224296293e-09
involvement O 0 1.0175353004626686e-08
of O 0 1.478421829403942e-09
ATM O 0 3.629293496487662e-05
mutations O 0 2.9921666282461956e-05
in O 0 2.640635088368981e-08
tumor B-Disease 0 4.6874276449671015e-05
risk O 0 3.208126372555853e-06
or O 0 4.708455847435289e-08
development O 0 1.0161310903811227e-08
. O 0 9.825020796938588e-09
. O 0 3.3778100316794735e-08

Ataxia B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
telangiectasia I-Disease 1 1.0
: O 0 4.936593995807925e-07
identification O 0 1.2300458251957025e-07
and O 0 4.8268917751670415e-09
detection O 0 1.5627789196059894e-07
of O 0 2.930965470326896e-09
founder O 0 3.2609176514597493e-07
- O 0 6.745541668351507e-06
effect O 0 1.0613926804126095e-07
mutations O 0 3.079053385590669e-07
in O 0 8.47158398986636e-10
the O 0 1.6929123658471212e-09
ATM O 0 5.184011229175667e-07
gene O 0 1.136984906224825e-07
in O 0 3.7039993294740725e-09
ethnic O 0 1.042174631038506e-07
populations O 0 8.736314498491993e-07
. O 0 2.7317202011545305e-07

To O 0 1.6761678978127748e-07
facilitate O 0 1.0931044158724035e-07
the O 0 5.732753827203396e-09
evaluation O 0 1.0371492109584324e-08
of O 0 8.392760930675536e-10
ATM O 0 7.001220183155965e-06
heterozygotes O 0 5.932811291131657e-07
for O 0 8.480378621555928e-10
susceptibility O 0 1.5319237434141542e-07
to O 0 5.106426836931632e-09
other O 0 2.0872814587846733e-08
diseases O 0 6.998080061748624e-05
, O 0 3.910604617907154e-10
such O 0 1.123891979482039e-09
as O 0 2.7805417630588636e-06
breast B-Disease 1 0.9999972581863403
cancer I-Disease 0 0.002176763489842415
, O 0 8.507016424630365e-09
we O 0 1.7616713421375607e-08
have O 0 2.3578656804801312e-09
attempted O 0 3.898335521057561e-08
to O 0 3.043283847148359e-09
define O 0 4.0116054833561066e-07
the O 0 2.365126317016575e-09
most O 0 1.0597409616508457e-09
common O 0 9.341632356552054e-09
mutations O 0 3.525509271185001e-07
and O 0 1.0157765295559784e-08
their O 0 2.1244259684749522e-08
frequencies O 0 1.3700730960408691e-05
in O 0 1.26890802221169e-06
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.0005224760388955474
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 4.804720177276067e-08
homozygotes O 0 1.3278678352435236e-06
from O 0 7.727250839195676e-09
10 O 0 1.2477379129904875e-08
ethnic O 0 4.788983787307188e-08
populations O 0 8.605243806414364e-07
. O 0 1.2283940975521546e-07

Both O 0 1.7551398059367784e-06
genomic O 0 1.0533901331655215e-05
mutations O 0 2.842264439095743e-05
and O 0 8.936118689462091e-08
their O 0 5.345045650528846e-08
effects O 0 5.763690182902792e-07
on O 0 1.5884410231592483e-08
cDNA O 0 1.3344268268156156e-07
were O 0 1.7838596022556885e-07
characterized O 0 4.3128179072482453e-07
. O 0 8.081398306103438e-08

Protein O 0 2.317368307558354e-05
- O 0 5.4022029871703126e-06
truncation O 0 2.153889681721921e-06
testing O 0 7.636849659320433e-07
of O 0 2.919382513510982e-09
the O 0 5.081089327063637e-09
entire O 0 3.1291996549498435e-08
ATM O 0 2.920231736425194e-07
cDNA O 0 1.8022537062734045e-07
detected O 0 1.8063108200294664e-06
92 O 0 1.9447482202394895e-07
( O 0 1.0864961375034454e-08
66 O 0 1.1838026381383315e-07
% O 0 1.5644827655592053e-08
) O 0 3.658152003538362e-09
truncating O 0 3.5337191661710676e-07
mutations O 0 7.172761229412572e-07
in O 0 2.92215696084952e-09
140 O 0 2.2389501808106615e-08
mutant O 0 2.0949726149410708e-06
alleles O 0 2.696402361834771e-06
screened O 0 2.7395404686103575e-05
. O 0 6.718615281897655e-07

The O 0 2.814268214024196e-07
haplotyping O 0 3.519023493936402e-06
of O 0 1.1394354793026196e-08
patients O 0 1.4495833511318779e-06
with O 0 1.0537673844623896e-08
identical O 0 0.0016250676708295941
mutations O 0 0.0007645651348866522
indicates O 0 5.802091322948399e-07
that O 0 2.139143973067803e-09
almost O 0 3.002900328397118e-08
all O 0 7.027987081187348e-10
of O 0 1.75952030723181e-10
these O 0 1.0645707648748726e-09
represent O 0 6.02646643699245e-09
common O 0 7.871189922070698e-08
ancestry O 0 1.3288560694491025e-05
and O 0 6.473144509300255e-08
that O 0 2.2825510370694246e-09
very O 0 3.205423482199876e-08
few O 0 6.49881428671506e-08
spontaneously O 0 3.7228807059364044e-07
recurring O 0 4.631358478945913e-06
ATM O 0 0.00022896970040164888
mutations O 0 0.0001411975099472329
exist O 0 1.4445462284129462e-06
. O 0 2.6853859935727087e-07

Assays O 0 0.00013695783854927868
requiring O 0 4.794289907295024e-06
minimal O 0 2.0151808257651282e-06
amounts O 0 4.275820231214311e-08
of O 0 1.0575037512339236e-09
genomic O 0 2.612810305890889e-07
DNA O 0 1.4644120938100968e-06
were O 0 1.10345268922174e-07
designed O 0 4.8072138270072173e-08
to O 0 1.5933893093844631e-09
allow O 0 8.480188107284903e-09
rapid O 0 9.931495981163607e-08
screening O 0 2.637293619045522e-07
for O 0 9.218599217319934e-09
common O 0 1.6101189714845532e-07
ethnic O 0 3.989538015503058e-07
mutations O 0 7.38413873477839e-05
. O 0 3.1195045835374913e-07

These O 0 7.234893928398378e-07
rapid O 0 1.3871400597054162e-06
assays O 0 1.1605061445152387e-05
detected O 0 5.734194928663783e-06
mutations O 0 1.5890583426880767e-06
in O 0 4.869409320207296e-09
76 O 0 1.2846759034346178e-07
% O 0 1.3381219687857993e-08
of O 0 8.615420044044697e-10
Costa O 0 4.4924459530193417e-07
Rican O 0 5.047105332778301e-06
patients O 0 5.123395681039256e-07
( O 0 1.0660906601955844e-09
3 O 0 2.768310691791953e-09
) O 0 6.683830711118333e-10
, O 0 8.706922960399766e-10
50 O 0 3.835568307408721e-09
% O 0 2.61814081525813e-09
of O 0 1.2185871200998122e-09
Norwegian O 1 0.9308382272720337
patients O 0 2.3120792320696637e-05
( O 0 1.5692337429484837e-09
1 O 0 2.3676356430968326e-09
) O 0 1.3523615560728786e-09
, O 0 9.996845573567725e-10
25 O 0 1.4331815734180964e-09
% O 0 1.1838128255448055e-09
of O 0 2.7625599030578485e-10
Polish O 0 0.01949828304350376
patients O 0 2.0742184005939635e-06
( O 0 6.157362952841083e-10
4 O 0 2.7535027591341077e-09
) O 0 1.1279077671844107e-09
, O 0 8.705892673432913e-10
and O 0 1.1536454458394019e-08
14 O 0 2.6985576440097248e-08
% O 0 3.1392173305277993e-09
of O 0 9.083310215096674e-10
Italian O 0 0.09992100298404694
patients O 0 6.495235993497772e-06
( O 0 1.9111410232142134e-09
1 O 0 2.24574936424915e-09
) O 0 9.151863156198203e-10
, O 0 5.75178571438073e-10
as O 0 1.6424770432621472e-09
well O 0 6.5761578404988086e-09
as O 0 7.995413220385217e-09
in O 0 2.0530472877311468e-09
patients O 0 7.939066293261021e-09
of O 0 5.624196663944758e-10
Amish O 0 5.200076429900946e-06
/ O 0 4.119719960726798e-06
Mennonite O 0 4.29769806942204e-06
and O 0 9.195595112032606e-07
Irish O 0 7.977615496201906e-06
English O 0 1.9476694433251396e-05
backgrounds O 0 3.0341559977387078e-05
. O 0 5.367049880078412e-07

Additional O 0 4.0569648263044655e-06
mutations O 0 5.582292578765191e-05
were O 0 2.0906466602355067e-07
observed O 0 3.984924745736862e-08
in O 0 9.007192769416861e-10
Japanese O 0 1.383041769997817e-08
, O 0 3.0285915442185285e-10
Utah O 0 1.283804063056948e-09
Mormon O 0 2.863703274513796e-09
, O 0 4.753950011426866e-10
and O 0 1.2613381450421457e-09
African O 0 5.955461013229524e-09
American O 0 4.7546169668066796e-08
patients O 0 1.3982298696646467e-07
. O 0 4.458539493157332e-08

These O 0 2.790110329442541e-07
assays O 0 3.561638777682674e-06
should O 0 7.787756572952276e-08
facilitate O 0 4.32125766280933e-08
screening O 0 6.507087846330251e-07
for O 0 3.1207068218463974e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
heterozygotes O 0 3.4919050904136384e-06
in O 0 1.6216921139289298e-09
the O 0 2.6239050932019836e-09
populations O 0 1.9566350317745673e-08
studied O 0 2.489999850752156e-08
. O 0 3.763850564553195e-09
. O 0 3.168200279901612e-08

The O 0 1.1262947737122886e-05
von B-Disease 1 0.6556787490844727
Hippel I-Disease 1 0.9993385672569275
- I-Disease 1 0.9936020970344543
Lindau I-Disease 1 0.9979555606842041
tumor I-Disease 0 0.0010147435823455453
suppressor O 0 7.154593731684145e-06
gene O 0 3.8940777358220657e-07
is O 0 4.1561700747649866e-09
required O 0 1.4188810126825047e-08
for O 0 4.485944504750705e-09
cell O 0 5.286642135615693e-06
cycle O 0 6.2514386627299245e-06
exit O 0 4.224541498842882e-06
upon O 0 1.286341984041428e-07
serum O 0 9.271869203075767e-06
withdrawal O 0 9.438802408112679e-06
. O 0 3.6147736182101653e-07

The O 0 8.016754691198003e-07
inactivation O 0 2.8939155072293943e-06
of O 0 1.930655280091287e-08
the O 0 9.250994281728708e-08
von B-Disease 1 0.9285404682159424
Hippel I-Disease 1 0.999849796295166
- I-Disease 1 0.9995232820510864
Lindau I-Disease 1 0.9998739957809448
( I-Disease 0 3.3142016491183313e-06
VHL I-Disease 0 0.001947931363247335
) I-Disease 0 2.586984635399858e-07
tumor I-Disease 0 1.264943421119824e-05
suppressor O 0 5.42708175998996e-06
gene O 0 1.862685962805699e-06
predisposes O 0 5.87451177125331e-06
affected O 0 3.957921137498488e-07
individuals O 0 9.26819332391915e-09
to O 0 1.7408573471655586e-09
the O 0 2.299761270307954e-08
human O 0 1.1897747754119337e-05
VHL B-Disease 1 0.9999998807907104
cancer I-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999990463256836
and O 0 9.405064282930198e-09
is O 0 1.8633512510746186e-09
associated O 0 3.7284408449522743e-08
with O 0 1.7707661470467428e-07
sporadic B-Disease 1 0.999992847442627
renal I-Disease 1 0.9999998807907104
cell I-Disease 1 0.9999994039535522
carcinomas I-Disease 1 1.0
( O 0 8.443556907877792e-06
RCC B-Disease 0 0.0005318078910931945
) O 0 6.228405169395046e-08
and O 0 1.338412261020494e-07
brain B-Disease 0 0.007233771029859781
hemangioblastomas I-Disease 0 0.0001517791097285226
. O 0 3.021457928298332e-07

VHL O 0 0.053626447916030884
- O 0 0.0007510693976655602
negative O 0 2.0521814803942107e-05
786 O 0 1.5261059161275625e-05
- O 0 3.4706299629760906e-05
0 O 0 9.861707894742722e-07
RCC B-Disease 0 1.33317416839418e-05
cells O 0 7.586124866065802e-07
are O 0 1.291698836780597e-08
tumorigenic O 0 8.066535883699544e-07
in O 0 1.5895532001763968e-08
nude O 0 0.1082102581858635
mice O 0 1.3583875443146098e-05
which O 0 1.1182261339115485e-08
is O 0 1.5286139021242207e-09
suppressed O 0 8.87459261633694e-09
by O 0 2.7135538260836256e-10
the O 0 1.4604453202338163e-09
reintroduction O 0 8.863685252435971e-08
of O 0 3.0123199934450895e-08
VHL B-Disease 0 0.00010014954023063183
. O 0 7.573164566565538e-07

Remarkably O 0 0.006064628716558218
, O 0 7.446139704825327e-08
this O 0 1.956268480540757e-09
occurs O 0 7.68539010209679e-09
without O 0 2.805787158166595e-09
affecting O 0 6.922490136673787e-09
the O 0 1.3101739693155423e-09
growth O 0 2.7802071755900215e-08
rate O 0 1.4953938887174445e-07
and O 0 3.9245193761416886e-09
cell O 0 9.427787261984122e-08
cycle O 0 8.509925208954883e-08
profile O 0 2.1803332472813963e-08
of O 0 9.40947320060559e-10
these O 0 1.2008788630168965e-08
cells O 0 3.367337697568473e-08
in O 0 3.0564306641167605e-09
culture O 0 8.568706277856108e-08
. O 0 8.415579344500657e-08

The O 0 9.700273722046404e-07
786 O 0 9.05137221707264e-06
- O 0 1.244230861630058e-05
0 O 0 3.6517965895654925e-07
cell O 0 7.95769949490932e-07
line O 0 2.9398265724012163e-06
, O 0 8.389927641516692e-10
like O 0 3.0606892575946176e-09
many O 0 3.432886641618893e-09
cancer B-Disease 0 1.0647580666045542e-06
cells O 0 1.4750932919582738e-08
, O 0 5.723944651592205e-10
fails O 0 2.987225045103514e-08
to O 0 3.922439262282751e-09
exit O 0 3.188805749232415e-06
the O 0 3.6280109583231024e-08
cell O 0 5.302557383402018e-06
cycle O 0 1.2612589443961042e-06
upon O 0 5.431672533973142e-08
serum O 0 2.398436663497705e-06
withdrawal O 0 2.395382807662827e-06
. O 0 1.584439814905636e-07

Here O 0 2.6557383989711525e-06
, O 0 2.260990861202572e-08
it O 0 2.086985695370913e-09
is O 0 5.904898237041323e-10
shown O 0 1.2322226572436534e-09
that O 0 1.1085139750566242e-10
reintroduction O 0 1.3752128324995283e-09
of O 0 8.039983262486672e-11
the O 0 6.514569994564567e-10
wild O 0 1.7573185573382943e-08
- O 0 2.2686795091431122e-06
type O 0 7.084820390446112e-05
VHL B-Disease 0 7.749974611215293e-05
gene O 0 8.619979325885652e-07
restores O 0 4.4133548726676963e-07
the O 0 5.081913112547909e-09
ability O 0 7.797967782607884e-08
of O 0 1.1064154037399021e-08
VHL O 0 0.0004824501520488411
- O 0 0.00021789006132166833
negative O 0 0.00011410628212615848
RCC B-Disease 0 0.0014524615835398436
cancer I-Disease 0 2.8189711883896962e-05
cells O 0 5.552309900735963e-08
to O 0 2.695099921012911e-09
exit O 0 3.8131406654429156e-07
the O 0 1.8179116878513923e-08
cell O 0 1.370422637592128e-06
cycle O 0 6.604757913919457e-07
and O 0 1.8421633996013043e-08
enter O 0 7.203472023320501e-07
G0 O 0 2.190083614550531e-05
/ O 0 2.342673496968928e-06
quiescence O 0 1.7452987322030822e-06
in O 0 8.593387690325471e-08
low O 0 0.0023468201979994774
serum O 0 3.6809251469094306e-05
. O 0 1.9517770510901755e-07

Both O 0 1.3183135706640314e-05
VHL O 0 0.0007372202235274017
- O 0 2.513191611797083e-05
positive O 0 3.124759757611173e-07
and O 0 5.745553366409695e-08
VHL O 0 5.921108095208183e-05
- O 0 6.11837685937644e-06
negative O 0 4.40410258306656e-06
RCC B-Disease 0 1.75012228282867e-05
cells O 0 5.333334911483689e-07
exit O 0 3.8301791960293485e-07
the O 0 2.3552148675776152e-08
cell O 0 2.166663080060971e-06
cycle O 0 5.53397626390506e-07
by O 0 5.761736865395051e-09
contact O 0 1.8054291786029353e-06
inhibition O 0 3.3847579743451206e-06
. O 0 3.44825821230188e-07

The O 0 3.6792625905945897e-06
cyclin O 0 0.00018103723414242268
- O 0 4.2069718801940326e-06
dependent O 0 1.0370225709266379e-06
kinase O 0 1.7073130038625095e-06
inhibitor O 0 5.080985374661395e-07
, O 0 5.712822215286906e-09
p27 O 0 5.20089258770895e-07
, O 0 4.186595070621024e-09
accumulates O 0 6.299227806039198e-08
upon O 0 6.623931625426849e-09
serum O 0 1.8011076008406235e-07
withdrawal O 0 2.0076143414371472e-07
, O 0 1.3529601883277564e-09
only O 0 1.2249862235691467e-09
in O 0 4.414524579221535e-10
the O 0 6.290876708447968e-10
presence O 0 3.632925738017434e-09
of O 0 4.5856185515447123e-10
VHL B-Disease 0 1.6732561789467582e-06
, O 0 1.7841608190849456e-09
as O 0 1.0289008534059008e-09
a O 0 1.3728567171966688e-09
result O 0 8.872832246709095e-09
of O 0 2.426057132964843e-10
the O 0 1.3695248268774662e-09
stabilization O 0 1.0130425387444575e-08
of O 0 6.348142567169646e-10
the O 0 5.108472755921412e-09
protein O 0 1.4233607714686514e-07
. O 0 8.247362615065867e-08

We O 0 9.477247999711835e-07
propose O 0 1.634185196053295e-07
that O 0 1.04654795940462e-09
the O 0 1.4904606437937673e-09
loss O 0 6.137667263317326e-09
of O 0 6.253849660353694e-10
wild O 0 5.740547237564897e-08
- O 0 1.628216341487132e-05
type O 0 0.003049186896532774
VHL B-Disease 0 0.0007320932927541435
gene O 0 5.3258495427144226e-06
results O 0 4.918670697406924e-07
in O 0 1.6021508564278975e-09
a O 0 2.903633777862069e-09
specific O 0 5.337629005452982e-08
cellular O 0 8.475327376800124e-06
defect O 0 8.581741894886363e-06
in O 0 3.5922311791836137e-09
serum O 0 9.310805353379692e-07
- O 0 4.254898158251308e-06
dependent O 0 2.4763842247921275e-06
growth O 0 2.654993807027495e-07
control O 0 3.5283281363263086e-07
, O 0 2.167284129939162e-09
which O 0 2.7192441631740394e-09
may O 0 2.5671159420426193e-08
initiate O 0 6.719704401803028e-07
tumor B-Disease 0 8.295151019410696e-06
formation O 0 9.414361556991935e-07
. O 0 2.149999431821925e-07

This O 0 4.5462857656275446e-07
is O 0 4.3735632004882063e-08
corrected O 0 5.405100864663837e-07
by O 0 5.141647663187143e-10
the O 0 1.313125302937479e-10
reintroduction O 0 5.766552568786665e-09
of O 0 9.535946476901813e-10
wild O 0 1.4834085959591903e-07
- O 0 0.0004287177580408752
type O 0 0.3537178039550781
VHL B-Disease 0 0.04596267268061638
, O 0 2.778860697105756e-08
implicating O 0 1.2564049939101096e-05
VHL B-Disease 0 2.1270923753036186e-05
as O 0 7.974608529082161e-09
the O 0 2.105296825760661e-09
first O 0 2.9028599968228264e-08
tumor B-Disease 0 2.8109931804465305e-07
suppressor O 0 9.447678905871726e-08
involved O 0 1.3937801135455175e-08
in O 0 4.160356226190487e-10
the O 0 9.676992540619267e-10
regulation O 0 1.9082863289554552e-08
of O 0 2.6318545121029047e-09
cell O 0 1.8170834437114536e-06
cycle O 0 2.659474148458685e-06
exit O 0 1.5603929568897e-05
, O 0 3.143053461940326e-08
which O 0 9.361288633158438e-09
is O 0 6.4179430658839465e-09
consistent O 0 7.825246939319186e-07
with O 0 1.8311032690121465e-09
its O 0 4.580114065788621e-09
gatekeeper O 0 8.538114570910693e-07
function O 0 1.4541926418587536e-07
in O 0 3.222303979200092e-09
the O 0 6.443703881586771e-08
kidney O 0 1.5996591855582665e-06
. O 0 4.6027608391341346e-09
. O 0 4.403739239933202e-08

Piebaldism B-Disease 1 1.0
with O 0 0.000498899316880852
deafness B-Disease 1 1.0
: O 0 1.3339649740373716e-07
molecular O 0 3.248681537115772e-07
evidence O 0 5.87425930120844e-08
for O 0 2.8710973598577993e-09
an O 0 4.2872368766211366e-08
expanded O 0 0.1659829020500183
syndrome O 1 0.9999970197677612
. O 0 3.131982850845816e-07

In O 0 3.78564664060832e-07
a O 0 4.649865203987247e-08
South O 0 7.812035818233198e-08
African O 0 2.5622290067417453e-08
girl O 0 1.700240233049044e-07
of O 0 7.102101129419225e-10
Xhosa O 0 5.1254560275992844e-06
stock O 0 1.7607600000246748e-07
with O 0 1.2687848993664375e-08
severe O 0 0.0001166452857432887
piebaldism B-Disease 0 0.0001390723919030279
and O 0 6.298807306848175e-07
profound O 0 0.00021361486869864166
congenital O 1 1.0
sensorineural B-Disease 1 0.9999990463256836
deafness I-Disease 1 1.0
we O 0 0.13166382908821106
identified O 0 4.826659733225824e-06
a O 0 1.1144403622154186e-08
novel O 0 2.0692334956606828e-08
missense O 0 3.667509247406997e-07
substitution O 0 3.419439664753554e-08
at O 0 5.106478795369185e-08
a O 0 5.691743965030582e-09
highly O 0 2.6680243792043257e-08
conserved O 0 4.683573706643074e-08
residue O 0 2.2003472111009614e-07
in O 0 1.0076116607748986e-09
the O 0 1.165030516503407e-09
intracellular O 0 9.582704052490953e-08
kinase O 0 1.8238075938370457e-07
domain O 0 1.381217451523753e-08
of O 0 1.3668238763031582e-09
the O 0 1.6293945748202532e-08
KIT O 0 1.1392482520022895e-05
proto O 0 0.0003952419792767614
- O 0 8.247065852629021e-05
oncogene O 0 2.2800562874181196e-05
, O 0 1.7963010634503007e-07
R796G O 0 6.575943189091049e-06
. O 0 2.4328323888767045e-07

Though O 0 7.344984169321833e-06
auditory B-Disease 0 2.7544383556232788e-05
anomalies I-Disease 0 0.000827119336463511
have O 0 1.1297146329525276e-06
been O 0 6.729118950943302e-08
observed O 0 2.100228257972958e-08
in O 0 9.3022978209234e-10
mice O 0 7.260003940245952e-07
with O 0 6.642187688754575e-09
dominant O 0 0.0001432337739970535
white O 0 1.137471258516598e-06
spotting O 0 4.30494656029623e-05
( O 0 8.271322826658434e-08
W O 0 0.06495026499032974
) O 0 2.0168315906232692e-09
due O 0 7.613228270031414e-09
to O 0 1.4372666612416651e-08
KIT O 0 0.17725007236003876
mutations O 0 0.14392809569835663
, O 0 1.348028604297724e-07
deafness B-Disease 1 1.0
is O 0 2.343018756789661e-08
not O 0 9.909126852392092e-09
typical O 0 8.233436687987705e-08
in O 0 1.3552130084804048e-08
human O 0 1.1344417316649924e-07
piebaldism B-Disease 0 2.3941996914800256e-05
. O 0 2.689299378744181e-07

Thus O 0 7.636342161276843e-06
, O 0 1.823353201757527e-08
the O 0 3.290812955469846e-09
occurrence O 0 2.8412031838342955e-07
of O 0 2.763142425976639e-08
sensorineural B-Disease 1 0.9946284890174866
deafness I-Disease 1 1.0
in O 0 1.8609551943882252e-07
this O 0 1.983713460163017e-08
patient O 0 2.1286498395056697e-06
extends O 0 4.050914270692374e-08
considerably O 0 6.917133532624575e-08
the O 0 2.0879651341232375e-09
phenotypic O 0 2.667437399850314e-07
range O 0 3.958993488595297e-07
of O 0 3.224006839275262e-09
piebaldism B-Disease 0 3.7542060908890562e-06
due O 0 3.3843107871689426e-08
to O 0 4.979752610267951e-09
KIT O 0 1.5579067621729337e-05
gene O 0 1.0850764056158368e-06
mutation O 0 3.8994215856291703e-07
in O 0 2.1434201080694493e-09
humans O 0 3.59845948594284e-08
and O 0 1.1496542384747954e-08
tightens O 0 9.28469034988666e-06
the O 0 1.0188772492369935e-08
clinical O 0 3.42295095379086e-07
similarity O 0 3.8592730788877816e-08
between O 0 1.917509884208357e-08
piebaldism B-Disease 0 2.0039382434333675e-05
and O 0 1.2811188554451292e-08
the O 0 1.0577417830504032e-09
various O 0 2.391367548426615e-09
forms O 0 9.863761363249068e-08
of O 0 2.8030186172145477e-07
Waardenburg B-Disease 1 0.9999998807907104
syndrome I-Disease 1 0.9999991655349731
. O 0 2.309585944715309e-08
. O 0 7.278882208083814e-08

Cycloheximide O 0 7.617515075253323e-05
facilitates O 0 2.4392636532866163e-06
the O 0 3.073150622867615e-08
identification O 0 8.957722030800142e-08
of O 0 3.3452889347529435e-09
aberrant O 0 1.5341474863816984e-06
transcripts O 0 4.135189556109253e-06
resulting O 0 5.94074890614138e-07
from O 0 8.394446027182312e-09
a O 0 1.8709982896325528e-08
novel O 0 1.1403393074260748e-07
splice O 0 0.003106833668425679
- O 0 0.0006038923747837543
site O 0 1.9215428892493946e-06
mutation O 0 2.2376837023330154e-06
in O 0 8.410569130035128e-09
COL17A1 O 0 1.6200950767597533e-06
in O 0 2.574950919154162e-09
a O 0 3.652938929121774e-08
patient O 0 1.6097654906843673e-06
with O 0 5.548096737584274e-08
generalized O 0 0.0005196550046093762
atrophic B-Disease 1 0.9999203681945801
benign I-Disease 1 0.9998055100440979
epidermolysis I-Disease 1 0.9996044039726257
bullosa I-Disease 1 0.9963600039482117
. O 0 1.0674385521269869e-05

Patients O 1 0.9988347887992859
with O 0 3.930008006136632e-06
generalized O 0 0.0008208401850424707
atrophic B-Disease 1 0.9999176263809204
benign I-Disease 1 0.999929666519165
epidermolysis I-Disease 1 0.9995918869972229
bullosa I-Disease 1 0.9937636256217957
often O 0 8.877224900061265e-05
show O 0 3.0370977128768573e-06
decreased O 0 2.566519469837658e-06
expression O 0 1.8708128379785194e-08
of O 0 2.2314117220645358e-09
type O 0 8.551872451789677e-05
XVII O 0 1.99653713934822e-05
collagen O 0 1.8261482637171866e-06
, O 0 9.778003295934923e-09
a O 0 1.637966562384463e-08
transmembrane O 0 2.616525762277888e-06
hemidesmosomal O 0 1.0876292435568757e-06
protein O 0 6.025089760441915e-08
encoded O 0 9.443211013149266e-08
by O 0 2.6531454366818252e-08
COL17A1 O 0 1.533985232526902e-05
. O 0 1.754224996375342e-07

This O 0 5.225252834861749e-07
report O 0 2.0985230264614074e-07
documents O 0 4.208373738379123e-08
a O 0 1.2643447178106726e-08
novel O 0 6.486653347792526e-08
splice O 0 0.0008639604202471673
- O 0 0.0006102301995269954
site O 0 1.6505731537108659e-06
mutation O 0 2.7781511562352534e-06
in O 0 9.43668965192046e-09
COL17A1 O 0 2.5517492758808658e-06
in O 0 2.9262283707254255e-09
a O 0 2.629291806499623e-08
patient O 0 2.0495251646934776e-06
with O 0 3.939370785133178e-08
generalized O 0 0.00018865584570448846
atrophic B-Disease 1 0.9998032450675964
benign I-Disease 1 0.9967706203460693
epidermolysis I-Disease 1 0.9711896777153015
bullosa I-Disease 1 0.9537417888641357
, O 0 2.2404672961329197e-07
and O 0 7.2601191725141234e-09
applies O 0 6.256692497430549e-09
a O 0 9.772069820002116e-10
new O 0 5.274894410156605e-10
methodology O 0 1.840333574421038e-08
to O 0 2.0044024218179857e-09
define O 0 3.486623256776511e-07
and O 0 2.0460197092120325e-08
characterize O 0 5.827611744280148e-07
the O 0 1.618578160389461e-08
resulting O 0 1.6924022361308744e-07
mRNA O 0 5.029535827816289e-07
splice O 0 3.275564085924998e-05
variants O 0 1.1889366760442499e-05
. O 0 7.809561566318735e-07

Mutational O 0 0.0006729422602802515
analysis O 0 3.3148085094580892e-06
of O 0 1.4172613305163395e-07
COL17A1 O 0 5.95453311689198e-05
identified O 0 1.4863869637338212e-06
a O 0 3.750151122972056e-08
maternally O 0 1.1338484000589233e-05
inherited O 0 7.746534720354248e-06
G O 0 9.154434792435495e-07
- O 0 1.0929915106316912e-06
to O 0 1.5241973017054988e-07
- O 0 0.002680756151676178
T O 0 5.918771057622507e-05
transversion O 0 1.2184991646790877e-06
at O 0 1.355733161290118e-07
the O 0 8.924531336163e-09
- O 0 2.0197416006340063e-07
1 O 0 4.681266929651429e-09
position O 0 3.159847850042752e-08
of O 0 1.0048978316135049e-09
exon O 0 5.74506486827886e-07
32 O 0 4.0285354430125153e-07
. O 0 1.0124016114332335e-07

This O 0 1.4182455743139144e-07
acceptor O 0 6.665211458312115e-07
splice O 0 5.997771586407907e-05
- O 0 1.2236801012477372e-05
site O 0 8.43563270791492e-07
mutation O 0 6.852865794826357e-07
led O 0 1.963948470518062e-08
to O 0 1.7315353595392935e-09
the O 0 3.7566785238141165e-09
formation O 0 1.588344034075817e-08
of O 0 4.677150333698421e-10
aberrant O 0 1.4139564541437721e-07
transcripts O 0 3.9399913021043176e-07
present O 0 5.105193068288827e-08
at O 0 4.4758616013496066e-07
extremely O 0 2.9107272894179914e-06
low O 0 0.03007110394537449
levels O 0 8.710355177754536e-05
. O 0 1.8217912156615057e-07

Based O 0 6.411082154045289e-07
on O 0 7.692931802694147e-08
our O 0 7.214032393676462e-08
recent O 0 1.2388287728981595e-08
finding O 0 3.2213961276283953e-08
that O 0 5.594178897894153e-09
cycloheximide O 0 6.318833584373351e-06
stabilized O 0 2.5101810024352744e-05
mutant O 0 2.2277081370702945e-06
COL17A1 O 0 5.957854682492325e-06
transcripts O 0 9.053832741301449e-07
in O 0 1.601097743275659e-08
keratinocytes O 0 1.0985634162352653e-06
homozygous O 0 1.4652292747996398e-06
for O 0 9.450391580401174e-10
a O 0 1.0100212222141636e-08
frameshift O 0 2.722819226619322e-05
mutation O 0 2.5897859359247377e-06
, O 0 1.3443326452033943e-09
the O 0 6.1273236484638e-10
effects O 0 1.199754109393325e-07
of O 0 5.350629939115947e-10
the O 0 3.933977588133075e-09
splice O 0 0.016963722184300423
- O 0 3.631778963608667e-05
site O 0 4.1254426719206094e-07
mutation O 0 2.570830872627994e-07
on O 0 2.2280601807977973e-09
splicing O 0 1.3120580888426048e-07
of O 0 3.4193075038047027e-09
COL17A1 O 0 1.2561753237605444e-06
transcripts O 0 3.525553040617524e-07
were O 0 2.685588356143853e-07
determined O 0 4.3145863770632786e-08
using O 0 3.987966579188651e-08
reverse O 0 1.1045008250221144e-06
transcriptase O 0 3.858872332784813e-06
polymerase O 0 7.982188776622934e-07
chain O 0 1.2441576018318301e-06
reaction O 0 3.900246525745388e-08
of O 0 1.5734116232124506e-09
total O 0 2.160104450865674e-08
RNA O 0 1.4761633337911917e-07
from O 0 1.917634229187115e-08
keratinocytes O 0 5.037504138272197e-07
incubated O 0 1.8073568242016336e-07
for O 0 2.9548097302267706e-09
2 O 0 6.789156259401352e-08
. O 0 8.627481662415448e-08

5 O 0 6.036148079147097e-06
h O 0 9.234789104084484e-06
in O 0 1.0170346342874836e-08
the O 0 3.737438802886572e-09
presence O 0 1.3513824725919221e-08
or O 0 5.8490815746381486e-08
absence O 0 4.0470144568871547e-08
of O 0 7.781290056740886e-10
10 O 0 1.743330457770753e-08
microg O 0 2.608697059258702e-06
cycloheximide O 0 2.008940782616264e-06
per O 0 2.374348753164668e-07
ml O 0 1.5054897630761843e-05
. O 0 1.4811524806646048e-07

Using O 0 1.386648023071757e-06
this O 0 2.4377623475402288e-08
approach O 0 1.2491445033901982e-07
, O 0 6.513294348309273e-09
an O 0 9.954780999521518e-09
abnormally O 0 9.400486305821687e-05
spliced O 0 0.000980176031589508
transcript O 0 7.702563016209751e-05
was O 0 6.508349088107934e-06
identified O 0 2.817708377733652e-07
that O 0 5.947012882145941e-10
contains O 0 7.565513771012888e-10
an O 0 1.1788804377133033e-09
extra O 0 2.604391013960594e-08
264 O 0 1.000877887236129e-07
bases O 0 3.111150022050424e-07
upstream O 0 5.2142315354331004e-08
from O 0 2.304185953150295e-09
exon O 0 1.6057134644142934e-07
32 O 0 1.7362745552418346e-07
, O 0 3.730686870540012e-09
resulting O 0 2.6111704798381652e-08
in O 0 3.0966611497262875e-09
a O 0 4.892761396035894e-08
premature O 0 8.302036803797819e-06
termination O 0 1.5130398196561146e-06
codon O 0 2.4640658011776395e-06
27 O 0 3.885101023115567e-07
bp O 0 1.2024727311654715e-06
downstream O 0 1.387126502550018e-07
from O 0 4.4974415303045134e-09
the O 0 6.284655906796388e-09
cryptic O 0 1.124784489547892e-06
splice O 0 5.8907855418510735e-05
site O 0 3.977062533522258e-06
. O 0 7.001888207014417e-07

Three O 0 1.5434618489962304e-06
other O 0 1.917930525507927e-08
splice O 0 2.2473124772659503e-05
variants O 0 4.312646979087731e-06
, O 0 1.1942912436779807e-08
including O 0 4.493411420725124e-09
one O 0 6.114415196378786e-09
derived O 0 8.226620273887875e-09
from O 0 7.868509732666951e-10
the O 0 5.242397627114315e-10
skipping O 0 1.0176633757907894e-08
of O 0 2.6833932298409024e-10
exon O 0 6.530512308700054e-08
32 O 0 2.5745922016540135e-07
, O 0 1.0033508246465317e-08
were O 0 2.9939963042124873e-07
also O 0 8.569915621592372e-08
identified O 0 1.3620889376397827e-06
. O 0 4.483996463022777e-08

These O 0 2.6146649361180607e-06
results O 0 4.042243801904988e-07
indicate O 0 1.2293808993035782e-07
the O 0 3.0901592396048727e-09
usefulness O 0 3.656235847415701e-08
of O 0 1.0672035477554687e-09
cycloheximide O 0 1.7164094288091292e-06
treatment O 0 5.9134364960300445e-08
in O 0 6.144434405719323e-10
evaluating O 0 2.6053648127799534e-08
the O 0 2.6254720619789396e-09
abnormal O 0 7.738050555872178e-08
processing O 0 1.8144787006235674e-08
of O 0 7.435417836987313e-10
mRNA O 0 3.4203917920194726e-08
due O 0 1.919793390925406e-08
to O 0 6.103543892521657e-09
splice O 0 0.017704278230667114
- O 0 0.00010970245784847066
site O 0 8.23092307200568e-07
mutations O 0 4.6319764805957675e-06
, O 0 2.6909083850057414e-09
because O 0 3.203368459381295e-09
( O 0 2.563870449279193e-09
i O 0 1.7159366905161733e-07
) O 0 3.05096725661258e-09
aberrant O 0 3.3161254009428376e-07
splicing O 0 2.0971456251572818e-06
often O 0 6.493443152066902e-07
generates O 0 7.590612938201957e-08
a O 0 5.757236110071062e-08
premature O 0 6.354372544592479e-06
termination O 0 7.65554659665213e-07
codon O 0 9.75620764620544e-07
, O 0 1.0667258187879725e-08
( O 0 4.017525423449797e-09
ii O 0 1.82001812731869e-07
) O 0 4.2059320470855255e-09
transcripts O 0 1.5928438301671122e-07
with O 0 2.7166018767843525e-08
premature O 0 9.376207344757859e-06
termination O 0 5.01710871958494e-07
codons O 0 3.905882692833984e-07
can O 0 5.398930369437949e-08
occur O 0 8.266859907735125e-08
at O 0 2.7143312308908207e-07
low O 0 0.030997345224022865
or O 0 0.00011906649160664529
undetectable O 0 0.0025460519827902317
levels O 0 8.909651114663575e-07
due O 0 3.2145216266599164e-08
to O 0 3.110242019488396e-08
nonsense O 0 9.928407052939292e-06
- O 0 1.2859757134719985e-06
mediated O 0 7.466390457011585e-07
mRNA O 0 1.0432943042815168e-07
decay O 0 1.7281502096011536e-07
, O 0 2.7948481307049633e-09
and O 0 3.6373144496337773e-09
( O 0 2.500774254343696e-09
iii O 0 2.5020590044277924e-08
) O 0 9.673338796645226e-10
the O 0 1.3120444730674308e-09
levels O 0 2.308564184261286e-08
of O 0 2.207387606034672e-10
these O 0 1.5825614152475964e-09
transcripts O 0 1.8134360857402498e-07
can O 0 4.1448370780017285e-07
be O 0 3.256882763480462e-08
increased O 0 2.6595698088272002e-08
by O 0 2.134710541668028e-08
cycloheximide O 0 9.83422069111839e-06
. O 0 6.121616991094925e-08

A O 0 7.285317224159371e-06
deletion O 0 7.301568984985352e-05
mutation O 0 2.207051875302568e-05
in O 0 2.8683949437890988e-08
COL17A1 O 0 4.49209574071574e-06
in O 0 6.9069798769305635e-09
five O 0 1.850294495397975e-08
Austrian O 0 3.114543142146431e-05
families O 0 1.946793162233007e-07
with O 0 6.275470809669059e-08
generalized O 0 0.000654372910503298
atrophic B-Disease 1 0.9999724626541138
benign I-Disease 1 0.9997015595436096
epidermolysis I-Disease 1 0.9889169931411743
bullosa I-Disease 0 0.15504005551338196
represents O 0 5.350507876755728e-07
propagation O 0 4.3858850062861165e-07
of O 0 5.600167884978191e-09
an O 0 9.084804908354727e-09
ancestral O 0 2.7915684768231586e-06
allele O 0 1.4465796084550675e-05
. O 0 2.884509342493402e-07

Patients O 1 0.9975820779800415
with O 0 2.7859168767463416e-06
generalized O 0 0.0023430678993463516
atrophic B-Disease 1 0.9999918937683105
benign I-Disease 1 0.9999799728393555
epidermolysis I-Disease 1 0.9998822212219238
bullosa I-Disease 1 0.9982411861419678
, O 0 1.8711416771566292e-07
a O 0 2.2110937081265547e-08
usually O 0 3.821739014142622e-08
nonlethal O 0 2.96847133540723e-07
form O 0 3.1197487260214984e-07
of O 0 1.0955361062769953e-07
junctional B-Disease 1 0.9957122802734375
epidermolysis I-Disease 1 0.9985470175743103
bullosa I-Disease 1 0.9669187664985657
, O 0 1.4363216394031042e-07
have O 0 1.92217495253999e-08
generalized O 0 3.888845014898834e-07
blistering B-Disease 0 0.001714389305561781
, O 0 1.146715717936786e-07
nail B-Disease 1 0.9999980926513672
dystrophy I-Disease 1 0.9979789853096008
, O 0 2.936333771685895e-07
patchy B-Disease 1 0.9965182542800903
alopecia I-Disease 1 0.9999997615814209
, O 0 1.7491431947291858e-07
and O 0 2.4095745629892917e-06
dental B-Disease 1 0.9999644756317139
abnormalities I-Disease 1 0.9999991655349731
. O 0 1.9781837181653827e-06

Skin B-Disease 1 0.9999958276748657
fragility I-Disease 0 0.00020290317479521036
in O 0 1.891674195064752e-08
most O 0 5.42012035253947e-09
cases O 0 3.000494297467071e-09
is O 0 5.904515210097827e-10
due O 0 9.50312273317877e-09
to O 0 8.867097278653091e-09
mutations O 0 1.9163949218636844e-06
in O 0 5.790024570906382e-10
the O 0 1.1020109269566092e-09
gene O 0 9.90319719562649e-08
encoding O 0 2.6006094344666053e-07
type O 0 0.00010754956747405231
XVII O 0 2.7545751436264254e-05
collagen O 0 5.32203148395638e-06
( O 0 2.802045742100745e-07
COL17A1 O 0 2.1901629224885255e-05
) O 0 4.598165048719238e-08
. O 0 9.881744489348421e-08

Recently O 0 4.455584712559357e-05
, O 0 1.7339644386993314e-07
we O 0 1.214983882391607e-07
reported O 0 4.223902294597792e-08
five O 0 7.051568662319596e-09
Austrian O 0 3.196527131876792e-06
families O 0 7.980546712360592e-08
with O 0 3.104493018213361e-08
generalized O 0 0.0001042463190970011
atrophic B-Disease 1 0.9995532631874084
benign I-Disease 1 0.9947609305381775
epidermolysis I-Disease 1 0.9738669991493225
bullosa I-Disease 1 0.9298165440559387
who O 0 4.083518433617428e-05
share O 0 2.787110418012162e-07
the O 0 2.2737401295103155e-08
same O 0 1.1325553828100965e-07
COL17A1 O 0 8.326504757860675e-05
mutation O 0 5.703054284822429e-06
. O 0 1.836573488844806e-07

Affected O 0 4.579219239531085e-05
individuals O 0 2.905808003106358e-07
in O 0 4.489565164078613e-09
three O 0 1.8857374328717924e-08
families O 0 1.3113647057139133e-08
are O 0 4.394817398889472e-09
homozygous O 0 3.9696925568932784e-07
for O 0 8.002824514186102e-10
4003delTC O 0 2.274040014071943e-07
, O 0 1.0933891569919751e-09
whereas O 0 7.144672409253872e-09
those O 0 1.9086348057584246e-09
in O 0 4.502125616756558e-10
two O 0 1.3913629359763036e-08
others O 0 7.364430842926595e-08
are O 0 8.652493832528307e-09
compound O 0 3.1974616376828635e-07
heterozygotes O 0 2.6100185550603783e-06
. O 0 8.264652251455118e-08

To O 0 7.964008545968682e-07
determine O 0 1.0272689223711495e-06
if O 0 1.9223802993906247e-08
the O 0 1.999034493493923e-09
occurrence O 0 5.332317343231807e-08
of O 0 1.8754207076199236e-09
4003delTC O 0 5.406255922935088e-07
in O 0 1.3448916424962931e-09
these O 0 2.462768877720123e-09
unrelated O 0 1.9857349542462543e-08
families O 0 2.5175102003061056e-09
signifies O 0 1.3825108835519018e-09
propagation O 0 1.5991110657864738e-08
of O 0 5.538934311211108e-10
an O 0 2.644832575171563e-09
ancestral O 0 7.849058647479978e-07
allele O 0 3.804303105425788e-06
or O 0 2.13802366033633e-07
a O 0 2.7203247654483675e-08
mutational O 0 4.585349961416796e-05
hot O 0 0.00014029671729076654
spot O 0 0.002461946103721857
, O 0 1.8049794547891906e-08
haplotypes O 0 3.5046619473178e-07
were O 0 6.700940957671264e-07
determined O 0 8.81257378182454e-08
for O 0 1.8409296309584988e-09
polymorphisms O 0 1.0271081919199787e-05
both O 0 8.204591495086788e-08
within O 0 4.710683398911897e-08
and O 0 1.2341571675733576e-07
flanking O 0 0.0001370947720715776
COL17A1 O 0 0.0006155912997201085
. O 0 5.039921120442159e-07

Five O 0 1.5078921933309175e-05
intragenic O 0 5.531431452254765e-05
polymorphisms O 0 0.00016981668886728585
were O 0 1.9270630673418054e-06
chosen O 0 8.21342283074955e-08
based O 0 1.1203995065045547e-08
on O 0 4.1017703011902995e-08
their O 0 2.8021685238854843e-07
informativeness O 0 1.3738544112129603e-05
. O 0 1.6037056127515825e-07

One O 0 3.352154180902289e-07
of O 0 4.9804271817777135e-09
these O 0 4.820653654036278e-09
, O 0 2.5825352967245863e-09
not O 0 2.2978232649961683e-08
previously O 0 1.392158765156637e-06
reported O 0 9.517635248812439e-07
, O 0 3.139049686851081e-09
was O 0 3.2749603917636705e-08
2988 O 0 4.977609080469847e-08
A O 0 3.3076414496235884e-08
or O 0 5.555572215598659e-07
C O 0 2.9663617624464678e-06
that O 0 5.224509713741554e-10
introduces O 0 2.0825243751687594e-09
a O 0 1.0888107082607235e-09
new O 0 7.478542229932827e-10
restriction O 0 1.644945157863731e-08
site O 0 3.137955673082615e-08
for O 0 7.651397737618026e-09
Eco0109 O 0 2.8488755106081953e-06
I O 0 1.0025302799476776e-05
. O 0 7.17801711402899e-08

All O 0 2.301368056123465e-07
the O 0 1.955933548458688e-08
4003delTC O 0 6.420835347853426e-07
alleles O 0 2.9353006425481e-07
showed O 0 2.099437779179425e-07
the O 0 1.066672417060488e-09
same O 0 1.2323025933014264e-09
haplotype O 0 2.4469535730986536e-08
for O 0 1.1697243174069172e-09
these O 0 2.653306019340107e-09
five O 0 1.3845223634234571e-08
polymorphic O 0 4.3858699427801184e-06
markers O 0 0.00016141646483447403
. O 0 4.560655213481368e-07

Fourteen O 0 0.00016443517233710736
microsatellite O 0 0.0001978270011022687
polymorphisms O 0 0.0005960532580502331
were O 0 4.023128440167056e-06
selected O 0 3.1762837693349866e-08
based O 0 4.8458206336476906e-09
on O 0 8.84613271523449e-09
their O 0 1.0982345699517282e-08
high O 0 5.928558266532491e-08
heterozygosity O 0 3.060022777390259e-07
and O 0 1.0456068011421848e-08
their O 0 1.9733770173502307e-08
location O 0 9.134554090906022e-08
within O 0 5.24666425860687e-08
10q23 O 0 2.3523025447502732e-06
- O 0 8.405795597354881e-06
q25 O 0 6.117606972111389e-06
near O 0 7.370455477939686e-06
COL17A1 O 0 5.707737000193447e-05
. O 0 3.0744877221877687e-07

Three O 0 6.051058790035313e-06
families O 0 9.470579698245274e-07
shared O 0 4.7378151180055283e-07
microsatellite O 0 2.7721600417862646e-05
polymorphisms O 0 0.0008938602404668927
covering O 0 0.00014029096928425133
at O 0 1.7552770259499084e-06
most O 0 1.3159899836523437e-08
19 O 0 3.546706750512385e-08
cM O 0 1.4391544311820326e-07
, O 0 2.292533718417644e-09
whereas O 0 1.148731421096727e-08
the O 0 4.480625648284331e-09
others O 0 2.6698977251271572e-08
shared O 0 1.2113945402347781e-08
smaller O 0 1.8663898870840967e-08
regions O 0 1.3777975027551292e-07
consistent O 0 7.289744189620251e-06
with O 0 2.0318910998184947e-08
cross O 0 0.00019628462905529886
- O 0 0.00011300634650979191
over O 0 6.464175328346755e-08
events O 0 2.8079837122163553e-08
during O 0 3.116382174539467e-08
passage O 0 3.962126182699421e-09
of O 0 4.0923028854500387e-10
this O 0 1.0278927708995411e-09
mutation O 0 5.5601521609105475e-08
through O 0 2.8476190294668413e-09
several O 0 7.846843175229878e-09
generations O 0 2.898263176120963e-07
. O 0 5.652755419305322e-08

These O 0 7.815387448317779e-07
results O 0 7.063625275804952e-07
indicate O 0 2.45812941557233e-07
that O 0 5.435245142848544e-09
4003delTC O 0 1.7011758473017835e-06
occurs O 0 1.5431210087513136e-08
on O 0 5.487139187465573e-09
a O 0 1.234088475854378e-08
single O 0 1.0587070846668212e-06
ancestral O 0 8.090032679319847e-07
allele O 0 1.5500999097639578e-06
. O 0 1.647086378397944e-08
. O 0 7.141010627265132e-08

The O 0 1.3549230288845138e-06
haptoglobin O 0 4.672953218687326e-05
- O 0 4.677779998019105e-06
gene O 0 1.858743075899838e-06
deletion O 0 4.826401891477872e-06
responsible O 0 4.836210791836493e-07
for O 0 3.0985891186219305e-08
anhaptoglobinemia B-Disease 0 3.7362024158937857e-05
. O 0 3.557052252745052e-07

We O 0 1.5115317182790022e-05
have O 0 6.307005406824828e-08
found O 0 4.360608318876302e-09
an O 0 8.225000125428039e-10
allelic O 0 3.343916432640981e-07
deletion O 0 1.0731704378486029e-06
of O 0 4.562171085353839e-09
the O 0 2.180520475292269e-08
haptoglobin O 0 3.2977061437122757e-06
( O 0 9.371864173601807e-09
Hp O 0 2.3782551039630562e-08
) O 0 8.080712765590192e-10
gene O 0 1.2733573306888957e-08
from O 0 1.126033377651936e-09
an O 0 1.0348407686322503e-09
individual O 0 2.6322373614107164e-08
with O 0 7.113468569741599e-08
anhaptoglobinemia B-Disease 0 0.0001785518106771633
. O 0 2.841354955762654e-07

The O 0 6.172479061206104e-07
Hp O 0 1.266493654838996e-06
gene O 0 9.621793424230418e-07
cluster O 0 1.3817199828736193e-07
consists O 0 5.949534198634865e-09
of O 0 8.807490847750898e-10
coding O 0 1.565169895911822e-07
regions O 0 2.555050393482361e-08
of O 0 6.343797709362775e-10
the O 0 4.563772026955348e-09
alpha O 0 1.7367689508773765e-08
chain O 0 2.535283556426293e-07
and O 0 8.272833973421712e-09
beta O 0 7.926991507645198e-09
chain O 0 5.2950003492924225e-08
of O 0 4.381892071414484e-10
the O 0 4.258676966628627e-09
haptoglobin O 0 4.659133594486775e-07
gene O 0 6.848606659559664e-08
( O 0 2.5819593130194107e-09
Hp O 0 8.024670705708559e-09
) O 0 4.841845258063415e-10
and O 0 1.2669078008897827e-09
of O 0 2.7048624451353476e-10
the O 0 3.414875271445794e-09
alpha O 0 1.1442246261594846e-08
chain O 0 2.72207444140804e-07
and O 0 6.4289817913731895e-09
beta O 0 5.207648978711177e-09
chain O 0 1.8078701202739467e-08
of O 0 2.600377690953337e-10
the O 0 1.4824653726819292e-09
haptoglobin O 0 4.2692562374213594e-07
- O 0 2.4781058982625837e-07
related O 0 2.2047389691692842e-08
gene O 0 1.4211593679647194e-07
( O 0 3.803571679839024e-09
Hpr O 0 1.5029729638627032e-07
) O 0 2.6408351061490976e-09
, O 0 9.052247840202199e-10
in O 0 8.124356187799719e-10
tandem O 0 1.4819778471064637e-06
from O 0 8.326927591895128e-09
the O 0 1.1050550696722894e-08
5 O 0 2.7339842390006197e-08
side O 0 2.623949740154785e-06
. O 0 9.833179603901954e-08

Southern O 0 1.768166657711845e-05
blot O 0 6.380613922374323e-05
and O 0 1.6030419658363826e-07
PCR O 0 3.945664502680302e-06
analyses O 0 4.757324404636165e-06
have O 0 1.7911024485783855e-07
indicated O 0 2.0890702501219494e-07
that O 0 1.2645611224826325e-09
the O 0 1.963685436479068e-09
individual O 0 6.37750297016737e-09
with O 0 7.863083517634095e-09
anhaptoglobinemia B-Disease 0 9.817727004701737e-06
was O 0 2.3576380669965147e-07
homozygous O 0 2.7077257414021005e-07
for O 0 5.503004718576676e-10
the O 0 9.864767891443194e-10
gene O 0 4.3136651584063657e-08
deletion O 0 1.6962786730800872e-07
and O 0 1.316954278962612e-08
that O 0 6.863717372240785e-10
the O 0 1.103428570736753e-09
gene O 0 4.9384961897658286e-08
deletion O 0 3.047491077268205e-07
was O 0 1.531536639731712e-07
included O 0 1.1335113292432197e-08
at O 0 1.118454875381758e-07
least O 0 6.374766936545484e-09
from O 0 6.966036081301752e-10
the O 0 1.1745285855013776e-09
promoter O 0 5.274990755310682e-08
region O 0 4.319640645178424e-09
of O 0 3.919460589418833e-10
Hp O 0 3.513707014235479e-08
to O 0 9.716484505872813e-09
Hpr O 0 9.046116815625282e-07
alpha O 0 3.965302752817479e-08
but O 0 8.249215532885046e-09
not O 0 6.640629379717211e-09
to O 0 7.646963062768464e-09
Hpr O 0 4.395877567731077e-06
beta O 0 3.197141325017583e-07
( O 0 5.282884885104977e-08
Hpdel O 0 4.075515789736528e-06
) O 0 4.7642664924296696e-08
. O 0 1.0165191355326897e-07

In O 0 3.917589310731273e-07
addition O 0 9.253888322291459e-08
, O 0 5.6654245739196085e-09
we O 0 1.6869501351379768e-08
found O 0 3.328740394437091e-09
seven O 0 6.0011631219936135e-09
individuals O 0 6.059392987367573e-10
with O 0 1.0537869465920835e-09
hypohaptoglobinemia B-Disease 0 8.514647902302386e-07
in O 0 3.755904476321348e-09
three O 0 3.305774498585379e-08
families O 0 1.4503361178697105e-08
, O 0 6.463404811363205e-10
and O 0 7.355973052902698e-10
the O 0 6.568721122590659e-10
genotypes O 0 4.326907188101359e-08
of O 0 3.2985281173125713e-10
six O 0 1.9250075311560977e-08
of O 0 7.740612040230133e-10
the O 0 7.457066075744478e-09
seven O 0 1.312258461894089e-07
individuals O 0 6.019458709261016e-09
were O 0 1.6917003620164905e-07
found O 0 5.2065067812634425e-09
to O 0 3.8934588886263555e-09
be O 0 1.5293414890038548e-07
Hp2 O 0 1.8773631381918676e-05
/ O 0 9.908731954055838e-06
Hpdel O 0 3.5255008697276935e-05
. O 0 2.6864131541515235e-07

The O 0 9.12528662411205e-07
phenotypes O 0 9.629242413211614e-06
and O 0 8.315313948514813e-08
genotypes O 0 1.063958166014345e-06
in O 0 3.3884104411185945e-09
one O 0 2.09425099484406e-09
of O 0 1.362627094492197e-10
these O 0 2.2532622434567884e-09
three O 0 1.8241776089666928e-08
families O 0 3.6395022107171826e-08
showed O 0 1.3467400776789873e-06
the O 0 4.161508915245804e-09
father O 0 7.29411482325304e-08
to O 0 3.6015819215862166e-09
be O 0 3.074522325619e-08
hypohaptoglobinemic B-Disease 0 1.1157344488310628e-06
( O 0 5.756661813904884e-09
Hp2 O 0 3.2111273640111904e-07
) O 0 2.703718804397681e-09
and O 0 1.190599885347865e-08
Hp2 O 0 3.771002411667723e-06
/ O 0 1.6317727613568422e-06
Hpdel O 0 1.7299306591667118e-06
, O 0 4.356152327744667e-09
the O 0 3.423437977545518e-09
mother O 0 1.0749942447318972e-07
to O 0 3.5459408742610776e-09
be O 0 2.633965046072717e-08
Hp2 O 0 9.301700174546568e-07
- O 0 4.909990707346878e-07
1 O 0 1.0627130286877673e-08
and O 0 1.0591757693134696e-08
Hp1 O 0 1.3688186299987137e-06
/ O 0 4.221703591156256e-07
Hp2 O 0 8.364927452930715e-07
, O 0 2.5899444811017247e-09
one O 0 1.402625349200548e-09
of O 0 1.2320010289723626e-10
the O 0 7.8363393551939e-10
two O 0 8.947695029348779e-09
children O 0 1.6995326035385006e-08
to O 0 3.797496983537485e-09
be O 0 5.4238874724887864e-08
hypohaptoglobinemic B-Disease 0 9.031040804075019e-07
( O 0 2.5242079537690643e-09
Hp2 O 0 1.294727098866133e-07
) O 0 1.9203307832782457e-09
and O 0 4.020369814838887e-09
Hp2 O 0 1.043882889462111e-06
/ O 0 8.93933815859782e-07
Hpdel O 0 1.4779300272493856e-06
, O 0 4.189966151812996e-09
and O 0 1.3544215748950705e-09
the O 0 4.253455088143454e-10
other O 0 6.72772615395445e-10
child O 0 3.348648647261143e-08
to O 0 2.872395432618191e-09
be O 0 2.6306613776228005e-08
Hp1 O 0 7.629133733644267e-07
and O 0 4.881566084691258e-08
Hp1 O 0 5.431596491689561e-06
/ O 0 1.9487097233650275e-06
Hpdel O 0 3.5068223951384425e-06
, O 0 4.761502747641089e-09
showing O 0 1.1038421376952101e-07
an O 0 7.187436201760988e-10
anomalous O 0 8.268247597698064e-08
inheritance O 0 1.4411156712412776e-07
of O 0 3.217464294991146e-09
Hp O 0 1.7832184084909386e-07
phenotypes O 0 2.0506279270193772e-06
in O 0 3.58531093702652e-09
the O 0 1.0206218981068105e-08
child O 0 1.16163278107706e-06
with O 0 2.265679377444485e-08
Hp1 O 0 1.9417218936723657e-05
. O 0 1.2446744790395314e-07

The O 0 1.248023409061716e-06
Hp2 O 0 4.573811384034343e-05
/ O 0 9.416467946721241e-06
Hpdel O 0 5.8582650126481894e-06
individuals O 0 9.82084600309463e-08
had O 0 4.978302214908581e-08
an O 0 1.6224626087080196e-09
extremely O 0 2.0229994390774664e-07
low O 0 5.695574145647697e-05
level O 0 9.523391781840473e-07
of O 0 1.9182881949575403e-09
Hp O 0 3.357179778618047e-08
( O 0 3.015433902575637e-09
mean O 0 3.09253103125684e-08
+ O 0 5.4073193922477e-08
/ O 0 2.841157140665018e-07
- O 0 1.2344554534138297e-06
SD O 0 0.00029937451472505927
= O 0 8.972117939265445e-06
0 O 0 4.90706035805033e-08
. O 0 4.130833453075411e-09
049 O 0 8.080394309217809e-07
+ O 0 2.32329199434389e-07
/ O 0 6.530400469273445e-07
- O 0 1.1171430287504336e-06
0 O 0 1.5540710762707022e-07
. O 0 4.818502485903764e-09
043 O 0 5.44025681392668e-07
mg O 0 2.4187738745240495e-07
/ O 0 3.836752284769318e-07
ml O 0 6.40188090983429e-07
; O 0 1.1432189417348582e-08
n O 0 1.0179001037613489e-06
= O 0 1.6814926766528515e-06
6 O 0 3.273498805356212e-08
) O 0 1.8569082937958115e-09
, O 0 9.140854739797533e-10
compared O 0 4.8551829223697496e-09
with O 0 7.213640240699704e-10
the O 0 2.2488613193871743e-09
level O 0 2.356262456260083e-07
( O 0 2.2393507048690253e-09
1 O 0 1.545028882610211e-09
. O 0 4.626117267036989e-10
64 O 0 1.1275684386191642e-08
+ O 0 2.5792978419758583e-08
/ O 0 1.313814834702498e-07
- O 0 6.100962650634756e-07
1 O 0 1.8281937741448928e-08
. O 0 1.5980002876503363e-09
07 O 0 3.398244246000104e-07
mg O 0 1.9951468743784062e-07
/ O 0 2.995452632603701e-07
ml O 0 3.351038628807146e-07
) O 0 3.3901363938326767e-09
obtained O 0 1.0395158511755653e-08
from O 0 7.156960801779633e-09
52 O 0 3.2579677622379677e-07
healthy O 0 1.7497990256742924e-07
volunteers O 0 5.022901206075403e-08
having O 0 1.6821987003368122e-07
phenotype O 0 7.104370070010191e-07
Hp2 O 0 6.468491733357951e-07
, O 0 3.243107560280123e-09
whereas O 0 1.1189984938653197e-08
the O 0 3.30233818068848e-09
serum O 0 1.0080123757916226e-07
Hp O 0 4.4985078773152054e-08
level O 0 4.495265670811932e-08
of O 0 4.2620551532479567e-10
an O 0 1.3561690659358305e-09
individual O 0 5.87618442793314e-09
with O 0 1.0676458828129398e-08
Hp1 O 0 2.184441291319672e-05
/ O 0 6.83791722622118e-06
Hpdel O 0 1.3262327229313087e-05
was O 0 1.4215620467439294e-06
0 O 0 3.8324591855598555e-07
. O 0 9.918055354773969e-08

50 O 0 7.396678029181203e-06
mg O 0 4.941534825775307e-06
/ O 0 4.2974643292836845e-06
ml O 0 2.7941091502725612e-06
, O 0 4.079562909709011e-09
which O 0 1.8128415435469947e-09
was O 0 1.7528863693883068e-08
approximately O 0 8.857035660447821e-10
half O 0 1.2864218579267117e-09
the O 0 3.915575086388401e-10
level O 0 1.2463940102236393e-08
of O 0 6.695876075824003e-10
Hp O 0 2.6398545571737486e-08
in O 0 5.7508673378947606e-09
control O 0 3.546772177287494e-06
sera O 0 3.836295036308002e-06
from O 0 4.366875305805706e-09
the O 0 1.02412407443353e-08
Hp1 O 0 1.1345753136993153e-06
phenotype O 0 2.933977043539926e-07
( O 0 2.3840764917792967e-09
1 O 0 2.224510353698861e-09
. O 0 8.198045575724677e-10
26 O 0 9.919337351504964e-09
+ O 0 2.3079611111143095e-08
/ O 0 1.2125657633532683e-07
- O 0 3.3773213203858177e-07
0 O 0 2.836800128136474e-08
. O 0 1.0523287796715408e-09
33 O 0 3.258467629052575e-08
mg O 0 1.4382543156443717e-07
/ O 0 2.72892094699273e-07
ml O 0 9.062618460120575e-07
; O 0 2.170951063362736e-08
n O 0 3.1825957194087096e-06
= O 0 1.5633080693078227e-05
9 O 0 1.7336090252229042e-07
) O 0 4.623737837050612e-09
, O 0 1.606618615923594e-09
showing O 0 9.042815918292035e-08
a O 0 1.7041939415207707e-08
gene O 0 2.2020005872036563e-06
- O 0 2.0960154870408587e-05
dosage O 0 4.792640538653359e-05
effect O 0 1.3356991530599771e-06
. O 0 9.038522108539837e-08

The O 0 1.2194182374969387e-07
other O 0 1.3461062486896935e-08
allele O 0 4.859197133555426e-07
( O 0 9.48058254124362e-09
Hp2 O 0 1.4220270827536297e-07
) O 0 7.409736157981683e-10
of O 0 1.628529117114752e-10
individuals O 0 2.0360682029263444e-09
with O 0 3.747453458657901e-09
Hp2 O 0 2.391721136518754e-05
/ O 0 6.958459380257409e-06
Hpdel O 0 1.042097392200958e-05
was O 0 6.7586512386697e-07
found O 0 7.304637339444753e-09
to O 0 4.855340574039246e-09
have O 0 4.0439365989186626e-07
, O 0 1.2350273026484615e-09
in O 0 5.197356434116784e-10
all O 0 1.538447702564838e-09
exons O 0 2.3453800679362757e-07
, O 0 1.0775680792107778e-08
no O 0 2.9008564439436668e-08
mutation O 0 1.5459927737992984e-07
, O 0 1.3209686677839727e-09
by O 0 2.171587576427214e-09
DNA O 0 1.688853501491394e-07
sequencing O 0 1.017894305732625e-06
. O 0 4.391752952415118e-07

On O 0 2.342644052077958e-07
the O 0 6.736011748387227e-09
basis O 0 5.000063030280444e-09
of O 0 2.500930296189807e-10
the O 0 1.27284671691541e-09
present O 0 1.515370717797282e-09
study O 0 2.7639317501382266e-09
, O 0 4.3352707534971557e-10
the O 0 2.7046354045268117e-10
mechanism O 0 7.557239278810357e-09
of O 0 5.54459977930577e-10
anhaptoglobinemia B-Disease 0 3.1682517942499544e-07
and O 0 3.978452234321139e-09
the O 0 8.838876297545539e-10
mechanism O 0 1.1516447351311854e-08
of O 0 2.73348066404111e-10
anomalous O 0 6.650569872590495e-08
inheritance O 0 2.1081029899505666e-07
of O 0 5.150651016805341e-09
Hp O 0 8.896898293642153e-07
phenotypes O 0 1.142992823588429e-05
were O 0 1.0244971235806588e-06
well O 0 2.274656054623847e-07
explained O 0 1.9603839973569848e-06
. O 0 8.120908745468114e-08

However O 0 1.9080825950368308e-06
, O 0 1.5195567470982496e-08
the O 0 2.1377570824654413e-09
mechanism O 0 2.6485443171964107e-08
of O 0 9.54361123461922e-09
hypohaptoglobinemia B-Disease 0 8.816533954814076e-05
remains O 0 4.066291694471147e-06
unknown O 0 9.168376891466323e-06

ATM O 0 0.0005084329168312252
mutations O 0 0.00034429278457537293
and O 0 3.167940860748786e-07
phenotypes O 0 6.144530198071152e-05
in O 0 7.593673672090517e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
families O 0 0.0003332638298161328
in O 0 1.7372361327261387e-08
the O 0 1.4080002941341263e-08
British O 0 2.5449980967096053e-06
Isles O 0 1.14070405743405e-06
: O 0 3.439112550296386e-09
expression O 0 3.538387360890738e-09
of O 0 3.992528807561513e-10
mutant O 0 7.03771831922495e-08
ATM O 0 3.2593072774034226e-07
and O 0 9.80138104011985e-09
the O 0 3.5817906418600387e-09
risk O 0 1.8779240917865536e-07
of O 0 3.94424048977271e-09
leukemia B-Disease 0 0.44368329644203186
, O 0 2.2946035187487723e-06
lymphoma B-Disease 1 1.0
, O 0 9.66914157629617e-08
and O 0 2.6826728571904823e-05
breast B-Disease 1 0.9999998807907104
cancer I-Disease 0 0.3591706454753876
. O 0 2.666516536464769e-07

We O 0 1.0397108781035058e-05
report O 0 6.440373567784263e-08
the O 0 1.9605641554676367e-09
spectrum O 0 1.835348939493997e-08
of O 0 1.5689464172297107e-09
59 O 0 1.5200762959466374e-07
ATM O 0 4.8259873437928036e-05
mutations O 0 5.434328704723157e-05
observed O 0 1.119666649174178e-06
in O 0 2.394795046711806e-07
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.0005581425502896309
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 2.87066637127964e-08
patients O 0 9.638281994739373e-08
in O 0 1.027610441184379e-09
the O 0 8.942115492516223e-09
British O 0 3.703002448673942e-06
Isles O 0 9.357538147014566e-06
. O 0 2.149657092331836e-07

Of O 0 4.479320523387287e-07
51 O 0 4.899559371551732e-06
ATM O 0 2.8740809284499846e-05
mutations O 0 1.8731656382442452e-05
identified O 0 2.375078054228652e-07
in O 0 2.7895332710414777e-09
families O 0 5.0174500110244935e-09
native O 0 1.8655310629611677e-09
to O 0 1.5338769143724562e-09
the O 0 1.3527802877888462e-08
British O 0 3.023146291525336e-06
Isles O 0 1.7999673218582757e-06
, O 0 2.158188516787618e-09
11 O 0 9.952160873183402e-09
were O 0 3.18909840757442e-08
founder O 0 1.1399397870093253e-08
mutations O 0 1.530873703359248e-07
, O 0 7.190069095663887e-10
and O 0 4.439935530342609e-09
2 O 0 2.2402477650729224e-09
of O 0 2.622822792286428e-10
these O 0 4.056812219488393e-09
11 O 0 2.2082446093918406e-08
conferred O 0 9.130108225008371e-09
a O 0 5.251187040755667e-09
milder O 0 3.7825464005436515e-06
clinical O 0 1.2147365850978531e-05
phenotype O 0 9.153596352007298e-07
with O 0 2.2735742177815155e-09
respect O 0 1.993178955217445e-09
to O 0 3.196831244167697e-09
both O 0 3.2288642159983283e-07
cerebellar B-Disease 0 0.00010557845962466672
degeneration I-Disease 0 0.0003618971386458725
and O 0 4.749577087181933e-08
cellular O 0 1.8528990040067583e-06
features O 0 7.341784112213645e-06
. O 0 3.755892805656913e-07

We O 0 5.317944669513963e-05
report O 0 1.7268865803998779e-07
, O 0 3.053272301656307e-09
in O 0 1.534658178314885e-09
two O 0 1.4248641377889726e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
families O 0 1.6721715212497656e-07
, O 0 8.145146779270362e-10
an O 0 1.4061315445346168e-09
ATM O 0 7.485736205126159e-06
mutation O 0 2.1318637664080597e-06
( O 0 1.2815929650855651e-08
7271T O 0 4.775739057549799e-07
- O 0 6.902840141265187e-06
- O 0 8.994992640509736e-06
> O 0 3.3263847853959305e-07
G O 0 5.777938554274442e-07
) O 0 1.6180153883382786e-09
that O 0 1.0966139107893014e-09
may O 0 8.375992877063254e-08
be O 0 4.708264889075053e-09
associated O 0 3.460807640465191e-09
with O 0 4.748585413771877e-10
an O 0 1.2309142594091327e-09
increased O 0 1.6783080525328842e-07
risk O 0 2.462146539983223e-06
of O 0 2.7551799064440274e-08
breast B-Disease 1 0.9999979734420776
cancer I-Disease 0 7.540947262896225e-05
in O 0 2.9559821257407748e-09
both O 0 3.4444777696762685e-08
homozygotes O 0 1.0915602615568787e-05
and O 0 4.895786176462025e-08
heterozygotes O 0 1.943246161317802e-06
( O 0 2.2268718424811595e-08
relative O 0 7.821024610166205e-07
risk O 0 3.375313099240884e-06
12 O 0 1.2985489128425343e-08
. O 0 5.451823437141456e-10
7 O 0 1.4386928093301776e-08
; O 0 1.1938335653383092e-08
P O 0 0.018730852752923965
= O 0 8.115277523756959e-06
. O 0 2.919805952572574e-09
0025 O 0 1.7442720263716183e-06
) O 0 3.2496338953080794e-09
, O 0 6.227947602077677e-10
although O 0 1.510064628895691e-09
there O 0 1.3961632960857173e-09
is O 0 4.279177290289482e-10
a O 0 3.7186806967071107e-09
less O 0 4.499666488300136e-07
severe O 1 0.7698537707328796
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
phenotype O 0 5.086743840365671e-06
in O 0 2.5778701395751114e-09
terms O 0 3.748768850897477e-09
of O 0 1.8836578130621007e-10
the O 0 1.0055439814138367e-09
degree O 0 1.4345443055674423e-08
of O 0 1.1413626488376849e-08
cerebellar B-Disease 0 0.000559916312340647
degeneration I-Disease 0 0.015528189018368721
. O 0 3.8987263906165026e-07

This O 0 1.0898584150709212e-06
mutation O 0 3.5146167647326365e-06
( O 0 6.652955164554442e-08
7271T O 0 9.147470336756669e-07
- O 0 2.8206923161633313e-06
- O 0 3.820751771854702e-06
> O 0 1.8126942791241163e-07
G O 0 3.303619280359271e-07
) O 0 1.3223299122344656e-09
also O 0 1.3964722711534705e-09
allows O 0 1.4891421429297225e-09
expression O 0 3.368312517793015e-09
of O 0 4.892532490252677e-10
full O 0 5.6448900664918256e-08
- O 0 6.933003646736324e-07
length O 0 1.933141362542301e-07
ATM O 0 2.3808320293028373e-06
protein O 0 4.816006082819513e-08
at O 0 1.6684195358607212e-08
a O 0 2.829087852873613e-09
level O 0 3.975056372951258e-08
comparable O 0 1.6089846610611858e-07
with O 0 5.272362546548948e-09
that O 0 2.420313283124642e-09
in O 0 4.262089792206325e-09
unaffected O 0 2.99782982438046e-06
individuals O 0 3.2720130604957376e-08
. O 0 3.262030290329676e-08

In O 0 3.341031629133795e-07
addition O 0 8.817062990829072e-08
, O 0 1.2455504183606081e-08
we O 0 1.2862483522724233e-08
have O 0 4.178513979269383e-09
studied O 0 1.555559947519214e-07
18 O 0 1.55680959323945e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.9040027837036178e-05
, O 0 5.900462340946433e-10
in O 0 3.6326605612480023e-10
15 O 0 2.64476707201311e-09
families O 0 1.1048332249075088e-09
, O 0 6.848704936501804e-10
who O 0 9.679379076033001e-09
developed O 0 1.0721182661654893e-05
leukemia B-Disease 1 0.9749310612678528
, O 0 1.2112186595913954e-06
lymphoma B-Disease 1 1.0
, O 0 2.0166826431022855e-08
preleukemic O 0 5.343779776012525e-05
T O 0 0.0006126230000518262
- O 0 1.5060381883813534e-05
cell O 0 1.039168728311779e-05
proliferation O 0 4.666400400310522e-06
, O 0 1.1382038422880214e-08
or O 0 0.0002317467296961695
Hodgkin B-Disease 1 1.0
lymphoma I-Disease 1 1.0
, O 0 1.3903973972162476e-08
mostly O 0 8.371325854739098e-09
in O 0 9.1626608522688e-09
childhood O 0 7.19529707566835e-05
. O 0 2.63648388454385e-07

A O 0 3.16506452691101e-06
wide O 0 5.570331040871679e-07
variety O 0 5.7387300245181905e-08
of O 0 3.277914384369751e-09
ATM O 0 2.8528549592010677e-05
mutation O 0 3.4078059343300993e-06
types O 0 3.667740031687572e-07
, O 0 4.052914004404329e-09
including O 0 5.006896230952407e-09
missense O 0 1.4309228390629869e-05
mutations O 0 2.8749087505275384e-05
and O 0 1.2241255831213493e-07
in O 0 1.3740440785170449e-08
- O 0 4.803392948815599e-05
frame O 0 0.009081728756427765
deletions O 0 2.990149732795544e-05
, O 0 1.0563073260527744e-07
were O 0 1.9549030128018785e-07
seen O 0 8.750851776540003e-08
in O 0 1.9804535789091915e-09
these O 0 5.496412214256452e-08
patients O 0 3.419016536554409e-07
. O 0 4.2191270921421165e-08

We O 0 6.7139530983695295e-06
also O 0 3.5556407596004647e-08
show O 0 5.4326363851942006e-08
that O 0 1.9080923507885927e-09
25 O 0 3.247168089970387e-09
% O 0 1.7884163039383338e-09
of O 0 5.523047019728722e-10
all O 0 2.6929745899906266e-07
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 2.83406025118893e-05
carried O 0 7.731846380920615e-07
in O 0 4.772385597817674e-09
- O 0 7.87518365541473e-06
frame O 0 0.0006098272278904915
deletions O 0 1.1431814527895767e-05
or O 0 6.121255751168064e-07
missense O 0 1.77386864379514e-05
mutations O 0 7.543325409642421e-06
, O 0 1.0179307396995796e-09
many O 0 2.1209904665919765e-10
of O 0 2.0789593657699612e-10
which O 0 4.7395683822060164e-08
were O 0 2.4400967504334403e-06
also O 0 2.401621479464211e-08
associated O 0 9.991017790866863e-09
with O 0 1.0358459645587459e-09
expression O 0 8.202491130759881e-09
of O 0 1.3161800538341595e-09
mutant O 0 7.291150723176543e-07
ATM O 0 7.656241905351635e-06
protein O 0 1.2511252407421125e-06
. O 0 2.0943704726050782e-07

The O 0 9.223154506798892e-07
DMPK O 0 1.5208463992166799e-05
gene O 0 6.577101316906919e-07
of O 0 4.890158677994805e-08
severely O 0 0.028377968817949295
affected O 0 0.00021267311240080744
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
patients O 1 0.9994094371795654
is O 0 5.471476427487687e-08
hypermethylated O 0 2.1641806142724818e-06
proximal O 0 1.137603589995706e-06
to O 0 3.2442226682860564e-08
the O 0 4.316924417935297e-08
largely O 0 3.02509960192765e-07
expanded O 0 1.9387387055758154e-06
CTG O 0 6.30912691121921e-05
repeat O 0 1.0552592357271351e-05
. O 0 1.8740043117304594e-07

Using O 0 7.820905011612922e-06
methylation O 0 1.9298367988085374e-05
- O 0 5.189474450162379e-06
sensitive O 0 2.714377615120611e-06
restriction O 0 1.837321406128467e-07
enzymes O 0 2.7575887884268013e-07
, O 0 2.705751400711165e-09
we O 0 4.844711742890695e-09
characterized O 0 3.2241851410930167e-09
the O 0 6.534606189489978e-10
methylation O 0 3.169953188830732e-08
pattern O 0 8.165038707375061e-07
on O 0 1.8541379986913853e-08
the O 0 3.790275204806903e-09
5 O 0 8.29164825688622e-09
side O 0 2.0532918654225796e-07
of O 0 5.701955019254967e-10
the O 0 1.4723835484176107e-08
CTG O 0 2.1785724584333366e-06
repeat O 0 2.597287789285474e-07
in O 0 1.2981444807991238e-09
the O 0 2.462158255056579e-09
DMPK O 0 4.147597110204515e-07
gene O 0 2.251154107568709e-08
of O 0 4.2932224442182587e-10
normal O 0 3.651866009590776e-08
individuals O 0 1.8533591328306898e-09
and O 0 1.0240923664639467e-09
of O 0 1.4431114081503438e-09
patients O 0 1.7681284703030542e-07
affected O 0 4.5894385181100006e-08
with O 0 1.5046522605643986e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
, O 0 1.350529998944694e-07
showing O 0 3.610429359923728e-07
expansions O 0 5.4781068570264324e-08
of O 0 1.4596071018502244e-09
the O 0 8.894520675539752e-09
repetitive O 0 4.93569859827403e-05
sequence O 0 1.7432359982194612e-06
. O 0 1.9779561455379735e-07

The O 0 3.6674603620667767e-07
gene O 0 1.5986709058779525e-06
segment O 0 8.940070870266936e-07
analyzed O 0 5.026859639656323e-07
corresponds O 0 9.271909817698543e-08
to O 0 1.2614590261250669e-08
the O 0 1.6593176610513183e-08
genomic O 0 4.125176928937435e-06
SacI O 0 0.000174868997419253
- O 0 4.350774179329164e-05
HindIII O 0 1.0592772014206275e-05
fragment O 0 1.2335093515503104e-06
carrying O 0 3.7567596677945403e-07
exons O 0 2.137246156053152e-06
11 O 0 5.811992878079764e-07
- O 0 1.5342689948738553e-05
15 O 0 6.104058911660104e-07
. O 0 1.8339446228310408e-07

There O 0 1.012100256048143e-06
is O 0 1.4096340095193227e-08
constitutive O 0 1.2637099189305445e-07
methylation O 0 2.1196484567553853e-07
in O 0 2.1803126415420593e-08
intron O 0 8.802124284557067e-06
12 O 0 1.0256805893504861e-07
at O 0 8.758678227138716e-09
restriction O 0 7.818814928839402e-09
sites O 0 6.845051636616972e-09
of O 0 1.2327961984581748e-09
SacII O 0 8.909319717531616e-07
and O 0 1.774418478817097e-08
HhaI O 0 9.80413119577861e-07
, O 0 1.0793530513808491e-09
localized O 0 4.2005389389032644e-08
1 O 0 8.797404582594481e-09
, O 0 9.772106457361929e-10
159 O 0 1.2287872053207138e-08
- O 0 2.457011589740432e-07
1 O 0 6.1386273841890215e-09
, O 0 1.7363341875409333e-09
232 O 0 1.7273766417247316e-08
bp O 0 1.762414711947713e-07
upstream O 0 1.3000283516362288e-08
of O 0 7.757994247015176e-10
the O 0 4.859639357590595e-09
CTG O 0 2.2583053578273393e-06
repeat O 0 3.3306605473626405e-07
, O 0 1.6708803229903424e-09
whereas O 0 4.592956237559065e-09
most O 0 6.825986997860412e-10
, O 0 1.6323177254307097e-09
if O 0 2.1423613993931667e-09
not O 0 9.631735409243447e-09
all O 0 9.665888089926966e-10
, O 0 1.821529871381955e-10
of O 0 2.0483515925096007e-11
the O 0 4.310748979996504e-10
other O 0 2.2719517933644795e-10
sites O 0 7.3201462669203465e-09
of O 0 7.16988246551864e-10
SacII O 0 5.105646323499968e-07
, O 0 3.528991987522545e-09
HhaI O 0 2.6903973093794775e-07
, O 0 3.3963238887935177e-09
and O 0 3.2154152673768976e-09
HpaII O 0 2.5047933149835444e-07
in O 0 1.4165600914495258e-09
this O 0 6.493133808405105e-10
region O 0 5.97694604920207e-09
are O 0 5.366638688997227e-09
unmethylated O 0 2.625714330406481e-07
, O 0 2.080277283766918e-09
in O 0 8.134279361193819e-10
normal O 0 3.924424163415097e-08
individuals O 0 1.7334355062459395e-09
and O 0 8.502502035767634e-10
most O 0 2.7640462141320654e-10
of O 0 4.359583249957666e-10
the O 0 6.441700861614663e-08
patients O 0 7.226922207337338e-07
. O 0 6.126231255620951e-08

In O 0 2.407510919510969e-07
a O 0 1.2221724077221552e-08
number O 0 4.564137956464265e-09
of O 0 6.884327552469927e-10
young O 0 3.2387696080604655e-08
and O 0 3.173086327024066e-08
severely O 0 0.00041941911331377923
affected O 0 9.579923698765924e-07
patients O 0 2.4448408453281445e-07
, O 0 1.1525430609893306e-09
however O 0 2.322674275134773e-09
, O 0 2.348098659954445e-10
complete O 0 1.9312582644204213e-09
methylation O 0 1.1216354067755674e-08
of O 0 1.7110124428398876e-10
these O 0 9.44813893788421e-10
restriction O 0 7.347310759797665e-09
sites O 0 6.916276618085249e-08
was O 0 3.939739485758764e-07
found O 0 6.340885594369183e-09
in O 0 3.9550868136117856e-10
the O 0 2.5648976276215762e-09
mutated O 0 6.918017447787861e-07
allele O 0 2.5454348815401318e-06
. O 0 1.6993972451473383e-07

In O 0 6.036108857188083e-08
most O 0 2.422553047054521e-09
of O 0 3.6563782557230695e-10
these O 0 5.907740519006666e-09
patients O 0 6.170359512225332e-08
, O 0 2.9031890780295555e-10
the O 0 1.0496745694865695e-09
onset O 0 3.831706180790206e-06
of O 0 3.283521232688713e-09
the O 0 3.4485319702071138e-06
disease O 1 0.8088594079017639
was O 0 8.301910384034272e-06
congenital O 1 0.9944722056388855
. O 0 3.630403000443039e-07

Preliminary O 0 2.557316838647239e-05
in O 0 3.119025677733589e-07
vivo O 0 1.9800483642029576e-05
footprinting O 0 3.121402551187202e-05
data O 0 1.8889996056259406e-07
gave O 0 4.4454370851099156e-08
evidence O 0 3.773612089474909e-09
for O 0 8.843463183971778e-10
protein O 0 1.1156339496665169e-07
- O 0 3.3151970910694217e-06
DNA O 0 7.211025376818725e-07
contact O 0 1.7599888906261185e-06
in O 0 1.0403290673366428e-08
normal O 0 3.375962194240856e-07
genes O 0 4.039561360968946e-07
at O 0 6.350110481889715e-08
an O 0 4.0088607988764124e-09
Sp1 O 0 3.9670547380410426e-07
consensus O 0 3.6883225362771555e-08
binding O 0 3.316909413797475e-08
site O 0 5.8350195786260883e-08
upstream O 0 1.5322868307521276e-08
of O 0 6.128445528830184e-10
the O 0 1.1438951119657759e-08
CTG O 0 3.102956270595314e-06
repeat O 0 1.3693056644115131e-06
and O 0 1.2352682432492657e-08
for O 0 6.53688714269407e-10
a O 0 1.9830239672558037e-09
significant O 0 5.133634406462306e-09
reduction O 0 6.327403045958135e-09
of O 0 6.821818110402944e-11
this O 0 1.1837174296314146e-10
interaction O 0 2.199932236379709e-09
in O 0 3.7209086922729284e-09
cells O 0 1.7664254059468476e-08
with O 0 8.78752237642999e-10
a O 0 1.528171544862289e-08
hypermethylated O 0 6.095465778344078e-06
DMPK O 0 3.3286357847828185e-06
gene O 0 4.1989528654085007e-07
. O 0 1.894656875833789e-08
. O 0 4.274955855976259e-08

The O 0 2.2873914531373885e-06
hemochromatosis B-Disease 1 0.9998680353164673
gene O 0 5.190761385165388e-06
product O 0 2.898376862958685e-07
complexes O 0 1.509298641622081e-07
with O 0 1.0156195884292174e-08
the O 0 1.0010683837435863e-08
transferrin O 0 6.786112862755544e-07
receptor O 0 2.8658857331720355e-07
and O 0 1.287836681740373e-08
lowers O 0 4.0506759546588e-07
its O 0 2.7794317958296233e-09
affinity O 0 1.6636242605727602e-08
for O 0 2.119814546119869e-09
ligand O 0 1.5638420336472336e-07
binding O 0 4.5373627699518693e-07
. O 0 1.0969203145805295e-07

We O 0 2.630307608342264e-05
recently O 0 1.3294820746523328e-06
reported O 0 9.70628164509435e-08
the O 0 1.0365573954729257e-09
positional O 0 1.287490789536605e-07
cloning O 0 6.601382551707502e-08
of O 0 9.035653336653127e-10
a O 0 1.1909769170870277e-08
candidate O 0 6.862675832053355e-07
gene O 0 1.1576797987800092e-05
for O 0 2.503534915376804e-06
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
called O 0 0.001921787508763373
HFE O 1 0.9405117034912109
. O 0 1.8548473690316314e-06

The O 0 2.561985752436158e-07
gene O 0 9.012903774419101e-07
product O 0 1.7176034816657193e-07
, O 0 2.693116396557116e-09
a O 0 1.8620296415861048e-09
member O 0 3.473478171756028e-09
of O 0 1.190612330947971e-10
the O 0 6.695352605667892e-10
major O 0 6.974893995703724e-09
histocompatibility O 0 1.2421914163951442e-07
complex O 0 1.865467957884448e-08
class O 0 7.263903967213992e-08
I O 0 1.3641125406138599e-05
- O 0 7.938469366308709e-07
like O 0 1.0464012234479014e-07
family O 0 3.725498132212124e-08
, O 0 3.3548610556266567e-09
was O 0 1.2565607221404207e-07
found O 0 4.886025806172256e-09
to O 0 3.85331322405591e-09
have O 0 5.466375441187665e-08
a O 0 7.107634036884747e-09
mutation O 0 6.641265031248622e-07
, O 0 5.302698724563015e-09
Cys O 0 5.5055006669135764e-06
- O 0 1.5721982435934478e-06
282 O 0 1.2380206726447796e-06
- O 0 2.021921318373643e-05
- O 0 7.249969257827615e-06
> O 0 4.6631257077933697e-07
Tyr O 0 1.5339338688136195e-06
( O 0 5.348041121067126e-09
C282Y O 0 6.788159367943081e-08
) O 0 7.157093806497983e-10
, O 0 2.8285793152171834e-10
in O 0 1.697638835063131e-10
85 O 0 4.436100820015554e-09
% O 0 1.7985863909331101e-09
of O 0 2.9466264983568635e-09
patient O 0 3.2231987461273093e-06
chromosomes O 0 4.185929356026463e-06
. O 0 2.0093496289064205e-07

This O 0 1.8512304222895182e-07
mutation O 0 1.5385077176688355e-06
eliminates O 0 2.641315859364113e-07
the O 0 3.193759701147769e-09
ability O 0 5.264165636731377e-08
of O 0 1.9845374232829727e-09
HFE O 0 7.126992841222091e-06
to O 0 1.1692965706799896e-08
associate O 0 2.3384698977224616e-07
with O 0 2.0083835039486075e-08
beta2 O 0 0.0003408911288715899
- O 0 0.0007133278413675725
microglobulin O 0 3.4331293136347085e-05
( O 0 1.7325570311754745e-08
beta2m O 0 5.401359999268607e-07
) O 0 4.26109858508994e-09
and O 0 6.11105743786311e-09
prevents O 0 8.460158795742245e-08
cell O 0 1.0671429890862782e-06
- O 0 7.206212103483267e-06
surface O 0 3.761659900192171e-05
expression O 0 1.7019741562762647e-06
. O 0 1.3819638411405322e-07

A O 0 4.21314689447172e-06
second O 0 6.496534297184553e-07
mutation O 0 8.722969369046041e-07
that O 0 3.933152470381174e-09
has O 0 9.231566622247556e-09
no O 0 1.990755826852819e-08
effect O 0 1.359661094824105e-08
on O 0 4.638474138118909e-08
beta2m O 0 5.104164301883429e-06
association O 0 2.2052141446238238e-08
, O 0 1.8813393065642003e-09
H63D O 0 5.955730557616334e-07
, O 0 3.0359788016909306e-09
was O 0 1.0612671985654742e-07
found O 0 5.782346601534982e-09
in O 0 9.731595529416381e-10
eight O 0 2.0868515804295384e-08
out O 0 1.2058986698093577e-08
of O 0 4.607299819436861e-10
nine O 0 5.223768084761105e-07
patients O 0 1.2222101020142873e-07
heterozygous O 0 1.8179122207584442e-07
for O 0 1.809556171572524e-09
the O 0 2.475193028317335e-08
C282Y O 0 2.4024336653383216e-06
mutant O 0 3.254428975196788e-06
. O 0 2.1263500116219802e-07

In O 0 1.9549757723780203e-07
this O 0 9.589721017277952e-09
report O 0 2.6590525337155668e-08
, O 0 1.576301311700945e-09
we O 0 5.692808002777383e-09
demonstrate O 0 5.994962304356477e-09
in O 0 9.520390031880765e-10
cultured O 0 1.1192936000270493e-07
293 O 0 1.523893615740235e-07
cells O 0 1.270495175731412e-07
overexpressing O 0 2.592019654912292e-06
wild O 0 6.946008568320394e-08
- O 0 1.6409080672019627e-06
type O 0 1.4113031284068711e-05
or O 0 2.0863704719431553e-07
mutant O 0 1.089526904252125e-06
HFE O 0 7.856729098421056e-06
proteins O 0 2.6529226815341644e-08
that O 0 1.4226306799258737e-09
both O 0 2.9778142174308186e-09
the O 0 1.7429803156332468e-09
wild O 0 3.04863050359927e-08
- O 0 2.680031229829183e-06
type O 0 7.234865188365802e-05
and O 0 2.2379390429705381e-07
H63D O 0 2.8933722205692902e-05
HFE O 0 2.1838894099346362e-05
proteins O 0 1.2230158574766392e-07
form O 0 1.3542910437536193e-07
stable O 0 1.1917970823560609e-06
complexes O 0 4.5000181359000635e-08
with O 0 6.7256773483848065e-09
the O 0 1.9394283512497168e-08
transferrin O 0 1.700611278465658e-06
receptor O 0 7.18059084192646e-07
( O 0 3.990188091052005e-08
TfR O 0 5.049185347161256e-06
) O 0 3.713295981810916e-08
. O 0 7.18387909159901e-08

The O 0 2.046767122010351e-06
C282Y O 0 2.101299469359219e-05
mutation O 0 6.734698217769619e-06
nearly O 0 2.6701223987402045e-07
completely O 0 5.972332814963011e-07
prevents O 0 2.840097046430401e-08
the O 0 8.925616912236478e-10
association O 0 2.0620816165717315e-09
of O 0 3.219881583582662e-10
the O 0 4.143063669914682e-09
mutant O 0 9.512789347354556e-07
HFE O 0 1.216570490214508e-05
protein O 0 1.362496533374724e-07
with O 0 1.3693791878210959e-08
the O 0 1.1290096324501064e-07
TfR O 0 8.056168007897213e-05
. O 0 2.2591638071389752e-07

Studies O 0 6.09403559792554e-06
on O 0 3.560494121757074e-07
cell O 0 3.1104609661269933e-06
- O 0 2.2638535028818296e-06
associated O 0 6.415974951323733e-08
transferrin O 0 2.1906802771809453e-07
at O 0 9.514099019725109e-08
37 O 0 8.013829955189067e-08
degrees O 0 6.522147373289044e-07
C O 0 3.774200740735978e-05
suggest O 0 1.1294673640804831e-07
that O 0 1.1881809980351932e-09
the O 0 4.3980539210508596e-09
overexpressed O 0 5.808120135952777e-07
wild O 0 6.382409623029162e-08
- O 0 8.959906381278415e-07
type O 0 9.758136911841575e-06
HFE O 0 3.0665327358292416e-05
protein O 0 2.1677197992175934e-07
decreases O 0 1.7118733808274555e-07
the O 0 2.1812389672248855e-09
affinity O 0 1.618355938148852e-08
of O 0 2.699519052740129e-09
the O 0 2.656593700578469e-08
TfR O 0 1.3682920325663872e-05
for O 0 4.1216505763941313e-08
transferrin O 0 1.0641637345543131e-05
. O 0 3.511433135372499e-07

The O 0 1.1108463695563842e-06
overexpressed O 0 5.5330252507701516e-05
H63D O 0 7.81996550358599e-06
protein O 0 2.130232843455815e-07
does O 0 4.932998720619253e-08
not O 0 1.8290586822899968e-08
have O 0 3.055789177253132e-09
this O 0 1.7594765922002154e-10
effect O 0 7.241849786510102e-09
, O 0 3.725806885235272e-10
providing O 0 3.258298075792254e-09
the O 0 4.423475474801819e-10
first O 0 4.163954514524448e-09
direct O 0 1.5834407562920205e-08
evidence O 0 5.4141402472396294e-08
for O 0 2.872428517264325e-09
a O 0 1.3020284406195515e-08
functional O 0 1.8220498532173224e-06
consequence O 0 2.1465289989919256e-07
of O 0 1.5854284551863884e-09
the O 0 3.3860025894227874e-08
H63D O 0 0.00010526562255108729
mutation O 0 4.6430068323388696e-06
. O 0 1.9030709097478393e-07

Addition O 0 7.571438231934735e-07
of O 0 1.9356107827661617e-08
soluble O 0 9.403701710652967e-07
wild O 0 1.2962257756043982e-07
- O 0 1.2984311069885734e-05
type O 0 0.001222912804223597
HFE O 0 0.062334608286619186
/ O 0 2.968143417092506e-05
beta2m O 0 1.3324674000614323e-05
heterodimers O 0 8.986196007754188e-06
to O 0 2.413178812332717e-08
cultured O 0 6.878453291392361e-07
cells O 0 3.142937146094482e-07
also O 0 9.609367523921719e-09
decreased O 0 1.3099676721139986e-07
the O 0 1.2092377099648388e-09
apparent O 0 1.337565702641541e-08
affinity O 0 4.223746685738661e-09
of O 0 7.093964859983259e-10
the O 0 5.7825007004908e-09
TfR O 0 5.628547796732164e-07
for O 0 5.180689210959599e-10
its O 0 1.1089015261589452e-09
ligand O 0 8.540702367554331e-09
under O 0 3.144756632877943e-08
steady O 0 4.322422228142386e-06
- O 0 5.142658210388618e-07
state O 0 6.3440066533360095e-09
conditions O 0 2.9658338007720886e-07
, O 0 3.655499791754835e-10
both O 0 9.218013574674444e-10
in O 0 7.658315093195256e-10
293 O 0 1.872747823483678e-08
cells O 0 1.0378180981263085e-08
and O 0 2.4667836662217724e-09
in O 0 5.86516613054755e-09
HeLa O 0 7.809316230122931e-06
cells O 0 6.640131005042349e-07
. O 0 1.0130777639005828e-07

Furthermore O 0 9.637179573473986e-06
, O 0 3.048142005468435e-08
at O 0 1.3001325349648596e-08
4 O 0 6.441956301728169e-09
degrees O 0 6.836377224317403e-07
C O 0 0.003892146749421954
, O 0 1.0704822805962522e-08
the O 0 5.519132262321591e-09
added O 0 4.910234565613791e-07
soluble O 0 3.776926504883704e-08
complex O 0 1.0062811917066483e-08
of O 0 4.504189465848185e-09
HFE O 0 0.00019465140940155834
/ O 0 5.119613433635095e-06
beta2m O 0 3.7278548461472383e-06
inhibited O 0 3.5268612919026054e-07
binding O 0 4.394735952928386e-08
of O 0 2.5343629417307056e-09
transferrin O 0 2.792050679545355e-07
to O 0 4.450832946645278e-08
HeLa O 0 1.3328220120456535e-05
cell O 0 3.5591262985690264e-06
TfR O 0 3.001800678248401e-06
in O 0 2.7557303106107156e-09
a O 0 1.2040094254928135e-08
concentration O 0 8.231369065470062e-06
- O 0 3.3392683690181e-05
dependent O 0 3.6453216125664767e-06
manner O 0 4.272455498721683e-06
. O 0 1.9893634828349605e-07

Scatchard O 0 0.0002486920275259763
plots O 0 2.7748362754209666e-06
of O 0 2.3868256704417945e-08
these O 0 1.0203649480899912e-08
data O 0 1.4541495829689666e-07
indicate O 0 1.414173766534077e-06
that O 0 4.192380220757741e-09
the O 0 6.867256541198685e-09
added O 0 1.0688443552453464e-07
heterodimer O 0 3.2534376259718556e-07
substantially O 0 3.115039532985975e-07
reduced O 0 2.2057356829918717e-08
the O 0 1.4347844023987477e-09
affinity O 0 2.17840874228159e-08
of O 0 4.430452449355471e-09
TfR O 0 4.8336564759665634e-06
for O 0 4.170768619360388e-08
transferrin O 0 7.141729838622268e-06
. O 0 4.018662593807676e-07

These O 0 2.720403017519857e-06
results O 0 6.47246565677051e-07
establish O 0 9.737880191096338e-08
a O 0 8.469228873764223e-09
molecular O 0 1.693992857099147e-07
link O 0 3.101444463027292e-06
between O 0 1.6250655221483612e-07
HFE O 0 0.006850726902484894
and O 0 7.210180541505906e-08
a O 0 1.0340559519761428e-08
key O 0 2.3810652294287138e-07
protein O 0 2.689452571758011e-08
involved O 0 1.986242459395271e-08
in O 0 1.8219372677208412e-09
iron O 0 5.012482688471209e-06
transport O 0 2.2399032673092734e-07
, O 0 2.7205204755631485e-09
the O 0 3.2490390378114853e-09
TfR O 0 7.325498359023186e-07
, O 0 2.364891837913774e-09
and O 0 3.2679075001595947e-09
raise O 0 1.2431770279874854e-08
the O 0 1.984779895991551e-09
possibility O 0 5.677421199834498e-09
that O 0 2.7395563595433714e-10
alterations O 0 6.463410784363077e-08
in O 0 6.982904254826394e-10
this O 0 3.844663476471055e-10
regulatory O 0 2.859529146803652e-08
mechanism O 0 7.494455758205731e-07
may O 0 5.669924121320946e-07
play O 0 5.472572084386229e-08
a O 0 1.5937571262725214e-09
role O 0 1.4729788944123356e-08
in O 0 4.708980982925937e-10
the O 0 2.8366091697762386e-09
pathogenesis O 0 8.855928967932414e-08
of O 0 4.814334531033637e-08
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 1.717601548989478e-06
. O 0 4.358681735538994e-07

Genomic O 0 3.40553633577656e-05
organization O 0 8.455817805952393e-07
of O 0 6.043341382877543e-09
the O 0 2.1430901497865307e-08
UBE3A O 0 2.492298517609015e-05
/ O 0 2.407300598861184e-06
E6 O 0 1.6325727756338893e-06
- O 0 1.3258039871288929e-05
AP O 0 1.2809675354219507e-05
gene O 0 6.185094321153883e-07
and O 0 2.188867043173559e-08
related O 0 2.730433266151522e-07
pseudogenes O 0 5.764449269918259e-06
. O 0 5.09951973981515e-07

The O 0 2.3081429390003905e-06
UBE3A O 0 9.953288099495694e-05
gene O 0 1.686482505647291e-06
encodes O 0 4.879625521425623e-07
the O 0 2.503701068690134e-08
E6 O 0 1.3829290992362075e-06
- O 0 6.706658041366609e-06
AP O 0 1.1395698493288364e-05
ubiquitin O 0 4.452761004358763e-07
- O 0 3.0660285688099975e-07
protein O 0 5.031943572930686e-08
ligase O 0 2.3781327129768215e-08
and O 0 9.276681645076224e-09
has O 0 7.424878045725336e-09
recently O 0 3.5993519276189545e-08
been O 0 7.622674047524924e-09
shown O 0 3.7973086897125086e-09
to O 0 1.5982258849689401e-09
be O 0 1.2882419575532822e-08
mutated O 0 3.9821097743697464e-06
in O 0 3.038210252270801e-06
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 0 0.0010053747100755572
who O 0 1.7579965572167566e-07
lack O 0 3.315138883408508e-07
15q11 O 0 1.099540531868115e-05
- O 0 3.432242010603659e-05
q13 O 0 4.972882379661314e-06
deletions O 0 1.098194934456842e-05
or O 0 4.5979554670338985e-06
chromosome O 0 0.0003934678970836103
15 O 0 9.202016144627123e-07
paternal O 0 0.0006398539408110082
uniparental B-Disease 0 0.05854819715023041
disomy I-Disease 0 0.0013650235487148166
. O 0 1.956514097400941e-06

Previous O 0 1.8550188542576507e-05
UBE3A O 0 8.741809870116413e-05
cDNA O 0 1.6001779385987902e-06
analysis O 0 3.729486763859313e-07
has O 0 1.8783355315576955e-08
shown O 0 1.4219804000958902e-08
a O 0 2.869487758516698e-09
coding O 0 4.3608108057924255e-07
region O 0 3.7081221648804785e-08
of O 0 1.3538946630475834e-09
approximately O 0 2.5151596361183692e-08
2 O 0 6.325341672663853e-08
. O 0 8.139982554666858e-08

6 O 0 1.2218050869705621e-05
kb O 0 6.8238068706705235e-06
and O 0 6.01734981842128e-08
a O 0 3.90096843716492e-08
3 O 0 2.795714237890934e-07
- O 0 1.3373943147598766e-05
untranslated O 0 0.00026583863655105233
region O 0 1.9442527445789892e-06
( O 0 2.6932921670663745e-08
UTR O 0 8.057878062572854e-07
) O 0 2.5247663959504507e-09
of O 0 1.6294403604177887e-09
< O 0 4.5062668618811585e-07
50 O 0 1.2088652567854297e-07
bp O 0 1.284556333303044e-06
, O 0 5.630091504116308e-09
whereas O 0 9.496056385671636e-09
Northern O 0 5.981438899738123e-09
analysis O 0 3.701882533846401e-08
has O 0 1.444108832515667e-08
indicated O 0 3.433398987340297e-08
mRNA O 0 1.0816907369814999e-08
sizes O 0 6.437402078063315e-08
of O 0 4.265408026782325e-09
5 O 0 6.159975640684934e-08
- O 0 4.202099717076635e-06
8 O 0 2.2250850406635436e-07
kb O 0 1.0359498446632642e-05
. O 0 2.6885302872869943e-07

We O 0 7.757994353596587e-06
have O 0 4.903486328089457e-08
analyzed O 0 5.9083514969415774e-08
additional O 0 7.733503615270365e-09
cDNA O 0 1.0730337862696615e-07
clones O 0 4.887165232503321e-07
and O 0 5.163684146936021e-09
provide O 0 1.2395543258492125e-08
evidence O 0 5.4724466735933674e-08
for O 0 2.0548924783980738e-09
an O 0 3.4499660905851215e-09
additional O 0 7.538987034649836e-08
0 O 0 3.3563717352080857e-06
. O 0 1.962222881957132e-07

5 O 0 1.6988541347018327e-06
kb O 0 4.437323241290869e-06
of O 0 2.3458984088620127e-08
5 O 0 6.25618170602138e-08
- O 0 1.2937671272084117e-06
UTR O 0 2.1886055492359446e-06
and O 0 2.3300945173332366e-08
> O 0 6.771632854452037e-08
2 O 0 1.5024378186012655e-08
kb O 0 6.851616944913985e-07
of O 0 1.7207867131219245e-08
3 O 0 4.019133825750032e-07
- O 0 4.0277449443237856e-05
UTR O 0 5.5484539188910276e-05
. O 0 3.7383750850494835e-07

We O 0 8.813304702925961e-06
have O 0 3.0665692207776374e-08
established O 0 1.1425584034441272e-08
the O 0 7.883727559665488e-10
genomic O 0 5.095708033309165e-08
organization O 0 6.1118967664697266e-09
of O 0 5.808253322747703e-10
UBE3A O 0 2.1655805539921857e-06
and O 0 1.3906546136865927e-08
the O 0 3.908622758785896e-09
sequence O 0 2.1858088672388476e-08
of O 0 4.6731756242479605e-09
intron O 0 5.271251211524941e-05
- O 0 5.814757969346829e-05
exon O 0 2.082119681290351e-05
borders O 0 9.908098945743404e-06
. O 0 5.927930715188268e-07

We O 0 1.94700278370874e-05
have O 0 9.836819003794517e-08
also O 0 1.229317092565907e-08
mapped O 0 7.819286338417442e-07
two O 0 2.990018188597787e-08
highly O 0 1.1527441046155218e-07
homologous O 0 4.2781536535585474e-07
processed O 0 4.079464304140856e-07
pseudogenes O 0 5.635455408992129e-07
, O 0 1.6541068958986216e-08
UBE3AP1 O 0 2.354861180720036e-06
and O 0 3.833485706650208e-08
UBE3AP2 O 0 2.713225967454491e-06
, O 0 2.3334201237901198e-09
to O 0 1.944765237738011e-09
chromosomes O 0 3.0080886403993645e-07
2 O 0 1.8202188201144054e-08
and O 0 3.1292415769712534e-08
21 O 0 8.977460197456821e-08
, O 0 4.749538540238518e-09
respectively O 0 1.2364237989004323e-07
, O 0 3.5523988195507172e-09
and O 0 8.875506551930812e-09
determined O 0 2.532883911499084e-07
their O 0 3.8108353805910156e-08
genomic O 0 7.352072657340614e-07
organization O 0 2.2414589295749465e-07
. O 0 7.296257820144092e-08

These O 0 1.5362337535407278e-06
results O 0 2.990281018355745e-07
will O 0 3.469035503300688e-09
form O 0 2.933750575806471e-09
the O 0 5.596449415001814e-10
basis O 0 2.6141140363478144e-09
for O 0 2.800321641238668e-10
studies O 0 2.88551960103689e-09
of O 0 3.828177219666884e-10
mutation O 0 2.5851051077552256e-07
and O 0 1.5270206432660416e-08
imprinting O 0 3.2087016279547242e-06
of O 0 9.202527451179776e-08
UBE3A O 0 0.0003016064583789557
. O 0 1.1391277894290397e-06

Mutation O 0 7.217823440441862e-05
spectrum O 0 4.179060852038674e-06
and O 0 2.752664727267984e-07
genotype O 0 0.0001774810953065753
- O 0 4.6531917178072035e-05
phenotype O 0 1.1964516488660593e-05
analyses O 0 1.4507036212307867e-06
in O 0 4.8792390572316435e-08
Cowden B-Disease 0 0.0029641897417604923
disease I-Disease 1 0.6249207258224487
and O 0 3.0843551712678163e-07
Bannayan B-Disease 1 0.9947551488876343
- I-Disease 1 0.9999985694885254
Zonana I-Disease 1 0.9999980926513672
syndrome I-Disease 1 1.0
, O 0 2.9451335592511896e-08
two O 0 1.6381579825974768e-07
hamartoma B-Disease 1 0.7715667486190796
syndromes I-Disease 0 0.014091449789702892
with O 0 2.2577509639631899e-07
germline O 0 0.0003935449931304902
PTEN O 0 0.0004539838701020926
mutation O 0 0.00012489085202105343
. O 0 7.277952249751252e-07

The O 0 1.4519710930471774e-05
tumour B-Disease 1 0.9999939203262329
suppressor O 0 4.55203335150145e-05
gene O 0 1.0037097126769368e-05
PTEN O 0 1.5680214346502908e-05
, O 0 2.3946871152702442e-08
which O 0 3.375335566602189e-09
maps O 0 1.9968982201135077e-07
to O 0 1.7810549479690962e-07
10q23 O 0 2.5544921300024725e-05
. O 0 3.2586919473942544e-07

3 O 0 3.3360120141878724e-06
and O 0 9.28612138295648e-08
encodes O 0 2.813463311213127e-07
a O 0 3.651573265983643e-08
403 O 0 1.9147292107390967e-07
amino O 0 2.495154092230223e-07
acid O 0 1.2630870571683772e-07
dual O 0 9.198121233566781e-07
specificity O 0 1.5040942571431515e-06
phosphatase O 0 0.32511308789253235
( O 0 1.0234371927708708e-07
protein O 0 4.827874704460555e-07
tyrosine O 0 5.629596671496984e-06
phosphatase O 0 0.00012137303565395996
; O 0 2.4092651429441503e-08
PTPase O 0 1.006880324894155e-06
) O 0 4.2190766436078775e-09
, O 0 1.572415531114757e-09
was O 0 3.986194485605665e-08
shown O 0 1.0046492526782913e-08
recently O 0 2.068471971483632e-08
to O 0 1.7540727759168817e-09
play O 0 6.063155666424791e-08
a O 0 3.9231125015248836e-09
broad O 0 7.004386759490444e-08
role O 0 3.531242498411302e-08
in O 0 6.950644504399861e-09
human O 0 1.0406133554852204e-07
malignancy B-Disease 0 2.048421447398141e-05
. O 0 1.3654454278366757e-07

Somatic O 0 0.000581833126489073
PTEN O 0 0.00042316835606470704
deletions O 0 3.099688910879195e-05
and O 0 1.1702200026775245e-06
mutations O 0 0.00010136609489563853
were O 0 2.2194264204244973e-07
observed O 0 1.1416243950179705e-07
in O 0 3.330232756226792e-09
sporadic B-Disease 0 0.2358389049768448
breast I-Disease 1 0.9999872446060181
, I-Disease 0 3.789768072692823e-07
brain I-Disease 0 0.006362312939018011
, I-Disease 0 1.1534918797906357e-07
prostate I-Disease 0 0.23148050904273987
and I-Disease 0 6.222174761205679e-06
kidney I-Disease 1 0.9155032634735107
cancer I-Disease 0 0.26813286542892456
cell O 0 2.5076042220462114e-05
lines O 0 0.0032990651670843363
and O 0 4.4732672677127994e-08
in O 0 6.704412580660346e-10
several O 0 8.086498581860724e-09
primary O 1 0.5564495921134949
tumours B-Disease 1 1.0
such O 0 3.644058921281612e-08
as O 0 1.6513980881427415e-05
endometrial B-Disease 1 0.9999995231628418
carcinomas I-Disease 1 1.0
, O 0 0.4006728231906891
malignant B-Disease 1 1.0
melanoma I-Disease 1 1.0
and O 0 0.1114407330751419
thyroid B-Disease 1 1.0
tumours I-Disease 1 1.0
. O 0 1.7548485402585356e-06

In O 0 1.8997309325641254e-07
addition O 0 8.198099976652884e-08
, O 0 6.7527219371754654e-09
PTEN O 0 1.0855721939151408e-06
was O 0 3.689412864105179e-08
identified O 0 1.293227303023059e-08
as O 0 3.369429180111183e-10
the O 0 4.1511138970662387e-10
susceptibility O 0 1.4241183521335188e-07
gene O 0 1.6975005223685002e-07
for O 0 1.1452770287689873e-08
two O 0 1.081123627955094e-05
hamartoma B-Disease 1 0.9999837875366211
syndromes I-Disease 1 0.9999785423278809
Cowden B-Disease 1 0.8448949456214905
disease I-Disease 1 0.9999562501907349
( O 0 2.1293696761404135e-07
CD B-Disease 0 4.985456143913325e-06
; O 0 1.0041303966090709e-07
MIM O 0 2.177716487494763e-05
158350 O 0 1.8484266774976277e-06
) O 0 7.71817809663844e-09
and O 0 2.0181985860290297e-08
Bannayan B-Disease 0 9.486304770689458e-05
- I-Disease 0 0.00028081220807507634
Zonana I-Disease 0 9.285610576625913e-05
( I-Disease 0 4.798483743684301e-08
BZS I-Disease 0 6.061877229512902e-06
) I-Disease 0 2.8266189389114516e-08
or I-Disease 0 1.0619981338777507e-07
Ruvalcaba I-Disease 0 1.9719080228242092e-05
- I-Disease 0 7.364784687524661e-05
Riley I-Disease 0 1.600079303898383e-05
- I-Disease 1 0.6181599497795105
Smith I-Disease 0 0.0526873841881752
syndrome I-Disease 1 0.9975662231445312
( O 0 1.3543220234168984e-07
MIM O 0 2.5334578822366893e-05
153480 O 0 3.741010914382059e-06
) O 0 7.75007436004671e-08
. O 0 7.323389183966356e-08

Constitutive O 0 6.423158629331738e-05
DNA O 0 5.2587647587643005e-06
from O 0 7.275329494405014e-08
37 O 0 3.2312053122041107e-07
CD B-Disease 0 7.251423994603101e-07
families O 0 6.976227240329536e-08
and O 0 1.2274707472670343e-08
seven O 0 6.947545472257843e-08
BZS B-Disease 0 1.8727852875599638e-05
families O 0 6.004325570074798e-08
was O 0 7.934981738344504e-08
screened O 0 7.705376106059703e-07
for O 0 3.883833699092065e-08
germline O 0 7.320331496885046e-05
PTEN O 0 0.00011305828957119957
mutations O 0 4.933440141030587e-05
. O 0 8.640167834528256e-07

PTEN O 0 0.002405214589089155
mutations O 0 0.0005704777431674302
were O 0 2.7754872462537605e-06
identified O 0 2.643268715019076e-07
in O 0 1.864798315764915e-09
30 O 0 2.9799278600251e-09
of O 0 4.16647077949861e-10
37 O 0 5.045455964136636e-08
( O 0 3.911516444077279e-09
81 O 0 1.2395926773933752e-07
% O 0 1.72019589683714e-08
) O 0 1.4209710075263615e-09
CD B-Disease 0 4.856408395426115e-07
families O 0 2.9329969564173552e-08
, O 0 5.132437252974853e-10
including O 0 4.374745454782669e-09
missense O 0 4.657019871956436e-06
and O 0 1.5885234461165965e-07
nonsense O 0 1.3101568583806511e-05
point O 0 1.0589434396024444e-06
mutations O 0 8.278571840492077e-06
, O 0 5.3189261883801464e-09
deletions O 0 2.693334124614921e-07
, O 0 7.066743190620173e-09
insertions O 0 1.830454948503757e-06
, O 0 8.400180107059896e-09
a O 0 1.553317829916523e-08
deletion O 0 1.2597186469065491e-05
/ O 0 4.534379513643216e-06
insertion O 0 1.2408255543050473e-06
and O 0 1.8709953053530626e-07
splice O 0 0.007765362970530987
site O 0 2.625198249006644e-05
mutations O 0 0.000161810326972045
. O 0 5.204822173254797e-07

These O 0 1.2713051091850502e-06
mutations O 0 1.1696304682118353e-05
were O 0 3.183738499501487e-07
scattered O 0 1.4446713691995683e-07
over O 0 1.3267618115264668e-08
the O 0 6.824975251618071e-09
entire O 0 3.088805300421882e-08
length O 0 2.0371221154391606e-08
of O 0 5.786237600169386e-10
PTEN O 0 6.484031587206118e-07
, O 0 1.51685708438265e-09
with O 0 4.3752440559430283e-10
the O 0 1.1860072923752796e-09
exception O 0 2.190824632819499e-09
of O 0 1.734645205253571e-10
the O 0 2.6730606617064723e-09
first O 0 1.3389957587151002e-07
, O 0 1.5159784538809618e-08
fourth O 0 4.9538962230144534e-06
and O 0 8.61294680021274e-08
last O 0 5.842926498189627e-08
exons O 0 3.3804255963332253e-06
. O 0 1.6571297578593658e-07

A O 0 7.624713362019975e-06
hot O 0 5.167664130567573e-05
spot O 0 3.4841999877244234e-05
for O 0 3.522698932556523e-08
PTEN O 0 8.746528692427091e-06
mutation O 0 9.746518117026426e-07
in O 0 1.670721871960268e-08
CD B-Disease 0 1.5501693724218057e-06
was O 0 7.884710839789477e-07
identified O 0 6.040762201564576e-08
in O 0 6.647431494144485e-10
exon O 0 1.0240972159181183e-07
5 O 0 1.1552506506973259e-08
that O 0 6.427029464184386e-10
contains O 0 2.3325301690135802e-09
the O 0 6.7556333860352424e-09
PTPase O 0 6.988246354922012e-07
core O 0 4.0124319866663427e-07
motif O 0 1.0414532169988888e-07
, O 0 2.6483308879221568e-09
with O 0 1.161999052534668e-09
13 O 0 5.663220559171123e-09
of O 0 4.3333858723570984e-10
30 O 0 6.983520428605061e-09
( O 0 3.3831408785545136e-09
43 O 0 4.883829163304654e-08
% O 0 1.4118297642085054e-08
) O 0 3.262066172737832e-09
CD B-Disease 0 7.893272027104103e-07
mutations O 0 9.8879363576998e-06
identified O 0 1.5350593685070635e-07
in O 0 1.3479477534161788e-09
this O 0 2.4019959354859566e-09
exon O 0 2.9837169677193742e-06
. O 0 2.5498368927401316e-07

Seven O 0 5.357264853955712e-06
of O 0 2.3270832372190853e-08
30 O 0 5.2824514540361633e-08
( O 0 7.031369264609566e-09
23 O 0 5.566242933241483e-08
% O 0 1.519197212473955e-08
) O 0 2.219365580202748e-09
were O 0 7.202277174656047e-08
within O 0 1.9966110986757712e-09
the O 0 1.0695286878359411e-09
core O 0 1.0100524150402634e-07
motif O 0 3.731329201173139e-08
, O 0 1.073124922257307e-09
the O 0 1.1745846517641212e-09
majority O 0 1.0187450882881421e-08
( O 0 1.6701284799580662e-09
five O 0 3.4532841031165162e-09
of O 0 3.6600278363607686e-10
seven O 0 3.1743820017027247e-08
) O 0 2.581204416873817e-10
of O 0 1.176934244506711e-10
which O 0 7.169175475496559e-09
were O 0 2.8821196451644937e-07
missense O 0 5.274847808323102e-06
mutations O 0 3.2015182114264462e-06
, O 0 6.281252851181307e-09
possibly O 0 8.185959643469687e-08
pointing O 0 6.023228706908412e-07
to O 0 6.923559503491106e-09
the O 0 5.2283204432512775e-09
functional O 0 3.6325641872281267e-07
significance O 0 1.3529066755779695e-08
of O 0 1.3345325955427256e-09
this O 0 4.0311425308914295e-09
region O 0 1.6629746824037284e-07
. O 0 4.481739068751267e-08

Germline O 0 0.0023446890991181135
PTEN O 0 0.000711108383256942
mutations O 0 0.0002056286612059921
were O 0 2.3951040475367336e-06
identified O 0 3.7078930859024695e-07
in O 0 1.9986150512352197e-09
four O 0 6.2973875003535795e-09
of O 0 1.315901498877281e-09
seven O 0 2.3876413024481735e-07
( O 0 1.1600508997844372e-08
57 O 0 1.7856059741916397e-07
% O 0 1.7813734487504007e-08
) O 0 5.468792085849827e-09
BZS B-Disease 0 6.711098194500664e-06
families O 0 6.983043476793682e-08
studied O 0 1.5071598227223149e-06
. O 0 2.231964515431173e-07

Interestingly O 0 2.0896390196867287e-05
, O 0 8.740708778987027e-08
none O 0 4.355598193228616e-08
of O 0 3.475650045547951e-10
these O 0 5.323443019733531e-09
mutations O 0 6.954651325941086e-06
was O 0 4.0980054905048746e-07
observed O 0 5.652000822919945e-08
in O 0 1.124618842496261e-09
the O 0 1.1229110974397827e-08
PTPase O 0 4.622753294825088e-06
core O 0 2.5449664917687187e-06
motif O 0 1.801705252546526e-06
. O 0 1.7182587441766373e-07

It O 0 5.855276299371326e-07
is O 0 1.3511969321200468e-08
also O 0 3.3122358189530132e-09
worthy O 0 8.597925038600351e-09
of O 0 8.938223494681097e-10
note O 0 1.4805452508426242e-07
that O 0 1.04994690719451e-09
a O 0 7.840918136992059e-09
single O 0 1.7905229469761252e-05
nonsense O 0 5.580493962042965e-06
point O 0 8.461192635422776e-08
mutation O 0 3.644316848294693e-07
, O 0 5.852526907546007e-09
R233X O 0 1.20122535918199e-07
, O 0 3.6663247993118375e-09
was O 0 6.270911967476422e-08
observed O 0 2.5267670622497462e-08
in O 0 6.309707201168635e-10
the O 0 2.491770567658591e-09
germline O 0 2.7687698889167223e-07
DNA O 0 6.401050001159092e-08
from O 0 1.4577569151796865e-09
two O 0 6.750262127042106e-09
unrelated O 0 8.646855320648683e-08
CD B-Disease 0 4.873640136793256e-06
families O 0 2.475134692758729e-07
and O 0 5.3759027451860675e-08
one O 0 7.784132804999899e-08
BZS B-Disease 0 6.229428254300728e-05
family O 0 4.649204754514358e-07
. O 0 1.7519779760277743e-07

Genotype O 0 0.0011629570508375764
- O 0 4.7947247367119417e-05
phenotype O 0 5.567310836340766e-06
studies O 0 4.6167258460627636e-07
were O 0 3.6360650028655073e-06
not O 0 4.824206811804288e-08
performed O 0 1.0384139841335127e-06
on O 0 7.530275070166681e-09
this O 0 4.739816872323388e-10
small O 0 6.877270308791594e-09
group O 0 7.72324337816599e-09
of O 0 2.6678348419295617e-09
BZS B-Disease 0 1.723091372696217e-05
families O 0 2.8107976390856493e-07
. O 0 1.6282892545405048e-07

However O 0 1.4233690990295145e-06
, O 0 5.388909585235524e-08
genotype O 0 5.570688699663151e-06
- O 0 1.0324861250410322e-06
phenotype O 0 1.1417325822549174e-06
analysis O 0 7.066382323728249e-08
inthe O 0 2.4273199414892588e-06
group O 0 3.768349188248976e-08
of O 0 1.58606061617661e-09
CD B-Disease 0 1.6526490753676626e-06
families O 0 6.276417252593092e-08
revealed O 0 1.3480413940669678e-07
two O 0 5.919809531462761e-09
possible O 0 1.0088890611825718e-08
associations O 0 2.6517492202060566e-08
worthy O 0 1.7229870863388896e-08
of O 0 1.1185199433327853e-09
follow O 0 2.2852493941627472e-07
- O 0 0.0006655681063421071
up O 0 5.445148872240679e-06
in O 0 5.111806089530546e-09
independent O 0 9.301277259510243e-08
analyses O 0 3.162445636917255e-06
. O 0 1.4590656860491436e-07

The O 0 4.182375334949029e-07
first O 0 1.5269426967279287e-07
was O 0 9.607720841131595e-08
an O 0 1.230296975407441e-09
association O 0 7.312861871611176e-09
noted O 0 1.759276990753733e-08
in O 0 1.0351447476963926e-09
the O 0 1.4067647047255605e-09
group O 0 2.008183175306044e-09
of O 0 1.1133812621855199e-10
CD B-Disease 0 4.975293563802552e-07
families O 0 6.603448099440357e-08
with O 0 3.1003914955363143e-06
breast B-Disease 1 0.9999996423721313
disease I-Disease 1 0.9295564293861389
. O 0 2.3194155573946773e-07

A O 0 4.047268703288864e-06
correlation O 0 4.353581971372478e-06
was O 0 4.837696110371326e-07
observed O 0 2.786641672969381e-08
between O 0 1.2915897240617369e-09
the O 0 2.9785527377867993e-09
presence O 0 4.679849752164955e-08
/ O 0 2.7175065042683855e-06
absence O 0 3.069881415740383e-08
of O 0 3.112737012589406e-10
a O 0 7.975613058874842e-09
PTEN O 0 1.7769961004887591e-06
mutation O 0 1.9830331154935266e-07
and O 0 9.820764201862175e-10
the O 0 6.61187327111179e-10
type O 0 9.127984981205373e-07
of O 0 1.0400850847247511e-08
breast O 1 0.5701915621757507
involvement O 0 4.373493993625743e-06
( O 0 2.711487923079403e-07
unaffected O 0 1.2352949852356687e-05
versus O 0 2.947833127109334e-05
benign O 0 0.21134789288043976
versus O 0 0.0004195742658339441
malignant O 0 0.3210912346839905
) O 0 1.5407970010983263e-07
. O 0 1.320853897368579e-07

Specifically O 0 3.6732394619320985e-06
and O 0 4.3597871979272895e-08
more O 0 3.27501492591864e-09
directly O 0 2.3356832912213576e-08
, O 0 1.2495139367629804e-09
an O 0 1.0167936492777585e-09
association O 0 3.6295475069891836e-08
was O 0 7.42044960588828e-07
also O 0 1.6423307158675016e-08
observed O 0 1.4832977512924117e-08
between O 0 8.792838124271896e-10
the O 0 8.743301638247658e-10
presence O 0 2.440380342250137e-09
of O 0 1.636313029518277e-10
a O 0 1.2586663267200038e-08
PTEN O 0 1.74722390511306e-05
mutation O 0 1.2606513337232172e-05
and O 0 1.093382525141351e-05
malignant B-Disease 1 0.9999995231628418
breast I-Disease 1 0.9999997615814209
disease I-Disease 1 0.99957674741745
. O 0 8.596778684477613e-07

Secondly O 0 0.0005303924554027617
, O 0 3.924911311514734e-07
there O 0 3.36523839905567e-08
appeared O 0 1.535675835384609e-07
to O 0 3.451255947695131e-09
be O 0 6.611183156479683e-09
an O 0 3.097380407712791e-10
interdependent O 0 1.0627463780110702e-06
association O 0 1.2961263173849602e-08
between O 0 6.889375736562897e-09
mutations O 0 1.0235049785478623e-06
upstream O 0 4.970939215809267e-08
and O 0 1.0810883743772592e-08
within O 0 3.462795161723875e-09
the O 0 3.996142083906307e-09
PTPase O 0 6.697746357531287e-07
core O 0 2.811939623370563e-07
motif O 0 1.0255104143652716e-07
, O 0 1.6154375614974015e-09
the O 0 1.5125061203491441e-09
core O 0 1.4554828453583468e-07
motif O 0 3.420809235876732e-08
containing O 0 9.355112240427843e-09
the O 0 1.661968007660164e-09
majority O 0 6.060864254919807e-09
of O 0 7.070365959371827e-10
missense O 0 3.712676971190376e-06
mutations O 0 3.7921429338894086e-06
, O 0 3.037438300879103e-09
and O 0 1.4331815734180964e-09
the O 0 1.124595305768139e-09
involvement O 0 1.1611400729805155e-08
of O 0 4.237405704099473e-10
all O 0 1.67578906307142e-09
major O 0 3.367877354776283e-08
organ O 0 3.4856432193919318e-06
systems O 0 1.8255929035149165e-06
( O 0 7.04818026164844e-09
central O 0 2.8303144716801398e-08
nervous O 0 1.1864184443766135e-06
system O 0 1.4588125907266658e-07
, O 0 1.7591631262803276e-08
thyroid O 0 0.007571229711174965
, O 0 3.3777265429080217e-08
breast O 0 0.4742225706577301
, O 0 2.962054850286222e-07
skin O 1 0.9995978474617004
and O 0 7.792466203682125e-05
gastrointestinal O 1 0.8998575806617737
tract O 0 0.007864527404308319
) O 0 9.792564981125906e-08
. O 0 1.1421764867236561e-07

However O 0 1.8980480263053323e-06
, O 0 9.181240656630507e-09
these O 0 7.115688038794588e-10
observations O 0 2.0697822122883736e-08
would O 0 1.0473172551428434e-08
need O 0 1.3646442198478326e-08
to O 0 1.1794478282922682e-08
be O 0 3.5464370284898905e-07
confirmed O 0 4.03404420978859e-08
by O 0 4.188126512261192e-10
studying O 0 6.597827284515745e-10
a O 0 3.834863815388445e-10
larger O 0 1.6292693860719965e-09
number O 0 4.036528000739281e-09
of O 0 1.783419190104496e-09
CD B-Disease 0 4.438555151864421e-06
families O 0 3.5173152923562157e-07
. O 0 5.885833687102604e-08

Molecular O 0 0.0004481197101995349
defects O 1 0.9997603297233582
leading O 0 9.858943030849332e-07
to O 0 1.737199717410931e-08
human O 0 6.337273106282737e-08
complement B-Disease 0 1.3706990102946293e-05
component I-Disease 1 0.9858397245407104
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 3.2502536218004252e-09
an O 0 3.3225622253496567e-09
African O 0 4.120958863040869e-08
- O 0 3.5118225696351146e-06
American O 0 8.76179058195703e-08
family O 0 6.428689403037424e-08
. O 0 2.5114683666060955e-08

Complement B-Disease 0 0.006950239650905132
component I-Disease 1 0.999392032623291
C6 I-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 8.351122460226179e-07
C6D B-Disease 0 3.676396590890363e-05
) O 0 4.531680630748269e-08
was O 0 4.964987510902574e-06
diagnosed O 0 0.00010582843970041722
in O 0 1.568988272637739e-09
a O 0 8.816352092821944e-09
16 O 0 4.233039874179667e-08
- O 0 7.522611440435867e-07
year O 0 1.6879026176752632e-08
- O 0 7.331508982133528e-07
old O 0 2.1241014565021032e-06
African O 0 8.0738917773715e-09
- O 0 6.247298500738907e-08
American O 0 2.5048953133932628e-08
male O 0 4.5710271479038056e-07
with O 0 6.11783548265521e-07
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.6526506669833907e-06

The O 0 1.2106343092455063e-06
patients O 0 3.174982703058049e-05
father O 0 2.940049341759732e-07
and O 0 2.1973166397515342e-08
two O 0 8.98595686749104e-08
brothers O 0 7.628754246979952e-05
also O 0 7.909596178024003e-08
had O 0 6.667360139545053e-07
C6D B-Disease 0 4.615735633706208e-06
, O 0 2.8362683313076786e-09
but O 0 3.168990181379172e-09
gave O 0 1.334479815540135e-08
no O 0 1.1234424057704473e-08
history O 0 1.6144095837944406e-08
of O 0 3.270128701160502e-08
meningitis B-Disease 1 1.0
or O 0 4.208577138342662e-06
other O 0 1.888082863388263e-07
neisserial B-Disease 1 0.8852257132530212
infection I-Disease 1 0.8893422484397888
. O 0 2.44014017880545e-07

By O 0 1.8010733526807599e-07
using O 0 1.2284080241897755e-07
exon O 0 1.5294290278689004e-06
- O 0 7.001020208008413e-07
specific O 0 3.717781638101769e-08
polymerase O 0 4.954318342242914e-07
chain O 0 5.340444886314799e-07
reaction O 0 4.7902808830713184e-08
( O 0 3.6672198611142903e-09
PCR O 0 4.623457812158449e-07
) O 0 5.986552586989546e-09
/ O 0 7.918381328408941e-08
single O 0 6.041177584847901e-07
- O 0 5.686375175173453e-07
strand O 0 2.043068434431916e-07
conformation O 0 1.3163759149392718e-07
polymorphism O 0 1.9693204933446395e-07
as O 0 4.991296709278004e-09
a O 0 2.028764933825755e-09
screening O 0 5.4319524878110315e-08
step O 0 5.053411555877574e-08
and O 0 4.94912999471353e-09
nucleotide O 0 7.134951829357306e-08
sequencing O 0 1.622203349427309e-08
of O 0 1.4683106952517733e-09
target O 0 3.5096957162750186e-07
exons O 0 4.1852243271023326e-07
, O 0 1.44998217876946e-08
we O 0 4.475776549384136e-08
determined O 0 5.762014509969049e-08
that O 0 1.0473607536809482e-09
the O 0 7.001285329266693e-09
proband O 0 7.062877102725906e-06
was O 0 8.086764324843898e-08
a O 0 6.290892695659522e-09
compound O 0 4.95330709782138e-08
heterozygote O 0 2.13452381103707e-07
for O 0 2.9118305544528766e-09
two O 0 5.172124772911957e-08
C6 O 0 1.9254175640526228e-05
gene O 0 7.879788427089807e-06
mutations O 0 2.3631002477486618e-05
. O 0 5.883549079044315e-07

The O 0 2.6175686684837274e-07
first O 0 1.2741692501094803e-07
, O 0 4.376982332132684e-09
1195delC O 0 4.514383533660293e-08
located O 0 5.842500261366013e-09
in O 0 4.791848029483958e-10
exon O 0 6.480470915448677e-08
7 O 0 6.421410603252298e-08
, O 0 1.382394976268131e-09
is O 0 3.1733496386188165e-10
a O 0 1.5830986521692125e-09
novel O 0 1.0557408280931213e-08
mutation O 0 9.20505556223361e-08
, O 0 2.9648246080427043e-09
while O 0 7.300597459902747e-09
the O 0 4.22659196530617e-09
second O 0 1.0853941603272688e-06
, O 0 2.6052937585063773e-09
1936delG O 0 4.462120983816931e-08
in O 0 8.376592197656407e-10
exon O 0 9.004521217548245e-08
12 O 0 7.581381566978962e-08
, O 0 4.357590288606161e-09
has O 0 7.722595007919608e-09
been O 0 4.0711540805205004e-08
described O 0 3.430963957384847e-08
before O 0 8.495373293726516e-09
to O 0 8.678822993601898e-09
cause O 0 2.3439511664946622e-07
C6D B-Disease 0 3.70504039892694e-06
in O 0 1.0982863507535967e-09
an O 0 1.4586357677259798e-09
unrelated O 0 4.709838918870446e-08
African O 0 5.0338730517296426e-08
- O 0 9.056656722350453e-07
American O 0 8.575899812512944e-08
individual O 0 5.324450924604207e-08
. O 0 1.3236090978807624e-07

Both O 0 3.387874585314421e-06
mutations O 0 0.0001574897178215906
result O 0 6.372921461661463e-07
in O 0 3.491313904646631e-08
premature O 0 2.5553350496920757e-05
termination O 0 5.6299618336197454e-06
codons O 0 3.523496388879721e-06
and O 0 2.1017557116920216e-07
C6 O 0 5.325018719304353e-05
null O 0 3.490398739813827e-05
alleles O 0 1.1537218597368337e-05
. O 0 3.8892119391675806e-07

Allele O 0 3.791599738178775e-05
- O 0 3.1912334179651225e-06
specific O 0 4.851843726783045e-08
PCR O 0 2.331667474209098e-06
indicated O 0 3.44116870110156e-07
that O 0 1.3363129491850145e-09
the O 0 6.728551049661746e-09
probands O 0 1.6199174979192321e-06
two O 0 1.1162405400000353e-07
brothers O 0 1.8101245586876757e-05
also O 0 2.0950592372059873e-08
inherited O 0 1.0099923883899464e-06
the O 0 5.36050048793868e-09
1195delC O 0 5.089035539640463e-07
mutation O 0 2.431368955058133e-07
from O 0 4.00042798887057e-09
their O 0 3.8619091924374516e-08
heterozygous O 0 9.21446735446807e-06
mother O 0 3.182126704359689e-07
and O 0 2.3972723806053864e-09
the O 0 3.633722434059905e-09
1936delG O 0 5.533469789043011e-07
mutation O 0 2.2282510769855435e-07
from O 0 5.820699033876053e-09
their O 0 1.0194744248792631e-07
homozygous O 0 3.6876012018183246e-05
father O 0 3.0122913585728384e-07
. O 0 7.284129299733877e-09
. O 0 2.5560447980410572e-08

PAX6 O 0 0.03692242503166199
mutations O 0 0.0025324225425720215
reviewed O 0 4.599276144290343e-05
. O 0 3.341976253068424e-06

Mutations O 0 0.0007009886903688312
in O 0 8.64901608110813e-08
PAX6 O 0 9.744363524077926e-06
are O 0 2.7306644057034646e-08
responsible O 0 6.276919606307274e-08
for O 0 3.3550977551755068e-09
human O 0 5.2632525893159254e-08
aniridia B-Disease 1 1.0
and O 0 2.0551110537780914e-06
have O 0 8.245835374509625e-07
also O 0 1.2284924366667838e-07
been O 0 6.751011483174807e-08
found O 0 7.554471714854571e-09
in O 0 1.8135297707999598e-09
patients O 0 9.41763360629011e-08
with O 0 4.7944126890797634e-08
Peters B-Disease 1 1.0
anomaly I-Disease 1 1.0
, O 0 5.951596904196776e-07
with O 0 4.151791654294357e-05
congenital B-Disease 1 1.0
cataracts I-Disease 1 0.9999912977218628
, O 0 1.9130457218352603e-08
with O 0 5.5686324884618443e-08
autosomal B-Disease 1 0.9926988482475281
dominant I-Disease 0 0.11185233294963837
keratitis I-Disease 0 0.004358910024166107
, O 0 4.370510708895381e-08
and O 0 2.990930525470503e-08
with O 0 3.49505256735938e-07
isolated B-Disease 1 0.8986351490020752
foveal I-Disease 1 1.0
hypoplasia I-Disease 1 1.0
. O 0 6.1072073549439665e-06

No O 0 3.803976369454176e-06
locus O 0 1.9518158751452575e-06
other O 0 1.3926373831907313e-08
than O 0 1.3061773884714967e-08
chromosome O 0 1.525701372884214e-05
11p13 O 0 8.357328056263214e-07
has O 0 2.1099127778256843e-08
been O 0 2.2517896880458466e-08
implicated O 0 5.509248239832232e-07
in O 0 2.5177419260558054e-08
aniridia B-Disease 1 1.0
, O 0 1.534498039745813e-08
and O 0 9.056879690660935e-09
PAX6 O 0 2.0900477011309704e-06
is O 0 7.400926538281283e-09
clearly O 0 2.4856200653289307e-08
the O 0 7.371956378676714e-10
major O 0 7.1818764268982704e-09
, O 0 3.952690619257737e-09
if O 0 1.704957064418977e-09
not O 0 2.0563510894078263e-09
only O 0 1.1787276710251149e-09
, O 0 1.3216491234757655e-09
gene O 0 1.602374055664768e-07
responsible O 0 5.092404649076343e-07
. O 0 7.014654812564913e-08

Twenty O 0 0.0002590515068732202
- O 0 6.807856698287651e-05
eight O 0 6.793611646571662e-07
percent O 0 9.115182564300994e-08
of O 0 1.9126507044830987e-09
identified O 0 2.7758474629990815e-07
PAX6 O 0 4.1862849684548564e-06
mutations O 0 1.4676571709060227e-06
are O 0 6.629192483842417e-08
C O 0 0.00021502278104890138
- O 0 0.014051586389541626
T O 0 0.00018623605137690902
changes O 0 6.938672925116407e-08
at O 0 6.776478045367185e-08
CpG O 0 9.505633897788357e-07
dinucleotides O 0 1.0669272114682826e-06
, O 0 2.396568499207774e-09
20 O 0 2.2451496217712474e-09
% O 0 2.1787400772410592e-09
are O 0 9.805340983604083e-10
splicing O 0 5.474215640788316e-07
errors O 0 9.308377048000693e-05
, O 0 8.588533439990442e-09
and O 0 3.7230880600702676e-09
more O 0 4.752291338228076e-10
than O 0 4.147000964849212e-09
30 O 0 1.6856892770533705e-08
% O 0 9.643206233533874e-09
are O 0 2.735704107692527e-09
deletion O 0 5.308743311616126e-07
or O 0 1.8428438863793417e-07
insertion O 0 1.1021775208064355e-06
events O 0 1.60157958362106e-06
. O 0 9.563547109792125e-07

There O 0 2.809028273986769e-06
is O 0 4.0162714043390224e-08
a O 0 2.1869141164643224e-08
noticeably O 0 7.139763624763873e-07
elevated O 0 4.413127498992253e-07
level O 0 5.417260240392352e-08
of O 0 1.1525825849290072e-09
mutation O 0 1.7650857841999823e-07
in O 0 1.055863174670435e-09
the O 0 3.061950470950592e-09
paired O 0 1.384731547204865e-07
domain O 0 2.166582646623283e-08
compared O 0 2.7706839489383128e-08
with O 0 2.6728821378441125e-09
the O 0 5.6299627182454515e-09
rest O 0 8.501306325570113e-09
of O 0 2.2539015098743675e-10
the O 0 7.07267577837456e-09
gene O 0 5.398121061261918e-07
. O 0 1.9258783368059085e-07

Increased O 0 1.3282542568049394e-05
mutation O 0 9.533401680528186e-06
in O 0 1.7213052316833455e-08
the O 0 5.0662727346661995e-09
homeodomain O 0 5.095392339171667e-07
is O 0 7.377699340338495e-09
accounted O 0 9.889607355262342e-08
for O 0 9.711347281893268e-10
by O 0 2.1090746926688553e-09
the O 0 1.6274006142680264e-08
hypermutable O 0 5.99033455728204e-06
CpG O 0 1.9273882116976893e-06
dinucleotide O 0 1.855462983257894e-06
in O 0 1.8885955910263874e-08
codon O 0 1.5301045550586423e-06
240 O 0 4.6541643428099633e-07
. O 0 2.6646659989637556e-07

Very O 0 2.0096574644412613e-06
nearly O 0 1.5254552465648885e-07
all O 0 6.479726089025917e-09
mutations O 0 4.804605850949883e-07
appear O 0 5.7088598737209395e-08
to O 0 1.486688017138249e-08
cause O 0 7.04976173437899e-06
loss O 0 2.355404120635285e-07
of O 0 6.690947795817692e-10
function O 0 2.4522845976093777e-08
of O 0 3.3043465186288756e-10
the O 0 2.4090343053728702e-09
mutant O 0 1.189933982459479e-07
allele O 0 1.1453845161213394e-07
, O 0 5.66840518967382e-10
and O 0 3.038178597591923e-10
more O 0 2.0605157857733758e-10
than O 0 7.518875522194435e-10
80 O 0 5.282609905066238e-09
% O 0 2.163146106681779e-09
of O 0 7.754059061504393e-10
exonic O 0 4.309596079110634e-06
substitutions O 0 1.2475295534386532e-06
result O 0 9.237018616659043e-07
in O 0 2.3590812858742538e-08
nonsense O 0 1.864877594925929e-05
codons O 0 3.4762881568894954e-06
. O 0 1.2677405436534173e-07

In O 0 2.668111278580909e-07
a O 0 3.038877238736859e-08
gene O 0 1.4380952961801086e-07
with O 0 1.1051262127637074e-09
such O 0 1.2380154679192401e-09
extraordinarily O 0 4.577911170144944e-07
high O 0 2.6398192076726446e-08
sequence O 0 1.2686107275783343e-08
conservation O 0 8.913435545210291e-10
throughout O 0 1.2052679965179891e-09
evolution O 0 2.6415605258733876e-09
, O 0 1.7706207611212221e-09
there O 0 2.6064965741312562e-09
are O 0 3.0004727591403935e-08
presumed O 0 7.835052201699e-06
undiscovered O 0 1.6353449154848931e-06
missense O 0 5.094545485917479e-06
mutations O 0 3.309627800263115e-06
, O 0 1.8993489003804598e-09
these O 0 1.1323352255843133e-09
are O 0 2.0359907093592255e-09
hypothesized O 0 1.8487845920844848e-08
to O 0 3.654448965662027e-09
exist O 0 8.928246586492605e-08
in O 0 3.133259207643846e-09
as O 0 2.160554117836e-07
- O 0 0.000647091306746006
yet O 0 1.0328240023227409e-06
unidentified O 0 3.774852757487679e-06
phenotypes O 0 1.035928448800405e-06
. O 0 8.926165584455248e-09
. O 0 5.722770879401651e-08

Genetic O 0 0.00018561433535069227
heterogeneity O 0 1.1736081432900392e-05
and O 0 2.5137143211395596e-07
penetrance O 0 7.468195690307766e-06
analysis O 0 5.546276682366624e-08
of O 0 4.573863510159981e-09
the O 0 2.110846608616157e-08
BRCA1 O 0 0.00016447454981971532
and O 0 1.6793327972663974e-07
BRCA2 O 0 0.0006515990826301277
genes O 0 3.1477682114200434e-06
in O 0 4.678377365507913e-07
breast B-Disease 1 0.9999983310699463
cancer I-Disease 0 0.16872045397758484
families O 0 1.6811544583106297e-06
. O 0 4.315722890169127e-07

The O 0 0.0010050323326140642
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.000504430616274476
Consortium O 0 1.2520392374426592e-05
. O 0 7.346416737163963e-07

The O 0 1.9651069749215822e-07
contribution O 0 8.183711486253742e-08
of O 0 8.727726985569007e-09
BRCA1 O 0 1.757241989253089e-05
and O 0 1.6747235065395216e-07
BRCA2 O 0 0.05908988416194916
to O 0 6.863617454655468e-05
inherited B-Disease 1 1.0
breast I-Disease 1 1.0
cancer I-Disease 1 1.0
was O 0 1.4661960449302569e-05
assessed O 0 1.9596683387135272e-07
by O 0 2.51349918656274e-09
linkage O 0 4.159073341725161e-06
and O 0 9.290709357401283e-08
mutation O 0 4.096618511084671e-07
analysis O 0 3.130238468429525e-08
in O 0 2.211252736472602e-09
237 O 0 2.4631084727388952e-08
families O 0 3.955090477347767e-08
, O 0 1.8151147251899147e-09
each O 0 8.676634410953454e-10
with O 0 6.440223909720544e-09
at O 0 2.5699165462356177e-07
least O 0 4.619612248291105e-09
four O 0 6.0802234358448e-09
cases O 0 4.069475423307267e-09
of O 0 3.599063447268236e-08
breast B-Disease 1 0.9999998807907104
cancer I-Disease 0 0.006385555025190115
, O 0 2.210645444478132e-09
collected O 0 1.0571614694754317e-08
by O 0 5.199728647653501e-09
the O 0 9.467724885325879e-05
Breast B-Disease 1 1.0
Cancer I-Disease 1 1.0
Linkage O 0 0.00017680447490420192
Consortium O 0 5.644519660563674e-06
. O 0 6.264695571189804e-07

Families O 0 7.781016756780446e-05
were O 0 1.3002759260416497e-06
included O 0 6.684843611992619e-08
without O 0 3.877024212783908e-08
regard O 0 7.258139422816612e-09
to O 0 1.1851073455915184e-09
the O 0 2.9509121812765216e-09
occurrence O 0 3.127380239220656e-07
of O 0 3.7231679073101986e-08
ovarian B-Disease 1 0.9930667877197266
or I-Disease 0 1.733727685859776e-06
other I-Disease 0 2.6416734044687473e-07
cancers I-Disease 1 0.9890521168708801
. O 0 2.3108556490569754e-07

Overall O 0 0.00045344067621044815
, O 0 2.435542228340637e-06
disease O 0 0.0007253571529872715
was O 0 7.568421267478698e-08
linked O 0 2.3076822230905236e-07
to O 0 2.8164568455224526e-09
BRCA1 O 0 2.333657357667107e-05
in O 0 4.167903355778435e-09
an O 0 1.5689912702399056e-09
estimated O 0 1.3772976537040904e-08
52 O 0 3.759769739986041e-08
% O 0 3.6127483227232915e-09
of O 0 3.8358077825151327e-10
families O 0 1.2597374698941621e-08
, O 0 8.25733370568571e-10
to O 0 6.404504038215464e-09
BRCA2 O 0 2.1256000763969496e-05
in O 0 3.6439180561842477e-09
32 O 0 4.5147537264256243e-08
% O 0 3.0527600447527448e-09
of O 0 2.60664462237159e-10
families O 0 8.068735013466721e-09
, O 0 7.69920682763825e-10
and O 0 1.6803628488659683e-09
to O 0 2.9229372255912267e-09
neither O 0 8.549670837965095e-08
gene O 0 3.645859791845396e-08
in O 0 1.6789692969254588e-09
16 O 0 1.7357855597310845e-08
% O 0 6.936949681346505e-09
( O 0 3.024731132228453e-09
95 O 0 5.2241862391610994e-08
% O 0 1.2690057360487117e-07
confidence O 0 4.833476850762963e-05
interval O 0 7.657938112970442e-05
[ O 0 7.792286282892746e-07
CI O 0 4.717832780443132e-06
] O 0 1.5277031195637392e-07
6 O 0 2.8059920609280198e-08
% O 0 3.03139771062888e-08
- O 0 2.5495601221336983e-06
28 O 0 8.204623469509897e-08
% O 0 6.849387279572738e-09
) O 0 1.1471565919407567e-09
, O 0 5.471418318414578e-10
suggesting O 0 5.5975867496727005e-08
other O 0 1.4039188478420783e-08
predisposition O 0 1.7312844647676684e-05
genes O 0 1.5021204262666288e-06
. O 0 1.432772904763624e-07

The O 0 4.770499799633399e-07
majority O 0 2.6279440135112964e-07
( O 0 1.903974400363495e-08
81 O 0 3.723267383293205e-08
% O 0 2.8951117059250464e-09
) O 0 1.647744579669208e-10
of O 0 4.2484848972179634e-10
the O 0 1.0582312825135887e-05
breast B-Disease 1 1.0
- I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 1.986281006338686e-07
were O 0 5.4539821547905376e-08
due O 0 7.337228158377229e-09
to O 0 5.374023448467824e-09
BRCA1 O 0 0.00012149936083005741
, O 0 3.0083218138798884e-09
with O 0 4.043322343605382e-10
most O 0 4.4940202670318286e-09
others O 0 3.9916496774594634e-08
( O 0 2.5815356519132138e-09
14 O 0 2.480003757909799e-08
% O 0 1.1271211519670032e-08
) O 0 1.6040710981712891e-09
due O 0 3.0462356193083906e-08
to O 0 2.1072307276881475e-07
BRCA2 O 0 0.0021984963677823544
. O 0 3.4183057096015546e-07

Conversely O 0 7.722156624367926e-06
, O 0 1.1924407239405355e-08
the O 0 1.0644367609558003e-09
majority O 0 1.9513566318352105e-09
of O 0 1.9395336725569479e-10
families O 0 2.9961135794565052e-09
with O 0 1.1030456548155598e-09
male B-Disease 0 8.806632081359567e-07
and I-Disease 0 3.6311058693172527e-07
female I-Disease 0 0.26024797558784485
breast I-Disease 1 0.9999997615814209
cancer I-Disease 0 0.04517941549420357
were O 0 1.5811144749022787e-07
due O 0 5.414212722598677e-08
to O 0 6.560312471037832e-08
BRCA2 O 0 0.0026798651088029146
( O 0 5.7083919813294415e-08
76 O 0 4.271557259016845e-07
% O 0 4.123970498426388e-08
) O 0 1.7954407738329792e-08
. O 0 7.036738480792337e-08

The O 0 8.038681471589371e-07
largest O 0 1.1874468697214979e-07
proportion O 0 1.6207999919970462e-07
( O 0 1.7686506481595643e-08
67 O 0 1.714232382710179e-07
% O 0 1.247028880158041e-08
) O 0 3.5399921882728336e-10
of O 0 2.5323612651284577e-10
families O 0 8.580314236894537e-09
due O 0 1.2979941566015896e-08
to O 0 4.802125364022913e-09
other O 0 7.306907967574716e-09
genes O 0 1.2786991874236264e-06
was O 0 4.953047323397186e-07
found O 0 1.088369039337067e-08
in O 0 1.6791166235208266e-09
families O 0 8.395774742098183e-09
with O 0 2.0910659870310155e-09
four O 0 7.663523859946508e-08
or O 0 7.40102876761739e-08
five O 0 5.386337598167756e-09
cases O 0 1.2718275321788042e-09
of O 0 2.57818477678029e-09
female O 1 0.8943471908569336
breast B-Disease 1 0.9999997615814209
cancer I-Disease 0 0.006174931768327951
only O 0 8.449902111351548e-08
. O 0 1.8907586252225883e-07

These O 0 2.847753876267234e-06
estimates O 0 1.5929911114653805e-06
were O 0 3.4521275438237353e-07
not O 0 2.0506611519977014e-08
substantially O 0 2.965873306948197e-07
affected O 0 5.895338617278867e-08
either O 0 6.564916610329874e-09
by O 0 8.291122788328664e-10
changing O 0 5.2748802659152716e-08
the O 0 1.8836157078538918e-09
assumed O 0 6.806933328107334e-08
penetrance O 0 5.3510230912934276e-08
model O 0 9.40179933905938e-09
for O 0 1.1670856503442906e-09
BRCA1 O 0 8.845621778164059e-06
or O 0 3.25930642475214e-08
by O 0 4.773749173736519e-10
including O 0 3.2738969313328425e-09
or O 0 2.0611021511740546e-07
excluding O 0 2.119669716194039e-06
BRCA1 O 0 0.00039897303213365376
mutation O 0 3.0417413654504344e-06
data O 0 1.4352798416439327e-06
. O 0 3.008168789619958e-07

Among O 0 5.643694294121815e-07
those O 0 4.7253426060933634e-08
families O 0 3.176186780251555e-08
with O 0 1.7531471385723307e-08
disease O 0 4.5944809244247153e-05
due O 0 2.1546069817190983e-08
to O 0 1.109943159605109e-08
BRCA1 O 0 0.0008719598990865052
that O 0 4.2319985738004107e-08
were O 0 2.5331185042887228e-06
tested O 0 8.399364901379158e-07
by O 0 5.392122304215263e-10
one O 0 6.563886656429929e-10
of O 0 6.888357245715682e-11
the O 0 3.752150534719334e-10
standard O 0 2.6532314123528522e-08
screening O 0 2.828776324292903e-08
methods O 0 5.106620051265054e-07
, O 0 1.0196062660838834e-08
mutations O 0 1.6459704283988685e-06
were O 0 2.9162379178160336e-07
detected O 0 2.5163888039969606e-07
in O 0 1.2499524748577073e-09
the O 0 2.0022055124968574e-09
coding O 0 2.9776037990814075e-07
sequence O 0 1.5709181866441213e-07
or O 0 4.9895671594413216e-08
splice O 0 1.2203949154354632e-05
sites O 0 1.0533342447160976e-06
in O 0 7.623167874726278e-09
an O 0 4.429793420968053e-09
estimated O 0 1.2740618338114018e-08
63 O 0 6.816728870262523e-08
% O 0 6.180533862476523e-09
( O 0 2.099050044890305e-09
95 O 0 2.5779696599670388e-08
% O 0 5.6531867187459284e-08
CI O 0 6.4509677031310275e-06
51 O 0 7.590090262965532e-07
% O 0 1.549753960716771e-07
- O 0 2.976652467623353e-05
77 O 0 7.833072004359565e-07
% O 0 7.615715702513626e-08
) O 0 2.0987107163250585e-08
. O 0 4.414907905925247e-08

The O 0 4.888531179858546e-07
estimated O 0 3.060977178392932e-07
sensitivity O 0 2.799433218569902e-07
was O 0 4.816924388251209e-07
identical O 0 1.1911193809055476e-07
for O 0 6.286762777030219e-10
direct O 0 1.0639217506991372e-08
sequencing O 0 5.062344854422918e-08
and O 0 1.7912745065018498e-08
other O 0 3.869191633754099e-09
techniques O 0 1.129825341195101e-05
. O 0 3.1575439152220497e-07

The O 0 7.52330038267246e-07
penetrance O 0 1.583532866789028e-05
of O 0 4.327526070824206e-08
BRCA2 O 0 0.00011093746434198692
was O 0 2.5770413003556314e-07
estimated O 0 1.2853972997106666e-08
by O 0 1.990033693388682e-09
maximizing O 0 1.2106858093829942e-07
the O 0 2.138308730081917e-08
LOD O 0 4.563551556202583e-05
score O 0 6.389185273292242e-06
in O 0 3.161656536576629e-08
BRCA2 O 0 0.006565561518073082
- O 0 4.968784924130887e-05
mutation O 0 9.25150015973486e-06
families O 0 2.720335068318036e-08
, O 0 9.729628214216746e-10
over O 0 2.1396378002691563e-09
all O 0 2.1123196525252297e-09
possible O 0 4.3044103392730904e-08
penetrance O 0 9.658405360823963e-06
functions O 0 5.748139528805041e-07
. O 0 2.007761708000544e-07

The O 0 3.9935770246302127e-07
estimated O 0 2.4272031851069187e-07
cumulative O 0 4.1584928567317547e-07
risk O 0 1.4105423815635731e-06
of O 0 2.716467228935926e-08
breast B-Disease 1 0.9999959468841553
cancer I-Disease 0 0.11386115849018097
reached O 0 3.063832537009148e-06
28 O 0 1.4075470744501217e-07
% O 0 1.4448636953545702e-08
( O 0 3.147689220384109e-09
95 O 0 3.867378239874597e-08
% O 0 4.411978338225708e-08
CI O 0 2.6404195523355156e-06
9 O 0 1.1490924123336299e-07
% O 0 3.463246045498636e-08
- O 0 4.5879946242166625e-07
44 O 0 4.096742500792061e-08
% O 0 4.028590794291631e-09
) O 0 2.83970430503544e-10
by O 0 4.10984773990819e-10
age O 0 2.295300305377168e-08
50 O 0 2.8112938643687357e-09
years O 0 1.7340041624791525e-09
and O 0 6.765820348419993e-09
84 O 0 3.143371074543211e-08
% O 0 3.855754382442456e-09
( O 0 1.332736698778092e-09
95 O 0 1.4980482632154235e-08
% O 0 3.169662932123174e-08
CI O 0 1.068169353857229e-06
43 O 0 9.870761630281777e-08
% O 0 3.240289814243624e-08
- O 0 3.17766875923553e-07
95 O 0 4.550111043499783e-08
% O 0 1.1518842768509785e-08
) O 0 7.434793891647473e-10
by O 0 1.4819000471177901e-09
age O 0 1.7927858664279483e-07
70 O 0 2.869697368623747e-08
years O 0 1.929183035542792e-08
. O 0 4.780478235488772e-08

The O 0 1.4952776837162673e-05
corresponding O 1 0.9995191097259521
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
risks O 0 0.0834854245185852
were O 0 4.89833098527015e-07
0 O 0 6.927841695869574e-07
. O 0 1.0994610732950605e-07

4 O 0 1.699755921436008e-05
% O 0 5.911609264330764e-07
( O 0 3.350903909904446e-08
95 O 0 1.1494145724100235e-07
% O 0 6.375693573090757e-08
CI O 0 2.664846306288382e-06
0 O 0 1.6605642372269358e-07
% O 0 3.88730185818531e-08
- O 0 7.007766953393002e-07
1 O 0 1.544351846405334e-08
% O 0 6.9945049752107025e-09
) O 0 3.173131757350234e-10
by O 0 4.6494347261116786e-10
age O 0 1.6774336586422578e-08
50 O 0 3.6412501902560734e-09
years O 0 2.725672576531224e-09
and O 0 6.996105916812212e-09
27 O 0 4.5413802496341305e-08
% O 0 4.394256070128222e-09
( O 0 1.745026234623026e-09
95 O 0 2.1388636639585457e-08
% O 0 3.67490997632558e-08
CI O 0 1.3865329719919828e-06
0 O 0 7.458463358034351e-08
% O 0 3.899882017321943e-08
- O 0 2.0585084712365642e-06
47 O 0 8.66381583364273e-07
% O 0 2.5252059998592813e-08
) O 0 1.7355196169077658e-09
by O 0 2.6950688347682217e-09
age O 0 1.5304679834571289e-07
70 O 0 3.196692688334224e-08
years O 0 3.030524453606631e-08
. O 0 7.071883345588503e-08

The O 0 2.0685606614279095e-06
lifetime O 0 1.0880143236136064e-05
risk O 0 5.1313595577084925e-06
of O 0 1.0221808111054997e-07
breast B-Disease 1 0.9999997615814209
cancer I-Disease 0 0.3359515964984894
appears O 0 5.161462013347773e-08
similar O 0 6.130226104517078e-09
to O 0 5.942367042877095e-09
the O 0 3.369997614299791e-08
risk O 0 1.127587665905594e-06
in O 0 2.5492172817109804e-09
BRCA1 O 0 1.0102244232257362e-05
carriers O 0 1.1903805443580495e-06
, O 0 6.759835358138844e-09
but O 0 4.889698423937716e-09
there O 0 3.192815567487628e-09
was O 0 3.1504598041465215e-08
some O 0 4.0069167428491426e-10
suggestion O 0 1.0608417255753011e-08
of O 0 8.260673256543782e-10
a O 0 5.4069992927452404e-08
lower O 0 6.582665810128674e-05
risk O 0 7.826613000361249e-06
in O 0 3.9242351590473845e-09
BRCA2 O 0 6.165998456708621e-06
carriers O 0 1.0344253098537592e-07
< O 0 1.3328013892532908e-07
50 O 0 2.9531717515851597e-08
years O 0 7.071556229476528e-09
of O 0 5.1959712088489596e-09
age O 0 1.3383730674831895e-06
. O 0 1.6762702159667242e-07

Eye B-Disease 1 0.9998425245285034
movement I-Disease 0 0.0017070277826860547
abnormalities I-Disease 1 0.9440900087356567
correlate O 0 1.350930779153714e-05
with O 0 8.77667716281394e-08
genotype O 0 0.00020931112521793693
in O 0 7.569619953073925e-08
autosomal O 1 0.9863959550857544
dominant O 0 0.17930057644844055
cerebellar B-Disease 0 0.056933287531137466
ataxia I-Disease 1 0.9999842643737793
type I-Disease 1 0.9999963045120239
I I-Disease 1 0.5191267132759094
. O 0 3.19580919949658e-07

We O 0 8.65488254930824e-06
compared O 0 4.889179194833559e-07
horizontal O 0 0.02909099869430065
eye O 1 0.9445847868919373
movements O 0 0.00045658694580197334
( O 0 9.95721478602718e-08
visually O 0 1.0201059694736614e-06
guided O 0 6.646018391620601e-06
saccades O 0 0.00020725255308207124
, O 0 4.1754962154527675e-08
antisaccades O 0 1.0678403441488626e-06
, O 0 4.899398664548471e-09
and O 0 5.788018064833977e-09
smooth O 0 9.411453447683016e-07
pursuit O 0 2.4427206426480552e-06
) O 0 3.1487159546372823e-09
in O 0 1.1132458288543035e-09
control O 0 3.4492381928430405e-07
subjects O 0 2.835082568708458e-06
( O 0 3.010941185266347e-08
n O 0 1.3645938452100381e-05
= O 0 2.4723804017412476e-05
14 O 0 4.403361231197778e-08
) O 0 1.6732404350960906e-09
and O 0 4.84536073486197e-08
patients O 0 9.027013447848731e-08
with O 0 6.440527555717779e-10
three O 0 3.637279810675409e-09
forms O 0 1.853943487617471e-08
of O 0 1.7655025885687792e-08
autosomal O 1 0.9903855323791504
dominant O 0 0.18637794256210327
cerebellar B-Disease 0 9.154557483270764e-05
ataxias I-Disease 0 0.0005207200301811099
type I-Disease 0 0.43483513593673706
I I-Disease 0 0.000645881169475615
spinocerebellar B-Disease 0 0.001127685303799808
ataxias I-Disease 0 4.461154458113015e-05
1 I-Disease 0 1.1366759622433165e-07
and I-Disease 0 4.810295806123577e-08
2 I-Disease 0 3.773945067564455e-08
( O 0 9.163850123172779e-09
SCA1 B-Disease 0 4.298923613532679e-06
, O 0 1.1600023164248796e-08
n O 0 3.2576399462413974e-06
= O 0 1.219221121573355e-05
11 O 0 9.567618519668031e-08
; O 0 1.0477029022126771e-08
SCA2 B-Disease 0 3.648138545031543e-06
, O 0 2.0757836338702873e-08
n O 0 1.8248686046717921e-06
= O 0 5.156333827471826e-06
10 O 0 1.595339504945059e-08
) O 0 4.186507140957474e-09
and O 0 2.3115123326533649e-07
SCA3 B-Disease 1 1.0
/ O 0 0.00011122993601020426
Machado B-Disease 0 3.049460610782262e-05
- I-Disease 0 0.00027882945141755044
Joseph I-Disease 0 0.00014383048983290792
disease I-Disease 0 0.008038550615310669
( O 0 4.674639697554994e-08
MJD B-Disease 1 0.9999995231628418
) O 0 2.4394044118025704e-08
( O 0 1.4505353362892492e-08
n O 0 1.6369103832403198e-05
= O 0 6.941128231119365e-05
16 O 0 1.600767092213573e-07
) O 0 9.661450306452934e-09
. O 0 5.1068973050405475e-08

In O 0 1.8388078615316772e-06
SCA1 B-Disease 0 3.420707434997894e-05
, O 0 3.3696764489832276e-08
saccade O 0 4.4887983676744625e-06
amplitude O 0 3.9937290807756654e-07
was O 0 1.7315468880951812e-07
significantly O 0 1.3234577522780455e-07
increased O 0 4.801092501338644e-08
, O 0 7.006415003729671e-09
resulting O 0 5.6115048607807694e-08
in O 0 1.283574491139916e-08
hypermetria B-Disease 0 1.7887665308080614e-05
. O 0 1.4391983427231025e-07

The O 0 7.501105301344069e-07
smooth O 0 2.0605709778465098e-06
pursuit O 0 2.8427500637917547e-06
gain O 0 1.3644599675899372e-05
was O 0 5.3022945394332055e-06
decreased O 0 8.528279067832045e-06
. O 0 1.4179941842940025e-07

In O 0 2.2919134607946035e-06
SCA2 B-Disease 0 4.068049383931793e-05
, O 0 6.461340262831072e-08
saccade O 0 6.279808985709678e-06
velocity O 0 2.7473327008920023e-06
was O 0 1.0565073580437456e-06
markedly O 0 5.623082415695535e-06
decreased O 0 1.0860767361009493e-05
. O 0 2.0583266291396285e-07

The O 0 5.467865662467375e-07
percentage O 0 1.5984392121026758e-06
of O 0 7.010960256792487e-09
errors O 0 2.543241407693131e-06
in O 0 4.331570213622626e-09
antisaccades O 0 4.666168933908921e-06
was O 0 7.502480059429217e-08
greatly O 0 6.451412293273506e-09
increased O 0 9.07931330118572e-09
and O 0 1.2205417121435858e-08
was O 0 2.8545974473104252e-08
significantly O 0 1.1270309130395617e-08
correlated O 0 2.400119569756498e-08
with O 0 2.477411609191904e-09
age O 0 1.222126684297109e-06
at O 0 3.537617430993123e-06
disease O 0 0.001433915109373629
onset O 0 6.500157905975357e-05
. O 0 2.479626175500016e-07

In O 0 1.6921779888434685e-07
addition O 0 4.5773131063242545e-08
, O 0 2.741115112669945e-09
a O 0 1.9532222506057906e-09
correlation O 0 7.309378702302638e-08
between O 0 2.4955626898304217e-08
smooth O 0 5.40530527359806e-06
pursuit O 0 3.903822744177887e-06
gain O 0 1.5279438230209053e-05
and O 0 1.4630842315455084e-07
the O 0 2.2065425042683273e-09
number O 0 3.790000313586006e-09
of O 0 4.089924843242443e-09
trinucleotide O 0 4.672494105761871e-05
repeats O 0 2.347055487916805e-05
was O 0 1.1132441386507708e-06
found O 0 1.7968974930226977e-07
. O 0 6.985387557278955e-08

In O 0 1.0871959602809511e-05
SCA3 B-Disease 1 0.9999969005584717
, O 0 4.1098763858826715e-07
gaze B-Disease 0 0.0002458997187204659
- I-Disease 0 5.001678073313087e-05
evoked I-Disease 0 5.400992449722253e-06
nystagmus I-Disease 0 0.0005009701126255095
was O 0 7.989713708411728e-07
often O 0 7.912236554830088e-08
present O 0 4.421824684186504e-09
as O 0 7.159965065284268e-09
was O 0 2.2686283074335734e-08
saccade O 0 9.448874038753274e-07
hypometria O 0 7.32336104647402e-07
and O 0 1.9172977872017327e-08
smooth O 0 1.489059854975494e-06
pursuit O 0 6.635176760028116e-06
gain O 0 7.73647625464946e-05
was O 0 1.6942147340159863e-05
markedly O 0 1.9878052626154386e-05
decreased O 0 1.807169792300556e-05
. O 0 2.924086004441051e-07

Three O 0 2.0212901290506124e-06
major O 0 4.0342257534575765e-07
criteria O 0 7.449598342645913e-07
, O 0 8.666566131410036e-09
saccade O 0 1.1773663572967052e-06
amplitude O 0 2.512427386136551e-07
, O 0 9.717021853816732e-09
saccade O 0 1.1196207196917385e-06
velocity O 0 6.384029234141053e-07
, O 0 6.6792713582231045e-09
and O 0 3.858240837928406e-09
presence O 0 8.828030750862581e-09
of O 0 3.958175565088595e-09
gaze B-Disease 0 0.010558506473898888
- I-Disease 0 8.862246613716707e-05
evoked I-Disease 0 3.2240195650956593e-06
nystagmus I-Disease 0 1.3317407137947157e-05
, O 0 3.996706077202816e-09
permitted O 0 1.1149463574611218e-08
the O 0 1.7122080420151065e-09
correct O 0 7.058998789943871e-07
assignment O 0 6.458530776853877e-08
of O 0 1.4472570919465966e-09
90 O 0 1.9226956027296183e-08
% O 0 9.955540392070361e-09
of O 0 8.539475793156726e-10
the O 0 8.818034302748856e-09
SCA1 B-Disease 0 6.020442469889531e-06
, O 0 2.9690803149406975e-09
90 O 0 2.430096568417639e-09
% O 0 6.855840894992582e-10
of O 0 1.5634192551683412e-10
the O 0 4.522335839141078e-09
SCA2 B-Disease 0 6.02110867475858e-06
, O 0 2.2880302097405547e-09
and O 0 5.856915397117746e-09
93 O 0 7.847321015219677e-09
% O 0 1.1952225875688782e-09
of O 0 1.8530188494736421e-10
the O 0 2.979974844663502e-08
patients O 0 1.875071546919571e-07
with O 0 1.9523703542745352e-08
SCA3 B-Disease 1 1.0
to O 0 3.7523189888588604e-08
their O 0 4.881417225988116e-07
genetically O 0 3.2984127074087155e-07
confirmed O 0 2.2389593823390896e-07
patient O 0 1.9340744472629012e-07
group O 0 1.081826805915398e-08
and O 0 5.423760551792611e-09
, O 0 1.4844602214125757e-09
therefore O 0 6.5196701370950905e-09
, O 0 1.3000672760554721e-09
may O 0 2.445255198324503e-08
help O 0 1.370377233911313e-08
orient O 0 2.7334162950864993e-06
diagnoses O 0 4.939239806844853e-05
of O 0 1.1334940097640356e-08
SCA1 B-Disease 0 2.1712054149247706e-05
, O 0 2.047659286574799e-08
SCA2 B-Disease 0 5.167705694475444e-06
, O 0 7.614913144493585e-09
and O 0 5.163224514603826e-08
SCA3 B-Disease 1 1.0
at O 0 2.018796152469804e-07
early O 0 3.300979400933102e-08
clinical O 0 2.7915578471038316e-07
stages O 0 2.27895512239229e-07
of O 0 1.124432325028124e-09
the O 0 4.865029978873281e-08
diseases O 0 9.909583604894578e-05
. O 0 5.103817368734553e-09
. O 0 3.090844558073513e-08

Genetic O 0 7.130672747734934e-05
basis O 0 9.852983566815965e-07
and O 0 9.122383914927923e-08
molecular O 0 6.846177257102681e-06
mechanism O 0 0.00016314299136865884
for O 0 2.08206802199129e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999997615814209
fibrillation I-Disease 1 1.0
. O 0 7.3537944444979075e-06

Ventricular B-Disease 1 0.9997668862342834
fibrillation I-Disease 1 0.9970384836196899
causes O 0 1.3302113075042143e-05
more O 0 1.5938248054681026e-08
than O 0 7.001526025618432e-09
300 O 0 5.91065996147222e-09
, O 0 1.2328150722495934e-09
000 O 0 1.6087444265622253e-08
sudden O 0 1.555760178462151e-07
deaths O 0 3.4234079748785007e-07
each O 0 1.0107342518494988e-08
year O 0 4.284913313057359e-09
in O 0 1.301449170654223e-09
the O 0 1.7376668992596933e-08
USA O 0 4.740440999739803e-06
alone O 0 2.573799235960905e-07
. O 0 3.465439490923927e-08

In O 0 2.554787954522908e-07
approximately O 0 1.2943011995503184e-07
5 O 0 4.847181855893723e-08
- O 0 9.993639196181903e-07
12 O 0 3.922673030842816e-08
% O 0 1.6393816304471898e-09
of O 0 1.0414994561225299e-10
these O 0 1.2839018737054175e-09
cases O 0 3.2809606143047176e-09
, O 0 1.3864613901404255e-09
there O 0 5.647795120466981e-09
are O 0 3.096580059036569e-08
no O 0 3.04810157558677e-07
demonstrable O 1 0.6172865629196167
cardiac O 0 0.00431273365393281
or O 0 3.860182550852187e-05
non O 1 0.7789892554283142
- O 1 0.9981670379638672
cardiac O 0 0.0141151649877429
causes O 0 5.6352672572757e-07
to O 0 1.444026143104793e-08
account O 0 2.864757107090554e-07
for O 0 1.0876960443439998e-09
the O 0 2.8774405080866927e-09
episode O 0 7.452746331182425e-07
, O 0 1.770999014105712e-09
which O 0 1.7310961553107518e-09
is O 0 1.3534893206212928e-09
therefore O 0 1.760334455980228e-08
classified O 0 1.04391187960573e-06
as O 0 2.0197554476908408e-05
idiopathic B-Disease 1 1.0
ventricular I-Disease 1 0.9999988079071045
fibrillation I-Disease 1 1.0
( O 0 7.795639976393431e-05
IVF B-Disease 1 1.0
) O 0 4.824394750357897e-07
. O 0 2.579999431873148e-07

A O 0 1.5009877643024083e-06
distinct O 0 3.8465307738988486e-07
group O 0 3.429472172911119e-08
of O 0 4.650732243760558e-09
IVF B-Disease 1 1.0
patients O 0 0.0906432718038559
has O 0 3.92202217369686e-08
been O 0 5.6091291611437555e-08
found O 0 1.5314279622202775e-08
to O 0 2.5540451975558653e-09
present O 0 7.864643158939089e-09
with O 0 3.230771872253513e-09
a O 0 6.083752879249005e-08
characteristic O 0 1.0944247151201125e-05
electrocardiographic O 0 4.6510402171406895e-05
pattern O 0 2.7781943572335877e-05
. O 0 2.307380668753467e-07

Because O 0 1.0770060043796548e-06
of O 0 3.4582539054639483e-09
the O 0 1.0557705820701813e-09
small O 0 1.0086634860684285e-09
size O 0 2.6224991067635983e-09
of O 0 2.448538316546234e-10
most O 0 9.942783263383603e-10
pedigrees O 0 5.417817305897188e-07
and O 0 1.669021010286542e-08
the O 0 3.3986438108257744e-09
high O 0 4.3740138266912254e-07
incidence O 0 0.00023890199372544885
of O 0 3.3778213559543246e-09
sudden B-Disease 0 5.321026492310921e-06
death I-Disease 0 6.449311058531748e-07
, O 0 2.0044064186208743e-09
however O 0 3.918064983565728e-09
, O 0 4.700572708848938e-10
molecular O 0 4.360120087198993e-08
genetic O 0 7.778476742714702e-07
studies O 0 1.7930316786873846e-08
of O 0 1.229239643407709e-08
IVF B-Disease 1 1.0
have O 0 0.0001982620742637664
not O 0 9.79571836978721e-07
yet O 0 4.1478068624201114e-07
been O 0 2.723435272855568e-07
done O 0 3.9838462839725253e-07
. O 0 6.465087665219471e-08

Because O 0 0.0001722963061183691
IVF B-Disease 1 1.0
causes O 0 0.03730455040931702
cardiac O 1 0.7424414157867432
rhythm O 0 0.0057693962007761
disturbance O 0 6.051439868315356e-06
, O 0 2.5241563506028797e-08
we O 0 2.6907352790317418e-08
investigated O 0 1.0468203726077263e-07
whether O 0 1.8179845184818078e-08
malfunction O 0 2.4997607397381216e-06
of O 0 1.2911069990906299e-09
ion O 0 9.010361878836193e-08
channels O 0 8.448453627352137e-06
could O 0 1.094193066819571e-05
cause O 0 6.759333928130218e-07
the O 0 1.3254011221874862e-08
disorder O 0 1.7802016373025253e-05
by O 0 6.484556780428363e-10
studying O 0 1.8339143537104974e-08
mutations O 0 3.611889383137168e-07
in O 0 1.3900783857323518e-09
the O 0 6.329116786218947e-09
cardiac O 0 1.7971800616578548e-06
sodium O 0 2.886518188915943e-07
channel O 0 9.740777386468835e-06
gene O 0 1.0181293873756658e-05
SCN5A O 0 4.981148595106788e-05
. O 0 4.084938041160058e-07

We O 0 4.301326771383174e-05
have O 0 2.000382437472581e-07
now O 0 2.8693142084534884e-08
identified O 0 8.917763238969201e-08
a O 0 9.363895436820258e-09
missense O 0 9.488756404607557e-06
mutation O 0 1.6911129705476924e-06
, O 0 4.870041259152913e-09
a O 0 8.505183224372104e-09
splice O 0 0.11186531186103821
- O 0 0.006557747721672058
donor O 0 7.575800395898113e-07
mutation O 0 1.4272716725827195e-05
, O 0 7.504495691534885e-09
and O 0 3.3173317426360427e-09
a O 0 1.8625314623932354e-08
frameshift O 0 4.6560275222873315e-05
mutation O 0 2.057678329947521e-06
in O 0 2.139650012722427e-09
the O 0 2.1522401638662814e-09
coding O 0 5.855901576978795e-07
region O 0 7.83349136668221e-08
of O 0 3.9069383284129344e-09
SCN5A O 0 9.221622349286918e-06
in O 0 9.376692311491297e-09
three O 0 8.150948929142032e-07
IVF B-Disease 1 1.0
families O 0 1.1137539104311145e-06
. O 0 2.3190416698071203e-07

We O 0 2.6983780117006972e-06
show O 0 1.6113369838421931e-07
that O 0 1.960586581972734e-09
sodium O 0 1.017593476149159e-08
channels O 0 4.1655212612567993e-08
with O 0 2.458948156203178e-09
the O 0 8.238491666645587e-09
missense O 0 6.167127594380872e-06
mutation O 0 4.065415396325989e-06
recover O 0 1.2217153653182322e-06
from O 0 4.673959885792556e-09
inactivation O 0 3.1704010439170816e-07
more O 0 4.20488133201502e-09
rapidly O 0 9.655651211915028e-08
than O 0 3.3733402737823326e-09
normal O 0 4.5396916448225966e-08
and O 0 7.617586561536882e-09
that O 0 8.653182614892785e-10
the O 0 4.6766350791926925e-09
frameshift O 0 7.749559881631285e-05
mutation O 0 3.798339548666263e-06
causes O 0 3.838717077542242e-08
the O 0 2.247004804445396e-09
sodium O 0 2.5250134427778903e-08
channel O 0 5.64194010621577e-07
to O 0 1.703144292264369e-08
be O 0 2.1288030893629184e-07
non O 0 2.7539826987776905e-06
- O 0 1.140213407779811e-05
functional O 0 9.950503226718865e-06
. O 0 2.766468014669954e-07

Our O 0 1.909514503495302e-05
results O 0 6.310326625680318e-07
indicate O 0 1.98816096030896e-07
that O 0 3.6078042775500307e-09
mutations O 0 2.430965366784221e-07
in O 0 1.7225425530398297e-09
cardiac O 0 2.252443209727062e-07
ion O 0 1.8393411949091387e-07
- O 0 2.8915374059579335e-06
channel O 0 1.7287892433159868e-06
genes O 0 1.594746805722025e-07
contribute O 0 9.034382131289931e-09
to O 0 1.7809717034467099e-09
the O 0 3.7252119167163755e-09
risk O 0 7.23450810369286e-08
of O 0 1.0733992583666918e-09
developing O 0 4.4149462041787046e-07
IVF B-Disease 1 0.9999996423721313
. O 0 4.4833633694452146e-08
. O 0 9.072410023236444e-08

Molecular O 0 9.648179002397228e-06
heterogeneity O 0 7.0611258706776425e-06
in O 0 9.3328374362045e-08
mucopolysaccharidosis B-Disease 0 1.4009199730935507e-05
IVA I-Disease 0 1.7348642359138466e-05
in O 0 4.091783978310559e-08
Australia O 0 2.91795458906563e-07
and O 0 3.350168853444302e-08
Northern O 0 1.8188174522038025e-07
Ireland O 0 6.6524230533104856e-06
: O 0 7.206217844668572e-09
nine O 0 3.169832396565653e-08
novel O 0 2.1420275331252014e-08
mutations O 0 2.4522080366295995e-07
including O 0 5.487076570886984e-09
T312S O 0 4.052336919357913e-07
, O 0 8.479278390538525e-10
a O 0 1.2670962057370616e-09
common O 0 7.35547178720708e-09
allele O 0 1.0184676568769646e-07
that O 0 2.1823001183918223e-09
confers O 0 1.31307075434961e-07
a O 0 1.4026213079887384e-07
mild O 0 0.00040476673166267574
phenotype O 0 0.0002768897684291005
. O 0 4.930420800519641e-07

Mucopolysaccharidosis B-Disease 1 0.5154999494552612
IVA I-Disease 1 0.9993384480476379
( O 0 0.002819964662194252
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
) O 0 7.97522119455607e-08
is O 0 5.351234566575158e-09
an O 0 8.42593461669594e-09
autosomal B-Disease 1 0.99997878074646
recessive I-Disease 1 0.9999990463256836
lysosomal I-Disease 1 0.9999912977218628
storage I-Disease 1 0.9999743700027466
disorder I-Disease 1 1.0
caused O 0 8.463252015644684e-06
by O 0 5.2870450240050104e-09
a O 0 2.983808542467159e-07
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
in O 0 7.662325884894017e-08
N O 0 0.0026869026478379965
- O 0 0.0009711563470773399
acetylgalactosamine O 0 0.014516821131110191
- O 0 0.00487728975713253
6 O 0 5.815280928800348e-06
- O 0 0.0016462885541841388
sulfate O 0 1.4151522009342443e-05
sulfatase O 0 1.7770889826351777e-05
( O 0 6.856265599708422e-08
GALNS O 0 6.597828360099811e-06
) O 0 2.3403478266459388e-08
. O 0 4.9260780343729493e-08

Previous O 0 3.767939688259503e-06
studies O 0 1.7663673190781992e-07
of O 0 7.475636998321988e-09
patients O 0 5.733149919251446e-07
from O 0 2.0735193562160248e-09
a O 0 2.036791890702716e-08
British O 0 0.0001255759270861745
- O 0 0.000527325551956892
Irish O 0 2.6720915684563806e-06
population O 0 1.4098490375147321e-08
showed O 0 2.2119886011751078e-07
that O 0 5.115597945248851e-10
the O 0 1.6722768725330184e-09
I113F O 0 2.0234335806890158e-07
mutation O 0 1.2411504712872556e-07
is O 0 5.105957323614518e-10
the O 0 2.691677158939143e-10
most O 0 4.118620999804534e-10
common O 0 8.572691001518251e-09
single O 0 4.235416781739332e-06
mutation O 0 6.230850431165891e-06
among O 0 3.277598068507359e-07
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 0.01011037826538086
and O 0 5.721319595863861e-08
produces O 0 2.1061538291178294e-07
a O 0 3.491920779197244e-07
severe O 1 0.6320515275001526
clinical O 0 0.000521548034157604
phenotype O 0 0.0002109025517711416
. O 0 5.638981974698254e-07

We O 0 4.9651389417704195e-06
studied O 0 1.129653242060158e-06
mutations O 0 2.8000260954286205e-06
in O 0 6.038248567818982e-09
the O 0 9.199751183075477e-09
GALNS O 0 1.7172051229863428e-06
gene O 0 1.2181432396118907e-07
from O 0 8.882551583155873e-09
23 O 0 4.5822744709766994e-08
additional O 0 1.7318855327630445e-07
MPS B-Disease 1 1.0
IVA I-Disease 1 1.0
patients O 0 0.0002475045621395111
( O 0 7.693515158280206e-09
15 O 0 8.99119978470253e-09
from O 0 2.774648732994933e-09
Australia O 0 7.712559835226784e-08
, O 0 7.537196977658311e-10
8 O 0 6.365994398294106e-09
from O 0 1.7695336307355092e-09
Northern O 0 3.6197235431245645e-08
Ireland O 0 2.6077020720549626e-06
) O 0 1.8853840710875147e-09
, O 0 2.3113684577413807e-10
with O 0 3.2103397717975213e-10
various O 0 1.4426332128891772e-08
clinical O 0 0.00015949908993206918
phenotypes O 0 0.00017591071082279086
( O 0 1.1422440593378269e-07
severe O 0 0.00039692295831628144
, O 0 5.153952820080576e-09
16 O 0 1.58671795702503e-08
cases O 0 3.4355918110406947e-09
; O 0 1.4242433898914442e-09
intermediate O 0 5.382612755511218e-08
, O 0 4.36449409946249e-09
4 O 0 1.957284467835052e-08
cases O 0 1.953443096169849e-08
; O 0 2.551300681830071e-08
mild O 0 0.00012026209151372313
, O 0 5.360799448794751e-08
3 O 0 5.8445095874049e-08
cases O 0 2.904383045176928e-08
) O 0 1.507409308487695e-08
. O 0 7.560269921214058e-08

We O 0 2.0547331587295048e-05
found O 0 3.5584495350349243e-08
two O 0 4.992439350814948e-09
common O 0 1.7267277385712987e-08
mutations O 0 7.171769311753451e-07
that O 0 1.7087204984278515e-09
together O 0 2.579322178064558e-08
accounted O 0 2.791941255964048e-07
for O 0 7.023752135459915e-10
32 O 0 4.471876735578917e-08
% O 0 3.270139714572906e-09
of O 0 3.445748963937234e-10
the O 0 5.613664644243954e-09
44 O 0 5.796528057544492e-08
unrelated O 0 3.8817155711967644e-08
alleles O 0 6.064382063186713e-08
in O 0 2.1803363559058653e-09
these O 0 4.174540890744538e-08
patients O 0 8.477044843857584e-07
. O 0 8.970356901727428e-08

One O 0 8.578907682021963e-07
is O 0 8.731174006015863e-09
the O 0 3.75349840098238e-09
T312S O 0 9.154740041594778e-07
mutation O 0 7.598680440423777e-07
, O 0 1.917329628398079e-09
a O 0 4.324042013337248e-09
novel O 0 5.647130407737677e-08
mutation O 0 5.569842187469476e-07
found O 0 1.837187824094144e-08
exclusively O 0 1.3050144964665833e-08
in O 0 3.7707916789031515e-09
milder O 0 1.7626041881158017e-05
patients O 0 1.6337302440661006e-05
. O 0 8.431484843640646e-08

The O 0 6.263524596761272e-07
other O 0 1.7583008826704827e-08
is O 0 3.4151619310307524e-09
the O 0 3.736654541341977e-09
previously O 0 1.8975887883243558e-07
described O 0 3.6772096478898675e-08
I113F O 0 2.3707805496542278e-07
that O 0 1.5330754443709793e-09
produces O 0 8.071031487588698e-08
a O 0 1.0610728651272439e-07
severe O 0 0.0005189038929529488
phenotype O 0 7.738143904134631e-05
. O 0 2.769279205949715e-07

The O 0 7.427713626384502e-07
I113F O 0 4.041972715640441e-06
and O 0 6.618200387720208e-08
T312S O 0 1.0744832934506121e-06
mutations O 0 1.5042777476992342e-06
accounted O 0 3.84599530889318e-07
for O 0 2.725994985297575e-09
8 O 0 2.4638602269533294e-08
( O 0 3.2839908570281295e-09
18 O 0 1.6422648130287598e-08
% O 0 5.739755781775102e-09
) O 0 1.0958988161391403e-09
and O 0 1.2355510392580982e-08
6 O 0 3.281625637896468e-08
( O 0 2.8749003178063504e-09
14 O 0 1.242707536874832e-08
% O 0 1.9843482412795765e-09
) O 0 1.5441795064852215e-10
of O 0 2.5006061110666167e-10
44 O 0 3.118605818031028e-08
unrelated O 0 5.916719558740624e-08
alleles O 0 2.0786052346011274e-07
, O 0 2.471970539374979e-08
respectively O 0 8.774615025686217e-07
. O 0 9.692222135981865e-08

The O 0 5.444279054245271e-07
relatively O 0 5.576368948823074e-07
high O 0 2.8804930707337917e-07
residual O 0 4.313547833589837e-06
GALNS O 0 1.099919063562993e-05
activity O 0 4.513754845447693e-07
seen O 0 4.0906689946496044e-07
when O 0 4.415537269153447e-09
the O 0 7.625170495018097e-10
T312S O 0 1.1135483646285138e-07
mutant O 0 1.6442980665942741e-07
cDNA O 0 7.00305022860448e-08
is O 0 4.075534132397252e-09
overexpressed O 0 1.8867706330638612e-07
in O 0 2.040500213240648e-09
mutant O 0 2.968451440210629e-07
cells O 0 4.8733515001231353e-08
provides O 0 3.182910601751132e-09
an O 0 3.705085405147912e-10
explanation O 0 2.4142043919539447e-09
for O 0 7.475604579809669e-10
the O 0 1.056186071934917e-08
mild O 0 4.2455369111848995e-05
phenotype O 0 1.0920351087406743e-05
in O 0 1.1685028056263036e-08
patients O 0 1.2767431201154977e-07
with O 0 2.759096284776774e-09
this O 0 5.643401745913934e-09
mutation O 0 5.711136509489734e-06
. O 0 1.0403989847418416e-07

The O 0 3.1788115961717267e-07
distribution O 0 7.69726185012587e-08
and O 0 8.338004953145628e-09
relative O 0 2.3186121467233534e-08
frequencies O 0 5.110444334377462e-08
of O 0 1.3092745776432935e-09
the O 0 4.6242583096045564e-09
I113F O 0 2.2409011535273748e-07
and O 0 9.001976053468752e-09
T312S O 0 1.1212615191880104e-07
mutations O 0 2.203463509431458e-07
in O 0 1.7072739888490673e-09
Australia O 0 4.90805041053477e-09
corresponded O 0 8.155472741577796e-09
to O 0 3.7810186093167886e-09
those O 0 2.254987485628135e-08
observed O 0 4.601297121098469e-08
in O 0 1.2197125531798747e-09
Northern O 0 6.110103356604668e-08
Ireland O 0 5.8514638112683315e-06
and O 0 3.149552441072956e-08
are O 0 7.998643414275364e-10
unique O 0 2.822252431755601e-10
to O 0 4.2839709557540573e-10
these O 0 7.430172588307471e-10
two O 0 1.90238358399597e-09
populations O 0 9.083765739603678e-09
, O 0 3.2248598236250814e-10
suggesting O 0 6.758391180028411e-09
that O 0 6.890870651865555e-10
both O 0 1.530514026626406e-08
mutations O 0 2.6919010451820213e-06
were O 0 2.7724925644179166e-07
probably O 0 2.1792482485238907e-08
introduced O 0 7.2304771059350514e-09
to O 0 7.752199771005053e-09
Australia O 0 5.796726654239137e-08
by O 0 2.766737727810664e-09
Irish O 0 1.0682492046498737e-07
migrants O 0 3.188995023606367e-08
during O 0 2.7003702385286488e-08
the O 0 6.3386962345646225e-09
19th O 0 1.4673337318527047e-06
century O 0 1.6619171674392419e-06
. O 0 1.981811834639302e-07

Haplotype O 0 6.213215237949044e-05
analysis O 0 6.039052209416695e-07
using O 0 8.036773238018213e-07
6 O 0 3.562627171049826e-07
RFLPs O 0 6.73087697578012e-07
provides O 0 4.646068418878713e-09
additional O 0 4.08803746410058e-09
data O 0 2.287386138277725e-07
that O 0 2.589964243071563e-09
the O 0 7.069263840975282e-09
I113F O 0 5.583904112427263e-07
mutation O 0 1.7886598868699366e-07
originated O 0 1.524433557165139e-08
from O 0 8.844677767960718e-10
a O 0 4.4692565204229595e-09
common O 0 3.888955646402792e-08
ancestor O 0 3.5450236168799165e-07
. O 0 9.602866413160882e-08

The O 0 1.5695076172050904e-07
other O 0 2.533247922542614e-08
9 O 0 5.950150239186769e-08
novel O 0 3.4234989954029516e-08
mutations O 0 4.977476351086807e-07
identified O 0 8.803182538485999e-08
in O 0 8.75548411549687e-10
these O 0 9.20350728961239e-09
23 O 0 9.774516911420505e-07
patients O 0 2.21532616251352e-07
were O 0 1.2852824227138626e-07
each O 0 2.452194447499778e-09
limited O 0 1.5510410733554636e-08
to O 0 1.3306038049165636e-08
a O 0 2.3085384270871145e-07
single O 0 0.0001391060941386968
family O 0 8.717414061720774e-07
. O 0 1.5737613523469918e-07

These O 0 2.81249214140189e-07
data O 0 1.3092906669953663e-07
provide O 0 3.662538361481893e-08
further O 0 2.7481839026677335e-08
evidence O 0 1.1029850810473363e-08
for O 0 1.5055179325429435e-09
extensive O 0 1.6909325495362282e-07
allelic O 0 1.234456431120634e-05
heterogeneity O 0 7.96487438492477e-06
in O 0 1.2467992291931296e-06
MPS B-Disease 1 1.0
IVA I-Disease 1 0.9999998807907104
in O 0 7.09452621094897e-08
British O 0 9.466524352319539e-05
- O 0 0.005930484738200903
Irish O 0 1.8831835404853337e-05
patients O 0 2.134454604174607e-07
and O 0 7.810627700166606e-10
provide O 0 4.162501454629819e-09
evidence O 0 6.0680589442085875e-09
for O 0 1.1348215700479614e-09
their O 0 1.3469799853282893e-07
transmission O 0 4.0573977457825094e-06
to O 0 2.1453271159543874e-08
Australia O 0 1.0432724195652554e-07
by O 0 1.610300115473251e-09
British O 0 3.411138777664746e-06
- O 0 6.476889666373609e-06
Irish O 0 1.789555540199217e-06
migrants O 0 1.1231301044745123e-07
. O 0 7.876953311836132e-09
. O 0 5.08809385735276e-08

Identification O 0 7.172827736212639e-06
of O 0 1.19329556014236e-07
constitutional O 0 5.49142328054586e-07
WT1 O 0 5.1838389481417835e-05
mutations O 0 2.4209961338783614e-05
, O 0 5.687793347419756e-09
in O 0 2.3904007662167714e-09
patients O 0 1.5700256028594595e-07
with O 0 9.925413380074133e-09
isolated O 0 9.498071449343115e-05
diffuse B-Disease 1 0.6400607228279114
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
, O 0 3.359857458917759e-08
and O 0 1.4283594307329395e-09
analysis O 0 3.851094110274289e-09
of O 0 4.1377568038569734e-09
genotype O 0 0.0002706476079765707
/ O 0 1.3327203305379953e-05
phenotype O 0 1.6210734656851855e-06
correlations O 0 3.1884025020190165e-07
by O 0 2.1705939268201746e-09
use O 0 1.2534317583856591e-08
of O 0 2.0645452014633747e-09
a O 0 4.1068584977210776e-08
computerized O 0 0.0037806699983775616
mutation O 0 6.628763367189094e-05
database O 0 1.3403017646851367e-06
. O 0 2.6664682195587375e-07

Constitutional O 0 1.1575527423701715e-05
mutations O 0 1.042017902364023e-05
of O 0 1.1816500666839147e-08
the O 0 1.7729703927216178e-08
WT1 O 0 3.7261559100443264e-06
gene O 0 2.7201696184420143e-07
, O 0 1.910055003051525e-09
encoding O 0 4.3647130354429464e-08
a O 0 2.5829243099906307e-07
zinc O 0 0.3248394727706909
- O 0 8.772523142397404e-05
finger O 0 0.0005796626210212708
transcription O 0 3.169432147842599e-06
factor O 0 1.3981738788970688e-07
involved O 0 6.30696987968804e-08
in O 0 1.6671185321115445e-08
renal O 0 4.969618748873472e-05
and O 0 9.761943431385589e-08
gonadal O 0 0.0001289838837692514
development O 0 2.4091134420700655e-08
, O 0 2.5216719823362155e-09
are O 0 1.754745460047502e-09
found O 0 1.637931346110122e-09
in O 0 2.792214792712855e-10
most O 0 3.4643807822476447e-09
patients O 0 1.1599351523727819e-07
with O 0 7.805824964179919e-08
Denys B-Disease 1 0.9999982118606567
- I-Disease 1 1.0
Drash I-Disease 1 0.9999997615814209
syndrome I-Disease 1 1.0
( O 0 2.2365222207554325e-07
DDS B-Disease 1 1.0
) O 0 7.703797422209391e-08
, O 0 2.1846334519182165e-08
or O 0 5.6923281590570696e-06
diffuse B-Disease 1 0.9996839761734009
mesangial I-Disease 1 1.0
sclerosis I-Disease 1 1.0
( O 0 2.1046371330157854e-06
DMS B-Disease 0 0.017695100978016853
) O 0 2.0753006424456544e-08
associated O 0 5.217146181735188e-08
with O 0 2.1339003453135774e-08
pseudohermaphroditism B-Disease 1 1.0
and O 0 3.0514338504872285e-06
/ O 0 0.002138368086889386
or O 0 3.0284498279797845e-05
Wilms B-Disease 1 0.9187759160995483
tumor I-Disease 0 0.017132112756371498
( O 0 8.053713713707111e-07
WT B-Disease 1 0.9999990463256836
) O 0 2.5589136498638254e-07
. O 0 3.095700549238245e-07

Most O 0 8.683414307597559e-06
mutations O 0 0.0002194554399466142
in O 0 2.394628495494544e-07
DDS B-Disease 1 1.0
patients O 1 0.9978027939796448
lie O 0 4.869590702583082e-05
in O 0 2.885833350063649e-09
exon O 0 1.72339710502456e-07
8 O 0 4.8727379464708065e-08
or O 0 1.5514316942244477e-08
exon O 0 1.8856464123473415e-07
9 O 0 1.1086233087098663e-07
, O 0 2.4402870835160684e-09
encoding O 0 4.885273483523633e-07
zinc O 0 0.30238255858421326
finger O 1 0.8874157667160034
2 O 0 3.886723334289854e-06
or O 0 2.171513915527612e-05
zinc O 0 0.30183395743370056
finger O 1 0.6663665771484375
3 O 0 7.467658633686369e-07
, O 0 1.3510963015050947e-08
respectively O 0 5.873743589290825e-07
, O 0 2.300102330821119e-09
with O 0 2.038897495282299e-09
a O 0 1.0138006700799451e-07
hot O 0 0.00056925427634269
spot O 0 0.12558048963546753
( O 0 2.4917909513533232e-08
R394W O 0 2.2216966044652509e-07
) O 0 1.5119119289863647e-09
in O 0 2.652799979685483e-09
exon O 0 1.3358239812077954e-06
9 O 0 9.884286100714235e-07
. O 0 1.9013221219665866e-07

We O 0 3.4671236335270805e-06
analyzed O 0 1.4744693999091396e-07
a O 0 4.13646272789947e-09
series O 0 8.817008456674102e-09
of O 0 1.4384451407778442e-09
24 O 0 1.1122223213533289e-06
patients O 0 2.8574856969498796e-07
, O 0 1.6822292447926657e-09
10 O 0 5.534205982371532e-09
with O 0 1.9911279736106735e-08
isolated B-Disease 0 9.829650662140921e-05
DMS I-Disease 0 0.22657209634780884
( O 0 6.371450922415534e-08
IDMS B-Disease 0 7.279947021743283e-05
) O 0 1.138086602736621e-08
, O 0 1.8420289737974826e-09
10 O 0 4.444366652478493e-09
with O 0 1.2018848138950489e-08
DDS B-Disease 1 1.0
, O 0 1.0825579721540635e-07
and O 0 1.1570147506745343e-08
4 O 0 1.170965990837658e-08
with O 0 1.0451960186230735e-08
urogenital B-Disease 0 0.01765788346529007
abnormalities I-Disease 1 0.9999912977218628
and O 0 5.175354999664705e-06
/ O 0 0.16797494888305664
or O 0 0.23061315715312958
WT B-Disease 1 1.0
. O 0 1.711799654913193e-06

We O 0 1.990643431781791e-05
report O 0 4.656299950056564e-07
WT1 O 0 1.4123763321549632e-05
heterozygous O 0 7.153782007662812e-06
mutations O 0 2.597934326331597e-06
in O 0 4.790927210507334e-09
16 O 0 9.777447473879874e-08
patients O 0 1.4042956308912835e-07
, O 0 4.960449828672608e-10
4 O 0 2.9273843349386652e-09
of O 0 1.8671186818863816e-09
whom O 0 4.464360188194405e-07
presented O 0 5.197510333232458e-08
with O 0 2.2388162790321076e-07
IDMS B-Disease 0 0.2789071202278137
. O 0 6.412861353055632e-07

One O 0 1.6507052578162984e-06
male O 0 2.510195599825238e-06
and O 0 1.6835620897381887e-08
two O 0 3.2453986165137394e-08
female O 0 3.554625072865747e-05
IDMS B-Disease 1 0.9940710663795471
patients O 0 4.733018431579694e-05
with O 0 4.229811523259741e-08
WT1 O 0 0.0024352248292416334
mutations O 0 0.004106178414076567
underwent O 0 8.840402006171644e-05
normal O 0 4.289128628442995e-05
puberty O 0 0.0035978942178189754
. O 0 5.338250161912583e-07

Two O 0 4.854333838011371e-06
mutations O 0 0.00017267886141780764
associated O 0 2.7558772330849024e-07
with O 0 2.5542998827177144e-08
IDMS B-Disease 0 0.005493771284818649
are O 0 3.25574021076136e-08
different O 0 2.9570876858286965e-09
from O 0 3.045316221417238e-09
those O 0 1.7256379436503266e-08
described O 0 8.164347775618808e-08
in O 0 3.9641989246774756e-08
DDS B-Disease 1 1.0
patients O 0 0.0017907522851601243
. O 0 1.812455678873448e-07

No O 0 3.2061572710517794e-05
WT1 O 0 0.00027081024018116295
mutations O 0 0.00020704713824670762
were O 0 5.752070819653454e-07
detected O 0 5.489863497132319e-07
in O 0 1.6737894403817677e-09
the O 0 1.3681149546584948e-09
six O 0 1.5540912556843978e-08
other O 0 1.1015639067579741e-08
IDMS B-Disease 1 0.9922822117805481
patients O 0 7.3495807555445936e-06
, O 0 1.9889900837455343e-09
suggesting O 0 5.543167702626306e-08
genetic O 0 4.075124877545022e-07
heterogeneity O 0 6.750148884293594e-08
of O 0 2.0383452703498506e-09
this O 0 3.928865410784965e-08
disease O 0 0.0025887952651828527
. O 0 8.962678066382068e-08

We O 0 5.874539510841714e-06
analyzed O 0 4.006060407846235e-06
genotype O 0 4.8788318963488564e-05
/ O 0 7.77265722717857e-06
phenotype O 0 2.3044478894007625e-06
correlations O 0 9.545732382321148e-07
, O 0 1.2282529660012642e-08
on O 0 5.838467487251364e-09
the O 0 2.0085433316552326e-09
basis O 0 8.140988327909326e-09
of O 0 7.295011816843555e-10
the O 0 5.881375386707077e-09
constitution O 0 1.0680288653475145e-08
of O 0 2.8525917739052886e-10
a O 0 1.181379705172958e-08
WT1 O 0 2.8650215426750947e-06
mutation O 0 1.4011666849000903e-07
database O 0 4.606943804219554e-08
of O 0 5.889829068905783e-09
84 O 0 4.3643967728712596e-07
germ O 0 4.5945507736178115e-05
- O 0 0.00016845716163516045
line O 0 7.229045877465978e-05
mutations O 0 3.517721552270814e-06
, O 0 8.563698083996485e-10
to O 0 4.951922760731975e-10
compare O 0 3.2338437705448086e-08
the O 0 1.9768495729266533e-09
distribution O 0 5.870582686640091e-09
and O 0 2.520565978159084e-09
type O 0 4.941501856592367e-07
of O 0 1.5617033222170562e-09
mutations O 0 3.7963150134601165e-06
, O 0 8.953631169816845e-10
according O 0 3.2238142710916406e-10
to O 0 1.2064041987613905e-09
the O 0 1.0528010463417559e-08
different O 0 8.048953645811707e-07
symptoms O 0 0.00010221083357464522
. O 0 6.12107982078669e-08

This O 0 1.9189812405784323e-07
demonstrated O 0 1.4150545268876158e-07
( O 0 3.021997763141826e-09
1 O 0 3.9631005144258324e-09
) O 0 8.560203101914965e-10
the O 0 1.7655251705051e-09
association O 0 5.2846251819005374e-09
between O 0 3.4062106468724096e-09
mutations O 0 3.470142928563291e-07
in O 0 5.377374101556143e-10
exons O 0 9.026084057950357e-08
8 O 0 3.600876397058528e-08
and O 0 1.7585389144869623e-08
9 O 0 6.892165060889965e-08
and O 0 5.5605340776310186e-08
DMS B-Disease 0 0.0019026488298550248
; O 0 5.15020914804154e-09
( O 0 1.129371596242379e-09
2 O 0 2.807114540814837e-09
) O 0 9.528710043227306e-10
among O 0 6.05291639033112e-09
patients O 0 6.496162541225203e-08
with O 0 3.822283822785266e-09
DMS B-Disease 0 0.0014129631454125047
, O 0 3.788265701132332e-09
a O 0 2.7679833980442936e-09
higher O 0 1.2043907204883908e-08
frequency O 0 9.259184707843815e-08
of O 0 6.600419655278245e-10
exon O 0 1.8676438173770293e-07
8 O 0 6.886750725243473e-08
mutations O 0 1.9770887149661576e-07
among O 0 2.8967523935108375e-09
46 O 0 1.0850427401010165e-07
, O 0 1.535212312830936e-08
XY O 0 0.0013108747079968452
patients O 0 6.03346791194781e-07
with O 0 3.2728104670809444e-09
female O 0 3.938045267659618e-07
phenotype O 0 3.914717296993331e-07
than O 0 1.6749518438885502e-09
among O 0 3.456137376289803e-09
46 O 0 1.4332648845538642e-07
, O 0 2.7347038411562608e-08
XY O 0 0.001235399628058076
patients O 0 3.8879920793988276e-07
with O 0 2.2816371014755532e-09
sexual O 0 1.4441891948990815e-07
ambiguity O 0 2.9230039899630356e-07
or O 0 2.0957020296918927e-06
male O 0 6.212456810317235e-06
phenotype O 0 1.1727281616913388e-06
; O 0 9.402678635694883e-09
and O 0 2.8166518006855767e-08
( O 0 6.6457994662982856e-09
3 O 0 1.567744689623396e-08
) O 0 4.8482613479450265e-09
statistically O 0 5.375060823098465e-07
significant O 0 1.1519545317639768e-08
evidence O 0 7.640638699513147e-08
that O 0 1.1981471814692668e-08
mutations O 0 1.9785647964454256e-06
in O 0 2.7436259930624374e-09
exons O 0 5.520493004951277e-07
8 O 0 1.372216615891375e-07
and O 0 2.01665173449328e-08
9 O 0 7.660192125058529e-08
preferentially O 0 1.4345091869927273e-07
affect O 0 9.294857505892651e-08
amino O 0 7.023852788279328e-08
acids O 0 3.978968710072195e-09
with O 0 3.3545904942755556e-10
different O 0 2.5442141726728096e-09
functions O 0 2.9649392274677666e-08
. O 0 8.058399281196671e-09
. O 0 5.774193567731345e-08

The O 0 1.8987667544934084e-06
185delAG O 0 4.643559077521786e-05
BRCA1 O 0 0.00014262591139413416
mutation O 0 3.875009042531019e-06
originated O 0 2.2221840367819823e-07
before O 0 1.4441969398149013e-08
the O 0 9.24294307758089e-10
dispersion O 0 4.976071110718294e-08
of O 0 1.1023830737144635e-09
Jews O 0 2.5334072617511083e-08
in O 0 4.979759382628401e-10
the O 0 7.52025219874497e-10
diaspora O 0 5.526811452938318e-09
and O 0 6.8165966204958295e-09
is O 0 9.79819891888667e-10
not O 0 3.165057549381345e-09
limited O 0 1.0881199941081832e-08
to O 0 3.4491716149887e-08
Ashkenazim O 0 0.0002478809910826385
. O 0 2.1562314600487298e-07

The O 0 1.909497086671763e-06
185delAG O 0 2.3934371711220592e-05
mutation O 0 5.647050329571357e-06
in O 0 1.6663237900615968e-08
BRCA1 O 0 4.3465232010930777e-05
is O 0 1.1842899994007894e-08
detected O 0 2.575088160483574e-07
in O 0 1.6526744417433292e-09
Ashkenazi O 0 3.873262812703615e-07
Jews O 0 1.5436391720413667e-08
both O 0 2.9573696824769513e-09
in O 0 6.824506293412469e-09
familial B-Disease 1 0.9995610117912292
breast I-Disease 1 1.0
and I-Disease 1 0.9999995231628418
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 1.7112482453285338e-07
in O 0 2.2247481634707356e-09
the O 0 6.051358081293756e-09
general O 0 7.813895308572683e-09
population O 0 1.7102244953548507e-08
. O 0 4.1633764880089075e-08

All O 0 2.0188549569866154e-06
tested O 0 9.16626140679e-06
Ashkenazi O 0 6.685813787044026e-06
mutation O 0 1.589509906807507e-06
carriers O 0 2.712393438741856e-07
share O 0 1.5886651993923806e-08
the O 0 1.5378374129682015e-09
same O 0 7.145026792443332e-09
allelic O 0 4.862488935941656e-07
pattern O 0 8.32703062769724e-06
at O 0 1.1667093957612451e-07
the O 0 2.7950843417556825e-08
BRCA1 O 0 4.944159445585683e-05
locus O 0 2.60430224443553e-05
. O 0 6.835640533608967e-07

Our O 0 3.335293058626121e-06
previous O 0 2.7285409487376455e-07
study O 0 5.200792685400302e-08
showed O 0 1.1758768891922955e-07
that O 0 3.0698552033747717e-10
this O 0 5.437253425277788e-10
Ashkenazi O 0 1.4917603721187334e-06
mutation O 0 4.831877049582545e-07
also O 0 9.527696853695033e-09
occurs O 0 5.5866400394677385e-09
in O 0 2.4969470935332083e-09
Iraqi O 0 5.298243763718347e-07
Jews O 0 3.412272420177942e-08
with O 0 1.3859616787570417e-09
a O 0 7.600359452908378e-09
similar O 0 4.1802618255815105e-08
allelic O 0 9.424365089216735e-06
pattern O 0 5.666693323291838e-05
. O 0 2.4938600517998566e-07

We O 0 7.75042917666724e-06
extended O 0 2.3831235296256637e-07
our O 0 1.3264987330785516e-08
analysis O 0 4.600935188392441e-09
to O 0 1.9089405611794064e-09
other O 0 4.570645639745408e-09
non O 0 7.341793661908014e-07
- O 0 6.124770948190417e-07
Ashkenazi O 0 5.695232516700344e-07
subsets O 0 8.757396585679089e-08
354 O 0 3.850611562938866e-08
of O 0 1.3553570488156197e-09
Moroccan O 0 3.01732001162236e-07
origin O 0 2.8633223791985074e-08
, O 0 2.2708914748648112e-09
200 O 0 4.947714682401738e-09
Yemenites O 0 3.599283786570595e-07
and O 0 1.052907450116436e-08
150 O 0 8.655976380111952e-09
Iranian O 0 1.577084702830689e-07
Jews O 0 2.7445233286016446e-07
. O 0 4.6927031149834875e-08

Heteroduplex O 0 0.0001607691665412858
analysis O 0 1.301124370911566e-06
complemented O 0 8.143916829794762e-07
by O 0 6.501577054507379e-09
direct O 0 2.445245961268938e-08
DNA O 0 5.940760772205067e-08
sequencing O 0 5.422718274417093e-08
of O 0 3.9542591423469275e-09
abnormally O 0 4.801912837137934e-06
migrating O 0 7.604147356232716e-08
bands O 0 9.056595899892272e-07
were O 0 7.374832193818293e-07
employed O 0 5.157017312740209e-06
. O 0 1.6034715599744231e-07

Four O 0 2.5559970708854962e-06
of O 0 2.3476935950839106e-08
Moroccan O 0 7.452845807165431e-07
origin O 0 2.2514461406331066e-08
( O 0 1.789962178477822e-09
1 O 0 1.5012567855521297e-09
. O 0 2.4626031769336976e-10
1 O 0 1.8205303931040362e-09
% O 0 5.2828110774783e-09
) O 0 7.291673376208507e-10
and O 0 1.5457841229249425e-08
none O 0 3.705668660813899e-08
of O 0 1.6267874547448713e-10
the O 0 4.913370155179564e-09
Yemenites O 0 2.7568733003136003e-06
or O 0 3.043575986794167e-07
Iranians O 0 9.507259335350682e-08
was O 0 8.402876261470738e-08
a O 0 6.779254935196377e-09
carrier O 0 1.0246598947105667e-07
of O 0 1.4550400884161263e-09
the O 0 1.9550384422473144e-08
185delAG O 0 1.0819220733537804e-05
mutation O 0 4.777192771143746e-06
. O 0 3.033566997601156e-07

BRCA1 O 0 0.00324252643622458
allelic O 0 5.1516395615180954e-05
patterns O 0 0.0002989939821418375
were O 0 3.7616850931954104e-06
determined O 0 1.0710442666095332e-07
for O 0 1.1428149537806576e-09
four O 0 8.62058602280058e-09
of O 0 2.3516125158273837e-10
these O 0 6.552656639513543e-09
individuals O 0 3.900981315752006e-09
and O 0 3.475791210405532e-09
for O 0 7.607824925592865e-10
12 O 0 1.1120791398866459e-08
additional O 0 1.7396233786826087e-08
non O 0 8.115107448247727e-06
- O 0 1.4715262295794673e-05
Ashkenazi O 0 1.1263730812061112e-05
185delAG O 0 7.839917088858783e-07
mutation O 0 4.284138981347496e-07
carriers O 0 1.7783646910629614e-07
who O 0 2.985556477597129e-07
had O 0 0.0025266092270612717
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 9.096873441194475e-07

Six O 0 4.464252560865134e-05
non O 0 0.00015178750618360937
- O 0 3.099620880675502e-05
Ashkenazi O 0 4.0830160287441686e-05
individuals O 0 1.987963216265598e-08
shared O 0 1.572116659076528e-08
the O 0 4.016843302423467e-09
common O 0 2.9644530386008228e-08
Ashkenazi O 0 2.0694369595730677e-06
haplotype O 0 2.564708836416685e-07
, O 0 9.59923696086662e-09
four O 0 1.0091935109812766e-07
had O 0 3.036724933735968e-07
a O 0 2.803443921450821e-09
closely O 0 4.824905985856276e-08
related O 0 2.3045693353651586e-08
pattern O 0 9.017839147418272e-06
, O 0 6.552881792742937e-09
and O 0 8.602042633754081e-09
the O 0 6.552031805995284e-09
rest O 0 9.10027821987569e-08
( O 0 1.054314147097557e-08
n O 0 1.2040520232403651e-05
= O 0 6.358516839100048e-05
6 O 0 2.776673397875129e-07
) O 0 5.000901914797851e-09
displayed O 0 1.4838316531040618e-07
a O 0 3.406511339676399e-08
distinct O 0 2.286429435116588e-06
BRCA1 O 0 8.147331391228363e-05
allelic O 0 3.7860136217204854e-05
pattern O 0 6.672804011031985e-05
. O 0 6.582346827599395e-07

We O 0 8.956157216744032e-06
conclude O 0 3.377404880211543e-07
that O 0 4.996382862998416e-09
the O 0 8.224048109184423e-09
185delAG O 0 5.039867119194241e-06
BRCA1 O 0 0.0001667136384639889
mutation O 0 2.7918479190702783e-06
occurs O 0 1.7736976332116683e-08
in O 0 4.256985597361762e-10
some O 0 1.1636669405845623e-09
non O 0 8.57936640841217e-07
- O 0 1.5057590871947468e-06
Ashkenazi O 0 3.431043751334073e-06
populations O 0 3.663866010583661e-08
at O 0 1.1137307076580782e-08
rates O 0 2.3265779702796863e-07
comparable O 0 5.757148002771828e-08
with O 0 2.1744390732436614e-09
that O 0 2.207384497410203e-09
of O 0 3.4655371905500942e-09
Ashkenazim O 0 4.9163823859998956e-05
. O 0 1.4462663955328026e-07

The O 0 5.500837687577587e-07
majority O 0 1.2988292041882232e-07
of O 0 3.3029681212326523e-09
Jewish O 0 4.783780127581849e-07
185delAG O 0 3.438233761698939e-06
mutation O 0 1.2948434005011222e-06
carriers O 0 1.601012940000146e-07
have O 0 2.7701962945769765e-09
a O 0 4.649880480656066e-09
common O 0 3.259741632177793e-08
allelic O 0 1.538899596198462e-06
pattern O 0 3.856514013023116e-05
, O 0 8.638576076691606e-09
supporting O 0 5.2904571390399724e-08
the O 0 5.075761588813066e-09
founder O 0 1.881053179886294e-08
effect O 0 5.633066901822303e-09
notion O 0 8.641180215818167e-09
, O 0 1.3179386471051657e-09
but O 0 1.5657835028548561e-09
dating O 0 1.0597500477160793e-07
the O 0 4.11043021841806e-09
mutations O 0 1.5592760860272392e-07
origin O 0 4.413709842054914e-09
to O 0 3.3020548517725956e-09
an O 0 4.0507348586515945e-09
earlier O 0 6.486653347792526e-08
date O 0 1.6646471578951605e-07
than O 0 8.384700933561362e-09
currently O 0 4.998806701905778e-08
estimated O 0 3.364320733112436e-08
. O 0 2.717855984712969e-08

However O 0 2.626854211484897e-06
, O 0 7.842801963420243e-09
the O 0 6.838914989870659e-10
different O 0 1.4243058954477306e-09
allelic O 0 1.8787912381412752e-07
pattern O 0 3.828725311905146e-06
at O 0 7.991697259512875e-08
the O 0 6.5200431720313645e-09
BRCA1 O 0 1.1193516002094839e-05
locus O 0 1.269995095753984e-06
even O 0 7.443129845796648e-08
in O 0 1.8344311625284604e-09
some O 0 4.750861037905452e-09
Jewish O 0 2.6098464900314866e-07
mutation O 0 4.297315001622337e-07
carriers O 0 2.130655474275045e-07
, O 0 3.3519953479554943e-09
might O 0 8.839167620067201e-09
suggest O 0 3.027202666316953e-08
that O 0 7.86157972054724e-10
the O 0 4.724177937731611e-09
mutation O 0 9.522773893877456e-07
arose O 0 6.277853259462063e-08
independently O 0 3.4887020206042507e-07
. O 0 2.2208231698073178e-08
. O 0 7.37840650799626e-08

Crystal O 0 1.7579359337105416e-05
structure O 0 5.423462425824255e-07
of O 0 7.1306365256873505e-09
the O 0 5.096446642482988e-08
hemochromatosis B-Disease 1 0.9999998807907104
protein O 0 3.7974989481881494e-06
HFE O 0 0.00012493037502281368
and O 0 2.7606137820157528e-08
characterization O 0 1.1833815705131201e-07
of O 0 7.99449451083234e-10
its O 0 2.390168285515415e-09
interaction O 0 1.498739976568686e-08
with O 0 1.2582487052270608e-08
transferrin O 0 2.581254648248432e-06
receptor O 0 2.7778598905570107e-06
. O 0 1.3780800145468675e-07

HFE O 0 0.003656029934063554
is O 0 3.445776144417323e-07
an O 0 1.4403677361940481e-08
MHC O 0 3.4823106034309603e-06
- O 0 9.686526709629106e-07
related O 0 1.2436891516642845e-08
protein O 0 1.5143774234616103e-08
that O 0 3.1129865352141906e-10
is O 0 3.1441113601538007e-10
mutated O 0 1.598488807985632e-08
in O 0 5.82752790467822e-10
the O 0 2.8575609434255966e-08
iron B-Disease 1 0.9998931884765625
- I-Disease 1 0.9999996423721313
overload I-Disease 1 0.9999979734420776
disease I-Disease 1 1.0
hereditary B-Disease 1 1.0
hemochromatosis I-Disease 1 1.0
. O 0 3.651034785434604e-05

HFE O 0 0.002034803619608283
binds O 0 8.430916750512552e-06
to O 0 2.7676503577822587e-07
transferrin O 0 6.256400865822798e-06
receptor O 0 1.9809306195384124e-06
( O 0 3.466272602281606e-08
TfR O 0 1.8551144194134395e-06
) O 0 6.526263973682944e-09
and O 0 3.4685196936834473e-09
reduces O 0 1.607115862611863e-08
its O 0 8.042027044297129e-10
affinity O 0 1.4831052830288627e-08
for O 0 5.72486458239041e-09
iron O 0 0.0010219577234238386
- O 0 0.0001974847400560975
loaded O 0 5.003646947443485e-06
transferrin O 0 6.772419851586164e-07
, O 0 1.0827309715466527e-08
implicating O 0 4.549926416075323e-06
HFE O 0 8.9368419139646e-05
in O 0 1.3407027665834903e-07
iron O 0 8.342289220308885e-05
metabolism O 0 3.30226102960296e-05
. O 0 4.302317790916277e-07

The O 0 1.938890363817336e-06
2 O 0 1.4964624597268994e-06
. O 0 5.065919026492338e-07

6 O 0 4.375297430669889e-05
A O 0 1.2131376934121363e-06
crystal O 0 1.2625501994989463e-06
structure O 0 4.624895666438533e-07
of O 0 1.0231127944848595e-08
HFE O 0 0.0001521002996014431
reveals O 0 3.945037008179497e-07
the O 0 5.736866537375818e-09
locations O 0 7.658293554868578e-08
of O 0 2.9376382215673402e-08
hemochromatosis B-Disease 1 1.0
mutations O 1 0.6894771456718445
and O 0 7.562462656096614e-08
a O 0 3.103521706293577e-08
patch O 0 0.00045457432861439884
of O 0 4.280493737240931e-09
histidines O 0 5.040848009230103e-06
that O 0 9.199856876307422e-09
could O 0 1.625479484346215e-07
be O 0 6.513729111645716e-09
involved O 0 2.100284390849083e-08
in O 0 5.955256288103783e-09
pH O 0 0.0001257358817383647
- O 0 2.2037855160306208e-05
dependent O 0 1.6259365338555654e-06
interactions O 0 7.249121836139238e-07
. O 0 1.898922903365019e-07

We O 0 3.5350342386664124e-06
also O 0 2.7377517142213037e-08
demonstrate O 0 3.0252458316226694e-08
that O 0 5.346409537310137e-09
soluble O 0 6.025383072483237e-07
TfR O 0 7.4907643465849105e-06
and O 0 4.6715914692185834e-08
HFE O 0 3.452328746789135e-05
bind O 0 1.1396862191759283e-06
tightly O 0 3.3016647194017423e-06
at O 0 9.243128573643844e-08
the O 0 2.6128079699816453e-09
basic O 0 3.086508826299905e-08
pH O 0 7.109019861673005e-08
of O 0 3.4038058482899203e-10
the O 0 2.8985762678956917e-09
cell O 0 2.613363392356405e-07
surface O 0 4.91799028168316e-06
, O 0 1.6856860796110595e-08
but O 0 2.0498282182757066e-08
not O 0 3.394240266629822e-08
at O 0 7.492026554700715e-08
the O 0 1.809681293707399e-08
acidic O 0 1.146606791735394e-06
pH O 0 5.482235678755387e-07
of O 0 6.3183573928426995e-09
intracellular O 0 3.6861426906398265e-06
vesicles O 0 1.1027285836462397e-05
. O 0 4.117608796150307e-07

TfR O 0 0.18547242879867554
HFE O 0 0.005149580538272858
stoichiometry O 0 5.092405262985267e-05
( O 0 5.542902385968773e-07
2 O 0 1.1912874953168284e-07
1 O 0 3.337553522442249e-08
) O 0 5.2789737026159855e-09
differs O 0 4.6533607189758186e-08
from O 0 3.2287530871144554e-08
TfR O 0 1.844097459979821e-05
transferrin O 0 9.592795322532766e-07
stoichiometry O 0 2.9043172844467335e-07
( O 0 1.9283955765558858e-08
2 O 0 1.3536319620754966e-08
2 O 0 2.2046336312087078e-08
) O 0 4.506440554052915e-09
, O 0 7.529179502085981e-10
implying O 0 9.819868473925908e-09
a O 0 1.0191643085022406e-09
different O 0 1.100133539821968e-09
mode O 0 4.440928691451518e-08
of O 0 1.0180783993618547e-09
binding O 0 2.933998466403409e-08
for O 0 4.426820687797317e-09
HFE O 0 2.144355676136911e-05
and O 0 2.7866205343229922e-08
transferrin O 0 1.6516423784196377e-07
to O 0 2.223230666231757e-08
TfR O 0 1.731953125272412e-05
, O 0 9.44587341678016e-09
consistent O 0 1.7873762203635124e-07
with O 0 2.727040371297562e-09
our O 0 2.548188149376074e-08
demonstration O 0 2.15607052211908e-08
that O 0 2.4429975820083882e-09
HFE O 0 3.7517936561926035e-06
, O 0 5.698369776041545e-09
transferrin O 0 1.4047469676370383e-07
, O 0 7.022939119138982e-09
and O 0 3.6214913734511356e-08
TfR O 0 4.928107955493033e-06
form O 0 4.566734901345626e-08
a O 0 3.6503337241811096e-08
ternary O 0 8.494290000271576e-07
complex O 0 8.22215099560708e-07
. O 0 1.610873141544289e-07

Identification O 0 3.2937396099441685e-06
of O 0 1.716688835529112e-08
three O 0 3.2025880614128255e-08
novel O 0 4.9706169846786e-08
mutations O 0 1.5771042853884865e-06
and O 0 1.0398371053099709e-08
a O 0 5.752205822773249e-09
high O 0 4.4573408075621046e-08
frequency O 0 4.546736533939111e-07
of O 0 9.368142928067869e-10
the O 0 9.275725965096626e-09
Arg778Leu O 0 4.008326868643053e-06
mutation O 0 3.0387442961909983e-07
in O 0 5.223824928179965e-09
Korean O 0 4.84825432067737e-06
patients O 0 2.0932861843903083e-07
with O 0 1.7061909218796245e-08
Wilson B-Disease 0 0.0005723029025830328
disease I-Disease 0 0.0001421760825905949
. O 0 6.748449976612392e-08

Four O 0 9.9122007668484e-06
mutations O 0 0.00013187690638005733
- O 0 4.3608848500298336e-05
- O 0 1.2956827049492858e-05
R778L O 0 1.3298422345542349e-06
, O 0 5.377704503928271e-09
A874V O 0 5.403895997346808e-08
, O 0 1.2174882213500382e-09
L1083F O 0 4.497666949987433e-08
, O 0 1.3282424049521069e-09
and O 0 2.1809851702414562e-09
2304delC O 0 1.753321896558191e-07
- O 0 8.935911068874702e-07
- O 0 1.5365327499239356e-06
in O 0 2.0441035530893714e-09
the O 0 4.140172205069348e-09
copper O 0 5.663352453666448e-07
- O 0 1.1251133713585659e-07
transporting O 0 6.361263160670205e-08
enzyme O 0 6.4805945498847e-08
, O 0 5.4086881640103e-09
P O 0 2.461155872879317e-06
- O 0 5.932358817517525e-07
type O 0 3.0255114324972965e-06
ATPase O 0 6.270204266911605e-06
( O 0 5.81928141230037e-08
ATP7B O 0 1.778993578227528e-06
) O 0 3.1646714138133802e-09
, O 0 7.30562277340141e-10
were O 0 8.99270968801602e-09
identified O 0 1.4209392773523177e-08
in O 0 4.4865583470610204e-10
Korean O 0 2.5578747226973064e-06
Patients O 0 7.029950666037621e-08
with O 0 8.960623354425934e-09
Wilson B-Disease 0 0.0001868773251771927
disease I-Disease 0 0.0001019018454826437
. O 0 5.727772744990034e-08

Arg778Leu O 0 0.00045816830242983997
, O 0 1.4459821784384985e-07
the O 0 9.822079150012542e-09
most O 0 9.605537698575972e-09
frequently O 0 2.7158068860444473e-06
reported O 0 1.5774006101310079e-07
mutation O 0 5.161914629070452e-08
of O 0 1.659939685705325e-10
this O 0 3.8181868777797945e-10
enzyme O 0 9.806284140267962e-08
, O 0 4.832455324788043e-09
was O 0 1.2928430237479915e-07
found O 0 6.0467546525444504e-09
in O 0 2.8310620514560014e-10
six O 0 5.907717870456963e-09
of O 0 2.3935523008056236e-10
eight O 0 7.240388555374011e-08
unrelated O 0 3.5744565707318543e-07
patients O 0 9.110836884929085e-08
studied O 0 2.8826988796026853e-08
, O 0 6.327217638713023e-10
an O 0 3.9323777567545903e-10
allele O 0 7.051787065393e-08
frequency O 0 2.2613366468249296e-07
of O 0 1.2982863673016709e-08
37 O 0 1.8888351860368857e-06
. O 0 2.2983675762588973e-07

5 O 0 8.845190677675419e-06
% O 0 4.781294364875066e-07
, O 0 4.087928218154957e-09
which O 0 1.187587361783926e-09
is O 0 4.745696613461803e-10
considerably O 0 5.7497926420069234e-09
higher O 0 8.172476917422955e-09
than O 0 1.1562949486787488e-09
those O 0 6.88528623005169e-10
in O 0 3.8953734682323216e-10
other O 0 1.247037806351159e-09
Asian O 0 9.04110919464074e-08
populations O 0 2.1577845643605542e-07
. O 0 9.246937082707518e-08

The O 0 1.0203268629993545e-06
novel O 0 1.287945565309201e-06
single O 0 7.485269861717825e-07
nucleotide O 0 2.4121932256093714e-06
deletion O 0 3.0035132567718392e-06
, O 0 2.7402174751500752e-08
2304delC O 0 6.138700427982258e-07
, O 0 8.107084781272533e-09
was O 0 8.027950570976827e-08
found O 0 7.273134094987199e-09
in O 0 1.5818401033484975e-09
one O 0 3.4632325451866564e-08
patient O 0 9.050293101608986e-07
. O 0 8.070923485092862e-08

Since O 0 1.826369498303393e-06
a O 0 1.0169884490096592e-07
mutation O 0 1.014192775983247e-06
at O 0 5.4550017836163534e-08
cDNA O 0 1.445177304049139e-06
nucleotide O 0 1.3740785107074771e-05
2302 O 0 4.0660750528331846e-05
( O 0 5.005609438057945e-08
2302insC O 0 6.177914428917575e-07
) O 0 1.2173170027551805e-08
had O 0 1.2504382311817608e-06
been O 0 1.2596250087426597e-07
previously O 0 3.2534066463085765e-07
described O 0 2.181190339456407e-08
, O 0 6.535952334907336e-10
this O 0 1.769769053527881e-10
region O 0 3.726270847437263e-09
of O 0 2.469602577992447e-10
the O 0 6.135349561731118e-09
ATP7B O 0 9.3476546680904e-06
gene O 0 3.634716279066197e-07
may O 0 8.690306430025885e-08
be O 0 6.400425522912201e-09
susceptible O 0 1.8717037164606154e-07
to O 0 6.369285543428305e-09
gene O 0 7.70351107348688e-06
rearrangements O 0 3.826120882877149e-05
causing O 0 0.00027585236239247024
Wilson B-Disease 0 0.0017386233666911721
disease I-Disease 0 0.02314162626862526
. O 0 1.9266646233973006e-07

Disruption O 0 4.0000239096116275e-05
of O 0 8.254539096697044e-08
splicing O 0 3.7934921692794887e-06
regulated O 0 8.639788688924455e-07
by O 0 7.0501160465141766e-09
a O 0 2.7963642068584704e-08
CUG O 0 7.581274076073896e-06
- O 0 5.244307885732269e-07
binding O 0 1.70664733900594e-07
protein O 0 2.788349036109139e-07
in O 0 1.0676667017150976e-07
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
. O 0 2.7044038688472938e-06

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.999404788017273
DM B-Disease 1 1.0
) O 0 1.1628931133600418e-06
is O 0 1.7103680249874742e-08
caused O 0 6.190883539147762e-08
by O 0 1.3246397312371982e-09
a O 0 1.1032397218002643e-08
CTG O 0 5.857510245732556e-07
expansion O 0 2.4030601508684413e-08
in O 0 1.9019554819976747e-09
the O 0 1.722125442249478e-09
3 O 0 6.656379003544544e-09
untranslated O 0 5.052289111517894e-07
region O 0 3.807812731793092e-08
of O 0 4.453284851990702e-09
the O 0 4.848938601753616e-07
DM B-Disease 1 1.0
gene O 0 3.6571258533513173e-05
. O 0 5.011838766222354e-07

One O 0 9.508508469480148e-07
model O 0 5.477103854900633e-07
of O 0 4.599700176299848e-08
DM B-Disease 1 0.9999998807907104
pathogenesis O 0 3.289994538135943e-06
suggests O 0 1.6200644381569873e-07
that O 0 2.372228413705102e-09
RNAs O 0 1.3414650368304137e-07
from O 0 4.120744634406037e-09
the O 0 2.95310820241923e-09
expanded O 0 3.7341273184665624e-08
allele O 0 4.9411536195975714e-08
create O 0 1.030299667803547e-08
a O 0 5.0828532494051615e-09
gain O 0 4.93584082050802e-07
- O 0 4.878373601968633e-06
of O 0 7.202095808622744e-09
- O 0 2.2365858967532404e-05
function O 0 1.6439831540537853e-07
mutation O 0 5.496233868029776e-08
by O 0 3.8688502401740266e-10
the O 0 4.747525705894873e-10
inappropriate O 0 2.3421520722877176e-08
binding O 0 1.0045400067326682e-08
of O 0 3.658666702932578e-10
proteins O 0 4.803343500725532e-09
to O 0 4.924478602674753e-09
the O 0 2.583975700076735e-08
CUG O 0 0.00011217535939067602
repeats O 0 1.2567753401526716e-05
. O 0 2.2871199689689092e-07

Data O 0 4.569777047436219e-06
presented O 0 4.309035546157247e-07
here O 0 1.1956952761238426e-08
indicate O 0 7.918743705204179e-08
that O 0 5.321298401916863e-10
the O 0 2.8753828207328525e-09
conserved O 0 7.045333916266827e-08
heterogeneous O 0 2.019121438934235e-07
nuclear O 0 5.389366037888976e-07
ribonucleoprotein O 0 2.1812834347656462e-06
, O 0 1.8665820888941198e-08
CUG O 0 2.990325810969807e-06
- O 0 3.941896693504532e-07
binding O 0 1.989780855637946e-07
protein O 0 1.203497959068045e-07
( O 0 2.2050752335189827e-08
CUG O 0 5.634322860714747e-06
- O 0 6.052957814972615e-06
BP O 0 4.970881491317414e-06
) O 0 3.6826266480716185e-09
, O 0 1.122409498677257e-09
may O 0 8.55607851235618e-09
mediate O 0 1.3558805278535146e-07
the O 0 2.7774618160947284e-08
trans O 0 6.630323241552105e-07
- O 0 1.0934837519016583e-05
dominant O 0 2.2152023575472413e-06
effect O 0 1.43926639495362e-08
of O 0 4.3495168577933896e-10
the O 0 4.136754494510342e-09
RNA O 0 2.805005294703733e-07
. O 0 1.2305139307500212e-07

CUG O 0 0.04234738647937775
- O 0 0.05890851467847824
BP O 0 4.04558377340436e-05
was O 0 5.1050665916818616e-08
found O 0 2.4020141431435604e-09
to O 0 7.53627715788241e-10
bind O 0 2.3328158960111978e-08
to O 0 1.7437018495769507e-09
the O 0 4.878240478234375e-09
human O 0 4.9323304551762703e-08
cardiac O 0 1.7350212146993726e-06
troponin O 0 7.739888133073691e-06
T O 0 1.5885911125224084e-05
( O 0 1.0659407578827995e-08
cTNT O 0 1.8575259730368998e-07
) O 0 7.325593465168367e-09
pre O 0 8.301894922624342e-06
- O 0 4.355998953542439e-06
messenger O 0 2.0163062686151534e-07
RNA O 0 1.302199024166839e-07
and O 0 4.2767966945689295e-09
regulate O 0 4.5737436948911636e-08
its O 0 6.2840088688176365e-09
alternative O 0 5.5983981894769386e-08
splicing O 0 4.826148597203428e-06
. O 0 1.9613587198819005e-07

Splicing O 0 5.594917820417322e-05
of O 0 6.914429491189367e-07
cTNT O 0 1.8576018192106858e-05
was O 0 8.027787430364697e-07
disrupted O 0 1.6456597222713754e-05
in O 0 5.836466598907464e-08
DM B-Disease 1 1.0
striated O 0 0.00012097080616513267
muscle O 0 7.682969226152636e-06
and O 0 3.1966440161568244e-08
in O 0 6.0703393423011676e-09
normal O 0 6.20886339675053e-07
cells O 0 1.1882602279911225e-07
expressing O 0 1.0918767223699888e-08
transcripts O 0 1.6912002820390626e-07
that O 0 8.487178959626362e-09
contain O 0 1.3848269873051322e-06
CUG O 0 0.00021394219947978854
repeats O 0 1.0620346074574627e-05
. O 0 1.5800232233686984e-07

Altered O 0 7.921444193925709e-05
expression O 0 8.627956731288577e-07
of O 0 1.14678524454348e-08
genes O 0 3.8456062156910775e-07
regulated O 0 6.322494527921663e-07
posttranscriptionally O 0 1.6740078763177735e-06
by O 0 2.10561914570917e-08
CUG O 0 5.3110416047275066e-05
- O 0 3.52156966982875e-05
BP O 0 4.434557013155427e-06
therefore O 0 2.310216018486244e-08
may O 0 9.508163145710569e-09
contribute O 0 9.667441069893812e-09
to O 0 8.452514066448202e-08
DM B-Disease 1 1.0
pathogenesis O 0 3.2084719805425266e-06
. O 0 2.9276703727987297e-08
. O 0 1.0586732912543084e-07

Identification O 0 5.5007662922434974e-06
of O 0 4.6341057213794556e-08
a O 0 4.117187657470822e-08
novel O 0 1.6570886884892388e-07
nonsense O 0 6.193143235577736e-06
mutation O 0 8.996750011647237e-07
and O 0 3.277245363975112e-09
a O 0 3.3735720883498743e-09
missense O 0 4.0919405819295207e-07
substitution O 0 7.621103748078895e-09
in O 0 1.1524374787796887e-09
the O 0 8.724216016275932e-09
vasopressin O 0 2.2733786408934975e-07
- O 0 2.2067197278374806e-06
neurophysin O 0 1.3241802889751852e-06
II O 0 3.838000282030407e-07
gene O 0 8.914548743632622e-08
in O 0 2.9047915184321482e-09
two O 0 2.5149390125989157e-08
Spanish O 0 1.9158649138262263e-06
kindreds O 0 8.730835361348e-06
with O 0 1.2496961687702424e-07
familial B-Disease 1 0.9987156391143799
neurohypophyseal I-Disease 1 0.9998557567596436
diabetes I-Disease 1 0.9999970197677612
insipidus I-Disease 1 0.9964073300361633
. O 0 2.999808884851518e-06

Familial B-Disease 1 0.9999911785125732
neurohypophyseal I-Disease 1 0.99998939037323
diabetes I-Disease 1 1.0
insipidus I-Disease 1 0.9999974966049194
( O 0 0.00370713509619236
FNDI B-Disease 1 1.0
) O 0 5.9328570500838396e-08
is O 0 3.83305254203492e-09
an O 0 1.6327794227777304e-08
autosomal B-Disease 1 0.9999988079071045
dominant I-Disease 1 0.9999990463256836
disease I-Disease 1 0.9999805688858032
caused O 0 2.241402171421214e-06
by O 0 3.367658862885037e-08
deficiency O 0 0.0005269497632980347
in O 0 1.6463097551877581e-09
the O 0 2.007211818977339e-08
antidiuretic O 0 8.039476233534515e-05
hormone O 0 3.1526110433333088e-06
arginine O 0 6.263548470997193e-07
vasopressin O 0 1.930013411310938e-07
( O 0 1.1066158656092284e-08
AVP O 0 1.6148474912824895e-07
) O 0 1.1978700253933994e-09
encoded O 0 5.047156914628204e-09
by O 0 2.110781105457704e-09
the O 0 6.667662866277624e-09
AVP O 0 2.3399206838803366e-06
- O 0 2.4632199711049907e-06
neurophysin O 0 4.212021849525627e-06
II O 0 2.389614792264183e-06
( O 0 6.175857691914644e-08
AVP O 0 4.3774707592092454e-06
- O 0 1.4254243978939485e-05
NPII O 0 7.75209173298208e-06
) O 0 6.2732783412400295e-09
gene O 0 1.1219824358477126e-07
on O 0 4.61894522629791e-08
chromosome O 0 1.8194632502854802e-05
20p13 O 0 5.657566816807957e-06
. O 0 2.556537879172538e-07

In O 0 1.9245123894506833e-07
this O 0 4.115513707603213e-09
study O 0 8.573279863810512e-09
, O 0 2.806150867229462e-09
we O 0 7.883746988568419e-09
analyzed O 0 3.193176212334947e-08
two O 0 3.4342768628903286e-08
families O 0 2.193250914217515e-08
with O 0 3.649735091926232e-08
FNDI B-Disease 1 1.0
using O 0 1.0576842157661304e-07
direct O 0 8.17472596281732e-08
automated O 0 9.30512833292596e-05
fluorescent O 0 7.406390523101436e-06
, O 0 1.5006477838142018e-08
solid O 0 3.6668131997430464e-07
phase O 0 7.49640136632479e-08
, O 0 1.4738333220520872e-08
single O 0 4.635971890820656e-06
- O 0 1.7627369288675254e-06
stranded O 0 1.9332556178142113e-07
DNA O 0 4.651568374924864e-08
sequencing O 0 5.063271757421717e-08
of O 0 5.620210075107934e-09
PCR O 0 9.126399163505994e-06
- O 0 1.8627697500051e-05
amplified O 0 1.7174203094327822e-05
AVP O 0 4.287116462364793e-05
- O 0 3.160569758620113e-05
NPII O 0 5.5309777962975204e-05
DNA O 0 6.293484602792887e-06
. O 0 3.046111203275359e-07

In O 0 3.0503119319291727e-07
one O 0 1.3212112293103928e-08
of O 0 4.22451851278538e-10
the O 0 2.291572043233714e-09
families O 0 4.978024215063215e-09
, O 0 6.645314298836524e-10
affected O 0 1.385769454742558e-08
individuals O 0 2.885635064231451e-09
presented O 0 2.246803187944124e-09
a O 0 6.951280884237576e-09
novel O 0 4.741846737488231e-08
nonsense O 0 6.363496254380152e-07
mutation O 0 1.0518219539790152e-07
in O 0 1.9987065336124488e-09
exon O 0 1.1038211056302316e-07
3 O 0 1.6211300746249435e-08
of O 0 9.72795843878771e-10
the O 0 8.38476488240758e-09
gene O 0 2.0347965801192913e-07
, O 0 2.554094047368949e-09
consisting O 0 3.0467801614975087e-09
in O 0 9.7922581154819e-10
a O 0 4.813946130610702e-09
G O 0 2.0943005551998795e-07
to O 0 1.5151950805147862e-08
T O 0 9.483708709012717e-06
transition O 0 1.0066021616239595e-07
at O 0 9.804208644936807e-08
nucleotide O 0 1.4438837752095424e-06
2101 O 0 9.512172596259916e-07
, O 0 4.928124575087622e-09
which O 0 1.149649264675645e-09
produces O 0 4.232827865990885e-09
a O 0 4.191580860180011e-09
stop O 0 9.737043882296348e-08
signal O 0 3.4989511732419487e-07
in O 0 1.1981928338400394e-08
codon O 0 1.159388261839922e-06
82 O 0 3.3998293247350375e-07
( O 0 2.6472010361544562e-08
Glu O 0 4.705745141109219e-06
) O 0 5.1210964358006095e-09
of O 0 6.7354335442360025e-09
NPII O 0 2.6003041057265364e-05
. O 0 2.1026296792570065e-07

The O 0 1.51263736825058e-06
premature O 0 1.3944434613222256e-05
termination O 0 1.2288128345971927e-06
eliminates O 0 2.473999529684079e-07
part O 0 6.880248815122059e-09
of O 0 8.300379272796476e-10
the O 0 2.7300446348021978e-08
C O 0 0.0001697341213002801
- O 0 3.660465154098347e-06
terminal O 0 1.0584734155827391e-07
domain O 0 1.5638830674902238e-08
of O 0 1.7293504406268312e-09
NPII O 0 2.3147783849708503e-06
, O 0 7.272603075314521e-10
including O 0 8.052004063507923e-10
a O 0 4.608242232251314e-09
cysteine O 0 1.7599784740696123e-08
residue O 0 6.169852895254735e-08
in O 0 1.4529270009333572e-09
position O 0 8.738156225263083e-07
85 O 0 3.747398125142354e-08
, O 0 1.7451259326506374e-09
which O 0 2.2105697272678526e-09
could O 0 9.508892162557459e-08
be O 0 5.123031332487926e-09
involved O 0 2.889247951998186e-09
in O 0 3.951452498540675e-10
the O 0 2.0881643081338552e-09
correct O 0 6.394951469701482e-06
folding O 0 1.797492018340563e-06
of O 0 2.7949655923009686e-09
the O 0 4.627375105314968e-08
prohormone O 0 4.801698378287256e-05
. O 0 1.8881513597079902e-07

In O 0 4.535031052910199e-07
the O 0 5.244623224598399e-08
second O 0 2.0334076111794275e-07
family O 0 2.0072883799571173e-08
, O 0 6.446734257536946e-10
a O 0 1.3633999484952142e-09
G279A O 0 4.094625793982232e-08
substitution O 0 7.340643648490186e-09
at O 0 4.314092905133293e-08
position O 0 1.6562338487347006e-06
- O 0 5.090860781820084e-07
1 O 0 1.8402346313450835e-09
of O 0 1.2741577237740387e-10
the O 0 9.989506999374953e-10
signal O 0 1.47824266605312e-07
peptide O 0 2.7649033285115365e-08
was O 0 1.9231652714779557e-08
observed O 0 9.851799376292547e-09
in O 0 5.916104273140377e-10
all O 0 3.3370555208023234e-09
affected O 0 6.634580529407685e-08
individuals O 0 1.5072684433903305e-08
. O 0 3.137638771022466e-08

This O 0 5.622807179861411e-07
missense O 0 2.9954726414871402e-05
mutation O 0 1.091460399038624e-05
, O 0 1.4757545407917405e-08
which O 0 1.4843674733810985e-08
replaces O 0 4.6629575081169605e-06
Ala O 0 4.441786131792469e-06
with O 0 2.0860078109308233e-08
Thr O 0 1.3928604857937898e-05
, O 0 4.2817758227897684e-09
is O 0 5.844124628673342e-10
frequent O 0 1.109513902974868e-07
among O 0 5.719911655432952e-07
FNDI B-Disease 1 1.0
patients O 0 0.00010192079207627103
and O 0 2.0722076499168907e-08
is O 0 1.5055752200510142e-09
thought O 0 6.979778088833655e-09
to O 0 1.0808569594900064e-09
reduce O 0 7.18977304359214e-08
the O 0 2.618875116766617e-09
efficiency O 0 1.8011688140973092e-08
of O 0 3.34817285008171e-10
cleavage O 0 7.44732517432567e-07
by O 0 9.057226080244618e-09
signal O 0 1.809629907256749e-06
peptidases O 0 2.725677177295438e-06
. O 0 2.5365647360331423e-08
. O 0 8.989282918037134e-08

Genetic O 0 6.45514446659945e-05
heterogeneity O 0 1.2481800695240963e-05
of O 0 3.160779726840701e-07
Saethre B-Disease 1 0.9323777556419373
- I-Disease 1 0.9999808073043823
Chotzen I-Disease 1 0.9999842643737793
syndrome I-Disease 1 0.9999996423721313
, O 0 8.91605900221748e-09
due O 0 1.6881216424735612e-08
to O 0 9.40484845557421e-09
TWIST O 0 8.306472409458365e-06
and O 0 9.5842460723361e-07
FGFR O 0 0.0024352530017495155
mutations O 0 4.432982677826658e-05
. O 0 2.993887733282463e-07

Thirty O 0 0.00018650847778189927
- O 0 0.00010319142165826634
two O 0 6.856959089418524e-08
unrelated O 0 4.0977789694807143e-07
patients O 0 2.3346817101810302e-07
with O 0 4.149008636655793e-10
features O 0 3.8641637445380184e-08
of O 0 4.2025021684821695e-08
Saethre B-Disease 1 0.9999370574951172
- I-Disease 1 0.9999995231628418
Chotzen I-Disease 1 0.9999969005584717
syndrome I-Disease 1 0.9999995231628418
, O 0 1.7251828854369933e-09
a O 0 3.6626901511738197e-09
common O 0 8.749154858378461e-07
autosomal B-Disease 1 0.9871785640716553
dominant I-Disease 1 0.8456433415412903
condition I-Disease 0 1.0128609574167058e-05
of O 0 3.5603420212027004e-09
craniosynostosis B-Disease 0 0.05683111026883125
and O 0 1.2060962717441726e-06
limb B-Disease 0 0.39370301365852356
anomalies I-Disease 0 0.010365377180278301
, O 0 5.622304044550219e-08
were O 0 1.8123175493656163e-07
screened O 0 4.005801770290418e-07
for O 0 4.430122935161762e-09
mutations O 0 1.2886421245639212e-06
in O 0 5.202000608051094e-09
TWIST O 0 1.5378756188511034e-06
, O 0 4.11653608978213e-08
FGFR2 O 0 1.1626662853814196e-05
, O 0 2.1067760869186714e-08
and O 0 6.173172550916206e-08
FGFR3 O 0 6.0893937188666314e-05
. O 0 1.9965592912285501e-07

Nine O 0 1.2895646250399295e-05
novel O 0 1.0083024335472146e-06
and O 0 7.915270572311783e-08
three O 0 7.596435125378775e-08
recurrent O 0 0.00012111070827813819
TWIST O 0 2.7473317459225655e-05
mutations O 0 0.05259145796298981
were O 0 2.777722102109692e-06
found O 0 3.9751398617227096e-08
in O 0 2.731027626268201e-09
12 O 0 9.57638164322816e-08
families O 0 1.0337724631881429e-07
. O 0 7.601479268259936e-08

Seven O 0 1.0018402463174425e-05
families O 0 4.091277219231415e-07
were O 0 1.3512425312001142e-07
found O 0 9.533022371499555e-09
to O 0 3.553483063356566e-09
have O 0 2.1844169140194936e-08
the O 0 8.245566007758498e-09
FGFR3 O 0 1.3816023965773638e-05
P250R O 0 4.440014151896321e-07
mutation O 0 2.718986991112615e-07
, O 0 9.930085642650965e-10
and O 0 1.4963340566609418e-09
one O 0 3.2343601130691013e-09
individual O 0 3.5280161014838995e-09
was O 0 2.1632777702507155e-07
found O 0 6.113995532075478e-09
to O 0 2.395170062285956e-09
have O 0 3.247064128686361e-08
an O 0 5.667002422882206e-09
FGFR2 O 0 2.1971838577883318e-05
VV269 O 0 2.972135689560673e-06
- O 0 4.0758582144917455e-06
270 O 0 6.633124485233566e-07
deletion O 0 1.9727280232473277e-05
. O 0 8.780223765825212e-07

To O 0 6.484526124950207e-07
date O 0 3.196760189894121e-07
, O 0 9.288969593512775e-09
our O 0 1.958972717375218e-08
detection O 0 1.1675453492898669e-07
rate O 0 2.437981834191305e-07
for O 0 1.0455782906149125e-09
TWIST O 0 1.4834399735264014e-06
or O 0 2.1159030438866466e-06
FGFR O 0 0.000109170148789417
mutations O 0 6.9130451265664306e-06
is O 0 1.256411685801595e-08
68 O 0 8.984911659126738e-08
% O 0 8.330963474634245e-09
in O 0 6.104975636134213e-09
our O 0 5.577258889388759e-06
Saethre B-Disease 1 0.536320149898529
- I-Disease 1 0.998803973197937
Chotzen I-Disease 1 0.9995357990264893
syndrome I-Disease 1 0.9999982118606567
patients O 0 1.6420539168393589e-06
, O 0 7.592531048317142e-10
including O 0 1.547919459277125e-09
our O 0 1.7775253979834815e-07
five O 0 1.9924962657569267e-07
patients O 0 1.4012815086061892e-07
elsewhere O 0 9.538683087839672e-08
reported O 0 7.082358166599079e-08
with O 0 7.725025952254327e-09
TWIST O 0 3.633275628089905e-05
mutations O 0 0.0001855628506746143
. O 0 3.138878241770726e-07

More O 0 2.9718162863900943e-07
than O 0 3.100847578707544e-08
35 O 0 4.4534996135325855e-08
different O 0 8.899374570603413e-09
TWIST O 0 7.738713634353189e-07
mutations O 0 1.805287138267886e-05
are O 0 2.7531470436770178e-08
now O 0 1.008912153821484e-08
known O 0 3.023646888422604e-09
in O 0 9.898412089981434e-10
the O 0 4.599934655402649e-09
literature O 0 5.049172102644661e-08
. O 0 5.3600835769884725e-08

The O 0 1.898521020393673e-07
most O 0 1.5897320793101244e-08
common O 0 7.800910140076667e-09
phenotypic O 0 1.4122974789643195e-07
features O 0 1.1819665814982727e-06
, O 0 9.73672520387936e-09
present O 0 7.447571448437884e-09
in O 0 9.350630270077431e-10
more O 0 7.918268263296113e-10
than O 0 1.6633951993583196e-09
a O 0 3.358805011899335e-09
third O 0 1.9800455675067496e-07
of O 0 9.087192109902276e-10
our O 0 7.27181884485617e-07
patients O 0 4.0209773288779616e-08
with O 0 1.8299928239429164e-09
TWIST O 0 4.014987098344136e-06
mutations O 0 8.134476229315624e-05
, O 0 4.473025949636167e-09
are O 0 6.6197385351074445e-09
coronal B-Disease 0 1.1954022738791537e-05
synostosis I-Disease 0 7.015478331595659e-05
, O 0 1.9992794975109973e-08
brachycephaly B-Disease 0 6.680727892671712e-06
, O 0 3.6246010637341897e-08
low B-Disease 0 0.10308502614498138
frontal I-Disease 1 1.0
hairline I-Disease 1 1.0
, O 0 4.508614892984042e-06
facial B-Disease 1 0.9897336363792419
asymmetry I-Disease 0 0.000285727612208575
, O 0 1.9196144762645417e-07
ptosis B-Disease 0 0.44596609473228455
, O 0 4.7565123395543196e-08
hypertelorism B-Disease 0 3.717932850122452e-05
, O 0 1.3913205698656839e-08
broad B-Disease 0 8.961384878602985e-07
great I-Disease 0 5.722895934923145e-07
toes I-Disease 1 0.9961621761322021
, O 0 5.198056030053522e-08
and O 0 9.139746737218957e-08
clinodactyly B-Disease 0 3.6146000638836995e-05
. O 0 2.1649844939020113e-07

Significant O 0 7.444119091815082e-06
intra O 0 0.00022813181567471474
- O 0 0.0034229252487421036
and O 0 1.0874128975046915e-07
interfamilial O 0 3.3776798318285728e-06
phenotypic O 0 2.3439674805558752e-06
variability O 0 9.611155746824807e-07
is O 0 7.133438728601504e-09
present O 0 4.38333191965512e-09
for O 0 3.6506382361523038e-09
either O 0 5.059844738752872e-07
TWIST O 0 2.118807788065169e-05
mutations O 0 0.000683808873873204
or O 0 2.623221689646016e-06
FGFR O 0 0.00036254257429391146
mutations O 0 7.860652112867683e-05
. O 0 3.511842123771203e-07

The O 0 2.1645097092459764e-07
overlap O 0 2.742775393471675e-07
in O 0 7.075523278388118e-09
clinical O 0 1.8956552594318055e-07
features O 0 1.7798306828353816e-07
and O 0 1.391023829455662e-07
the O 0 4.5884731569856285e-09
presence O 0 1.958501982812777e-08
, O 0 6.162438337398157e-10
in O 0 1.332425836331197e-10
the O 0 1.602315086168815e-10
same O 0 1.3475672799856397e-09
genes O 0 8.658238570546928e-09
, O 0 2.3354315703549844e-10
of O 0 1.0039164638486753e-10
mutations O 0 2.4191006531282255e-08
for O 0 1.5858903079646325e-10
more O 0 3.8982275740728767e-10
than O 0 2.4475261817258342e-09
one O 0 4.7447421991364536e-08
craniosynostotic B-Disease 0 0.00013612328621093184
condition I-Disease 0 2.5653669126768364e-06
- O 0 1.1782588416053841e-07
such O 0 3.457620634250702e-09
as O 0 5.134136316087279e-08
Saethre B-Disease 0 6.026617029419867e-06
- I-Disease 0 4.415183411765611e-06
Chotzen I-Disease 0 1.672297344157414e-06
, I-Disease 0 3.7797778240644675e-09
Crouzon I-Disease 0 1.9661754890876182e-07
, I-Disease 0 2.448063307625148e-09
and I-Disease 0 1.7291236886762817e-08
Pfeiffer I-Disease 0 1.2933322068420239e-05
syndromes I-Disease 0 3.513026240398176e-05
- O 0 2.537508976274694e-07
support O 0 5.870627539650286e-09
the O 0 9.962335401070277e-10
hypothesis O 0 1.2644557401131351e-08
that O 0 4.753215598896077e-10
TWIST O 0 6.304900779241507e-08
and O 0 1.503028279614682e-08
FGFRs O 0 6.653392006228387e-07
are O 0 3.5762885985946014e-09
components O 0 2.7708688676852944e-08
of O 0 2.5591057051244093e-10
the O 0 1.3325638370531578e-09
same O 0 3.7511367345643976e-09
molecular O 0 4.791505503476401e-08
pathway O 0 2.985482083772695e-08
involved O 0 9.732008976470752e-09
in O 0 3.494774747370144e-10
the O 0 5.652512347076311e-10
modulation O 0 2.532895315709993e-08
of O 0 5.647127210295366e-09
craniofacial O 0 7.48859893064946e-05
and O 0 4.913054567623476e-07
limb O 0 3.9878512325230986e-05
development O 0 1.2833100804243713e-08
in O 0 3.735899589685232e-09
humans O 0 1.0335792666182897e-07
. O 0 7.1508479138060466e-09
. O 0 4.748073934024433e-08

Mutation O 0 4.3874355469597504e-05
analysis O 0 6.604309987778834e-07
of O 0 1.277013410572181e-07
UBE3A O 0 0.026046860963106155
in O 0 7.428407116094604e-05
Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
patients O 1 0.9716890454292297
. O 0 6.078017804611591e-07

Angelman B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 1 0.7768908143043518
AS B-Disease 1 0.9999998807907104
) O 0 4.014157539700136e-08
is O 0 3.183305175014084e-09
caused O 0 3.8081758191310655e-08
by O 0 4.392052055379736e-09
chromosome O 0 7.594001363031566e-05
15q11 O 0 3.7144336602068506e-06
- O 0 2.036380010395078e-06
q13 O 0 5.75530293644988e-07
deletions O 0 5.402009151111997e-07
of O 0 6.425475707061423e-09
maternal O 0 1.6351985323126428e-05
origin O 0 1.1032611979544527e-07
, O 0 4.093561489781905e-09
by O 0 6.70339295183453e-09
paternal O 0 0.0002353663876419887
uniparental B-Disease 0 0.11832618713378906
disomy I-Disease 0 0.008171592839062214
( O 0 2.0158806819381425e-06
UPD B-Disease 1 1.0
) O 0 1.7486186720816477e-08
15 O 0 6.598459556528269e-09
, O 0 3.787368196839225e-10
by O 0 1.1642886654783524e-09
imprinting O 0 0.00013144976401235908
defects O 1 0.9974018335342407
, O 0 6.094423632418966e-09
and O 0 1.7010690633867398e-09
by O 0 1.8092317644047284e-09
mutations O 0 1.9695441721978568e-07
in O 0 1.0099243663574953e-09
the O 0 1.925235082467225e-08
UBE3A O 0 3.130968980258331e-05
gene O 0 4.935614470014116e-06
. O 0 3.9523877148894826e-07

UBE3A O 0 0.0013910459820181131
encodes O 0 1.570651147630997e-05
a O 0 3.628329920957185e-07
ubiquitin O 0 1.806917452995549e-06
- O 0 9.371292435389478e-07
protein O 0 1.8665737400169746e-07
ligase O 0 1.2163229712314205e-07
and O 0 3.5670527864795076e-08
shows O 0 2.297220135005773e-06
brain O 0 0.0005283844657242298
- O 0 7.6174965215614066e-06
specific O 0 9.184429359265778e-07
imprinting O 0 6.538983143400401e-05
. O 0 7.682387490604015e-07

Here O 0 6.6670186242845375e-06
we O 0 4.811901703760668e-07
describe O 0 6.753484171895252e-07
UBE3A O 0 2.6446117772138678e-05
coding O 0 4.712032387033105e-05
- O 0 0.00017199233116116375
region O 0 1.3250720485302736e-06
mutations O 0 2.1531630409299396e-05
detected O 0 7.82943516242085e-07
by O 0 2.5047126595012514e-09
SSCP O 0 2.933780933744856e-07
analysis O 0 1.975994656788771e-08
in O 0 5.521743506875509e-09
13 O 0 2.260911742268945e-07
AS B-Disease 1 0.9999737739562988
individuals O 0 4.413501741851178e-08
or O 0 1.880580242641372e-07
families O 0 8.083926417157272e-08
. O 0 6.751152881179223e-08

Two O 0 2.4080920411506668e-05
identical O 0 0.00039442424895241857
de O 0 0.0001070899743353948
novo O 0 9.663943274063058e-06
5 O 0 3.1892449214865337e-07
- O 0 1.150637899627327e-06
bp O 0 7.291165502465446e-07
duplications O 0 1.0736475815065205e-06
in O 0 8.537347717663124e-09
exon O 0 4.1100997805187944e-07
16 O 0 1.8450262473379553e-07
were O 0 8.383889849028492e-08
found O 0 5.27522239224254e-08
. O 0 5.574168682187519e-08

Among O 0 4.5428313910633733e-07
the O 0 8.786252614356727e-09
other O 0 2.1012849238388753e-09
11 O 0 1.1926932330652562e-08
unique O 0 6.7080483390213885e-09
mutations O 0 1.5137586615310283e-06
, O 0 3.0570368458882058e-09
8 O 0 1.0946647144294275e-08
were O 0 1.4854550478560213e-08
small O 0 1.296634910552541e-09
deletions O 0 7.181405976552924e-07
or O 0 2.1576137498868775e-07
insertions O 0 8.101598723442294e-06
predicted O 0 3.331882180646062e-05
to O 0 9.090129537980829e-08
cause O 0 2.2106856704340316e-05
frameshifts O 0 0.00013255719386506826
, O 0 2.231531937013642e-08
1 O 0 1.1639627928161644e-08
was O 0 9.954423774161114e-08
a O 0 3.474266874192722e-09
mutation O 0 9.699952840946935e-08
to O 0 2.1147019690914703e-09
a O 0 2.3920941671917717e-08
stop O 0 5.669280653819442e-07
codon O 0 5.359071906241297e-07
, O 0 2.9858677752514495e-09
1 O 0 3.672679937949397e-09
was O 0 2.0891294028047014e-08
a O 0 3.5955078914184924e-09
missense O 0 1.8373335706201033e-06
mutation O 0 4.588300726027228e-07
, O 0 2.5230670885889595e-09
and O 0 2.875591542661482e-09
1 O 0 1.0461493005209377e-08
was O 0 3.195766566932434e-07
predicted O 0 1.6459911478250433e-07
to O 0 9.335148654088243e-09
cause O 0 4.374764728254377e-08
insertion O 0 9.604001860452627e-08
of O 0 5.568087324547832e-09
an O 0 2.8097515425429265e-08
isoleucine O 0 0.0055824024602770805
in O 0 4.8655288686916265e-09
the O 0 2.789831254901287e-09
hect O 0 1.2640595059565385e-07
domain O 0 4.739131753694892e-09
of O 0 5.64835234140304e-10
the O 0 2.522547504213435e-09
UBE3A O 0 8.483385727231507e-07
protein O 0 2.566577350648913e-08
, O 0 1.6514896117314493e-09
which O 0 3.3168112700820984e-10
functions O 0 5.918477263833211e-09
in O 0 1.6980219452733536e-09
E2 O 0 1.1818578826705561e-07
binding O 0 4.3590471676679954e-08
and O 0 4.678499809784853e-09
ubiquitin O 0 9.265968969884852e-08
transfer O 0 1.124626365367476e-07
. O 0 7.438176652385664e-08

Eight O 0 1.8729891735347337e-06
of O 0 9.451190052800484e-09
the O 0 9.016857482890828e-09
cases O 0 1.536565719106875e-08
were O 0 3.074704864047817e-07
familial O 0 3.2587082387181e-05
, O 0 1.0677929651592422e-07
and O 0 2.6585382784105605e-07
five O 0 7.122353622435185e-07
were O 0 1.8816722331393976e-06
sporadic O 0 3.427878618822433e-05
. O 0 3.904125094322808e-07

In O 0 2.7959941917288234e-07
two O 0 4.4271605048606943e-08
familial O 0 0.00015242102381307632
cases O 0 5.124187509863987e-07
and O 0 9.74587024415996e-08
one O 0 6.119667261827999e-08
sporadic O 0 7.427670061588287e-05
case O 0 3.72232307199738e-08
, O 0 4.61168925269817e-09
mosaicism O 0 8.256166665887577e-07
for O 0 8.27891177834772e-09
UBE3A O 0 3.222013037884608e-05
mutations O 0 1.0151867172680795e-05
was O 0 1.978731631879782e-07
detected O 0 1.8387483180504205e-07
in O 0 1.5481911308512508e-09
the O 0 5.9292792897736035e-09
mother O 0 6.35265450910083e-07
of O 0 1.1129358545858281e-09
three O 0 3.375659503035422e-07
AS B-Disease 1 1.0
sons O 0 0.0002673331764526665
, O 0 1.6898025201328437e-09
in O 0 4.0766670594827303e-10
the O 0 4.780220663747059e-09
maternal O 0 3.870806722261477e-06
grandfather O 0 1.1412807907618117e-06
of O 0 4.657582652889403e-10
two O 0 7.303748361664475e-08
AS B-Disease 1 0.9999988079071045
first O 0 2.532929670451267e-07
cousins O 0 1.288623025175184e-05
, O 0 7.029465010077729e-09
and O 0 8.145228491684975e-09
in O 0 1.0770374592183884e-09
the O 0 4.172039158589769e-09
mother O 0 2.7173851435691176e-07
of O 0 2.6410856834857555e-10
an O 0 2.6389987084485256e-08
AS B-Disease 1 1.0
daughter O 0 0.000534601102117449
. O 0 8.41094163206435e-08

The O 0 2.333477482352464e-07
frequencies O 0 4.007265488326084e-07
with O 0 1.0072144895900692e-08
which O 0 7.303467164376798e-09
we O 0 1.3503775875278734e-08
detected O 0 2.0420378632479697e-07
mutations O 0 8.015799721761141e-07
were O 0 4.184776969395898e-08
5 O 0 1.2704988172629328e-09
( O 0 8.592690448061546e-10
14 O 0 1.4719820029540642e-08
% O 0 1.860094966943393e-09
) O 0 2.4534094200667766e-10
of O 0 2.4434299028541773e-10
35 O 0 2.5284304427941606e-08
in O 0 1.9702055542580865e-09
sporadic O 0 4.31285188824404e-05
cases O 0 1.6939766567247716e-07
and O 0 8.269067564015131e-08
8 O 0 1.1681044043143629e-07
( O 0 3.4247247260310587e-09
80 O 0 9.2979561827633e-09
% O 0 2.5183508611803518e-09
) O 0 3.499210643465034e-10
of O 0 2.551726330235482e-10
10 O 0 8.28924573426093e-09
in O 0 4.198558389845175e-09
familial O 0 0.0003521564940456301
cases O 0 2.6753986048788647e-07
. O 0 1.6446064066144572e-08
. O 0 6.27928997687377e-08

The O 0 5.813595180370612e-06
hemochromatosis B-Disease 1 0.9999817609786987
845 O 0 2.2519614503835328e-05
G O 0 2.2263753635343164e-05
- O 0 1.6828525986056775e-05
- O 0 1.9280391825304832e-06
> O 0 1.466031278596347e-07
A O 0 7.291541237464116e-08
and O 0 8.884263102970635e-09
187 O 0 5.2275652251410065e-08
C O 0 5.401841917773709e-06
- O 0 1.1161399015691131e-05
- O 0 1.6751922885305248e-05
> O 0 1.6012265859899344e-06
G O 0 4.402531430969248e-06
mutations O 0 5.124048584548291e-06
: O 0 1.7733796653374156e-08
prevalence O 0 3.866121460305294e-06
in O 0 1.529483739659554e-08
non O 0 4.5534274249803275e-05
- O 0 0.0004014190344605595
Caucasian O 0 9.145134390564635e-05
populations O 0 1.896068738460599e-06
. O 0 1.4447390128680127e-07

Hemochromatosis B-Disease 1 0.7153868079185486
, O 0 1.909870434246841e-06
the O 0 8.894539860193618e-07
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
of I-Disease 0 8.919664118423043e-09
iron I-Disease 0 0.0028525786474347115
metabolism I-Disease 0 0.00039260988705791533
, O 0 1.2007162375482494e-08
leads O 0 8.696375175532012e-08
, O 0 4.137393538883316e-09
if O 0 1.6034814365184502e-08
untreated O 0 3.1391493848786922e-06
, O 0 6.64678478923264e-10
to O 0 5.636560107546984e-09
progressive O 0 0.00012076405982952565
iron B-Disease 1 0.9973747730255127
overload I-Disease 0 0.016162605956196785
and O 0 6.109555215516593e-06
premature B-Disease 0 8.345202513737604e-05
death I-Disease 0 8.080302222879254e-07
. O 0 9.728746164228141e-08

The O 0 4.187342710793018e-06
hemochromatosis B-Disease 1 0.9999979734420776
gene O 0 2.555315768404398e-05
, O 0 2.8706500287967174e-08
HFE O 0 2.826667514455039e-05
, O 0 3.443039275907722e-08
recently O 0 1.1780588948795412e-07
has O 0 2.735538551235095e-08
been O 0 3.6312094664481265e-08
identified O 0 4.52818973428748e-08
, O 0 3.932295045139256e-10
and O 0 4.019914956465698e-10
characterization O 0 1.0711174169841797e-08
of O 0 2.8134006235802644e-10
this O 0 4.923255136901616e-10
gene O 0 6.389974060994064e-08
has O 0 2.094867390667332e-08
shown O 0 2.395573339697421e-08
that O 0 7.998369189188281e-10
it O 0 5.790157242557825e-10
contains O 0 7.646711597253386e-10
two O 0 1.3136026488780317e-08
mutations O 0 1.725083961900964e-06
that O 0 3.374447166137884e-09
result O 0 5.8654819667935953e-08
in O 0 3.3011984257313998e-09
amino O 0 1.1056332738235142e-07
acid O 0 3.753786259608205e-08
substitutions O 0 5.765521748912761e-08
- O 0 9.630416286654508e-08
cDNA O 0 2.686756488401443e-07
nucleotides O 0 1.4446052887251426e-07
845 O 0 2.2123492726677796e-07
G O 0 6.318528562587744e-07
- O 0 2.7395963115850464e-06
- O 0 4.1875782699207775e-06
> O 0 2.1818711104515387e-07
A O 0 6.229284110759181e-08
( O 0 6.818937414720949e-09
C282Y O 0 7.782870881101189e-08
) O 0 9.29467169896725e-10
and O 0 1.3854938307744646e-09
187 O 0 2.2586721826201028e-08
C O 0 4.1192956814484205e-06
- O 0 7.3907758633140475e-06
- O 0 1.2584770047396887e-05
> O 0 1.1033765758838854e-06
G O 0 6.100629434513394e-06
( O 0 8.913664828469336e-08
H63D O 0 1.3365731319936458e-05
) O 0 7.055500361730083e-08
. O 0 7.550989522542295e-08

Although O 0 0.00013347293133847415
hemochromatosis B-Disease 1 1.0
is O 0 1.0254419180455443e-07
common O 0 4.8089194848444095e-08
in O 0 3.6832938921094183e-09
Caucasians O 0 5.081082576907647e-07
, O 0 3.1181282000858346e-09
affecting O 0 6.619904979743296e-08
> O 0 1.2098281843009318e-07
= O 0 1.621292994968826e-06
1 O 0 1.9595109534975563e-08
/ O 0 1.1572248581614986e-07
300 O 0 5.609276154672216e-09
individuals O 0 1.523438708517233e-09
of O 0 4.4199333082417525e-10
northern O 0 3.847528162737035e-08
European O 0 9.798792461879202e-07
origin O 0 6.386952122738876e-08
, O 0 1.7621643033649548e-09
it O 0 8.193606348960714e-10
has O 0 3.443483942433545e-09
not O 0 1.3851562563615971e-08
been O 0 6.492208548536382e-09
recognized O 0 1.9122603500676405e-09
in O 0 3.1674718403706947e-10
other O 0 1.700060203724263e-09
populations O 0 1.30216804450356e-07
. O 0 4.903140293777142e-08

The O 0 2.6657232865545666e-07
present O 0 3.131695436309201e-08
study O 0 7.2196453260175986e-09
used O 0 2.3391784509385616e-08
PCR O 0 1.9009428342542378e-06
and O 0 1.9151267238726177e-08
restriction O 0 3.46882593760256e-08
- O 0 7.694663395341195e-08
enzyme O 0 8.842527421393243e-08
digestion O 0 3.7483559367501584e-08
to O 0 2.330004411632558e-09
analyze O 0 3.278384852478666e-08
the O 0 2.1311252762501454e-09
frequency O 0 2.5533939407296202e-08
of O 0 3.9358069581219013e-10
the O 0 3.1412776824168986e-09
845 O 0 3.380491619964232e-08
G O 0 2.3908813773232396e-07
- O 0 1.3626073496197932e-06
- O 0 9.214433589477267e-07
> O 0 9.40479836231134e-08
A O 0 2.9715407023900298e-08
and O 0 8.746508406431985e-09
187 O 0 2.5770455991391827e-08
C O 0 8.531944217793352e-07
- O 0 8.065281349445286e-07
- O 0 1.3473259059537668e-06
> O 0 2.728150718667166e-07
G O 0 8.304613174914266e-07
mutations O 0 6.395949299076165e-07
in O 0 8.849643684527564e-09
HLA O 0 1.6733805523472256e-06
- O 0 8.619567779533099e-07
typed O 0 1.5003795397205977e-06
samples O 0 1.450778057687785e-07
from O 0 1.2522726855479505e-08
non O 0 2.127746711266809e-06
- O 0 4.755569079861743e-06
Caucasian O 0 3.263747430537478e-06
populations O 0 1.2413576655490033e-07
, O 0 1.3571160861758358e-09
comprising O 0 2.7868423124743913e-09
Australian O 0 1.3202337889595128e-08
Aboriginal O 0 1.2083024358844341e-08
, O 0 6.952072806321041e-10
Chinese O 0 5.981458661707961e-10
, O 0 5.70216207584906e-10
and O 0 2.5772899370224422e-09
Pacific O 0 5.249727408340732e-08
Islanders O 0 4.045112973471987e-07
. O 0 3.3376679198227066e-08

Results O 0 9.227890404872596e-05
showed O 0 3.00381111628667e-06
that O 0 4.512134221812403e-09
the O 0 2.500626372636816e-09
845 O 0 8.983283805719111e-08
G O 0 1.1992328836640809e-06
- O 0 9.11109509615926e-06
- O 0 7.216148787847487e-06
> O 0 1.1583135517412302e-07
A O 0 5.50930145948314e-08
mutation O 0 8.885925808499451e-07
was O 0 2.940076626600785e-08
present O 0 1.067242294539028e-09
in O 0 2.8701321874713415e-10
these O 0 6.878106972862952e-10
populations O 0 4.891060889633536e-09
( O 0 4.377931905885646e-10
allele O 0 1.2080350941801044e-08
frequency O 0 1.1158360990748406e-07
0 O 0 2.0818818668999484e-08
. O 0 5.61203417070999e-10
32 O 0 1.8411974167520384e-08
% O 0 4.098764883053718e-09
) O 0 7.870041285329421e-10
, O 0 1.0039820086404916e-09
and O 0 2.3147016747770977e-08
, O 0 3.6825000826468113e-09
furthermore O 0 1.2179580011206781e-08
, O 0 1.870804844372742e-09
it O 0 4.395857011729731e-09
was O 0 1.1567287856451003e-06
always O 0 9.884816876137847e-08
seen O 0 7.974551863298984e-08
in O 0 4.460874447609342e-10
conjunction O 0 1.0198143662876191e-08
with O 0 9.718227111932265e-09
HLA O 0 2.2971455564402277e-06
haplotypes O 0 3.217337791738828e-07
common O 0 3.226105960152381e-08
in O 0 2.7258391099849177e-09
Caucasians O 0 1.569486727248659e-07
, O 0 3.516199553743604e-09
suggesting O 0 2.7179492434470376e-08
that O 0 1.239052638268845e-09
845 O 0 5.993592822051141e-08
G O 0 1.2749073903250974e-06
- O 0 2.0822168153245002e-05
- O 0 2.9693661417695694e-05
> O 0 2.4668656806170475e-07
A O 0 1.956201032271565e-07
may O 0 6.92353523845668e-07
have O 0 2.198138204789757e-08
been O 0 2.83361334396659e-09
introduced O 0 8.951974717064104e-10
into O 0 4.586703239439771e-10
these O 0 9.477070239682917e-10
populations O 0 5.544772196941494e-09
by O 0 2.6744018111202195e-09
Caucasian O 0 1.0610217486828333e-06
admixture O 0 4.7473131417064e-06
. O 0 3.913306159120111e-07

187 O 0 4.928263297188096e-05
C O 0 4.9874135584104806e-05
- O 0 8.424446605204139e-06
- O 0 1.9599540337367216e-06
> O 0 4.196350573693053e-07
G O 0 1.9198100744688418e-06
was O 0 5.423649440672307e-08
present O 0 2.855450986771757e-09
at O 0 5.256557855659594e-09
an O 0 3.1363789343430426e-10
allele O 0 3.899979006405374e-08
frequency O 0 6.52101590503662e-08
of O 0 6.594433443751768e-09
2 O 0 1.7207052849244064e-07
. O 0 1.4132379533293715e-07

68 O 0 0.0003493719268590212
% O 0 1.8624054973770399e-06
in O 0 6.591867940386464e-09
the O 0 1.6651601209005662e-09
two O 0 3.1938509614803934e-09
populations O 0 1.6037292382975465e-08
analyzed O 0 1.9511306348363178e-08
( O 0 1.3817991195708146e-09
Australian O 0 1.9016662022863784e-08
Aboriginal O 0 3.5237338380511574e-08
and O 0 7.9724191692776e-09
Chinese O 0 3.011272786679342e-09
) O 0 4.655063001735016e-09
. O 0 1.7456128986736985e-08

In O 0 1.9677248985772167e-07
the O 0 1.4735016762301711e-08
Australian O 0 1.846067654298622e-08
Aboriginal O 0 2.665603204832223e-08
samples O 0 1.148722716948214e-08
, O 0 9.510208176521928e-10
187 O 0 9.591293981259241e-09
C O 0 2.3527557004854316e-06
- O 0 6.164552360132802e-06
- O 0 1.2215278729854617e-05
> O 0 3.2226930102297047e-07
G O 0 2.1455291516758734e-06
was O 0 1.6108023714878072e-07
found O 0 6.077707670471e-09
to O 0 2.269432197721244e-09
be O 0 1.6123539836598866e-08
associated O 0 1.4982711959987682e-08
with O 0 1.154666939839899e-08
HLA O 0 5.069077360531082e-06
haplotypes O 0 3.1238451470017026e-07
common O 0 5.515999035310415e-08
in O 0 5.882306641780133e-09
Caucasians O 0 4.4007839505866286e-07
, O 0 4.6630783678836e-09
suggesting O 0 3.4820367034171795e-08
that O 0 1.3279587429693152e-09
it O 0 2.872143411991601e-09
was O 0 1.835793739246583e-08
introduced O 0 3.549026406091116e-09
by O 0 1.4402212755726396e-09
recent O 0 1.844216512836283e-08
admixture O 0 1.3730953014601255e-06
. O 0 2.7198143470741343e-07

In O 0 3.1676506750955014e-07
the O 0 1.3731034975705825e-08
Chinese O 0 1.6580102846219802e-09
samples O 0 1.3090855510711208e-08
analyzed O 0 3.6931794511474436e-08
, O 0 1.758997725254119e-09
187 O 0 2.008364496930426e-08
C O 0 1.1755779496525065e-06
- O 0 3.5116686376568396e-06
- O 0 3.5972734622191638e-06
> O 0 3.105781445356115e-07
G O 0 1.617499947315082e-06
was O 0 1.0395976346444513e-07
present O 0 6.209767366982533e-09
in O 0 9.980384296781608e-10
association O 0 3.8991960771284084e-09
with O 0 4.6359749372726355e-10
a O 0 2.237267038296409e-09
wide O 0 3.3075910010893494e-08
variety O 0 1.812444772042454e-08
of O 0 3.506127166374995e-09
HLA O 0 1.917325334943598e-06
haplotypes O 0 5.979474053674494e-07
, O 0 6.345119984985104e-09
showing O 0 2.6895071414401173e-07
this O 0 1.3295072820440623e-09
mutation O 0 4.534014763635241e-08
to O 0 1.5360551719467708e-09
be O 0 4.479224102738044e-09
widespread O 0 1.1192888393907197e-08
and O 0 1.423611877271469e-07
likely O 0 2.817772895014059e-07
to O 0 7.487224173985396e-09
predate O 0 2.595992782516987e-06
the O 0 3.3204716753942876e-09
more O 0 1.8453309991173228e-09
genetically O 0 3.15319503840783e-08
restricted O 0 1.8217820141330776e-08
845 O 0 4.956378418796703e-08
G O 0 1.1091261740148184e-06
- O 0 1.5273784811142832e-05
- O 0 3.453428507782519e-05
> O 0 1.1526807384143467e-06
A O 0 6.521102591250383e-07
mutation O 0 1.5076247109391261e-05
. O 0 3.302013169559359e-07

Genotype O 0 0.007545108441263437
- O 0 0.0015841162530705333
phenotype O 0 0.0002560516004450619
correlations O 0 8.701240585651249e-05
in O 0 2.5923066004907014e-06
attenuated B-Disease 1 0.9998989105224609
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999995231628418
coli I-Disease 1 0.9999998807907104
. O 0 1.6835139831528068e-05

Germ O 0 0.005899063311517239
- O 0 0.001713496632874012
line O 0 6.60162413623766e-06
mutations O 0 1.0890365729210316e-06
of O 0 2.513815600124758e-09
the O 0 1.1941795996506244e-08
tumor B-Disease 0 1.9890990188287105e-06
suppressor O 0 1.7501339470982202e-06
APC O 0 3.970964712607383e-07
are O 0 1.537140192908737e-08
implicated O 0 1.74877573044796e-06
in O 0 3.1026641522657883e-07
attenuated B-Disease 1 0.9999511241912842
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
( O 0 0.00020950539328623563
AAPC B-Disease 1 1.0
) O 0 1.0110431247767337e-07
, O 0 3.8628797938145e-09
a O 0 1.0772105873968485e-08
variant O 0 0.00013094772293698043
of O 0 4.772351985593559e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 1.585839163453784e-05
FAP B-Disease 0 4.5131320803193375e-05
) O 0 3.6350974141896586e-07
. O 0 1.6949009307154483e-07

AAPC B-Disease 1 0.9999990463256836
is O 0 8.973083822638728e-07
recognized O 0 6.348003722678186e-08
by O 0 9.103203191251907e-10
the O 0 1.0553619089748167e-09
occurrence O 0 3.902374956510357e-08
of O 0 2.430639023387471e-09
< O 0 2.400894800302922e-06
100 O 0 1.0186424503899616e-07
colonic B-Disease 0 9.90335684036836e-06
adenomas I-Disease 0 8.302457717945799e-05
and O 0 3.160197437068746e-08
a O 0 3.170545781472356e-08
later O 0 1.6957126547367807e-07
onset O 0 0.004358831327408552
of O 0 0.0001552286121295765
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 1.9739330525680998e-07
age O 0 4.4633642914959637e-07
> O 0 1.9985975541203516e-07
40 O 0 1.811944230212248e-07
years O 0 3.350411859059932e-08
) O 0 2.141610977446362e-08
. O 0 5.603622454941615e-08

The O 0 4.298278497572028e-07
aim O 0 3.700891113567195e-07
of O 0 8.629481018651575e-10
this O 0 5.868194818958727e-10
study O 0 3.1448565973590803e-09
was O 0 1.9362682124324238e-08
to O 0 6.996399459779923e-09
assess O 0 2.2856816030980553e-06
genotype O 0 0.0003901470627170056
- O 0 6.100843893364072e-05
phenotype O 0 1.160766350949416e-05
correlations O 0 5.063830485596554e-06
in O 0 6.896786430843349e-07
AAPC B-Disease 1 0.9999995231628418
families O 0 2.5701567665237235e-06
. O 0 1.8227643749924027e-07

By O 0 7.006390205788193e-07
protein O 0 1.936595253937412e-06
- O 0 1.9951062313339207e-06
truncation O 0 5.41014287591679e-06
test O 0 1.016864916891791e-05
( O 0 2.8132049578744045e-08
PTT O 0 4.254198131548037e-07
) O 0 2.3501607326892326e-09
assay O 0 6.705799648898392e-08
, O 0 1.303667840346634e-09
the O 0 7.54503626243519e-10
entire O 0 8.917180771561561e-09
coding O 0 1.2616075650839775e-07
region O 0 7.45501882448707e-09
of O 0 5.554730009293962e-10
the O 0 7.179739913709682e-09
APC B-Disease 0 1.2643187119465438e-07
gene O 0 8.44800140953339e-08
was O 0 3.104812762444453e-08
screened O 0 9.522214128310225e-08
in O 0 3.889220945296756e-09
affected O 0 7.412259606098814e-08
individuals O 0 8.288897568320408e-09
from O 0 9.389380828395133e-09
11 O 0 1.981869672817993e-06
AAPC B-Disease 1 0.9999998807907104
kindreds O 0 0.000134976944536902
, O 0 3.029651907127118e-08
and O 0 1.3697604828166732e-08
their O 0 4.494991046044561e-08
phenotypic O 0 4.884337158728158e-06
differences O 0 5.0172326155006886e-05
were O 0 1.7140675481641665e-05
examined O 0 1.2130486538808327e-05
. O 0 2.93184569954974e-07

Five O 0 1.0401016879768576e-05
novel O 0 5.0067069423676e-06
germ O 0 9.102971671381965e-05
- O 0 0.00014721360639669
line O 0 3.182773434673436e-05
APC B-Disease 0 2.066048864435288e-06
mutations O 0 3.135361794193159e-06
were O 0 1.2352168710094702e-07
identified O 0 1.531801103737962e-07
in O 0 9.751928153889367e-09
seven O 0 5.370470148591266e-07
kindreds O 0 5.244906424195506e-05
. O 0 4.828026476388914e-07

Mutations O 0 0.0017307739472016692
were O 0 4.2184460653516e-06
located O 0 5.7470110448321066e-08
in O 0 3.827558714419865e-09
three O 0 3.1835967195803505e-09
different O 0 1.2597752840903809e-09
regions O 0 3.128458159196157e-09
of O 0 2.686137978713532e-10
the O 0 1.2565548601628507e-09
APC B-Disease 0 3.071673759791338e-08
gene O 0 2.0831528502185392e-08
( O 0 1.0300201802593278e-09
1 O 0 2.1330732735691527e-09
) O 0 1.584237518947873e-09
at O 0 3.765834222235753e-08
the O 0 7.099856258463433e-09
5 O 0 1.0994166466105071e-08
end O 0 5.436710281969681e-08
spanning O 0 1.1247593789676102e-07
exons O 0 5.170389272279863e-07
4 O 0 7.266454105092635e-08
and O 0 4.819304422198911e-08
5 O 0 2.3931347570282924e-08
, O 0 2.0788097909729686e-09
( O 0 1.0613674383819216e-09
2 O 0 2.6051147905548078e-09
) O 0 5.991301343932776e-10
within O 0 2.061837811595524e-09
exon O 0 4.6466912095866064e-08
9 O 0 8.71254570711244e-08
, O 0 3.054338559849157e-09
and O 0 8.925382211089072e-09
( O 0 1.486639145120705e-09
3 O 0 3.6192588925842983e-09
) O 0 7.435261850652353e-10
at O 0 8.475822710352077e-09
the O 0 2.849612990019068e-09
3 O 0 1.2199551591152158e-08
distal O 0 2.1302592756455851e-07
end O 0 9.21788085861408e-08
of O 0 1.0751942669529058e-09
the O 0 3.082261201825531e-08
gene O 0 1.7732903643263853e-06
. O 0 1.240025397919453e-07

Variability O 0 3.515690332278609e-05
in O 0 8.757296399153347e-08
the O 0 1.1973407154641791e-08
number O 0 7.486926989486165e-08
of O 0 1.5685513972130138e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
was O 0 0.0003573437570594251
most O 0 6.361770221730012e-09
apparent O 0 3.68670463046783e-08
in O 0 1.8329552320395237e-09
individuals O 0 6.721240008999985e-09
with O 0 3.3031635204849863e-09
mutations O 0 4.597393854055554e-06
in O 0 2.4758339822739117e-09
region O 0 2.86474808319781e-08
1 O 0 1.181699627039734e-08
, O 0 1.8127481737906237e-09
and O 0 4.140900955462712e-08
upper O 0 0.08081355690956116
- O 1 0.9977495074272156
gastrointestinal O 0 0.001271700020879507
manifestations O 0 6.360842235153541e-06
were O 0 6.493264095297491e-07
more O 0 2.3232236134873574e-09
severe O 0 4.445878221304156e-05
in O 0 9.908919018641882e-09
them O 0 1.261865065771417e-07
. O 0 6.343597647173738e-08

In O 0 3.707656333062914e-07
individuals O 0 5.6288492089606734e-08
with O 0 5.142062331486841e-09
mutations O 0 1.9319097646075534e-06
in O 0 1.7046741795923026e-09
either O 0 1.8856896133456758e-07
region O 0 8.405777407460846e-08
2 O 0 5.881479836489234e-08
or O 0 4.4013296474076924e-07
region O 0 6.585185019503115e-08
3 O 0 7.321517614400364e-08
, O 0 1.8484027641818557e-09
the O 0 1.2735607013425465e-09
average O 0 5.9462475832106065e-08
number O 0 2.6692650312298838e-09
of O 0 5.604204322828821e-10
adenomas B-Disease 0 1.1899231822098955e-06
tended O 0 1.7068765600924962e-06
to O 0 2.3211210731233223e-08
be O 0 5.952125547992182e-08
lower O 0 6.680789965685108e-08
than O 0 3.0453450872158783e-09
those O 0 3.0310145504586217e-09
in O 0 4.2546560719003423e-10
individuals O 0 1.3590277792019378e-09
with O 0 2.7493516352450342e-09
mutations O 0 2.152171191482921e-06
in O 0 1.1754451856305081e-09
region O 0 6.844489863766512e-09
1 O 0 6.33899910340574e-09
, O 0 1.555264694808045e-09
although O 0 1.732946941501723e-08
age O 0 6.526017841679277e-07
at O 0 6.411131039385509e-07
diagnosis O 0 0.06337446719408035
was O 0 4.4789621256313694e-07
similar O 0 1.3760562467268755e-07
. O 0 1.1465211002814613e-07

In O 0 1.5420434920088155e-06
all O 0 7.075295798131265e-07
AAPC B-Disease 1 0.9999985694885254
kindreds O 0 8.069808245636523e-05
, O 0 1.5985985868383068e-08
a O 0 1.1457270687742493e-08
predominance O 0 6.401820087376109e-07
of O 0 2.5290862737392672e-08
right O 1 0.9504939317703247
- O 1 0.9999996423721313
sided O 1 1.0
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and O 0 0.002139176009222865
rectal B-Disease 1 0.9999977350234985
polyp I-Disease 0 0.20061029493808746
sparing O 0 4.592915502144024e-06
was O 0 4.91520097511966e-07
observed O 0 9.231821991306788e-07
. O 0 8.40278033820141e-08

No O 0 0.00029354015714488924
desmoid B-Disease 1 0.9554409384727478
tumors I-Disease 1 1.0
were O 0 5.7701210607774556e-05
found O 0 8.23786692194517e-08
in O 0 3.75829811716244e-09
these O 0 3.1244166365240744e-08
kindreds O 0 3.607013786677271e-05
. O 0 2.698128582778736e-07

Our O 0 2.7181158657185733e-06
data O 0 2.503520590835251e-07
suggest O 0 1.318447715448201e-07
that O 0 6.459464518826508e-09
, O 0 2.7381470424359122e-09
in O 0 6.927641127418838e-09
AAPC B-Disease 1 1.0
families O 0 2.591829399989365e-07
, O 0 3.769236589512559e-10
the O 0 3.518579039241132e-10
location O 0 1.5363781358246342e-08
of O 0 6.419433318249901e-10
the O 0 1.968583873690477e-08
APC B-Disease 0 3.439493184487219e-06
mutation O 0 1.2707106179732364e-05
may O 0 9.975727834898862e-07
partially O 0 3.999242835561745e-06
predict O 0 2.418450719687826e-07
specific O 0 8.976809340310865e-08
phenotypic O 0 1.0898172149609309e-05
expression O 0 5.585701273957966e-06
. O 0 6.562427188328002e-07

This O 0 3.630004812293919e-07
should O 0 1.0342043310629379e-07
help O 0 5.9287135201202545e-09
in O 0 5.963141647136183e-10
the O 0 4.812897302919339e-10
design O 0 2.1467393196417106e-08
of O 0 2.3479744815091408e-09
tailored O 0 2.1539064618991688e-05
clinical O 0 5.638231959892437e-05
- O 0 0.00010524012759560719
management O 0 3.832579409390746e-08
protocols O 0 2.0220440433149633e-08
in O 0 4.6061662817287186e-10
this O 0 1.9131679573902716e-10
subset O 0 3.38593597604131e-09
of O 0 1.519242842640267e-09
FAP B-Disease 0 1.0995445336448029e-06
patients O 0 4.2654917820073024e-07
. O 0 4.952321663864723e-09
. O 0 6.19649469513206e-08

Wilms B-Disease 0 0.05421200767159462
' I-Disease 0 0.0003896749985869974
tumor I-Disease 0 4.324630936025642e-05
1 O 0 2.923277122590662e-07
and O 0 6.979900746273415e-08
Dax O 0 0.07686009258031845
- O 0 2.732436314545339e-06
1 O 0 2.7469157615200857e-08
modulate O 0 3.1749880236020545e-07
the O 0 1.0811873174532138e-08
orphan O 0 2.848137228284031e-07
nuclear O 0 5.07727520471235e-07
receptor O 0 4.641943291971984e-07
SF O 0 2.6054372938233428e-05
- O 0 8.541470037926047e-07
1 O 0 2.1816896733639624e-08
in O 0 3.162426764902193e-09
sex O 0 1.5944807785217563e-07
- O 0 2.5257872948714066e-07
specific O 0 4.833130873294067e-08
gene O 0 6.541757784361835e-07
expression O 0 4.3618669565148593e-07
. O 0 6.813921515913535e-08

Products O 0 5.652244453813182e-06
of O 0 4.8520934825546647e-08
steroidogenic O 0 6.1778532653988805e-06
factor O 0 1.7349057657156663e-07
1 O 0 2.5879213438884108e-08
( O 0 2.9321187255959558e-08
SF O 0 0.003015954280272126
- O 0 4.789008016814478e-05
1 O 0 9.047595028732758e-08
) O 0 7.2307524412451585e-09
and O 0 4.3625242085454374e-08
Wilms B-Disease 0 0.0008138391422107816
tumor I-Disease 0 8.800143405096605e-06
1 O 0 1.9158136410624138e-08
( O 0 9.270278766848605e-09
WT1 O 0 1.0036801540991291e-06
) O 0 5.257701385374958e-09
genes O 0 3.848541041406861e-08
are O 0 1.4035484996455239e-09
essential O 0 3.713803931049142e-09
for O 0 9.85807213638168e-10
mammalian O 0 1.5287130850083486e-07
gonadogenesis O 0 7.851072609810217e-07
prior O 0 4.799408159783525e-08
to O 0 8.224345648955023e-09
sexual O 0 5.254295842860301e-07
differentiation O 0 2.1074770302220713e-06
. O 0 3.45160088954799e-07

In O 0 8.075910500338068e-07
males O 0 1.6543206129426835e-06
, O 0 1.1189216664320156e-08
SF O 0 3.468201248324476e-05
- O 0 1.8399603050056612e-06
1 O 0 1.0095435598600488e-08
participates O 0 8.861906763968364e-09
in O 0 6.458056311942073e-10
sexual O 0 8.644443383332145e-09
development O 0 9.774716591692822e-10
by O 0 2.9028124348684514e-10
regulating O 0 1.68112350706906e-08
expression O 0 2.555897271605545e-09
of O 0 6.190806756123379e-10
the O 0 5.364233501836679e-09
polypeptide O 0 5.504287855728762e-06
hormone O 0 1.9742033146030735e-06
Mullerian O 0 9.127461453317665e-06
inhibiting O 0 2.3099883037502877e-06
substance O 0 7.726914645900251e-07
( O 0 6.629785787026776e-08
MIS O 0 0.00035489024594426155
) O 0 5.5027165046794835e-08
. O 0 8.95106069265239e-08

Here O 0 1.7107992107412429e-06
, O 0 5.4490744361146426e-08
we O 0 3.523062019894496e-08
show O 0 5.7072487180676035e-08
that O 0 1.4247278024015486e-08
WT1 O 0 1.2555282410176005e-05
- O 0 2.7779367428593105e-06
KTS O 0 7.41987923902343e-06
isoforms O 0 2.5445703499826777e-07
associate O 0 5.118326384945249e-07
and O 0 2.3207446631090534e-08
synergize O 0 5.502266958501423e-06
with O 0 1.2097612511752232e-07
SF O 0 0.13640396296977997
- O 0 7.684668526053429e-05
1 O 0 6.956828002557813e-08
to O 0 1.4603847908745138e-08
promote O 0 9.994773790822364e-07
MIS O 1 0.8078616261482239
expression O 0 2.771305616988684e-06
. O 0 2.574771258423425e-07

In O 0 5.793222612737736e-07
contrast O 0 7.54048926410178e-07
, O 0 3.7550609732761586e-08
WT1 O 0 1.8140955944545567e-05
missense O 0 1.8854982045013458e-05
mutations O 0 1.3272031537781004e-05
, O 0 4.76991068865118e-09
associated O 0 4.673355746831476e-08
with O 0 3.899078748759166e-08
male B-Disease 0 0.030720751732587814
pseudohermaphroditism I-Disease 1 1.0
in O 0 6.718512395309517e-07
Denys B-Disease 1 0.9999781847000122
- I-Disease 1 0.9999985694885254
Drash I-Disease 1 0.999985933303833
syndrome I-Disease 1 0.9999997615814209
, O 0 2.387076314391834e-08
fail O 0 1.9853428057103883e-06
to O 0 2.2220435269559857e-08
synergize O 0 1.5798237654962577e-05
with O 0 5.551938784265076e-07
SF O 1 0.9553800821304321
- O 0 0.0023985111620277166
1 O 0 8.62670617607364e-07
. O 0 2.39961650549958e-07

Additionally O 0 1.5624955267412588e-05
, O 0 5.627732946322794e-08
the O 0 1.328055621030444e-08
X O 0 9.196397877531126e-05
- O 0 5.9147088904865086e-05
linked O 0 3.358842877787538e-05
, O 0 3.290825389967722e-09
candidate O 0 4.6906450279493583e-08
dosage O 0 6.891421548971266e-07
- O 0 4.0007282109399966e-07
sensitive O 0 2.1857208594155964e-06
sex O 0 8.222331757679058e-07
- O 0 3.86899529303264e-07
reversal O 0 1.0213643264478378e-07
gene O 0 1.5445411349901406e-07
, O 0 1.007410421749455e-08
Dax O 0 0.01953461393713951
- O 0 4.755759619001765e-06
1 O 0 3.981399743224756e-08
, O 0 5.5041202706718195e-09
antagonizes O 0 2.413533763956366e-07
synergy O 0 1.1463800575484129e-07
between O 0 5.7224220029183925e-08
SF O 0 0.0031823141034692526
- O 0 8.880030691216234e-06
1 O 0 3.3523615883268576e-08
and O 0 1.1494743823448061e-08
WT1 O 0 1.669989615038503e-06
, O 0 2.9683895341747757e-09
most O 0 9.871657935534017e-10
likely O 0 8.437819332129948e-09
through O 0 1.364260926450811e-09
a O 0 2.1849240194882213e-09
direct O 0 7.1096133424930485e-09
interaction O 0 5.3727450932683496e-08
with O 0 4.172161709448119e-07
SF O 1 0.9702757000923157
- O 0 0.006166302599012852
1 O 0 4.811984695152205e-07
. O 0 1.467111019337608e-07

We O 0 3.907461632479681e-06
propose O 0 6.786676181036455e-07
that O 0 8.60479953956883e-09
WT1 O 0 2.2867784537083935e-06
and O 0 6.257279494548129e-08
Dax O 1 0.9500227570533752
- O 0 1.1649914995359723e-05
1 O 0 3.596154130036666e-08
functionally O 0 1.9362059333616344e-07
oppose O 0 2.035681134771039e-08
each O 0 2.2210466799066353e-09
other O 0 7.158432180354168e-10
in O 0 7.3175743242615e-10
testis O 0 3.228707043945178e-07
development O 0 5.480006670666171e-09
by O 0 6.873506652738115e-09
modulating O 0 4.105400876142085e-06
SF O 0 0.0009889015927910805
- O 0 2.205886266892776e-05
1 O 0 2.2596853455070232e-07
- O 0 3.747795744857285e-06
mediated O 0 5.034554305893835e-06
transactivation O 0 1.1328528671583626e-05
. O 0 4.302358647123583e-08
. O 0 1.040220425352345e-07

A O 0 2.3095212782209273e-06
mouse O 0 1.0377951184636913e-05
model O 0 2.776567271212116e-06
for O 0 5.053984750702512e-07
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
imprinting O 0 0.0006181902717798948
- O 0 0.0005016132490709424
centre O 0 1.2581002010847442e-05
mutations O 0 9.683706593932584e-05
. O 0 2.6046546963698347e-07

Imprinting O 0 0.00013366196071729064
in O 0 3.281379008512886e-07
the O 0 6.142447261936468e-08
15q11 O 0 2.452428361721104e-06
- O 0 3.994805865659146e-06
q13 O 0 1.3429041700874222e-06
region O 0 4.548775223156554e-08
involves O 0 1.2995424292228108e-08
an O 0 2.0850956516937913e-09
imprinting O 0 7.763750886624621e-07
centre O 0 2.9906772169852047e-07
( O 0 5.942661918112435e-09
IC O 0 2.2981527081356035e-07
) O 0 3.0950788598715917e-09
, O 0 5.953618154030949e-10
mapping O 0 1.68057212590611e-08
in O 0 1.5278180942601693e-09
part O 0 3.0832238984146443e-09
to O 0 2.542011934281163e-09
the O 0 5.601898500628977e-09
promoter O 0 1.411550130114847e-07
and O 0 4.576655943111518e-09
first O 0 9.133975353847745e-09
exon O 0 2.5572768436177284e-07
of O 0 1.67714251375628e-08
SNRPN O 0 7.167670992203057e-05
. O 0 1.832582796623683e-07

Deletion O 0 6.26579494564794e-05
of O 0 1.16700654473334e-07
this O 0 3.988529329035373e-08
IC O 0 7.061705218802672e-06
abolishes O 0 2.7435444280854426e-06
local O 0 1.0269764771919654e-07
paternally O 0 2.4674920950928936e-06
derived O 0 5.1105317311339604e-08
gene O 0 8.926374306383877e-08
expression O 0 3.312944940603302e-08
and O 0 4.230101779967299e-08
results O 0 5.190979209146462e-06
in O 0 8.154197530529927e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.2382270142552443e-05
PWS B-Disease 1 0.9999998807907104
) O 0 6.200248208187986e-07
. O 0 1.410735990248213e-07

We O 0 1.3728695194004104e-05
have O 0 5.392045210328433e-08
created O 0 1.1649288644832723e-08
two O 0 6.591339918315953e-09
deletion O 0 1.1208054274902679e-05
mutations O 0 1.0178876436839346e-05
in O 0 3.5040277346354287e-09
mice O 0 5.659681505676417e-07
to O 0 1.3252696717813706e-08
understand O 0 5.614616384264082e-06
PWS B-Disease 1 1.0
and O 0 6.505933924927376e-08
the O 0 2.7518749501354023e-09
mechanism O 0 2.2332818261361354e-08
of O 0 8.400464213131897e-10
this O 0 3.9123522199702165e-09
IC O 0 1.3486574061971623e-05
. O 0 2.51139255169619e-07

Mice O 0 0.27386802434921265
harbouring O 0 0.0021664926316589117
an O 0 1.9345559110206523e-07
intragenic O 0 1.5125670870475005e-05
deletion O 0 9.595297342457343e-06
in O 0 3.7480774039977405e-08
Snrpn O 0 1.066048935172148e-05
are O 0 4.005805109841276e-08
phenotypically O 0 1.9938775039918255e-06
normal O 0 2.103778911077825e-07
, O 0 1.1626042351053911e-09
suggesting O 0 2.5643315026968594e-08
that O 0 9.430171088453676e-10
mutations O 0 1.4747620014077256e-07
of O 0 6.855710443787189e-10
SNRPN O 0 3.089108531639795e-06
are O 0 4.987005031154013e-09
not O 0 2.8786644179490395e-09
sufficient O 0 1.8503932608382456e-08
to O 0 1.0984947351744268e-07
induce O 0 0.002886286936700344
PWS B-Disease 1 1.0
. O 0 1.5929485925880726e-06

Mice O 0 0.002794662257656455
with O 0 5.610413111867274e-08
a O 0 1.4879391052602386e-08
larger O 0 6.5297252049845156e-09
deletion O 0 2.9375493681982334e-07
involving O 0 2.7028436377918297e-08
both O 0 4.866552316684647e-08
Snrpn O 0 4.683243787440006e-06
and O 0 1.3700165446550727e-08
the O 0 4.6081037652356827e-08
putative O 0 0.0001702148438198492
PWS O 1 1.0
- O 0 0.00012453242379706353
IC O 0 7.528571131842909e-06
lack O 0 2.3270527549357212e-07
expression O 0 1.9387959682148903e-08
of O 0 7.492705345057971e-10
the O 0 7.997441819895812e-09
imprinted O 0 1.8018978380496264e-06
genes O 0 5.623214747174643e-07
Zfp127 O 0 3.7270621078278054e-07
( O 0 8.170793819317623e-09
mouse O 0 1.8086139164097403e-07
homologue O 0 3.42775962280939e-07
of O 0 6.333318758322548e-09
ZNF127 O 0 5.941530162090203e-06
) O 0 7.762349873985386e-09
, O 0 4.466631953192746e-09
Ndn O 0 1.5432175359819666e-06
and O 0 5.160690985661631e-09
Ipw O 0 9.795458026928827e-07
, O 0 8.188017375232448e-09
and O 0 4.263602360055074e-09
manifest O 0 4.376200024580612e-08
several O 0 2.980701019339449e-09
phenotypes O 0 1.974135329874116e-06
common O 0 1.8393427581031574e-07
to O 0 1.6802439404273173e-06
PWS B-Disease 1 1.0
infants O 1 0.9812038540840149
. O 0 6.401618293239153e-07

These O 0 1.518431673730447e-07
data O 0 5.6188735442219695e-08
demonstrate O 0 2.0039141901406765e-08
that O 0 7.142992308750706e-10
both O 0 1.9442756293841512e-09
the O 0 1.149252470966644e-09
position O 0 1.800628410819627e-07
of O 0 1.167260871293152e-10
the O 0 5.081008946916654e-10
IC O 0 1.1897842711050544e-07
and O 0 5.002982472745998e-09
its O 0 5.676281111810511e-10
role O 0 1.015499506706874e-08
in O 0 4.834020406185857e-10
the O 0 4.403592213098051e-10
coordinate O 0 3.486436028765638e-08
expression O 0 1.731969057061633e-08
of O 0 8.138997253936964e-10
genes O 0 3.823940986080743e-08
is O 0 4.836473443958766e-10
conserved O 0 3.058389763666014e-09
between O 0 1.6736105834525006e-09
mouse O 0 2.1298163233041123e-07
and O 0 1.5206699899295018e-08
human O 0 5.27419308227195e-09
, O 0 1.3848967528318212e-09
and O 0 4.032126632580457e-09
indicate O 0 5.558661655413744e-07
that O 0 7.478913044423052e-10
the O 0 1.2366820900666653e-09
mouse O 0 2.1197838862008211e-07
is O 0 8.207574064833523e-10
a O 0 1.428939966352516e-09
suitable O 0 6.801949581358713e-08
model O 0 2.36911034789955e-07
system O 0 5.3284335166381425e-08
in O 0 8.661256711839371e-10
which O 0 1.2982336317080012e-09
to O 0 6.403132468690842e-10
investigate O 0 7.327997320061286e-09
the O 0 1.3964189804482885e-09
molecular O 0 2.8955826181231714e-08
mechanisms O 0 4.6692395727632174e-08
of O 0 9.24599397045256e-10
imprinting O 0 2.1933978189281333e-07
in O 0 1.98247196436796e-09
this O 0 7.891234887758003e-10
region O 0 2.8978686117397956e-09
of O 0 3.439438733821021e-10
the O 0 3.330582254434944e-09
genome O 0 2.66339750254474e-08
. O 0 6.4505263352998554e-09
. O 0 4.10281089102682e-08

Mutations O 0 0.00010086046677315608
of O 0 1.6890364662458524e-08
the O 0 7.903620868887629e-09
ATM O 0 1.8534893797550467e-06
gene O 0 4.575881860091613e-07
detected O 0 5.077125138086558e-07
in O 0 4.925446273063017e-09
Japanese O 0 0.00015335401985794306
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9998177886009216
: O 0 1.1419984957683482e-08
possible O 0 1.9512757631900968e-08
preponderance O 0 2.8430707743609673e-07
of O 0 1.6114001244460496e-09
the O 0 4.3842431907137325e-09
two O 0 4.3204664734730613e-08
founder O 0 9.250584867004363e-07
mutations O 0 2.5553194973326754e-06
4612del165 O 0 8.3592897226481e-07
and O 0 6.21463911443243e-08
7883del5 O 0 6.742428922734689e-06
. O 0 2.1976062214434933e-07

The O 0 1.654762286307232e-06
ATM O 0 4.1843530198093504e-05
( O 0 1.2140079661548953e-06
A O 1 0.9999979734420776
- O 1 0.9999992847442627
T O 1 1.0
, O 0 3.303024964651513e-09
mutated O 0 4.966722144672531e-08
) O 0 9.221847729889987e-10
gene O 0 2.3438053275981474e-08
on O 0 7.973939730732127e-09
human O 0 4.458344093904998e-08
chromosome O 0 2.452803346386645e-05
11q22 O 0 9.230448085872922e-06
. O 0 3.372120431777148e-07

3 O 0 2.3167074687080458e-05
has O 0 3.487015760583745e-07
recently O 0 1.2588300535298913e-07
been O 0 2.921991359983167e-08
identified O 0 1.6901772426081152e-08
as O 0 3.7357547610916697e-10
the O 0 3.1749600171160353e-10
gene O 0 3.2189635845725206e-08
responsible O 0 1.174842978457491e-08
for O 0 6.135393304518288e-10
the O 0 6.2882770102135055e-09
human O 0 3.6745177567354403e-07
recessive B-Disease 1 0.9999992847442627
disease I-Disease 1 0.9999982118606567
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.07783754169940948
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.3863885328646575e-07
. O 0 8.316059307844625e-08

In O 0 2.7647720912682416e-07
order O 0 2.7674147418110806e-08
to O 0 3.1021945012810193e-09
define O 0 8.268452234005963e-08
the O 0 1.3734801074249958e-09
types O 0 7.580513994298599e-08
of O 0 1.7648863703811912e-08
disease O 0 0.42176052927970886
- O 0 0.00011039758828701451
causing O 0 2.7342714474798413e-06
ATM O 0 2.5734465452842414e-05
mutations O 0 8.16786450741347e-06
in O 0 7.740439400549803e-09
Japanese O 0 1.2700781553576235e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 1.0036686035164166e-05
as O 0 2.7032855953734725e-09
well O 0 4.753635263199385e-09
as O 0 1.954933104286738e-09
to O 0 1.5173314826810724e-09
look O 0 9.57601642426198e-08
for O 0 1.2299965490569775e-09
possible O 0 2.4946062993080886e-08
mutational O 0 7.658448339498136e-06
hotspots O 0 3.0732496725249803e-06
, O 0 2.3451649511230244e-08
reverse O 0 1.556654751766473e-05
- O 0 1.0420883882034104e-05
transcribed O 0 3.5184730222681537e-06
RNA O 0 3.000144204179378e-07
derived O 0 3.1807577016707e-08
from O 0 3.3541440735973538e-09
ten O 0 8.725584876856374e-08
patients O 0 4.241234918822556e-08
belonging O 0 1.5440926759424656e-08
to O 0 2.214181726856168e-09
eight O 0 6.278559538941408e-08
unrelated O 0 1.4339593690237962e-07
Japanese O 0 1.6539244825253263e-05
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
families O 0 5.747273235101602e-07
was O 0 3.706912821144215e-08
analyzed O 0 2.731409232126225e-08
for O 0 1.6218654197430737e-09
mutations O 0 1.499535500215643e-07
by O 0 6.031385391125355e-10
the O 0 1.3094043627148721e-09
restriction O 0 2.7722220963255495e-08
endonuclease O 0 1.5432984810104244e-06
fingerprinting O 0 1.4932292060620966e-06
method O 0 9.217457090926473e-07
. O 0 2.8037084121024236e-07

As O 0 2.1853124962945003e-06
has O 0 6.558322951377704e-08
been O 0 4.180995105684815e-08
reported O 0 3.111012958356696e-08
by O 0 8.478696078562109e-10
others O 0 5.688140625181859e-09
, O 0 5.557877491568775e-10
mutations O 0 5.035332506508894e-08
that O 0 6.006301567218486e-10
lead O 0 2.020131972813033e-08
to O 0 2.77741274423704e-09
exon O 0 8.86545819867024e-07
skipping O 0 7.329171239689458e-06
or O 0 3.887105322064599e-06
premature O 0 4.046964932058472e-07
protein O 0 5.1484043694927095e-08
truncation O 0 1.1347894997015828e-06
were O 0 2.913710204666131e-06
also O 0 2.9394765732604355e-08
predominant O 0 9.88805709312146e-07
in O 0 1.3427828626788596e-08
our O 0 2.983620674967824e-07
mutants O 0 9.55063228502695e-07
. O 0 2.0718960058729863e-07

Six O 0 1.7668419332039775e-06
different O 0 7.626428555340681e-08
mutations O 0 4.232521405356238e-06
were O 0 2.902769438151154e-07
identified O 0 1.3653632890964218e-07
on O 0 8.767687909028155e-09
12 O 0 1.1999882865154632e-08
of O 0 6.108361594314715e-10
the O 0 4.091672778372413e-09
16 O 0 7.684279523800797e-08
alleles O 0 8.865864060680906e-07
examined O 0 5.745175258198287e-06
. O 0 3.796195926497603e-07

Four O 0 6.205576028150972e-06
were O 0 1.47746476386601e-07
deletions O 0 7.99303677467833e-07
involving O 0 9.455358451759821e-08
a O 0 1.403035980729328e-07
loss O 0 4.880402570961451e-07
of O 0 9.206663209582189e-10
a O 0 9.81118208898124e-09
single O 0 2.0431306779755687e-07
exon O 0 1.6039562922287587e-07
exon O 0 4.920078140457917e-07
7 O 0 9.548312362994693e-08
, O 0 1.999022947174467e-09
exon O 0 9.016465440936372e-08
16 O 0 4.5979721363664794e-08
, O 0 2.034073132151093e-09
exon O 0 1.8416967861867306e-07
33 O 0 1.511832721234896e-07
or O 0 4.6496079875169016e-08
exon O 0 1.970249513760791e-06
35 O 0 1.780482079993817e-06
. O 0 3.93256584629853e-07

The O 0 1.0766671039164066e-06
others O 0 7.046622840789496e-07
were O 0 5.957077320317694e-08
minute O 0 9.014797797135543e-08
deletions O 0 8.293216069432674e-07
, O 0 9.298790182299399e-09
4649delA O 0 1.1410681821644175e-07
in O 0 1.2131325943798288e-09
exon O 0 1.9760349800890253e-07
33 O 0 1.8220985964489955e-07
and O 0 1.2392471049338383e-08
7883del5 O 0 3.3625633477640804e-07
in O 0 9.884662865999871e-09
exon O 0 1.710554556666466e-06
55 O 0 1.1979732335021254e-06
. O 0 2.8937230922565504e-07

The O 0 1.5245739177771611e-06
mutations O 0 1.1635027476586401e-05
4612del165 O 0 1.3375832850215374e-06
and O 0 3.295588157925522e-08
7883del5 O 0 7.529832259933755e-07
were O 0 4.391677634885127e-07
found O 0 7.566873350128844e-09
in O 0 3.456722130756873e-10
more O 0 2.424683231971869e-10
than O 0 1.4664802705510738e-09
two O 0 5.414509729462225e-09
unrelated O 0 3.4142519922397696e-08
families O 0 1.0127024552275543e-08
; O 0 1.5676272502318511e-09
44 O 0 2.773099971875581e-08
% O 0 5.53927526070197e-09
( O 0 1.952611405897642e-09
7 O 0 7.131887524991498e-09
of O 0 5.581759499051486e-10
16 O 0 2.715783331552757e-08
) O 0 2.1005867878454154e-10
of O 0 9.760812991199685e-11
the O 0 1.0681708850768246e-09
mutant O 0 1.0501441494170649e-07
alleles O 0 1.0963053398427292e-07
had O 0 2.6059518631882383e-07
one O 0 1.3770579121441529e-09
of O 0 2.661069142817496e-10
the O 0 3.692600225591036e-09
two O 0 9.84676802318063e-08
mutations O 0 1.287991563003743e-05
. O 0 1.0135454431292601e-07

The O 0 1.2085764637959073e-06
4612del165 O 0 8.531898856745102e-06
mutations O 0 3.162777147736051e-06
in O 0 6.275241215547567e-09
three O 0 5.567322602928471e-09
different O 0 3.185552710505135e-09
families O 0 2.6855669688075068e-08
were O 0 8.26288726329949e-08
all O 0 8.551423458236229e-10
ascribed O 0 1.3830020684224564e-08
to O 0 2.1103261360622128e-09
the O 0 1.3735278692195152e-08
same O 0 1.590931049122446e-07
T O 0 3.8589972973568365e-05
- O 0 2.3502082058257656e-06
- O 0 6.401337486749981e-07
> O 0 2.2158475943001577e-08
A O 0 6.588310785815565e-09
substitution O 0 8.477212709578907e-09
at O 0 1.212087941127038e-08
the O 0 9.17731390881471e-10
splice O 0 4.323172106523998e-06
donor O 0 7.55655094053509e-08
site O 0 8.239375404173188e-08
in O 0 1.0708600228781506e-08
intron O 0 2.71963253908325e-05
33 O 0 6.614057838305598e-06
. O 0 3.605725282795902e-07

Microsatellite O 0 0.0005464408313855529
genotyping O 0 7.334375550271943e-05
around O 0 1.2273862921574619e-06
the O 0 1.600114707400735e-08
ATM O 0 1.2803220670321025e-06
locus O 0 1.8148302842746489e-06
also O 0 1.1177191083788784e-07
indicated O 0 3.3229380846933054e-07
that O 0 5.613907672064045e-10
a O 0 3.1221156771010783e-09
common O 0 5.675745740063576e-08
haplotype O 0 8.494387770952017e-07
was O 0 5.563291551879956e-07
shared O 0 1.9251029215183735e-08
by O 0 5.225626042992815e-10
the O 0 8.147943986180906e-10
mutant O 0 1.0210156631274003e-07
alleles O 0 4.364396488654165e-08
in O 0 1.8281927083307892e-09
both O 0 1.363787447417053e-07
mutations O 0 2.3867336494731717e-05
. O 0 1.6510895761712163e-07

This O 0 1.0277779693979028e-07
suggests O 0 1.6516312939529598e-07
that O 0 1.5181479406933818e-09
these O 0 6.437432809036636e-10
two O 0 4.5154315841955395e-09
founder O 0 1.112066883024454e-07
mutations O 0 2.6375755624030717e-06
may O 0 1.568378849015062e-08
be O 0 1.55733070883457e-09
predominant O 0 7.059619377969284e-08
among O 0 3.5491818373145634e-09
Japanese O 0 6.277925024278375e-08
ATM O 0 2.3184500150819076e-06
mutant O 0 2.4124831270455616e-06
alleles O 0 1.8000943100560107e-06
. O 0 1.2519232939212088e-07

W474C O 0 0.0004785095516126603
amino O 0 2.102181315422058e-05
acid O 0 8.639351563033415e-07
substitution O 0 7.665453694016833e-08
affects O 0 4.7286246029898393e-08
early O 0 7.6027228956832e-09
processing O 0 5.9502611726713894e-09
of O 0 2.906807294866809e-10
the O 0 9.352021379527287e-10
alpha O 0 5.481072484769811e-09
- O 0 1.0224573188111208e-08
subunit O 0 1.3507742480101115e-08
of O 0 1.0151387508372522e-09
beta O 0 5.784500345384913e-08
- O 0 9.817134696277208e-07
hexosaminidase O 0 7.119630254237563e-07
A O 0 4.082756177581359e-08
and O 0 9.150976865157645e-09
is O 0 2.8556197406715e-09
associated O 0 1.9041959120613683e-08
with O 0 2.6874628744621987e-08
subacute O 0 0.0005392678431235254
G B-Disease 0 2.9957984224893153e-05
( I-Disease 0 8.434219722630587e-08
M2 I-Disease 0 6.169764674268663e-05
) I-Disease 0 1.5708538114722614e-07
gangliosidosis I-Disease 0 2.7930655051022768e-05
. O 0 3.485792205992766e-07

Mutations O 0 0.00038012833101674914
in O 0 1.0563314845057903e-07
the O 0 2.76667577736589e-08
HEXA O 0 2.414044865872711e-05
gene O 0 2.9762210829176183e-07
, O 0 1.1638645602829456e-09
encoding O 0 1.3613841609583233e-08
the O 0 1.5955211596363483e-09
alpha O 0 5.689399618091784e-09
- O 0 1.1702425695148122e-08
subunit O 0 2.8967647835997923e-08
of O 0 2.931809683914821e-09
beta O 0 1.6320048246143415e-07
- O 0 7.934836503409315e-06
hexosaminidase O 0 2.871723381758784e-06
A O 0 1.0608502520881302e-07
( O 0 5.327353225226261e-09
Hex O 0 1.0869463551443914e-07
A O 0 1.7477683300626268e-08
) O 0 7.686485337110582e-10
, O 0 3.5099456674458906e-10
that O 0 3.674058557390225e-10
abolish O 0 1.1247121278756822e-07
Hex O 0 2.4384814878430916e-07
A O 0 1.4396178471542953e-08
enzyme O 0 5.078747449260845e-07
activity O 0 1.512813355475373e-06
cause O 0 0.00028865100466646254
Tay B-Disease 1 1.0
- I-Disease 1 1.0
Sachs I-Disease 1 1.0
disease I-Disease 1 0.9795396327972412
( O 0 2.7127752488809165e-08
TSD B-Disease 0 6.163118086988106e-06
) O 0 8.353684854967014e-09
, O 0 1.5020988897163079e-09
the O 0 7.309124416821078e-09
fatal O 0 3.7125053495401517e-05
infantile B-Disease 0 1.622792478883639e-05
form I-Disease 0 8.742126311744869e-08
of I-Disease 0 1.313542519199018e-08
G I-Disease 0 6.887945346534252e-06
( I-Disease 0 2.8097515425429265e-08
M2 I-Disease 0 1.5509898730670102e-05
) I-Disease 0 1.8628865561254315e-08
gangliosidosis I-Disease 0 1.2051017392877839e-06
, I-Disease 0 4.4755861239309525e-09
Type I-Disease 0 1.335508045485767e-06
1 I-Disease 0 1.461463767782334e-07
. O 0 1.777276281700324e-07

Less O 0 3.986125739174895e-05
severe O 0 0.118975430727005
, O 0 1.5786662288519437e-07
subacute O 0 0.0008872095495462418
( O 0 2.940899150871701e-07
juvenile O 0 0.00028402847237885
- O 0 0.3162249028682709
onset O 1 0.9950140118598938
) O 0 7.39881329536729e-08
and O 0 1.5427466451001237e-06
chronic O 1 0.997825026512146
( O 0 4.362798478041441e-08
adult O 0 0.001673289341852069
- O 1 0.9869872331619263
onset O 1 0.9511358141899109
) O 0 1.1599824212282783e-08
variants O 0 1.0235811487291357e-06
are O 0 8.916435945138801e-08
characterized O 0 3.537741477543932e-08
by O 0 6.003083030670098e-10
a O 0 1.7187258283257734e-09
broad O 0 4.872905279285078e-08
spectrum O 0 2.19084270725034e-08
of O 0 1.1296257262927156e-09
clinical O 0 7.476444352505496e-07
manifestations O 0 3.3714513847371563e-07
and O 0 6.350595072035503e-08
are O 0 3.43299291216681e-08
associated O 0 4.483688798018193e-08
with O 0 9.338194217889395e-09
residual O 0 2.728719664446544e-05
levels O 0 3.893471330229659e-06
of O 0 1.7009879060836397e-09
Hex O 0 3.2954474704638415e-07
A O 0 2.870710069657889e-08
enzyme O 0 3.8439122818090254e-07
activity O 0 4.249251333021675e-07
. O 0 1.5727020752365206e-07

We O 0 1.2188083928776905e-05
identified O 0 1.9183423773938557e-06
a O 0 4.8453056677999484e-08
1422 O 0 3.1823526569496607e-06
G O 0 5.096678705740487e-06
- O 0 6.648769613093464e-06
- O 0 1.9510844140313566e-05
> O 0 1.9450558284006547e-06
C O 0 1.9685106963152066e-05
( O 0 2.566802592696149e-08
amino O 0 1.4632237821388117e-07
acid O 0 7.296076631746473e-08
W474C O 0 4.0302218451415683e-08
) O 0 6.735173530003635e-10
substitution O 0 1.4376578816310825e-09
in O 0 4.857440560890325e-10
the O 0 9.910823273173719e-10
first O 0 3.6280642934372054e-09
position O 0 7.875995322592644e-08
of O 0 3.4028582729384027e-10
exon O 0 9.629755481910252e-08
13 O 0 1.497045687415266e-08
of O 0 1.4985162000158425e-09
HEXA O 0 1.6906946257222444e-05
of O 0 6.400401098005659e-09
a O 0 3.946424698142437e-08
non O 0 8.404408617934678e-06
- O 0 6.281401965679834e-06
Jewish O 0 4.4528289322443015e-07
proband O 0 4.578300831781235e-06
who O 0 8.896900283161813e-08
manifested O 0 1.4201620501808065e-07
a O 0 2.3988013353459792e-08
subacute O 0 6.457449671870563e-06
variant O 0 3.0396131478482857e-06
of O 0 2.8329015577810424e-08
G B-Disease 0 1.0711586583056487e-05
( I-Disease 0 5.027242622190897e-08
M2 I-Disease 0 6.143346399767324e-05
) I-Disease 0 1.3743238014285453e-07
gangliosidosis I-Disease 0 1.4843843928247225e-05
. O 0 2.386692017353198e-07

On O 0 7.499260163967847e-07
the O 0 3.239257750919933e-08
second O 0 4.827446105082345e-07
maternally O 0 1.7334503354504704e-05
inherited O 0 2.1395178464445053e-06
allele O 0 3.334528457799024e-07
, O 0 3.310429708136553e-09
we O 0 6.6870344817004934e-09
identified O 0 1.3056642877984359e-08
the O 0 2.5392596914031174e-09
common O 0 4.528467798081692e-06
infantile O 1 0.9998397827148438
disease O 1 0.9997873902320862
- O 0 0.0372522808611393
causing O 0 8.245154458563775e-05
4 O 0 4.0853237237570283e-07
- O 0 2.1169998944969848e-05
bp O 0 4.536598680715542e-06
insertion O 0 8.227297030316549e-07
, O 0 3.491580358172541e-08
+ O 0 3.06555790530183e-07
TATC O 0 5.6396665968350135e-06
1278 O 0 1.3385696320256102e-06
, O 0 6.690798137753973e-09
in O 0 5.455540019738692e-09
exon O 0 2.4335083708137972e-06
11 O 0 1.2534468396552256e-06
. O 0 3.775875256906147e-07

Pulse O 0 0.0015525366179645061
- O 0 0.00011698291200445965
chase O 0 4.156833256274695e-06
analysis O 0 1.1643817998674422e-07
using O 0 9.64922577395555e-08
proband O 0 4.238980636728229e-06
fibroblasts O 0 3.72316833363584e-07
revealed O 0 2.157996590312905e-07
that O 0 2.3165642737410508e-09
the O 0 4.98781327351594e-09
W474C O 0 4.1068162204283e-07
- O 0 1.2443231867109716e-07
containing O 0 4.959924737590882e-08
alpha O 0 2.396432563500639e-08
- O 0 5.09005460003209e-08
subunit O 0 5.826111504347864e-08
precursor O 0 8.425311648352363e-08
was O 0 7.491912157320257e-08
normally O 0 1.139831073970754e-08
synthesized O 0 3.886174937406395e-08
, O 0 1.2187173492606007e-09
but O 0 9.233657172202925e-10
not O 0 1.3541736620936717e-09
phosphorylated O 0 2.7604665220337665e-08
or O 0 2.628624962142112e-08
secreted O 0 3.681251925513607e-08
, O 0 1.0592984267532302e-09
and O 0 1.729370313618972e-09
the O 0 3.19559378958445e-09
mature O 0 4.130662034640409e-08
lysosomal O 0 2.460493533362751e-07
alpha O 0 2.546905264466659e-08
- O 0 4.0926657618456375e-08
subunit O 0 8.610581403445394e-08
was O 0 1.8275075319706957e-07
not O 0 3.258722358623345e-08
detected O 0 2.597946831883746e-06
. O 0 1.0619596224614725e-07

When O 0 1.4094183597990195e-06
the O 0 6.374939687248116e-08
W474C O 0 1.1907688985957066e-06
- O 0 1.8923947209259495e-07
containing O 0 2.4234372730802534e-08
alpha O 0 4.4299056867203035e-08
- O 0 5.2831769181693744e-08
subunit O 0 9.017032454039509e-08
was O 0 1.5168497213835508e-07
transiently O 0 1.2369396245048847e-06
co O 0 4.7500302002845274e-07
- O 0 1.8629883413723292e-07
expressed O 0 5.077291476140999e-09
with O 0 9.032121162100282e-10
the O 0 1.4187042651769843e-09
beta O 0 1.1166446434174304e-08
- O 0 1.5963225408199833e-08
subunit O 0 2.064861170936183e-08
to O 0 4.474553616518051e-09
produce O 0 3.4745998078733464e-08
Hex O 0 5.795145625597797e-07
A O 0 3.0400482131653916e-08
( O 0 2.973432833286438e-09
alphabeta O 0 1.297495941798843e-07
) O 0 1.3764118733661235e-09
in O 0 3.442059082203741e-09
COS O 0 4.9294892960460857e-05
- O 0 2.0614356799342204e-06
7 O 0 1.4944188819754345e-07
cells O 0 4.059337399553442e-08
, O 0 6.545395891954797e-10
the O 0 6.461506329991096e-10
mature O 0 2.37097541599951e-09
alpha O 0 1.868009302796736e-09
- O 0 5.6440905282784115e-09
subunit O 0 9.146143398197637e-09
was O 0 5.401597746867992e-08
present O 0 4.6853134705315824e-09
, O 0 1.1791143617045918e-09
but O 0 8.279728569426936e-10
its O 0 3.9061018308750306e-10
level O 0 4.8804118080170156e-08
was O 0 7.208008412362688e-08
much O 0 1.3902428097622987e-09
lower O 0 4.0338822060448365e-08
than O 0 1.5955211596363483e-09
that O 0 6.83651468769142e-10
from O 0 1.2973078167277663e-09
normal O 0 2.5458222197016767e-08
alpha O 0 6.07196071200633e-09
- O 0 2.3307968888275354e-08
subunit O 0 5.172953621013221e-08
transfections O 0 2.8678377361757157e-07
, O 0 3.0829416797217846e-09
although O 0 2.741026294827975e-09
higher O 0 6.367913307769868e-09
than O 0 1.3731552561679905e-09
in O 0 6.42892905577952e-10
those O 0 1.7537491459052035e-08
cells O 0 1.1673354727292917e-08
transfected O 0 4.518009788512245e-08
with O 0 5.311401318763842e-10
an O 0 3.510876589452039e-10
alpha O 0 7.956407976905666e-09
- O 0 6.294135346252006e-08
subunit O 0 1.5774682537994522e-07
associated O 0 3.0564441999558767e-07
with O 0 1.5703086830853863e-07
infantile O 0 0.10407193750143051
TSD B-Disease 0 0.0010565317934378982
. O 0 1.0205886837866274e-06

Furthermore O 0 7.854773684812244e-06
, O 0 2.4392647901549935e-08
the O 0 1.235083813000415e-09
precursor O 0 8.490935066163274e-09
level O 0 1.4752451704680425e-08
of O 0 3.4583447217073626e-10
the O 0 1.6455656837166543e-09
W474C O 0 6.352315295998778e-08
alpha O 0 1.1064301475016691e-08
- O 0 1.1726176474269323e-08
subunit O 0 1.7616812897358614e-08
was O 0 1.4821579519264105e-08
found O 0 4.1004226680740885e-09
to O 0 2.442746005471008e-09
accumulate O 0 1.5880175396887353e-07
in O 0 7.3930644939324e-10
comparison O 0 1.6202028163547766e-08
to O 0 4.261586195042355e-09
the O 0 4.318322144314379e-09
normal O 0 1.3872186066521408e-08
alpha O 0 1.1750512562969107e-08
- O 0 2.787162678430377e-08
subunit O 0 2.192132626532839e-07
precursor O 0 5.394862796492816e-07
levels O 0 1.4080816299610888e-06
. O 0 1.4544048099196516e-07

We O 0 8.066873306233902e-06
conclude O 0 5.453596259030746e-07
that O 0 4.39929603857081e-09
the O 0 5.914336131951359e-09
1422 O 0 7.733055440439784e-07
G O 0 1.0690753242670326e-06
- O 0 6.348769602482207e-06
- O 0 1.7610180293559097e-05
> O 0 8.531831099389819e-07
C O 0 2.225980642833747e-05
mutation O 0 1.2401949334162055e-06
is O 0 1.61896629435887e-09
the O 0 1.2679641780977136e-09
cause O 0 9.005789003424525e-09
of O 0 7.49533601851482e-10
Hex B-Disease 0 1.6859721654327586e-05
A I-Disease 0 3.8088284782133996e-05
enzyme I-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 7.68684138563458e-09
the O 0 5.0074334012606414e-08
proband O 0 2.9878010536776856e-05
. O 0 2.7387162049308245e-07

The O 0 1.1234861858611112e-06
resulting O 0 1.3756878161075292e-06
W474C O 0 2.6046625407616375e-06
substitution O 0 4.402706395012501e-07
clearly O 0 2.1013987350215757e-07
interferes O 0 2.2087380102675525e-07
with O 0 2.279931576865124e-09
alpha O 0 1.2294577800275874e-08
- O 0 1.7091679183067754e-08
subunit O 0 3.1825418744801937e-08
processing O 0 7.074122265748883e-08
, O 0 5.027835037196837e-09
but O 0 2.736773918599056e-09
because O 0 1.2250493952592478e-09
the O 0 9.752574303689698e-10
base O 0 2.6394719299105418e-08
substitution O 0 1.8861333828112947e-08
falls O 0 1.6569763374718605e-06
at O 0 6.547736575157614e-08
the O 0 1.7373810168308523e-09
first O 0 1.8752928099274868e-08
position O 0 1.2572847651881602e-07
of O 0 5.197058894346185e-10
exon O 0 9.737025408185218e-08
13 O 0 3.853837426959217e-08
, O 0 1.6233479005478557e-09
aberrant O 0 1.039230852484252e-07
splicing O 0 1.3116881518726586e-06
may O 0 7.170647791099327e-07
also O 0 1.74940595343287e-08
contribute O 0 1.4961178962380473e-08
to O 0 1.1045662162700864e-08
Hex B-Disease 0 4.70259583380539e-05
A I-Disease 0 1.1666469617921393e-05
deficiency I-Disease 0 3.771549017983489e-05
in O 0 8.21426093811084e-10
this O 0 1.149600969974074e-09
proband O 0 1.391277464790619e-06
. O 0 6.571781785424946e-09
. O 0 2.796700115936801e-08

Two O 0 6.043953362677712e-06
frequent O 0 7.141356763895601e-05
missense O 0 0.0136493481695652
mutations O 0 0.3501577079296112
in O 0 1.393817274220055e-05
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 3.1849062906985637e-06

Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 7.24781193639501e-06
an O 0 3.026333433808759e-05
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 0.0018102902686223388
by O 0 5.562825222682477e-08
early O 0 1.278902345802635e-05
childhood O 1 0.9998748302459717
deafness B-Disease 1 1.0
and O 0 0.12480317801237106
goiter B-Disease 1 1.0
. O 0 4.2908673094643746e-06

A O 0 6.501828920590924e-06
century O 0 1.1048369970012573e-06
after O 0 2.418930122871643e-08
its O 0 2.3594672882154555e-09
recognition O 0 4.935423625340718e-09
as O 0 1.0948359552287457e-08
a O 0 2.1325907084701612e-07
syndrome O 0 0.31448793411254883
by O 0 1.5693384369797059e-09
Vaughan O 0 4.1344225110151456e-07
Pendred O 0 3.255337333030184e-07
, O 0 1.4908529966106698e-09
the O 0 6.03016925282418e-09
disease O 0 2.142732000720571e-06
gene O 0 1.198458363660393e-07
( O 0 1.1086948248362205e-08
PDS O 0 2.4026285245781764e-06
) O 0 6.6381726782083206e-09
was O 0 2.3333944554337904e-08
mapped O 0 1.1781245348174707e-06
to O 0 1.0140134065750317e-07
chromosome O 0 0.0006177409086376429
7q22 O 0 4.675204399973154e-05
- O 0 0.00010076876787934452
q31 O 0 4.206509765936062e-05
. O 0 8.404164191233576e-07

1 O 0 3.734530309884576e-06
and O 0 1.0199683941891635e-07
, O 0 1.1237295538535363e-08
recently O 0 4.8013493625376213e-08
, O 0 8.882716784341937e-10
found O 0 6.572681288119497e-10
to O 0 7.411871116858038e-10
encode O 0 1.4641004497661925e-07
a O 0 4.2557235957474404e-08
putative O 0 5.8185319176118355e-06
sulfate O 0 4.4870989768242e-06
transporter O 0 2.5401690436410718e-05
. O 0 3.6250025914341677e-07

We O 0 1.0675434168661013e-05
performed O 0 1.3047974789515138e-06
mutation O 0 1.6506943723015866e-07
analysis O 0 9.379518495222783e-09
of O 0 1.2731332654780658e-09
the O 0 1.1562823587496496e-08
PDS B-Disease 0 5.63784351470531e-06
gene O 0 2.969932211271953e-07
in O 0 1.2964007645166475e-08
patients O 0 2.8372284077704535e-07
from O 0 4.0125707201355e-09
14 O 0 3.230120526609426e-08
Pendred B-Disease 0 9.600007615517825e-07
families O 0 1.1525347787255669e-08
originating O 0 8.028238518420494e-09
from O 0 3.8606771113336436e-09
seven O 0 8.378226112881748e-09
countries O 0 2.651226793659589e-09
and O 0 2.6412092068994752e-08
identified O 0 2.883541014853108e-07
all O 0 1.1411558809015787e-08
mutations O 0 3.4130748645111453e-06
. O 0 1.0727411847710755e-07

The O 0 3.7559607335424516e-07
mutations O 0 3.172686092511867e-06
include O 0 2.7329102536555183e-08
three O 0 5.34017488007521e-08
single O 0 2.3386110115097836e-06
base O 0 2.9258626454975456e-07
deletions O 0 2.6093091491929954e-06
, O 0 1.196185728247201e-08
one O 0 9.340937801027849e-09
splice O 0 8.251006511272863e-05
site O 0 1.5517180145252496e-06
mutation O 0 2.4431353722320637e-06
and O 0 7.378997679552413e-08
10 O 0 9.905804887466729e-08
missense O 0 5.5531749239889905e-05
mutations O 0 0.00011380722571630031
. O 0 2.765384010672278e-07

One O 0 6.037967978045344e-06
missense O 0 0.00013460434274747968
mutation O 0 1.2974198398296721e-05
( O 0 9.416663004913062e-08
L236P O 0 7.689908443353488e-07
) O 0 1.7342433267231172e-08
was O 0 2.0758280072641355e-07
found O 0 1.7618090097926142e-08
in O 0 4.3758449641551067e-10
a O 0 3.363677336665205e-09
homozygous O 0 1.3292780067786225e-06
state O 0 6.427286480814587e-10
in O 0 3.1887484319703674e-10
two O 0 4.919953333626381e-09
consanguineous O 0 5.840209632879123e-05
families O 0 2.0427020785973582e-07
and O 0 1.15805240952227e-08
in O 0 1.1278001865733245e-09
a O 0 5.3556763468520785e-09
heterozygous O 0 4.173450633970788e-07
state O 0 8.534086770595195e-10
in O 0 3.023472028296226e-10
five O 0 2.444232816145586e-09
additional O 0 2.3200366072728684e-08
non O 0 1.086989686882589e-05
- O 0 6.0304962971713394e-05
consanguineous O 0 0.0005378749337978661
families O 0 5.666691436090332e-07
. O 0 8.938811646430622e-08

Another O 0 7.523325166403083e-06
missense O 0 0.00019350077491253614
mutation O 0 1.7649657820584252e-05
( O 0 6.746596170614794e-08
T416P O 0 6.924103104211099e-07
) O 0 1.749299194386822e-08
was O 0 1.4814746407409984e-07
found O 0 2.0407114220688527e-08
in O 0 7.880330277210135e-10
a O 0 4.009303999907843e-09
homozygous O 0 1.1132208328490378e-06
state O 0 3.2459399057493954e-10
in O 0 3.237864421024028e-10
one O 0 2.21830753766028e-09
family O 0 5.41372457973921e-09
and O 0 4.340891202048169e-09
in O 0 9.523730692961863e-10
a O 0 4.484250748504337e-09
heterozygous O 0 4.016490038338816e-07
state O 0 1.1347047745857708e-09
in O 0 1.3731710213349402e-09
four O 0 3.313058982712391e-08
families O 0 5.960542637239996e-08
. O 0 6.505275962354062e-08

Pendred B-Disease 0 0.013603964820504189
patients O 1 0.9676368236541748
in O 0 1.2465966392483097e-07
three O 0 1.6452565887448145e-07
non O 0 1.0054284757643472e-05
- O 0 9.910546395985875e-06
consanguineous O 0 0.0001726613991195336
families O 0 1.653014862768032e-07
were O 0 9.352189778155662e-08
shown O 0 8.718360255954849e-09
to O 0 1.8791446176891213e-09
be O 0 5.995716811924012e-09
compound O 0 2.0305467529624366e-08
heterozygotes O 0 9.425576052990436e-08
for O 0 2.3777186886064783e-09
L236P O 0 5.351288905330875e-07
and O 0 6.744100033984068e-08
T416P O 0 4.596000053425087e-06
. O 0 1.1767080820845877e-07

In O 0 1.0022893093264429e-06
total O 0 1.4868162168113486e-07
, O 0 4.213921656059938e-09
one O 0 1.923208259313469e-09
or O 0 6.657827178457865e-09
both O 0 1.052971154713589e-09
of O 0 1.5304393863324606e-10
these O 0 6.017323972429267e-09
mutations O 0 1.25401845707529e-06
were O 0 8.864815868037113e-07
found O 0 2.3529249659759444e-08
in O 0 1.174206065712724e-09
nine O 0 3.921588387356678e-08
of O 0 5.309355177729458e-10
the O 0 2.3661607784219996e-08
14 O 0 2.030202637115508e-07
families O 0 1.722047393570847e-08
analyzed O 0 4.0574377635493875e-07
. O 0 8.982957666603397e-08

The O 0 9.055052885287296e-08
identification O 0 7.733019913302996e-08
of O 0 1.6087252641128202e-09
two O 0 6.40765618342698e-09
frequent O 0 2.7741004942072323e-06
PDS B-Disease 0 0.011437052860856056
mutations O 0 1.3781898815068416e-05
will O 0 1.8131907086882393e-09
facilitate O 0 1.3977706991852301e-08
the O 0 1.8087565223368074e-08
molecular O 0 3.2345215004170313e-05
diagnosis O 1 0.998007595539093
of O 0 7.974428626766894e-06
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 1.35500704345759e-06

Insertional O 0 0.0005122420261614025
mutation O 0 1.4422391359403264e-05
by O 0 2.528903131349125e-08
transposable O 0 2.3108652840164723e-06
element O 0 2.567185219959356e-07
, O 0 1.2724541420539026e-08
L1 O 0 5.7249440033046994e-06
, O 0 1.7500934035297178e-08
in O 0 2.5460056285453447e-09
the O 0 2.5097111944205608e-08
DMD B-Disease 1 0.9999998807907104
gene O 0 7.242885658342857e-06
results O 0 1.5483860806853045e-06
in O 0 1.0009007667122205e-07
X B-Disease 1 0.9999979734420776
- I-Disease 1 0.9999995231628418
linked I-Disease 1 0.9999996423721313
dilated I-Disease 1 0.999998927116394
cardiomyopathy I-Disease 1 1.0
. O 0 2.444985966576496e-06

X B-Disease 1 0.9999858140945435
- I-Disease 1 0.9999946355819702
linked I-Disease 1 0.9999825954437256
dilated I-Disease 1 0.9999995231628418
cardiomyopathy I-Disease 1 1.0
( O 0 3.3704402540024603e-06
XLDCM B-Disease 0 0.00013649332686327398
) O 0 9.806655043576029e-09
is O 0 1.0352869672658471e-09
a O 0 6.213439984747993e-09
clinical O 0 1.0246730198559817e-05
phenotype O 0 2.2863880531076575e-06
of O 0 4.016376120574705e-09
dystrophinopathy B-Disease 0 6.627195944020059e-06
which O 0 8.718360255954849e-09
is O 0 1.2610157362757946e-09
characterized O 0 1.9509037940679264e-08
by O 0 2.5817079585266356e-09
preferential O 0 5.6664503063075244e-05
myocardial B-Disease 0 0.023402877151966095
involvement I-Disease 0 4.669208806262759e-07
without O 0 6.681975150968356e-08
any O 0 6.888350334577353e-09
overt O 0 7.174305210355669e-06
clinical O 0 0.0020161429420113564
signs O 0 0.00011281888146186247
of O 0 6.679146622445842e-07
skeletal B-Disease 1 1.0
myopathy I-Disease 1 1.0
. O 0 5.961048373137601e-06

To O 0 7.873927643231582e-07
date O 0 4.61301112864021e-07
, O 0 3.613092935950135e-09
several O 0 2.6503015337908664e-09
mutations O 0 3.987834134022705e-07
in O 0 1.4109136081685847e-09
the O 0 1.729552501217313e-08
Duchenne B-Disease 1 0.6161402463912964
muscular I-Disease 0 0.004571771714836359
dystrophy I-Disease 0 0.08589790016412735
gene O 0 5.37314590474125e-05
, O 0 1.525116317679931e-07
DMD O 1 1.0
, O 0 1.0118842652673266e-07
have O 0 1.1327013282880216e-07
been O 0 5.2629914648605336e-08
identified O 0 1.2326397325068683e-07
in O 0 1.5846394196827873e-09
patients O 0 5.3726122217767625e-08
with O 0 5.4032849305940545e-09
XLDCM B-Disease 0 0.00025990750873461366
, O 0 4.8275730080149515e-09
but O 0 5.168510064379461e-10
a O 0 6.980946376522468e-10
pathogenic O 0 2.435090173946719e-08
correlation O 0 3.276759841241983e-08
of O 0 1.1218830309189798e-09
these O 0 2.0955067014938322e-08
cardiospecific O 0 6.703162216581404e-05
mutations O 0 6.265466072363779e-05
in O 0 5.33817896553046e-08
DMD O 1 1.0
with O 0 1.0502963476710647e-07
the O 0 7.725339656872166e-08
XLDCM B-Disease 0 0.00018817937234416604
phenotype O 0 4.978258857590845e-06
has O 0 8.36551947713815e-08
remained O 0 1.0179447826885735e-06
to O 0 9.189720096003384e-09
be O 0 9.378770471357711e-08
elucidated O 0 3.3308683669019956e-06
. O 0 1.8756421127363865e-07

We O 0 9.212726581608877e-06
report O 0 6.379659112099034e-08
here O 0 1.96250971029599e-09
the O 0 3.0153057828385954e-10
identification O 0 7.5101365126784e-09
of O 0 8.459409284178321e-10
a O 0 1.075440891895596e-08
unique O 0 1.203759723011899e-07
de O 0 3.0528390198014677e-05
novo O 0 1.2713111345874495e-06
L1 O 0 2.8174904400657397e-06
insertion O 0 4.7490834731434006e-07
in O 0 1.6540059988301437e-08
the O 0 1.3976134027871012e-08
muscle O 0 1.4760564681637334e-07
exon O 0 2.646126517902303e-07
1 O 0 4.422543753435093e-08
in O 0 1.5768915062608357e-08
DMD O 1 1.0
in O 0 7.946280078385826e-08
three O 0 3.165850728237274e-07
XLDCM B-Disease 0 0.008615498431026936
patients O 0 8.43329246436042e-07
from O 0 9.983698312510114e-10
two O 0 3.1769242792023533e-09
unrelated O 0 5.909027933626021e-08
Japanese O 0 2.2494270979223074e-07
families O 0 1.0799367800018445e-07
. O 0 1.2517955383373192e-07

The O 0 3.8556908066311735e-07
insertion O 0 3.372780838617473e-06
was O 0 5.592143565991137e-07
a O 0 1.2101891044835611e-08
5 O 0 2.1607514000265837e-08
- O 0 1.1286640955177063e-07
truncated O 0 4.736243042202659e-08
form O 0 1.8614588981336055e-08
of O 0 8.249824712258658e-10
human O 0 8.016547425881981e-09
L1 O 0 1.3491388699549134e-06
inversely O 0 2.8601272106243414e-07
integrated O 0 2.006384875130607e-06
in O 0 4.472923809117901e-09
the O 0 6.036878108517385e-09
5 O 0 2.371976215442828e-08
- O 0 1.6171159131772583e-06
untranslated O 0 9.94574020296568e-06
region O 0 3.5564420386435813e-07
in O 0 2.397428033873439e-09
the O 0 3.196843456620968e-09
muscle O 0 8.14552763017673e-08
exon O 0 1.0758208901506805e-07
1 O 0 1.117499071057182e-08
, O 0 1.8036294680001674e-09
which O 0 1.2770292601160804e-09
affected O 0 9.893112107306479e-09
the O 0 5.796853552730852e-10
transcription O 0 5.571192573938788e-08
or O 0 1.3402298293385684e-07
the O 0 5.279044312800352e-09
stability O 0 1.1181732872955763e-07
of O 0 3.4176494967397275e-10
the O 0 5.43404299335748e-09
muscle O 0 1.0184792387235575e-07
form O 0 1.3285750277702846e-08
of O 0 7.876242991144977e-10
dystrophin O 0 3.2597827726021933e-07
transcripts O 0 7.735688427601417e-07
but O 0 5.270464953355258e-08
not O 0 4.151401000740407e-09
that O 0 1.8410445390415475e-10
of O 0 1.5023990385110153e-10
the O 0 8.07931410662377e-09
brain O 0 1.33101448227535e-05
or O 0 3.576618325951131e-07
Purkinje O 0 2.2397459815692855e-06
cell O 0 1.4752979495824547e-06
form O 0 3.800125796260545e-07
, O 0 3.024467076784276e-08
probably O 0 2.957217191124073e-07
due O 0 2.313240798912375e-08
to O 0 2.1840407260498296e-09
its O 0 1.8456900452434866e-09
unique O 0 3.4628941936176716e-09
site O 0 1.8554469960463393e-08
of O 0 1.0175502662690405e-09
integration O 0 2.251214965554027e-07
. O 0 1.6685538639649167e-07

We O 0 1.9690173758135643e-06
speculate O 0 1.264639593046013e-07
that O 0 7.357151554643337e-10
this O 0 1.1229743523966107e-10
insertion O 0 1.0715424991758482e-08
of O 0 4.832379496555461e-10
an O 0 5.339907183099513e-09
L1 O 0 7.965006079757586e-05
sequence O 0 1.072850182026741e-06
in O 0 9.081377783104472e-08
DMD O 1 1.0
is O 0 4.411431575590541e-08
responsible O 0 3.592082009618025e-08
for O 0 3.0857991162314136e-10
some O 0 1.796226778427723e-10
of O 0 1.3436038392988792e-10
the O 0 5.925997470512812e-10
population O 0 5.441196382349744e-10
of O 0 1.448714481711022e-10
Japanese O 0 4.810121936316136e-07
patients O 0 2.0157564506462222e-07
with O 0 4.296796252134527e-09
XLDCM B-Disease 0 2.1936035409453325e-05
. O 0 1.7418877007457922e-08
. O 0 7.139376378972884e-08

Severe O 1 0.9766071438789368
early O 0 0.0002694329305086285
- O 1 0.9998149275779724
onset O 1 0.9999986886978149
obesity B-Disease 1 1.0
, O 0 0.0016035616863518953
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 2.954687261080835e-06
red O 0 1.0742101949290372e-05
hair O 1 0.9991828799247742
pigmentation O 0 0.37032660841941833
caused O 0 5.0352600737824105e-06
by O 0 1.8436644211305975e-08
POMC O 0 0.00012747528671752661
mutations O 0 1.3612197108159307e-05
in O 0 2.6068359915143446e-08
humans O 0 7.272193442986463e-07
. O 0 1.3989794922508736e-07

Sequential O 0 2.5327142793685198e-05
cleavage O 0 4.027737304568291e-05
of O 0 2.5184432317360006e-08
the O 0 1.3938278975444973e-08
precursor O 0 7.773138577249483e-08
protein O 0 6.143689290638576e-08
pre O 0 5.437174695543945e-05
- O 0 9.140268957708031e-05
pro O 0 5.723129288526252e-05
- O 0 0.000264569855062291
opiomelanocortin O 0 1.1449795238149818e-05
( O 0 2.071116966817499e-08
POMC O 0 1.7593830534679e-06
) O 0 4.170002565473396e-09
generates O 0 1.999084986437083e-08
the O 0 1.5473652581476927e-08
melanocortin O 0 9.226214388036169e-06
peptides O 0 1.3912203939980827e-06
adrenocorticotrophin O 0 6.086241228331346e-06
( O 0 9.108734388973971e-08
ACTH O 0 1.2937157407577615e-05
) O 0 1.3455697889241947e-08
, O 0 5.344451547983908e-09
melanocyte O 0 5.339682957128389e-06
- O 0 1.3793129255645908e-05
stimulating O 0 6.150458830234129e-06
hormones O 0 4.147266736254096e-06
( O 0 6.7201888498402695e-09
MSH O 0 8.57353484207124e-07
) O 0 1.1531894328342673e-09
alpha O 0 2.65762123419222e-09
, O 0 2.0940582601269853e-10
beta O 0 1.2610638089327608e-09
and O 0 4.17397921781415e-10
gamma O 0 4.698791133961322e-09
as O 0 1.369906188486425e-09
well O 0 1.139543570616297e-09
as O 0 6.543773301004308e-10
the O 0 7.955356928768254e-10
opioid O 0 1.2582726860443927e-08
- O 0 6.885174741455558e-08
receptor O 0 1.8388097089427902e-07
ligand O 0 2.8567362164722e-07
beta O 0 7.599462605867302e-07
- O 0 6.742293408024125e-06
endorphin O 0 9.431473154108971e-05
. O 0 5.993815648253076e-07

While O 0 1.3781537973045488e-06
a O 0 3.9124735451423476e-08
few O 0 9.818969637365171e-09
cases O 0 3.473392240493922e-09
of O 0 7.991632244852553e-09
isolated O 0 0.18896707892417908
ACTH B-Disease 1 0.9999915361404419
deficiency I-Disease 1 0.9145573377609253
have O 0 2.883365084471734e-07
been O 0 2.9599621598208614e-07
reported O 0 3.2771225733085885e-07
( O 0 2.3209572930227296e-08
OMIM O 0 2.030282121268101e-05
201400 O 0 4.8685393494452e-07
) O 0 4.6712149703864725e-09
, O 0 9.4436525266417e-10
an O 0 7.649735067616348e-09
inherited O 0 0.05986185371875763
POMC O 0 0.001001681317575276
defect O 0 0.00022167956922203302
has O 0 8.57603126291906e-08
not O 0 5.5248857933065665e-08
been O 0 3.765266853861249e-08
described O 0 2.8571740529059753e-08
so O 0 2.3594143527816414e-08
far O 0 1.677255312415582e-07
. O 0 9.579925830394131e-08

Recent O 0 1.360096348435036e-06
studies O 0 3.106323731572047e-07
in O 0 7.335912766137653e-09
animal O 0 2.4439684054300415e-08
models O 0 1.3385181318881223e-07
elucidated O 0 3.5064704206888564e-07
a O 0 3.610791887709297e-09
central O 0 2.6132167540993123e-09
role O 0 4.033057443564303e-09
of O 0 5.019304416542525e-10
alpha O 0 1.7582975075924878e-08
- O 0 3.731842070919811e-07
MSH O 0 1.8636847016750835e-06
in O 0 1.0761401769698864e-09
the O 0 5.980044237574589e-10
regulation O 0 1.199965371512235e-08
of O 0 4.485394833331213e-10
food O 0 4.717433998990828e-09
intake O 0 5.999629237862791e-09
by O 0 1.919235048664092e-10
activation O 0 3.9695691178565085e-09
of O 0 6.754508619088995e-10
the O 0 1.2332320054042611e-08
brain O 0 8.842407055453805e-07
melanocortin O 0 1.5839746083656792e-06
- O 0 7.294601118701394e-07
4 O 0 9.166668490934171e-08
- O 0 2.569759658399562e-07
receptor O 0 2.779709689093579e-07
( O 0 2.018860811858758e-08
MC4 O 0 3.461361984591349e-06
- O 0 2.298263098055031e-06
R O 0 2.5156693936878582e-06
; O 0 4.792014784982257e-09
refs O 0 5.055787823948776e-07
3 O 0 3.712941776257139e-08
- O 0 5.996245135975187e-07
5 O 0 5.742602837699451e-09
) O 0 4.5110823410077217e-10
and O 0 4.4552114775164853e-10
the O 0 8.5659845883157e-10
linkage O 0 2.0720422355680057e-07
of O 0 2.0790000831993893e-09
human O 0 1.2383307534946653e-07
obesity B-Disease 1 0.9999997615814209
to O 0 4.027455702271254e-08
chromosome O 0 4.5737459004158154e-05
2 O 0 3.8869906404670473e-08
in O 0 2.274858079687192e-09
close O 0 3.4106597013305873e-07
proximity O 0 9.512229581787324e-08
to O 0 1.7788337913771102e-08
the O 0 1.708366248465154e-08
POMC O 0 2.190284249081742e-06
locus O 0 2.521979354241921e-07
, O 0 4.752882531988689e-09
led O 0 3.960312522366394e-09
to O 0 1.3063385928546722e-09
the O 0 1.260395343649634e-09
proposal O 0 2.0820714041747124e-09
of O 0 2.608783189472774e-10
an O 0 1.4391037250760519e-09
association O 0 4.234345762910152e-09
of O 0 1.1672860456002354e-09
POMC O 0 1.0740616744442377e-05
with O 0 3.880604992900771e-08
human O 0 1.0796612741614808e-06
obesity B-Disease 1 1.0
. O 0 7.83496886924695e-07

The O 0 6.084704864406376e-07
dual O 0 7.707955660407606e-07
role O 0 8.239689464062394e-08
of O 0 2.563757872664496e-09
alpha O 0 8.544356688844346e-08
- O 0 3.3406602142349584e-06
MSH O 0 6.690712780255126e-06
in O 0 3.5951785992693885e-09
regulating O 0 1.2972373042430263e-07
food O 0 2.5557033822565245e-08
intake O 0 5.251530055261355e-08
and O 0 6.540943786603748e-09
influencing O 0 1.0705086879170267e-06
hair O 0 0.2833559513092041
pigmentation O 0 1.9439821699052118e-05
predicts O 0 3.1608428230356367e-07
that O 0 1.3246979069236886e-09
the O 0 3.0441895670918484e-09
phenotype O 0 1.1227642744415789e-06
associated O 0 2.7143279623942362e-08
with O 0 2.602244419946942e-09
a O 0 8.051335953496164e-08
defect O 0 5.2818180847680196e-05
in O 0 3.881402754757346e-09
POMC O 0 3.2429811653855722e-06
function O 0 3.540468540563779e-08
would O 0 4.858314195388402e-09
include O 0 7.261230905442062e-08
obesity B-Disease 1 1.0
, O 0 1.4548355409260694e-08
alteration O 0 3.055266688534175e-07
in O 0 2.7403324054375844e-08
pigmentation O 0 0.4182715117931366
and O 0 0.0021015102975070477
ACTH B-Disease 1 0.9999912977218628
deficiency I-Disease 0 0.17258456349372864
. O 0 1.937229257009676e-07

The O 0 1.505377156263421e-07
observation O 0 6.67099186557607e-07
of O 0 3.5354597027748014e-09
these O 0 3.325143893562199e-08
symptoms O 0 5.197362042963505e-05
in O 0 2.1935342431333993e-09
two O 0 9.459178329507267e-09
probands O 0 1.1455553021733067e-06
prompted O 0 2.5026125172189495e-08
us O 0 6.224827320266968e-09
to O 0 1.1500133068054197e-09
search O 0 3.429864747772626e-08
for O 0 7.500345233779626e-09
mutations O 0 1.4670847576780943e-06
within O 0 1.1940612054672783e-08
their O 0 5.8739793473705504e-08
POMC O 0 2.9212696972535923e-05
genes O 0 2.2890628770255717e-06
. O 0 2.469054436460283e-07

Patient O 1 0.9721482396125793
1 O 0 1.943792995007243e-06
was O 0 2.633332769619301e-07
found O 0 1.7339454316811498e-08
to O 0 3.916025281824886e-09
be O 0 5.495853550030461e-09
a O 0 3.68000052652917e-09
compound O 0 5.6125113445659736e-08
heterozygote O 0 1.751234606217622e-07
for O 0 1.526947124297351e-09
two O 0 1.6537221370072075e-08
mutations O 0 5.304815999807033e-07
in O 0 2.0661485855555384e-09
exon O 0 2.5472968445683364e-07
3 O 0 5.7739072190088336e-08
( O 0 9.86514958611906e-09
G7013T O 0 2.7302328931000375e-07
, O 0 3.738864773339401e-09
C7133delta O 0 2.0255882304809347e-07
) O 0 9.866255590296191e-10
which O 0 7.179900007869833e-10
interfere O 0 8.972920184646682e-09
with O 0 1.4787658875192733e-09
appropriate O 0 1.1841228442222018e-08
synthesis O 0 2.07927062234603e-08
of O 0 5.5854254554787985e-09
ACTH O 0 1.223556409968296e-05
and O 0 8.786005878391734e-08
alpha O 0 6.159988856779819e-07
- O 0 2.2389633159036748e-05
MSH O 0 0.00014379265485331416
. O 0 3.448863026278559e-07

Patient O 1 0.8713769316673279
2 O 0 4.875369086221326e-06
was O 0 7.60213026751444e-07
homozygous O 0 9.94704805634683e-07
for O 0 1.0934705363396802e-09
a O 0 6.314309519694916e-09
mutation O 0 1.8352935171606077e-07
in O 0 2.12866746451823e-09
exon O 0 2.86872420929285e-07
2 O 0 1.7269030649913475e-07
( O 0 2.5343545928535605e-08
C3804A O 0 1.0424743095427402e-06
) O 0 9.774758780167758e-09
which O 0 1.8223657249905045e-08
abolishes O 0 9.592955393600278e-06
POMC O 0 7.857279706513509e-05
translation O 0 4.714549049822381e-06
. O 0 3.4675892379709694e-07

These O 0 4.232491050970566e-07
findings O 0 8.482069091542144e-08
represent O 0 1.927785220345868e-08
the O 0 1.6523686863223475e-09
first O 0 2.1096460134373274e-09
examples O 0 5.102289257763459e-09
of O 0 1.0143877959833958e-09
a O 0 1.8833167132470408e-06
genetic B-Disease 1 1.0
defect I-Disease 1 1.0
within O 0 6.965218091181669e-08
the O 0 8.838981990777484e-09
POMC O 0 3.2227624160441337e-06
gene O 0 1.9304498266592418e-07
and O 0 1.2986850705942743e-08
define O 0 3.8079619457676017e-07
a O 0 1.8398282009002287e-08
new O 0 7.029092330412823e-08
monogenic B-Disease 1 0.9920175075531006
endocrine I-Disease 1 0.9847880601882935
disorder I-Disease 0 0.002704748185351491
resulting O 0 7.242157096243318e-08
in O 0 2.7391084955752376e-09
early O 0 2.598526862129802e-06
- O 1 0.9999885559082031
onset O 1 0.9999997615814209
obesity B-Disease 1 1.0
, O 0 0.0007233490468934178
adrenal B-Disease 1 1.0
insufficiency I-Disease 1 1.0
and O 0 1.936973831107025e-06
red O 0 3.4168037927884143e-06
hair O 0 0.2739657163619995
pigmentation O 0 0.00010714154632296413
. O 0 2.2568462654248833e-08
. O 0 6.933102980610784e-08

A O 0 6.5100380197691265e-06
European O 0 2.502935785742011e-06
multicenter O 0 4.281797009753063e-05
study O 0 6.995133503551187e-07
of O 0 2.4584253424109193e-06
phenylalanine B-Disease 1 1.0
hydroxylase I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 1.3428571143947465e-08
classification O 0 3.549657634493997e-08
of O 0 9.885469109960354e-10
105 O 0 7.828876391613449e-08
mutations O 0 5.252709797787247e-06
and O 0 9.05603414480538e-09
a O 0 3.3249714093130933e-09
general O 0 2.161562484559454e-09
system O 0 7.420432712734737e-09
for O 0 1.900802182319694e-09
genotype O 0 3.2148211630556034e-06
- O 0 1.733448357299494e-06
based O 0 1.2591561571184684e-08
prediction O 0 1.3266712528547941e-07
of O 0 5.116078671818514e-09
metabolic O 0 0.0007911997381597757
phenotype O 0 3.555777948349714e-05
. O 0 2.293626835125906e-07

Phenylketonuria B-Disease 1 0.9507516026496887
( O 0 2.235274587292224e-05
PKU B-Disease 0 0.00015433614316862077
) O 0 1.6487624066030548e-07
and O 0 1.3146221533588687e-07
mild B-Disease 1 0.96584552526474
hyperphenylalaninemia I-Disease 1 1.0
( O 0 0.002544795162975788
MHP B-Disease 1 1.0
) O 0 2.216904348983917e-08
are O 0 2.467175619358386e-08
allelic B-Disease 0 0.00020394162856973708
disorders I-Disease 1 0.9989311099052429
caused O 0 6.084931101213442e-07
by O 0 6.2083578278304685e-09
mutations O 0 1.7452703104936518e-06
in O 0 2.1521744386632236e-09
the O 0 1.3229940698522569e-08
gene O 0 1.7315119293925818e-06
encoding O 0 6.555017534992658e-06
phenylalanine O 0 0.12935982644557953
hydroxylase O 0 0.0539633110165596
( O 0 1.0876043461394147e-06
PAH O 0 9.537352161714807e-05
) O 0 6.958897813547082e-08
. O 0 7.080925712443786e-08

Previous O 0 5.0523067329777405e-06
studies O 0 2.891637223001453e-07
have O 0 6.839729849161813e-08
suggested O 0 2.215281114104073e-08
that O 0 7.243490252051288e-10
the O 0 2.1219586088250253e-09
highly O 0 5.085910714797137e-08
variable O 0 4.254228315403452e-06
metabolic O 0 0.00818532332777977
phenotypes O 0 0.0001850627886597067
of O 0 5.720211788684537e-07
PAH B-Disease 1 0.9999862909317017
deficiency I-Disease 1 0.9255061149597168
correlate O 0 2.8351983928587288e-05
with O 0 2.0797879187739454e-06
PAH O 0 0.19114865362644196
genotypes O 0 0.0009137226152233779
. O 0 1.2628344165932504e-06

We O 0 4.775120487465756e-06
identified O 0 4.7559456106682774e-07
both O 0 2.4165736078884947e-08
causative O 0 3.66118752026523e-06
mutations O 0 7.974352342898783e-07
in O 0 3.2393980831102454e-09
686 O 0 5.089059413876384e-07
patients O 0 1.2769406794177485e-06
from O 0 8.432800235880222e-09
seven O 0 9.540720213863096e-08
European O 0 9.43633040151326e-07
centers O 0 1.622587546989962e-06
. O 0 4.0032091419561766e-07

On O 0 2.611855904888216e-07
the O 0 5.029302307946182e-09
basis O 0 4.744160619907234e-09
of O 0 1.9873924728130987e-10
the O 0 3.7839170685671775e-10
phenotypic O 0 2.423160481157538e-07
characteristics O 0 3.5276551102469966e-07
of O 0 2.093176743045433e-09
297 O 0 3.9480818259107764e-07
functionally O 0 5.86276928515872e-06
hemizygous O 0 6.02576665187371e-06
patients O 0 8.159426556630933e-07
, O 0 1.1992074000488628e-09
105 O 0 3.1023603686008983e-09
of O 0 3.4455188702153805e-10
the O 0 5.575111927669241e-09
mutations O 0 4.639288817998022e-06
were O 0 7.646397648386483e-08
assigned O 0 2.9998833639410805e-08
to O 0 2.0932047206656534e-09
one O 0 4.035066059060455e-09
of O 0 5.799717928134385e-10
four O 0 2.2158896939572514e-08
arbitrary O 0 1.243186147803499e-06
phenotype O 0 1.1630766493908595e-05
categories O 0 5.206931382417679e-05
. O 0 3.0972068998380564e-07

We O 0 2.00074623535329e-06
proposed O 0 4.806205566865174e-08
and O 0 3.401044779138829e-08
tested O 0 6.432376267184736e-07
a O 0 3.867487219366694e-09
simple O 0 8.146797014774165e-09
model O 0 4.9097753418436696e-08
for O 0 2.3197168630417764e-09
correlation O 0 3.9903218862491485e-07
between O 0 3.622050570584179e-08
genotype O 0 4.940686721965903e-06
and O 0 5.1593360694823787e-08
phenotypic O 0 1.4435435332416091e-05
outcome O 0 5.83163091505412e-06
. O 0 4.2083297557837795e-07

The O 0 1.8829073269444052e-06
observed O 0 3.422354211579659e-06
phenotype O 0 2.845812332452624e-06
matched O 0 1.3650081882587983e-06
the O 0 1.3903231455003606e-08
predicted O 0 2.1281859119426372e-07
phenotype O 0 5.171054908714723e-07
in O 0 2.8709878918675713e-09
79 O 0 9.217072971523521e-08
% O 0 7.621452802197837e-09
of O 0 2.7470281604990987e-10
the O 0 8.977028009837795e-09
cases O 0 4.572243383904606e-08
, O 0 1.560286833068858e-08
and O 0 6.723306711364785e-08
in O 0 2.107144680962847e-09
only O 0 5.355921484095916e-09
5 O 0 1.153233508688345e-09
of O 0 2.1997004218121674e-10
184 O 0 2.588207692610922e-08
patients O 0 1.9353217339812545e-07
was O 0 5.317570028751106e-08
the O 0 2.177626745591965e-09
observed O 0 2.4931411601869513e-08
phenotype O 0 2.1890548040914837e-08
more O 0 7.892529407804716e-10
than O 0 3.3255547204902314e-09
one O 0 1.3109194618721176e-08
category O 0 1.0431446071379469e-06
away O 0 3.2661151294632873e-07
from O 0 8.177591936942008e-09
that O 0 4.931979713518331e-09
expected O 0 5.066333841341475e-08
. O 0 6.259559626187183e-08

Among O 0 8.549586709705181e-07
the O 0 2.3652988900835226e-08
seven O 0 2.3624403766575597e-08
contributing O 0 3.562660211287039e-08
centers O 0 1.0418919060839471e-08
, O 0 6.599311652699669e-10
the O 0 4.112059026617487e-10
proportion O 0 4.5346180144179016e-09
of O 0 7.196352402871753e-10
patients O 0 2.9813335800099594e-08
for O 0 8.21761436675672e-10
whom O 0 4.445962886734378e-08
the O 0 3.455524311135605e-09
observed O 0 7.652277389524897e-08
phenotype O 0 2.2670782584555127e-07
did O 0 3.6351460153127846e-07
not O 0 6.856814849243165e-08
match O 0 3.1544818739348557e-06
the O 0 3.658586678056963e-08
predicted O 0 2.161977363357437e-06
phenotype O 0 1.3369888165470911e-06
was O 0 7.675988200617212e-08
4 O 0 1.1893106943716703e-08
% O 0 2.145093880301374e-08
- O 0 3.0389871881197905e-06
23 O 0 3.2625723633827874e-07
% O 0 2.4166935119751543e-08
( O 0 1.0080350776320302e-08
P O 0 1.2119015991629567e-05
< O 0 3.595136206513416e-07
. O 0 4.266766939764466e-09
0001 O 0 2.752638579295308e-07
) O 0 1.5503187622556425e-09
, O 0 3.6374861456245355e-10
suggesting O 0 1.0189413757188959e-08
that O 0 3.447714613802333e-10
differences O 0 1.2686276917861505e-08
in O 0 4.4211642680203056e-10
methods O 0 5.8691188797865834e-08
used O 0 8.337165979810379e-08
for O 0 8.900528314370604e-09
mutation O 0 2.4499620394635713e-06
detection O 0 6.0199836298124865e-06
or O 0 5.7816432672552764e-06
phenotype O 0 6.698950892314315e-05
classification O 0 3.037010355910752e-05
may O 0 3.7306785998225678e-06
account O 0 7.145261093910449e-08
for O 0 8.363724712801002e-10
a O 0 2.486007621982367e-09
considerable O 0 1.8340612584211158e-08
proportion O 0 2.7263041602054727e-07
of O 0 1.2795877246674081e-08
genotype O 0 0.0007331467932090163
- O 0 0.01544237695634365
phenotype O 0 0.00010138135985471308
inconsistencies O 0 1.3471148122334853e-05
. O 0 5.004836225452891e-07

Our O 0 6.479576768469997e-06
data O 0 2.941224579444679e-07
indicate O 0 5.184337510399928e-07
that O 0 6.25289908740001e-09
the O 0 3.801122261393175e-08
PAH O 0 4.873446960118599e-05
- O 0 4.086565695615718e-06
mutation O 0 1.8118108755516005e-06
genotype O 0 7.15295129793958e-07
is O 0 2.4966708700446816e-09
the O 0 6.414402897725324e-10
main O 0 2.33876811250866e-08
determinant O 0 8.080304070290367e-08
of O 0 1.4446012164270883e-09
metabolic O 0 7.952173473313451e-05
phenotype O 0 1.135497541326913e-06
in O 0 3.442459650671026e-09
most O 0 3.6967456651382236e-08
patients O 0 1.0315529834770132e-05
with O 0 1.688065276539419e-05
PAH B-Disease 1 0.9999686479568481
deficiency I-Disease 1 0.8245550990104675
. O 0 2.9762978215330804e-07

In O 0 2.267508563136289e-07
the O 0 1.3030942547231916e-08
present O 0 3.5535172582257246e-09
study O 0 3.700186157473695e-09
, O 0 1.0126479654815057e-09
the O 0 6.556403753243956e-10
classification O 0 6.035314470409503e-08
of O 0 2.3360606782318882e-09
105 O 0 8.413161936005054e-07
PAH O 0 3.848171400022693e-05
mutations O 0 7.586011633975431e-06
may O 0 3.671028991902858e-08
allow O 0 4.725710045505593e-09
the O 0 3.978604112830908e-09
prediction O 0 8.860929767706693e-08
of O 0 2.8348767777686135e-10
the O 0 4.949847642876648e-09
biochemical O 0 1.3996749430589261e-06
phenotype O 0 4.0037969029071974e-07
in O 0 1.3564587231229552e-09
> O 0 2.7152239567840297e-08
10 O 0 1.092995649543127e-08
, O 0 9.930426481119525e-10
000 O 0 9.636917930322397e-09
genotypes O 0 2.976397297516087e-07
, O 0 3.4958835826159884e-09
which O 0 5.1431707781546265e-09
may O 0 1.0077624068571822e-07
be O 0 1.6712150552322669e-09
useful O 0 4.881507642551242e-09
for O 0 4.6397613528981196e-10
the O 0 2.747501115507589e-09
management O 0 7.900787579728785e-09
of O 0 4.832445998914636e-09
hyperphenylalaninemia B-Disease 1 1.0
in O 0 1.7168257215871563e-07
newborns O 0 0.00017228713841177523
. O 0 1.2805244864466658e-07

Somatic O 0 0.00022451052791438997
instability O 0 2.1334370103431866e-05
of O 0 4.171858236645676e-08
the O 0 7.795559042733657e-08
CTG O 0 1.104979219235247e-05
repeat O 0 1.5272703421942424e-06
in O 0 5.147066772792641e-09
mice O 0 1.8801964074555144e-07
transgenic O 0 1.4478492005309818e-07
for O 0 2.4643478369057448e-09
the O 0 9.048078197793075e-08
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
region O 0 1.8926471057056915e-06
is O 0 2.250544639537111e-08
age O 0 8.036392529220393e-08
dependent O 0 3.8291961601544244e-08
but O 0 5.262637436942441e-09
not O 0 2.483320438173564e-09
correlated O 0 1.808363414568248e-08
to O 0 3.746460475184676e-09
the O 0 6.8167267386343156e-09
relative O 0 2.0574042025600647e-07
intertissue O 0 2.0211666651448468e-06
transcription O 0 9.80787149273965e-07
levels O 0 6.160763632578892e-07
and O 0 9.275058232560696e-08
proliferative O 0 0.00022579813958145678
capacities O 0 1.549901753605809e-05
. O 0 4.879481139141717e-07

A O 0 1.1024447303498164e-05
( O 0 7.253298690557131e-07
CTG O 0 3.798814077526913e-06
) O 0 2.2866919024977506e-08
nexpansion O 0 6.281333071456174e-07
in O 0 3.0470823642048117e-09
the O 0 3.96598176521934e-09
3 O 0 9.742449691430011e-08
- O 0 1.1790511052822694e-05
untranslated O 0 5.647972648148425e-05
region O 0 3.862307664803666e-07
( O 0 8.399475781573074e-09
UTR O 0 3.002276400820847e-07
) O 0 2.989737124536873e-09
of O 0 7.031956128500383e-10
the O 0 6.693277043723356e-08
DM O 1 1.0
protein O 0 1.0831503232111572e-06
kinase O 0 6.909775493113557e-06
gene O 0 2.4389312329731183e-06
( O 0 2.875132310009576e-08
DMPK O 0 1.574738689669175e-06
) O 0 1.709088870427422e-09
is O 0 9.960929858721101e-10
responsible O 0 4.1886021762138625e-08
for O 0 2.343519334147004e-08
causing O 0 0.007879333570599556
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.00022882630582898855
DM B-Disease 1 1.0
) O 0 5.218957994657103e-07
. O 0 1.848323023523335e-07

Major O 0 1.660104862821754e-05
instability O 0 1.565593629493378e-05
, O 0 2.3174628438482614e-08
with O 0 8.259775086116861e-10
very O 0 2.2837094437733185e-09
large O 0 5.821984561116267e-10
expansions O 0 1.2455741327244141e-08
between O 0 2.28508190147636e-09
generations O 0 1.673001825963638e-08
and O 0 2.802674092805546e-09
high O 0 3.172917217852955e-08
levels O 0 2.1688236984118703e-08
of O 0 2.793045794646787e-10
somatic O 0 4.5030017759017937e-07
mosaicism O 0 2.1353309875848936e-06
, O 0 8.399362982913772e-09
is O 0 3.788670710491715e-09
observed O 0 7.823442871313091e-08
in O 0 1.4917924673341076e-08
patients O 0 6.089848056944902e-07
. O 0 6.394058260639213e-08

There O 0 1.9862745830323547e-06
is O 0 3.095977874068012e-08
a O 0 9.545486179263207e-09
good O 0 5.1601425354874664e-08
correlation O 0 1.6056122831287212e-07
between O 0 2.4703634693423737e-08
repeat O 0 4.410671863297466e-06
size O 0 9.164097747316191e-08
( O 0 8.110037974518036e-09
at O 0 7.072706154076513e-08
least O 0 1.133481042359108e-08
in O 0 2.438114599101482e-09
leucocytes O 0 1.3928971611676388e-06
) O 0 2.0918797805080658e-09
, O 0 8.48558778798747e-10
clinical O 0 1.950889441104664e-07
severity O 0 1.5169379139479133e-06
and O 0 1.0564261287981935e-07
age O 0 3.7044716805212374e-07
of O 0 8.595563372182369e-09
onset O 0 0.0003109108947683126
. O 0 5.254140091892623e-07

The O 0 4.075041942996904e-06
trinucleotide O 0 0.0008377139456570148
repeat O 0 4.7949903091648594e-05
instability O 0 2.256755351481843e-06
mechanisms O 0 1.4535480659105815e-06
involved O 0 9.990659322056672e-08
in O 0 1.7584115497015773e-08
DM B-Disease 1 1.0
and O 0 4.233572781231487e-08
other O 0 7.07557701318251e-09
human O 0 1.3205873301558313e-06
genetic B-Disease 1 1.0
diseases I-Disease 1 1.0
are O 0 5.721253160118067e-07
unknown O 0 1.7304653283645166e-06
. O 0 1.292844302724916e-07

We O 0 3.4231081826874288e-06
studied O 0 4.052943722854252e-07
somatic O 0 2.749993427642039e-06
instability O 0 9.570773045197711e-07
by O 0 1.0119031834676662e-08
measuring O 0 5.749836054746993e-05
the O 0 8.665098505389324e-08
CTG O 0 1.4749273759662174e-05
repeat O 0 1.6713391914890963e-06
length O 0 3.9455412093047926e-07
at O 0 6.099752170030115e-08
several O 0 5.379910295033596e-09
ages O 0 2.946069912468374e-07
in O 0 4.6006609633053586e-10
various O 0 2.801658682827224e-09
tissues O 0 3.273742663623125e-07
of O 0 9.340433981819274e-10
transgenic O 0 5.823711148877919e-07
mice O 0 1.3609345614895574e-06
carrying O 0 6.741065305959637e-08
a O 0 1.018529438567839e-08
( O 0 1.4332342423983846e-08
CTG O 0 9.759613703863579e-07
) O 0 4.857776847444484e-09
55expansion O 0 2.1020844087615842e-07
surrounded O 0 3.656270664009753e-08
by O 0 6.750194847526814e-10
45 O 0 1.6107671862997108e-09
kb O 0 3.4146815153235366e-08
of O 0 5.296812988220267e-10
the O 0 7.796194800846479e-09
human O 0 1.4258986880122393e-07
DM B-Disease 1 1.0
region O 0 2.403413930096576e-07
, O 0 1.3003326193583575e-09
using O 0 1.4024040595472798e-08
small O 0 2.770055687051354e-07
- O 0 0.00010642186680343002
pool O 0 9.394591870659497e-06
PCR O 0 2.762712028925307e-05
. O 0 3.9945405205799034e-07

These O 0 1.2328166576480726e-06
mice O 0 8.503777280566283e-06
have O 0 3.595138764467265e-08
been O 0 9.013315427353064e-09
shown O 0 2.1794590576718065e-09
to O 0 1.3300752721434606e-09
reproduce O 0 3.3129404073406477e-06
the O 0 2.4916708696309797e-09
intergenerational O 0 7.807492607980748e-08
and O 0 6.339446745329269e-09
somatic O 0 2.1598785338028392e-07
instability O 0 1.1001050381764799e-07
of O 0 2.1399193528282012e-09
the O 0 2.2066361182737637e-08
55 O 0 5.953146455794922e-07
CTG O 0 4.172489752818365e-06
repeat O 0 7.941724788906868e-07
suggesting O 0 1.0965311503241537e-07
that O 0 1.2098375634650438e-09
surrounding O 0 5.176040041021679e-09
sequences O 0 4.569889355821033e-08
and O 0 1.276499084212901e-08
the O 0 1.820683270814527e-09
chromatin O 0 1.9273537077424407e-07
environment O 0 9.467304806776156e-08
are O 0 6.192203194643753e-09
involved O 0 7.4363866175986004e-09
in O 0 3.3617146844022727e-09
instability O 0 7.221892701636534e-07
mechanisms O 0 3.988084245065693e-06
. O 0 2.5102647782659915e-07

As O 0 1.223319600285322e-06
observed O 0 1.2671493720972649e-07
in O 0 5.645013900767992e-10
some O 0 1.5475318249080772e-10
of O 0 1.7310820832339147e-10
the O 0 2.2917208131190137e-09
tissues O 0 4.568900635604223e-07
of O 0 1.4836202488766048e-08
DM B-Disease 1 1.0
patients O 0 0.007634908426553011
, O 0 5.614992026892196e-09
there O 0 3.319667429835249e-09
is O 0 1.1023368884366391e-09
a O 0 2.7591489093481414e-09
tendency O 0 1.7912239513862005e-07
for O 0 3.954138350081848e-09
repeat O 0 4.597464339894941e-06
length O 0 3.6420652804736164e-07
and O 0 1.1844074165878737e-08
somatic O 0 2.1784239834232721e-07
mosaicism O 0 3.614897821080376e-07
to O 0 5.576632933212977e-09
increase O 0 2.1102668057437768e-08
with O 0 1.5127145758242477e-08
the O 0 3.7094164184736655e-08
age O 0 9.258408795176365e-08
of O 0 4.026468325424304e-10
the O 0 1.3696063838608552e-08
mouse O 0 4.195317160338163e-06
. O 0 2.068358355700184e-07

Furthermore O 0 1.5846402675379068e-05
, O 0 1.6822036741359625e-07
we O 0 3.661937597598808e-08
observed O 0 3.5585582480734956e-08
no O 0 3.398617831606998e-09
correlation O 0 3.8868272156378225e-08
between O 0 5.352368326327905e-09
the O 0 3.5483764815325003e-09
somatic O 0 1.0698248615881312e-06
mutation O 0 1.9700692064361647e-06
rate O 0 9.889868124446366e-07
and O 0 1.1253526110976964e-07
tissue O 0 8.764029189478606e-05
proliferation O 0 3.7829464417882264e-05
capacity O 0 4.638040422833001e-07
. O 0 1.5648056717054715e-07

The O 0 9.715762416817597e-07
somatic O 0 1.792821058188565e-05
mutation O 0 9.289013178204186e-06
rates O 0 1.7259018250115332e-06
in O 0 2.1353283585767713e-09
different O 0 9.482788776438156e-09
tissues O 0 3.239269062760286e-06
were O 0 3.9834284848438983e-07
also O 0 3.1897782193368585e-09
not O 0 1.1637735219949263e-09
correlated O 0 1.2196619714188728e-08
to O 0 2.3677848570713422e-09
the O 0 6.471919888895172e-09
relative O 0 4.271532816346735e-07
inter O 0 3.2544907298870385e-05
- O 0 0.0015266998670995235
tissue O 0 8.022384463401977e-06
difference O 0 5.520198342878757e-08
in O 0 6.404146102312325e-10
transcriptional O 0 1.492279722015155e-07
levels O 0 1.8532210788180237e-07
of O 0 4.4479941951891533e-10
the O 0 1.6184815709863187e-09
three O 0 9.389291122374743e-09
genes O 0 9.126229372213857e-08
( O 0 5.919289947087236e-09
DMAHP O 0 1.120472006732598e-06
, O 0 3.9858352174348965e-09
DMPK O 0 1.0478067906660726e-06
and O 0 5.9382681882880206e-08
59 O 0 9.480785223558996e-08
) O 0 1.1358068929823162e-09
surrounding O 0 5.397578384247481e-09
the O 0 9.906782949542503e-09
repeat O 0 3.0311055070342263e-06
. O 0 1.4306914764006251e-08
. O 0 5.794250412805013e-08

A O 0 2.384811068623094e-06
novel O 0 5.94524919961259e-07
missense O 0 1.641097514948342e-05
mutation O 0 7.428729531966383e-06
in O 0 1.8851945782216717e-08
patients O 0 2.4693681552889757e-06
from O 0 2.7429771787268464e-09
a O 0 1.6164863225753834e-08
retinoblastoma B-Disease 0 1.4688201190438122e-05
pedigree O 0 0.0020413401070982218
showing O 0 0.00010214214125880972
only O 0 8.776442683711139e-08
mild O 0 6.5179647208424285e-06
expression O 0 5.595153140802722e-08
of O 0 2.5205610931777755e-09
the O 0 1.6260004542800743e-07
tumor B-Disease 0 1.795870230125729e-05
phenotype O 0 6.831275186414132e-06
. O 0 1.6743130970553466e-07

We O 0 2.6367546524852514e-05
have O 0 5.643275358124811e-08
used O 0 3.76210103070207e-08
single O 0 3.8341883623616013e-07
strand O 0 1.5760501526074222e-07
conformation O 0 2.0097752440051408e-07
polymorphism O 0 2.9647819133060693e-07
analysis O 0 3.588575836488417e-08
to O 0 6.102647720496179e-09
study O 0 1.647036107499389e-08
the O 0 7.1300649828742735e-09
27 O 0 2.8192317813591217e-08
exons O 0 5.593616592136641e-08
of O 0 8.234717352451071e-10
the O 0 4.553225796399829e-09
RB1 O 0 9.775011449164595e-07
gene O 0 3.719540941915511e-08
in O 0 2.2924027121007384e-09
individuals O 0 3.2686431339357114e-09
from O 0 1.1262953902857475e-09
a O 0 8.461849887453354e-09
family O 0 9.136731904391127e-08
showing O 0 1.2580594557221048e-05
mild O 0 8.359787898370996e-06
expression O 0 3.690602312644842e-08
of O 0 1.6493805210515688e-09
the O 0 3.532751691182057e-08
retinoblastoma B-Disease 0 1.2578147106978577e-05
phenotype O 0 1.5573987184325233e-05
. O 0 2.6590683432914375e-07

In O 0 9.162874903267948e-08
this O 0 5.731507268791347e-09
family O 0 2.5269116576964734e-08
affected O 0 3.573855877903043e-08
individuals O 0 4.4448924541029555e-09
developed O 0 1.8660735179309995e-07
unilateral B-Disease 1 0.9865013957023621
tumors I-Disease 1 1.0
and O 0 4.92622393721831e-06
, O 0 1.0535180727799798e-08
as O 0 2.3825581507708193e-09
a O 0 4.097967742922037e-09
result O 0 1.4658237290632314e-08
of O 0 4.5587064678720424e-10
linkage O 0 1.7505728919786634e-06
analysis O 0 4.702909279785672e-07
, O 0 2.614843452874993e-08
unaffected O 0 1.252597257916932e-06
mutation O 0 9.533332558930852e-07
carriers O 0 9.70744622463826e-07
were O 0 5.224809456194635e-07
also O 0 1.684840533755505e-08
identified O 0 1.6153002491137158e-07
within O 0 4.38869429686406e-09
the O 0 1.4269442516479103e-08
pedigree O 0 2.732824214035645e-05
. O 0 2.4493635919498047e-07

A O 0 4.2345927795395255e-06
single O 0 2.011133801715914e-06
band O 0 3.1902001751404896e-07
shift O 0 1.926690345044335e-07
using O 0 1.6287955872940074e-07
SSCP O 0 2.152707202185411e-05
was O 0 8.560309794347631e-08
identified O 0 3.144972282598246e-08
in O 0 1.312865482994141e-09
exon O 0 1.6470823993586237e-07
21 O 0 9.393342992325415e-08
which O 0 6.360763027402072e-09
resulted O 0 2.9531998180232222e-08
in O 0 1.8056258710430484e-09
a O 0 2.9179590299577285e-08
missense O 0 1.020712352328701e-05
mutation O 0 1.4764802926947596e-06
converting O 0 5.872265091966256e-07
a O 0 1.319849047831667e-07
cys O 0 0.0005698217428289354
- O 0 7.0340080128517e-05
- O 0 1.6339607100235298e-05
> O 0 9.131415481533622e-07
arg O 0 1.4472489056061022e-06
at O 0 8.01578678988335e-08
nucleotide O 0 1.3366791336011374e-06
position O 0 9.81814650913293e-07
28 O 0 4.486750881937951e-08
in O 0 1.186475695469369e-09
the O 0 7.015468206361675e-09
exon O 0 1.6986111859296216e-06
. O 0 1.7777101390947792e-07

The O 0 1.7878053313324926e-06
mutation O 0 1.698075902822893e-05
destroyed O 0 4.840760539082112e-06
an O 0 1.8243376587179227e-08
NdeI O 0 4.5734827835985925e-06
restriction O 0 2.8557582254506997e-07
enzyme O 0 2.07725088330335e-06
site O 0 1.5441479490618804e-06
. O 0 2.697765921766404e-07

Analysis O 0 4.733068692530651e-07
of O 0 4.7313104545310125e-09
all O 0 3.7321958856750825e-09
family O 0 6.943674524251264e-09
members O 0 1.9545676188670313e-09
demonstrated O 0 7.223998288452549e-09
that O 0 4.882613757750676e-10
the O 0 3.1924500820679214e-09
missense O 0 8.367293958144728e-06
mutation O 0 4.0679437915969174e-06
co O 0 2.9829830054950435e-06
- O 0 2.820038616846432e-06
segregated O 0 4.2858409869950265e-06
with O 0 2.967858847569005e-08
patients O 0 1.5283470702343038e-06
with O 0 3.7134665831217717e-07
tumors B-Disease 1 1.0
or O 0 0.0006909153307788074
who O 0 1.6883893749763956e-06
, O 0 2.0432109337775728e-09
as O 0 1.5367759287343574e-09
a O 0 3.3145488576025173e-09
result O 0 1.1052911474962457e-08
of O 0 4.406398301792791e-10
linkage O 0 1.1966407100771903e-06
analysis O 0 1.6916806089284364e-06
had O 0 8.169130160240456e-05
been O 0 1.1612457484488914e-07
predicted O 0 4.3601364296819156e-08
to O 0 3.3491578399491573e-09
carry O 0 1.52069389969256e-07
the O 0 2.4663426856363913e-08
predisposing O 0 2.3055486963130534e-05
mutation O 0 2.399878212600015e-06
. O 0 2.0463950534121977e-07

These O 0 3.8428785842370417e-07
observations O 0 2.4223288619396044e-07
point O 0 1.6593658358488028e-07
to O 0 1.0025168251104333e-08
another O 0 1.7459857559742886e-08
region O 0 1.2650250624801629e-08
of O 0 6.813291597573823e-10
the O 0 9.236920561761508e-09
RB1 O 0 2.6872687612922164e-06
gene O 0 7.819205904979754e-08
where O 0 7.231525156470298e-09
mutations O 0 2.0610571027646074e-07
only O 0 3.9016958552906544e-09
modify O 0 1.374932026010356e-07
the O 0 2.542933419391602e-09
function O 0 6.553906306550061e-09
of O 0 1.8504053844736745e-10
the O 0 4.858617397296427e-10
gene O 0 2.9636275655775535e-08
and O 0 2.8501294657701237e-09
raise O 0 1.0398529148858415e-08
important O 0 4.1586050159025945e-09
questions O 0 1.425896822837558e-08
for O 0 1.2751649736131299e-09
genetic O 0 2.4859484710759716e-06
counseling O 0 3.578672362891666e-07
in O 0 5.813908465768236e-09
families O 0 1.8383831346113766e-08
with O 0 2.0881005813322417e-09
these O 0 1.0326447252850812e-08
distinctive O 0 1.842696178755432e-06
phenotypes O 0 4.271526904631173e-06
. O 0 1.1881407857572412e-08
. O 0 5.0132438644823196e-08

Maternal B-Disease 0 0.20265063643455505
disomy I-Disease 0 0.06868425756692886
and O 0 0.0005888138548471034
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
consistent O 0 0.00010294728417648003
with O 0 1.4827092442715184e-08
gamete O 0 1.194849232888373e-06
complementation O 0 1.165677258541109e-05
in O 0 2.8585627198651764e-09
a O 0 3.2399047888986843e-09
case O 0 1.9369912340749806e-09
of O 0 8.560693265380337e-10
familial O 0 1.2301669812586624e-05
translocation O 0 1.1474140819700551e-06
( O 0 1.6459464902141008e-08
3 O 0 1.4136189108171493e-08
; O 0 2.357852135759231e-09
15 O 0 1.5549808551895694e-08
) O 0 1.4012856430767329e-09
( O 0 1.7437618016202805e-09
p25 O 0 6.251017481417875e-08
; O 0 2.4183566260660427e-09
q11 O 0 1.187283800163641e-07
. O 0 1.9989583321944338e-09
2 O 0 1.740031585484303e-08
) O 0 1.1593453308478274e-08
. O 0 3.258803005223854e-08

Maternal B-Disease 1 0.7934439182281494
uniparental I-Disease 1 0.9776396751403809
disomy I-Disease 1 0.5018770098686218
( I-Disease 0 3.67535903933458e-05
UPD I-Disease 1 0.9999997615814209
) I-Disease 0 1.4197598829923663e-07
for I-Disease 0 7.042831651205006e-09
chromosome I-Disease 0 6.2426901422441e-05
15 I-Disease 0 3.817601168520923e-08
is O 0 1.5577258372090341e-09
responsible O 0 1.7634764759577592e-08
for O 0 4.976901113451504e-10
an O 0 6.725776602323208e-10
estimated O 0 8.573427301428183e-09
30 O 0 3.7786462847577695e-09
% O 0 1.342692623751418e-09
of O 0 2.1018212170709205e-10
cases O 0 5.6094577871590445e-09
of O 0 1.3568264876084868e-06
Prader B-Disease 1 1.0
- I-Disease 1 1.0
Willi I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 1.6189049347303808e-05
PWS B-Disease 1 1.0
) O 0 3.172542335505568e-07
. O 0 1.0752280132919623e-07

We O 0 3.861957520712167e-05
report O 0 3.939122805718398e-08
on O 0 1.8744372720647107e-09
an O 0 4.451609636468845e-10
unusual O 0 3.2570055541469856e-09
case O 0 2.3866424392338104e-09
of O 0 1.0382689152876878e-09
maternal B-Disease 0 3.55815609509591e-05
disomy I-Disease 0 5.247638182481751e-05
15 I-Disease 0 2.1372736114244617e-07
in O 0 3.968919770613866e-08
PWS B-Disease 1 1.0
that O 0 1.860287390798021e-08
is O 0 2.94078739138115e-09
most O 0 2.622168926436075e-09
consistent O 0 6.39948780190025e-07
with O 0 6.489472514914496e-09
adjacent O 0 5.347707769942645e-07
- O 0 5.3026387831778266e-06
1 O 0 1.4592209218733387e-08
segregation O 0 5.710657191571045e-08
of O 0 4.0990599803336636e-10
a O 0 1.6797324420281257e-08
paternal O 0 3.3290241844952106e-05
t O 0 7.175715381890768e-06
( O 0 2.46785658575277e-09
3 O 0 5.508940859044742e-09
; O 0 2.300804213817287e-09
15 O 0 6.415409536941752e-09
) O 0 8.30623958503196e-10
( O 0 9.889636887194797e-10
p25 O 0 4.827354516123705e-08
; O 0 2.5073128018249236e-09
q11 O 0 6.968235055637706e-08
. O 0 1.3939122078809874e-09
2 O 0 3.734901721230699e-09
) O 0 1.043311215198628e-09
with O 0 1.0653506965496717e-09
simultaneous O 0 5.321229764376767e-06
maternal O 0 0.006782167591154575
meiotic O 0 5.145859904587269e-05
nondisjunction O 0 2.265329021611251e-05
for O 0 3.227620126722286e-08
chromosome O 0 8.139931014738977e-05
15 O 0 5.420649245024833e-07
. O 0 1.2632918355848233e-07

The O 0 3.190737515978981e-06
patient O 0 2.35348597925622e-05
( O 0 1.1463559701496706e-07
J O 0 3.0174605853972025e-05
. O 0 1.8508167443087586e-08
B O 0 4.986269686924061e-06
. O 0 1.7612906688668772e-09
) O 0 8.504902893058386e-10
, O 0 1.0502834157932739e-09
a O 0 7.71829533618984e-09
17 O 0 1.062443857335893e-07
- O 0 6.928654556759284e-07
year O 0 1.2927685588692839e-08
- O 0 2.967213504234678e-06
old O 0 4.045524292450864e-06
white O 0 1.1293058577166448e-07
male O 0 1.0387334015149463e-07
with O 0 2.308806301698496e-08
PWS B-Disease 1 1.0
, O 0 2.7362794696728088e-08
was O 0 4.906527095727142e-08
found O 0 4.430283695455728e-09
to O 0 4.940849063217456e-09
have O 0 1.9820839725070982e-07
47 O 0 6.951992190806777e-07
chromosomes O 0 5.347544060896325e-07
with O 0 6.971755617257713e-09
a O 0 3.133296999635604e-08
supernumerary O 0 1.895003515528515e-05
, O 0 3.994132313778209e-08
paternal O 0 8.880408859113231e-05
der O 1 0.6567349433898926
( O 0 2.1252931858839474e-08
15 O 0 8.2981035376406e-09
) O 0 3.3678099198297673e-10
consisting O 0 8.15609191295863e-10
of O 0 2.482916650059508e-10
the O 0 1.1203973748763474e-08
short O 0 3.013739114976488e-05
arm O 1 0.6408293843269348
and O 0 5.2529124161537766e-08
the O 0 5.953053161533717e-09
proximal O 0 2.545444658608176e-06
long O 0 3.4100015909643844e-05
arm O 0 0.008755364455282688
of O 0 1.6589782880771509e-09
chromosome O 0 2.160621625080239e-05
15 O 0 6.810569175286219e-08
, O 0 5.395128788165948e-09
and O 0 2.8146864394784643e-08
distal O 0 0.00016157598292920738
chromosome O 0 0.2822222411632538
arm O 1 0.5204936861991882
3p O 0 0.0016334087122231722
. O 0 1.8836473145711352e-06

The O 0 2.1686928448616527e-06
t O 0 1.0851533261302393e-05
( O 0 8.365628190176722e-09
3 O 0 6.285471254585673e-09
; O 0 1.5902286154556577e-09
15 O 0 8.532659023785527e-09
) O 0 1.3808716392560427e-09
was O 0 3.959528882546692e-08
present O 0 2.2383555009497513e-09
in O 0 3.0068633694035896e-10
the O 0 1.4562340222568082e-09
balanced O 0 1.3583235869418786e-08
state O 0 4.862539260130916e-10
in O 0 3.7275127429126087e-10
the O 0 5.219551901802788e-09
patients O 0 5.504900002506474e-08
father O 0 2.4436326739873948e-08
and O 0 5.628653099165604e-09
a O 0 8.260870032472667e-08
sister O 0 5.329997293301858e-05
. O 0 1.4095995481966384e-07

Fluorescent O 0 2.1007364921388216e-05
in O 0 8.021567765581494e-08
situ O 0 6.36122649666504e-07
hybridization O 0 9.216175556048256e-08
analysis O 0 6.733097990263559e-08
demonstrated O 0 5.456083940202916e-08
that O 0 2.33675145899781e-09
the O 0 3.673774529033835e-08
PWS B-Disease 1 1.0
critical O 0 1.0877027989408816e-06
region O 0 1.945894751997912e-07
resided O 0 2.215334546917802e-07
on O 0 9.163116487798106e-09
the O 0 4.119534491309196e-09
derivative O 0 1.5462832436696772e-07
chromosome O 0 5.676881755789509e-07
3 O 0 7.642238841754079e-09
and O 0 1.3031017154219171e-08
that O 0 8.469519308107465e-09
there O 0 7.919982181192609e-08
was O 0 6.747027327946853e-07
no O 0 1.229204471542289e-08
deletion O 0 1.805238127872144e-07
of O 0 5.001903780055272e-09
the O 0 1.104949774344277e-06
PWS B-Disease 1 1.0
region O 0 5.054539542470593e-07
on O 0 6.50188951567543e-08
the O 0 1.0302525055294609e-08
normal O 0 4.8300989874405786e-08
pair O 0 1.4521982905080222e-07
of O 0 1.0162062302754293e-09
15s O 0 2.308633213488065e-07
present O 0 2.2291368750870788e-08
in O 0 2.1386595605576986e-08
J O 0 0.002559640910476446
. O 0 3.365181271419715e-07

B O 0 0.00700378930196166
. O 0 7.811133400537074e-06

Methylation O 0 5.0879416448879056e-06
analysis O 0 5.807488605569233e-07
at O 0 7.462419659987063e-08
exon O 0 3.269621231538622e-07
alpha O 0 1.067568522472584e-08
of O 0 5.872169972498398e-10
the O 0 2.9604285689543985e-09
small O 0 2.7619622144925415e-08
nuclear O 0 2.278666897836956e-06
ribonucleoprotein O 0 2.4722239686525427e-06
- O 0 1.107498519559158e-05
associated O 0 2.781006287477794e-07
polypeptide O 0 1.2337117141214549e-06
N O 0 4.2335673242632765e-06
( O 0 7.086962572344646e-09
SNRPN O 0 5.518824082173523e-07
) O 0 1.9631085645954727e-09
gene O 0 1.171307104641528e-07
showed O 0 1.1151935552788927e-07
a O 0 4.8035908584154186e-09
pattern O 0 7.729369144726661e-07
characteristic O 0 1.0347193324378168e-07
of O 0 7.189630002457648e-10
only O 0 8.255384820188283e-09
the O 0 7.921958200540757e-09
maternal O 0 0.00013439219037536532
chromosome O 0 4.745366095448844e-05
15 O 0 1.3424529754502146e-07
in O 0 2.423950462571156e-08
J O 0 0.008882368914783001
. O 0 4.368485804207012e-07

B O 0 0.01186618022620678
. O 0 9.036468327394687e-06

Maternal B-Disease 0 0.03609810769557953
disomy I-Disease 0 0.00103675271384418
was O 0 2.391744146734709e-06
confirmed O 0 1.5235666239732382e-07
by O 0 2.8622288983370936e-09
polymerase O 0 1.4869523567995202e-07
chain O 0 4.838489644498623e-07
reaction O 0 1.584416509103903e-08
analysis O 0 1.0605988975953551e-08
of O 0 2.071921967328194e-09
microsatellite O 0 9.074121408048086e-06
repeats O 0 4.257073669577949e-06
at O 0 1.560113531695606e-07
the O 0 1.0279246787092688e-08
gamma O 0 7.436261171278602e-07
- O 0 2.3092408810043707e-05
aminobutyric O 0 3.744220157386735e-05
acid O 0 1.2385414720483823e-06
receptor O 0 3.57376819692945e-07
beta3 O 0 7.626194360454974e-07
subunit O 0 4.3541697891669173e-07
( O 0 1.2988613207198796e-07
GABRB3 O 0 7.000846380833536e-06
) O 0 5.4813259708907935e-08
locus O 0 6.968048637645552e-06
. O 0 4.901316970062908e-07

A O 0 1.7756372471922077e-05
niece O 0 8.389708818867803e-05
( O 0 5.529349778043979e-07
B O 0 6.9007210186100565e-06
. O 0 5.880601339214309e-09
B O 0 3.8532863300133613e-07
. O 0 5.64363555888292e-10
) O 0 3.2557678775191334e-10
with O 0 4.5856185515447123e-10
45 O 0 4.951905996364303e-09
chromosomes O 0 1.137655232241741e-07
and O 0 4.653287533074035e-09
the O 0 4.563058819684329e-09
derivative O 0 3.528775494032743e-07
3 O 0 3.269405723926866e-08
but O 0 5.294889504625644e-08
without O 0 8.78855388464217e-08
the O 0 5.5687063849063634e-08
der O 0 0.05871151387691498
( O 0 5.490426335796883e-09
15 O 0 4.117829632832581e-09
) O 0 6.370606819849911e-10
demonstrated O 0 4.150102927980015e-09
a O 0 4.343533532846777e-09
phenotype O 0 6.705991495437047e-07
consistent O 0 4.0106911569637305e-07
with O 0 5.379879652878117e-09
that O 0 1.513184955115321e-08
reported O 0 1.1029350588387388e-07
for O 0 1.3538017373804223e-09
haploinsufficiency O 0 4.61017890529547e-07
of O 0 4.92525842332725e-09
distal O 0 9.980685717891902e-06
3 O 0 8.664923143442138e-07
p O 0 0.0003606294048950076
. O 0 3.543218838331086e-07

Uniparental B-Disease 1 0.9999991655349731
disomy I-Disease 1 0.9999970197677612
associated O 0 2.615604898892343e-05
with O 0 3.943212334434065e-08
unbalanced O 0 1.9642595361801796e-05
segregation O 0 4.38159759141854e-06
of O 0 8.414419383484528e-09
non O 0 1.5606667147949338e-05
- O 0 3.691911479108967e-05
Robertsonian O 0 7.152124453568831e-06
translocations O 0 1.785300082701724e-05
has O 0 5.032467242926941e-07
been O 0 6.260562486204435e-07
reported O 0 4.1477946410850564e-07
previously O 0 5.682514938598615e-07
but O 0 1.2419706152400067e-08
has O 0 7.111973676643402e-09
not O 0 1.5382930484975077e-08
, O 0 4.4077932970232325e-10
to O 0 5.809405734247264e-10
our O 0 1.0510534664831539e-08
knowledge O 0 8.368165715921805e-09
, O 0 3.6695708693912366e-09
been O 0 8.477957003094616e-09
observed O 0 6.5804113269507525e-09
in O 0 2.169417007147345e-10
a O 0 3.226005906853402e-09
case O 0 1.1285624879064926e-08
of O 0 3.028149819783721e-08
PWS B-Disease 1 0.9999998807907104
. O 0 5.25319364896859e-07

Furthermore O 0 1.9427699953666888e-05
, O 0 6.908774707881093e-08
our O 0 2.8649393968294135e-08
findings O 0 1.2505970481413442e-08
are O 0 2.194643355935e-09
best O 0 1.5463385238945193e-08
interpreted O 0 3.387798130916053e-08
as O 0 5.712124551138231e-09
true O 0 2.8688875275406645e-08
gamete O 0 2.687181961391616e-07
complementation O 0 4.810479367733933e-06
resulting O 0 5.471527515510388e-07
in O 0 9.840497483537547e-08
maternal B-Disease 1 0.796236515045166
UPD I-Disease 1 1.0
15 I-Disease 0 1.866206366685219e-05
and O 0 1.4647313037130516e-05
PWS B-Disease 1 0.9999997615814209

Schwartz B-Disease 1 0.9232462644577026
- I-Disease 1 0.998977541923523
Jampel I-Disease 1 0.9903899431228638
syndrome I-Disease 1 0.9999939203262329
type I-Disease 0 2.9807262762915343e-05
2 I-Disease 0 2.3366484924736142e-07
and O 0 5.855153517586587e-07
Stuve B-Disease 1 0.9947298765182495
- I-Disease 1 0.9999992847442627
Wiedemann I-Disease 1 0.9999996423721313
syndrome I-Disease 1 1.0
: O 0 9.22980625261971e-09
a O 0 4.859963986802995e-09
case O 0 4.2020191770575366e-09
for O 0 3.0512115056779976e-09
" O 0 6.502807536890032e-08
lumping O 0 1.595159005773894e-06
" O 0 1.5121383967198199e-07
. O 0 7.724469952563595e-08

Recent O 0 2.2895321762916865e-06
studies O 0 9.337152846455865e-07
demonstrated O 0 1.3687869682144083e-07
the O 0 3.1879352491159807e-09
existence O 0 9.791365940259311e-09
of O 0 3.7416736375917026e-10
a O 0 5.702925687245397e-09
genetically O 0 6.546962794118372e-08
distinct O 0 7.930107237541506e-09
, O 0 6.521059803255014e-10
usually O 0 8.31264568290635e-09
lethal O 0 5.392803981152383e-09
form O 0 2.4049666702552486e-09
of O 0 5.757625487490259e-10
the O 0 8.964148179302356e-08
Schwartz B-Disease 0 0.21859443187713623
- I-Disease 1 0.9998855590820312
Jampel I-Disease 1 0.9999216794967651
syndrome I-Disease 1 0.9999957084655762
( O 0 4.971915856799569e-08
SJS B-Disease 0 0.003051124047487974
) O 0 3.307835338972609e-09
of O 0 1.5663750296823764e-09
myotonia B-Disease 0 0.0002720604243222624
and O 0 2.328953172536785e-07
skeletal B-Disease 0 0.00032857205951586366
dysplasia I-Disease 0 0.17574883997440338
, O 0 1.4893246635949708e-08
which O 0 9.66972812932454e-09
we O 0 5.7271282827286996e-08
called O 0 1.4820906812929024e-07
SJS B-Disease 0 0.4554772973060608
type I-Disease 0 6.875054532429203e-05
2 I-Disease 0 4.0995729477799614e-07
. O 0 1.4216961119473126e-07

This O 0 1.3052742815489182e-06
disorder O 0 0.1488041877746582
is O 0 7.587598993552547e-09
reminiscent O 0 4.319658586382502e-08
of O 0 1.4258796365851367e-09
another O 0 2.1313621090257584e-08
rare O 0 1.9393179684357165e-07
condition O 0 1.5408000763272867e-05
, O 0 3.201596987523203e-09
the O 0 2.6775063943773603e-08
Stuve B-Disease 1 0.8401383757591248
- I-Disease 1 0.9999908208847046
Wiedemann I-Disease 1 0.9999972581863403
syndrome I-Disease 1 0.9999992847442627
( O 0 5.14976008503254e-08
SWS B-Disease 0 0.00015303821419365704
) O 0 1.5585914781013344e-08
, O 0 6.755268566749351e-10
which O 0 1.7172512301044662e-09
comprises O 0 1.700035134888367e-08
campomelia B-Disease 0 2.030682253462146e-06
at O 0 1.5390801877401827e-07
birth O 0 3.2715286124584964e-06
with O 0 1.9934384809516814e-08
skeletal B-Disease 0 0.00010644246503943577
dysplasia I-Disease 0 0.09121962636709213
, O 0 3.2483338685551644e-08
contractures B-Disease 0 0.000105675047961995
, O 0 1.6908156652561956e-08
and O 0 2.8780071659184614e-08
early B-Disease 0 7.406316626656917e-07
death I-Disease 0 9.036149890562228e-07
. O 0 1.0125117455572763e-07

To O 0 7.876759013925039e-07
test O 0 6.611242042708909e-07
for O 0 6.1951568319784656e-09
possible O 0 4.948377707592044e-08
nosologic O 0 1.8535918115958339e-06
identity O 0 6.022975185260293e-08
between O 0 4.952501519994712e-09
these O 0 8.334383494457143e-08
disorders O 0 0.006452836096286774
, O 0 3.154679184547149e-09
we O 0 1.2554055572877587e-08
reviewed O 0 7.043906791182053e-09
the O 0 8.543761254031779e-10
literature O 0 3.017102345737044e-09
and O 0 7.478688779372078e-09
obtained O 0 1.1816410072640338e-08
a O 0 1.188061471424362e-08
follow O 0 1.4552067284512304e-07
- O 0 2.1153879060875624e-05
up O 0 2.96829568924295e-07
of O 0 2.675339116908759e-10
the O 0 1.4801090353344648e-09
only O 0 4.413861720564682e-09
two O 0 1.265613924772424e-08
surviving O 0 9.843040061241481e-06
patients O 0 5.996931662366478e-08
, O 0 2.5242982704121175e-10
one O 0 5.881709563837489e-10
with O 0 3.0092630609601656e-09
SJS B-Disease 0 0.002078036777675152
type I-Disease 0 7.278810244315537e-06
2 I-Disease 0 1.7180024514118486e-08
at O 0 1.5581790080432256e-07
age O 0 2.386059350101277e-07
10 O 0 3.5552050192677598e-09
years O 0 1.6077221776100714e-09
and O 0 3.094500211631157e-09
another O 0 5.049949347579741e-09
with O 0 1.8668135481902937e-08
SWS B-Disease 0 0.03493029996752739
at O 0 2.1007667783123907e-06
age O 0 7.409700515381701e-07
7 O 0 1.2271505056560272e-07
years O 0 5.8834540794805434e-08
. O 0 7.777499178018843e-08

Patients O 1 0.9997099041938782
reported O 0 5.791062903881539e-06
as O 0 3.120938174561161e-08
having O 0 6.319077101579751e-07
either O 0 8.851283382682595e-06
neonatal O 1 0.9999996423721313
SJS B-Disease 1 0.9999998807907104
or O 0 0.0002688427339307964
SWS B-Disease 1 0.6072787046432495
presented O 0 8.990517130769149e-08
a O 0 6.654449880016955e-09
combination O 0 4.261571717734114e-08
of O 0 4.2875430983357887e-10
a O 0 1.4581414298220352e-08
severe O 0 0.000193478845176287
, O 0 2.0671940603733674e-08
prenatal O 1 0.9999998807907104
- O 1 0.9999998807907104
onset O 1 0.9999997615814209
neuromuscular B-Disease 1 1.0
disorder I-Disease 1 0.9999994039535522
( O 0 9.90856321436695e-08
with O 0 2.111120949166434e-07
congenital B-Disease 1 1.0
joint I-Disease 0 0.07231034338474274
contractures I-Disease 1 0.999996542930603
, O 0 2.1312741864676354e-06
respiratory O 0 0.23326195776462555
and O 0 6.632316029708818e-08
feeding O 0 7.960029506648425e-06
difficulties O 0 2.0232919268892147e-06
, O 0 1.3091646655638556e-09
tendency O 0 5.695841309716343e-08
to O 0 2.5333203979016616e-08
hyperthermia B-Disease 0 6.010791548760608e-05
, O 0 2.1439854336335884e-08
and O 0 1.4529000225138589e-08
frequent O 0 4.3215482037339825e-06
death O 0 6.4481082517886534e-06
in O 0 2.9747049268280534e-08
infancy O 0 0.02234388142824173
) O 0 3.3544771405047413e-09
with O 0 1.1423398893484205e-09
a O 0 2.8803137652744226e-08
distinct O 0 1.1317483767925296e-06
campomelic B-Disease 0 0.0006322544068098068
- I-Disease 0 0.02035536989569664
metaphyseal I-Disease 0 0.0006703760591335595
skeletal I-Disease 0 0.0011312831193208694
dysplasia I-Disease 0 0.38714104890823364
. O 0 1.6103044799820054e-06

The O 0 5.85182640122639e-08
similarity O 0 9.992031380079425e-08
of O 0 1.8981356486591494e-09
the O 0 6.930125806547949e-09
clinical O 0 1.717147824820131e-06
and O 0 7.483514963269045e-08
radiographic O 0 0.0035178239922970533
findings O 0 2.4460259737679735e-06
is O 0 3.8703729110523e-09
so O 0 3.1213178708355827e-09
extensive O 0 2.1265421423777298e-08
that O 0 3.5028784317603368e-09
these O 0 1.7308535404936265e-07
disorders O 0 0.21969632804393768
appear O 0 7.8530644032071e-07
to O 0 2.3442881413870964e-08
be O 0 8.367849346768708e-08
a O 0 5.1343029383588146e-08
single O 0 4.0178092604037374e-05
entity O 0 6.626841695833718e-06
. O 0 2.1383378623340832e-07

The O 0 4.786080012308958e-07
follow O 0 5.809737899653555e-07
- O 0 4.23610345023917e-06
up O 0 1.1137012734252494e-07
observation O 0 2.005777162139566e-07
of O 0 1.0497026581290925e-09
an O 0 2.3027713069723177e-09
identical O 0 4.323733264754992e-06
and O 0 6.764633742051274e-09
unique O 0 5.3251696385814284e-09
pattern O 0 1.0919370652118232e-06
of O 0 1.6911471112379672e-09
progressive O 0 0.0049450211226940155
bone B-Disease 1 0.9986147880554199
dysplasia I-Disease 1 0.9880538582801819
in O 0 2.5686929916446388e-08
the O 0 1.9191052302858225e-08
two O 0 6.51844118237932e-07
patients O 0 7.100115908542648e-07
( O 0 1.09609943343969e-09
one O 0 3.4804348292283294e-09
with O 0 3.5570923984096225e-08
SJS B-Disease 1 0.9632707834243774
type I-Disease 0 0.00023073298507370055
2 I-Disease 0 2.8516696559677257e-08
, O 0 1.8686294733782916e-09
one O 0 4.980056367287489e-09
with O 0 2.4807038201402065e-08
SWS B-Disease 0 0.10098372399806976
) O 0 2.680234878482679e-08
surviving O 0 7.275134521478321e-07
beyond O 0 2.4929326514211425e-07
infancy O 0 5.502497970155673e-06
adds O 0 2.2568462654248833e-08
to O 0 3.902916212439322e-09
the O 0 5.036568939686958e-09
evidence O 0 1.1204422278865422e-08
in O 0 1.586835218780891e-09
favor O 0 2.553569267149669e-08
of O 0 2.993308934051697e-09
identity O 0 1.0157957603951218e-06
. O 0 8.56202433396902e-08

The O 0 5.43381702300394e-07
hypothesis O 0 1.177531430585077e-06
that O 0 2.6829148680462822e-08
SWS B-Disease 0 0.00018195199663750827
and O 0 1.7295054988153424e-07
SJS B-Disease 0 0.14180557429790497
type I-Disease 0 1.3730685168411583e-05
2 I-Disease 0 2.5236364109559872e-08
are O 0 2.8153075426473606e-09
the O 0 2.020377642963922e-09
same O 0 7.952077680783987e-07
disorder O 0 0.00043953463318757713
should O 0 1.5600249980707304e-08
be O 0 1.5435648315076378e-09
testable O 0 1.8658168343677062e-08
by O 0 4.251378971087405e-10
molecular O 0 3.7655755846799366e-08
methods O 0 1.1684101082209963e-06
. O 0 2.779539265418407e-08
. O 0 6.814545372435532e-08

A O 0 1.8502362308936426e-06
mouse O 0 3.869743977702456e-06
model O 0 6.744563734173425e-07
of O 0 1.1657228782269158e-07
severe O 1 0.9999479055404663
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
: O 0 0.0010478643234819174
defects O 1 0.9999957084655762
in O 0 1.8914782629053661e-07
hemostasis O 1 0.9853207468986511
and O 0 2.974269045807887e-05
thrombosis B-Disease 1 0.872366189956665
. O 0 7.380692750302842e-07

von B-Disease 1 0.9984256029129028
Willebrand I-Disease 1 0.9844707250595093
factor I-Disease 0 0.0002728082472458482
( I-Disease 0 4.505550350586418e-06
vWf I-Disease 0 0.0013116853078827262
) I-Disease 0 7.223794818855822e-05
deficiency I-Disease 1 0.999622106552124
causes O 0 0.0010363188339397311
severe O 1 0.9999966621398926
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
in O 0 4.1568313235984533e-07
humans O 0 4.401150363264605e-06
. O 0 1.560595705996093e-07

We O 0 1.4142655118121183e-06
generated O 0 9.780968923678302e-09
a O 0 4.2571746128317045e-09
mouse O 0 6.31305994147624e-08
model O 0 4.3272784466807934e-08
for O 0 8.973891629793229e-10
this O 0 2.6533111263660203e-09
disease O 0 6.375839234351588e-07
by O 0 2.9935473544462354e-10
using O 0 5.6420052629846396e-08
gene O 0 7.749769679321616e-07
targeting O 0 4.399601948534837e-06
. O 0 2.0987232574043446e-07

vWf B-Disease 0 0.019268276169896126
- I-Disease 1 0.988427460193634
deficient I-Disease 0 0.0906328409910202
mice O 0 0.00012314373452682048
appeared O 0 3.089632855335367e-06
normal O 0 2.1008338535466464e-07
at O 0 8.879506907533141e-08
birth O 0 2.431717348372331e-06
; O 0 4.110727758188659e-09
they O 0 2.189163517130055e-08
were O 0 1.5262118324699259e-07
viable O 0 1.8309249583126075e-07
and O 0 2.6962272414721156e-08
fertile O 0 7.68080496982293e-07
. O 0 1.1374665120911231e-07

Neither O 0 0.00030627314117737114
vWf O 0 0.000871601514518261
nor O 0 4.4516014895634726e-05
vWf O 0 0.00012132939446019009
propolypeptide O 0 0.00010047054092865437
( O 0 9.286791282647755e-07
von B-Disease 0 0.00095772446366027
Willebrand I-Disease 0 0.0006283873808570206
antigen O 0 1.8201606508227997e-05
II O 0 9.97069673758233e-06
) O 0 1.4504191625519525e-08
were O 0 7.957549286174981e-08
detectable O 0 1.0028276165030547e-06
in O 0 1.1501317676021472e-09
plasma O 0 3.8272975899644734e-08
, O 0 8.467839762715812e-09
platelets O 0 1.2202163190977444e-07
, O 0 1.7891907955203123e-09
or O 0 2.2151290579586203e-08
endothelial O 0 3.8646430056132886e-08
cells O 0 7.02007296737861e-09
of O 0 3.4935221382426107e-10
the O 0 9.330111794270124e-09
homozygous O 0 1.3280223356559873e-05
mutant O 0 2.843761421900126e-06
mice O 0 6.126580501586432e-06
. O 0 1.2995242570923438e-07

The O 0 6.840602964075515e-07
mutant O 0 1.4940676010155585e-05
mice O 0 0.00023660615261178464
exhibited O 0 6.61458179820329e-05
defects O 1 0.9982838034629822
in O 0 1.9677768747783375e-08
hemostasis O 0 0.0006558425957337022
with O 0 9.12178865775104e-09
a O 0 3.3436574398137964e-08
highly O 0 3.5333387131686322e-06
prolonged O 1 0.7291055917739868
bleeding O 1 0.7939274907112122
time O 0 1.6914179923332995e-07
and O 0 8.217685376621375e-08
spontaneous O 0 5.755990059697069e-06
bleeding O 0 0.0014287205412983894
events O 0 5.2923347482192185e-08
in O 0 7.05022396019217e-09
approximately O 0 1.173035979462611e-08
10 O 0 1.3223179884391811e-08
% O 0 1.1849225600712998e-08
of O 0 8.894605940668043e-09
neonates O 0 1.5789397366461344e-05
. O 0 2.992500469645165e-07

As O 0 8.539147984265583e-07
in O 0 1.477678246430969e-08
the O 0 6.849936173836113e-09
human O 0 5.4082576639302715e-08
disease O 0 3.5671930618264014e-06
, O 0 7.626974607433112e-10
the O 0 1.6987636852761057e-09
factor O 0 1.8448252703251455e-08
VIII O 0 3.1297435043597943e-07
level O 0 4.1023380958904454e-07
in O 0 3.4871994181173704e-09
these O 0 2.346377314665915e-08
mice O 0 1.1623037607932929e-05
was O 0 4.0325215877601295e-07
reduced O 0 1.9818982011088337e-08
strongly O 0 1.836883001260503e-08
as O 0 1.3135518228679643e-09
a O 0 3.46710415932705e-09
result O 0 1.0055214438864368e-08
of O 0 2.158372508498374e-10
the O 0 2.197596327135898e-09
lack O 0 2.715803937292094e-08
of O 0 4.998610969586537e-10
protection O 0 1.1938335653383092e-08
provided O 0 1.757680578862164e-08
by O 0 1.5164701494541077e-08
vWf O 0 6.179155207064468e-06
. O 0 2.0062840633272572e-07

Defective O 1 0.8483150005340576
thrombosis B-Disease 1 0.5407685041427612
in O 0 4.908034156869689e-07
mutant O 0 7.860094228817616e-06
mice O 0 4.0041231841314584e-05
was O 0 3.6496660982265894e-07
also O 0 1.353577694374053e-08
evident O 0 4.445462309377035e-08
in O 0 5.203267816611401e-10
an O 0 1.756144896170042e-09
in O 0 2.860160552842217e-09
vivo O 0 4.369769328604889e-07
model O 0 7.821443404054662e-08
of O 0 1.200258292755052e-08
vascular B-Disease 0 0.0014592993538826704
injury I-Disease 1 0.6813712120056152
. O 0 5.778489935437392e-07

In O 0 2.781237071758369e-07
this O 0 5.339927611203166e-09
model O 0 5.888371745754739e-08
, O 0 1.8143531121950218e-09
the O 0 5.660812263386106e-09
exteriorized O 0 2.4633116026961943e-06
mesentery O 0 1.5462977899005637e-05
was O 0 3.671467254662275e-07
superfused O 0 9.63059733294358e-07
with O 0 1.679046945923801e-08
ferric O 0 1.6487937273268471e-06
chloride O 0 3.9489066239184467e-07
and O 0 3.837765660819059e-08
the O 0 7.11547398779544e-09
accumulation O 0 5.08260384890491e-08
of O 0 4.759386662556153e-09
fluorescently O 0 5.526422683033161e-05
labeled O 0 3.422133158892393e-05
platelets O 0 1.0259980626869947e-05
was O 0 2.3706698470959964e-07
observed O 0 3.4198830434206684e-08
by O 0 3.0292401920206657e-09
intravital O 0 6.294519607763505e-07
microscopy O 0 1.1108253374914057e-06
. O 0 2.258183826597815e-07

We O 0 6.670337825198658e-06
conclude O 0 4.271280431566993e-07
that O 0 1.8329552320395237e-09
these O 0 3.6742211495521815e-09
mice O 0 4.395482164909481e-07
very O 0 2.021064737789402e-08
closely O 0 4.042425132411154e-07
mimic O 0 0.003861622419208288
severe O 0 0.07517409324645996
human O 0 1.842037272581365e-05
von B-Disease 1 1.0
Willebrand I-Disease 1 1.0
disease I-Disease 1 1.0
and O 0 2.5408377041458152e-05
will O 0 1.7233165294783248e-07
be O 0 3.963904049442135e-08
very O 0 4.993696567368033e-09
useful O 0 9.179734306030696e-09
for O 0 6.250129302998175e-10
investigating O 0 6.196433144367575e-09
the O 0 7.594689876988525e-10
role O 0 5.236863831470373e-09
of O 0 3.5985311952480004e-10
vWf O 0 4.2544169076563776e-08
in O 0 1.637006974419819e-09
normal O 0 1.1735085791997335e-07
physiology O 0 4.8416470832535197e-08
and O 0 2.3010864325101466e-08
in O 0 2.3545052130202748e-08
disease O 0 2.649751513672527e-05
models O 0 3.2064451715996256e-07
. O 0 6.3041047937417716e-09
. O 0 4.025481814551313e-08

Oral O 0 0.0010325305629521608
contraceptives O 1 0.8617115616798401
and O 0 4.2839428715524264e-07
the O 0 6.187129031332006e-08
risk O 0 1.1433013241912704e-05
of O 0 2.3296263407246443e-07
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.982137973755016e-06

Hereditary B-Disease 1 1.0
Ovarian I-Disease 1 1.0
Cancer I-Disease 1 0.9999804496765137
Clinical O 0 0.0007983597461134195
Study O 0 1.6932785911194514e-06
Group O 0 1.081471964425873e-06
. O 0 1.4023858341261075e-07

BACKGROUND O 0 0.0008995513198897243
Women O 0 5.9936657635262236e-05
with O 0 3.1485495100014305e-08
mutations O 0 3.5317789297550917e-06
in O 0 1.6484684728368393e-09
either O 0 2.705102453148811e-08
the O 0 5.624360532863193e-09
BRCA1 O 0 5.8043759054271504e-05
or O 0 9.398719669206912e-08
the O 0 1.4139639681332028e-08
BRCA2 O 0 2.9442368031595834e-05
gene O 0 1.53031024296979e-07
have O 0 7.535806645364573e-09
a O 0 6.148165088148971e-09
high O 0 1.2119766097384854e-06
lifetime O 0 1.8122194887837395e-05
risk O 0 9.745679562911391e-05
of O 0 2.1622417989419773e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.98303336371464e-07

Oral O 0 0.0014273374108597636
contraceptives O 1 0.9967445135116577
protect O 0 0.006896904204040766
against O 1 0.9926432967185974
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 1.0098285763149306e-08
general O 0 5.045799778002902e-09
, O 0 2.8139119923054068e-09
but O 0 3.905455514541245e-09
it O 0 1.1718501724544694e-09
is O 0 5.246799106295441e-10
not O 0 6.260461593576849e-10
known O 0 1.3821445099537755e-09
whether O 0 1.039913932743275e-09
they O 0 4.627707994586672e-09
also O 0 2.5474578002615544e-09
protect O 0 1.082099299054562e-08
against O 0 1.5296354405336388e-08
hereditary B-Disease 0 6.548892997670919e-05
forms I-Disease 0 1.969190179806901e-06
of I-Disease 0 0.06890928745269775
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 8.813319709588541e-07

METHODS O 0 1.970629637071397e-05
We O 0 8.452560678051668e-07
enrolled O 0 5.369256541598588e-07
207 O 0 7.927559977360943e-07
women O 0 1.015594307318679e-06
with O 0 5.174224952497752e-06
hereditary B-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 5.1900507003210805e-08
161 O 0 1.6973556782318155e-08
of O 0 2.253988773404103e-09
their O 0 8.615705269221507e-07
sisters O 0 1.6316735127475113e-05
as O 0 1.0330663435809129e-08
controls O 0 1.6216686162806582e-06
in O 0 4.755857041516265e-09
a O 0 1.7184644818257766e-08
case O 0 3.865726583285323e-08
- O 0 1.3540468899009284e-05
control O 0 1.7823576854425482e-06
study O 0 1.4336079345866892e-07
. O 0 9.711060044992337e-08

All O 0 9.326019494437787e-07
the O 0 8.21007120066497e-08
patients O 0 3.716421019817062e-07
carried O 0 4.899111161194014e-08
a O 0 3.2089821910830096e-09
pathogenic O 0 2.196064485815441e-07
mutation O 0 2.3543350380350603e-07
in O 0 1.2513456937313094e-09
either O 0 4.3173031372134574e-08
BRCA1 O 0 5.382024937716778e-06
( O 0 9.07985064912964e-09
179 O 0 3.869887521545934e-08
women O 0 4.5072940224599733e-07
) O 0 8.313818966598774e-09
or O 0 4.2907220176857663e-07
BRCA2 O 0 0.00017308967653661966
( O 0 1.6839475591723385e-08
28 O 0 9.911701681630802e-08
women O 0 3.3776015584408015e-07
) O 0 1.3408761212474474e-08
. O 0 4.1577582265972524e-08

The O 0 4.4567926238414657e-07
control O 0 3.3076589716074523e-06
women O 0 8.690950608070125e-07
were O 0 2.803595400280301e-08
enrolled O 0 1.489336121096585e-08
regardless O 0 6.346100089871243e-09
of O 0 1.6852953754753486e-10
whether O 0 6.240174599270176e-09
or O 0 4.784277507496881e-07
not O 0 5.037830419496458e-07
they O 0 4.7160867211459845e-07
had O 0 1.0396059906270239e-06
either O 0 2.2090476647917967e-07
mutation O 0 3.029463869097526e-06
. O 0 1.2683101147104026e-07

Lifetime O 0 4.4164888095110655e-05
histories O 0 6.927511549292831e-06
of O 0 2.809488997002063e-08
oral O 0 2.148553448932944e-06
- O 0 2.8622347599593922e-05
contraceptive O 0 0.0002440791722619906
use O 0 4.4406301640265156e-06
were O 0 7.386202923953533e-06
obtained O 0 1.1852933745615246e-08
by O 0 1.956529604996149e-09
interview O 0 6.530718223984877e-07
or O 0 8.389872618863592e-08
by O 0 7.038745697407478e-10
written O 0 9.693844837954657e-09
questionnaire O 0 3.282276850313792e-08
and O 0 1.9251690019927992e-08
were O 0 1.0883092471658529e-07
compared O 0 6.5859113718147455e-09
between O 0 1.6190782048397523e-08
patients O 0 1.4132554326806712e-07
and O 0 1.4470701081847892e-08
control O 0 2.0590525309671648e-05
women O 0 1.1156003893120214e-05
, O 0 2.066294468860974e-09
after O 0 1.758310053112666e-09
adjustment O 0 1.3445383473253969e-08
for O 0 5.179721096482126e-10
year O 0 1.3164287437916755e-09
of O 0 6.302587340911714e-10
birth O 0 6.103213308961131e-06
and O 0 2.3318423814089329e-07
parity O 0 5.1938735850853845e-05
. O 0 2.452495664329035e-07

RESULTS O 0 2.608181966934353e-05
The O 0 1.764439474527535e-07
adjusted O 0 0.0002466515579726547
odds O 0 9.024501196108758e-05
ratio O 0 0.00023324659559875727
for O 0 0.015869708731770515
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
associated O 0 1.1658846688078484e-06
with O 0 3.9044798505472045e-09
any O 0 6.267035779217167e-09
past O 0 2.0267082234681766e-08
use O 0 1.0447574361194256e-08
of O 0 4.574212564278923e-09
oral O 0 2.5805729819694534e-06
contraceptives O 1 0.9904318451881409
was O 0 2.344903077755589e-05
0 O 0 4.5902439183009847e-07
. O 0 1.365141883979959e-07

5 O 0 5.978623903502012e-06
( O 0 3.3003161092892697e-07
95 O 0 7.647344659744704e-07
percent O 0 1.7724095187077182e-06
confidence O 0 2.501019707779051e-06
interval O 0 8.219501523853978e-07
, O 0 3.7037448663568284e-09
0 O 0 7.66261454288042e-09
. O 0 7.096929155459009e-10
3 O 0 4.44852243930427e-09
to O 0 9.732416650365394e-09
0 O 0 1.301279155541124e-07
. O 0 4.044419910087527e-09
8 O 0 8.21332903910843e-08
) O 0 1.657555870338001e-08
. O 0 4.8221824755501075e-08

The O 0 1.2409830105752917e-06
risk O 0 5.247902663541026e-06
decreased O 0 4.2838530589506263e-07
with O 0 1.8762149611717405e-09
increasing O 0 2.149099209702854e-08
duration O 0 1.2164912277512485e-07
of O 0 1.0064035160795015e-09
use O 0 5.1714145854475646e-08
( O 0 1.2626217404942963e-08
P O 0 3.23518770528608e-06
for O 0 1.561328066834733e-09
trend O 0 5.33968091076531e-07
, O 0 4.786442353577058e-09
< O 0 1.3678813104434084e-07
0 O 0 2.9175916793633405e-08
. O 0 1.3621080929837603e-09
001 O 0 5.093638222319896e-08
) O 0 2.0042190129743176e-09
; O 0 2.6918825501986987e-10
use O 0 7.568331739093992e-09
for O 0 6.250692852205475e-09
six O 0 3.5204831760893285e-07
or O 0 8.478542667944566e-08
more O 0 1.3616223704104868e-09
years O 0 2.317396230466784e-08
was O 0 1.4034307582733163e-07
associated O 0 5.762363475270149e-09
with O 0 6.606062363800902e-10
a O 0 1.2082517208966692e-08
60 O 0 6.1448382382423e-08
percent O 0 2.2974425917254848e-07
reduction O 0 2.754985573005797e-08
in O 0 1.0204077582898208e-08
risk O 0 2.735742555159959e-06
. O 0 5.3954611445306e-08

Oral O 0 0.0003495682030916214
- O 0 5.3799500165041536e-05
contraceptive O 0 0.00012363048153929412
use O 0 2.330851657461608e-06
protected O 0 0.01919178105890751
against O 1 0.642871618270874
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
both O 0 7.518851319332498e-09
for O 0 1.794419723921692e-09
carriers O 0 5.3133728528109714e-08
of O 0 2.7257024415305864e-10
the O 0 1.1750020512124593e-08
BRCA1 O 0 0.00012725921988021582
mutation O 0 1.1983548802163568e-06
( O 0 1.504829683085518e-08
odds O 0 4.2268907236575615e-06
ratio O 0 1.7302771766480873e-06
, O 0 3.4240847934796648e-09
0 O 0 6.539421892881592e-09
. O 0 3.0812469242746943e-10
5 O 0 1.3690181210890273e-09
; O 0 1.0230615243855823e-09
95 O 0 6.124104601212821e-08
percent O 0 1.6227654668909963e-06
confidence O 0 2.1225856471573934e-05
interval O 0 1.0244689292449038e-05
, O 0 1.02756585462771e-08
0 O 0 1.1064048344167077e-08
. O 0 4.1658035354608103e-10
3 O 0 1.9305734788588325e-09
to O 0 2.228336626330929e-09
0 O 0 4.895039040775373e-08
. O 0 7.36456451377876e-10
9 O 0 8.406751739187257e-09
) O 0 2.3297988538395487e-10
and O 0 1.0066051325807734e-09
for O 0 4.599985115039118e-10
carriers O 0 2.1422726703690387e-08
of O 0 4.631361683049562e-10
the O 0 1.6800401070327098e-08
BRCA2 O 0 0.0001065453325281851
mutation O 0 5.126298674440477e-07
( O 0 8.751014135555124e-09
odds O 0 1.5544994766969467e-06
ratio O 0 1.4301465398602886e-06
, O 0 2.751680883150698e-09
0 O 0 7.328136764073179e-09
. O 0 6.441276956259401e-10
4 O 0 4.606168335641314e-09
; O 0 3.2958256124260288e-09
95 O 0 7.528353762609186e-08
percent O 0 7.593502687086584e-06
confidence O 0 0.00015167970559559762
interval O 0 1.9697989046107978e-05
, O 0 7.354629794065204e-09
0 O 0 5.20615905941213e-09
. O 0 1.6766452115568597e-10
2 O 0 2.699575674114385e-09
to O 0 3.6321636809333313e-09
1 O 0 1.4823530847252187e-08
. O 0 1.599067434021606e-09
1 O 0 1.7086758674622615e-08
) O 0 1.1836124969022421e-08
. O 0 5.209192011079722e-08

CONCLUSIONS O 0 2.6903589969151653e-05
Oral O 0 2.628958463901654e-05
- O 0 4.107569839106873e-05
contraceptive O 0 7.165900751715526e-05
use O 0 3.783354713959852e-07
may O 0 3.537080885962496e-07
reduce O 0 1.355777072831188e-07
the O 0 8.930474137969213e-09
risk O 0 9.116161891142838e-06
of O 0 1.4895142612658674e-06
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 6.530485041622569e-09
women O 0 1.1729458293530115e-07
with O 0 2.0785202448081463e-09
pathogenic O 0 7.197470495157177e-07
mutations O 0 1.3678464938493562e-06
in O 0 1.7073944480472392e-09
the O 0 1.2160707996144993e-08
BRCA1 O 0 0.0002889671304728836
or O 0 1.566171704325825e-05
BRCA2 O 0 0.002847899217158556
gene O 0 0.00023033250181470066

A O 0 3.7709810385422315e-06
Japanese O 0 1.5113813560674316e-06
family O 0 1.9695121977747476e-07
with O 0 4.316397550496731e-08
adrenoleukodystrophy B-Disease 1 1.0
with O 0 3.922800217992517e-08
a O 0 5.742353792470567e-08
codon O 0 2.4443422717013163e-06
291 O 0 1.4004318416027672e-07
deletion O 0 1.8727729411693872e-06
: O 0 1.2444936636768489e-08
a O 0 1.3347725591472681e-08
clinical O 0 4.978343895345461e-06
, O 0 6.128332508126277e-09
biochemical O 0 1.8579987681732746e-06
, O 0 4.8882253800286435e-09
pathological O 0 1.9223020331082807e-07
, O 0 1.2976451024826474e-08
and O 0 6.467603697046798e-08
genetic O 0 9.670048893895e-05
report O 0 1.3545045476348605e-06
. O 0 1.8547682145708677e-07

We O 0 5.61139904675656e-06
report O 0 6.500203397763471e-08
a O 0 3.994762742820512e-09
Japanese O 0 2.835020218583395e-08
family O 0 2.471890603317206e-08
with O 0 1.3202871684825368e-07
adrenoleukodystrophy B-Disease 1 1.0
( O 0 3.1631836463930085e-05
ALD B-Disease 1 1.0
) O 0 3.563835804243354e-08
with O 0 4.088668958956987e-09
a O 0 3.446961827080486e-08
three O 0 7.917550703950837e-08
base O 0 4.753891573727742e-07
pair O 0 2.954292767753941e-06
deletion O 0 6.37166067463113e-06
( O 0 3.0284617480447196e-08
delGAG O 0 2.0226156038916088e-07
291 O 0 7.189581197053485e-08
) O 0 2.7434481353338924e-09
in O 0 2.8271944785274172e-09
the O 0 1.9647640669973043e-07
ALD B-Disease 1 1.0
gene O 0 2.1829086108482443e-05
. O 0 2.6300548938706925e-07

A O 0 8.832226399135834e-07
variety O 0 7.884592889695341e-08
of O 0 8.161603837208986e-09
phenotypes O 0 5.976303327770438e-06
were O 0 3.809890927186643e-07
observed O 0 4.1999701494432884e-08
within O 0 4.761965932686962e-09
this O 0 1.0515823767320853e-09
family O 0 8.716818200582566e-08
. O 0 5.9284001707737843e-08

While O 0 3.244246499889414e-06
the O 0 5.96546740894155e-08
proband O 0 5.574254828388803e-06
( O 0 5.422180748837491e-08
patient O 0 1.7026137584252865e-06
1 O 0 1.2124855786055377e-08
) O 0 3.2438498553943873e-09
was O 0 8.268153095514208e-08
classified O 0 3.094579028584121e-07
as O 0 1.9557171881956492e-08
having O 0 1.6141716230322345e-07
a O 0 1.8363495168927102e-09
rare O 0 2.6961588517337987e-09
intermediate O 0 3.4684418892538815e-08
type O 0 7.725772661615338e-07
of O 0 1.656442538688907e-09
adult O 0 2.6959446586261038e-06
cerebral O 0 0.0005226662615314126
and O 0 1.5385473943752004e-06
cerebello O 0 0.2614672780036926
- O 0 0.196819007396698
brain O 0 0.0042755440808832645
stem O 0 4.3037047703364806e-07
forms O 0 4.277549692233151e-08
, O 0 4.283238208557805e-09
his O 0 2.894627293414942e-08
younger O 0 8.040843795242836e-07
brother O 0 1.1397438584026531e-06
( O 0 1.8433057746847226e-08
patient O 0 3.646145501079445e-07
2 O 0 1.1725616921864912e-08
) O 0 2.2617145933878646e-09
and O 0 5.265813030064237e-08
nephew O 0 2.8000153179164045e-05
( O 0 7.805378743341862e-08
patient O 0 1.903912902889715e-06
3 O 0 2.6733321334404536e-08
) O 0 6.735562330106859e-09
had O 0 1.7670176077899669e-07
a O 0 1.8849577543278428e-07
childhood O 1 0.8673717379570007
ALD B-Disease 1 1.0
type O 0 0.29443418979644775
. O 0 1.006379193313478e-06

Another O 0 7.736863153695595e-06
nephew O 0 3.3735872420948e-05
( O 0 5.368656843529607e-07
patient O 0 4.939343853038736e-06
4 O 0 4.0529005929101913e-08
) O 0 3.2137477123939107e-09
of O 0 2.7134570146358783e-09
patient O 0 1.5891000657575205e-05
1 O 0 4.176786916332276e-08
was O 0 2.9144476343390124e-07
classified O 0 2.517687391900836e-07
as O 0 2.1410800243870654e-08
having O 0 5.44634588095505e-07
an O 0 7.220031239540958e-09
adolescent O 0 8.435025847575162e-06
form O 0 1.2476568826969014e-06
. O 0 2.713435947043763e-07

The O 0 1.8081327368690836e-07
tau O 0 2.736225326316344e-07
level O 0 3.181174008659582e-07
in O 0 1.518658443444565e-08
the O 0 7.87293075177331e-08
cerebrospinal O 0 0.00500909611582756
fluid O 0 3.978708264185116e-05
( O 0 3.006344968525809e-07
CSF O 0 0.0007420187466777861
) O 0 4.121829544345701e-09
in O 0 2.347965377680339e-09
patient O 0 2.019232397287851e-06
1 O 0 1.1323660231710164e-08
was O 0 1.8544976398970903e-07
as O 0 3.060735886961652e-09
high O 0 2.6462014801609257e-08
as O 0 1.003197191984384e-09
that O 0 2.0617973994774275e-10
of O 0 6.357618320684821e-10
patients O 0 1.318983322562417e-07
with O 0 1.8394604239801993e-07
Alzheimers B-Disease 1 0.9999998807907104
disease I-Disease 1 0.984863817691803
( O 0 3.292333872195741e-08
AD B-Disease 0 8.131197319016792e-06
) O 0 4.964761046721833e-08
. O 0 9.319852267708484e-08

His O 0 7.521258794440655e-06
brain O 0 1.2732652066915762e-05
magnetic O 0 9.937045888364082e-07
resonance O 0 1.6958724700089078e-06
image O 0 4.854438884649426e-05
( O 0 1.0587641696702121e-07
MRI O 0 0.00019106057879980654
) O 0 9.367060727072385e-08
showed O 0 1.7785148884286173e-05
abnormalities B-Disease 1 0.9129844307899475
in I-Disease 0 1.4164547312844888e-09
the I-Disease 0 3.179809748843354e-09
bilateral I-Disease 0 9.175604418487637e-07
cerebellar I-Disease 0 1.1526506568770856e-05
hemispheres I-Disease 0 5.9558224165812135e-05
and O 0 4.749776678636408e-07
brain O 0 6.892187229823321e-05
stem O 0 8.311228612001287e-07
, O 0 6.652749462432439e-09
but O 0 6.20707929499531e-09
not O 0 7.725159179017282e-09
in O 0 1.253433468129117e-09
the O 0 1.208551303477634e-08
cerebral O 0 6.379154365276918e-05
white O 0 8.64967319103016e-07
matter O 0 6.212906633606963e-09
, O 0 1.5263502683993124e-09
where O 0 1.9886070568020386e-09
marked O 0 3.803080161901562e-08
reductions O 0 6.114020578706914e-08
of O 0 9.158253599927946e-10
the O 0 1.5195682934177057e-08
cerebral O 0 8.970362250693142e-05
blood O 0 2.76885134553595e-06
flow O 0 1.0388840365749274e-07
and O 0 1.0097153335664188e-07
oxygen O 0 3.3068408811232075e-07
metabolism O 0 5.763739636677201e-07
were O 0 1.551139376942956e-07
clearly O 0 3.0916581295059586e-08
demonstrated O 0 2.5548541060516072e-09
by O 0 9.089965447017789e-10
positron O 0 2.3111641667128424e-07
emission O 0 1.3492057178154937e-06
tomography O 0 6.0746438066416886e-06
( O 0 1.9482510538182396e-07
PET O 0 4.1486946429358795e-06
) O 0 5.768557542751296e-08
. O 0 7.572970162073034e-08

In O 0 1.9575666101445677e-06
patients O 0 2.7897483960259706e-05
2 O 0 3.530636405457699e-08
and O 0 1.1195343319059248e-08
3 O 0 1.6546371384151826e-08
, O 0 9.911730325384838e-10
the O 0 4.719053592339151e-09
autopsy O 0 1.409046399203362e-05
findings O 0 2.997612966737506e-07
showed O 0 2.2250030724535463e-06
massive O 0 1.09526092728629e-06
demyelination B-Disease 1 1.0
of I-Disease 0 8.815579377596805e-09
the I-Disease 0 3.655838298755043e-08
cerebral I-Disease 0 0.0007170860772021115
white I-Disease 0 3.6103810430176964e-07
matter I-Disease 0 2.947750932236204e-09
with O 0 9.231174713519863e-10
sparing O 0 1.1547086842256249e-08
of O 0 6.729009571770916e-10
the O 0 1.3768118201085144e-08
U O 0 1.8809847460943274e-05
- O 0 0.008285829797387123
fibers O 0 4.0220722439698875e-05
, O 0 1.7908944327515997e-09
compatible O 0 2.1537031713592114e-08
with O 0 2.1336754585377093e-09
the O 0 4.461301994496125e-09
findings O 0 2.806773480301672e-08
of O 0 1.1521984255580264e-08
childhood O 0 0.3986905515193939
ALD B-Disease 1 1.0
. O 0 7.37964398922486e-07

Oleic O 0 0.0055600423365831375
and O 0 5.37055029781186e-06
erucic O 0 0.000938551442231983
acids O 0 4.113320756005123e-06
( O 0 7.646951871720375e-08
Lorenzos O 0 1.100667077480466e-06
Oil O 0 6.856945589106545e-08
) O 0 2.166333556985478e-09
were O 0 8.702526699266855e-09
administered O 0 7.90157095309496e-09
to O 0 4.563615707553481e-09
patients O 0 6.297425159118575e-08
1 O 0 1.9610204571307577e-09
and O 0 1.0233802250070312e-08
4 O 0 1.774631641637825e-08
, O 0 1.655873882455694e-09
but O 0 1.2558599715717378e-09
sufficient O 0 2.5966482297690163e-08
effectiveness O 0 4.2443346615073096e-07
was O 0 4.4789405251322023e-07
not O 0 2.8406821783732994e-08
obtained O 0 1.414059056514816e-07
. O 0 8.737575285522325e-08

The O 0 3.2770384450486745e-07
findings O 0 1.3224610029283212e-07
in O 0 1.703244101314283e-09
this O 0 8.537896500904196e-10
family O 0 1.0835284669497014e-08
suggest O 0 3.0982342025254184e-08
that O 0 1.5774321848738282e-09
delGAG291 O 0 1.0438974840099036e-07
is O 0 2.2971462232401763e-10
part O 0 3.3842556534935397e-10
of O 0 2.492425432709666e-10
the O 0 2.9342432927847995e-09
cause O 0 3.758744426818339e-08
of O 0 1.8865964346304054e-09
Japanese O 0 5.072388375992887e-05
ALD B-Disease 1 1.0
with O 0 2.3127112669385497e-08
phenotypic O 0 4.522550625551958e-06
variations O 0 2.32245001825504e-05
. O 0 3.5539872556000773e-07

Moreover O 0 1.7994532754528336e-05
, O 0 6.903584903739102e-08
although O 0 7.426804060628456e-09
the O 0 1.1709385683289497e-09
scale O 0 8.508025928222196e-08
of O 0 6.900787163921507e-10
the O 0 2.892782458019383e-09
study O 0 3.775008305950678e-09
is O 0 4.673077480532584e-09
limited O 0 3.453812880138685e-08
, O 0 3.0085973712346004e-09
there O 0 3.879359944392036e-09
is O 0 4.752182536371663e-10
a O 0 1.290154316713199e-09
possibility O 0 3.8310350447545716e-09
that O 0 5.089923482692882e-10
PET O 0 3.102693710843596e-07
can O 0 1.0119344295844712e-07
detect O 0 0.0042802500538527966
an O 0 1.5134650865888943e-08
insidious B-Disease 0 3.5000048228539526e-05
lesion I-Disease 0 0.07358569651842117
which O 0 1.5006483522483904e-07
is O 0 2.118607156376129e-08
undetectable O 0 2.905155952248606e-06
by O 0 2.076202321177334e-09
computed O 0 3.4186382436018903e-07
tomogram O 0 9.928851341101108e-07
( O 0 7.214855379800156e-09
CT O 0 6.697217941109557e-06
) O 0 7.960293757491854e-09
or O 0 2.3383666558629557e-08
MRI O 0 1.2382237173369504e-06
analysis O 0 1.0680189888034874e-07
, O 0 1.520687398226528e-08
and O 0 1.4990257923841455e-08
that O 0 1.5697606547959708e-09
the O 0 2.1376267422823503e-09
higher O 0 2.7416080072839577e-08
level O 0 5.943117997730951e-08
of O 0 1.850850028795037e-10
tau O 0 4.705706047047897e-09
reflects O 0 3.688700456194738e-09
the O 0 7.659337608600936e-10
process O 0 1.1949490286156106e-09
of O 0 2.1611130662790856e-09
neuronal B-Disease 0 3.677161430459819e-06
degeneration I-Disease 0 0.00016689242329448462
in O 0 6.765215516679746e-07
ALD B-Disease 1 1.0
. O 0 2.5436925170652103e-06

Lorenzos O 0 0.00022066042583901435
Oil O 0 4.209845428704284e-06
should O 0 9.27564229868949e-08
be O 0 1.2607944688269868e-09
given O 0 1.3681011878929894e-10
in O 0 1.1082729178824025e-10
the O 0 5.382381207397202e-10
early O 0 4.545583465187519e-08
stage O 0 2.8097438189433888e-06
. O 0 7.891721054420486e-09
. O 0 3.635478407204573e-08

Nonsense O 0 0.00022424290364142507
mutation O 0 1.0198570635111537e-05
in O 0 2.7717250716818853e-08
exon O 0 6.430161647585919e-07
4 O 0 4.159058875075061e-08
of O 0 2.440510460388623e-09
human O 0 2.0967021896467486e-08
complement O 0 2.311450657543901e-07
C9 O 0 7.548248049715767e-06
gene O 0 8.4626185525849e-07
is O 0 4.050309865277768e-09
the O 0 1.6811098069169361e-09
major O 0 2.408484078841866e-08
cause O 0 3.5193679082112794e-08
of O 0 1.3531356035656472e-09
Japanese O 0 1.3022142866248032e-06
complement B-Disease 0 6.653214950347319e-05
C9 I-Disease 1 0.6043154001235962
deficiency I-Disease 0 0.004914009477943182
. O 0 2.5682186333142454e-07

Deficiency B-Disease 1 0.9995902180671692
of I-Disease 0 3.317789065704346e-08
the I-Disease 0 1.99061158667746e-08
ninth I-Disease 0 8.524315830982232e-07
component I-Disease 0 2.8958698550241024e-08
of I-Disease 0 4.844893930489036e-10
human I-Disease 0 7.83069520338131e-09
complement I-Disease 0 1.1183545467474687e-07
( O 0 7.587367178985005e-09
C9 O 0 9.010720987134846e-07
) O 0 8.659654660014837e-10
is O 0 1.4064366338217837e-10
the O 0 1.7745316327477667e-10
most O 0 1.8189407757773779e-09
common O 0 1.7939264580490999e-06
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 3.1513838205654565e-09
Japan O 0 1.3516485353193275e-07
but O 0 2.8118838368840215e-09
is O 0 2.5309707107901147e-10
rare O 0 3.5363481587502577e-10
in O 0 3.082304966817162e-10
other O 0 1.608958521970294e-09
countries O 0 1.267183957764928e-08
. O 0 5.5224418815669196e-08

We O 0 3.342228183100815e-06
studied O 0 1.2544748528853233e-07
the O 0 2.4293551614817943e-09
molecular O 0 2.9466731277238978e-08
basis O 0 1.301025598365868e-08
of O 0 4.794254326867531e-09
C9 B-Disease 1 0.9800862073898315
deficiency I-Disease 0 0.2501961886882782
in O 0 2.3851134400842966e-09
four O 0 2.3188643893945482e-08
Japanese O 0 4.821998800252913e-07
C9 B-Disease 0 0.00011757203901652247
- I-Disease 0 0.0006393531220965087
deficient I-Disease 0 0.002133031841367483
patients O 0 3.8578123167098965e-06
who O 0 3.681477096506569e-07
had O 0 1.7260816093767062e-05
suffered O 1 0.9855204224586487
from O 0 1.1135628483316395e-05
meningococcal B-Disease 1 1.0
meningitis I-Disease 1 1.0
. O 0 1.3971224461784004e-06

Direct O 0 6.435305294871796e-06
sequencing O 0 2.5460467441007495e-06
of O 0 4.896869043591323e-08
amplified O 0 2.9531377094826894e-06
C9 O 0 1.1360348253219854e-05
cDNA O 0 1.4388760973815806e-06
and O 0 9.880481144364239e-08
DNA O 0 8.974838578978961e-07
revealed O 0 2.246205355049824e-07
a O 0 1.8806012747063505e-08
nonsense O 0 2.5787915092223557e-07
substitution O 0 3.178101692924429e-08
( O 0 1.6735731023231892e-08
CGA O 0 7.041517164907418e-07
- O 0 2.5902263587340713e-05
- O 0 1.5074809198267758e-05
> O 0 6.160164502944099e-07
TGA O 0 3.7513500501518138e-06
) O 0 2.112816410715368e-08
at O 0 2.18525038064854e-08
codon O 0 1.0383649851064547e-07
95 O 0 1.648217740068958e-08
in O 0 1.1566324564782349e-09
exon O 0 9.693738434179977e-08
4 O 0 2.30003340817575e-08
in O 0 8.81690331855367e-10
the O 0 4.733928360423079e-09
four O 0 3.741806438029016e-07
C9 B-Disease 0 0.00022951043501961976
- I-Disease 0 0.00982139352709055
deficient I-Disease 0 0.00017845261027105153
individuals O 0 1.1841796521139258e-07
. O 0 2.8752582537094895e-08

An O 0 4.367007306882442e-07
allele O 0 4.4570278987521306e-06
- O 0 6.855924539195257e-07
specific O 0 7.218849873424915e-08
polymerase O 0 8.690370805197745e-07
chain O 0 8.564030622437713e-07
reaction O 0 1.719152997736728e-08
system O 0 1.5782847029299774e-08
designed O 0 6.61080790109736e-08
to O 0 3.4544238580735964e-09
detect O 0 0.000625851156655699
exclusively O 0 1.5201457870261947e-07
only O 0 7.826902681529191e-09
one O 0 7.856782446857835e-10
of O 0 1.254676501583063e-10
the O 0 2.2152464307367836e-09
normal O 0 4.7634763689075044e-08
and O 0 3.94130772463086e-09
mutant O 0 9.611002127485335e-08
alleles O 0 3.899227607462308e-08
indicated O 0 4.307482015519781e-08
that O 0 5.143648285077518e-10
all O 0 8.698324838185556e-10
the O 0 1.204022659351267e-09
four O 0 3.486576645173045e-07
patients O 0 2.3431579165844596e-07
were O 0 1.0048986354149747e-07
homozygous O 0 1.5819230725355737e-07
for O 0 2.884379124434844e-10
the O 0 1.4975333195721419e-09
mutation O 0 4.4651010000507085e-08
in O 0 2.468439341818396e-10
exon O 0 3.028750583666806e-08
4 O 0 2.095210938080072e-08
and O 0 6.011335873523649e-09
that O 0 9.237215436996848e-10
the O 0 4.138340781167926e-09
parents O 0 2.7892047782529517e-08
of O 0 8.410211971288106e-10
patient O 0 1.6136621638906945e-07
2 O 0 3.4776498125665967e-08
were O 0 6.244766836971394e-07
heterozygous O 0 7.3035080276895314e-06
. O 0 1.705192858025839e-07

The O 0 5.209698770158866e-07
common O 0 4.3725080445256026e-07
mutation O 0 1.9319061266287463e-06
at O 0 6.557710463539479e-08
codon O 0 3.481732164800633e-07
95 O 0 2.744867799719941e-08
in O 0 1.5847180234729308e-09
exon O 0 1.2602727395005786e-07
4 O 0 8.450675892390791e-08
might O 0 9.27282854945588e-08
be O 0 7.619243014289623e-09
responsible O 0 2.841175295031917e-08
for O 0 5.87902837523302e-10
most O 0 6.100262073260865e-09
Japanese O 0 5.884620804863516e-06
C9 B-Disease 1 0.9060858488082886
deficiency I-Disease 0 0.00019799081201199442
. O 0 9.697100011862858e-09
. O 0 5.9362072590829484e-08

BRCA1 O 0 0.0017183935269713402
required O 0 2.4959449547168333e-06
for O 0 2.7445796746405904e-08
transcription O 0 7.3568107836763375e-06
- O 0 0.00017123043653555214
coupled O 0 3.453665704000741e-05
repair O 0 0.00039234760333783925
of O 0 1.5630272187650007e-08
oxidative O 0 7.908908446552232e-05
DNA O 0 0.00021697331976611167
damage O 0 0.000313614058541134
. O 0 4.651054155146994e-07

The O 0 2.7597676307777874e-05
breast B-Disease 1 0.9999988079071045
and I-Disease 1 0.9998939037322998
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
susceptibility O 0 0.0030286642722785473
gene O 0 9.360163676319644e-05
BRCA1 O 0 0.0003642492229118943
encodes O 0 3.473345486781909e-06
a O 0 1.6150706869666465e-06
zinc O 1 0.7559853196144104
finger O 0 0.020541410893201828
protein O 0 1.47373987147148e-06
of O 0 2.0744497675195817e-08
unknown O 0 9.41180303470901e-07
function O 0 7.317315180443984e-07
. O 0 1.871184451829322e-07

Association O 0 1.8306487845620723e-06
of O 0 1.511001812559698e-08
the O 0 2.6930047525297596e-08
BRCA1 O 0 6.361442501656711e-06
protein O 0 8.862281930532845e-08
with O 0 4.252232344015283e-09
the O 0 7.32771754385908e-09
DNA O 0 8.120565553326742e-07
repair O 0 9.678709830041043e-06
protein O 0 3.993828556758672e-07
Rad51 O 0 2.4349428713321686e-06
and O 0 1.4688660066042303e-08
changes O 0 5.112235523796471e-09
in O 0 5.311898143567362e-10
the O 0 4.70854966128087e-10
phosphorylation O 0 1.7515194628003883e-08
and O 0 1.3897557771258562e-08
cellular O 0 8.502251347408674e-08
localization O 0 1.467533650156838e-07
of O 0 7.111508604218386e-10
the O 0 2.566018064698028e-09
protein O 0 2.2106508623664922e-08
after O 0 1.6466936259007525e-08
exposure O 0 7.195932880676992e-07
to O 0 1.2000110238830075e-08
DNA O 0 1.295147740165703e-05
- O 0 8.008723671082407e-05
damaging O 0 6.546145596075803e-05
agents O 0 4.441627652340685e-07
are O 0 2.2607666849694397e-08
consistent O 0 1.4419239846574783e-07
with O 0 1.0051048882075975e-09
a O 0 3.9250438454985215e-09
role O 0 2.9824938962974556e-08
for O 0 5.614242404305969e-09
BRCA1 O 0 7.5896800808550324e-06
in O 0 1.3726060288377084e-08
DNA O 0 3.199750835847226e-06
repair O 0 0.0006087781512178481
. O 0 5.227585688771796e-07

Here O 0 1.5984116998879472e-06
, O 0 1.6796555257769796e-08
it O 0 7.960805903373114e-10
is O 0 2.1839148545144127e-10
shown O 0 9.9063635072838e-10
that O 0 4.711891987696504e-10
mouse O 0 6.029729320289334e-07
embryonic O 0 1.5792564909133944e-06
stem O 0 1.6299342178172083e-06
cells O 0 6.086921757741948e-07
deficient B-Disease 0 7.04048318311834e-07
in I-Disease 0 2.68408562043021e-09
BRCA1 I-Disease 0 6.497255071735708e-06
are O 0 2.1495171864671647e-08
defective O 0 1.3568471786129521e-06
in O 0 1.7779576699794575e-09
the O 0 1.7756566217386194e-09
ability O 0 2.594445192016792e-08
to O 0 3.849934149258161e-09
carry O 0 3.5873927117791027e-07
out O 0 6.509731775850014e-08
transcription O 0 1.9397707546886522e-06
- O 0 8.3570193964988e-05
coupled O 0 1.7446365745854564e-05
repair O 0 0.0001744343462632969
of O 0 5.213960374561566e-09
oxidative O 0 1.8042095689452253e-05
DNA O 0 6.264421244850382e-05
damage O 0 6.406367174349725e-05
, O 0 5.802210267802366e-09
and O 0 3.57503382453217e-09
are O 0 3.3184011094533616e-09
hypersensitive O 0 7.370550179075508e-07
to O 0 1.9113134186454772e-08
ionizing O 0 0.007161029614508152
radiation O 0 0.030269764363765717
and O 0 1.4904293266226887e-07
hydrogen O 0 7.995552095962921e-07
peroxide O 0 9.018280252348632e-05
. O 0 2.655854984823236e-07

These O 0 1.7710729025566252e-06
results O 0 8.3519347526817e-07
suggest O 0 1.2097717672077124e-07
that O 0 2.2853652303922445e-09
BRCA1 O 0 2.3273553324543172e-06
participates O 0 6.510402528192571e-08
, O 0 3.162125228328705e-09
directly O 0 2.1348244061414334e-08
or O 0 8.374603055472107e-08
indirectly O 0 2.3755424649607448e-07
, O 0 2.079214134198537e-09
in O 0 5.018596094252814e-10
transcription O 0 9.742531119627529e-07
- O 0 7.094183092704043e-05
coupled O 0 1.548400723550003e-05
repair O 0 7.129041478037834e-05
of O 0 4.469273839902144e-09
oxidative O 0 1.5703380995546468e-05
DNA O 0 8.030526805669069e-05
damage O 0 0.00023597691324539483
. O 0 3.6553363003122286e-08
. O 0 8.363908676756182e-08

Truncation O 0 0.0007448596297763288
mutations O 0 0.0007046671817079186
in O 0 8.69400409442278e-08
the O 0 1.5435420053222515e-08
transactivation O 0 2.1867863324587233e-06
region O 0 5.734199959306352e-08
of O 0 3.743117815702135e-09
PAX6 O 0 6.8114663918095175e-06
result O 0 1.298248406556013e-07
in O 0 7.120877665300895e-09
dominant O 0 4.565231574815698e-05
- O 0 6.211503205122426e-05
negative O 0 1.3083276826364454e-05
mutants O 0 3.863349775201641e-06
. O 0 2.443330515689013e-07

PAX6 O 0 0.0005491082556545734
is O 0 1.4248846014197625e-07
a O 0 1.6962099280704024e-08
transcription O 0 2.578304645339813e-07
factor O 0 6.998885027087454e-08
with O 0 2.0048538384997983e-09
two O 0 1.54689310249978e-08
DNA O 0 9.522937602923776e-07
- O 0 1.4747746490684221e-06
binding O 0 3.6688174986920785e-07
domains O 0 6.279847752921341e-07
( O 0 1.3829230205431031e-08
paired O 0 9.174816568702227e-07
box O 0 7.590712698402058e-07
and O 0 2.5224476729590606e-08
homeobox O 0 1.9461842271084606e-07
) O 0 3.6703409200811166e-09
and O 0 2.107176877430561e-09
a O 0 1.3087359640451268e-08
proline O 0 2.4794940145511646e-06
- O 0 5.080121354694711e-06
serine O 0 3.336387408126029e-06
- O 0 4.4424086809158325e-06
threonine O 0 2.823394197548623e-06
( O 0 3.3536469601358476e-08
PST O 0 4.4580806957128516e-07
) O 0 1.9318710187121724e-08
- O 0 2.5324877128696244e-07
rich O 0 5.9911698713222e-08
transactivation O 0 3.2389107218477875e-06
domain O 0 4.5549043647952203e-07
. O 0 2.0020830504563492e-07

PAX6 O 0 0.004447066690772772
regulates O 0 8.35386454127729e-05
eye O 0 0.0017769529949873686
development O 0 6.733946378290057e-08
in O 0 8.240361282219055e-09
animals O 0 7.68684138563458e-09
ranging O 0 1.3924090325190264e-08
from O 0 2.2927875154010735e-09
jellyfish O 0 5.9474354330291135e-09
to O 0 1.2843428542907986e-09
Drosophila O 0 2.1288107276973278e-08
to O 0 1.4061753539351685e-08
humans O 0 2.9387152267190686e-07
. O 0 8.941777451809685e-08

Heterozygous O 0 0.0008997232653200626
mutations O 0 4.961683225701563e-05
in O 0 1.1745001415874867e-08
the O 0 3.925882285926718e-09
human O 0 1.6452275986011955e-08
PAX6 O 0 6.72926080369507e-06
gene O 0 1.2233406323503004e-06
result O 0 9.467304806776156e-08
in O 0 2.560698542097839e-09
various O 0 1.6143419045988594e-08
phenotypes O 0 7.110034403012833e-06
, O 0 4.884143312011702e-09
including O 0 7.628494813616271e-08
aniridia B-Disease 1 1.0
, O 0 1.2107866496080533e-06
Peters B-Disease 1 1.0
anomaly I-Disease 1 0.9999994039535522
, O 0 1.5366748584710876e-07
autosomal B-Disease 1 0.7420851588249207
dominant I-Disease 0 0.03564026579260826
keratitis I-Disease 0 0.007139360997825861
, O 0 6.167382338162497e-08
and O 0 2.4524044306417636e-07
familial B-Disease 1 0.9932356476783752
foveal I-Disease 1 0.8406621813774109
dysplasia I-Disease 1 0.9997965693473816
. O 0 2.275186261613271e-06

It O 0 7.205271685961634e-07
is O 0 1.707522478966439e-08
believed O 0 1.924144754639201e-08
that O 0 1.2334518129097916e-10
the O 0 6.341777103457957e-10
mutated O 0 6.499421800754135e-08
allele O 0 7.525295586674474e-08
of O 0 1.0475265099785247e-09
PAX6 O 0 2.2078543224779423e-06
produces O 0 4.8360078608311596e-08
an O 0 3.2193674392999583e-09
inactive O 0 3.4320510167162865e-07
protein O 0 6.273567976222694e-08
and O 0 8.859980766828812e-07
aniridia B-Disease 1 1.0
is O 0 1.157600166834527e-07
caused O 0 3.696389967444702e-07
due O 0 4.714557633178629e-08
to O 0 4.461534075517193e-08
genetic O 0 0.0008519105613231659
haploinsufficiency O 0 0.00022041313059162349
. O 0 2.361371116421651e-07

However O 0 2.026029960688902e-06
, O 0 1.0328457200614594e-08
several O 0 5.01500085903217e-09
truncation O 0 7.42424333566305e-07
mutations O 0 1.2544008313852828e-05
have O 0 9.844026038763332e-08
been O 0 2.302183865765528e-08
found O 0 5.170642136675951e-09
to O 0 1.65878843993994e-09
occur O 0 2.713504976270542e-08
in O 0 1.079501377176939e-09
the O 0 6.6016845323702e-08
C O 0 0.001155457110144198
- O 0 1.159970724984305e-05
terminal O 0 4.644237208140112e-07
half O 0 1.803912397235763e-08
of O 0 7.728338524692902e-10
PAX6 O 0 1.2077387054887367e-06
in O 0 1.7401744045741907e-08
patients O 0 4.4193143367010634e-07
with O 0 2.6108168071914406e-08
Aniridia B-Disease 1 1.0
resulting O 0 4.4600707838071685e-07
in O 0 2.067761073476504e-09
mutant O 0 5.822500881436099e-08
proteins O 0 5.429898308761949e-09
that O 0 9.059571426384139e-10
retain O 0 2.1657486115600477e-07
the O 0 6.23936502464062e-09
DNA O 0 2.8664541673606436e-07
- O 0 1.9842494225486007e-07
binding O 0 7.103896138005439e-08
domains O 0 3.020677183940279e-07
but O 0 1.2087868128674017e-07
have O 0 1.188211555813723e-07
lost O 0 1.4351909385368344e-06
most O 0 1.4230703282436252e-09
of O 0 7.724743067427653e-10
the O 0 1.0746104450731764e-08
transactivation O 0 9.700721420813352e-06
domain O 0 7.33338254121918e-07
. O 0 1.1448231163058153e-07

It O 0 5.252091455076879e-07
is O 0 1.4983111640276547e-08
not O 0 3.3858327253000198e-09
clear O 0 5.39909184027465e-09
whether O 0 1.880159139489024e-09
such O 0 1.2631002910268307e-09
mutants O 0 3.785433477787592e-07
really O 0 2.554485831751663e-07
behave O 0 3.9565843934497025e-08
as O 0 3.806968518205167e-09
loss O 0 1.3856848113391607e-08
- O 0 1.7145920594430208e-07
of O 0 4.5514889635001055e-09
- O 0 5.73869738218491e-06
function O 0 1.7276063601912028e-07
mutants O 0 3.915736499493505e-07
as O 0 2.0804449718525575e-08
predicted O 0 3.8989458062133053e-07
by O 0 2.4811392052015435e-08
haploinsufficiency O 0 9.334756214229856e-06
. O 0 2.0829074287576077e-07

Contrary O 0 3.4710178624663968e-06
to O 0 1.6867762298033995e-08
this O 0 7.52607809406669e-10
theory O 0 3.728012121229085e-09
, O 0 7.757446907064036e-10
our O 0 2.7802375957008962e-09
data O 0 2.125252684948009e-08
showed O 0 1.6785962486665085e-07
that O 0 1.8668472323568608e-10
these O 0 8.194043776832416e-10
mutants O 0 2.5971187866957735e-08
are O 0 3.810273874194081e-09
dominant O 0 8.973862577477121e-07
- O 0 3.877881681546569e-06
negative O 0 4.980482231076166e-07
in O 0 4.692897626057402e-09
transient O 0 2.0111959031510196e-07
transfection O 0 1.94653853213822e-06
assays O 0 5.16700083608157e-06
when O 0 2.0783970455795497e-07
they O 0 1.3121051800624173e-08
are O 0 2.6344411097056764e-09
coexpressed O 0 1.331708716634239e-07
with O 0 3.6366971656320857e-09
wild O 0 1.923886685517573e-07
- O 0 2.1581461624009535e-05
type O 0 0.0003711827739607543
PAX6 O 0 0.0003647607518360019
. O 0 4.7002100700410665e-07

We O 0 3.591144832171267e-06
found O 0 2.738576831973205e-08
that O 0 1.6193431040534279e-09
the O 0 2.2289359247196217e-09
dominant O 0 2.796671424221131e-06
- O 0 6.548788405780215e-06
negative O 0 7.983057003002614e-06
effects O 0 6.8471376835077535e-06
result O 0 3.717526553259631e-08
from O 0 7.90449150578354e-10
the O 0 1.075112221471386e-09
enhanced O 0 5.0005997564994686e-08
DNA O 0 1.4472169596047024e-07
binding O 0 2.7516350087353203e-08
ability O 0 3.6507305622990316e-08
of O 0 7.395052903369503e-10
these O 0 5.807790692813342e-09
mutants O 0 5.386987140809651e-07
. O 0 5.9266138663360834e-08

Kinetic O 0 4.576144419843331e-06
studies O 0 5.535770810638496e-07
of O 0 1.4535597614440121e-08
binding O 0 2.2821132006356493e-07
and O 0 7.447745531408145e-08
dissociation O 0 2.442613322273246e-06
revealed O 0 2.0653463650432968e-07
that O 0 2.695088319182304e-10
various O 0 1.278647743241379e-09
truncation O 0 3.188393407071999e-07
mutants O 0 3.925532894299977e-07
have O 0 1.4680900939367802e-08
3 O 0 1.1393767707090774e-08
- O 0 1.3304104413691675e-06
5 O 0 8.337277535019894e-08
- O 0 5.161334115655336e-07
fold O 0 1.1141580813500696e-07
higher O 0 1.0161969932198645e-08
affinity O 0 2.6673463437987266e-09
to O 0 9.67409596874802e-10
various O 0 3.2682068162870337e-09
DNA O 0 1.6347665621196938e-07
- O 0 1.2022339035411278e-07
binding O 0 2.409200838826564e-08
sites O 0 6.559312026865882e-08
when O 0 1.5994404023444986e-08
compared O 0 6.076537051313835e-09
with O 0 6.474187852489877e-10
the O 0 3.7066494318338528e-09
wild O 0 2.7171614291887636e-08
- O 0 7.177850875450531e-06
type O 0 5.1628423534566537e-05
PAX6 O 0 9.284601401304826e-05
. O 0 4.1619009039095545e-07

These O 0 2.76584796665702e-06
results O 0 4.840409815187741e-07
provide O 0 3.103107815149997e-08
a O 0 4.4165564538900526e-09
new O 0 6.042715772203167e-10
insight O 0 5.147694714935369e-09
into O 0 1.2585936737252723e-09
the O 0 6.50415277192451e-10
role O 0 4.1830992003610845e-09
of O 0 6.630855309275319e-10
mutant O 0 3.784909949899884e-07
PAX6 O 0 6.4391483647341374e-06
in O 0 6.992826939722363e-08
causing O 0 1.8058210116578266e-05
aniridia B-Disease 1 0.9999996423721313
. O 0 7.477465402416783e-08
. O 0 9.246937082707518e-08

Reversal O 0 6.937349098734558e-05
of O 0 1.267637912860664e-06
severe O 1 0.9990787506103516
hypertrophic B-Disease 1 0.9999964237213135
cardiomyopathy I-Disease 1 1.0
and O 0 5.606964350590715e-06
excellent O 0 3.3285479730693623e-05
neuropsychologic O 0 0.00017042693798430264
outcome O 0 3.5476614357321523e-07
in O 0 1.1513307640598214e-08
very B-Disease 0 1.6549391546050174e-07
- I-Disease 0 0.001042200718075037
long I-Disease 0 0.00013531805598177016
- I-Disease 0 3.632274456322193e-05
chain I-Disease 0 9.02386091183871e-06
acyl I-Disease 0 4.368479494587518e-06
- I-Disease 0 3.2443269901705207e-06
coenzyme I-Disease 0 3.5031621337111574e-06
A I-Disease 0 4.939325322084187e-07
dehydrogenase I-Disease 0 0.0033761037047952414
deficiency I-Disease 0 0.021181024610996246
. O 0 2.0643342679704801e-07

Very B-Disease 0 1.783965853974223e-05
- I-Disease 0 0.0002432117471471429
long I-Disease 0 3.746691800188273e-05
- I-Disease 0 2.726428101595957e-05
chain I-Disease 0 5.58408737560967e-06
acyl I-Disease 0 3.2051170819613617e-06
- I-Disease 0 8.501129968863097e-07
coenzyme I-Disease 0 2.5340312959087896e-07
A I-Disease 0 2.3552015449013197e-08
dehydrogenase I-Disease 0 3.4123752357118065e-06
( I-Disease 0 5.1092161612587006e-08
VLCAD I-Disease 0 0.00014490769535768777
) I-Disease 0 1.7921156825195794e-07
deficiency I-Disease 0 2.0546862288028933e-05
is O 0 5.525301882691735e-10
a O 0 1.240699187832206e-08
disorder O 0 0.0011455079074949026
of O 0 3.8704541793777025e-09
fatty O 0 1.8413193174637854e-05
acid O 0 3.3849568126242957e-07
beta O 0 1.9129435813169948e-08
oxidation O 0 3.918268731695207e-08
that O 0 8.214766644698557e-09
reportedly O 0 1.7316922651389177e-07
has O 0 4.711292245218601e-09
high O 0 8.471850776459178e-08
rates O 0 4.713690486823907e-06
of O 0 6.486848835862702e-09
morbidity O 0 0.00012539836461655796
and O 0 8.713125794201915e-07
mortality O 0 0.0004042375076096505
. O 0 8.79472423775951e-08

We O 0 9.203207810060121e-06
describe O 0 7.745366588096658e-07
the O 0 1.2941994143034208e-08
outcome O 0 2.4505872886493307e-08
of O 0 7.151144676420529e-10
a O 0 1.1642181441118282e-08
5 O 0 2.157045386752543e-08
- O 0 4.699973032984417e-06
year O 0 4.9685031200397134e-08
- O 0 4.421309131430462e-05
old O 0 0.00033671787241473794
girl O 0 6.711502646794543e-05
with O 0 6.893728254908638e-07
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
who O 0 3.188442292412219e-07
was O 0 4.2005947165080215e-08
first O 0 1.1154931200962892e-08
seen O 0 4.826912345379242e-07
at O 0 3.9951380870206776e-08
5 O 0 4.482754167867142e-09
months O 0 2.4968613843157073e-09
of O 0 4.2177472625581913e-10
age O 0 9.74674094322836e-07
with O 0 5.56152997432946e-07
severe O 1 0.9998949766159058
hypertrophic B-Disease 1 0.9999970197677612
cardiomyopathy I-Disease 1 1.0
, O 0 2.671791662578471e-05
hepatomegaly B-Disease 1 1.0
, O 0 3.6829981127084466e-06
encephalopathy B-Disease 0 0.16695617139339447
, O 0 1.9152508912156918e-08
and O 0 6.451315925914969e-08
hypotonia B-Disease 0 0.0032474545296281576
. O 0 3.4907753843071987e-07

Biochemical O 0 0.00035970660974271595
studies O 0 0.00015412451466545463
indicated O 1 0.9995731711387634
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
caused O 0 1.29492045743973e-05
by O 0 9.825359192916494e-09
a O 0 3.9984769273360143e-08
stable O 0 2.872488767025061e-05
yet O 0 9.399795430908853e-08
inactive O 0 7.283298373295111e-07
enzyme O 0 7.994896691343456e-07
. O 0 9.920761101511744e-08

Molecular O 0 1.6216878066188656e-05
genetic O 0 1.1576631550269667e-05
analysis O 0 1.9415904262132244e-07
of O 0 1.1478597627956333e-08
her O 0 3.3830926895461744e-06
VLCAD O 0 0.0035811394918709993
gene O 0 1.2206894098198973e-05
revealed O 0 3.737747647392098e-06
a O 0 7.521306599755917e-08
T1372C O 0 5.404083822213579e-06
( O 0 5.7357972593763407e-08
F458L O 0 8.976335834631755e-07
) O 0 2.157139888936399e-08
missense O 0 3.687999424073496e-06
mutation O 0 7.261795417434769e-06
and O 0 1.0381788229096856e-07
a O 0 3.72072634036158e-07
1668 O 0 0.0006809770129621029
ACAG O 0 0.0004256254178471863
1669 O 0 1.1622274541878141e-05
splice O 0 0.0005675057764165103
site O 0 2.1596224542008713e-05
mutation O 0 8.237798465415835e-05
. O 0 8.560568289794901e-07

After O 0 2.724201294768136e-06
initial O 0 6.571470407834568e-07
treatment O 0 4.132554067837191e-07
with O 0 1.5069607783857464e-08
intravenous O 0 2.7860921818501083e-06
glucose O 0 4.905867899651639e-05
and O 0 9.474639739437407e-08
carnitine O 0 2.7192797915631672e-06
, O 0 8.705399956454585e-09
the O 0 9.002834922000602e-09
patient O 0 6.215149142008158e-07
has O 0 8.971396958656896e-09
thrived O 0 1.2439245722362102e-07
on O 0 1.2805227100898264e-08
a O 0 3.472400322834801e-08
low O 0 0.0012054999824613333
- O 0 3.073383413720876e-05
fat O 0 1.2794311032848782e-06
diet O 0 6.04145355964647e-08
supplemented O 0 1.0790946447514216e-07
with O 0 9.709166803872904e-09
medium O 0 2.3470307496609166e-05
- O 0 3.4737360692815855e-05
chain O 0 3.9720284803479444e-06
triglyceride O 0 2.544813696658821e-06
oil O 0 7.51379332086799e-08
and O 0 5.4575277630419805e-09
carnitine O 0 5.717658950743498e-07
and O 0 1.1790880272144477e-08
avoidance O 0 3.4842298646253766e-07
of O 0 2.6007077380540977e-08
fasting O 0 1.5647472537239082e-05
. O 0 2.3423893935614615e-07

Her O 0 0.0009836185490712523
ventricular O 0 0.03915753588080406
hypertrophy O 0 0.0008121290593408048
resolved O 0 3.4144225082854973e-06
significantly O 0 4.0275483570439974e-07
over O 0 1.1949178535530791e-08
1 O 0 1.2320822584399593e-08
year O 0 5.268824043724862e-09
, O 0 1.3746384031065872e-09
and O 0 1.9305522513946016e-08
cognitively O 0 5.816013072035275e-06
, O 0 3.3324059067751932e-09
she O 0 4.548081022903716e-08
is O 0 3.363546940970963e-10
in O 0 2.5645585655098557e-10
the O 0 7.617000918891392e-10
superior O 0 2.9173580884389594e-08
range O 0 9.085224661475877e-08
for O 0 2.3333232235245305e-08
age O 0 1.6799394870758988e-06
. O 0 6.551771747353996e-08

Clinical O 0 0.0016088715055957437
recognition O 0 5.404815510701155e-06
of O 0 1.2829333172703627e-05
VLCAD B-Disease 1 1.0
deficiency I-Disease 1 1.0
is O 0 1.7550709330294012e-08
important O 0 1.0081811829820708e-08
because O 0 1.085315481930138e-08
it O 0 1.3373685492368281e-09
is O 0 2.416769284696585e-10
one O 0 4.1590469956886977e-10
of O 0 7.46804701412529e-11
the O 0 2.6186253165860762e-09
few O 0 8.515542759823802e-08
directly O 0 4.8804304242366925e-06
treatable O 0 0.025868285447359085
causes O 0 4.184537516493947e-08
of O 0 2.0992471760905573e-08
cardiomyopathy B-Disease 1 1.0
in O 0 9.329740890962057e-08
children O 0 1.763825025591359e-06
. O 0 6.240626682085804e-09
. O 0 2.445091951130962e-08

Cloning O 0 7.575723429908976e-06
of O 0 2.9865695694297756e-08
a O 0 1.4254399438584642e-08
novel O 0 1.4180286278531185e-08
member O 0 5.078560239013541e-09
of O 0 3.395130288019743e-10
the O 0 8.64137827960576e-09
low O 0 0.005974774248898029
- O 0 7.075697794789448e-05
density O 0 7.254252523125615e-07
lipoprotein O 0 0.00041515129851177335
receptor O 0 1.1466929208836518e-05
family O 0 5.430195528788317e-07
. O 0 1.204549704425517e-07

A O 0 1.240180836248328e-06
gene O 0 1.5951499108268763e-06
encoding O 0 2.0128749156356207e-07
a O 0 3.032357298593524e-08
novel O 0 7.320666384202923e-08
transmembrane O 0 4.811952294403454e-07
protein O 0 2.8612950586648367e-07
was O 0 4.265044424300868e-07
identified O 0 5.107345302235444e-08
by O 0 5.036989159101779e-10
DNA O 0 2.5177323337288726e-08
sequence O 0 1.294127915940635e-08
analysis O 0 1.0686401985537941e-08
within O 0 1.3603354886981833e-08
the O 0 6.118955298006767e-08
insulin B-Disease 1 0.9932992458343506
- I-Disease 1 0.9999963045120239
dependent I-Disease 1 0.9999977350234985
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
( O 0 3.4387451250950107e-06
IDDM B-Disease 0 0.0001799881865736097
) O 0 4.259475261392254e-08
locus O 0 5.284499820845667e-06
IDDM4 O 0 3.167923568980768e-05
on O 0 3.581492364901351e-07
chromosome O 0 0.00012969983799848706
11q13 O 0 2.3078804588294588e-05
. O 0 4.7385697143909056e-07

Based O 0 2.929129152562382e-07
on O 0 6.374015271148892e-08
its O 0 8.16292722305434e-09
chromosomal O 0 2.9920382075943053e-05
position O 0 7.2224001996801235e-06
, O 0 1.8961598957645265e-09
this O 0 1.6619101927961566e-10
gene O 0 1.222860213090371e-08
is O 0 2.5480834109359307e-10
a O 0 8.805088880237122e-10
candidate O 0 9.704575809621474e-09
for O 0 9.288380620198211e-10
conferring O 0 1.8495875053758937e-07
susceptibility O 0 1.0201361874351278e-05
to O 0 6.329462962639809e-07
diabetes B-Disease 1 0.9992092847824097
. O 0 5.678251682184055e-07

The O 0 8.627454803900036e-07
gene O 0 1.4930825500414358e-06
, O 0 2.9281171265438388e-08
termed O 0 5.567049470300844e-07
low O 0 0.0001509289286332205
- O 0 1.845367660280317e-05
density O 0 6.023826131240639e-07
lipoprotein O 0 0.00016243408026639372
receptor O 0 1.689176997388131e-06
related O 0 1.316457485245337e-07
protein O 0 3.2662396165505925e-07
5 O 0 5.8984433337627706e-08
( O 0 1.2691335093961698e-08
LRP5 O 0 2.569139724073466e-06
) O 0 1.4395319380966498e-09
, O 0 1.772322844040275e-10
encodes O 0 5.175023076731122e-09
a O 0 2.758601791441606e-09
protein O 0 1.662913717837e-08
of O 0 1.170809005301976e-09
1615 O 0 1.4941837207516073e-06
amino O 0 2.569080947978364e-07
acids O 0 1.729117116155976e-08
that O 0 4.0841230397603567e-10
contains O 0 9.842028303452821e-10
conserved O 0 4.3010928152398265e-09
modules O 0 7.898828258134927e-09
which O 0 4.759169058843327e-09
are O 0 1.8500639908936023e-09
characteristic O 0 8.403320705951955e-09
of O 0 8.096001091750793e-10
the O 0 1.8484319852518638e-08
low O 0 0.3051830232143402
- O 0 0.003357155481353402
density O 0 1.1656844662866206e-06
lipoprotein O 0 0.0055194334127008915
( O 0 1.6347524933735258e-07
LDL O 0 2.0135050363023765e-05
) O 0 1.7227833382094104e-08
receptor O 0 2.7722174422706303e-07
family O 0 1.3425669465050305e-07
. O 0 6.776826921850443e-08

These O 0 4.6882746573828626e-07
modules O 0 2.263524407908335e-07
include O 0 1.1228554086528675e-08
a O 0 1.055161114038583e-08
putative O 0 2.584695835139428e-07
signal O 0 1.0159958208078024e-07
peptide O 0 1.7913498240318404e-08
for O 0 2.792465148004908e-10
protein O 0 7.9713551315308e-09
export O 0 4.624833849220522e-08
, O 0 1.9031674014513555e-09
four O 0 1.10031441735714e-08
epidermal O 0 1.6406703196025774e-07
growth O 0 9.663942535098613e-08
factor O 0 5.9403980401384615e-08
( O 0 1.7794546280924806e-08
EGF O 0 1.7604741060495144e-06
) O 0 9.312101312275445e-09
repeats O 0 2.335554682986185e-07
with O 0 6.363857441016307e-09
associated O 0 6.076539449395568e-08
spacer O 0 2.5047434064617846e-06
domains O 0 3.484479975668364e-06
, O 0 2.5189860863861213e-08
three O 0 7.008422642229561e-08
LDL O 0 2.2761760192224756e-05
- O 0 1.7395743270753883e-05
receptor O 0 1.2963508879693109e-06
( O 0 2.9218686137255645e-08
LDLR O 0 1.2635077837330755e-06
) O 0 5.117386514541522e-09
repeats O 0 3.825207386398688e-07
, O 0 2.0795472011059246e-09
a O 0 8.174410481842642e-09
single O 0 1.2300040452828398e-06
transmembrane O 0 3.545885931544035e-07
spanning O 0 3.0800580930190335e-07
domain O 0 2.8708888066830696e-07
, O 0 1.4812846060863194e-08
and O 0 8.117760685877329e-09
a O 0 1.7822978648496246e-08
cytoplasmic O 0 5.1114079724357e-06
domain O 0 1.8559478576207766e-06
. O 0 2.1463488053541369e-07

The O 0 7.375367516715414e-08
encoded O 0 1.457444227526139e-07
protein O 0 1.775013203086928e-07
has O 0 7.252327183238094e-09
a O 0 1.7088541692800163e-09
unique O 0 3.213355137532403e-09
organization O 0 3.4630194267748493e-09
of O 0 1.2264544935192134e-09
EGF O 0 7.982851457200013e-06
and O 0 1.4396293579466146e-07
LDLR O 0 8.707217057235539e-05
repeats O 0 5.755331585532986e-06
; O 0 1.1604272209808641e-08
therefore O 0 7.37439620479563e-08
, O 0 5.091896682074548e-09
LRP5 O 0 1.8774492218653904e-06
likely O 0 1.2493768508647918e-07
represents O 0 4.008738230254494e-09
a O 0 1.8849490857064666e-09
new O 0 2.6515960538375793e-09
category O 0 2.3808949833892257e-07
of O 0 1.5166111699826956e-09
the O 0 5.042156203671766e-08
LDLR O 0 0.00014850065053906292
family O 0 4.6171706458153494e-07
. O 0 1.7018332698626182e-07

Both O 0 1.512227754574269e-06
human O 0 1.4927977076695242e-07
and O 0 2.6293871968618987e-08
mouse O 0 3.011182343470864e-06
LRP5 O 0 2.046954796242062e-05
cDNAs O 0 9.89435875453637e-07
have O 0 5.0508095483792204e-08
been O 0 3.3250362463377314e-08
isolated O 0 1.6740494857003796e-07
and O 0 1.0569956021555527e-09
the O 0 4.783811680120209e-10
encoded O 0 1.442121533301588e-08
mature O 0 1.4577048901287526e-08
proteins O 0 2.2669273125330847e-09
are O 0 3.482719446168403e-09
95 O 0 2.782350527752442e-08
% O 0 7.585257577602533e-08
identical O 0 1.5724721379228868e-05
, O 0 1.4857158170400453e-08
indicating O 0 2.873104563150264e-07
a O 0 4.014124588280765e-09
high O 0 1.331287080574839e-07
degree O 0 5.573740580189224e-09
of O 0 3.8102790367311457e-10
evolutionary O 0 2.236730622939831e-08
conservation O 0 8.976121179671281e-09
. O 0 3.3899036910867153e-09
. O 0 3.295726713758995e-08

The O 0 7.835335509298602e-07
APC B-Disease 0 3.3527662708365824e-06
variants O 0 8.643983733236382e-07
I1307K O 0 1.0725054835347692e-06
and O 0 1.6559251747594317e-08
E1317Q O 0 5.161112994755968e-07
are O 0 1.353458944919339e-08
associated O 0 1.2313596471358323e-06
with O 1 0.9709531664848328
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 1.4565047422365751e-05
but O 0 2.3714905239557993e-07
not O 0 3.213195043372252e-07
always O 0 3.4647166557988385e-07
with O 0 1.8114416633352448e-09
a O 0 2.7735868712852607e-08
family O 0 1.091523174068243e-07
history O 0 2.675996029211092e-07
. O 0 1.3081063343634014e-07

Classical O 1 0.6394422054290771
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 0.002676992444321513
FAP B-Disease 0 6.250732258195058e-05
) O 0 2.865529680207146e-08
is O 0 2.263173204397617e-09
a O 0 1.1603164651319275e-08
high O 0 0.0005874917842447758
- O 1 0.9999741315841675
penetrance O 1 0.9999737739562988
autosomal B-Disease 1 0.9999936819076538
dominant I-Disease 1 0.979341447353363
disease I-Disease 0 0.003640700364485383
that O 0 8.632476955483526e-10
predisposes O 0 1.8470191776032152e-07
to O 0 3.956809102589887e-09
hundreds O 0 7.1778361032670546e-09
or O 0 1.7134928143036632e-08
thousands O 0 1.2557240580690632e-08
of O 0 1.1381949889255338e-06
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9683830142021179
carcinoma I-Disease 1 1.0
and O 0 9.352808774565347e-06
that O 0 2.06334167529576e-08
results O 0 2.027462784326417e-07
from O 0 8.945800544779559e-09
truncating O 0 1.806762270462059e-06
mutations O 0 6.258168809836206e-07
in O 0 1.6349287479400232e-09
the O 0 6.742066016585113e-09
APC B-Disease 0 5.331086754267744e-07
gene O 0 1.6331442793671158e-06
. O 0 2.3130164095164218e-07

A O 0 2.7003782179235714e-06
variant O 0 9.146458069153596e-06
of O 0 8.043170396376809e-08
FAP B-Disease 0 4.945441833115183e-05
is O 0 9.269023735214432e-07
attenuated B-Disease 1 0.9287821650505066
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 0.9999957084655762
coli I-Disease 1 1.0
, O 0 3.197882563199528e-07
which O 0 1.750240308240336e-08
results O 0 1.0007900641539891e-07
from O 0 8.756005698273839e-09
germ O 0 8.598859858466312e-05
- O 0 6.942584877833724e-05
line O 0 9.0661364083644e-05
mutations O 0 8.70052076606953e-07
in O 0 8.723246014419317e-10
the O 0 2.356687511806399e-09
5 O 0 6.011541930917019e-09
and O 0 8.260583328478788e-09
3 O 0 8.72211902702702e-09
regions O 0 9.47788958427509e-09
of O 0 1.952883410538675e-09
the O 0 3.9944982432871257e-08
APC B-Disease 0 7.200669642770663e-07
gene O 0 7.280950740096159e-07
. O 0 1.1786499243271464e-07

Attenuated B-Disease 1 0.999990701675415
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
coli I-Disease 1 1.0
patients O 1 0.9999998807907104
have O 0 3.3015494409482926e-05
" O 0 1.6068698869275977e-06
multiple O 0 0.0008484428399242461
" O 1 0.978801429271698
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
( O 0 3.09735440851e-07
typically O 0 1.5118413898562721e-07
fewer O 0 6.122025553167987e-08
than O 0 4.076661674901061e-09
100 O 0 1.1282375034227243e-08
) O 0 1.8954728897568884e-09
without O 0 6.239889049908243e-09
the O 0 3.4339213694778437e-09
florid O 0 6.961864983168198e-06
phenotype O 0 1.3504762819138705e-06
of O 0 5.566133776113702e-09
classical O 0 7.985752290551318e-07
FAP B-Disease 0 2.2024827558198012e-05
. O 0 5.996417371534335e-07

Another O 0 3.000378228534828e-06
group O 0 9.502890208068493e-08
of O 0 2.9274453972050196e-09
patients O 0 3.5140161003255344e-07
with O 0 1.5378990303460682e-09
multiple O 0 1.4820731848885771e-05
adenomas B-Disease 0 0.10396011173725128
has O 0 1.550438355479855e-07
no O 0 1.2816789762837288e-07
mutations O 0 9.41840255563875e-07
in O 0 5.909945866022781e-10
the O 0 2.373160779001182e-09
APC B-Disease 0 4.6732846925579e-08
gene O 0 4.145136500710578e-08
, O 0 1.7433693377810755e-09
and O 0 4.418865273692063e-09
their O 0 4.196935066147489e-08
phenotype O 0 1.5165127251748345e-06
probably O 0 3.3696707646413415e-07
results O 0 2.132130560994483e-08
from O 0 7.602878326906648e-10
variation O 0 6.5080683953056e-08
at O 0 2.605524400678405e-07
a O 0 1.3960788969313853e-08
locus O 0 1.4055257224754314e-06
, O 0 7.22364035254941e-09
or O 0 1.6015407666714054e-08
loci O 0 3.6102427714013174e-08
, O 0 2.24995533315564e-09
elsewhere O 0 1.3966381828822705e-08
in O 0 8.037825405260435e-10
the O 0 4.017908672437898e-09
genome O 0 1.2358437118109578e-07
. O 0 4.712364187753337e-08

Recently O 0 4.1053062886931e-05
, O 0 3.6227625344054104e-08
however O 0 1.0110022152787224e-08
, O 0 3.3547825628588157e-10
a O 0 1.4050700603007726e-09
missense O 0 3.2352940593227686e-07
variant O 0 5.715342012990732e-07
of O 0 5.590691021239991e-09
APC B-Disease 0 5.943638825556263e-07
( O 0 9.309792936562644e-09
I1307K O 0 3.1880892947810935e-07
) O 0 2.5086999144718902e-09
was O 0 1.2815025485224396e-08
described O 0 2.6468058855755316e-09
that O 0 1.2808976102007819e-10
confers O 0 5.79055781102511e-09
an O 0 7.216943154197963e-10
increased O 0 5.213446456764359e-07
risk O 0 0.0022156524937599897
of O 0 0.001337043708190322
colorectal B-Disease 1 1.0
tumors I-Disease 1 1.0
, O 0 3.1963091373654606e-07
including O 0 1.2110710656543233e-08
multiple O 0 7.992031896719709e-05
adenomas B-Disease 0 0.0010954175377264619
, O 0 4.57671056608433e-08
in O 0 3.0179325705148585e-08
Ashkenazim O 0 0.00031726007000543177
. O 0 2.138639700888234e-07

We O 0 1.3640552424476482e-05
have O 0 6.471255886708605e-08
studied O 0 3.058817199530495e-08
a O 0 4.686493415562154e-09
set O 0 1.1919996545373124e-08
of O 0 3.3921915276735604e-10
164 O 0 1.967587905937762e-07
patients O 0 6.916790198374656e-07
with O 0 7.727520312528213e-08
multiple O 1 0.9999998807907104
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 0 0.004345611669123173
/ I-Disease 1 0.9987903237342834
or I-Disease 1 0.9947102069854736
carcinoma I-Disease 1 1.0
and O 0 5.8866862673312426e-06
analyzed O 0 8.886188879841939e-06
codons O 0 5.070286078989739e-06
1263 O 0 5.079316906630993e-06
- O 0 1.721402782095538e-06
1377 O 0 1.7138970633823192e-06
( O 0 3.229467537835262e-08
exon O 0 7.199749916253495e-07
15G O 0 2.2188114598975517e-06
) O 0 3.315914876012016e-09
of O 0 5.438146044589587e-10
the O 0 1.9177284205085243e-09
APC B-Disease 0 9.047732874023495e-08
gene O 0 4.950171117457103e-08
for O 0 6.6682352972691206e-09
germ O 0 4.557006832328625e-05
- O 0 7.1557609771844e-05
line O 0 2.224821764684748e-05
variants O 0 3.5053881219937466e-06
. O 0 2.425412333195709e-07

Three O 0 1.5671814253437333e-05
patients O 0 7.613361231051385e-05
with O 0 3.973083639863262e-09
the O 0 4.266059061563965e-09
I1307K O 0 2.2382590714187245e-07
allele O 0 3.505213612697844e-07
were O 0 7.404953805689729e-08
detected O 0 1.839776189171971e-07
, O 0 9.6628283152711e-10
each O 0 5.594741891989941e-10
of O 0 1.2464100862530358e-09
Ashkenazi O 0 9.289065928896889e-06
descent O 0 1.1248756891291123e-05
. O 0 1.9927280447973317e-07

Four O 0 3.723695772350766e-05
patients O 0 0.00093558628577739
had O 0 4.824877919418213e-07
a O 0 6.261327456513754e-08
germ O 0 0.007201587315648794
- O 0 0.0031637735664844513
line O 0 2.87964448943967e-05
E1317Q O 0 9.494607979831926e-07
missense O 0 1.8943787836178672e-06
variant O 0 2.9167108550609555e-07
of O 0 1.3302630108569247e-09
APC O 0 7.720625205820397e-08
that O 0 2.449511260493864e-09
was O 0 8.933902506669256e-08
not O 0 4.706397049858424e-09
present O 0 1.9889634383929433e-09
in O 0 5.783666878755866e-10
controls O 0 6.048399427527329e-06
; O 0 4.818291099439875e-09
one O 0 8.638571524777205e-10
of O 0 1.201892751989675e-10
these O 0 6.531743590443284e-09
individuals O 0 2.2229974305787437e-08
had O 0 2.3710586560810043e-07
an O 0 3.789463742798205e-10
unusually O 0 4.538358311378943e-08
large O 0 2.9216220553962557e-09
number O 0 9.013486845788066e-09
of O 0 1.7925246842409592e-09
metaplastic B-Disease 0 5.100151975057088e-05
polyps I-Disease 0 9.55553878156934e-06
of I-Disease 0 3.312387253373572e-09
the I-Disease 0 4.2537596556257995e-08
colorectum I-Disease 0 5.674923522747122e-05
. O 0 3.9593143696947664e-07

There O 0 1.222197738570685e-06
is O 0 8.467420542501713e-09
increasing O 0 4.3024876994479655e-09
evidence O 0 8.120641048492416e-09
that O 0 1.4135803638737343e-09
there O 0 4.364260952627319e-09
exist O 0 8.233123338641235e-08
germ O 0 3.919752089132089e-06
- O 0 6.564307113876566e-06
line O 0 1.9961644284194335e-06
variants O 0 5.0609738622142686e-08
of O 0 3.579077589854762e-10
the O 0 2.2089596818375412e-09
APC B-Disease 0 2.6255884577608413e-08
gene O 0 1.0940927275271406e-08
that O 0 2.567809020970202e-10
predispose O 0 1.2592618503504127e-08
to O 0 6.187831913528896e-10
the O 0 9.076140394803645e-10
development O 0 2.6001902853067804e-09
of O 0 1.3996409364835927e-08
multiple O 1 0.9999992847442627
colorectal B-Disease 1 1.0
adenomas I-Disease 1 1.0
and I-Disease 1 0.9993696808815002
carcinoma I-Disease 1 1.0
, O 0 2.492486146365991e-06
but O 0 6.416391329366888e-08
without O 0 2.4143758992067887e-08
the O 0 3.1532114697085944e-09
florid O 0 4.475333753362065e-06
phenotype O 0 6.043102303010528e-07
of O 0 5.715434792108454e-10
classical O 0 5.065106734036817e-08
FAP B-Disease 0 2.340888585194989e-07
, O 0 2.1405397454543618e-09
and O 0 1.5330754443709793e-09
possibly O 0 1.0721312726502674e-08
with O 0 8.008351759514198e-10
importance O 0 1.3431650813799934e-07
for O 0 0.2644079029560089
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
risk O 0 0.00024520905571989715
in O 0 1.8405855728431675e-09
the O 0 1.7004947450161012e-09
general O 0 5.072761322111319e-09
population O 0 7.991419082031825e-09
. O 0 6.781077921402812e-09
. O 0 4.9012516711854914e-08

Genomic O 0 1.657671782595571e-05
structure O 0 4.669213353736268e-07
of O 0 5.661103585907767e-09
the O 0 3.189226305266857e-08
human O 0 3.7349079775594873e-06
congenital B-Disease 1 1.0
chloride I-Disease 1 0.9999969005584717
diarrhea I-Disease 1 1.0
( O 0 1.4892920262354892e-05
CLD B-Disease 0 0.22427266836166382
) O 0 1.7225377746399317e-07
gene O 0 4.174009973212378e-06
. O 0 2.56633825301833e-07

Congenital B-Disease 1 1.0
chloride I-Disease 1 1.0
diarrhea I-Disease 1 1.0
( O 0 0.0012316199718043208
CLD B-Disease 1 0.9930182695388794
) O 0 1.9420052410623612e-07
is O 0 9.449117044368904e-09
caused O 0 3.466662690243538e-08
by O 0 1.1525650434052181e-09
mutations O 0 9.123799031840463e-07
in O 0 5.922742851716123e-10
a O 0 2.905073959169613e-09
gene O 0 1.1933342136671854e-07
which O 0 3.555802097210403e-09
encodes O 0 1.6239532385498023e-07
an O 0 4.538860665093125e-08
intestinal O 0 3.2877534977160394e-05
anion O 0 6.3698803387524094e-06
transporter O 0 4.834315041080117e-05
. O 0 6.482102321569982e-07

We O 0 4.627477392205037e-05
report O 0 2.7907435651286505e-07
here O 0 4.688593957524745e-09
the O 0 6.938057905969686e-10
complete O 0 6.477897329659754e-09
genomic O 0 4.604027736831995e-08
organization O 0 5.615827358695924e-09
of O 0 1.725300458055301e-10
the O 0 2.1680699457959918e-09
human O 0 1.3388111952394866e-08
CLD B-Disease 0 5.5836562751210295e-06
gene O 0 1.6014665504826553e-07
which O 0 1.0618498968995027e-08
spans O 0 3.2802745408844203e-07
approximately O 0 8.236767001790213e-08
39kb O 0 3.7299955693015363e-06
, O 0 1.3881396476733698e-08
and O 0 1.873491051185283e-08
comprises O 0 7.735040696843498e-08
21 O 0 1.3882620919503097e-07
exons O 0 3.596415808715392e-06
. O 0 4.215596334233851e-07

All O 0 1.2822283679270186e-06
exon O 0 1.6809663065942004e-05
/ O 0 1.5216486644931138e-05
intron O 0 5.363439777283929e-05
boundaries O 0 7.564072348031914e-06
conform O 0 1.0982031426465255e-06
to O 0 1.426263995796262e-08
the O 0 1.632614221591666e-08
GT O 0 1.1927202194783604e-06
/ O 0 6.593855505343527e-05
AG O 0 0.03699927031993866
rule O 0 1.2179962141090073e-06
. O 0 3.056770765397232e-07

An O 0 1.346494400422671e-07
analysis O 0 7.221493802944678e-08
of O 0 3.156737982124014e-09
the O 0 1.0513241832654785e-08
putative O 0 3.311423029117577e-07
promoter O 0 3.905208529886295e-07
region O 0 3.8162617954640154e-08
sequence O 0 8.097815396013175e-08
shows O 0 9.636995201844911e-08
a O 0 2.8661473194802056e-08
putative O 0 1.3049169638179592e-06
TATA O 0 2.5829660899034934e-06
box O 0 2.488035534042865e-06
and O 0 2.872457471880807e-08
predicts O 0 2.504248755030858e-07
multiple O 0 7.566421800220269e-07
transcription O 0 2.7767316623794613e-06
factor O 0 3.261334313719999e-07
binding O 0 4.164382119142829e-07
sites O 0 1.3152582596376305e-06
. O 0 2.9540009904849285e-07

The O 0 3.9839110854700266e-07
genomic O 0 1.988302528843633e-06
structure O 0 7.013797471699945e-07
was O 0 9.779928689113149e-08
determined O 0 3.319922114997098e-08
using O 0 1.403688631995692e-08
DNA O 0 1.0416141549285385e-07
from O 0 1.1719284431777055e-09
several O 0 9.60234558533557e-10
sources O 0 5.872464292622226e-09
including O 0 4.207247883414311e-09
multiple O 0 1.5652982483516098e-06
large O 0 2.360304506510147e-06
- O 0 0.018021348863840103
insert O 0 0.00015208883269224316
libaries O 0 8.250874998338986e-06
and O 0 1.4521408964185412e-08
genomic O 0 3.560463426310889e-07
DNA O 0 6.515334121104388e-07
from O 0 2.2097614404970045e-08
Finnish O 0 0.0002914773067459464
CLD B-Disease 1 0.9880075454711914
patients O 0 0.00015157865709625185
and O 0 8.651375082990853e-08
controls O 0 3.197119804099202e-05
. O 0 4.2949221779053914e-07

Exon O 0 7.511278090532869e-05
- O 0 1.358220379188424e-05
specific O 0 1.8137595247935678e-07
primers O 0 3.031672122233431e-06
developed O 0 1.5473452208425442e-07
in O 0 1.2384759884298546e-09
this O 0 2.627168760316323e-10
study O 0 6.900234827966756e-10
will O 0 8.589511879542044e-10
facilitate O 0 1.0054236554424278e-08
mutation O 0 1.8542978352797945e-07
screening O 0 4.452301993751462e-08
studies O 0 5.4382107705919225e-09
of O 0 9.986192983646447e-10
patients O 0 1.549969823599895e-07
with O 0 8.305323540014342e-09
the O 0 1.3337057680473663e-06
disease O 0 0.046719130128622055
. O 0 1.7505450955468405e-07

Genomic O 0 4.8380599764641374e-05
sequencing O 0 5.694494575436693e-06
of O 0 1.1999108551208337e-07
a O 0 4.668794701956358e-07
BAC O 0 0.0003629078855738044
clone O 0 4.884790541836992e-05
H O 1 1.0
_ O 0 2.3475104171666317e-07
RG364P16 O 0 9.477084859099705e-07
revealed O 0 1.732733068138259e-07
the O 0 1.7485645154025065e-09
presence O 0 3.95386701157463e-09
of O 0 2.895601813879267e-10
another O 0 4.382747054165748e-09
, O 0 7.867039242270835e-10
highly O 0 3.2781584113905637e-09
homologous O 0 3.9302747723013454e-08
gene O 0 8.747480251258821e-08
3 O 0 4.623534888281711e-09
of O 0 5.359863664011755e-10
the O 0 3.152359084879208e-08
CLD B-Disease 0 0.00024227255198638886
gene O 0 9.171378678729525e-07
, O 0 3.104230650308182e-09
with O 0 7.443307081800299e-10
a O 0 3.3979112856741267e-09
similar O 0 6.583009692917585e-09
genomic O 0 1.679345587035641e-07
structure O 0 1.144542011388694e-06
, O 0 4.11149647661091e-09
recently O 0 4.311871748541307e-08
identified O 0 7.61285434691672e-08
as O 0 4.037636891496277e-09
the O 0 2.429296728223562e-07
Pendred B-Disease 1 1.0
syndrome I-Disease 1 1.0
gene O 0 2.6599916509439936e-06
( O 0 2.4028997458458434e-08
PDS B-Disease 0 1.4997814332673443e-06
) O 0 4.9274664348786246e-09
. O 0 3.711559282137955e-09
. O 0 3.295223649502077e-08

The O 0 8.264303801297501e-07
APCI1307K O 0 3.0516077458742075e-05
allele O 0 5.303093985276064e-06
and O 0 2.1078167264931835e-06
cancer B-Disease 0 0.007110398728400469
risk O 0 1.9676847387017915e-06
in O 0 7.171496729796445e-10
a O 0 3.272198734194376e-09
community O 0 4.43273462380489e-09
- O 0 1.6192409475479508e-06
based O 0 2.773278495737941e-09
study O 0 2.3194823839389755e-09
of O 0 1.7274153218949095e-09
Ashkenazi O 0 2.6902841909759445e-06
Jews O 0 1.7770017279872263e-07
. O 0 5.175104789145735e-08

Mutations O 0 0.0007326907943934202
in O 0 1.0860324550776568e-07
APC O 0 1.3767547670795466e-06
are O 0 2.7250193213035345e-08
classically O 0 4.885414819000289e-05
associated O 0 7.765816576466023e-07
with O 0 8.959685146692209e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 1.3957833289168775e-05
FAP B-Disease 0 1.9183649783371948e-05
) O 0 2.5495932476360395e-08
, O 0 2.8728941448008527e-09
a O 0 2.101510609975321e-08
highly O 0 0.00014471921895164996
penetrant O 1 0.9999953508377075
autosomal B-Disease 1 1.0
dominant I-Disease 1 1.0
disorder I-Disease 1 1.0
characterized O 0 1.7625670807319693e-05
by O 0 1.2859466380632512e-08
multiple O 0 0.0005731411511078477
intestinal O 0 0.019349101930856705
polyps B-Disease 0 0.025509821251034737
and O 0 5.287209248194813e-08
, O 0 2.3242030522396817e-09
without O 0 1.6179052764186963e-08
surgical O 0 2.017871338466648e-06
intervention O 0 1.0003930128732463e-07
, O 0 3.2188394172294466e-09
the O 0 1.6619934317674279e-09
development O 0 2.0313290605145085e-08
of O 0 0.00028868738445453346
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 3.7628407767442695e-07
CRC B-Disease 0 5.250386038824217e-06
) O 0 7.881946118004635e-08
. O 0 8.451691968502928e-08

APC B-Disease 0 7.662767166038975e-05
is O 0 2.7555671522350167e-07
a O 0 4.119293919302436e-07
tumour O 1 0.9999996423721313
- O 0 4.189747414784506e-06
suppressor O 0 1.6667756881361129e-06
gene O 0 2.5380026613675e-07
, O 0 2.103699214828225e-09
and O 0 3.5063409953295377e-09
somatic O 0 2.2050789993954822e-06
loss O 0 1.6873672166184406e-06
occurs O 0 2.012233863979418e-07
in O 0 2.220120762785882e-07
tumours B-Disease 1 1.0
. O 0 8.806186428955698e-07

The O 0 3.227311253795051e-06
germline O 0 5.4806314437882975e-05
T O 0 3.653963722172193e-05
- O 0 1.5814207472431008e-06
to O 0 4.759389327091412e-08
- O 0 2.340974106118665e-06
A O 0 7.42978301104813e-08
transversion O 0 1.8351656763115898e-06
responsible O 0 3.2822644158159164e-08
for O 0 3.9891187575413767e-10
the O 0 1.4318208840791158e-09
APC O 0 5.8342404685163274e-08
I1307K O 0 6.40963904174896e-08
allele O 0 2.987435721024667e-08
converts O 0 1.168533980688835e-08
the O 0 2.3512682911785987e-09
wild O 0 1.1966101887139757e-08
- O 0 1.6188735685318534e-07
type O 0 9.354988037557632e-07
sequence O 0 9.356185870501577e-08
to O 0 1.7623971615421397e-08
a O 0 3.289073617906979e-07
homopolymer O 0 0.15809185802936554
tract O 0 0.00017013192700687796
( O 0 2.106237673160649e-08
A8 O 0 5.971893642708892e-06
) O 0 3.127109904355052e-09
that O 0 6.036103838980011e-10
is O 0 1.8244307176118468e-09
genetically O 0 1.0712158626802193e-07
unstable O 0 4.020481810584897e-06
and O 0 2.5663620561999778e-08
prone O 0 1.229866666108137e-05
to O 0 2.1391450388819067e-08
somatic O 0 4.745764454128221e-05
mutation O 0 0.00012026450713165104
. O 0 4.87481599975581e-07

The O 0 7.448134624610248e-07
I1307K O 0 3.8474186112580355e-06
allele O 0 1.8500262513043708e-06
was O 0 9.807144607520968e-08
found O 0 1.0902742708651658e-08
in O 0 2.0468813310969836e-09
6 O 0 8.510655646887244e-08
. O 0 4.565724864846743e-08

1 O 0 5.609339041257044e-06
% O 0 2.7249888034930336e-07
of O 0 5.508405287457663e-09
unselected O 0 1.032644559018081e-05
Ashkenazi O 0 1.0089324860018678e-05
Jews O 0 2.970597847706813e-07
and O 0 3.228642242447677e-08
higher O 0 1.5809065700977953e-07
proportions O 0 1.8309127369775524e-07
of O 0 1.0837759578663508e-09
Ashkenazim O 0 2.6706911739893258e-05
with O 0 3.2147053019571104e-08
family O 0 9.112053334092707e-08
or O 0 2.5787744561966974e-07
personal O 0 3.426358034630539e-06
histories O 0 3.157918399665505e-05
of O 0 2.7358620258155497e-08
CRC B-Disease 0 2.0305240468587726e-05
( O 0 3.4206529164748645e-08
ref O 0 6.282866524998099e-05
. O 0 4.969514577624068e-09
2 O 0 3.210918464446877e-08
) O 0 1.2293310369670962e-08
. O 0 5.2348692491932525e-08

To O 0 4.0078847973745724e-07
evaluate O 0 5.917497674090555e-07
the O 0 9.658778665766476e-09
role O 0 1.816289518785652e-08
of O 0 1.2536917060046449e-09
I1307K O 0 2.545138215737097e-07
in O 0 1.93103097956282e-08
cancer B-Disease 0 4.096249540452845e-06
, O 0 4.003282594311486e-09
we O 0 4.892574878567757e-08
genotyped O 0 1.1735594398487592e-06
5 O 0 1.763927315323599e-08
, O 0 9.440110027014725e-09
081 O 0 4.890418949798914e-06
Ashkenazi O 0 3.972581907873973e-06
volunteers O 0 2.5414757942598953e-07
in O 0 4.008172460601145e-09
a O 0 1.2695426043762836e-08
community O 0 1.7149348607858883e-08
survey O 0 2.8350962111289846e-06
. O 0 1.884743880964379e-07

Risk O 0 0.0004133988404646516
of O 0 1.407098721983857e-07
developing O 0 3.628992271842435e-05
colorectal B-Disease 1 1.0
, I-Disease 0 8.82560811987787e-07
breast I-Disease 1 0.6865749359130859
and I-Disease 0 3.6685830195892777e-07
other I-Disease 0 3.8893492160241294e-07
cancers I-Disease 1 0.9997764229774475
were O 0 1.7624092834012117e-06
compared O 0 5.234210576077203e-08
between O 0 1.3829335010484556e-08
genotyped O 0 3.4894048894784646e-06
I1307K O 0 3.5663595099322265e-07
carriers O 0 9.767568087681866e-08
and O 0 9.415474622187503e-09
non O 0 9.119457899942063e-07
- O 0 5.581026016443502e-06
carriers O 0 7.491990459129738e-07
and O 0 1.301422614119474e-08
their O 0 2.100036056162935e-08
first O 0 6.560512844089317e-08
- O 0 3.151453938698978e-06
degree O 0 2.7033004812437866e-07
relatives O 0 1.0488894304216956e-06
. O 0 2.747948713022197e-07

Sperm O 0 0.00018369837198406458
DNA O 0 5.325422989699291e-06
analysis O 0 3.731806543783023e-07
in O 0 2.075775817900194e-08
a O 0 1.0673734607280494e-07
Friedreich B-Disease 0 0.0033889086917042732
ataxia I-Disease 1 0.9137578010559082
premutation O 0 0.0006909733056090772
carrier O 0 9.706143828225322e-06
suggests O 0 1.1355263040968566e-07
both O 0 1.6885275400113642e-08
meiotic O 0 1.1842627145597362e-06
and O 0 2.9069378015833536e-08
mitotic O 0 2.139648586307885e-06
expansion O 0 1.300197425280203e-07
in O 0 7.750839969844492e-09
the O 0 7.342858765468918e-08
FRDA B-Disease 0 1.6207679436774924e-05
gene O 0 2.458186145304353e-06
. O 0 1.9299066877920268e-07

Friedreich B-Disease 1 0.986336350440979
ataxia I-Disease 1 0.999990701675415
is O 0 1.958987741090823e-05
usually O 0 2.590431358839851e-05
caused O 0 6.912800927239005e-07
by O 0 1.2941691052148485e-09
an O 0 5.625087062810508e-10
expansion O 0 8.217337033045169e-09
of O 0 2.067784610204626e-09
a O 0 2.0250918453257327e-07
GAA O 0 9.788336319616064e-05
trinucleotide O 0 4.0050701500149444e-05
repeat O 0 3.030325160580105e-06
in O 0 6.668807728260617e-09
intron O 0 4.191042535239831e-06
1 O 0 1.546851891021106e-08
of O 0 9.513836385366403e-10
the O 0 3.906836099076827e-08
FRDA B-Disease 0 2.191330713685602e-05
gene O 0 2.125728542523575e-06
. O 0 1.5035004707897315e-07

Occasionally O 0 0.0037213654723018408
, O 0 1.6954021475612535e-07
a O 0 6.249646133937858e-08
fully O 0 5.730002072823481e-08
expanded O 0 1.2883869082713773e-08
allele O 0 1.2386992409574304e-07
has O 0 4.83498174830288e-09
been O 0 3.07097502982856e-09
found O 0 1.6977886874158798e-09
to O 0 2.328875980950329e-09
arise O 0 1.6684481352058356e-08
from O 0 1.4110805857114883e-09
a O 0 5.45909983884485e-09
premutation O 0 5.682428536601947e-07
of O 0 2.082170658113114e-09
100 O 0 3.590417563259507e-08
or O 0 1.1848541703329829e-07
less O 0 1.465336652017868e-07
triplet O 0 0.0006488257204182446
repeats O 0 4.723126403405331e-05
. O 0 2.323189960407035e-07

We O 0 9.427475561096799e-06
have O 0 4.614876658592948e-08
examined O 0 1.9216312807657232e-07
the O 0 4.89259077696147e-09
sperm O 0 1.7101861260471196e-07
DNA O 0 8.678181728782874e-08
of O 0 3.786272184669315e-09
a O 0 1.9165086939665343e-07
premutation O 0 0.0001512330345576629
carrier O 0 3.4488868550397456e-05
. O 0 2.419369025119522e-07

This O 0 5.845846544616506e-07
mans O 0 1.0260175258736126e-05
leucocyte O 0 2.2642274416284636e-05
DNA O 0 4.1203370528819505e-06
showed O 0 1.193735215565539e-06
one O 0 1.2576295560506878e-08
normal O 0 5.053758300732625e-08
allele O 0 2.0008231160772993e-07
and O 0 5.0420094765968315e-09
one O 0 1.8868662188253893e-09
allele O 0 1.5129280939163436e-08
of O 0 3.8920758282934287e-10
approximately O 0 1.5174046907873162e-08
100 O 0 6.295143606394049e-08
repeats O 0 4.354196335043525e-06
. O 0 3.476188226159138e-07

His O 0 1.1831443771370687e-05
sperm O 0 1.5943796825013123e-05
showed O 0 7.00088662597409e-07
an O 0 6.1973075560217694e-09
expanded O 0 8.235258519562194e-08
allele O 0 1.8481891572719178e-07
in O 0 2.8343161151411778e-09
a O 0 1.6796491308923578e-08
tight O 0 2.3427496671502013e-06
range O 0 1.6041246908571338e-07
centering O 0 1.9526427763594256e-07
on O 0 2.5024979422028082e-08
a O 0 3.5672753639914845e-09
size O 0 1.040541430796793e-08
of O 0 1.2029828244664031e-09
approximately O 0 3.5840749035287445e-08
320 O 0 4.982121026841924e-07
trinucleotide O 0 5.553344453801401e-05
repeats O 0 1.1958344657614361e-05
. O 0 4.569880616145383e-07

His O 0 6.057104201317998e-06
affected O 0 1.4949269825592637e-05
son O 0 7.059113158902619e-06
has O 0 2.8608821978082233e-08
repeat O 0 2.5753533350325597e-07
sizes O 0 2.26346827503221e-07
of O 0 3.7487617454701194e-09
1040 O 0 3.869386091537308e-07
and O 0 3.536472803489232e-08
540 O 0 5.452930622595886e-07
. O 0 1.4266277048591292e-07

These O 0 2.8590119427462923e-07
data O 0 1.4722155583513086e-07
suggest O 0 6.50135660862361e-08
that O 0 9.285032742667454e-10
expansion O 0 5.588985274584957e-09
occurs O 0 3.847731910866514e-09
in O 0 5.054640039858782e-10
two O 0 1.2955282180371341e-08
stages O 0 1.3832679996994557e-06
, O 0 1.937464189083471e-09
the O 0 8.268398188349124e-10
first O 0 5.240540446038722e-09
during O 0 1.0921350046544376e-08
meiosis O 0 8.6655113307188e-08
followed O 0 2.6308118350470977e-08
by O 0 3.0225799640959394e-09
a O 0 1.1399071908613223e-08
second O 0 2.232026332649184e-07
mitotic O 0 3.702723233800498e-06
expansion O 0 1.2297424518692424e-06
. O 0 2.9292465342223295e-07

We O 0 8.468524356430862e-06
also O 0 3.7196471680545073e-08
show O 0 5.4379651004410334e-08
that O 0 6.783131833998368e-10
in O 0 4.060665415028808e-10
all O 0 7.597862339281392e-10
informative O 0 6.615953651589734e-08
carrier O 0 6.911791956554225e-07
father O 0 5.489413368309215e-08
to O 0 2.2072497163350135e-09
affected O 0 6.112971817628932e-08
child O 0 2.6541962938608776e-07
transmissions O 0 4.3619118514470756e-05
, O 0 7.2950299134788565e-09
with O 0 9.831820912964417e-10
the O 0 1.732562870948584e-09
notable O 0 1.1864468518751892e-08
exception O 0 7.600142737373972e-09
of O 0 3.9621991798632905e-10
the O 0 1.0892143187390957e-08
premutation O 0 2.812097591231577e-06
carrier O 0 2.695045395739726e-07
, O 0 1.010446615268279e-09
the O 0 6.103854643946249e-10
expansion O 0 9.777816778466786e-09
size O 0 5.4540443272799166e-08
decreases O 0 2.1481938006218115e-07
. O 0 1.140559646728434e-08
. O 0 6.966268273345122e-08

The O 0 1.0443469591336907e-06
R496H O 0 9.095259883906692e-06
mutation O 0 1.7972863588511245e-06
of O 0 8.06805733333249e-09
arylsulfatase O 0 3.024645820914884e-06
A O 0 2.522121178571979e-07
does O 0 3.525408374116523e-07
not O 0 8.772606747697864e-07
cause O 0 0.0001726130285533145
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
. O 0 2.1859270873392234e-06

Deficiency B-Disease 1 0.9998065829277039
of I-Disease 0 1.485771576881234e-07
arylsulfatase I-Disease 0 1.6095760656753555e-05
A I-Disease 0 2.179412916802903e-07
( O 0 6.725474577251589e-08
ARSA O 0 5.7423010730417445e-05
) O 0 1.9212148316682942e-08
enzyme O 0 9.648854302213294e-07
activity O 0 6.831574864918366e-06
causes O 0 0.0001487683766754344
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 7.334815745707601e-05
MLD B-Disease 1 0.9999998807907104
) O 0 5.692104423360433e-07
. O 0 1.8242059240947128e-07

A O 0 1.6970421938822255e-06
number O 0 9.733182082527492e-08
of O 0 1.5260162911090447e-08
ARSA O 0 0.0012653954327106476
gene O 0 5.580238394031767e-06
mutations O 0 1.1855547199957073e-05
responsible O 0 4.5724527808488347e-07
for O 0 5.438037220528713e-08
MLD B-Disease 1 1.0
have O 0 6.216706424311269e-06
been O 0 5.318366333995073e-07
identified O 0 6.303121722339711e-07
. O 0 4.2788879994759554e-08

Recently O 0 3.619021663325839e-05
, O 0 4.491468885703398e-08
the O 0 8.616197533228842e-09
R496H O 0 4.42156590452214e-07
mutation O 0 2.410483830317389e-07
of O 0 3.433292539156696e-09
ARSA O 0 2.945410778920632e-05
was O 0 4.1550151763658505e-08
proposed O 0 2.8767652704431157e-09
to O 0 2.863921544360437e-09
be O 0 1.2074268695982937e-08
a O 0 1.3184773273167139e-08
cause O 0 1.777349183385013e-07
of O 0 1.9501001702337817e-08
MLD B-Disease 1 1.0
( O 0 1.7229812954155932e-07
Draghia O 0 1.555826747789979e-05
et O 0 0.00019167257414665073
al O 0 0.017038464546203613
. O 0 1.6472560204761066e-08
, O 0 1.0679228168442023e-08
1997 O 0 3.710329465889117e-08
) O 0 1.183364251033936e-08
. O 0 5.97315263917153e-08

We O 0 1.0509097592148464e-05
have O 0 5.193952645754507e-08
investigated O 0 1.8075758134727948e-07
the O 0 6.933007945519876e-09
R496H O 0 8.494387770952017e-07
mutation O 0 4.768821781908628e-07
and O 0 1.0595394783763368e-08
found O 0 1.091730972291316e-08
this O 0 5.146965631475098e-10
mutation O 0 1.0261384630894099e-07
at O 0 1.988759734672385e-08
a O 0 3.855871621993856e-09
relatively O 0 1.7639138150116196e-08
high O 0 1.746165523286436e-08
frequency O 0 3.0789567517786054e-07
in O 0 1.1088190365882156e-09
an O 0 1.684737016560689e-09
African O 0 7.565660986585954e-09
American O 0 6.559209175804881e-09
population O 0 1.355323520080276e-09
( O 0 2.6834972022271586e-09
f O 0 1.1302793154754909e-06
= O 0 1.380894332214666e-06
0 O 0 7.50494137946589e-08
. O 0 3.767973488777443e-09
09 O 0 1.4464997093455167e-06
, O 0 4.694484800893406e-08
n O 0 9.36980632104678e-06
= O 0 1.9297465769341215e-05
61 O 0 1.0819568387887557e-06
subjects O 0 5.8230502872902434e-06
) O 0 1.3616131866456271e-07
. O 0 1.1723967219268161e-07

The O 0 1.623216007828887e-06
ARSA O 0 0.00013429329555947334
enzyme O 0 1.4400155805560644e-06
activity O 0 2.158964065301916e-07
in O 0 2.245873487183303e-09
subjects O 0 2.0791483734683425e-07
with O 0 3.766638556612634e-08
and O 0 1.6617285325537523e-07
without O 0 6.106771621716689e-08
the O 0 2.238347063254764e-09
R496H O 0 1.4895370270551211e-07
mutation O 0 1.3145128718861088e-07
was O 0 5.565775751392721e-08
determined O 0 4.3874326394188756e-08
and O 0 5.911403810898719e-09
found O 0 1.658498227641303e-08
to O 0 9.802428202476676e-09
be O 0 1.0620973966979363e-07
normal O 0 5.055956648902793e-07
. O 0 4.12801561822107e-08

It O 0 5.725494247599272e-07
is O 0 7.148093228437347e-09
therefore O 0 6.8775332096038255e-09
concluded O 0 5.1654969190906286e-09
that O 0 2.425585010623621e-10
the O 0 1.9072154966437438e-09
R496H O 0 1.596910976786603e-07
mutation O 0 7.530938717081881e-08
of O 0 1.4649146340417474e-09
ARSA O 0 2.2056694433558732e-05
does O 0 2.8668635465578518e-08
not O 0 6.137561570085381e-09
negatively O 0 6.3014362616797825e-09
influence O 0 3.216691357721402e-09
the O 0 1.7145642683402684e-09
activity O 0 1.0701535657631212e-08
of O 0 9.005406420570239e-10
ARSA O 0 8.773427543928847e-05
and O 0 1.2298792739784403e-07
is O 0 4.656803831437628e-09
not O 0 7.285074321572438e-09
a O 0 1.7732240564782842e-08
cause O 0 5.749635647589457e-07
of O 0 2.549336102219968e-07
MLD B-Disease 1 0.9999997615814209

Down O 0 0.00035501530510373414
- O 0 1.3480454072123393e-05
regulation O 0 3.8071669905548333e-07
of O 0 8.43328251676212e-09
transmembrane O 0 2.668956312845694e-06
carbonic O 0 4.741575594380265e-06
anhydrases O 0 7.450020802934887e-06
in O 0 1.4728391306562116e-07
renal B-Disease 1 0.9995344877243042
cell I-Disease 1 0.9999915361404419
carcinoma I-Disease 1 1.0
cell O 0 0.1061006411910057
lines O 0 1.8515904230298474e-05
by O 0 5.06541297795593e-09
wild O 0 7.126858747596998e-08
- O 0 4.373937554191798e-05
type O 0 0.2897288501262665
von B-Disease 1 0.9992107152938843
Hippel I-Disease 1 0.9993160963058472
- I-Disease 1 0.9417617321014404
Lindau I-Disease 1 0.754395604133606
transgenes O 0 0.0007472613360732794
. O 0 2.877955239455332e-06

To O 0 7.612679269186629e-07
discover O 0 2.1590392407233594e-06
genes O 0 6.271031907090219e-07
involved O 0 1.1758611151435616e-07
in O 0 3.088334210588073e-08
von B-Disease 1 0.9822408556938171
Hippel I-Disease 1 0.9999697208404541
- I-Disease 1 0.9999042749404907
Lindau I-Disease 1 0.9999198913574219
( O 0 7.080263344505511e-07
VHL B-Disease 0 0.0001508578279754147
) O 0 4.5295717399085333e-08
- O 0 1.674391114647733e-06
mediated O 0 7.462485882570036e-06
carcinogenesis O 0 1.0820644092746079e-05
, O 0 1.1522138798625292e-08
we O 0 1.7599248280930624e-08
used O 0 6.109624791861279e-06
renal B-Disease 1 0.9998568296432495
cell I-Disease 1 0.9999971389770508
carcinoma I-Disease 1 1.0
cell O 1 0.7640134692192078
lines O 0 0.014542329125106335
stably O 0 7.328516221605241e-05
transfected O 0 9.2044283519499e-06
with O 0 1.4249560642554115e-08
wild O 0 3.059459459109348e-07
- O 0 0.00014378115884028375
type O 1 0.5682844519615173
VHL O 1 0.8160038590431213
- O 0 0.0005540820420719683
expressing O 0 2.6098416583408834e-06
transgenes O 0 3.640361319412477e-05
. O 0 9.055430041371437e-07

Large O 0 1.7958265061679413e-06
- O 0 4.027873274026206e-06
scale O 0 7.134923976082064e-07
RNA O 0 3.277679070379236e-07
differential O 0 2.2535861887718056e-07
display O 0 9.37354869279261e-08
technology O 0 3.252463187664034e-08
applied O 0 3.299437523196502e-08
to O 0 4.895969851759219e-09
these O 0 6.95566058084296e-08
cell O 0 6.077877515053842e-06
lines O 0 2.9138131139916368e-05
identified O 0 1.9147000784869306e-07
several O 0 1.992228604308366e-09
differentially O 0 1.8431549619890575e-07
expressed O 0 2.4471855653018793e-09
genes O 0 3.275222582033166e-08
, O 0 5.020951432399556e-10
including O 0 4.5012152338763656e-10
an O 0 1.5243659667873999e-09
alpha O 0 1.9217870317334018e-07
carbonic O 0 7.786090918671107e-07
anhydrase O 0 8.943157467911078e-07
gene O 0 4.608895380897593e-07
, O 0 2.1695104379659824e-08
termed O 0 2.310790250703576e-06
CA12 O 0 6.028575444361195e-05
. O 0 3.3965724810514075e-07

The O 0 7.85311726758664e-07
deduced O 0 3.0453143153863493e-06
protein O 0 6.332059001579182e-07
sequence O 0 2.979725479690387e-07
was O 0 2.0300865344324848e-07
classified O 0 2.724853516156145e-07
as O 0 1.3111395524845193e-08
a O 0 1.6720033357842112e-08
one O 0 1.77858680672216e-07
- O 0 0.0006231378647498786
pass O 0 1.6969168427749537e-05
transmembrane O 0 4.692508082371205e-05
CA O 0 0.00014374851889442652
possessing O 0 1.926694039866561e-07
an O 0 9.981989457230611e-09
apparently O 0 1.6826074897835497e-06
intact O 0 1.1276226530299027e-07
catalytic O 0 2.8536719653970977e-08
domain O 0 5.493435750736353e-08
in O 0 5.186010287872023e-09
the O 0 1.606610133819686e-08
extracellular O 0 2.3296581730392063e-06
CA O 0 0.00028390312218107283
module O 0 5.240846348897321e-06
. O 0 3.5143713716934144e-07

Reintroduced O 0 2.5267987439292483e-05
wild O 0 3.921872121281922e-06
- O 0 2.0389417841215618e-05
type O 0 9.085366764338687e-05
VHL B-Disease 0 0.0003320358810015023
strongly O 0 6.645173584729491e-07
inhibited O 0 4.1493220237498463e-07
the O 0 4.378335027865887e-09
overexpression O 0 5.846628070571569e-08
of O 0 9.436773584781122e-10
the O 0 5.132048563893932e-09
CA12 O 0 9.906576678986312e-07
gene O 0 7.738523066791458e-08
in O 0 1.411441297172189e-09
the O 0 1.56138835194497e-08
parental O 1 0.6537951231002808
renal B-Disease 1 0.9999865293502808
cell I-Disease 1 0.9999899864196777
carcinoma I-Disease 1 1.0
cell O 1 0.5073184370994568
lines O 0 0.015310926362872124
. O 0 5.822611797157151e-07

Similar O 0 4.341608018876286e-06
results O 0 4.771665317093721e-06
were O 0 2.0811602041703736e-07
obtained O 0 3.957293870371359e-08
with O 0 8.74163852415677e-09
CA9 O 0 1.7953016140381806e-05
, O 0 2.2417607770108816e-09
encoding O 0 2.5354955468515072e-08
another O 0 7.383277278449896e-08
transmembrane O 0 1.9940369384130463e-05
CA O 0 0.0026368568651378155
with O 0 1.217591005797658e-08
an O 0 3.571675222246995e-08
intact O 0 9.854818017629441e-06
catalytic O 0 1.132182319452113e-06
domain O 0 2.510892272766796e-06
. O 0 3.726663635461591e-07

Although O 0 1.3550987887356314e-06
both O 0 3.6025799232675126e-08
domains O 0 9.448543636381146e-08
of O 0 1.8904253717977326e-09
the O 0 8.032556841897076e-09
VHL B-Disease 0 4.563266884360928e-06
protein O 0 2.6618231174779794e-08
contribute O 0 8.571987564209849e-09
to O 0 2.0215187301886317e-09
regulation O 0 1.455116489523789e-07
of O 0 2.727399417423726e-09
CA12 O 0 7.582351827295497e-06
expression O 0 1.0366473190970282e-07
, O 0 4.4862868975314996e-09
the O 0 3.1780755804788896e-09
elongin O 0 7.940308819343045e-07
binding O 0 1.02647128130684e-07
domain O 0 2.425638854219869e-07
alone O 0 3.2931069426922477e-07
could O 0 2.4315684754583344e-07
effectively O 0 2.606951284178649e-06
regulate O 0 5.795577180833789e-06
CA9 O 0 0.00020885380217805505
expression O 0 2.6003538096119883e-06
. O 0 3.991185906215833e-07

We O 0 7.050265594443772e-06
mapped O 0 2.5336077669635415e-05
CA12 O 0 6.686511187581345e-05
and O 0 2.0435632563930994e-07
CA9 O 0 8.482170960633084e-05
loci O 0 1.9213832729292335e-06
to O 0 5.842480987894305e-08
chromosome O 0 2.4828828827594407e-05
bands O 0 3.4676695577218197e-06
15q22 O 0 5.685405540134525e-06
and O 0 1.9362539660505718e-07
17q21 O 0 1.1886543688888196e-05
. O 0 3.979183418323373e-07

2 O 0 4.8778106247482356e-06
respectively O 0 1.151013179878646e-06
, O 0 7.921353351036942e-09
regions O 0 6.234882476974235e-08
prone O 0 3.6035518860444427e-05
to O 0 8.678674667805808e-09
amplification O 0 8.898035162019369e-07
in O 0 2.7585123074658213e-09
some O 0 6.032355059915062e-09
human O 0 2.8078935088160506e-07
cancers B-Disease 0 0.2759441137313843
. O 0 1.9822087438114977e-07

Additional O 0 1.450266495339747e-06
experiments O 0 1.4771957239645417e-06
are O 0 2.149664801720519e-08
needed O 0 2.578309121759048e-08
to O 0 3.077665677864161e-09
define O 0 3.41562042649457e-07
the O 0 4.1459253807829555e-09
role O 0 2.3596484766130743e-08
of O 0 3.4189551190166867e-09
CA O 0 1.3615858733828645e-05
IX O 0 1.1997019555565203e-06
and O 0 4.6271543396869674e-07
CA O 0 1.7023319742293097e-05
XII O 0 3.498243756894226e-07
enzymes O 0 1.8834160186997906e-07
in O 0 1.1991524440091439e-09
the O 0 1.0813022699451835e-09
regulation O 0 3.736143483479282e-08
of O 0 5.672254888011707e-10
pH O 0 5.294455149851274e-07
in O 0 1.574210095611761e-09
the O 0 1.8447680050215354e-09
extracellular O 0 7.531571100116707e-08
microenvironment O 0 3.781774466915522e-07
and O 0 6.726343926288791e-09
its O 0 2.555746059229591e-09
potential O 0 1.872297872296258e-08
impact O 0 8.139237905879781e-08
on O 0 5.297131906445429e-07
cancer B-Disease 0 3.0978477298049256e-05
cell O 0 9.806318530536373e-07
growth O 0 5.981989374959085e-07
. O 0 8.160736086892939e-08

A O 0 1.7874167497211602e-06
gene O 0 1.5612729384884005e-06
encoding O 0 2.508666057110531e-07
a O 0 3.349670762986534e-08
transmembrane O 0 4.3568613250499766e-07
protein O 0 6.642405026013876e-08
is O 0 1.7251828854369933e-09
mutated O 0 1.641952422914983e-07
in O 0 4.4681489619335935e-09
patients O 0 3.7953957416902995e-06
with O 0 1.074758438335266e-05
diabetes B-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 0.03406364843249321
optic B-Disease 1 1.0
atrophy I-Disease 1 0.9999985694885254
( O 0 0.005406828131526709
Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
) O 0 4.386160981084686e-07
. O 0 1.8455224903846101e-07

Wolfram B-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 0.00034411062370054424
WFS B-Disease 0 0.1466178148984909
; O 0 1.6390594055337715e-06
OMIM O 0 0.000610488757956773
222300 O 0 6.471455890277866e-06
) O 0 1.981883102075699e-08
is O 0 2.4960136180141035e-09
an O 0 1.977155861254687e-08
autosomal B-Disease 1 0.999998927116394
recessive I-Disease 1 1.0
neurodegenerative I-Disease 1 0.9999927282333374
disorder I-Disease 1 0.9965097308158875
defined O 0 4.14968610584765e-07
by O 0 4.138435372169624e-09
young O 0 9.515986221231287e-08
- O 0 1.658767541812267e-05
onset O 0 0.09386740624904633
non O 0 0.09532112628221512
- O 1 0.996505856513977
immune O 1 0.8112744092941284
insulin B-Disease 1 0.8096766471862793
- I-Disease 1 0.5424387454986572
dependent I-Disease 1 0.9576501250267029
diabetes I-Disease 1 1.0
mellitus I-Disease 1 1.0
and O 0 4.356007138994755e-06
progressive O 0 0.0025076710153371096
optic B-Disease 1 0.9999990463256836
atrophy I-Disease 1 0.932324230670929
. O 0 2.8575502710737055e-06

Linkage O 0 2.5693461793707684e-05
to O 0 6.074569682823494e-07
markers O 0 3.833213122561574e-05
on O 0 4.518725233992882e-07
chromosome O 0 0.01352685410529375
4p O 0 0.0007848604000173509
was O 0 6.503956228698371e-06
confirmed O 0 3.0293750796772656e-07
in O 0 5.665381053177043e-09
five O 0 9.846279880321163e-08
families O 0 8.466616918667569e-08
. O 0 6.257076989868438e-08

On O 0 3.0692908126184193e-07
the O 0 9.279017554320035e-09
basis O 0 8.465159240245157e-09
of O 0 1.355331180619146e-09
meiotic O 0 6.925074103492079e-06
recombinants O 0 0.0003704761038534343
and O 0 1.4336164895212278e-05
disease O 1 0.9049217104911804
- O 0 0.0001571641769260168
associated O 0 8.454301791971375e-07
haplotypes O 0 2.0903028143948177e-06
, O 0 4.185652713317722e-09
the O 0 6.779461880768167e-09
WFS B-Disease 0 1.0797254617500585e-05
gene O 0 3.544181765846588e-07
was O 0 2.5743041476289363e-08
localized O 0 6.864141965934323e-08
to O 0 6.507966610058702e-09
a O 0 8.369126902607604e-08
BAC O 0 8.618726133136079e-05
/ O 0 1.7435918380215298e-06
P1 O 0 5.434508693724638e-06
contig O 0 2.096659500239184e-06
of O 0 3.960252126233854e-09
less O 0 1.6098402610964513e-08
than O 0 7.395790202480157e-09
250 O 0 3.1054995019985654e-08
kb O 0 1.0212030247203074e-05
. O 0 3.5449693314149044e-07

Mutations O 0 0.00044998625526204705
in O 0 7.195562545803114e-08
a O 0 3.69477213268965e-08
novel O 0 6.654020268115346e-08
gene O 0 8.468972509945161e-07
( O 0 2.656629405350941e-08
WFS1 O 0 2.60306069321814e-06
) O 0 1.4426214667295767e-09
encoding O 0 2.6255383644979702e-08
a O 0 2.296736667517507e-08
putative O 0 6.961744816180726e-07
transmembrane O 0 4.999369593861047e-07
protein O 0 2.6529565388955234e-07
were O 0 8.134555855576764e-07
found O 0 2.1646163972377508e-08
in O 0 7.185352313143767e-10
all O 0 2.616079353146006e-09
affected O 0 3.1378242226764996e-08
individuals O 0 2.6127930929931154e-09
in O 0 7.281055758312505e-10
six O 0 1.8186162265010353e-07
WFS B-Disease 0 2.373894676566124e-05
families O 0 3.221764544036887e-08
, O 0 8.595313349957223e-10
and O 0 6.953769782214181e-10
these O 0 2.0790238419721163e-09
mutations O 0 1.4743443443876458e-06
were O 0 5.8094556720789114e-08
associated O 0 8.780641103101061e-09
with O 0 6.2895004759866424e-09
the O 0 5.577240926868399e-07
disease O 0 0.00031358355772681534
phenotype O 0 5.638870788970962e-06
. O 0 1.4787673308092053e-07

WFS1 O 0 0.0006680639926344156
appears O 0 2.7457588203105843e-06
to O 0 3.2909778013845425e-08
function O 0 9.218513952191643e-08
in O 0 4.33742375349766e-09
survival O 0 3.766596421428403e-07
of O 0 1.814533190369616e-09
islet O 0 1.764009994076332e-06
beta O 0 2.644718790634215e-07
- O 0 1.8102937247022055e-05
cells O 0 9.289558278169352e-08
and O 0 4.127115982299756e-09
neurons O 0 6.583677958360568e-08
. O 0 2.486519656841324e-09
. O 0 2.1593216104065505e-08

Stable O 0 5.195840640226379e-05
interaction O 0 2.0387240340369317e-07
between O 0 9.351187379991188e-09
the O 0 1.7667378671148981e-09
products O 0 7.962298376185117e-09
of O 0 1.9438482767863974e-10
the O 0 3.02043035027566e-09
BRCA1 O 0 1.67077305377461e-05
and O 0 9.364184450078028e-08
BRCA2 O 0 0.0004845960938837379
tumor B-Disease 0 2.4934038265200797e-06
suppressor O 0 1.0326427855034126e-06
genes O 0 2.2569371083136502e-07
in O 0 4.8789106088520384e-09
mitotic O 0 9.740709856487229e-07
and O 0 1.0426080621073197e-07
meiotic O 0 0.00014626327902078629
cells O 0 1.1722926501533948e-05
. O 0 2.3693475270647468e-07

BRCA1 O 0 0.15515224635601044
and O 0 4.106669621251058e-06
BRCA2 O 0 0.00024979107547551394
account O 0 1.288730260284865e-07
for O 0 1.029362262094935e-09
most O 0 8.765075332206607e-10
cases O 0 5.482136411494309e-10
of O 0 2.2573951041771068e-10
familial O 0 1.6285393940052018e-05
, O 0 6.332811608444899e-09
early O 0 2.402112500021758e-07
onset O 0 0.022192876785993576
breast B-Disease 1 0.9987351298332214
and I-Disease 0 0.0002848368603736162
/ I-Disease 1 0.9999995231628418
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 9.923387445098797e-09
encode O 0 6.053726053778519e-08
products O 0 6.273831445469114e-07
that O 0 2.3236845780871818e-09
each O 0 4.380556806182767e-09
interact O 0 2.9626384900893754e-08
with O 0 2.0535106060037833e-08
hRAD51 O 0 1.106684430851601e-05
. O 0 1.578691666281884e-07

Results O 0 8.886604518920649e-06
presented O 0 1.3878198501515726e-07
here O 0 1.6948323633414475e-08
show O 0 2.8090710202377522e-08
that O 0 4.225551908376701e-09
BRCA1 O 0 2.087985740217846e-05
and O 0 1.8826474956767925e-07
BRCA2 O 0 0.00035714934347197413
coexist O 0 6.152215519250603e-07
in O 0 1.0950609308224557e-09
a O 0 2.8435482857247507e-09
biochemical O 0 2.436480315282097e-07
complex O 0 4.343916515381352e-08
and O 0 3.3296057466714046e-08
colocalize O 0 1.3962659295430058e-06
in O 0 3.7277709807881365e-09
subnuclear O 0 8.073253638940514e-07
foci O 0 6.538613774864643e-07
in O 0 3.897537848018828e-09
somatic O 0 4.593098879013269e-07
cells O 0 2.440046955598518e-07
and O 0 6.6193091008415195e-09
on O 0 3.1025142455121113e-09
the O 0 1.053433229536438e-09
axial O 0 1.60524109560356e-08
elements O 0 1.6312570849663643e-08
of O 0 4.370642070483655e-09
developing O 0 4.596008409407659e-07
synaptonemal O 0 1.037629772326909e-05
complexes O 0 1.156723214990052e-06
. O 0 1.6623056353637367e-07

Like O 0 2.4141692847479135e-05
BRCA1 O 0 0.0007456089369952679
and O 0 1.257719191016804e-06
RAD51 O 0 0.00016583752585574985
, O 0 9.439644799158486e-08
BRCA2 O 0 1.88737285498064e-05
relocates O 0 1.6311829540427425e-06
to O 0 5.4528484838556324e-08
PCNA O 0 2.771716026472859e-05
+ O 0 4.35284135846814e-07
replication O 0 7.096745093804202e-07
sites O 0 1.4902516909387487e-07
following O 0 4.358723160180489e-08
exposure O 0 1.223367348757165e-06
of O 0 2.5625455091216054e-09
S O 0 1.1246107760598534e-06
phase O 0 1.501851016882938e-07
cells O 0 1.0047415344160981e-07
to O 0 8.321466182792392e-09
hydroxyurea O 0 3.7474669625225943e-06
or O 0 1.0104935199706233e-06
UV O 0 0.0003631656873039901
irradiation O 0 4.89868125441717e-06
. O 0 3.9437014720533625e-07

Thus O 0 7.348648523475276e-06
, O 0 9.812383439111727e-08
BRCA1 O 0 7.451597866747761e-06
and O 0 6.176976796723466e-08
BRCA2 O 0 2.472259984642733e-05
participate O 0 1.0526748894790217e-07
, O 0 9.248010357509884e-09
together O 0 5.228821819969198e-08
, O 0 1.871068855407998e-09
in O 0 7.028925219643156e-10
a O 0 5.428272498164688e-09
pathway O 0 9.302944903311072e-08
( O 0 7.2391430627760656e-09
s O 0 1.0267606285196962e-06
) O 0 1.7219808912116719e-09
associated O 0 2.648421704165571e-09
with O 0 5.993861518227561e-10
the O 0 7.10874192844102e-10
activation O 0 1.0957488250085134e-08
of O 0 3.882009380618001e-09
double O 0 5.2761792176170275e-05
- O 0 0.0006829006597399712
strand O 0 2.4429244149359874e-05
break O 0 0.00021958793513476849
repair O 0 0.018058573827147484
and O 0 5.072266162642336e-07
/ O 0 9.538603080727626e-06
or O 0 1.6542260539154086e-07
homologous O 0 2.311971684321179e-06
recombination O 0 7.155500952649163e-06
. O 0 5.005418870496214e-07

Dysfunction O 0 0.26159149408340454
of O 0 9.799216371675357e-08
this O 0 9.387715493858195e-09
pathway O 0 2.857940444300766e-07
may O 0 4.446743560038158e-07
be O 0 3.4852976060761875e-09
a O 0 1.0159949548338432e-09
general O 0 6.525239792942727e-10
phenomenon O 0 8.778965998601507e-09
in O 0 2.306268787055643e-10
the O 0 3.507616697095983e-10
majority O 0 6.895813919882698e-10
of O 0 8.626645925380316e-11
cases O 0 9.041876691817663e-10
of O 0 2.061129933395023e-09
hereditary B-Disease 1 0.9975080490112305
breast I-Disease 1 0.9999395608901978
and I-Disease 0 0.0008949597249738872
/ I-Disease 1 0.9999998807907104
or I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 4.190759739230998e-08
. O 0 1.0460679078505564e-07

A O 0 3.5058928915532306e-06
novel O 0 1.2994478311156854e-06
Arg362Ser O 0 8.306424206239171e-06
mutation O 0 1.142094106398872e-06
in O 0 4.448573065474193e-09
the O 0 7.828544923427216e-09
sterol O 0 5.612544100586092e-06
27 O 0 9.934126410371391e-07
- O 0 1.5620488511558506e-06
hydroxylase O 0 6.94020764058223e-06
gene O 0 5.078558729110227e-07
( O 0 2.1932928362389248e-08
CYP27 O 0 8.191197480300616e-07
) O 0 2.5426036831532883e-09
: O 0 7.145336544667202e-10
its O 0 2.451072234066487e-09
effects O 0 3.1011404644232243e-07
on O 0 9.18493867629877e-08
pre O 0 2.535246494517196e-05
- O 0 4.243225362188241e-07
mRNA O 0 1.0530203553571482e-07
splicing O 0 2.9385134325821127e-07
and O 0 2.0481907725411475e-08
enzyme O 0 5.801847464681487e-07
activity O 0 5.403369414125336e-07
. O 0 1.7554366138483601e-07

A O 0 5.657729161612224e-06
novel O 0 1.552338176225021e-06
C O 0 2.0142740595474606e-06
to O 0 1.9321436894870203e-08
A O 0 9.594627670139744e-08
mutation O 0 5.204703370509378e-07
in O 0 1.814443151282319e-09
the O 0 1.069496491368227e-08
sterol O 0 3.5032192045036936e-06
27 O 0 5.718122224607214e-07
- O 0 1.4623661854784586e-06
hydroxylase O 0 4.576213996188017e-06
gene O 0 8.277697816083673e-07
( O 0 2.424528489086697e-08
CYP27 O 0 1.3238505971457926e-06
) O 0 5.340610176318705e-09
was O 0 1.3506713081312682e-08
identified O 0 1.530902338231499e-08
by O 0 4.72069827672783e-10
sequencing O 0 7.45967341231335e-08
amplified O 0 3.057610342693806e-07
CYP27 O 0 1.6527404795851908e-06
gene O 0 2.0269834521968733e-07
products O 0 7.106525146127751e-08
from O 0 6.823152709500846e-09
a O 0 7.483543384978475e-08
patient O 0 1.502474788139807e-05
with O 0 1.3236663107818458e-06
cerebrotendinous B-Disease 1 1.0
xanthomatosis I-Disease 1 1.0
( O 0 9.574433761372347e-07
CTX B-Disease 0 0.00028194187325425446
) O 0 1.753504221824187e-07
. O 0 1.5396997810057655e-07

The O 0 2.04152888727549e-06
mutation O 0 8.367189366254024e-06
changed O 0 3.959393666264077e-07
the O 0 1.0648231629772908e-08
adrenodoxin O 0 7.115591529327503e-07
cofactor O 0 2.0129304800775571e-07
binding O 0 3.6102053968534165e-07
residue O 0 3.9501524042862e-06
362Arg O 0 2.7778755793406162e-06
to O 0 4.325289637563401e-08
362Ser O 0 3.1912882150209043e-06
( O 0 8.241057258828732e-08
CGT O 0 7.795366400387138e-06
362Arg O 0 1.0477638170414139e-06
to O 0 1.740990995813263e-08
AGT O 0 6.270461199164856e-06
362Ser O 0 1.3938312122263596e-06
) O 0 7.14923853450955e-09
, O 0 1.3246219676688042e-09
and O 0 5.371728395431319e-09
was O 0 2.581015792202379e-07
responsible O 0 1.1448570091943111e-07
for O 0 3.0839547804362155e-08
deficiency O 0 8.774149137025233e-06
in O 0 5.66177049687866e-10
the O 0 4.9266017931870465e-09
sterol O 0 1.6513192804268328e-06
27 O 0 1.5441553102846228e-07
- O 0 2.1066560407234647e-07
hydroxylase O 0 5.245088914307416e-07
activity O 0 1.9557570851702621e-07
, O 0 2.2024344570326093e-09
as O 0 2.0997508176634483e-09
confirmed O 0 5.429525717914885e-09
by O 0 1.7797006923725434e-10
expression O 0 2.8220494829866993e-09
of O 0 4.480828763586686e-10
mutant O 0 7.855950912016851e-08
cDNA O 0 1.1645339270671684e-07
into O 0 9.106250331569754e-08
COS O 0 0.00010003080387832597
- O 0 1.5223759874061216e-05
1 O 0 3.140468152196263e-07
cells O 0 8.50893286497012e-07
. O 0 1.6221576970565366e-07

Quantitative O 0 7.710228601354174e-06
analysis O 0 1.2624431064978126e-06
showed O 0 2.2582064502785215e-06
that O 0 9.32464550018608e-10
the O 0 7.935155865723686e-10
expression O 0 2.4626278793959955e-09
of O 0 3.362520817340453e-10
CYP27 O 0 2.428520815556112e-07
gene O 0 3.936741777010866e-08
mRNA O 0 3.604634812859331e-08
in O 0 2.660603515280968e-09
the O 0 7.312861871611176e-09
patient O 0 3.4179569752268435e-07
represented O 0 1.0868738087310703e-07
52 O 0 1.2782504654751392e-06
. O 0 1.4412269422336976e-07

5 O 0 6.198266419232823e-06
% O 0 3.5717374657906475e-07
of O 0 4.435745548647674e-09
the O 0 1.9408531670705997e-08
normal O 0 8.787326919446059e-07
level O 0 4.840575911657652e-06
. O 0 2.2808599453583156e-07

As O 0 6.127972369540657e-07
the O 0 3.440098339524411e-08
mutation O 0 5.582014068750141e-07
occurred O 0 1.059202432429629e-07
at O 0 1.8819216407450767e-08
the O 0 2.152691802592699e-09
penultimate O 0 4.2228751340189774e-07
nucleotide O 0 1.831527356443985e-07
of O 0 9.697909142403205e-10
exon O 0 8.915790061791995e-08
6 O 0 6.775805871939156e-08
( O 0 4.586460544686588e-09
- O 0 6.444515179282462e-07
2 O 0 1.69837885977131e-08
position O 0 6.929784746034784e-08
of O 0 5.829784988087283e-10
exon O 0 3.1124855581765587e-07
6 O 0 1.4807174864017725e-07
- O 0 1.4950131799196242e-06
intron O 0 2.572806079115253e-05
6 O 0 8.842729926072934e-08
splice O 0 9.233010132447816e-06
site O 0 1.6081040143944847e-07
) O 0 1.2677731087151756e-09
of O 0 1.313491121424093e-10
the O 0 1.7024907039697723e-09
gene O 0 7.152515024699824e-08
, O 0 2.1471517896998193e-09
we O 0 3.878782628419231e-09
hypothesized O 0 7.649632927098082e-09
that O 0 6.188185519562239e-10
the O 0 6.864414814344855e-09
mutation O 0 5.674961812474066e-06
may O 0 2.166066650488574e-07
partially O 0 1.494691105108359e-06
affect O 0 1.791182313581885e-08
the O 0 1.3880331328763873e-09
normal O 0 1.8266600676497546e-08
splicing O 0 1.593749487938112e-07
efficiency O 0 7.256122103171947e-08
in O 0 1.329192755861186e-09
exon O 0 1.2877940491762274e-07
6 O 0 7.740973728687095e-08
and O 0 8.188985489709921e-09
cause O 0 3.350897870291192e-08
alternative O 0 3.879776144799507e-08
splicing O 0 2.1346752419049153e-06
elsewhere O 0 1.5672117115173023e-06
, O 0 2.5654895985383064e-09
which O 0 8.049577671087604e-10
resulted O 0 2.577006164017348e-08
in O 0 1.960829720815127e-09
decreased O 0 4.3262511439934315e-07
transcript O 0 9.446669935186947e-08
in O 0 2.9949422941655257e-09
the O 0 3.504323586867031e-08
patient O 0 2.4505650344508467e-06
. O 0 5.803630287459782e-08

Transfection O 0 0.00027335991035215557
of O 0 3.385528373200941e-07
constructed O 0 2.9496109164028894e-06
minigenes O 0 1.795712705643382e-05
, O 0 1.4622522748197753e-08
with O 0 4.5558752326257945e-09
or O 0 4.081799147570564e-07
without O 0 2.0548897694538937e-08
the O 0 1.882746625270215e-09
mutation O 0 1.4074073817482713e-07
, O 0 1.2594005838195699e-09
into O 0 8.900103765085987e-09
COS O 0 3.589281186577864e-05
- O 0 2.3083300675352803e-06
1 O 0 2.662259745989104e-08
cells O 0 4.8009280106953156e-08
confirmed O 0 1.1611666295152645e-08
that O 0 2.479514094044788e-10
the O 0 7.98093480192108e-10
mutant O 0 2.2723273218616669e-07
minigene O 0 2.0091804344701814e-06
was O 0 3.0590570077038137e-07
responsible O 0 2.022684419955567e-08
for O 0 2.729500514497829e-10
a O 0 1.0855613075122506e-09
mRNA O 0 1.7779925087779702e-08
species O 0 1.000617477764365e-09
alternatively O 0 1.5951659548818498e-08
spliced O 0 1.3087143315715366e-06
at O 0 2.619634074108035e-07
an O 0 7.016338177123771e-09
activated O 0 1.4135359833744587e-06
cryptic O 0 4.399772706165095e-07
5 O 0 1.5401688813199144e-08
splice O 0 5.699117991753155e-06
site O 0 8.452310567008681e-07
88 O 0 4.1117345972452313e-07
bp O 0 6.778998340450926e-07
upstream O 0 5.8901463262373e-08
from O 0 6.1822906793906895e-09
the O 0 2.445533775485842e-09
3 O 0 9.222643981843248e-09
end O 0 2.1867180066692526e-08
of O 0 2.6612634318468054e-09
exon O 0 1.3720584775001043e-06
6 O 0 5.058850547356997e-07
. O 0 1.560799489652709e-07

Our O 0 2.464326598783373e-06
data O 0 2.8403957230693777e-07
suggest O 0 6.771348637357733e-08
that O 0 1.58401691763288e-09
the O 0 2.381658648076268e-09
C O 0 3.588254742226127e-07
to O 0 2.234307627801968e-09
A O 0 3.180660712587269e-08
mutation O 0 2.456432923736429e-07
at O 0 2.5647569401598957e-08
the O 0 2.6062081381894586e-09
penultimate O 0 2.704300925415737e-07
nucleotide O 0 7.471078333765035e-08
of O 0 4.732662040041191e-10
exon O 0 4.798127051230949e-08
6 O 0 1.1602124594389807e-08
of O 0 5.493964727598666e-10
the O 0 6.5603598109476025e-09
CYP27 O 0 1.278168838325655e-06
gene O 0 1.4181361507326073e-07
not O 0 2.2257040654949378e-08
only O 0 1.2867121590431907e-08
causes O 0 1.092333263841283e-07
the O 0 2.6010806664089614e-07
deficiency B-Disease 0 3.4522105124779046e-05
in I-Disease 0 8.528782124983536e-10
the I-Disease 0 5.661092927766731e-09
sterol I-Disease 0 1.8536908328314894e-06
27 I-Disease 0 2.137591650352988e-07
- I-Disease 0 2.787551522942522e-07
hydroxylase I-Disease 0 1.3870302382201771e-06
activity I-Disease 0 4.4154387524031335e-07
, O 0 6.641427408027312e-09
but O 0 7.646817401507633e-09
also O 0 1.913381453277907e-08
partially O 0 1.399271923219203e-06
leads O 0 1.2387791237244983e-08
to O 0 3.3200282523182523e-09
alternative O 0 1.0953146301062588e-07
pre O 0 1.0097669473907445e-05
- O 0 2.716257938573108e-07
mRNA O 0 7.65090604204488e-08
splicing O 0 1.932741326982068e-07
of O 0 2.849835922802413e-09
the O 0 2.540123134053829e-08
gene O 0 1.0972693189614802e-06
. O 0 1.7266808072236017e-07

To O 0 3.611462204844429e-07
our O 0 1.2404051119574433e-07
knowledge O 0 1.790892056874327e-08
, O 0 1.2243742686379733e-09
this O 0 9.475114443047161e-11
is O 0 3.450675023497496e-10
the O 0 4.3359738022274996e-10
first O 0 1.9801751349746155e-08
report O 0 9.740551476511428e-09
regarding O 0 8.286447084060455e-09
effects O 0 2.508869556550053e-07
on O 0 9.488093155596289e-08
pre O 0 9.55214818532113e-06
- O 0 1.235311088976232e-07
mRNA O 0 2.4593997949295954e-08
splicing O 0 7.358575970783932e-08
of O 0 1.8756138864262084e-09
a O 0 1.2502869850550269e-08
mutation O 0 2.103448082380055e-07
at O 0 5.947858383592575e-08
the O 0 1.887983280823846e-08
- O 0 4.754227120429277e-06
2 O 0 4.6560064248524213e-08
position O 0 5.728416567762906e-07
of O 0 9.946881096567495e-10
a O 0 3.748470689401984e-08
5 O 0 3.643051371682304e-08
splice O 0 7.087103585945442e-05
site O 0 4.350212293502409e-06
. O 0 3.9748331914779556e-07

ATM O 0 0.0022360796574503183
germline O 0 0.0011752179125323892
mutations O 0 0.00022236333461478353
in O 0 1.3433111689664656e-07
classical O 0 0.00022407919459510595
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
patients O 1 0.9999934434890747
in O 0 2.8921053996100454e-08
the O 0 4.667360897769868e-08
Dutch O 0 3.5727487556869164e-05
population O 0 6.946034858401617e-08
. O 0 8.703510445684515e-08

Germline O 0 0.001348479650914669
mutations O 0 0.00020675732230301946
in O 0 2.1460147436869192e-08
the O 0 3.251648950097774e-09
ATM O 0 6.65317031689483e-07
gene O 0 1.5142957465741347e-07
are O 0 2.3608177635026095e-09
responsible O 0 1.480776123941041e-08
for O 0 2.564569667740102e-09
the O 0 0.00033190802787430584
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
disorder I-Disease 1 1.0
ataxia B-Disease 1 1.0
- I-Disease 1 1.0
telangiectasia I-Disease 1 1.0
( O 0 0.22624731063842773
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
) O 0 1.1543855293894012e-07
. O 0 9.489866670264746e-08

In O 0 3.096326679496997e-07
our O 0 7.479961539047508e-08
study O 0 8.507210935704279e-09
, O 0 4.9135580049153305e-09
we O 0 9.850389837140483e-09
have O 0 2.8672231255910674e-09
determined O 0 2.2834667490201355e-08
the O 0 1.3667430520669654e-09
ATM O 0 1.1999810567431268e-06
mutation O 0 1.7437901078665163e-07
spectrum O 0 2.80029244237312e-08
in O 0 4.006659004573976e-09
19 O 0 5.749785003672514e-08
classical O 0 1.0862743238249095e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
patients O 0 7.26907046555425e-06
, O 0 2.624514217064444e-10
including O 0 1.5887909043943438e-10
some O 0 3.730613873376143e-10
immigrant O 0 8.652365579564503e-08
populations O 0 2.895196082874918e-08
, O 0 6.484816572616126e-10
as O 0 2.1675528039111214e-09
well O 0 2.807967369733433e-08
as O 0 7.2881318757822555e-09
12 O 0 1.8407057211788924e-08
of O 0 2.1446511233591536e-09
Dutch O 0 1.2284283911867533e-05
ethnic O 0 1.1125888477181434e-07
origin O 0 3.9004780205686984e-07
. O 0 1.8961902981118328e-07

Both O 0 5.957423354630009e-07
the O 0 6.774914140805777e-08
protein O 0 2.278029711533236e-07
truncation O 0 1.7398743921148707e-06
test O 0 1.504906867921818e-05
( O 0 4.0653038269056196e-08
PTT O 0 1.1409097169234883e-06
) O 0 2.442373414623944e-09
and O 0 7.212718755589265e-10
the O 0 6.685909048620431e-10
restriction O 0 8.217587499359524e-09
endonuclease O 0 7.207815428955655e-07
fingerprinting O 0 9.236877644980268e-07
( O 0 2.8232891580159958e-08
REF O 0 4.03848935093265e-06
) O 0 3.863808384352296e-09
method O 0 4.8991488199590094e-08
were O 0 3.256693901221297e-07
used O 0 1.2695214479663264e-07
and O 0 7.078131147864042e-08
compared O 0 5.2963237351377757e-08
for O 0 1.1739754723905094e-09
their O 0 1.1624851303793093e-08
detection O 0 2.6886172577178513e-07
efficiency O 0 1.8524029599120695e-07
, O 0 2.7493516352450342e-09
identifying O 0 1.6684519721366087e-07
76 O 0 2.728821080211219e-08
% O 0 3.3348666050869724e-09
and O 0 4.117853613649913e-09
60 O 0 9.596710093262573e-09
% O 0 2.36623609595199e-09
of O 0 3.4066247045494435e-10
the O 0 2.0308874582042336e-08
mutations O 0 7.14532689016778e-06
, O 0 9.881551576995662e-09
respectively O 0 6.373602445819415e-07
. O 0 6.189112156107512e-08

Most O 0 3.2658770123816794e-06
patients O 0 0.00027906615287065506
were O 0 3.8294706428132486e-07
found O 0 1.634960788976514e-08
to O 0 5.0513748739433595e-09
be O 0 5.489057386398599e-08
compound O 0 3.740736076451867e-07
heterozygote O 0 5.015614988224115e-06
. O 0 8.013707741838516e-08

Seventeen O 0 0.00013137134374119341
mutations O 0 0.00027608522213995457
were O 0 2.8213199243509735e-07
distinct O 0 4.078459880929586e-08
, O 0 1.2507777036319112e-09
of O 0 4.1665743077956563e-10
which O 0 1.8776658450292416e-08
10 O 0 3.421409644488449e-08
were O 0 9.772168141353177e-07
not O 0 1.0581544529486564e-07
reported O 0 6.255179414438317e-07
previously O 0 8.59723741086782e-07
. O 0 6.452238920928721e-08

Mutations O 0 0.001408193726092577
are O 0 9.290461377986503e-08
small O 0 1.8775118348912656e-08
deletions O 0 2.589267523944727e-06
or O 0 8.277040251414292e-06
point O 0 5.134947969054338e-06
mutations O 0 0.000256534171057865
frequently O 0 3.5611562907433836e-06
affecting O 0 1.3746871445619036e-06
splice O 0 0.00024275953182950616
sites O 0 1.3116370610077865e-05
. O 0 8.953107339948474e-07

Moreover O 0 4.4348558731144294e-05
, O 0 1.624641043918018e-07
a O 0 8.05408504334082e-08
16 O 0 2.471518598667899e-07
. O 0 1.0871225697428599e-07

7 O 0 3.352382191224024e-05
- O 0 6.224738626769977e-06
kb O 0 4.432197783899028e-06
genomic O 0 1.1729104016922065e-06
deletion O 0 1.3655654811373097e-06
of O 0 4.2043679648884336e-09
the O 0 6.07456707157894e-09
3 O 0 9.236286402369842e-09
end O 0 8.162382769683063e-09
of O 0 1.1639194469337255e-10
the O 0 8.93142393376678e-10
gene O 0 2.2470445060207567e-08
, O 0 6.899813498328911e-10
most O 0 1.2828788031882254e-09
likely O 0 2.1759129609222327e-08
a O 0 3.0966023079059823e-09
result O 0 5.264374269842165e-09
of O 0 2.180543107188626e-10
recombination O 0 1.8732622564243684e-08
between O 0 2.9574160009815387e-08
two O 0 8.679032248437579e-07
LINE O 0 0.029079915955662727
elements O 0 6.740582989550603e-07
, O 0 6.028859900197858e-08
was O 0 2.8209674951540364e-07
identified O 0 3.6176118101138854e-07
. O 0 2.7657261369995467e-08

The O 0 7.610980219396879e-07
most O 0 4.570560818706326e-08
frequently O 0 5.083282985651749e-07
found O 0 8.082677993570542e-08
mutation O 0 5.821012791784597e-07
, O 0 1.6226977539446352e-09
identified O 0 5.5241901719682573e-08
in O 0 1.1209675410128739e-09
three O 0 1.0542538397828594e-08
unrelated O 0 2.0317250459811476e-07
Turkish O 0 5.759471605415456e-06
A B-Disease 1 1.0
- I-Disease 1 1.0
T I-Disease 1 1.0
individuals O 0 1.8449769356720935e-07
, O 0 4.3190060416975484e-09
was O 0 5.344903186710326e-08
previously O 0 3.8775862520878945e-08
described O 0 5.089527466139998e-09
to O 0 3.3036047231149723e-09
be O 0 1.6865865148929515e-08
a O 0 2.7948443559466796e-08
Turkish O 0 2.0444225810933858e-05
A B-Disease 1 1.0
- I-Disease 1 0.9999998807907104
T I-Disease 1 1.0
founder O 0 3.598511966629303e-06
mutation O 0 9.69350821833359e-06
. O 0 2.205119926657062e-07

The O 0 2.0867982186700829e-07
presence O 0 4.026825806136003e-08
of O 0 1.1508515251890117e-09
a O 0 6.33052898990627e-09
founder O 0 4.2985362824765616e-08
mutation O 0 1.3034888013407908e-07
among O 0 2.328103043680585e-09
relatively O 0 6.8647678652666855e-09
small O 0 3.6438971839913847e-09
ethnic O 0 1.2134896643090087e-08
population O 0 5.973355587940432e-09
groups O 0 1.8501945531212982e-09
in O 0 2.980869995283797e-10
Western O 0 4.577424661533769e-09
Europe O 0 3.140520902888966e-06
could O 0 5.211885536482441e-07
indicate O 0 1.720843272323691e-07
a O 0 6.573198430004368e-09
high O 0 1.3158650347122602e-07
carrier O 0 1.0258038685151405e-07
frequency O 0 7.63609335763249e-08
in O 0 1.4050700603007726e-09
such O 0 7.614942454381435e-09
communities O 0 2.0284259960590134e-07
. O 0 1.1962090695760708e-07

In O 0 1.879355295386631e-06
patients O 0 2.9107970476616174e-05
of O 0 5.49176748521063e-09
Dutch O 0 4.5901610974397045e-06
ethnic O 0 2.998607939730391e-08
origin O 0 9.520016419628519e-08
, O 0 5.72000757870228e-09
however O 0 7.715763139515275e-09
, O 0 1.1825873613702242e-09
no O 0 5.108044209833906e-09
significant O 0 5.742778252937342e-09
founder O 0 4.5555822225651355e-08
effect O 0 3.475646792594489e-08
could O 0 1.5476285852855654e-07
be O 0 2.3501531387637442e-08
identified O 0 3.728981710082735e-07
. O 0 3.2192215115856015e-08

The O 0 5.777696401310095e-07
observed O 0 6.265818797146494e-07
genetic O 0 3.8954112824285403e-07
heterogeneity O 0 1.4827354277713312e-07
including O 0 9.725273031335746e-09
the O 0 8.693883835064753e-09
relative O 0 3.3040291214092576e-07
high O 0 1.543538360238017e-06
percentage O 0 1.438515118934447e-05
of O 0 5.025534211000604e-09
splice O 0 0.06598217785358429
- O 0 0.0085520651191473
site O 0 5.690661510016071e-06
mutations O 0 0.00015027810877654701
had O 0 9.824552762438543e-07
no O 0 1.7472217450631433e-08
reflection O 0 4.097266170788316e-08
on O 0 3.3806202281994047e-08
the O 0 3.576304052899104e-08
phenotype O 0 4.5225633584777825e-06
. O 0 1.012193209248835e-07

All O 0 3.7084660107211675e-06
patients O 0 2.5685527361929417e-05
manifested O 0 7.749733299533546e-07
classical O 0 7.227128548947803e-07
A B-Disease 1 0.9999997615814209
- I-Disease 1 0.9999940395355225
T I-Disease 1 1.0
and O 0 2.2879090622041076e-08
increased O 0 5.7627950411642814e-08
cellular O 0 1.6793356962807593e-06
radioresistant O 0 2.788340907500242e-06
DNA O 0 5.479386686602084e-07
synthesis O 0 6.298404287008452e-07
. O 0 4.940841904499393e-07

Determination O 0 3.328569391669589e-06
of O 0 1.4860303210184611e-08
the O 0 5.220567977914925e-09
genomic O 0 1.2870857801772217e-07
structure O 0 4.884378768110764e-08
of O 0 8.15671363785242e-10
the O 0 4.512056950289889e-09
COL4A4 O 0 1.13018654701591e-06
gene O 0 8.424813557894595e-08
and O 0 2.564432888263468e-09
of O 0 2.4350055305433216e-09
novel O 0 1.2153784609836293e-06
mutations O 0 0.08420529216527939
causing O 0 0.0003842287405859679
autosomal B-Disease 1 0.9999991655349731
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 3.003733809237019e-06

Autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
is O 0 4.125890882278327e-07
a O 0 1.7653989914379054e-07
progressive O 0 0.0005918826209381223
hematuric B-Disease 1 0.9928551316261292
glomerulonephritis I-Disease 1 1.0
characterized O 0 0.00030944711761549115
by O 0 1.1811288658236663e-07
glomerular B-Disease 0 0.0036795472260564566
basement I-Disease 1 0.5801706314086914
membrane I-Disease 0 0.0828280821442604
abnormalities I-Disease 1 0.9999412298202515
and O 0 1.86390892054078e-07
associated O 0 1.1753902384725734e-07
with O 0 1.1269040811612285e-08
mutations O 0 1.3903642866353039e-05
in O 0 4.895110983227369e-09
either O 0 1.4964867034450435e-07
the O 0 1.8929736000927733e-08
COL4A3 O 0 1.6222786143771373e-05
or O 0 7.727048512151669e-08
the O 0 1.0587637433445707e-08
COL4A4 O 0 8.081503892753972e-07
gene O 0 1.3190638981086522e-07
, O 0 2.185378322749898e-09
which O 0 6.60059618073916e-10
encode O 0 2.6239163730679138e-08
the O 0 3.7355576409936475e-09
alpha3 O 0 8.096269539237255e-07
and O 0 9.765664721328449e-09
alpha4 O 0 1.7602557136342512e-06
type O 0 1.446554688300239e-05
IV O 0 1.1769177945097908e-05
collagen O 0 1.7553606994624715e-06
chains O 0 2.502379720681347e-05
, O 0 5.345871301187799e-08
respectively O 0 1.3005239907215582e-06
. O 0 8.544878227212394e-08

To O 0 2.877799261113978e-07
date O 0 3.836763369235996e-07
, O 0 2.2365160834425524e-09
mutation O 0 4.22821457846112e-08
screening O 0 2.455209724416818e-08
in O 0 1.5083748694522114e-09
the O 0 1.8182402250488394e-09
two O 0 1.2084407252643814e-08
genes O 0 2.1595961641196482e-07
has O 0 4.559267807735523e-08
been O 0 1.6329543939264113e-07
hampered O 0 3.365763177498593e-06
by O 0 1.7865922075088747e-09
the O 0 1.9784602844907795e-09
lack O 0 9.907009435039527e-09
of O 0 1.0928470350890507e-09
genomic O 0 2.416214783806936e-07
structure O 0 7.437828344336594e-07
information O 0 1.7512446959244699e-07
. O 0 1.424040902975321e-07

We O 0 2.1920477593084797e-05
report O 0 1.1874433880620927e-07
here O 0 3.0470475032018385e-09
the O 0 1.1955373357963595e-09
complete O 0 5.895088861507247e-09
characterization O 0 2.2585428638421945e-08
of O 0 1.0324512356163495e-09
the O 0 5.927130786176349e-09
48 O 0 4.6438827894235146e-08
exons O 0 6.934914864586972e-08
of O 0 1.7920733785814491e-09
the O 0 1.510062475063023e-08
COL4A4 O 0 3.7056306609883904e-06
gene O 0 1.837826175687951e-07
, O 0 1.2862941822788798e-09
a O 0 2.246006491901653e-09
comprehensive O 0 1.2152968054124358e-07
gene O 0 2.813538344526023e-07
screen O 0 7.892845314927399e-05
, O 0 2.8939924234805403e-08
and O 0 4.6863322111789785e-09
the O 0 1.072785305034074e-09
subsequent O 0 1.4870595421712096e-08
detection O 0 1.7721090728173294e-07
of O 0 1.6821489756679853e-09
10 O 0 1.2309829600098965e-08
novel O 0 1.9447401911065754e-08
mutations O 0 6.781416459489265e-07
in O 0 2.8800484219715372e-09
eight O 0 6.387289886333747e-06
patients O 0 0.0007566732820123434
diagnosed O 0 0.07453128695487976
with O 0 1.2206567134853685e-06
autosomal B-Disease 1 1.0
recessive I-Disease 1 1.0
Alport I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.0949166810169118e-06

Furthermore O 0 2.6002966478699818e-05
, O 0 1.945167440453588e-07
we O 0 8.649461591403451e-08
identified O 0 3.64537982022739e-08
a O 0 1.7824941522803783e-09
glycine O 0 9.710799986351049e-08
to O 0 7.830022852317597e-09
alanine O 0 1.7298337695592636e-07
substitution O 0 2.612041960503575e-08
in O 0 3.3464504500813064e-09
the O 0 3.303529005904693e-09
collagenous O 0 7.098890364432009e-07
domain O 0 4.718281942928115e-08
that O 0 3.7724028345564875e-09
is O 0 4.535716691123071e-09
apparently O 0 2.88931062186748e-07
silent O 0 2.4751227556407684e-07
in O 0 1.2060498155719301e-09
the O 0 2.9162827708262284e-09
heterozygous O 0 8.402377034144592e-07
carriers O 0 1.223791628035542e-07
, O 0 1.8846146865314495e-09
in O 0 2.4050674785058845e-09
11 O 0 9.479772700160538e-08
. O 0 4.1309771603437184e-08

5 O 0 2.695805733310408e-06
% O 0 8.575933208021524e-08
of O 0 9.69343383339094e-10
all O 0 3.0480935553356403e-09
control O 0 1.8449013339250087e-07
individuals O 0 1.2159316220561323e-08
, O 0 2.0653960763894474e-09
and O 0 7.940398560890571e-09
in O 0 9.081578267178259e-10
one O 0 8.70813909870094e-09
control O 0 1.9306007459363173e-07
individual O 0 4.081726512339401e-09
homozygous O 0 1.5775374606619152e-07
for O 0 2.3991422737346113e-10
this O 0 4.826695709780893e-10
glycine O 0 1.987341988751723e-07
substitution O 0 1.4597365805002482e-07
. O 0 9.608454831777635e-08

There O 0 2.970965397253167e-06
has O 0 8.11661919897233e-08
been O 0 7.129877843681243e-08
no O 0 2.1036441921751248e-08
previous O 0 1.1771111019243108e-07
finding O 0 1.4873035247831012e-08
of O 0 2.030583340362213e-10
a O 0 1.7376395877732875e-09
glycine O 0 8.030998799313238e-08
substitution O 0 8.526688688448303e-09
that O 0 9.213689811105041e-10
is O 0 9.585985338844694e-10
not O 0 3.1268834188580286e-09
associated O 0 3.7228964355762173e-09
with O 0 1.0663041560832198e-09
any O 0 3.3968696300235024e-08
obvious O 0 5.019817308493657e-07
phenotype O 0 7.889900643931469e-07
in O 0 1.27695214402479e-08
homozygous O 0 1.3480286725098267e-05
individuals O 0 9.884647766966737e-08
. O 0 6.330918012054099e-08

Founder O 0 5.7911289331968874e-05
BRCA1 O 0 0.0008779946365393698
and O 0 7.330160087803961e-07
BRCA2 O 0 0.0007611618493683636
mutations O 0 9.500789929006714e-06
in O 0 1.2271289762111337e-08
French O 0 2.509477553758188e-06
Canadian O 0 0.00010462316276971251
breast B-Disease 1 0.9999998807907104
and I-Disease 1 0.9999963045120239
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 3.55660176865058e-06
. O 0 2.2737276594853029e-07

We O 0 3.03934866678901e-05
have O 0 1.1712243974670855e-07
identified O 0 1.4218643684671406e-07
four O 0 5.520269574788017e-09
mutations O 0 8.138724894024563e-08
in O 0 3.493828559797407e-10
each O 0 8.7683527105753e-10
of O 0 8.726907529954531e-10
the O 0 3.512679995765211e-06
breast B-Disease 1 0.9999995231628418
cancer I-Disease 0 0.05236239358782768
- O 0 2.013529956457205e-05
susceptibility O 0 7.119720248738304e-05
genes O 0 2.7714772841136437e-06
, O 0 8.51328163520293e-09
BRCA1 O 0 1.2061263078066986e-05
and O 0 4.78903885436921e-08
BRCA2 O 0 4.621827247319743e-05
, O 0 5.59812818323735e-09
in O 0 1.4867411746166681e-09
French O 0 1.3888384273741394e-06
Canadian O 0 3.3196087315445766e-05
breast B-Disease 1 0.9999979734420776
cancer I-Disease 0 0.018906481564044952
and O 0 7.89685727795586e-05
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 8.686989758643904e-07
from O 0 6.176305333838172e-08
Quebec O 0 6.831659447925631e-06
. O 0 2.6745823333840235e-07

To O 0 1.2865522194260848e-06
identify O 0 3.4640897865756415e-06
founder O 0 4.642881776817376e-07
effects O 0 4.542897841020022e-06
, O 0 2.5420810345622158e-08
we O 0 7.850887584481825e-08
examined O 0 3.9029637832754815e-07
independently O 0 1.0606746627672692e-06
ascertained O 0 6.243760140023369e-07
French O 0 4.850261348110507e-07
Canadian O 0 6.038521860318724e-07
cancer B-Disease 0 7.702658876951318e-06
families O 0 1.0618396828476762e-08
for O 0 3.668890191654839e-10
the O 0 4.725049240761336e-10
distribution O 0 1.754256739872062e-09
of O 0 3.476903487342753e-10
these O 0 5.65404656427404e-09
eight O 0 5.05846514897712e-07
mutations O 0 1.3290207789395936e-05
. O 0 1.0907052683251095e-07

Mutations O 0 0.002325308509171009
were O 0 1.6610647435300052e-06
found O 0 3.418643856889503e-08
in O 0 1.5130660058204626e-09
41 O 0 3.087403399604227e-08
of O 0 2.1532502447740853e-09
97 O 0 4.4794231257583306e-07
families O 0 2.75989862075221e-07
. O 0 1.3833654577410925e-07

Six O 0 3.382237764526508e-06
of O 0 1.7587133527285914e-08
eight O 0 2.1834094354744593e-07
mutations O 0 3.1225752081809333e-06
were O 0 1.7461964318954415e-07
observed O 0 1.6275626535389165e-07
at O 0 2.2328225668388768e-07
least O 0 1.2633665846806252e-07
twice O 0 4.592955065163551e-06
. O 0 9.22016667459502e-08

The O 0 1.6207194448725204e-06
BRCA1 O 0 0.00031498161843046546
C4446T O 0 1.2477550626499578e-05
mutation O 0 9.543043233861681e-06
was O 0 3.3097556695338426e-08
the O 0 9.521861077388394e-10
most O 0 1.0708840481044035e-09
common O 0 1.991739573270479e-08
mutation O 0 1.6363106851713383e-06
found O 0 8.587423394601501e-08
, O 0 1.1861475135432897e-09
followed O 0 8.403738149809215e-09
by O 0 3.9194252288154985e-09
the O 0 3.607448206821573e-08
BRCA2 O 0 0.0001672313956078142
8765delAG O 0 1.113374855776783e-05
mutation O 0 6.428055257856613e-06
. O 0 1.7245200467641553e-07

Together O 0 4.27210488851415e-06
, O 0 1.98479970237031e-08
these O 0 3.474240006795526e-09
mutations O 0 8.118853997984843e-07
were O 0 1.89386270221803e-07
found O 0 1.2667054960502355e-08
in O 0 5.818587278660914e-10
28 O 0 3.580895802102191e-09
of O 0 1.772322844040275e-10
41 O 0 5.0430315923222224e-08
families O 0 6.397178786698987e-09
identified O 0 4.348492410599647e-08
to O 0 4.587641821984789e-09
have O 0 9.433957615101463e-08
a O 0 7.577015992410452e-08
mutation O 0 7.807023393979762e-06
. O 0 1.3567898804467404e-07

The O 0 2.1423426233013743e-07
odds O 0 7.369734476014855e-07
of O 0 8.924238015239894e-10
detection O 0 5.855421747469336e-08
of O 0 7.826211345651757e-10
any O 0 2.890515604647703e-09
of O 0 3.1316088611177406e-10
the O 0 5.095093236207049e-09
four O 0 6.563760734934476e-07
BRCA1 O 0 0.003197084181010723
mutations O 0 7.612925401190296e-05
was O 0 1.45377816807013e-06
18 O 0 2.6498793204154936e-07
. O 0 7.755101449902213e-08

7x O 0 0.00029230883228592575
greater O 0 7.774775667712674e-07
if O 0 1.1966265844876034e-07
one O 0 4.639577166898334e-09
or O 0 5.728425289674988e-09
more O 0 6.356308812627276e-10
cases O 0 1.2696129481071239e-08
of O 0 1.5979385352693498e-05
ovarian B-Disease 1 1.0
cancer I-Disease 1 1.0
were O 0 9.036600386025384e-05
also O 0 3.507332735352975e-08
present O 0 1.0209276091188713e-08
in O 0 1.501795243719073e-09
the O 0 1.5610787329478626e-08
family O 0 9.416285706720373e-08
. O 0 2.8471479396330324e-08

The O 0 3.259083314333111e-07
odds O 0 1.6737284340706537e-06
of O 0 2.4075825777458704e-09
detection O 0 6.057641854795293e-08
of O 0 7.768596321788834e-10
any O 0 2.9717430738429584e-09
of O 0 5.71480252009593e-10
the O 0 2.299761270307954e-08
four O 0 2.5292561076639686e-06
BRCA2 O 0 0.013824555091559887
mutations O 0 1.5391316992463544e-05
was O 0 1.8295180836958025e-07
5 O 0 4.232741446230648e-08
. O 0 5.468064401270567e-08

3x O 0 0.0002094652591040358
greater O 0 2.049576096396777e-06
if O 0 2.323207723975429e-07
there O 0 2.8147507435960506e-08
were O 0 1.3403422371993656e-07
at O 0 1.3886216621017411e-08
least O 0 1.6000926139625449e-09
five O 0 1.854158271363815e-09
cases O 0 1.9246320093202485e-09
of O 0 2.83586398808211e-08
breast B-Disease 1 0.9999998807907104
cancer I-Disease 0 0.059738799929618835
in O 0 7.239639998601888e-09
the O 0 3.2485321099784414e-08
family O 0 3.8439711147475464e-07
. O 0 1.1450875092577917e-07

Interestingly O 0 2.7089756258646958e-05
, O 0 6.172136579607468e-08
the O 0 3.639667234267563e-09
presence O 0 5.674356984286533e-09
of O 0 1.2331606846771592e-09
a O 0 7.759272762086766e-07
breast B-Disease 1 0.9999938011169434
cancer I-Disease 0 4.895338861388154e-05
case O 0 8.364223980095176e-09
< O 0 2.264904281901181e-07
36 O 0 6.084356130031665e-08
years O 0 5.103924838323337e-09
of O 0 1.5247991758116086e-09
age O 0 6.623466219934926e-07
was O 0 3.931376824084509e-08
strongly O 0 4.7458619256701695e-09
predictive O 0 2.6460600821565095e-08
of O 0 2.2637201835262744e-10
the O 0 8.882174440394408e-10
presence O 0 1.5117188612023824e-09
of O 0 7.59193402588565e-11
any O 0 9.03768726523424e-10
of O 0 3.451168517631942e-10
the O 0 1.0906383351994009e-08
eight O 0 1.2125674402341247e-06
mutations O 0 5.3445228331838734e-06
screened O 0 1.06070456240559e-05
. O 0 3.6776381762138044e-07

Carriers O 0 1.0573798135737889e-05
of O 0 1.295824780811472e-08
the O 0 5.371840750001411e-09
same O 0 8.257889483331837e-09
mutation O 0 1.5065519676227268e-07
, O 0 7.961064030226339e-10
from O 0 3.011374760664154e-10
different O 0 5.194593644120005e-09
families O 0 2.3303078577896486e-08
, O 0 1.3434251489030657e-09
shared O 0 1.711565644768598e-08
similar O 0 9.174343063023116e-09
haplotypes O 0 2.519729207506316e-07
, O 0 2.378780283862625e-09
indicating O 0 3.528885983428154e-08
that O 0 4.132943431933711e-10
the O 0 8.353298608376747e-10
mutant O 0 4.702415523638592e-08
alleles O 0 7.182125472127154e-08
were O 0 5.858918257217738e-07
likely O 0 3.2324933840754966e-08
to O 0 1.0764012792208177e-08
be O 0 1.6375628320020041e-07
identical O 0 1.0962882015519426e-06
by O 0 1.6693640914056118e-09
descent O 0 2.735967257194716e-07
for O 0 1.0147670481686077e-09
a O 0 1.5112293638708252e-08
mutation O 0 7.407750217680587e-07
in O 0 4.030388911502314e-09
the O 0 1.8000697821207723e-08
founder O 0 2.462059285335272e-07
population O 0 4.7517882961756186e-08
. O 0 7.796896994705094e-08

The O 0 1.0143654094463272e-07
identification O 0 4.472089898399645e-08
of O 0 2.632893680853954e-09
common O 0 7.02834199728386e-08
BRCA1 O 0 0.0001929158461280167
and O 0 2.698982939364214e-07
BRCA2 O 0 0.0009471157682128251
mutations O 0 6.31965895081521e-06
will O 0 9.794354660641602e-09
facilitate O 0 8.31125390732268e-08
carrier O 0 1.369523829453101e-06
detection O 0 1.0402378620710806e-06
in O 0 1.1925862963835243e-08
French O 0 4.628025180863915e-06
Canadian O 0 4.956263001076877e-05
breast B-Disease 1 0.9999984502792358
cancer I-Disease 1 0.6288959383964539
and O 0 0.0010225119767710567
breast B-Disease 1 1.0
/ I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
families O 0 4.827837983611971e-06
. O 0 3.389007474652317e-07

Are O 0 3.871607987093739e-06
Dp71 O 0 2.1933130483375862e-05
and O 0 1.0343602241391636e-07
Dp140 O 0 7.021640612947522e-06
brain O 0 7.0285946094372775e-06
dystrophin O 0 3.1394249617733294e-06
isoforms O 0 3.432889172927389e-07
related O 0 9.840346848477566e-08
to O 0 2.631554707477335e-08
cognitive B-Disease 0 0.001880593947134912
impairment I-Disease 0 0.00035539575037546456
in O 0 2.4611131266283337e-07
Duchenne B-Disease 1 0.9999815225601196
muscular I-Disease 1 0.999943733215332
dystrophy I-Disease 1 0.9999673366546631
? O 0 0.00011608083877945319

Molecular O 0 6.200145890034037e-06
study O 0 3.520587199545844e-07
and O 0 5.809654979316292e-08
neuropsychological O 0 6.700476205878658e-06
analysis O 0 2.196240274088268e-07
were O 0 6.784152333239035e-07
performed O 0 5.793056629954663e-07
concurrently O 0 8.885130853286682e-08
on O 0 1.0285113916097544e-07
49 O 0 1.0942098015220836e-05
patients O 0 2.11894715107519e-07
with O 0 3.563026851338691e-08
Duchenne B-Disease 1 0.9927240014076233
muscular I-Disease 1 0.9786772727966309
dystrophy I-Disease 1 0.9987566471099854
( O 0 2.577594386821147e-06
DMD B-Disease 1 1.0
) O 0 7.234453391902207e-08
in O 0 2.447204217048693e-09
order O 0 3.045583341076963e-09
to O 0 2.0691810487249995e-09
find O 0 3.725668662468706e-08
a O 0 3.9091148096304096e-09
molecular O 0 1.525673525293314e-07
explanation O 0 1.2235998880782972e-08
for O 0 1.0486059798253677e-09
the O 0 1.1627446561135457e-08
cognitive B-Disease 0 3.711209865286946e-05
impairment I-Disease 0 1.7823831512941979e-06
observed O 0 1.0104744063710314e-07
in O 0 4.438893697056301e-09
most O 0 2.2799420662522607e-07
DMD B-Disease 1 1.0
patients O 0 0.0014071345794945955
. O 0 1.9784410199008562e-07

Complete O 0 1.0266313665852067e-06
analysis O 0 8.350917113375544e-08
of O 0 4.198830616530813e-09
the O 0 1.0924996018957245e-08
dystrophin O 0 1.4696963717142353e-06
gene O 0 1.1772316383940051e-06
was O 0 1.6026811522351636e-07
performed O 0 1.4409287985017727e-07
to O 0 4.129856456813741e-09
define O 0 4.79043649193045e-07
the O 0 2.49312082090114e-09
localization O 0 6.623226056490239e-08
of O 0 4.1521591720439233e-10
deletions O 0 2.2079713346556673e-07
and O 0 3.072160126293966e-08
duplications O 0 1.6254761021627928e-06
in O 0 4.456590207979616e-09
relation O 0 8.114947291915087e-08
to O 0 5.917551781919883e-09
the O 0 1.731222631917717e-08
different O 0 8.737939651837223e-07
DMD B-Disease 1 1.0
promoters O 0 4.03112280764617e-05
. O 0 5.112306666887889e-07

Qualitative O 0 8.221984899137169e-06
analysis O 0 2.4307198032147426e-07
of O 0 5.281481918473219e-09
the O 0 1.6013544268389523e-08
Dp71 O 0 7.454878527823894e-07
transcript O 0 3.358345850301703e-07
and O 0 5.385981083350089e-08
testing O 0 3.790895561905927e-07
for O 0 8.425415920498835e-10
the O 0 1.0430366570446381e-09
specific O 0 2.345879490661673e-09
first O 0 2.6643309780638447e-09
exon O 0 4.103726780613215e-08
of O 0 4.30158531017355e-09
Dp140 O 0 9.115145758187282e-07
were O 0 1.6047612234615372e-06
also O 0 4.261961805696046e-08
carried O 0 1.923845957207959e-06
out O 0 2.2369914631781285e-07
. O 0 6.688504328167255e-08

Neuropsychological O 0 0.00028638733783736825
analysis O 0 1.28677550037537e-06
assessed O 0 1.0990717100867187e-06
verbal O 0 9.218369996233378e-06
and O 0 9.221785290947082e-08
visuospatial O 0 3.8579415559070185e-05
intelligence O 0 1.0467447282280773e-05
, O 0 1.4486441379801818e-08
verbal O 0 6.965557076910045e-06
memory O 0 6.287265568971634e-05
, O 0 1.7297967502827305e-08
and O 0 2.5725862329295524e-08
reading O 0 7.413669663947076e-06
skills O 0 3.366029341123067e-05
. O 0 1.6011442482977145e-07

Comparison O 0 1.5945020095387008e-06
of O 0 1.1062403437733792e-08
molecular O 0 4.4907193341714446e-07
and O 0 1.6390698576174145e-08
psychometric O 0 3.5933397157350555e-05
findings O 0 3.487501203380816e-07
demonstrated O 0 2.1819849038706707e-08
that O 0 5.206166608928697e-10
deletions O 0 1.4142625559543376e-07
and O 0 2.451045411078212e-08
duplications O 0 1.77311449078843e-06
that O 0 2.6636413963387895e-08
were O 0 2.105591505596749e-07
localized O 0 1.7942380736712948e-07
in O 0 4.301576872478563e-09
the O 0 6.5088356926423785e-09
distal O 0 3.759450919460505e-07
part O 0 9.577126647286605e-09
of O 0 6.531166718559689e-10
the O 0 3.3338172222840967e-09
gene O 0 1.1230829954911314e-07
seemed O 0 5.806353797765951e-08
to O 0 1.6183303586103648e-09
be O 0 7.127699319653402e-09
preferentially O 0 3.384407420981006e-08
associated O 0 2.6922549523078487e-08
with O 0 3.1667621414044334e-08
cognitive B-Disease 0 0.000200231748749502
impairment I-Disease 0 3.856532566715032e-05
. O 0 1.398361888504951e-07

Two O 0 2.1883781755605014e-06
altered O 0 5.83577593715745e-06
Dp71 O 0 3.7431200325954705e-06
transcripts O 0 8.449795814158279e-07
and O 0 2.9253428124320635e-08
two O 0 8.228989933911635e-09
deleted O 0 4.832522336073453e-06
Dp140 O 0 3.7321055401662306e-07
DNA O 0 9.537445322393978e-08
sequences O 0 1.5337086267663835e-07
were O 0 4.126174246721348e-07
found O 0 1.233333080108423e-08
in O 0 2.1141657313705764e-09
four O 0 2.1092533586397622e-07
patients O 0 8.089971288427478e-07
with O 0 8.370867021767481e-08
severe O 1 0.9945987462997437
cerebral B-Disease 1 0.9999645948410034
dysfunction I-Disease 0 0.21989452838897705
. O 0 4.6811533138679806e-07

These O 0 3.814922706624202e-07
findings O 0 1.5380413742605015e-07
suggest O 0 6.045372202834187e-08
that O 0 9.662348698924461e-10
some O 0 7.367542687042317e-10
sequences O 0 2.135989340956712e-08
located O 0 2.602653026428925e-08
in O 0 1.744693278737941e-09
the O 0 2.3915820435149726e-09
distal O 0 2.1042065156962053e-07
part O 0 4.492605842898456e-09
of O 0 4.358876593002492e-10
the O 0 1.2153884565435646e-09
gene O 0 4.1956305096846336e-08
and O 0 1.5844982215185155e-08
, O 0 1.1350986817149078e-09
in O 0 2.544834065698609e-10
particular O 0 2.6793749441367254e-09
, O 0 6.359122672883188e-10
some O 0 1.3411005639341056e-09
DMD B-Disease 1 0.9999724626541138
isoforms O 0 6.291303122907266e-08
expressed O 0 3.764273781570182e-09
in O 0 1.1477868655518364e-09
the O 0 1.3565474965560043e-08
brain O 0 4.352907490101643e-05
may O 0 8.492396830206417e-08
be O 0 1.8314035843403076e-09
related O 0 1.960190232352943e-09
to O 0 1.1990816117801728e-09
the O 0 1.9369478465591783e-08
cognitive B-Disease 0 0.0001391352852806449
impairment I-Disease 0 1.2417914149409626e-05
associated O 0 1.9359143266228784e-07
with O 0 1.4394920810900658e-07
DMD B-Disease 1 1.0
. O 0 2.479649765518843e-07
. O 0 2.0364409181183873e-07

I1307K O 0 0.00026213907403871417
APC O 0 2.2394033294403926e-05
and O 0 1.282148502923519e-07
hMLH1 O 0 3.087565119130886e-06
mutations O 0 2.365007048865664e-06
in O 0 3.115322444458002e-09
a O 0 1.2467007870498037e-08
non O 0 7.618360996275442e-06
- O 0 5.436167157313321e-06
Jewish O 0 1.471783264150872e-07
family O 0 2.194606807393029e-08
with O 0 1.761439349934335e-08
hereditary B-Disease 1 0.9998579025268555
non I-Disease 1 0.9999740123748779
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 2.686123480089009e-06

We O 0 8.56542192195775e-06
describe O 0 1.096410528589331e-06
a O 0 6.23603639837711e-08
French O 0 1.3903013496019412e-06
Canadian O 0 2.323567741768784e-06
hereditary B-Disease 1 0.999839186668396
non I-Disease 1 0.9999985694885254
- I-Disease 1 1.0
polyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
( O 0 2.2247815650189295e-05
HNPCC B-Disease 1 0.5028164386749268
) O 0 8.899038306253715e-08
kindred O 0 1.7240313354704995e-06
which O 0 6.714474309887919e-09
carries O 0 6.717961298363662e-08
a O 0 3.0234115655503047e-08
novel O 0 1.6904810706819262e-07
truncating O 0 4.121614438190591e-06
mutation O 0 6.41066844764282e-06
in O 0 4.31253823762745e-08
hMLH1 O 0 1.0824711353052408e-05
. O 0 2.530829021907266e-07

Interestingly O 0 2.819678047671914e-05
, O 0 5.7280349352595294e-08
the O 0 1.216196032771677e-08
I1307K O 0 6.159477266010072e-07
APC O 0 2.183627998419979e-07
polymorphism O 0 1.054712356562959e-06
, O 0 4.431619071709747e-09
associated O 0 9.920662513707157e-09
with O 0 4.3265810378834146e-10
an O 0 1.3780143692798674e-09
increased O 0 1.3981327811052324e-06
risk O 0 0.0008982212166301906
of O 0 3.925331839127466e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 2.3935639248406915e-08
is O 0 1.3455740965895302e-09
also O 0 3.822276717357909e-09
present O 0 4.733874181539477e-09
in O 0 1.0309301190503106e-09
this O 0 2.8005047170154285e-09
family O 0 9.165322012449906e-08
. O 0 4.381896445693201e-08

The O 0 1.8660873593034921e-06
I1307K O 0 8.976816388894804e-06
polymorphism O 0 1.2016201253572945e-05
has O 0 1.1911364339312058e-07
previously O 0 6.432056807170738e-07
only O 0 1.9780120652512778e-08
been O 0 4.8866617419207614e-08
identified O 0 4.061289260448575e-08
in O 0 3.199397691222572e-10
individuals O 0 1.7483977599042078e-09
of O 0 1.866193199973054e-09
self O 0 0.0008814511238597333
- O 0 0.06143255904316902
reported O 0 3.481105522951111e-06
Ashkenazi O 0 5.787706413684646e-06
Jewish O 0 2.793243822907243e-07
origins O 0 7.860519986024883e-07
. O 0 1.871555639354483e-07

In O 0 1.8993432604474947e-07
addition O 0 3.726869834963509e-08
, O 0 2.242239727223705e-09
in O 0 2.407360977230155e-10
this O 0 2.816273048100726e-10
family O 0 4.506835793449682e-09
, O 0 5.498084210131537e-10
there O 0 1.5369343575599714e-09
appears O 0 6.524620843606499e-09
to O 0 2.4592390346356297e-09
be O 0 4.909363227056929e-08
no O 0 1.3622464045681681e-08
relationship O 0 9.6388657055968e-09
between O 0 1.4771872614005588e-09
the O 0 2.826315625981124e-09
I1307K O 0 6.859901446887307e-08
polymorphism O 0 2.2457169279732625e-07
and O 0 1.0860610188956343e-08
the O 0 2.5901025768604313e-09
presence O 0 1.648007064147805e-08
or O 0 8.149007868496483e-08
absence O 0 1.5181696255694987e-07
of O 0 1.2409950400638081e-08
cancer B-Disease 0 1.7226051568286493e-05
. O 0 5.33920463396953e-09
. O 0 5.374651479428394e-08

Identification O 0 4.2279107219656e-06
of O 0 2.4260780051577058e-08
a O 0 1.231034651993923e-08
novel O 0 2.820726940910845e-08
mutation O 0 7.779873101299017e-08
of O 0 3.6728461938473345e-10
the O 0 5.7896083482944505e-09
CPO O 0 8.00522684585303e-06
gene O 0 8.643161919508202e-08
in O 0 1.6084337195465537e-09
a O 0 1.3502977402879424e-08
Japanese O 0 1.0316573479940416e-06
hereditary B-Disease 0 0.01808958873152733
coproporphyria I-Disease 0 9.729922021506354e-05
family O 0 6.855219112367195e-07
. O 0 1.5141759490688855e-07

Hereditary B-Disease 1 0.9999779462814331
coproporphyria I-Disease 1 0.599367618560791
( O 0 5.320777745509986e-06
HCP B-Disease 0 8.027809235500172e-05
) O 0 1.7813393426990842e-08
is O 0 1.50166346024605e-09
an O 0 4.104108164426634e-09
autosomal B-Disease 1 0.9999743700027466
dominant I-Disease 1 0.9999655485153198
disease I-Disease 1 0.9249047040939331
characterized O 0 3.4491560541027866e-07
by O 0 4.1687462370987305e-09
a O 0 3.7090634918968135e-07
deficiency B-Disease 0 0.0032545896247029305
of I-Disease 0 5.540448544394394e-09
coproporphyrinogen I-Disease 0 2.3989488909137435e-05
oxidase I-Disease 0 5.437089839688269e-06
( O 0 7.912674249155316e-08
CPO O 0 7.642848686373327e-06
) O 0 4.280746868090546e-09
caused O 0 1.2037017604882294e-08
by O 0 4.068030079462659e-10
a O 0 3.5096732187156476e-09
mutation O 0 1.8014219449469238e-07
in O 0 1.7960838372133026e-09
the O 0 1.278009609251285e-08
CPO O 0 6.704643510602182e-06
gene O 0 1.023237587105541e-06
. O 0 1.4941508652555058e-07

Only O 0 1.0920422255367157e-06
11 O 0 2.214071486150715e-07
mutations O 0 2.312760472023001e-07
of O 0 8.39556313358969e-10
the O 0 1.140102345864591e-09
gene O 0 1.8947334012864303e-07
have O 0 9.197017902806692e-08
been O 0 1.5115732310277963e-07
reported O 0 1.2438771079814614e-07
in O 0 1.1132591737350594e-08
HCP B-Disease 0 0.00045084362500347197
patients O 0 3.5125729027640773e-06
. O 0 1.6131851054979052e-07

We O 0 4.858133615925908e-05
report O 0 2.0487871665864077e-07
another O 0 3.8237079280634134e-08
mutation O 0 1.8985861061082687e-07
in O 0 1.5055494628768429e-09
a O 0 8.946704710410813e-09
Japanese O 0 5.819259172312741e-07
family O 0 2.3889600697657443e-07
. O 0 9.045524507200753e-08

Polymerase O 0 0.0001638354588067159
chain O 0 3.573982758098282e-05
reaction O 0 1.9831477402476594e-06
- O 0 3.6710084714286495e-06
single O 0 5.686342774424702e-07
strand O 0 2.509242733594874e-07
conformational O 0 1.8054132411293722e-08
polymorphism O 0 3.353167983277672e-07
and O 0 1.2032885798873849e-08
direct O 0 7.360610965179148e-08
sequence O 0 3.719335381902056e-07
analyses O 0 8.927819408199866e-07
demonstrated O 0 1.2236480984029185e-07
a O 0 3.174079310497291e-08
C O 0 8.819179697638901e-07
to O 0 1.8492853470775117e-08
T O 0 2.390177087363554e-07
substitution O 0 5.318256945940902e-09
in O 0 6.110564276795571e-10
exon O 0 1.675329741601672e-08
1 O 0 1.9957924202174127e-09
of O 0 3.882333343696587e-10
the O 0 8.180945698654796e-09
CPO O 0 1.2285034927117522e-06
gene O 0 8.520790828470126e-08
at O 0 2.2548970690650094e-08
nucleotide O 0 4.6846633949826355e-07
position O 0 2.677706333997776e-06
85 O 0 1.8425100734020816e-07
, O 0 4.8246735495638404e-09
which O 0 3.484606159176451e-09
lies O 0 4.977799150651663e-08
in O 0 1.0575683662139568e-09
the O 0 3.513021873402522e-09
putative O 0 3.871227818308398e-07
presequence O 0 8.700919238435745e-07
for O 0 3.481298138652278e-09
targeting O 0 2.4409035859207506e-07
to O 0 7.105088428716044e-08
mitochondria O 0 1.8797638858814025e-06
. O 0 2.138492760650479e-07

This O 0 1.9329331735207234e-07
mutation O 0 6.680407409476175e-07
changes O 0 1.1418308076827088e-08
the O 0 1.7483944292351339e-09
codon O 0 9.462430483608841e-08
for O 0 8.076583291050099e-10
glutamine O 0 2.3463551102054225e-08
to O 0 1.700005025639939e-09
a O 0 1.2371168978120295e-08
termination O 0 4.401044293445011e-07
codon O 0 1.3423625659925165e-06
at O 0 2.9168305104576575e-07
amino O 0 5.222931349635473e-07
acid O 0 4.75235481189884e-07
position O 0 1.6788120547062135e-06
29 O 0 8.236081612267299e-07
. O 0 2.045731548605545e-07

MaeI O 0 0.00011062593694077805
restriction O 0 1.0391480600446812e-06
analysis O 0 2.0903537745198264e-07
showed O 0 5.913464633522381e-07
two O 0 9.019437641200057e-09
other O 0 3.867804743151737e-09
carriers O 0 1.4379635615568986e-07
in O 0 1.5717889212396585e-09
the O 0 1.581123143523655e-08
family O 0 1.3335235848899174e-07
. O 0 6.92983732619723e-08

The O 0 6.142439815448597e-06
C O 0 0.0028089508414268494
- O 0 0.00781930610537529
T O 0 0.0003480344021227211
mutation O 0 5.042007273914351e-07
is O 0 2.521652664455587e-09
located O 0 1.1081620066022424e-08
within O 0 7.708820248808479e-09
a O 0 1.373318259112466e-08
recently O 0 4.0337518214528245e-08
proposed O 0 8.829748487926281e-09
putative O 0 1.1870925220591744e-07
alternative O 0 2.8782652705672263e-08
translation O 0 6.212862047050294e-08
initiation O 0 5.8465051466782825e-08
codon O 0 5.438296284410171e-07
( O 0 2.149099209702854e-08
TIC O 0 3.324852855257632e-07
- O 0 4.020471635612921e-07
1 O 0 7.970746729313305e-09
) O 0 6.684978126614283e-10
, O 0 3.5246983109971097e-10
supporting O 0 6.240840733084951e-09
that O 0 1.6537496927426787e-09
TIC O 0 4.0423091718366777e-07
- O 0 1.8559426280262414e-06
1 O 0 6.912066918829396e-09
is O 0 8.604499335262972e-10
the O 0 1.3783114649612571e-09
real O 0 8.147656416213067e-08
TIC O 0 1.7278584607538505e-07
rather O 0 1.3914798202563361e-08
than O 0 2.9724234185124487e-09
TIC O 0 4.69288238491572e-07
- O 0 1.1158653023812803e-06
2 O 0 2.2940529476045413e-08
. O 0 5.210162523638928e-09
. O 0 4.717382040553275e-08

Human B-Disease 0 5.710864115826553e-06
complement I-Disease 0 1.9747812984860502e-05
factor I-Disease 0 0.005072754342108965
H I-Disease 1 1.0
deficiency I-Disease 1 0.9999921321868896
associated O 0 4.955242548021488e-05
with O 0 0.002730786334723234
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
. O 0 2.7027897431253223e-06

This O 0 9.26600449702164e-08
study O 0 1.8754180430846645e-08
reports O 0 2.2231839480468807e-08
on O 0 6.8462266966662355e-09
six O 0 1.6530503188505463e-08
cases O 0 6.3853300424909776e-09
of O 0 8.984068600170758e-09
deficiency B-Disease 0 0.00018616594024933875
in I-Disease 0 5.577012740509701e-10
the I-Disease 0 9.63452317925828e-10
human I-Disease 0 1.3533265619258827e-09
complement I-Disease 0 8.313279842298016e-09
regulatory I-Disease 0 2.2836236013290545e-08
protein I-Disease 0 6.869315427593392e-08
Factor I-Disease 0 7.94949926330446e-07
H I-Disease 1 1.0
( O 0 1.9885743540726253e-07
FH O 0 4.17844312323723e-05
) O 0 2.7911459810070482e-09
in O 0 3.3098407348219894e-10
the O 0 2.8110994088059726e-10
context O 0 3.576090978896218e-09
of O 0 1.0225992275181284e-09
an O 0 1.395042772855959e-06
acute B-Disease 1 1.0
renal I-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.7585779232831555e-06

Five O 0 8.246117886301363e-07
of O 0 2.0337551642768403e-09
the O 0 2.2539112798369842e-09
cases O 0 3.807215431805844e-09
were O 0 5.0891614478132396e-08
observed O 0 2.593257875105337e-08
in O 0 1.4393425340486488e-09
children O 0 6.667411156513481e-08
presenting O 0 2.3254864345290116e-07
with O 0 3.161392669426277e-05
idiopathic O 1 0.9999997615814209
hemolytic B-Disease 1 1.0
uremic I-Disease 1 1.0
syndrome I-Disease 1 1.0
( O 0 2.6140885893255472e-05
HUS B-Disease 1 0.9995386600494385
) O 0 1.044779310177546e-06
. O 0 4.687532566549635e-07

Two O 0 1.8909246080056619e-07
of O 0 4.0498848719039415e-09
the O 0 4.883714765924196e-09
children O 0 5.740689701383417e-08
exhibited O 0 2.3458051146008074e-07
a O 0 1.7067091562239511e-07
homozygous O 1 0.9975718855857849
deficiency O 0 9.180836786981672e-05
characterized O 0 2.0107677300984506e-08
by O 0 6.492762438803368e-10
the O 0 1.1394001298015155e-09
absence O 0 1.5924390694976864e-08
of O 0 1.683740369351483e-10
the O 0 9.453365867884145e-10
150 O 0 1.8970860438116688e-09
- O 0 1.7899390414299887e-08
kD O 0 5.642877098921417e-08
form O 0 6.7003891324191045e-09
of O 0 1.7626214932064954e-09
Factor O 0 2.472553717325354e-07
H O 1 1.0
and O 0 6.147300268821709e-08
the O 0 3.779129453818086e-09
presence O 0 7.850645467044615e-09
, O 0 4.3406905847476196e-10
upon O 0 3.3957328615663585e-10
immunoblotting O 0 2.643517582612276e-08
, O 0 3.435432771592417e-10
of O 0 1.1936637789311533e-10
the O 0 2.6749529258296434e-09
42 O 0 5.389845014747152e-08
- O 0 1.7982104338898353e-07
kD O 0 7.717797529949166e-07
Factor O 0 3.002196251600253e-07
H O 1 0.9999991655349731
- O 0 5.696454991266364e-06
like O 0 4.445504941941181e-08
protein O 0 6.448757261523497e-08
1 O 0 2.7788978229636996e-08
( O 0 5.568416838741541e-09
FHL O 0 1.0775228247439372e-06
- O 0 6.341359721773188e-07
1 O 0 9.697026293054023e-09
) O 0 9.457279404045948e-10
and O 0 1.1306130476285148e-09
other O 0 3.1473170736262546e-09
FH O 0 4.785904093296267e-05
- O 0 7.181508294706873e-07
related O 0 6.761514015352077e-08
protein O 0 1.0677929651592422e-07
( O 0 1.527081927577001e-08
FHR O 0 9.359280284115812e-07
) O 0 7.244833621911084e-09
bands O 0 8.781689189163444e-07
. O 0 1.5382202889213659e-07

Southern O 0 1.229801000590669e-05
blot O 0 5.525320739252493e-05
and O 0 3.928588299118019e-08
PCR O 0 5.210786753195862e-07
analysis O 0 1.0932750704739647e-08
of O 0 3.588633834539223e-10
DNA O 0 3.869791598276606e-08
of O 0 5.941185321489684e-10
one O 0 4.8667935459434375e-08
patient O 0 4.560599791147979e-06
with O 0 1.3200907744703727e-07
homozygous O 1 0.9994957447052002
deficiency O 0 0.0023274854756891727
ruled O 0 8.160611031371445e-08
out O 0 1.5653006002480652e-08
the O 0 2.0549200119290845e-09
presence O 0 4.7780690515253355e-09
of O 0 2.522228814694216e-10
a O 0 1.110133096560162e-09
large O 0 1.0750383916402484e-09
deletion O 0 8.453352506876399e-08
of O 0 4.5035855600339403e-10
the O 0 4.046024848491925e-09
FH O 0 6.97984660291695e-06
gene O 0 4.726460645088082e-08
as O 0 4.6187933477881415e-09
the O 0 8.676192209122746e-09
underlying O 0 1.1490368478916935e-06
defect O 0 1.2771026831615018e-06
for O 0 9.838128534056523e-09
the O 0 9.476018476561876e-07
deficiency O 0 0.0015141995390877128
. O 0 1.1826222845456869e-07

The O 0 1.2249546443854342e-07
other O 0 8.49864800755995e-09
four O 0 1.569737584361519e-08
children O 0 3.4853393060529925e-08
presented O 0 4.008814613598588e-09
with O 0 1.7053025658242404e-08
heterozygous O 1 0.968424379825592
deficiency O 0 7.986027776496485e-05
and O 0 5.810704806208378e-09
exhibited O 0 9.416052648703044e-08
a O 0 8.6593283654679e-09
normal O 0 1.9808935292076058e-07
immunoblotting O 0 6.540204253724369e-07
pattern O 0 1.8806412072081002e-07
of O 0 3.9189823608509755e-10
proteins O 0 3.566846817903979e-09
of O 0 1.554206097154065e-09
the O 0 1.0110412063113472e-07
FH O 0 0.0022164371330291033
family O 0 6.826825824646221e-07
. O 0 1.2944542504556011e-07

Factor B-Disease 1 0.91163569688797
H I-Disease 1 1.0
deficiency I-Disease 1 0.9995889067649841
is O 0 5.2314126364194635e-09
the O 0 3.315307584017546e-09
only O 0 1.066905838342791e-06
complement B-Disease 1 1.0
deficiency I-Disease 1 1.0
associated O 0 4.479897484088724e-07
with O 0 8.136800744296124e-08
HUS B-Disease 1 0.9989219903945923
. O 0 6.977963380450092e-07

These O 0 3.15978780918158e-07
observations O 0 5.218126375439169e-07
suggest O 0 1.6001887104266643e-07
a O 0 7.775627253181483e-09
role O 0 3.233141043779142e-08
for O 0 4.257637353788368e-09
FH O 0 3.87765649065841e-05
and O 0 6.058127155483817e-08
/ O 0 4.657335466617951e-06
or O 0 1.0262681371386861e-06
FH O 0 2.777956069621723e-05
receptors O 0 9.229228226104169e-08
in O 0 3.0933791084208906e-09
the O 0 6.800377150284476e-09
pathogenesis O 0 2.316177187822177e-07
of O 0 1.8983611127509903e-08
idiopathic O 0 0.00011128020560136065
HUS B-Disease 1 0.9598638415336609
. O 0 3.7414636722132855e-07
. O 0 2.188454146789809e-07

Further O 0 1.7041863884514896e-06
evidence O 0 2.1230006552741543e-07
for O 0 6.365059146418162e-09
a O 0 5.8666427271703014e-09
major O 0 4.061466896132515e-08
ancient O 0 5.372150724269886e-08
mutation O 0 0.009198916144669056
underlying O 0 0.0001613958302186802
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
from O 0 1.9017845431790192e-07
linkage O 0 2.3654203687328845e-05
disequilibrium O 0 1.335538490820909e-05
studies O 0 3.12963294391011e-07
in O 0 7.591609119117493e-09
the O 0 6.09414474439518e-09
Japanese O 0 4.828569899473223e-07
population O 0 2.5626347266438643e-08
. O 0 3.1645523534962194e-08

The O 0 3.184519300702959e-05
myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 0.04256746172904968
DM B-Disease 1 1.0
) O 0 4.929532337882847e-07
mutation O 0 3.0683706881973194e-06
is O 0 6.08374994826022e-09
an O 0 5.72844705004627e-09
unstable O 0 9.813982615014538e-05
( O 0 5.560449523045463e-08
CTG O 0 2.0798079276573844e-06
) O 0 1.2375464208957965e-08
n O 0 5.681009156432992e-07
repeat O 0 2.9909990644227946e-06
, O 0 8.400724560431172e-09
present O 0 1.5030396482984543e-08
at O 0 5.674944603129006e-08
a O 0 2.6544499931446808e-09
copy O 0 3.27725970805659e-08
number O 0 3.874907950063289e-09
of O 0 7.755419639821071e-10
5 O 0 3.361523681633116e-08
- O 0 1.1096361959062051e-05
37 O 0 4.789029617313645e-07
repeats O 0 4.460032698716532e-07
on O 0 3.638933065985839e-08
normal O 0 1.4250475999233458e-07
chromosomes O 0 1.4753751997886866e-07
but O 0 4.876677728304912e-09
amplified O 0 7.1498142517612e-08
to O 0 1.1023646884211757e-08
50 O 0 1.0100524150402634e-07
- O 0 4.855139650317142e-07
3000 O 0 8.99013983257646e-08
copies O 0 7.011792035882536e-08
on O 0 1.4190197816787986e-06
DM B-Disease 1 1.0
chromosomes O 0 4.526635893853381e-05
. O 0 5.435330194814014e-07

Previous O 0 2.499662878108211e-05
findings O 0 5.751099934059312e-07
in O 0 7.681491887012726e-09
Caucasian O 0 1.1993838597845752e-06
populations O 0 8.363605275008013e-08
of O 0 2.03587413594164e-09
a O 0 5.71606165067351e-07
DM B-Disease 1 1.0
founder O 0 1.2363382211333374e-06
chromosome O 0 8.932757737056818e-06
raise O 0 4.0278550272887514e-08
a O 0 4.418486021506851e-09
question O 0 6.87236623164722e-09
about O 0 3.3833263968219285e-10
the O 0 6.205548852555864e-10
molecular O 0 8.69327010377674e-09
events O 0 2.2297449220332055e-08
involved O 0 4.774036099775003e-08
in O 0 8.519807637163979e-10
the O 0 2.158369483140632e-09
expansion O 0 8.041436672101554e-08
mutation O 0 2.8263414151297184e-06
. O 0 1.0846702735989311e-07

To O 0 3.9457103184759035e-07
investigate O 0 2.9731373274444195e-07
whether O 0 4.110745521757053e-08
a O 0 1.1198055815953012e-08
founder O 0 5.475579101243966e-08
chromosome O 0 1.3543443628805107e-06
for O 0 2.884171346195785e-09
the O 0 9.645601295460438e-08
DM B-Disease 1 1.0
mutation O 0 2.3529517420683987e-05
exists O 0 1.6058137930485827e-08
in O 0 8.859636912994517e-10
the O 0 9.725491523226992e-10
Japanese O 0 3.931518932631661e-08
population O 0 1.7824329789917215e-09
, O 0 8.594362999048144e-10
we O 0 1.1157973212050365e-08
genotyped O 0 1.6002054792352283e-07
families O 0 2.2841710745069577e-09
using O 0 9.8315631191781e-09
polymorphic O 0 6.267026151363098e-07
markers O 0 7.088165148161352e-05
near O 0 4.825274118047673e-06
the O 0 1.0261169336445164e-07
( O 0 4.419061383487133e-08
CTG O 0 1.5174616692092968e-06
) O 0 9.35186506012542e-09
n O 0 1.454310677218018e-06
repeat O 0 1.986327561098733e-06
region O 0 2.587157155176101e-07
and O 0 9.392590527568245e-08
constructed O 0 7.782551620039158e-06
haplotypes O 0 6.156069048302015e-06
. O 0 2.0998862737542368e-07

Six O 0 4.5203082663647365e-06
different O 0 1.4443394036334212e-07
haplotypes O 0 1.2441992112144362e-06
were O 0 2.8959038900211453e-07
found O 0 3.987738139699104e-08
and O 0 4.2090039187314687e-07
DM B-Disease 1 1.0
alleles O 0 2.922069324995391e-05
were O 0 5.495717232406605e-06
always O 0 3.2452970799567993e-07
haplotype O 0 6.509067702609173e-07
A O 0 2.376666259351623e-07
. O 0 1.3229491457877884e-07

To O 0 6.175858402457379e-07
find O 0 2.670356593625911e-07
an O 0 1.584980924285162e-09
origin O 0 3.154679184547149e-09
of O 0 5.155572635473504e-10
the O 0 8.235381265819797e-09
( O 0 1.704518837186697e-08
CTG O 0 8.543538569938391e-07
) O 0 4.098233308269528e-09
n O 0 5.489292789206957e-07
repeat O 0 1.0759969200080377e-06
mutation O 0 4.239682311890647e-07
and O 0 4.045530577201362e-09
to O 0 1.4036557471897027e-09
investigate O 0 3.055714969946166e-08
the O 0 1.4336081211041574e-09
mechanism O 0 1.1296349633482805e-08
of O 0 4.893839222752661e-10
the O 0 1.9720931554445542e-09
expansion O 0 1.1393767707090774e-08
mutation O 0 8.534860285180912e-08
in O 0 6.947207809027134e-10
the O 0 1.7647273642396044e-09
Japanese O 0 3.436478479557081e-08
population O 0 1.2013020578294231e-09
we O 0 2.468694804136362e-09
have O 0 2.1104993308540543e-09
studied O 0 1.5282706655739275e-08
90 O 0 2.235284846108243e-08
Japanese O 0 1.1564817441467312e-06
DM B-Disease 1 1.0
families O 0 7.954317027270008e-08
comprising O 0 2.0998838223817984e-08
190 O 0 4.7292378013708e-08
affected O 0 1.1215459494451352e-07
and O 0 8.845694843273577e-09
130 O 0 5.480730180806859e-08
unaffected O 0 1.5611166190865333e-06
members O 0 4.3097504232036954e-08
. O 0 8.709422871788775e-08

The O 0 6.833215593360364e-07
results O 0 3.6305382877799275e-07
suggest O 0 6.365510785144579e-08
that O 0 6.010255071409176e-10
a O 0 1.529331439265036e-09
few O 0 2.6595075031110582e-09
common O 0 1.1775731501018072e-08
ancestral O 0 2.752402394889941e-07
mutations O 0 2.2698245629726443e-06
in O 0 9.169789927376826e-10
both O 0 5.78738879042362e-09
Caucasian O 0 2.325987935591911e-07
and O 0 8.204337653694438e-09
Japanese O 0 1.0658070692670663e-07
populations O 0 2.0091574626235342e-08
have O 0 1.714750674786103e-09
originated O 0 8.431959575005976e-10
by O 0 7.220258418927372e-11
expansion O 0 7.617597108655616e-10
of O 0 2.1219534462879608e-10
an O 0 2.781807895146926e-09
ancestral O 0 6.291260774560214e-07
n O 0 3.65062769560609e-05
= O 0 1.0768062566057779e-05
5 O 0 9.694588953834682e-08
repeat O 0 8.902159720491909e-07
to O 0 9.371474618546927e-08
n O 0 0.0013289909111335874
= O 0 0.00018299663497600704
19 O 0 2.5474748781562084e-06
- O 0 1.87807745533064e-05
37 O 0 1.7101418734455365e-06
copies O 0 5.572264853981324e-07
. O 0 2.8794028139600414e-07

These O 0 2.5622958332860435e-07
data O 0 1.0956991047805786e-07
support O 0 1.762464307830669e-08
multistep O 0 4.167155225331953e-07
models O 0 2.772043217191822e-07
of O 0 4.986462798228786e-09
triplet O 0 2.493353713362012e-05
repeat O 0 7.848647669561615e-07
expansion O 0 1.5857953172826456e-08
that O 0 3.892656863513366e-09
have O 0 1.4784281354707218e-08
been O 0 2.63657740084966e-09
proposed O 0 1.273837590964888e-09
for O 0 1.5528164309941417e-09
both O 0 1.9902470285160234e-06
DM B-Disease 1 1.0
and O 0 3.923102667613421e-06
Friedreichs B-Disease 0 0.00018571845430415124
ataxia I-Disease 0 0.0014924358110874891
. O 0 9.198140560329193e-08
. O 0 2.662118276930414e-07

The O 0 1.2138767147007457e-07
molecular O 0 3.32487189780295e-07
basis O 0 1.0002175798717872e-07
of O 0 2.0534582745312946e-07
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
in O 0 1.536073490626677e-08
the O 0 3.166603645965438e-09
western O 0 1.3531519016396487e-08
Cape O 0 2.6874687364397687e-07
, O 0 7.937657642287377e-09
South O 0 3.555912186925525e-08
Africa O 0 6.503898930532159e-08
. O 0 2.256222053631518e-08

Deficiency B-Disease 1 0.9992126226425171
of I-Disease 0 2.9600347062341825e-08
the I-Disease 0 2.166855317398131e-08
sixth I-Disease 0 9.818503485803376e-07
component I-Disease 0 8.316519028994662e-08
of I-Disease 0 8.809591389713489e-10
human I-Disease 0 3.4735512244310485e-09
complement I-Disease 0 8.154948005767437e-08
( O 0 7.356018905113615e-09
C6 O 0 3.8614052755292505e-07
) O 0 3.822145266951793e-09
has O 0 1.3627507122748739e-08
been O 0 2.4329622760888014e-07
reported O 0 1.2233856239163288e-07
in O 0 4.310272139207427e-10
a O 0 1.2049140574177386e-09
number O 0 3.1544988843279498e-09
of O 0 3.8271039115578276e-10
families O 0 6.743917868590188e-09
from O 0 1.1201788385761802e-09
the O 0 9.158061531344686e-10
western O 0 9.677624923654093e-09
Cape O 0 7.628815268390099e-08
, O 0 3.6406808678890457e-09
South O 0 4.049222823709897e-08
Africa O 0 4.6973060108257414e-08
. O 0 2.202095217285205e-08

Meningococcal B-Disease 1 0.999957799911499
disease I-Disease 1 0.9999808073043823
is O 0 4.86883600103738e-08
endemic O 0 6.054349910300516e-08
in O 0 3.0656084337721268e-09
the O 0 5.891783505518333e-09
Cape O 0 2.1953525219942094e-07
and O 0 2.0524845822933457e-08
almost O 0 1.1678833899964047e-08
all O 0 6.869113056140463e-10
pedigrees O 0 1.2375008395792975e-07
of O 0 3.2381628489730474e-09
total O 0 0.05846394971013069
C6 B-Disease 1 1.0
deficiency I-Disease 1 1.0
( O 0 1.150117512338511e-07
C6Q0 O 0 1.1202294444956351e-05
) O 0 8.750530078316388e-09
have O 0 2.8910795535352918e-08
been O 0 3.8539031521622746e-08
ascertained O 0 2.3750168054448295e-07
because O 0 2.3599713294686353e-09
of O 0 7.117863187744433e-09
recurrent O 1 0.9969441294670105
disease O 1 0.6124722957611084
. O 0 1.4153272331896005e-07

We O 0 1.0864549039979465e-05
have O 0 7.217142439230884e-08
sequenced O 0 1.220523557776687e-07
the O 0 1.663686965969191e-09
expressed O 0 9.852113569408516e-10
exons O 0 3.860900221752672e-08
of O 0 6.316426270913666e-10
the O 0 5.016627113718641e-09
C6 O 0 5.68293785363494e-07
gene O 0 8.468133927408417e-08
from O 0 2.070918547758538e-09
selected O 0 1.056633358587078e-08
cases O 0 4.061007974343056e-09
and O 0 7.278313773895206e-08
have O 0 4.442064209797536e-07
found O 0 8.725051969804554e-08
three O 0 3.035968632048025e-08
molecular O 0 2.2547035769093782e-05
defects O 1 0.9948771595954895
leading O 0 1.40394502068375e-06
to O 0 6.01419429813177e-08
total O 0 0.00013720135029871017
deficiency O 0 0.018851405009627342
879delG O 0 9.472774991081678e-07
, O 0 1.8762149611717405e-09
which O 0 1.1471740224422433e-09
is O 0 4.57668847264614e-10
the O 0 1.2641174773619923e-09
common O 0 1.2585263675646274e-07
defect O 0 4.277972038835287e-06
in O 0 1.570644059256665e-09
the O 0 4.687851884455085e-09
Cape O 0 5.1655391075655643e-08
and O 0 5.637108113631939e-09
hitherto O 0 3.2429920793219935e-07
unreported O 0 9.316084259580748e-08
, O 0 3.817737237454821e-09
and O 0 5.049304085957829e-09
1195delC O 0 5.189075977796165e-07
and O 0 2.272240173795126e-08
1936delG O 0 4.350604285718873e-07
, O 0 4.6750119331306905e-09
which O 0 4.088380745059794e-09
have O 0 7.332222651257325e-08
been O 0 1.9010809637620696e-07
previously O 0 1.1320656767566106e-06
reported O 0 1.0694601826344297e-07
in O 0 1.6900281174514475e-09
African O 0 5.581487982908584e-08
- O 0 9.367966413265094e-06
Americans O 0 3.7788942108818446e-07
. O 0 3.393308389831873e-08

We O 0 1.7785012460080907e-05
also O 0 4.0531404010835104e-08
show O 0 6.19470981177983e-08
that O 0 8.757521929858569e-10
the O 0 1.2841321339607248e-09
879delG O 0 4.1524333482811926e-07
and O 0 6.380852113352375e-08
1195delC O 0 0.00010290783393429592
defects O 1 0.8963241577148438
are O 0 8.781813498615065e-09
associated O 0 1.4030273831622253e-08
with O 0 7.961599379768813e-09
characteristic O 0 5.058978786109947e-05
C6 O 0 0.0005220458842813969
/ O 0 9.620511264074594e-05
C7 O 0 0.00020524824503809214
region O 0 1.0924225080088945e-06
DNA O 0 2.5684244064905215e-06
marker O 0 1.0531471161812078e-05
haplotypes O 0 2.543331220294931e-06
, O 0 1.3820977251555178e-08
although O 0 3.7257659180056635e-09
small O 0 7.005132474091624e-09
variations O 0 5.099951067677466e-06
were O 0 8.180641088983975e-06
observed O 0 8.298454190480697e-07
. O 0 8.306785304057485e-08

The O 0 1.7517485275675426e-06
1936delG O 0 2.308111470483709e-05
defect O 0 5.7932164054363966e-05
was O 0 1.9292828312700294e-07
observed O 0 4.277215026604608e-08
only O 0 8.158055564422284e-09
once O 0 4.4053102499219676e-08
in O 0 6.428414467407606e-10
the O 0 2.2113961772873836e-09
Cape O 0 5.592912089014135e-08
, O 0 1.4708445572608753e-09
but O 0 6.336650093530238e-10
its O 0 1.1541577693563454e-09
associated O 0 1.822873407775205e-08
haplotype O 0 2.7580068717725226e-07
could O 0 2.2950339939598052e-07
be O 0 3.795160097297412e-08
deduced O 0 1.138598804573121e-06
. O 0 7.751907560304971e-08

The O 0 2.2245248487706704e-07
data O 0 1.3809467702685652e-07
from O 0 5.237243083655585e-09
the O 0 2.444843660853735e-09
haplotypes O 0 2.3226850487390038e-07
indicate O 0 3.150793759232329e-07
that O 0 2.5568431816225257e-09
these O 0 5.94682258991952e-09
three O 0 3.654659863627785e-08
molecular O 0 7.948700658744201e-05
defects O 1 0.9989093542098999
account O 0 3.591548249914922e-07
for O 0 6.081035230920406e-09
the O 0 2.023854364097133e-07
defects O 1 0.9810593724250793
in O 0 3.4923912650697275e-09
all O 0 3.6272620462796112e-09
the O 0 6.089276194387594e-09
38 O 0 4.6589203606117735e-08
unrelated O 0 4.947773746266648e-08
C6Q0 O 0 1.2226828403072432e-06
individuals O 0 1.6923998202855728e-08
we O 0 4.9105807420346537e-08
have O 0 6.212918624015629e-09
studied O 0 4.07210940522873e-08
from O 0 3.876608367647805e-09
the O 0 9.37819510937743e-09
Cape O 0 4.289580317617947e-07
. O 0 5.066285879706811e-08

We O 0 1.176530531665776e-05
have O 0 1.0429779706555564e-07
also O 0 9.510067400242406e-09
observed O 0 4.0123968148009226e-08
the O 0 4.810256637455268e-09
879delG O 0 1.178315528704843e-06
defect O 0 2.475130258972058e-06
in O 0 6.347770753478699e-09
two O 0 5.358239150154986e-07
Dutch O 1 0.9999939203262329
C6 B-Disease 1 1.0
- I-Disease 1 0.999997615814209
deficient I-Disease 1 1.0
kindreds O 0 1.3061772733635735e-05
, O 0 8.179432242627627e-09
but O 0 3.0537734563296226e-09
the O 0 3.5617275795374326e-09
879delG O 0 9.557437579132966e-07
defect O 0 1.0272080999129685e-06
in O 0 2.291047573876881e-09
the O 0 3.1797735555727513e-09
Cape O 0 8.26225701189287e-08
probably O 0 7.591655304395317e-08
did O 0 1.1805680344423308e-07
not O 0 8.306606957830809e-09
come O 0 2.5371680312247236e-09
from O 0 6.96890656293192e-10
The O 0 1.3760497186154907e-09
Netherlands O 0 9.327745260634401e-07
. O 0 2.8907249927101475e-09
. O 0 1.8910034427221944e-08

Complement B-Disease 1 0.9985195994377136
C7 I-Disease 1 1.0
deficiency I-Disease 1 1.0
: O 0 3.308026634840644e-07
seven O 0 9.141786705413324e-08
further O 0 7.63859873131878e-08
molecular O 0 8.700211037648842e-05
defects O 1 0.9999866485595703
and O 0 1.4499579492621706e-07
their O 0 3.319770769394381e-07
associated O 0 8.721156063984381e-07
marker O 0 4.6825040044495836e-05
haplotypes O 0 1.1397557500458788e-05
. O 0 2.1702683739022177e-07

Seven O 0 4.7494686441496015e-06
further O 0 1.6393269675063493e-07
molecular O 0 7.035516773612471e-07
bases O 0 1.6891586710698903e-05
of O 0 1.7833064021033351e-06
C7 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 6.312289428933582e-07
described O 0 1.1155545962537872e-06
. O 0 1.0901083413727974e-07

All O 0 1.5265888464455202e-07
these O 0 4.042322032660195e-09
new O 0 3.712048002313395e-09
molecular O 0 4.411462668940658e-06
defects O 0 0.19331419467926025
involve O 0 1.6254003298854514e-07
single O 0 1.2182797036075499e-05
- O 0 2.978301154143992e-06
nucleotide O 0 1.0157386896025855e-06
events O 0 3.314082519523254e-08
, O 0 1.8650401223396784e-09
deletions O 0 1.5893539284661529e-07
and O 0 7.849061489650921e-08
substitutions O 0 3.119347127267247e-07
, O 0 2.4411901389242985e-09
some O 0 3.6636804701117853e-10
of O 0 8.505389170743172e-10
which O 0 7.664690215847259e-09
alter O 0 4.6389516228373395e-07
splice O 0 1.623995376576204e-05
sites O 0 1.126585857491591e-06
, O 0 1.8842348126213437e-08
and O 0 2.550074640339517e-08
others O 0 2.2778210961860168e-07
codons O 0 1.423542812517553e-06
. O 0 1.0701253927436483e-07

They O 0 7.616624770889757e-06
are O 0 1.5626158145209956e-08
distributed O 0 3.0700613162792934e-09
along O 0 2.6501802974365773e-09
the O 0 1.108681590977767e-09
C7 O 0 2.3379866433970165e-06
gene O 0 2.825746605594759e-07
, O 0 1.975722474512054e-09
but O 0 1.0421815632710718e-09
predominantly O 0 4.682401133493386e-09
towards O 0 1.4448803042910185e-08
the O 0 1.6044115369595602e-08
3 O 0 7.632424114945024e-08
end O 0 3.409463147363567e-07
. O 0 1.106417926166614e-07

All O 0 1.8776748902382678e-06
were O 0 5.907776881031168e-07
found O 0 2.206493121548192e-08
in O 0 1.861489851151532e-09
compound O 0 1.5508479123127472e-07
heterozygous O 0 3.039815965166781e-06
individuals O 0 6.56694751910436e-08
. O 0 5.1092456487822346e-08

The O 0 6.8389667831070255e-06
C6 O 0 0.0014232606627047062
/ O 0 0.000402162317186594
C7 O 0 0.00035370909608900547
marker O 0 3.474842378636822e-05
haplotypes O 0 8.081310625129845e-06
associated O 0 2.8967602361262834e-07
with O 0 1.2266890614398562e-08
most O 0 1.964192648529206e-07
C7 B-Disease 1 0.9996505975723267
defects I-Disease 1 0.9999990463256836
are O 0 9.506686069471471e-07
tabulated O 0 0.03664727136492729
. O 0 1.167509200428185e-08
. O 0 5.695091687130116e-08

A O 0 4.369879661680898e-06
genome O 0 1.6155790945049375e-06
- O 0 1.3032355354880565e-06
wide O 0 2.360648352350836e-07
search O 0 1.1033369418100847e-07
for O 0 6.444254463389143e-09
chromosomal O 0 0.0003054453118238598
loci O 0 3.4377976589894388e-06
linked O 0 1.039445214701118e-05
to O 0 3.8267138791070465e-08
mental O 0 0.03300376981496811
health O 0 2.1106145595695125e-06
wellness O 0 1.1481562296467018e-06
in O 0 6.378342742863197e-09
relatives O 0 8.50945482966381e-08
at O 0 2.9370331944278405e-08
high O 0 8.239978228630207e-07
risk O 0 9.675498404249083e-06
for O 0 2.156411937903613e-08
bipolar B-Disease 1 0.9995834231376648
affective I-Disease 1 0.9864249229431152
disorder I-Disease 1 0.9769649505615234
among O 0 2.1204586531098357e-08
the O 0 9.272206114019355e-09
Old O 0 6.420690624509007e-06
Order O 0 4.856204327552405e-08
Amish O 0 6.6878424149763305e-06
. O 0 1.723635563166681e-07

Bipolar B-Disease 1 0.9999997615814209
affective I-Disease 1 0.9999957084655762
disorder I-Disease 1 0.9999998807907104
( O 0 0.00019900998449884355
BPAD B-Disease 1 1.0
; O 0 6.133745046099648e-05
manic B-Disease 1 0.9999998807907104
- I-Disease 1 1.0
depressive I-Disease 1 1.0
illness I-Disease 1 0.9999899864196777
) O 0 1.1099601238129253e-08
is O 0 1.6209468212124989e-09
characterized O 0 6.743609226589342e-09
by O 0 3.0836927455979435e-10
episodes O 0 4.453966795381348e-08
of O 0 2.295973411392538e-09
mania B-Disease 0 2.897063495765906e-06
and O 0 2.112762444994587e-07
/ O 0 5.487697490025312e-05
or O 0 1.9877791146427626e-06
hypomania B-Disease 0 0.0009237282793037593
interspersed O 0 9.830488124862313e-06
with O 0 2.071211824272723e-08
periods O 0 1.184566599476966e-06
of O 0 2.1450366816111455e-08
depression B-Disease 0 0.0012825557496398687
. O 0 2.3704707530214364e-07

Compelling O 0 5.9439107644720934e-06
evidence O 0 1.3180591906802874e-07
supports O 0 3.085107636024986e-08
a O 0 4.9071515739740335e-09
significant O 0 1.2392186832244079e-08
genetic O 0 3.741635055121151e-07
component O 0 1.228429198363301e-07
in O 0 2.4117650099242383e-09
the O 0 6.045508982310821e-09
susceptibility O 0 1.0667318974810769e-06
to O 0 1.1910898933820135e-07
develop O 0 0.0016229577595368028
BPAD B-Disease 1 1.0
. O 0 2.202491941716289e-06

To O 0 7.923017051325587e-07
date O 0 6.714720370837313e-07
, O 0 7.2120482919046935e-09
however O 0 4.941980158434944e-09
, O 0 8.087419622881953e-10
linkage O 0 2.9377736154856393e-07
studies O 0 4.2248608167483326e-08
have O 0 1.6672615288371162e-08
attempted O 0 1.8274324986577994e-07
only O 0 5.977413231050832e-09
to O 0 5.8776752354106065e-09
identify O 0 5.230665010458324e-06
chromosomal O 0 0.0002577929990366101
loci O 0 4.541475675523543e-07
that O 0 7.006321300906393e-09
cause O 0 2.3718300212749455e-07
or O 0 1.84844651585081e-07
increase O 0 4.374263795625666e-08
the O 0 1.3677848187398922e-07
risk O 0 5.44933027413208e-06
of O 0 6.419877518482053e-09
developing O 0 1.5432116924785078e-05
BPAD B-Disease 1 1.0
. O 0 5.705920216314553e-07

To O 0 5.50514073438535e-07
determine O 0 4.675874833992566e-07
whether O 0 2.1266963301513897e-08
there O 0 7.992578154869534e-09
could O 0 2.0623264873620428e-08
be O 0 4.20014423241355e-09
protective O 0 9.52168690560029e-08
alleles O 0 4.246706808430645e-08
that O 0 7.680286406852588e-10
prevent O 0 1.294565379339474e-07
or O 0 9.011049684204409e-08
reduce O 0 3.7343414760471205e-07
the O 0 1.5069494097019742e-08
risk O 0 1.9037534570998105e-07
of O 0 7.796384093872177e-10
developing O 0 2.4079297418211354e-06
BPAD B-Disease 1 1.0
, O 0 2.5602737707686174e-09
similar O 0 6.464538904182859e-10
to O 0 1.0197652722254702e-09
what O 0 7.889805475613798e-10
is O 0 1.142263089670692e-10
observed O 0 1.7506935900968301e-09
in O 0 1.8191688433422115e-10
other O 0 6.48187992169369e-08
genetic B-Disease 1 1.0
disorders I-Disease 1 1.0
, O 0 1.1535485455738126e-08
we O 0 3.328970521465635e-08
used O 0 1.4234600484996918e-06
mental O 0 0.06505320221185684
health O 0 1.0556281040408066e-06
wellness O 0 1.2500519233071827e-06
( O 0 7.965108572705049e-09
absence O 0 1.7733087886995236e-08
of O 0 6.710387245867366e-10
any O 0 4.6889411464690056e-07
psychiatric B-Disease 0 0.33855047821998596
disorder I-Disease 0 0.030798738822340965
) O 0 1.938580407312429e-09
as O 0 1.561768825375509e-09
the O 0 1.8378631949644841e-09
phenotype O 0 1.792688379964602e-07
in O 0 2.9673592472079235e-09
our O 0 3.0645342263824205e-08
genome O 0 3.496525380342064e-08
- O 0 2.2537261656907503e-07
wide O 0 2.3187055830931058e-07
linkage O 0 9.69912980508525e-06
scan O 0 0.00028054192080162466
of O 0 7.984776395630888e-09
several O 0 1.6855702611451306e-08
large O 0 5.738379371678093e-08
multigeneration O 0 7.818109224899672e-06
Old O 0 2.2182762222655583e-06
Order O 0 1.5656381080475512e-08
Amish O 0 9.154076678896672e-07
pedigrees O 0 2.8272202143853065e-06
exhibiting O 0 3.4494814826757647e-07
an O 0 3.2738343147542537e-09
extremely O 0 5.487345902110974e-07
high O 0 2.79504479294701e-06
incidence O 1 0.7211177945137024
of O 0 7.256348908413202e-07
BPAD B-Disease 1 1.0
. O 0 2.2174554032972082e-06

We O 0 7.025264039839385e-06
have O 0 2.3548151872887502e-08
found O 0 9.531986755462185e-09
strong O 0 1.4603847908745138e-08
evidence O 0 6.878870806303894e-09
for O 0 1.8239608712278255e-09
a O 0 1.1432996771532089e-08
locus O 0 2.703679228943656e-06
on O 0 4.5822486072211177e-07
chromosome O 0 0.0003880524600390345
4p O 0 3.5319855669513345e-05
at O 0 2.832645691341895e-07
D4S2949 O 0 8.895311225387559e-07
( O 0 2.103234741923643e-08
maximum O 0 1.8749071273305162e-07
GENEHUNTER O 0 3.679963629110716e-05
- O 0 5.797357061965158e-06
PLUS O 0 8.349211384484079e-07
nonparametric O 0 5.2690757001983e-06
linkage O 0 6.945769655430922e-06
score O 0 8.23462542030029e-05
= O 0 7.788581569911912e-06
4 O 0 5.8905506250539474e-08
. O 0 3.826762906555814e-09
05 O 0 3.2401310363638913e-06
, O 0 4.7255589663564024e-08
P O 0 2.7174233764526434e-05
= O 0 6.626852382396464e-07
5 O 0 1.1547307110504335e-08
. O 0 7.497223397656683e-10
22 O 0 9.346551088640354e-09
x O 0 2.6885248871622025e-07
10 O 0 3.880546017853703e-08
( O 0 1.1415237644030185e-08
- O 0 1.3806979950459208e-06
4 O 0 4.793077934550638e-08
) O 0 5.535895741815011e-09
; O 0 4.454584701107933e-09
SIBPAL O 0 1.244219333784713e-06
Pempirical O 0 3.539719841683109e-07
value O 0 1.1506545938289037e-08
< O 0 1.1657384391128289e-07
3 O 0 1.6627678789404854e-08
x O 0 6.191013426359859e-07
10 O 0 7.95185997048975e-08
( O 0 1.8179081351377135e-08
- O 0 7.762958489365701e-07
5 O 0 9.012266488639398e-09
) O 0 1.1097690544303873e-09
) O 0 5.383736234598757e-10
and O 0 2.371368879039437e-09
suggestive O 0 3.329548053443432e-05
evidence O 0 3.186210406624923e-08
for O 0 1.7586589962093058e-09
a O 0 2.9503173237799274e-08
locus O 0 4.93292327519157e-06
on O 0 1.3206037010604632e-06
chromosome O 0 0.011054448783397675
4q O 0 0.0003810491762124002
at O 0 2.8679033903245e-07
D4S397 O 0 1.0072375289382762e-06
( O 0 4.046057355822086e-08
maximum O 0 2.2092309848176228e-07
GENEHUNTER O 0 2.2464020730694756e-05
- O 0 4.842741418542573e-06
PLUS O 0 9.259887860935123e-07
nonparametric O 0 6.307526291493559e-06
linkage O 0 1.2464611245377455e-05
score O 0 4.4307977077551186e-05
= O 0 3.0458340916084126e-06
3 O 0 6.161292276374297e-08
. O 0 7.394703960272864e-09
29 O 0 1.079164633210894e-07
, O 0 5.530386371077611e-09
P O 0 5.395262633101083e-06
= O 0 3.854190708807437e-07
2 O 0 1.1219734474821053e-08
. O 0 2.263881082598118e-09
57 O 0 2.967360757111237e-08
x O 0 5.137771381669154e-07
10 O 0 2.6874628744621987e-08
( O 0 1.2760293266467215e-08
- O 0 3.327236527184141e-06
3 O 0 7.018107339717972e-08
) O 0 1.911512725882858e-09
; O 0 3.04227398828516e-09
SIBPAL O 0 9.309047754868516e-07
Pempirical O 0 4.605520871336921e-07
value O 0 6.717497669228578e-09
< O 0 8.462451006607807e-08
1 O 0 9.803269307440132e-09
x O 0 1.5171015093073947e-06
10 O 0 7.847025784712969e-08
( O 0 2.35107222579245e-08
- O 0 8.495298061461654e-06
3 O 0 1.6074869435556138e-08
) O 0 4.3054243503704015e-10
) O 0 1.5237808237422712e-10
that O 0 2.3204148325017826e-10
are O 0 2.964055667575849e-09
linked O 0 4.952693188897683e-07
to O 0 2.603636062303849e-08
mental O 0 0.007889021188020706
health O 0 3.829821253020782e-06
wellness O 0 1.1713897038134746e-05
. O 0 1.9968753406374162e-07

These O 0 9.195471761813678e-07
findings O 0 5.571112069446826e-07
are O 0 4.380968832151666e-08
consistent O 0 2.598987407509412e-07
with O 0 8.489376424059003e-10
the O 0 1.299675478350082e-09
hypothesis O 0 1.2028135820685293e-08
that O 0 3.2607955224861485e-10
certain O 0 4.645120288415683e-09
alleles O 0 1.1995608417691983e-07
could O 0 2.1426633622922964e-07
prevent O 0 7.467415912287834e-07
or O 0 5.982913364732667e-08
modify O 0 2.1289331186835625e-07
the O 0 6.192321322373573e-09
clinical O 0 2.4716507596167503e-07
manifestations O 0 1.2625956458123255e-07
of O 0 9.094756059369047e-09
BPAD B-Disease 1 1.0
and O 0 2.466672697210015e-07
perhaps O 0 3.119700409115467e-08
other O 0 1.0958868479349348e-08
related O 0 1.9139090454700636e-06
affective B-Disease 1 0.969940185546875
disorders I-Disease 1 0.9998452663421631
. O 0 3.8351427633642743e-07

Segregation O 0 0.0021228701807558537
distortion O 0 0.0015568643575534225
in O 0 1.4525306141877081e-05
myotonic B-Disease 1 0.9999998807907104
dystrophy I-Disease 1 1.0
. O 0 1.0900541383307427e-05

Myotonic B-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 1 0.9999037981033325
DM B-Disease 1 1.0
) O 0 3.396060606064566e-07
is O 0 4.595550162633799e-09
an O 0 6.593150914113721e-09
autosomal B-Disease 1 0.9901212453842163
dominant I-Disease 1 0.9999074935913086
disease I-Disease 1 0.9839208126068115
which O 0 1.4840221496115191e-08
, O 0 1.2102484570064576e-09
in O 0 3.1557487178979216e-10
the O 0 1.6792831569745204e-09
typical O 0 1.5592462432323373e-07
pedigree O 0 1.1392319720471278e-05
, O 0 7.702941395848484e-09
shows O 0 3.0822963736909514e-08
a O 0 1.6764165167160172e-08
three O 0 4.1811389905888063e-08
generation O 0 2.0709715897737624e-07
anticipation O 0 1.3996493919421482e-07
cascade O 0 2.6378675102023408e-06
. O 0 2.067044988507405e-07

This O 0 3.0096899195086735e-07
results O 0 4.0570003534412535e-07
in O 0 3.187511055102732e-08
infertility B-Disease 1 0.9907138347625732
and O 0 0.00011420293594710529
congenital B-Disease 1 1.0
myotonic I-Disease 1 1.0
dystrophy I-Disease 1 1.0
( O 0 1.3864378161088098e-06
CDM B-Disease 0 7.919687050161883e-06
) O 0 6.335566293813599e-09
with O 0 1.2278448258129515e-09
the O 0 2.502430040962622e-09
disappearance O 0 1.3456433123337774e-07
of O 0 1.4775909384923125e-08
DM B-Disease 1 1.0
in O 0 2.8082354219804984e-08
that O 0 2.073361926591133e-08
pedigree O 0 4.770252053276636e-05
. O 0 1.8712682958721416e-07

The O 0 6.506628125180214e-08
concept O 0 3.708440488026099e-08
of O 0 4.31669189282502e-09
segregation O 0 4.548606113985443e-07
distortion O 0 2.793507292153663e-06
, O 0 9.094808461895809e-09
where O 0 2.567148937870911e-09
there O 0 7.763826803675045e-10
is O 0 2.0388576937868663e-10
preferential O 0 6.640556193815428e-08
transmission O 0 4.3933878259849735e-06
of O 0 9.667731060147844e-10
the O 0 1.988280651232799e-09
larger O 0 1.077596856191576e-08
allele O 0 1.7096708404551464e-07
at O 0 5.599102692599445e-08
the O 0 5.317387774539384e-08
DM B-Disease 1 0.9999997615814209
locus O 0 5.198708095122129e-06
, O 0 4.210228254919457e-08
has O 0 1.388642889565972e-08
been O 0 4.031913292124045e-08
put O 0 5.01062444868694e-08
forward O 0 3.1275707357281135e-08
to O 0 7.809842550443591e-09
explain O 0 3.965099324432231e-07
partially O 0 1.0938946616079193e-05
the O 0 3.2927340853916576e-09
maintenance O 0 1.89140621387196e-07
of O 0 6.6693930378392e-09
DM B-Disease 1 1.0
in O 0 1.963750051459101e-08
the O 0 2.2938735355637618e-08
population O 0 4.054361824046282e-08
. O 0 5.536341518563859e-08

In O 0 3.935057009130105e-07
a O 0 6.328974677671795e-08
survey O 0 8.197878855753515e-07
of O 0 2.457964853874728e-08
DM B-Disease 1 1.0
in O 0 6.581706912811569e-08
Northern O 0 3.8488425957439176e-07
Ireland O 0 3.6464969070948428e-06
, O 0 1.5110362738823824e-08
59 O 0 1.5371087158655428e-07
pedigrees O 0 2.946400400105631e-06
were O 0 1.645625161472708e-06
ascertained O 0 5.5290038289967924e-06
. O 0 7.054019590668759e-08

Sibships O 0 0.0001656150125199929
where O 0 2.0675457790275686e-07
the O 0 3.2491132007095302e-09
status O 0 3.2254274806575722e-09
of O 0 2.0324006366756464e-10
all O 0 8.888411673346752e-10
the O 0 1.2709642227548557e-09
members O 0 3.462570674628296e-09
had O 0 1.9278593299532076e-07
been O 0 3.534328740784076e-08
identified O 0 1.552915591673809e-07
were O 0 3.5962774092013206e-08
examined O 0 1.34928592743222e-08
to O 0 1.335128230195437e-09
determine O 0 1.2247863878656062e-07
the O 0 2.5876139009284316e-09
transmission O 0 2.127653260686202e-06
of O 0 9.717165960765328e-10
the O 0 3.255647129662975e-08
DM B-Disease 1 1.0
expansion O 0 2.770224227788276e-08
from O 0 8.996191347421245e-09
affected O 0 1.1692657153616892e-07
parents O 0 3.393761005554552e-08
to O 0 8.225490510938016e-09
their O 0 7.794753855705494e-07
offspring O 0 3.4048528050334426e-06
. O 0 7.44297352639478e-08

Where O 0 1.7643329783822992e-06
the O 0 5.8662873669845794e-08
transmitting O 0 4.584086127579212e-05
parent O 0 9.927487099048449e-07
was O 0 9.688248781003495e-08
male O 0 2.89141382836533e-07
, O 0 1.049586995094387e-08
58 O 0 3.558830314887018e-07
. O 0 1.0012597329023265e-07

3 O 0 5.2914242587576155e-06
% O 0 1.548005030826971e-07
of O 0 1.118037884495493e-09
the O 0 3.6895448918272677e-09
offspring O 0 4.957555574947037e-07
were O 0 4.045803621011146e-07
affected O 0 4.199369385560203e-08
, O 0 1.239927382989947e-09
and O 0 6.637210780979785e-09
in O 0 3.60489943451725e-10
the O 0 5.027794292011833e-10
case O 0 7.416579572705473e-10
of O 0 1.0857823667942412e-10
a O 0 1.0101675940177302e-08
female O 0 2.737906243055477e-06
transmitting O 0 0.002288003684952855
parent O 0 3.1063195820024703e-06
, O 0 1.4359978983691235e-08
68 O 0 4.322407960444252e-07
. O 0 9.758667829373735e-08

7 O 0 5.289327964419499e-05
% O 0 5.1941387937404215e-06
were O 0 1.2037347687510191e-06
affected O 0 1.732367422846437e-06
. O 0 1.0098251124190938e-07

Studies O 0 4.2990222937078215e-06
on O 0 1.886493663505462e-07
meiotic O 0 4.119994628126733e-06
drive O 0 1.4408053630177164e-06
in O 0 4.095281624927338e-08
DM B-Disease 1 1.0
have O 0 5.903732969159137e-08
shown O 0 1.9662161676592405e-08
increased O 0 8.519860372757648e-09
transmission O 0 3.2006101946535637e-07
of O 0 1.8615421704115676e-10
the O 0 9.54959666898958e-10
larger O 0 6.508897421042548e-09
allele O 0 2.21707409764349e-07
at O 0 4.676387987956332e-08
the O 0 5.360318766634009e-08
DM B-Disease 1 0.9999995231628418
locus O 0 4.619593710231129e-06
in O 0 6.454232703845264e-08
non O 0 0.0023881064262241125
- O 1 0.9917227625846863
DM O 1 1.0
heterozygotes O 0 8.332328434335068e-05
for O 0 2.0316669235853624e-07
CTGn O 0 3.630629362305626e-05
. O 0 4.556625015084137e-07

This O 0 7.328377904514127e-08
study O 0 1.744414745985523e-08
provides O 0 4.179159684980505e-09
further O 0 5.550909509821622e-09
evidence O 0 7.583417449552599e-09
that O 0 1.888277534334293e-09
the O 0 3.206732301919146e-08
DM B-Disease 1 0.9999997615814209
expansion O 0 3.124488401340386e-08
tends O 0 2.4123647790474934e-07
to O 0 6.681539765907019e-09
be O 0 3.0885932034152574e-08
transmitted O 0 3.935176209779456e-06
preferentially O 0 2.0069915080966894e-06
. O 0 1.859399390014005e-07

Diagnosis O 1 0.9999568462371826
of O 0 1.1138930858578533e-05
hemochromatosis B-Disease 1 1.0
. O 0 1.008100480248686e-05

If O 0 8.90297960722819e-05
untreated O 0 0.05520562827587128
, O 0 2.2697933843573992e-07
hemochromatosis B-Disease 1 1.0
can O 0 0.0035000788047909737
cause O 0 0.0013560265069827437
serious O 0 0.06354600936174393
illness O 1 0.686271607875824
and O 0 5.7976226486289306e-08
early B-Disease 0 6.240843504201621e-07
death I-Disease 0 3.6480651033343747e-07
, O 0 1.5442922496333722e-09
but O 0 3.3358462658839017e-09
the O 0 3.278059779177056e-08
disease O 0 1.9947312466683798e-05
is O 0 2.0633876829379005e-09
still O 0 1.2761771017721912e-07
substantially O 0 1.0699218364607077e-06
under O 0 2.9610002911795164e-06
- O 1 0.9975534081459045
diagnosed O 0 0.46378493309020996
. O 0 1.2435521057341248e-07

The O 0 1.6869122987372975e-07
cornerstone O 0 3.2122915172294597e-07
of O 0 1.108548364214812e-09
screening O 0 3.208359444784037e-08
and O 0 9.17059850280566e-09
case O 0 2.4481985327895472e-09
detection O 0 1.3092532924474654e-07
is O 0 1.6012648984542466e-09
the O 0 8.243108418071188e-10
measurement O 0 3.0706053166795755e-07
of O 0 2.195928550108306e-09
serum O 0 5.662358830704761e-07
transferrin O 0 8.557834121347696e-07
saturation O 0 1.804389512471971e-06
and O 0 6.630380511296607e-08
the O 0 4.016225219061198e-08
serum O 0 2.76035120805318e-06
ferritin O 0 4.873261059401557e-05
level O 0 2.6579997211229056e-05
. O 0 6.329094617285591e-07

Once O 0 7.588210792164318e-06
the O 0 5.517808787658396e-08
diagnosis O 0 0.0005727600073441863
is O 0 5.661578761362307e-09
suspected O 0 8.848041943565477e-07
, O 0 3.303415541111576e-09
physicians O 0 3.4515739599783046e-08
must O 0 8.779769800071335e-09
use O 0 6.121932472069602e-08
serum O 0 3.1679384846938774e-05
ferritin O 0 0.005005197133868933
levels O 0 0.009861420840024948
and O 0 8.92313778422249e-07
hepatic O 0 0.00017928163288161159
iron O 0 0.0023344450164586306
stores O 0 4.995312792743789e-06
on O 0 3.888451658440317e-07
liver O 0 1.4861876479699276e-05
biopsy O 0 7.015766459517181e-05
specimens O 0 2.1202160027655736e-08
to O 0 5.5055480174814875e-09
assess O 0 1.3096697330183815e-05
patients O 0 6.70370400257525e-06
for O 0 7.874065288682175e-10
the O 0 5.237323019713358e-09
presence O 0 3.0811442286449164e-08
of O 0 9.190683769588759e-09
iron B-Disease 0 0.14232200384140015
overload I-Disease 0 0.00021527407807298005
. O 0 4.3620335077321215e-07

Liver O 1 0.9999202489852905
biopsy O 1 0.9988380074501038
is O 0 2.828610092819872e-07
also O 0 1.0807132078127779e-08
used O 0 1.4066313447358425e-08
to O 0 1.543455918628922e-09
establish O 0 7.257644085711945e-08
the O 0 2.8669713270090824e-09
presence O 0 1.1895694207453289e-08
or O 0 6.012026432244966e-08
absence O 0 6.066903779355926e-08
of O 0 2.4369197770823803e-09
cirrhosis B-Disease 0 2.9459164579748176e-05
, O 0 4.004122811096522e-09
which O 0 7.090072529081226e-09
can O 0 8.558242257095117e-07
affect O 0 2.2072454157751054e-05
prognosis O 0 0.0004545405099634081
and O 0 8.700157394514463e-08
management O 0 4.764207801599696e-07
. O 0 5.703766703391011e-08

A O 0 3.877988547174027e-06
DNA O 0 1.5995035482774256e-06
- O 0 1.7533965319671552e-06
based O 0 2.0443422954485868e-08
test O 0 1.607752864174472e-07
for O 0 7.333726403935259e-10
the O 0 3.036152440571982e-09
HFE O 0 6.938817932677921e-06
gene O 0 1.312553763455071e-07
is O 0 1.6331241914357975e-09
commercially O 0 1.4724481189887229e-08
available O 0 8.894045500085213e-09
, O 0 2.386068898019289e-09
but O 0 1.159696338959293e-09
its O 0 6.55945575633865e-10
place O 0 2.3937007043173253e-08
in O 0 4.2698827806830764e-10
the O 0 6.295765686559207e-09
diagnosis O 0 0.0007896482129581273
of O 0 2.4001744591828356e-08
hemochromatosis B-Disease 1 1.0
is O 0 1.3898732049710816e-06
still O 0 1.823205707296438e-06
being O 0 3.322485042644985e-07
evaluated O 0 6.498777906926989e-07
. O 0 7.549707703446984e-08

Currently O 0 1.1597141565289348e-05
, O 0 2.1801461969062075e-08
the O 0 5.381334267084981e-10
most O 0 4.398572062136452e-10
useful O 0 3.891617694762317e-09
role O 0 8.881976043539908e-09
for O 0 7.434539095463322e-10
this O 0 7.93739629578738e-10
test O 0 4.5878414312028326e-07
is O 0 7.991171058208124e-10
in O 0 1.257292603362714e-10
the O 0 5.095138755351059e-10
detection O 0 1.1527374965680792e-07
of O 0 5.352837284533507e-09
hemochromatosis B-Disease 1 1.0
in O 0 1.8282007019365665e-08
the O 0 3.647492308189726e-09
family O 0 2.5864492769755998e-09
members O 0 5.882617726271633e-10
of O 0 6.941896502077327e-10
patients O 0 5.376025669079354e-08
with O 0 1.1882874684232547e-09
a O 0 4.6536449360701226e-08
proven O 0 4.9185250645678025e-06
case O 0 5.058963470361277e-09
of O 0 1.638640667600555e-09
the O 0 2.306359760950727e-07
disease O 0 0.00037786082248203456
. O 0 8.605426415897455e-08

It O 0 2.693501244266372e-07
is O 0 7.784501043772707e-09
crucial O 0 2.0382361753945588e-07
to O 0 3.225291322905832e-07
diagnose O 1 1.0
hemochromatosis B-Disease 1 1.0
before O 0 0.21133911609649658
hepatic B-Disease 1 0.9999819993972778
cirrhosis I-Disease 1 0.9998007416725159
develops O 0 1.6076292013167404e-05
because O 0 2.6789629714585317e-07
phlebotomy O 0 0.012043630704283714
therapy O 0 0.003764614462852478
can O 0 6.016918177920161e-06
avert O 1 0.7362567782402039
serious O 1 0.9978508949279785
chronic O 1 1.0
disease O 1 0.9995310306549072
and O 0 6.778882521984997e-08
can O 0 5.72366559481452e-07
even O 0 7.693091674809693e-07
lead O 0 3.547245796653442e-06
to O 0 5.8021910831485e-08
normal O 0 3.177355210937094e-06
life O 0 7.418793757096864e-08
expectancy O 0 6.822543241469248e-07
. O 0 3.681825733181654e-09
. O 0 3.344703713992203e-08

Prevalence O 0 0.0026196236722171307
of O 0 5.6197738018681775e-08
the O 0 2.12892850015578e-08
I1307K O 0 8.696223403603653e-07
APC B-Disease 0 3.336955956001475e-07
gene O 0 1.5033255351681873e-07
variant O 0 2.166380852486327e-07
in O 0 3.294782224827486e-09
Israeli O 0 4.851871153732645e-07
Jews O 0 1.3560869760453897e-08
of O 0 1.7387062622997718e-10
differing O 0 6.441059685613482e-09
ethnic O 0 8.441538135173232e-09
origin O 0 5.371126476916288e-08
and O 0 1.7276575192681776e-07
risk O 0 0.00015175175212789327
for O 0 9.12767427507788e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.2351786153885769e-06

BACKGROUND O 0 0.0002604000910650939
& O 0 1.5977373550413176e-05
AIMS O 0 4.6464838305837475e-06
Israeli O 0 1.689860255282838e-06
Jews O 0 4.542393838846692e-08
of O 0 1.0637426495208047e-09
European O 0 6.284310529736103e-07
birth O 0 0.00012423896987456828
, O 0 2.874282500897607e-08
i O 0 6.657701874246413e-07
. O 0 7.542921287573279e-10
e O 0 1.0038986886229395e-07
. O 0 5.112310574872936e-10
, O 0 4.6553802479643025e-10
Ashkenazim O 0 4.905357400275534e-07
, O 0 1.3594010361828168e-09
have O 0 2.1567030383806696e-09
the O 0 4.088585114914167e-08
highest O 1 0.9999856948852539
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
incidence O 0 0.01744820736348629
of O 0 1.205871136278347e-08
any O 0 1.786992669394749e-07
Israeli O 0 0.003426085226237774
ethnic O 0 7.461970312760968e-07
group O 0 2.0337733985797968e-06
. O 0 1.2279724614927545e-07

The O 0 1.022710762299539e-06
I1307K O 0 1.3811688404530287e-05
APC B-Disease 0 3.2346940770366928e-06
gene O 0 9.750478966452647e-07
variant O 0 4.056337729707593e-06
was O 0 9.393895084031101e-07
found O 0 6.10143899848481e-08
in O 0 7.68832197906022e-09
6 O 0 3.12520398892957e-07
. O 0 1.0855064402903736e-07

1 O 0 2.839899480022723e-06
% O 0 1.339096513675031e-07
of O 0 2.3553303751810972e-09
American O 0 2.2732242754841536e-08
Jews O 0 2.8765310133849198e-08
, O 0 1.0860852217575712e-09
28 O 0 5.8889302323450465e-09
% O 0 1.5547131360094113e-09
of O 0 9.245764154286462e-10
their O 0 0.0108206020668149
familial O 1 1.0
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
cases O 0 6.115039923315635e-06
, O 0 2.352996730792256e-08
but O 0 1.9070855117320207e-08
not O 0 2.636317297799451e-08
in O 0 4.9600825668960624e-09
non O 0 2.1574134734692052e-05
- O 0 5.955333836027421e-05
Jews O 0 1.6249382497335318e-06
. O 0 1.0078682066705369e-07

We O 0 7.018755241006147e-06
assessed O 0 1.1860507811434218e-06
the O 0 2.840546642346453e-08
I1307K O 0 8.172369803105539e-07
prevalence O 0 2.692142516025342e-06
in O 0 2.5873276854326832e-09
Israeli O 0 8.579153814025631e-07
Jews O 0 1.8084771014059697e-08
of O 0 2.8983423994155544e-10
differing O 0 1.1042586400833443e-08
ethnic O 0 1.2442823660308022e-08
origin O 0 6.383164219414539e-08
and O 0 3.119822906683112e-07
risk O 0 0.00022271598572842777
for O 0 9.67145970207639e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.1085510323027847e-06

METHODS O 0 3.045784069399815e-05
DNA O 0 3.236360498704016e-06
samples O 0 2.659643882907403e-07
from O 0 7.7237443107947e-09
500 O 0 5.945564041098805e-09
unrelated O 0 1.5312147993995495e-08
Jews O 0 9.938124101438461e-09
of O 0 4.982030343825272e-10
European O 0 6.217858867785253e-07
or O 0 3.874406957038445e-06
non O 0 3.2796211598906666e-05
- O 0 4.9468344514025375e-06
European O 0 6.998257049417589e-07
origin O 0 2.347742622532678e-08
, O 0 7.42699901579158e-10
with O 0 1.5482295445679028e-09
or O 0 2.660250402186648e-07
without O 0 9.198522832321032e-09
a O 0 2.8433475574018985e-09
personal O 0 1.4107173456068267e-06
and O 0 1.031600390888343e-06
/ O 0 3.247871791245416e-05
or O 0 7.9253067042373e-07
family O 0 1.642853852956705e-08
history O 0 4.3846193342744755e-09
of O 0 1.6823800130794098e-09
neoplasia B-Disease 0 7.168922456912696e-05
, O 0 3.554603367206255e-08
were O 0 1.3067759141449642e-07
examined O 0 9.716247006963386e-08
for O 0 9.295522684915625e-10
the O 0 2.5150528326634003e-09
I1307K O 0 1.3889294336877356e-07
variant O 0 8.290766828622509e-08
by O 0 1.001442262449359e-09
the O 0 1.7549662834071e-09
allele O 0 1.3375586149777519e-07
- O 0 1.2564672147163947e-07
specific O 0 2.1084082035827123e-08
oligonucleotide O 0 1.604848307579232e-06
( O 0 5.289428273158592e-08
ASO O 0 2.6186942704953253e-05
) O 0 1.2325711118421623e-08
method O 0 2.675500923032814e-07
. O 0 1.1470198302276913e-07

RESULTS O 0 3.8791655242675915e-05
In O 0 2.273679378106408e-08
persons O 0 7.715620853332439e-08
at O 0 3.130793757577521e-08
average O 0 5.471232725540176e-06
risk O 0 0.0001968699652934447
for O 0 0.00030559414881281555
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, O 0 4.9507377752888715e-08
I1307K O 0 1.9080152924288996e-06
was O 0 5.922178161199554e-07
found O 0 1.627630297207361e-08
in O 0 3.9834331388988176e-09
5 O 0 5.235208533349578e-08
. O 0 6.878860858705593e-08

0 O 0 1.8162145352107473e-05
% O 0 4.535762343493843e-07
of O 0 5.238272038354808e-09
120 O 0 1.5782335438530026e-08
European O 0 1.7794452844555053e-07
and O 0 8.44374810071713e-08
1 O 0 1.7231472781986668e-07
. O 0 7.638773524831777e-08

6 O 0 1.911504296003841e-05
% O 0 2.430089125482482e-07
of O 0 8.862345524107695e-09
188 O 0 1.276526404581091e-07
non O 0 8.950571555033093e-07
- O 0 1.1529017456268775e-06
European O 0 2.4900955963857996e-07
Jews O 0 2.3780924607308407e-07
( O 0 1.998844822992396e-08
P O 0 4.101623926544562e-05
= O 0 4.2655260585888755e-06
0 O 0 1.1427376023220859e-07
. O 0 4.3027750251667385e-09
08 O 0 5.367541007217369e-07
) O 0 2.0847508608312637e-08
. O 0 4.63156943908416e-08

It O 0 1.5666961417082348e-06
occurred O 0 1.0355530548622482e-06
in O 0 2.218097172601574e-08
15 O 0 9.161022518355821e-08
. O 0 8.244720106631576e-08

4 O 0 2.975629513457534e-06
% O 0 1.1843502534247818e-07
of O 0 3.060140363331243e-09
52 O 0 1.4084842803185893e-07
Ashkenazi O 0 3.2922478112595854e-06
Israelis O 0 2.374757059442345e-06
with O 0 1.3342332749743946e-07
familial O 1 0.9969833493232727
cancer B-Disease 0 0.23888377845287323
( O 0 1.4252677260628843e-07
P O 0 0.004438219126313925
= O 0 1.9684786821017042e-05
0 O 0 1.1991077997208777e-07
. O 0 5.188751206475217e-09
02 O 0 9.934705076375394e-07
) O 0 3.145162796869272e-09
and O 0 1.2959829653880206e-08
was O 0 2.903187521496875e-07
not O 0 6.9898904442311505e-09
detected O 0 1.3437851009712176e-07
in O 0 3.093060474412823e-09
51 O 0 1.657757309203589e-07
non O 0 4.1991688704001717e-07
- O 0 5.028460918765632e-07
European O 0 1.4078690924179682e-07
Jews O 0 1.208729116797258e-07
at O 0 1.5001261033376068e-07
increased O 0 3.888002538587898e-06
cancer B-Disease 0 0.0001677963591646403
risk O 0 2.3120160221878905e-06
. O 0 9.479103368903452e-08

Colorectal B-Disease 1 0.9999815225601196
neoplasia I-Disease 1 0.7477338314056396
occurred O 0 6.327449955279008e-05
personally O 0 2.3066833819029853e-05
or O 0 2.9476294116648205e-07
in O 0 2.861759496042282e-09
the O 0 2.5601956110676838e-09
families O 0 8.890856939558489e-09
of O 0 2.372725071975168e-10
13 O 0 9.965096303687915e-09
of O 0 4.35334324144776e-10
20 O 0 9.611035522993916e-09
Ashkenazi O 0 1.735100880750906e-07
I1307K O 0 9.480260843020005e-08
carriers O 0 3.2928110016428036e-08
, O 0 4.0283426594456273e-10
8 O 0 6.833333898725868e-10
of O 0 1.6707202288301914e-10
whom O 0 8.398838247103413e-08
also O 0 1.754623184524462e-07
had O 0 7.075194616845693e-07
a O 0 5.350397902503801e-09
personal O 0 1.5635541785741225e-06
or O 0 2.5811193609115435e-06
family O 0 3.398781700525433e-08
history O 0 2.0229080632816476e-08
of O 0 1.955948647491823e-08
noncolonic O 0 0.0007345213671214879
neoplasia B-Disease 0 0.002669466659426689
. O 0 1.135296201937308e-06

CONCLUSIONS O 0 4.420406912686303e-05
The O 0 5.33538468516781e-07
I1307K O 0 9.50363482843386e-06
APC O 0 4.690681635111105e-06
variant O 0 5.167370545677841e-06
may O 0 1.5999384572751296e-07
represent O 0 1.6125785151643868e-08
a O 0 9.890546159851965e-09
susceptibility O 0 2.1760140498372493e-06
gene O 0 1.9882115793734556e-06
for O 0 9.817325974381674e-08
colorectal B-Disease 1 1.0
, I-Disease 0 1.3854435110260965e-07
or I-Disease 0 1.1074165939817249e-07
other I-Disease 0 5.32815658260688e-09
, I-Disease 0 6.604682312172372e-08
cancers I-Disease 0 0.004025528207421303
in O 0 1.8452817052150294e-09
Ashkenazi O 0 1.861068426478596e-06
Jews O 0 9.941160783455416e-08
, O 0 4.734786340776509e-09
and O 0 3.901928380400932e-08
partially O 0 7.830398317310028e-06
explains O 0 4.9186517969701526e-08
the O 0 4.705248635161752e-09
higher O 0 1.2092001497876481e-06
incidence O 1 0.7998450994491577
of O 0 0.0013911817222833633
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
in O 0 3.604050746730536e-08
European O 0 5.644288194162073e-06
Israelis O 0 1.544688166177366e-05
. O 0 1.716143032126638e-07

Systematic O 0 9.610846973373555e-06
analysis O 0 5.847575152984064e-07
of O 0 7.949160618636597e-08
coproporphyrinogen O 0 0.00016064288502093405
oxidase O 0 0.00038061608211137354
gene O 0 0.0008394974865950644
defects O 1 0.8898382782936096
in O 0 2.8450417133285555e-08
hereditary B-Disease 1 0.7234994769096375
coproporphyria I-Disease 0 0.0023526642471551895
and O 0 5.942125653746189e-07
mutation O 0 9.90998960332945e-05
update O 0 1.1242139407841023e-05
. O 0 3.9852525901551417e-07

Hereditary B-Disease 1 0.9999397993087769
coproporphyria I-Disease 0 0.3523266315460205
( O 0 5.279024662740994e-06
HC B-Disease 0 0.000845839676912874
) O 0 1.2188415610125958e-07
is O 0 1.4275185478140884e-08
an O 0 5.647249068374549e-08
acute O 1 0.9985740184783936
hepatic B-Disease 1 0.9999896287918091
porphyria I-Disease 1 0.9999967813491821
with O 0 1.3060499668426928e-06
autosomal O 1 0.9999855756759644
dominant O 1 0.5448049306869507
inheritance O 0 0.00019862459157593548
caused O 0 3.3258850180573063e-06
by O 0 1.535748417325067e-08
deficient B-Disease 0 4.3108539102831855e-06
activity I-Disease 0 1.0104648140440986e-07
of I-Disease 0 3.1371703013149954e-09
coproporphyrinogen I-Disease 0 1.2263892131159082e-05
III I-Disease 0 3.474737241049297e-06
oxidase I-Disease 0 8.534079825039953e-06
( O 0 2.0422754687388078e-07
CPO O 0 8.830188562569674e-06
) O 0 6.869709068269003e-08
. O 0 1.1265499466617257e-07

Clinical O 0 0.004067193251103163
manifestations O 0 1.3482818758348003e-05
of O 0 1.2862630072163483e-08
the O 0 2.1805544747621752e-07
disease O 0 0.052912961691617966
are O 0 1.0170967179590207e-08
characterized O 0 2.228946129889664e-07
by O 0 8.252834859945324e-09
acute O 0 0.0003522516635712236
attacks O 0 2.400370067334734e-05
of O 0 1.942920277997473e-07
neurological B-Disease 1 0.9999997615814209
dysfunction I-Disease 0 0.1564864218235016
often O 0 1.1859692676807754e-06
precipitated O 0 3.703817981204338e-07
by O 0 9.378158694062222e-09
drugs O 0 6.021666365541023e-08
, O 0 1.7917042294257612e-09
fasting O 0 1.3881005145321978e-07
, O 0 2.563112388997979e-09
cyclical O 0 1.0412926712888293e-05
hormonal O 0 3.062791802221909e-05
changes O 0 6.788664563828206e-08
, O 0 7.921097555652068e-09
or O 0 5.528017936740071e-06
infectious B-Disease 0 0.0002555508981458843
diseases I-Disease 0 0.0008909357711672783
. O 0 1.6281074977086973e-07

Skin O 1 0.9999990463256836
photosensitivity O 1 0.9936169385910034
may O 0 0.0008443341939710081
also O 0 3.9260868334167753e-07
be O 0 4.5859554376193046e-08
present O 0 1.2655371506298252e-07
. O 0 1.1827847146150816e-07

The O 0 3.589637458389916e-07
seven O 0 6.186468226587749e-08
exons O 0 4.206551977858908e-07
, O 0 4.598417202572591e-09
the O 0 4.496687022736978e-09
exon O 0 6.905881946295267e-07
/ O 0 1.273788143407728e-06
intron O 0 1.0593842489470262e-05
boundaries O 0 2.9523622288252227e-05
and O 0 9.02360497434529e-08
part O 0 5.764902777372072e-09
of O 0 1.3347311034195286e-09
3 O 0 8.420585118074086e-09
noncoding O 0 1.5829130006750347e-07
sequence O 0 3.034926621126033e-08
of O 0 1.9386028338175265e-09
the O 0 8.575373300345746e-09
CPO O 0 5.417397005658131e-06
gene O 0 4.1007928075487143e-07
were O 0 2.1658850357653137e-07
systematically O 0 4.156324280302215e-07
analyzed O 0 2.132805754229139e-08
by O 0 1.0811064266036396e-09
an O 0 2.165738699488884e-09
exon O 0 3.6709664641421114e-07
- O 0 1.2429728712959331e-06
by O 0 1.6440733219269532e-08
- O 0 1.266862000193214e-06
exon O 0 8.171892659447622e-06
denaturing O 0 0.0002394050097791478
gradient O 0 3.0238092222134583e-05
gel O 0 0.0005121885915286839
electrophoresis O 0 1.832119596656412e-05
( O 0 7.034752513845888e-08
DGGE O 0 1.6041874459915562e-06
) O 0 5.1373270082422096e-09
strategy O 0 3.035459172906485e-08
followed O 0 5.972934147280284e-09
by O 0 4.223615623910604e-10
direct O 0 3.1337494821315204e-09
sequencing O 0 2.1281326922917287e-08
in O 0 2.7611599673349474e-09
seven O 0 1.81624795203561e-08
unrelated O 0 5.668648483947436e-08
heterozygous O 0 2.557818561399472e-06
HC B-Disease 0 2.607637179607991e-05
patients O 0 2.730802862060955e-06
from O 0 6.4481890937884145e-09
France O 0 0.0001966378913493827
, O 0 1.473765909310032e-08
Holland O 0 3.044997583856457e-06
, O 0 7.578269567432017e-09
and O 0 3.435324913425575e-08
Czech O 0 1.120600245485548e-05
Republic O 0 3.023660042345e-07
. O 0 6.938116570154307e-08

Seven O 0 8.374255230592098e-06
novel O 0 7.565562327727093e-07
mutations O 0 3.320550831631408e-06
and O 0 9.723140514950046e-09
two O 0 4.1379459858603695e-09
new O 0 1.15385230259335e-08
polymorphisms O 0 0.0003639236674644053
were O 0 2.979886403409182e-06
detected O 0 7.60802868171595e-06
. O 0 1.1654950071715575e-07

Among O 0 1.361631802865304e-06
these O 0 5.519156331956765e-08
mutations O 0 1.1840177194244461e-06
two O 0 9.434206305058979e-09
are O 0 7.152621606110188e-09
missense O 0 1.8254535234518698e-06
( O 0 6.966624610527106e-09
G197W O 0 1.2497105217335047e-07
, O 0 2.271285826083158e-09
W427R O 0 5.4077215594361405e-08
) O 0 1.0646824533111499e-09
, O 0 3.422973016142805e-10
two O 0 1.9638874970695497e-09
are O 0 2.1358427915174616e-08
nonsense O 0 7.62954073252331e-07
( O 0 2.4293365097349806e-09
Q306X O 0 1.7624348913614085e-07
, O 0 2.8974596055775237e-09
Q385X O 0 1.0103646275183564e-07
) O 0 1.3283107946904238e-09
, O 0 4.45530501380631e-10
two O 0 1.9083945534958957e-09
are O 0 4.19925516581543e-09
small O 0 6.81161882454262e-09
deletions O 0 2.548123575252248e-06
( O 0 2.105707430644088e-08
662de14bp O 0 3.232132996799919e-07
; O 0 6.14837647461286e-09
1168del3bp O 0 6.782709647268348e-07
removing O 0 8.722489042156667e-08
a O 0 5.372302158690445e-09
glycine O 0 2.0731907568460883e-07
at O 0 2.7244951184002275e-07
position O 0 6.782244099667878e-07
390 O 0 9.85525705488044e-09
) O 0 1.2395607873472159e-09
, O 0 4.3127887372484963e-10
and O 0 1.9593864308831144e-09
one O 0 2.822070799268772e-09
is O 0 3.632812939358132e-10
a O 0 2.2462633975095514e-09
splicing O 0 1.9363681076356443e-06
mutation O 0 1.2058960692229448e-06
( O 0 2.2933660304147452e-08
IVS1 O 0 2.6071900265378645e-06
- O 0 1.8861333046515938e-06
15c O 0 1.1820729923783801e-05
- O 0 6.116609256423544e-06
- O 0 4.384472958918195e-06
> O 0 2.1732839172727836e-07
g O 0 2.982243927363015e-07
) O 0 1.957761508464273e-09
which O 0 8.554686403705603e-10
creates O 0 2.562134948647099e-09
a O 0 1.649270386927526e-09
new O 0 3.32561822524724e-09
acceptor O 0 1.491033572165179e-07
splice O 0 2.3634269382455386e-05
site O 0 2.8994959393457975e-06
. O 0 3.2696712537472195e-07

The O 0 6.028883490216685e-07
pathological O 0 8.157489332916157e-07
significance O 0 3.957324068437629e-08
of O 0 1.4424893501896463e-09
the O 0 5.6302527084994836e-09
point O 0 2.6525137286625977e-07
mutations O 0 7.457054493897886e-07
G197W O 0 1.1395304966299591e-07
, O 0 1.1954460754637353e-09
W427R O 0 5.3197613425481904e-08
, O 0 1.6868687557902717e-09
and O 0 1.268747995553099e-09
the O 0 2.419883848858717e-09
in O 0 5.048341300550874e-09
- O 0 1.2633026017283555e-05
frame O 0 0.0017050470924004912
deletion O 0 1.7393604139215313e-05
390delGly O 0 3.692507561936509e-06
were O 0 1.7304441257692815e-07
assessed O 0 2.960057265966043e-08
by O 0 6.406003505432523e-10
their O 0 6.501539751013752e-09
respective O 0 5.833884131334344e-08
expression O 0 1.6351664910985164e-08
in O 0 7.861249429197414e-10
a O 0 3.981101670547105e-09
prokaryotic O 0 1.1414170941748125e-08
system O 0 1.2494002277207983e-08
using O 0 4.408185105830853e-08
site O 0 1.2273511629246059e-06
- O 0 3.696594603752601e-06
directed O 0 5.623316496894404e-07
mutagenesis O 0 6.863749604235636e-06
. O 0 1.7513582406536443e-07

These O 0 1.6859808056324255e-06
mutations O 0 1.1737513887055684e-05
resulted O 0 1.9492584613090003e-07
in O 0 4.1276746465257474e-09
the O 0 8.132825080053863e-09
absence O 0 2.991182270761783e-07
or O 0 7.303302851369153e-08
a O 0 1.2843777597026929e-08
dramatic O 0 3.060054893921915e-07
decrease O 0 9.700698910819483e-07
of O 0 8.760432379517624e-09
CPO O 0 4.0358958358410746e-05
activity O 0 1.2043296919728164e-06
. O 0 1.316801530037992e-07

The O 0 5.545979888665897e-07
two O 0 1.2395169335377432e-07
polymorphisms O 0 2.0839792341575958e-05
were O 0 2.0994058047563158e-07
localized O 0 3.948661913000251e-07
in O 0 3.034757112274633e-09
noncoding O 0 1.638951800941868e-07
part O 0 1.2214545819233535e-08
of O 0 4.073542614335679e-10
the O 0 1.7219874415275171e-09
gene O 0 2.4908976214987888e-08
1 O 0 3.965482608947468e-09
) O 0 9.70197922001148e-10
a O 0 6.428344079267845e-09
C O 0 2.3134232378652086e-06
/ O 0 1.9574905252284225e-07
G O 0 1.219653142925381e-07
polymorphism O 0 4.968214852851816e-07
in O 0 5.442870154581669e-09
the O 0 6.506961192087601e-09
promotor O 0 6.123930234025465e-07
region O 0 3.575246765308293e-08
, O 0 1.2996879128479577e-09
142 O 0 1.4412442794764502e-08
bp O 0 9.949982171519878e-08
upstream O 0 1.0829706020842877e-08
from O 0 7.744806462817166e-10
the O 0 5.898774801949003e-10
transcriptional O 0 9.568859837827404e-08
initiation O 0 1.859372389390046e-08
site O 0 7.855381767285508e-08
( O 0 1.606944266541177e-08
- O 0 3.754241788556101e-07
142C O 0 5.945532279838517e-07
/ O 0 4.597126235239557e-07
G O 0 3.7176900491431297e-07
) O 0 3.2396700877512785e-09
, O 0 1.3349220617797641e-09
and O 0 3.302924156400877e-09
2 O 0 5.614414266830181e-09
) O 0 5.323957941172353e-10
a O 0 3.6990641660850088e-09
6 O 0 2.072476235071008e-08
bp O 0 1.861061633690042e-07
deletion O 0 1.7566206622632308e-07
polymorphism O 0 6.714822688991262e-07
in O 0 5.492668098128206e-09
the O 0 3.2129874316666474e-09
3 O 0 1.3599670722896917e-08
noncoding O 0 7.625904885344426e-08
part O 0 5.6239204404562315e-09
of O 0 1.142740901904915e-09
the O 0 1.8396983492152685e-08
CPO O 0 1.178701040771557e-06
gene O 0 1.158035232151633e-07
, O 0 3.2053240062168697e-09
574 O 0 5.288227811206525e-08
bp O 0 2.204138240813336e-07
downstream O 0 1.8374155530409553e-08
of O 0 5.778263978406528e-10
the O 0 1.7276063912774475e-09
last O 0 3.840150863965164e-09
base O 0 7.816235658708592e-09
of O 0 4.346713544656211e-10
the O 0 6.064402757743892e-09
normal O 0 3.434814743741299e-07
termination O 0 6.220462296369078e-07
codon O 0 8.06078332971083e-07
( O 0 3.407745907679782e-08
+ O 0 3.9097139392652025e-07
574 O 0 7.145307563405368e-07
delATTCTT O 0 2.3230227270687465e-06
) O 0 6.293642940136124e-08
. O 0 1.3447440494473994e-07

Five O 0 1.5027987501525786e-05
intragenic O 0 3.9702674257569015e-05
dimorphisms O 0 2.4772938559181057e-05
are O 0 8.213924473920997e-08
now O 0 2.199023008131462e-08
well O 0 8.50140313701786e-09
characterized O 0 7.74679307369297e-08
and O 0 1.5206090608899103e-08
the O 0 2.181109959309424e-09
high O 0 3.631444656093663e-08
degree O 0 4.120367158577665e-09
of O 0 4.688762156312976e-10
allelic O 0 4.875745958088373e-07
heterogeneity O 0 2.5680151338747237e-07
in O 0 7.822783310018622e-09
HC B-Disease 0 0.00010033172293333337
is O 0 4.3208125077853765e-08
demonstrated O 0 4.583961654702762e-08
with O 0 3.5528868735923425e-09
seven O 0 5.919403189835748e-09
new O 0 1.0337616318523146e-09
different O 0 8.156391118063766e-09
mutations O 0 4.4789359776586934e-07
making O 0 1.855238096482026e-08
a O 0 4.1143519702302456e-09
total O 0 6.370196814486917e-09
of O 0 3.4335543297459026e-09
nineteen O 0 1.0570995073067024e-05
CPO O 0 0.00474888551980257
gene B-Disease 0 0.0005079222028143704
defects I-Disease 1 0.9817512631416321
reported O 0 1.0069053359984537e-06
so O 0 4.8079474623818896e-08
far O 0 3.0396307693081326e-08
. O 0 5.395345059611145e-09
. O 0 3.659494041130529e-08

Coincidence O 0 3.4172664982179413e-06
of O 0 2.9134431756006052e-08
two O 0 4.148371246515126e-08
novel O 0 1.3880701033031073e-07
arylsulfatase O 0 7.681786655666656e-07
A O 0 3.868986908628358e-08
alleles O 0 4.956667112310242e-07
and O 0 4.1980797504947986e-08
mutation O 0 2.1471544187079417e-06
459 O 0 4.7673211156507023e-07
+ O 0 6.57996793052007e-07
1G O 0 1.0607744115986861e-05
> O 0 1.008731487672776e-06
A O 0 1.1645983732933018e-07
within O 0 3.2998276111584346e-08
a O 0 2.7113735256989457e-08
family O 0 3.3039410141100234e-07
with O 0 1.661909323047439e-06
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
: O 0 1.7958518228056164e-08
molecular O 0 1.1782476860844326e-07
basis O 0 3.785552138424464e-08
of O 0 1.0728103738699701e-08
phenotypic O 0 3.332218693685718e-05
heterogeneity O 0 8.1190541095566e-05
. O 0 1.4530962744174758e-06

In O 0 4.1367928815816413e-07
a O 0 9.310293336284303e-08
family O 0 5.965194560531017e-08
with O 0 3.3797031839810643e-09
three O 0 5.310535655667081e-08
siblings O 0 5.785697339888429e-06
, O 0 1.0662818406004249e-09
one O 0 1.8098323950610506e-09
developed O 0 6.060126622742246e-08
classical O 0 2.6849735945688735e-07
late O 0 8.857278589857742e-05
infantile O 1 0.9999727010726929
metachromatic B-Disease 1 1.0
leukodystrophy I-Disease 1 1.0
( O 0 1.646838973101694e-05
MLD B-Disease 1 0.9999996423721313
) O 0 7.486113418053719e-08
, O 0 1.1319167825263321e-08
fatal O 0 3.520695372571936e-06
at O 0 5.897182404623891e-07
age O 0 1.8498127474231296e-06
5 O 0 1.4559849326190033e-08
years O 0 8.703207932114765e-09
, O 0 2.43136710764702e-09
with O 0 9.68604574325127e-09
deficient O 0 0.00010507477418286726
arylsulfatase O 0 1.5490551277252962e-06
A O 0 3.56410794211115e-08
( O 0 7.70932029325877e-09
ARSA O 0 4.339025053923251e-06
) O 0 2.2492729900847053e-09
activity O 0 1.7902292981375467e-08
and O 0 1.1014945400233955e-08
increased O 0 3.3811176081144367e-07
galactosylsulfatide O 0 5.928148311795667e-05
( O 0 3.841640250357159e-07
GS O 1 0.9999991655349731
) O 0 1.1016210521574976e-07
excretion O 0 5.16137333761435e-07
. O 0 9.140462253753867e-08

The O 0 1.3797513531699224e-07
two O 0 1.4609810250476585e-08
other O 0 3.8784424560844855e-09
siblings O 0 2.5570161596988328e-06
, O 0 1.1933644294970236e-08
apparently O 0 8.931012871471466e-07
healthy O 0 5.697656035863474e-08
at O 0 1.2478236222079886e-08
12 O 0 9.267768774634533e-09
( O 0 8.000107798444844e-10
1 O 0 2.266672183282026e-09
/ O 0 4.834514300000592e-08
2 O 0 5.81792436449291e-09
) O 0 1.1875850303155744e-09
and O 0 7.547789060424748e-09
15 O 0 1.114691183801142e-08
years O 0 6.306570377034859e-09
, O 0 1.6028721683269964e-09
respectively O 0 8.791504768623781e-08
, O 0 1.1234932983938961e-09
and O 0 1.1170835811924462e-08
their O 0 1.7925961515175004e-07
father O 0 3.5515748209036246e-07
, O 0 2.314206160036747e-09
apparently O 0 1.3901367879043391e-07
healthy O 0 8.467097245556943e-09
as O 0 7.888435460401411e-10
well O 0 6.093005655571915e-09
, O 0 1.3695665712631921e-09
presented O 0 1.6546497505487423e-08
ARSA O 0 4.9465692427475005e-05
and O 0 4.98384167713084e-07
GS O 1 0.9999966621398926
values O 0 2.762479311968491e-07
within O 0 5.110246448225553e-09
the O 0 2.413403255019375e-09
range O 0 1.3306372181887127e-07
of O 0 1.0273526385162768e-07
MLD B-Disease 1 1.0
patients O 0 8.704626088729128e-05
. O 0 1.7546902597587177e-07

Mutation O 0 4.24559366365429e-05
screening O 0 2.9318475753825624e-06
and O 0 2.957918354695721e-08
sequence O 0 3.437750351054092e-08
analysis O 0 2.7833058524606713e-08
disclosed O 0 1.3159127831841033e-07
the O 0 1.5198079461598013e-09
involvement O 0 2.6577392731041982e-08
of O 0 1.7906349736307448e-09
three O 0 2.0026227787184325e-08
different O 0 5.044397610731721e-08
ARSA O 0 0.015666428953409195
mutations O 0 6.288511940510944e-05
being O 0 5.4033499452543765e-08
the O 0 7.278569968960369e-10
molecular O 0 3.6125435087797086e-08
basis O 0 3.164323203463937e-08
of O 0 1.687873840694465e-08
intrafamilial O 0 3.493615804472938e-05
phenotypic O 0 0.00010457209282321855
heterogeneity O 0 0.00011398197966627777
. O 0 3.1699853479949525e-06

The O 0 2.0140050764894113e-06
late O 0 3.5582640975917457e-06
infantile O 0 0.10507587343454361
patient O 0 0.002852421486750245
inherited O 0 0.00018214121519122273
from O 0 3.635991419059792e-08
his O 0 6.435947170757572e-07
mother O 0 8.28141492092982e-06
the O 0 6.159327270438553e-09
frequent O 0 1.0399184020570829e-06
0 O 0 1.8986744407811784e-06
- O 0 3.436241240706295e-05
type O 0 0.003126188414171338
mutation O 0 2.458742710587103e-05
459 O 0 8.257497370323108e-07
+ O 0 6.391497890945175e-07
1G O 0 5.327998678694712e-06
> O 0 3.7821928344783373e-07
A O 0 1.794469142168964e-07
, O 0 4.809320941490114e-09
and O 0 7.476748997703453e-09
from O 0 3.6093459332420252e-09
his O 0 1.2318101028085948e-07
father O 0 3.422833287913818e-07
a O 0 4.361548011644345e-09
novel O 0 1.419265238666867e-08
, O 0 3.366514400582332e-09
single O 0 5.6654056379557e-07
basepair O 0 1.0774765542009845e-06
microdeletion O 0 5.444232442641805e-07
of O 0 2.971386026118239e-09
guanine O 0 1.647567842155695e-07
at O 0 6.651736583762613e-08
nucleotide O 0 4.488818490244739e-07
7 O 0 5.841311079279876e-08
in O 0 2.2582402614546027e-09
exon O 0 3.152296415009914e-07
1 O 0 8.024138509199474e-08
( O 0 4.413838539107928e-08
7delG O 0 1.4441606026593945e-06
) O 0 2.414491007129982e-08
. O 0 4.473966797036155e-08

The O 0 1.069894324245979e-06
two O 0 1.135472643909452e-06
clinically O 0 0.01229167077690363
unaffected O 0 2.24698906095e-05
siblings O 0 6.848881184851052e-06
carried O 0 3.2536115668335697e-07
the O 0 1.5550817522580473e-08
maternal O 0 8.870491001289338e-06
mutation O 0 2.0711190700239968e-06
459 O 0 3.5395407849136973e-07
+ O 0 2.5910139811458066e-07
1G O 0 5.803839940199396e-06
> O 0 5.849706212757155e-07
A O 0 2.7519007517184946e-07
and O 0 1.1710132952202912e-07
, O 0 3.5435745449063916e-09
on O 0 9.003040979393973e-09
their O 0 4.511138484986077e-08
paternal O 0 1.4132866681393352e-06
allele O 0 1.7786581452128303e-07
, O 0 1.599274823682606e-09
a O 0 2.3106467850197987e-09
novel O 0 2.2953965839178636e-08
cytosine O 0 1.4565479489192512e-07
to O 0 5.0884598756795185e-09
thymidine O 0 8.597303349233698e-07
transition O 0 3.2832417673489545e-07
at O 0 1.114215493203119e-07
nucleotide O 0 1.7465258679294493e-06
2435 O 0 2.4005191789910896e-06
in O 0 5.397846170041021e-09
exon O 0 3.1587123316967336e-07
8 O 0 8.568640907924419e-08
, O 0 2.552029476632356e-09
resulting O 0 1.4353161326141617e-08
in O 0 1.0360198254844022e-09
substitution O 0 8.269805285010534e-09
of O 0 2.4887782945626213e-09
alanine O 0 2.0477218640735373e-06
464 O 0 1.2487990375120717e-07
by O 0 2.7381172884588523e-08
valine O 0 5.583000893238932e-05
( O 0 4.917835383366764e-08
A464V O 0 1.1821999805761152e-06
) O 0 2.7408969316411458e-08
. O 0 5.2385448867653395e-08

The O 0 1.2178451243016752e-06
fathers O 0 1.1624468243098818e-05
genotype O 0 1.161053114628885e-05
thus O 0 5.265582103675115e-07
was O 0 5.323324216988112e-07
7delG O 0 1.122028970712563e-05
/ O 0 9.965106983145233e-06
A464V O 0 3.340313196531497e-05
. O 0 7.02915883721289e-07

Mutation O 0 0.0002791963052004576
A464V O 0 1.935207546921447e-05
was O 0 7.820099199307151e-07
not O 0 1.0535301520064877e-08
found O 0 5.820233184294921e-09
in O 0 1.2292320494822206e-09
18 O 0 7.337930441053686e-08
unrelated O 0 1.55117061240162e-06
MLD B-Disease 1 0.9999998807907104
patients O 0 2.3009821234154515e-05
and O 0 4.188897761991939e-08
50 O 0 1.4038523943327164e-07
controls O 0 2.4184184439945966e-05
. O 0 4.7486804533036775e-07

A464V O 0 0.00020236740238033235
, O 0 3.110102966275008e-07
although O 0 3.860399644395329e-08
clearly O 0 1.386118810842163e-07
modifying O 0 6.339581659631222e-07
ARSA O 0 9.761007822817191e-05
and O 0 2.398994865870918e-06
GS O 1 1.0
levels O 0 0.00015847488248255104
, O 0 4.0572626147650226e-08
apparently O 0 1.5853331092330336e-07
bears O 0 1.942404814769816e-08
little O 0 2.33041341779483e-09
significance O 0 2.3782267266625468e-09
for O 0 2.1794632765193e-09
clinical O 0 1.16767841973342e-06
manifestation O 0 3.0111510795904906e-07
of O 0 5.53347057064002e-08
MLD B-Disease 1 1.0
, O 0 8.003320317584439e-08
mimicking O 0 6.152723017294193e-06
the O 0 1.5138321884933248e-07
frequent O 0 2.099776793329511e-05
ARSA O 0 0.02191310003399849
pseudodeficiency O 0 0.00014948791067581624
allele O 0 1.789490124792792e-05
. O 0 7.644997026545752e-07

Our O 0 1.1796686521847732e-05
results O 0 3.6712219753098907e-07
demonstrate O 0 4.627746008623035e-08
that O 0 7.55288331877324e-10
in O 0 4.538578957102857e-10
certain O 0 1.0849864118256392e-08
genetic O 0 3.649993959697895e-05
conditions O 0 0.0003581746423151344
MLD B-Disease 1 1.0
- O 0 0.00044464663369581103
like O 0 6.490701025541057e-07
ARSA O 0 0.0034187734127044678
and O 0 2.580380851213704e-06
GS O 1 0.9999998807907104
values O 0 9.327611678600078e-07
need O 0 8.421311292750033e-08
not O 0 4.7062713726120364e-09
be O 0 1.0347184220549366e-09
paralleled O 0 2.2210647543374762e-08
by O 0 3.1977034353758427e-09
clinical O 0 0.0033735584001988173
disease O 0 0.00014090795593801886
, O 0 6.634245930392524e-10
a O 0 3.171221285569459e-09
finding O 0 2.4227578165891828e-08
with O 0 1.1452857329175004e-08
serious O 0 2.0214636151649756e-06
diagnostic O 0 9.674826287664473e-05
and O 0 8.105246251943754e-07
prognostic O 0 0.0005499869585037231
implications O 0 6.383757863659412e-06
. O 0 3.5481590998642787e-07

Moreover O 0 1.7918451703735627e-05
, O 0 1.4372891143921152e-07
further O 0 3.204137328793877e-07
ARSA O 0 0.0007943453383632004
alleles O 0 5.9977260207233485e-06
functionally O 0 3.1907281936582876e-06
similar O 0 2.0018667612475838e-08
to O 0 1.8179324712264133e-08
A464V O 0 1.4121777667241986e-06
might O 0 2.7075705588686105e-07
exist O 0 5.523969193177436e-08
which O 0 1.196135457348646e-08
, O 0 1.694643980698629e-09
together O 0 1.990812847907364e-08
with O 0 5.106573386370883e-09
0 O 0 1.5833583120183903e-06
- O 0 0.00020949500321876258
type O 0 0.2314276546239853
mutations O 0 0.017824796959757805
, O 0 2.3631255174905164e-08
may O 0 1.330886050254776e-07
cause O 0 9.961394908941656e-08
pathological O 0 1.4733408306710771e-06
ARSA O 0 0.023186717182397842
and O 0 1.921642615343444e-05
GS O 1 1.0
levels O 0 0.00030695978784933686
, O 0 5.62211877053187e-09
but O 0 1.9944490503576162e-09
not O 0 1.140527050580431e-08
clinical O 0 4.635298864741344e-07
outbreak O 0 3.430915569424542e-07
of O 0 1.2579360886277868e-09
the O 0 2.7830517979055003e-07
disease O 0 0.0005927656311541796
. O 0 7.2489529934216534e-09
. O 0 7.922762534917638e-08

Human O 0 0.00047040428034961224
MLH1 O 1 0.9984447360038757
deficiency O 1 0.9012248516082764
predisposes O 0 0.00010092396405525506
to O 0 1.1570256219783914e-06
hematological B-Disease 1 0.9988605976104736
malignancy I-Disease 1 0.9961372017860413
and O 0 1.6165438410098432e-06
neurofibromatosis B-Disease 1 0.9974889755249023
type I-Disease 0 0.012327097356319427
1 I-Disease 0 1.1183988135599066e-06
. O 0 3.037657734239474e-07

Heterozygous O 0 0.0012577885063365102
germ O 0 0.001235672039911151
- O 0 0.00033617758890613914
line O 0 1.7812544683692977e-05
mutations O 0 1.1074024541812832e-06
in O 0 1.1506189334653527e-09
the O 0 1.3002756649171943e-09
DNA O 0 6.354993615786952e-07
mismatch O 0 3.102223126916215e-05
repair O 0 0.0001659783156355843
genes O 0 2.1550735255004838e-05
lead O 0 4.654222721001133e-06
to O 0 9.628549832996214e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 6.287599262577714e-06

The O 0 1.2338834949332522e-06
disease O 0 8.935060759540647e-05
susceptibility O 0 5.278594130686542e-07
of O 0 5.996940721786359e-09
individuals O 0 1.3723985148317297e-07
who O 0 9.952219670594786e-07
constitutionally O 0 3.354707223479636e-05
lack O 0 5.252952206546979e-08
both O 0 1.9719209376489744e-08
wild O 0 9.44807538871828e-08
- O 0 1.4607458979298826e-05
type O 0 0.0003011507506016642
alleles O 0 4.569445991364773e-06
is O 0 4.499571915062006e-08
unknown O 0 2.8487892222983646e-07
. O 0 4.7044792950146075e-08

We O 0 1.2315157619013917e-05
have O 0 5.456958263039269e-08
identified O 0 1.2065535770489078e-07
three O 0 6.166156918396837e-09
offspring O 0 1.9014962049368478e-07
in O 0 2.632597473350984e-09
a O 0 4.5734211084891285e-07
hereditary B-Disease 1 1.0
nonpolyposis I-Disease 1 1.0
colorectal I-Disease 1 1.0
cancer I-Disease 1 1.0
family O 0 1.5202906524791615e-06
who O 0 1.7501243121387233e-07
developed O 0 3.374215793883195e-06
hematological B-Disease 1 0.9846845865249634
malignancy I-Disease 0 0.24845565855503082
at O 0 1.8369114229699335e-07
a O 0 9.584966598197298e-09
very O 0 1.7791254691701397e-08
early O 0 7.766499976469277e-08
age O 0 1.0900631650656578e-06
, O 0 1.816479189287179e-09
and O 0 1.666406390654629e-08
at O 0 1.46501520248421e-07
least O 0 4.734298286734884e-09
two O 0 3.2691669371587295e-09
of O 0 5.343592790474361e-10
them O 0 9.081097651630898e-09
displayed O 0 4.597121687766048e-07
signs O 0 6.904209612912382e-07
of O 0 1.9066335177342353e-09
neurofibromatosis B-Disease 0 0.005474789068102837
type I-Disease 0 1.4919489331077784e-05
1 I-Disease 0 6.7450265817115e-08
( O 0 4.184425606013065e-08
NF1 B-Disease 0 1.2223714293213561e-05
) O 0 6.802235219538488e-08
. O 0 1.4036328366273665e-07

DNA O 0 7.676421773794573e-06
sequence O 0 3.1592125537827087e-07
analysis O 0 2.5469150344292757e-08
and O 0 6.826198273301998e-09
allele O 0 4.682072756168054e-07
- O 0 5.359220267564524e-07
specific O 0 3.1876631112481846e-08
amplification O 0 8.138319458339538e-07
in O 0 7.231566456766814e-09
two O 0 2.0761784469414124e-07
siblings O 0 2.750516614469234e-05
revealed O 0 9.66503648669459e-07
a O 0 1.336427573050969e-07
homozygous O 0 0.0002732572902459651
MLH1 O 0 0.00026682286988943815
mutation O 0 3.915773049811833e-06
( O 0 8.215397429012228e-08
C676T O 0 3.4423544548189966e-06
- O 0 7.804454071447253e-05
- O 0 0.00013215206854511052
> O 0 3.1324539122579154e-06
Arg226Stop O 0 2.2050595362088643e-05
) O 0 7.622298880960443e-08
. O 0 1.468068262511224e-07

Thus O 0 8.539599548385013e-06
, O 0 7.769655496758787e-08
a O 0 7.539087931718313e-08
homozygous O 0 3.545017898431979e-05
germ O 0 0.00018124103371519595
- O 0 0.00012592272832989693
line O 0 0.00010469981498317793
MLH1 O 0 0.0017197667621076107
mutation O 0 4.071273906447459e-06
and O 0 4.011157272998389e-08
consequent O 0 4.763315155287273e-05
mismatch O 1 0.9999102354049683
repair O 1 0.9999998807907104
deficiency O 1 0.9999992847442627
results O 0 4.556869953376008e-06
in O 0 3.1871325578691767e-09
a O 0 2.198460968827476e-08
mutator O 0 0.0001866707461886108
phenotype O 0 5.595938091573771e-06
characterized O 0 2.9334398732316913e-07
by O 0 1.1798258370276926e-08
leukemia B-Disease 0 0.013836749829351902
and O 0 1.047873638526653e-06
/ O 1 0.9996540546417236
or O 1 0.9999985694885254
lymphoma B-Disease 1 1.0
associated O 0 4.7804122004890814e-05
with O 0 2.5665266889518534e-07
neurofibromatosis B-Disease 1 0.9992524981498718
type I-Disease 0 0.029427293688058853
1 I-Disease 0 2.0811562251310534e-07
. O 0 1.4283928706504412e-08
. O 0 5.060095276121501e-08

Missense O 0 0.0012380335247144103
mutations O 0 0.0002912161871790886
in O 0 4.0758628472303826e-08
the O 0 3.4091289791149393e-09
most O 0 8.990286293197869e-10
ancient O 0 2.3142281424526345e-09
residues O 0 8.656557781705487e-08
of O 0 5.076165598971727e-10
the O 0 7.69815322598788e-09
PAX6 O 0 9.88127249001991e-06
paired O 0 1.0033834314526757e-06
domain O 0 8.791269578978245e-08
underlie O 0 3.130262768991088e-07
a O 0 6.104440064547134e-09
spectrum O 0 1.0243980597124391e-07
of O 0 1.0365955205315913e-08
human O 0 9.212190889229532e-06
congenital B-Disease 1 1.0
eye I-Disease 1 0.9999915361404419
malformations I-Disease 1 0.8967270255088806
. O 0 7.180782972682209e-07

Mutations O 0 6.236776243895292e-05
of O 0 2.1409247707993018e-08
the O 0 1.7515194628003883e-08
human O 0 7.698333348571396e-08
PAX6 O 0 7.775489939376712e-05
gene O 0 4.705808169092052e-05
underlie O 0 0.0069463239051401615
aniridia B-Disease 1 1.0
( O 0 0.00010781305172713473
congenital B-Disease 1 0.9999992847442627
absence I-Disease 0 1.9741580672416603e-06
of I-Disease 0 1.4563061867534088e-09
the I-Disease 0 1.3233424134284633e-08
iris I-Disease 0 2.155064976250287e-06
) O 0 3.6028668937149178e-09
, O 0 4.220378768682309e-10
a O 0 2.4826150024637172e-09
rare O 0 6.866630286594955e-08
dominant O 1 0.5644710659980774
malformation B-Disease 0 0.28410324454307556
of I-Disease 0 4.552322518946994e-09
the I-Disease 0 1.316432332032491e-07
eye I-Disease 1 0.7400151491165161
. O 0 5.090967647447542e-07

The O 0 1.5010748199983937e-07
spectrum O 0 3.163997348565317e-07
of O 0 1.4312973029007026e-08
PAX6 O 0 8.612859528511763e-05
mutations O 0 0.00010613769700285047
in O 0 7.630401199776315e-08
aniridia B-Disease 1 1.0
patients O 0 0.00016938117914833128
is O 0 1.7932084706018259e-09
highly O 0 7.19218462563731e-09
biased O 0 9.420432434126269e-07
, O 0 4.646493856341749e-09
with O 0 1.7434059751408881e-09
92 O 0 3.2882795153454936e-08
% O 0 2.3962942741206916e-09
of O 0 3.6462036168138923e-10
all O 0 1.0069051370464877e-08
reported O 0 1.0047067462437553e-06
mutations O 0 5.647319540003082e-06
leading O 0 2.2574666047603387e-07
to O 0 3.267005510565468e-08
premature O 0 1.7314160913883825e-06
truncation O 0 1.234472648548035e-07
of O 0 2.191660852801647e-09
the O 0 1.0512459347467029e-08
protein O 0 8.338469825730499e-08
( O 0 1.3019241684730787e-08
nonsense O 0 4.6102888973109657e-07
, O 0 3.153873162631271e-09
splicing O 0 1.1744837991045642e-07
, O 0 2.722627900908492e-09
insertions O 0 2.9504815302061616e-07
and O 0 3.604971965387449e-08
deletions O 0 6.943093922018306e-07
) O 0 1.3784619667944753e-08
and O 0 4.5835772510827155e-08
just O 0 1.2526864168194152e-07
2 O 0 1.01311208311472e-08
% O 0 9.068877204754244e-09
leading O 0 9.769316022811836e-09
to O 0 1.1464303950603494e-09
substitution O 0 7.067807672456183e-09
of O 0 2.1873132194372147e-09
one O 0 7.150864433924653e-08
amino O 0 3.7055457369206124e-07
acid O 0 4.6135212983244855e-08
by O 0 1.7385943795744652e-09
another O 0 2.223544370849595e-08
( O 0 1.0686503237877787e-08
missense O 0 2.758054051810177e-06
) O 0 1.9282449414959046e-08
. O 0 4.4858783354584375e-08

The O 0 1.2299260276904533e-07
extraordinary O 0 5.8710110550919126e-08
conservation O 0 1.2019352624292878e-08
of O 0 7.25713933391603e-10
the O 0 2.9498261611138332e-09
PAX6 O 0 2.2130823253974086e-06
protein O 0 5.171503048018167e-08
at O 0 2.6045400502994198e-08
the O 0 7.942822399797933e-09
amino O 0 2.38330983393098e-07
acid O 0 5.374426237381158e-08
level O 0 2.5211058130025776e-08
amongst O 0 2.4051880487263588e-08
vertebrates O 0 3.5986378321695156e-08
predicts O 0 1.0051670784605449e-07
that O 0 2.7787108169974317e-09
pathological O 0 8.730642662158061e-07
missense O 0 0.0001511403388576582
mutations O 0 0.0004977142089046538
should O 0 3.354156206114567e-07
in O 0 2.306952184838451e-09
fact O 0 1.7746721425737633e-08
be O 0 8.898253689437752e-09
common O 0 1.7825595222120683e-08
even O 0 4.285945109927525e-08
though O 0 2.1091443258569598e-08
they O 0 2.4509706264552733e-08
are O 0 5.4321982467797625e-09
hardly O 0 2.32373508879391e-07
ever O 0 7.957319212437142e-07
seen O 0 5.704207524104277e-06
in O 0 9.931855515787902e-08
aniridia B-Disease 1 1.0
patients O 0 4.7015426389407367e-05
. O 0 8.749015023568063e-08

This O 0 6.040146445229766e-07
indicates O 0 3.8475067754006886e-07
that O 0 2.9947651025707955e-09
there O 0 4.7889536780587605e-09
is O 0 8.346577873297178e-10
a O 0 3.9234118176523225e-09
heavy O 0 2.640280217747204e-05
ascertainment O 0 0.00011020677629858255
bias O 0 9.055414011527319e-06
in O 0 1.8318856431775998e-09
the O 0 5.477954756472059e-10
selection O 0 7.981604821516441e-10
of O 0 9.039876069927288e-10
patients O 0 3.5766994699315546e-08
for O 0 2.2127886190048685e-09
PAX6 O 0 7.781698514008895e-06
mutation O 0 5.169886208022945e-07
analysis O 0 4.227714711646513e-08
and O 0 4.4768182050347605e-08
that O 0 6.015189679686728e-09
the O 0 2.8291539777569596e-08
missing O 0 6.3828933889453765e-06
PAX6 O 0 0.0002335280878469348
missense O 0 0.00034586992114782333
mutations O 0 0.0005693337297998369
frequently O 0 3.257537173340097e-05
may O 0 2.4112985101965023e-06
underlie O 0 1.0777740499179345e-05
phenotypes O 0 1.1222173270653002e-05
distinct O 0 4.655669272324303e-07
from O 0 4.993070490399987e-08
textbook O 0 0.00030592820257879794
aniridia B-Disease 1 1.0
. O 0 1.6645501546008745e-06

Here O 0 3.1862462037679506e-06
we O 0 2.8291898956922523e-07
present O 0 2.2442431912850225e-08
four O 0 3.174999818611468e-08
novel O 0 1.6337239117092395e-07
PAX6 O 0 1.9954635718022473e-05
missense O 0 3.4506931115174666e-05
mutations O 0 7.347038626903668e-05
, O 0 7.66495400483791e-09
two O 0 5.4374229563336485e-09
in O 0 2.103009100196118e-09
association O 0 1.0029279629009125e-08
with O 0 6.1672627005293634e-09
atypical O 0 1.036956200550776e-05
phenotypes O 0 0.0001725162728689611
ectopia B-Disease 0 3.799729165621102e-05
pupillae I-Disease 0 4.5405919081531465e-05
( O 0 2.6082037862806828e-08
displaced B-Disease 0 7.784979771940925e-08
pupils I-Disease 0 2.2263168375502573e-06
) O 0 2.5538907877376005e-08
and O 0 1.0495058404558222e-06
congenital B-Disease 1 0.9999980926513672
nystagmus I-Disease 0 0.003582867095246911
( O 0 2.2308084268729544e-08
searching B-Disease 0 4.768730264004262e-07
gaze I-Disease 0 2.263387432321906e-05
) O 0 7.490880804539302e-09
, O 0 2.213468297540544e-09
and O 0 7.131017110140192e-09
two O 0 1.7699566257078914e-08
in O 0 2.88049895047493e-09
association O 0 9.755630081542677e-09
with O 0 4.0852938809621264e-09
more O 0 1.9541287699098575e-08
recognizable O 0 0.001431516371667385
aniridia B-Disease 1 0.9999998807907104
phenotypes O 0 8.883416012395173e-05
. O 0 3.923971974018059e-07

Strikingly O 0 0.00018547104264143854
, O 0 1.3732639558838855e-07
all O 0 4.388393204379781e-09
four O 0 1.074208810791788e-08
mutations O 0 6.308275146693632e-07
are O 0 3.4102867196850184e-09
located O 0 6.635540117372329e-09
within O 0 7.220692488374425e-09
the O 0 3.573588314154108e-09
PAX6 O 0 2.5906060727720615e-06
paired O 0 4.223205678499653e-07
domain O 0 6.291003273872775e-08
and O 0 3.796890624130356e-08
affect O 0 1.3566152290422906e-07
amino O 0 5.361965094152765e-08
acids O 0 5.925152368746467e-09
which O 0 7.999985673912136e-10
are O 0 6.073753167079587e-10
highly O 0 1.5030159339346483e-09
conserved O 0 3.044717811206965e-09
in O 0 3.72407327198232e-10
all O 0 1.2969219032044066e-09
known O 0 7.071664143154521e-09
paired O 0 1.1543304623273798e-07
domain O 0 5.696829674661785e-08
proteins O 0 9.673089351736053e-08
. O 0 5.733926400353084e-08

Our O 0 7.94151310401503e-06
results O 0 2.687653193333972e-07
support O 0 1.6504763777902554e-08
the O 0 3.073770349359961e-09
hypothesis O 0 2.1570741637333413e-08
that O 0 5.851240048038164e-10
the O 0 9.951548474163019e-10
under O 0 5.5054116820940635e-09
- O 0 4.087431193511293e-08
representation O 0 1.1111462860924348e-08
of O 0 4.031511569024815e-09
missense O 0 7.057193579385057e-05
mutations O 0 3.809467671089806e-05
is O 0 6.8820735776853326e-09
caused O 0 4.3772768520966565e-08
by O 0 3.5781033691506536e-09
ascertainment O 0 3.514281615935033e-06
bias O 0 3.104264351350139e-06
and O 0 4.420207488919914e-08
suggest O 0 2.2715754255386855e-07
that O 0 1.0077076950665287e-09
a O 0 4.116785135011014e-09
substantial O 0 3.2272751582240744e-08
burden O 0 6.156511744848103e-07
of O 0 3.6032448136325e-09
PAX6 B-Disease 0 0.000580633815843612
- I-Disease 0 0.04015669971704483
related I-Disease 0 3.551785630406812e-05
disease I-Disease 1 0.6812504529953003
remains O 0 1.1507955122169733e-07
to O 0 8.483391766844761e-09
be O 0 6.776348726589276e-08
uncovered O 0 5.363169748306973e-06
. O 0 1.0691457497102874e-08
. O 0 5.152913828965211e-08

The O 0 5.861896852366044e-07
chromosomal O 0 1.5150401850405615e-05
order O 0 4.2108304398880136e-08
of O 0 3.556690719719313e-09
genes O 0 6.929229243723967e-07
controlling O 0 1.552626940792834e-06
the O 0 5.495948141032159e-09
major O 0 1.6111366463178456e-08
histocompatibility O 0 3.59617189360506e-07
complex O 0 1.8197120255081245e-08
, O 0 1.5364184369204281e-09
properdin O 0 3.328761692955595e-07
factor O 0 9.564826086716494e-08
B O 0 9.808763024921063e-06
, O 0 5.621239029807157e-09
and O 0 2.7594222729021567e-07
deficiency B-Disease 0 3.9960518734005746e-06
of I-Disease 0 4.177850565501018e-10
the I-Disease 0 3.5565481670829513e-09
second I-Disease 0 1.2619300093774655e-07
component I-Disease 0 1.3611067117835773e-07
of I-Disease 0 4.110900508891291e-09
complement I-Disease 0 3.820318568159564e-07
. O 0 1.6393551049986854e-07

The O 0 1.876048258964147e-07
relationship O 0 8.75355539164957e-08
of O 0 8.665635986560005e-10
the O 0 7.404594160043132e-10
genes O 0 1.16325926668992e-08
coding O 0 6.535397290008405e-08
for O 0 2.034562074371138e-09
HLA O 0 2.304429500554761e-07
to O 0 4.217934002070933e-09
those O 0 6.251539286239449e-09
coding O 0 4.547985668068577e-07
for O 0 1.1841679636859226e-08
properdin O 0 4.7146299948508386e-06
Factor O 0 2.627838853186404e-07
B O 0 5.340024017641554e-06
allotypes O 0 6.97000871241471e-07
and O 0 1.990057363343567e-08
for O 0 1.537157956477131e-08
deficiency B-Disease 0 1.070670441549737e-05
of I-Disease 0 5.265385905062203e-10
the I-Disease 0 3.21409077130852e-09
second I-Disease 0 7.758031728144488e-08
component I-Disease 0 6.518229866969705e-08
of I-Disease 0 1.4423050531675585e-09
complement I-Disease 0 1.615602371884961e-07
( O 0 1.9945488816119905e-08
C2 O 0 1.0201050827163272e-05
) O 0 5.348112619429912e-09
was O 0 8.934852857578335e-09
studied O 0 2.363484963296969e-09
in O 0 4.279830378983718e-10
families O 0 8.948492502547367e-10
of O 0 3.8465922114205853e-10
patients O 0 1.034198433558231e-07
with O 0 6.823077569606539e-08
connective O 1 0.9999241828918457
tissue O 1 0.9999501705169678
disorders O 1 0.999915599822998
. O 0 6.059843826733413e-07

Patients O 1 0.9997947812080383
were O 0 2.7661119474942097e-06
selected O 0 6.172324873432444e-08
because O 0 1.77488885810817e-08
they O 0 1.5244598472463622e-08
were O 0 2.1414555462229146e-08
heterozygous O 0 4.852260531151842e-07
or O 0 9.045731275136859e-08
homozygous O 0 8.373508899239823e-05
for O 0 5.171782959223492e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
. O 0 4.1765559899431537e-07

12 O 0 2.2874848582432605e-05
families O 0 4.0797485212351603e-07
with O 0 1.1206346073322493e-08
15 O 0 2.0270794820476112e-08
matings O 0 1.12800501028687e-06
informative O 0 1.3360710909182671e-05
for O 0 0.0016773390816524625
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
were O 0 8.42946974444203e-06
found O 0 2.3547528371636872e-07
. O 0 6.631367455156578e-08

Of O 0 3.537091117777891e-07
57 O 0 2.1536166059377138e-06
informative O 0 2.336796342206071e-06
meioses O 0 1.4729595932294615e-05
, O 0 8.085743630203979e-09
two O 0 3.6475342746200567e-09
crossovers O 0 5.16321506438544e-07
were O 0 4.2884553863586916e-07
noted O 0 1.8549231484144002e-08
between O 0 1.9044829713266154e-08
the O 0 9.150244295597076e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 0.9999994039535522
gene O 0 3.057531614558684e-07
and O 0 1.0078081480457968e-08
the O 0 1.0257427796034335e-08
HLA O 0 1.8784951407724293e-06
- O 0 3.030645711987745e-05
B O 0 2.2999816792435013e-05
gene O 0 1.2533604376585572e-07
, O 0 1.409633298976587e-09
with O 0 2.9367949738734467e-10
a O 0 1.9477646162613382e-09
recombinant O 0 9.04155417202901e-09
fraction O 0 1.666705173875016e-08
of O 0 6.233393801124976e-09
0 O 0 7.928368859211332e-07
. O 0 2.103544289866477e-07

035 O 0 0.033643025904893875
. O 0 5.4087257012724876e-05

A O 0 1.0053459845948964e-05
lod O 0 0.0001934851024998352
score O 0 1.1047579391743056e-05
of O 0 1.3664986475703245e-08
13 O 0 3.4781006519324364e-08
was O 0 4.921513863109794e-08
calculated O 0 4.8548983500040777e-08
for O 0 1.9449322152809145e-09
linkage O 0 3.086883225478232e-05
between O 0 0.0007769782678224146
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.7488696357759181e-07
HLA O 0 1.2419408221830963e-06
- O 0 4.937742050969973e-05
B O 0 5.547247201320715e-05
at O 0 1.6707282668448897e-08
a O 0 2.4619142280357664e-09
maximum O 0 6.660837659211438e-09
likelihood O 0 9.546615054034646e-09
value O 0 4.2734188410165075e-10
of O 0 8.250591876368674e-11
the O 0 5.856019003047663e-10
recombinant O 0 4.443019285815808e-09
fraction O 0 1.8292540815423308e-08
of O 0 5.968264993327921e-09
0 O 0 6.161650958347309e-07
. O 0 1.700827283457329e-07

04 O 0 0.010816565714776516
. O 0 3.109806129941717e-05

18 O 0 9.016759577207267e-05
families O 0 4.315553780998016e-07
with O 0 1.222137413492419e-08
21 O 0 2.613048621924463e-08
informative O 0 5.641467382133669e-08
matings O 0 6.392241402863874e-07
for O 0 4.8355994763937815e-09
both O 0 4.281353227497675e-08
properdin O 0 2.9439761419780552e-06
Factor O 0 1.2673210392222245e-07
B O 0 1.2354765885902452e-06
allotype O 0 4.119859795537195e-07
and O 0 5.06130213295819e-08
HLA O 0 3.5712507724383613e-06
- O 0 0.0011030848836526275
B O 0 0.004053937736898661
were O 0 2.16447659795449e-07
found O 0 1.271981489026075e-07
. O 0 4.698184241647141e-08

Of O 0 6.550447437803086e-07
72 O 0 3.2295465643983334e-06
informative O 0 1.6107529745568172e-06
meioses O 0 1.167052050732309e-05
, O 0 1.6547444303682823e-08
three O 0 2.0984465720630396e-08
recombinants O 0 7.843844286981039e-06
were O 0 1.927610810525948e-06
found O 0 2.2851528669320942e-08
, O 0 6.048780920586694e-10
giving O 0 9.694136604565529e-10
a O 0 7.644421762265097e-10
recombinant O 0 5.974119421381374e-09
fraction O 0 1.3897583528432733e-08
of O 0 7.167643811811786e-09
0 O 0 8.032451432882226e-07
. O 0 1.843960291125768e-07

042 O 0 0.0034675204660743475
. O 0 2.974569724756293e-05

A O 0 8.039164640649687e-06
lod O 0 7.233030919451267e-05
score O 0 3.6698500025522662e-06
of O 0 3.6179548246195736e-09
16 O 0 2.9161785874975976e-08
between O 0 8.263577377931597e-09
HLA O 0 7.81148287387623e-07
- O 0 1.4458292753261048e-05
B O 0 2.00996710191248e-05
and O 0 2.1500502711546687e-08
Factor O 0 1.1434134705723409e-07
B O 0 1.7940633370017167e-06
allotypes O 0 7.853042234273744e-07
was O 0 1.0678662931695726e-07
calculated O 0 7.030379123307284e-08
at O 0 1.08637596696326e-08
a O 0 1.668415516853372e-09
maximum O 0 8.434311915550552e-09
likelihood O 0 1.4053039620876007e-08
value O 0 1.1377301323278743e-09
of O 0 1.702613050547086e-10
the O 0 6.653735340478306e-10
recombinant O 0 6.231587246219306e-09
fraction O 0 2.380106600696763e-08
of O 0 8.115501159977612e-09
0 O 0 1.037701281347836e-06
. O 0 1.3587153091521031e-07

04 O 0 0.009966900572180748
. O 0 2.5300343622802757e-05

A O 0 1.7283510942434077e-06
crossover O 0 5.354806376089982e-07
was O 0 2.788990229873889e-07
shown O 0 2.094124162965727e-08
to O 0 4.838671685547524e-09
have O 0 1.3365761830641532e-08
occurred O 0 1.6012657866326663e-08
between O 0 1.0897456270697603e-09
genes O 0 2.1852752496442918e-08
for O 0 6.950614528378196e-10
Factor O 0 3.576283447159767e-08
B O 0 7.043398113637522e-07
and O 0 1.4222814037623266e-08
HLA O 0 5.967675633655745e-07
- O 0 1.4311631275631953e-05
D O 0 1.6463583961012773e-05
, O 0 4.411580434293683e-09
in O 0 1.0001327543918137e-09
which O 0 4.867979352951579e-09
HLA O 0 6.867232400509238e-07
- O 0 5.865845196240116e-06
D O 0 5.218448222876759e-06
segregared O 0 4.4020515588272247e-07
with O 0 9.42866584807689e-09
HLA O 0 1.1315271422063233e-06
- O 0 1.186182998935692e-06
A O 0 2.0857022775544465e-07
and O 0 1.4057816599688522e-07
B O 0 1.532654459879268e-05
. O 0 6.93029988951821e-08

These O 0 3.418892333684198e-07
studies O 0 5.38933093707783e-08
suggest O 0 2.646994090582666e-08
that O 0 3.6232358779919593e-10
the O 0 2.777215402094413e-10
genes O 0 5.116820300798963e-09
for O 0 8.014433561243095e-10
Factor O 0 2.6856420731746766e-07
B O 0 0.17590788006782532
and O 0 0.026979554444551468
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
are O 0 5.583636220052313e-09
located O 0 5.216188370127384e-09
outside O 0 1.2887851674747708e-08
those O 0 1.0588419030455043e-09
for O 0 6.765107363193579e-10
HLA O 0 1.4053286179205315e-07
, O 0 3.441546825300179e-09
that O 0 3.604390674816216e-10
the O 0 5.359475641064648e-10
order O 0 9.379782506258039e-10
of O 0 2.8317154177059933e-10
genese O 0 1.8349155084251834e-07
is O 0 2.5518054336259866e-09
HLA O 0 9.263689548788534e-08
- O 0 5.121495405546739e-07
A O 0 2.4936983322731976e-07
, O 0 9.561010649861146e-09
- O 0 1.439372908862424e-06
B O 0 5.292615242069587e-06
, O 0 5.280564874254878e-09
- O 0 2.9455193839567073e-07
D O 0 1.0228366136288969e-06
, O 0 3.1324227656170933e-09
Factor O 0 5.578082351576086e-08
B O 0 3.4230397432111204e-06
allotype O 0 1.7808757547754794e-05
, O 0 5.5880136642372236e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
, O 0 3.297649042721673e-09
that O 0 3.705848683477342e-10
the O 0 1.3489147576706273e-09
genes O 0 6.013780762259557e-08
coding O 0 1.5569551123917336e-06
for O 0 6.238848072825931e-06
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
and O 0 1.7751351322203845e-07
Factor O 0 3.716463936598302e-07
B O 0 7.950242434162647e-06
allotypes O 0 7.124955914150632e-07
are O 0 3.8737182350701005e-09
approximately O 0 6.9902634791674245e-09
3 O 0 2.1097436686545734e-08
- O 0 2.3106074422685197e-06
- O 0 1.26086695217964e-06
5 O 0 2.2810290545294265e-08
centimorgans O 0 2.3575412910759042e-07
from O 0 2.7389777113029368e-09
the O 0 3.447058860572838e-09
HLA O 0 1.6050320539306995e-07
- O 0 2.0058843119841185e-07
A O 0 4.7589534091230234e-08
and O 0 4.8278334219276076e-08
HLA O 0 1.2255417232154286e-06
- O 0 5.1225142669864e-06
B O 0 1.2963879498784081e-06
loci O 0 3.208922549902127e-08
, O 0 7.589664452467559e-10
and O 0 5.733887809000748e-10
that O 0 1.5655737817255044e-10
the O 0 5.55285484260537e-10
apparent O 0 1.689268458449078e-08
lack O 0 8.179681820763562e-09
of O 0 5.01249319828645e-10
recombinants O 0 1.3570370072102378e-07
between O 0 1.7509874661314484e-09
the O 0 3.4520721836628354e-09
Factor O 0 6.499409010984891e-08
B O 0 1.1214363439648878e-05
gene O 0 1.7877746358863078e-06
and O 0 0.014097943902015686
C2 B-Disease 1 1.0
deficiency I-Disease 1 1.0
gene O 0 9.192613106279168e-07
suggests O 0 3.5810685972137435e-08
that O 0 5.336869834948743e-10
these O 0 7.72727715148136e-10
two O 0 5.853297402325097e-09
genes O 0 7.336740281971288e-07
lie O 0 1.443434757675277e-05
in O 0 5.7104472261926276e-09
close O 0 8.773209287937789e-07
proximity O 0 4.015949741642544e-07
to O 0 9.776086073998158e-08
one O 0 1.5611985304531117e-07
another O 0 4.7530573965559597e-07
. O 0 1.5627416871666355e-07

Distribution O 0 1.3230593367552501e-06
of O 0 4.632753203281936e-08
emerin O 0 4.729319243779173e-06
and O 0 5.2306571518556666e-08
lamins O 0 1.110086031985702e-05
in O 0 7.472415575193736e-09
the O 0 1.9777669280074406e-08
heart O 0 7.432673783114296e-07
and O 0 7.76825981319007e-09
implications O 0 6.5141783522904e-08
for O 0 5.205752273695907e-09
Emery B-Disease 0 0.00016384138143621385
- I-Disease 1 0.5934597253799438
Dreifuss I-Disease 1 0.9985820055007935
muscular I-Disease 1 0.9208081364631653
dystrophy I-Disease 1 0.8961526155471802
. O 0 1.0603703231026884e-06

Emerin O 0 0.0009035501279868186
is O 0 3.476224605947209e-07
a O 0 5.6501683332044195e-08
nuclear O 0 1.0007457831306965e-06
membrane O 0 1.4753021559954504e-07
protein O 0 7.3038044945406e-08
which O 0 1.5463916369640174e-08
is O 0 4.634456374219553e-09
missing O 0 2.720439624681603e-07
or O 0 1.1896741369810115e-07
defective O 0 2.3269039957085624e-05
in O 0 1.6567023308766693e-08
Emery B-Disease 0 0.00024228110851254314
- I-Disease 0 0.32336926460266113
Dreifuss I-Disease 1 0.9992103576660156
muscular I-Disease 1 0.9990366697311401
dystrophy I-Disease 1 0.9999194145202637
( O 0 8.549671292712446e-06
EDMD B-Disease 1 1.0
) O 0 3.031666722108639e-07
. O 0 8.748481405973507e-08

It O 0 4.2449133275113127e-07
is O 0 5.176898909553529e-09
one O 0 1.3867126336108981e-09
member O 0 1.9036032750108234e-09
of O 0 1.9378475213382984e-10
a O 0 3.4265934534261078e-09
family O 0 1.1007069922186474e-08
of O 0 1.0185774446114237e-09
lamina O 0 1.2227421848365339e-06
- O 0 2.1071507944725454e-05
associated O 0 1.1935298971366137e-07
proteins O 0 8.772906845422312e-09
which O 0 2.1839408059776133e-09
includes O 0 6.475056490984343e-09
LAP1 O 0 3.0588578283641255e-06
, O 0 5.819678072782608e-09
LAP2 O 0 1.7743221860655467e-06
and O 0 3.1768411901111904e-08
lamin O 0 3.824201849056408e-05
B O 0 0.0005840473459102213
receptor O 0 1.879466367427085e-06
( O 0 1.56615698188034e-07
LBR O 0 0.0002011559990933165
) O 0 1.782455001375638e-07
. O 0 1.445173012371015e-07

A O 0 2.450927240715828e-06
panel O 0 4.494468441862409e-07
of O 0 1.7943383667784474e-08
16 O 0 1.187216938092206e-07
monoclonal O 0 5.038810968471807e-07
antibodies O 0 6.486937991212471e-07
( O 0 1.0803772987344473e-08
mAbs O 0 5.968575464976311e-07
) O 0 6.80329614866082e-09
has O 0 2.537623000620215e-09
been O 0 4.264773423301449e-09
mapped O 0 1.02647128130684e-07
to O 0 6.2484639684612375e-09
six O 0 1.6469105190708433e-08
specific O 0 6.203741520494077e-09
sites O 0 9.592468330765769e-08
throughout O 0 1.6343308928412625e-08
the O 0 4.374128170780978e-09
emerin O 0 2.0193775185362028e-07
molecule O 0 9.826089275577488e-09
using O 0 2.203569948733275e-08
phage O 0 1.9639696802187245e-07
- O 0 4.928836574435991e-07
displayed O 0 5.8828259597021315e-08
peptide O 0 1.1979711445064822e-08
libraries O 0 3.5605933756954755e-09
and O 0 4.9431112536524324e-09
has O 0 3.1102995734499927e-09
been O 0 2.250908348599978e-09
used O 0 5.236703515265617e-09
to O 0 5.9054308110262355e-09
localize O 0 7.301105597434798e-06
emerin O 0 7.527946308982791e-06
in O 0 7.412482627700001e-09
human O 0 1.2838953011851117e-08
and O 0 1.2579479857777187e-07
rabbit O 0 9.643822704674676e-05
heart O 0 2.8265783839742653e-05
. O 0 1.1193831994660286e-07

Several O 0 1.078679474630917e-06
mAbs O 0 2.53057514782995e-05
against O 0 9.908242759593122e-08
different O 0 1.9985971988489837e-08
emerin O 0 3.3866178910102462e-06
epitopes O 0 1.8134322772311862e-06
did O 0 4.3119626980114845e-07
not O 0 1.8819791947066733e-08
recognize O 0 6.403919883268827e-08
intercalated O 0 2.737039608291525e-07
discs O 0 1.0872717211896088e-05
in O 0 1.6838832550547522e-08
the O 0 3.9573393451064476e-08
heart O 0 1.0807090120579232e-06
, O 0 3.742196774680906e-09
though O 0 7.3522170573880885e-09
they O 0 9.12478181902543e-09
recognized O 0 1.5937427377821223e-08
cardiomyocyte O 0 3.4257791980962793e-07
nuclei O 0 5.655861556874697e-08
strongly O 0 6.759038484460689e-08
, O 0 3.076398025214644e-09
both O 0 1.1762061546960467e-08
at O 0 2.059661881048669e-07
the O 0 4.99287722277586e-09
rim O 0 1.3242998875284684e-07
and O 0 8.476954249658775e-09
in O 0 2.3342479060772803e-09
intranuclear O 0 6.665833893748641e-07
spots O 0 2.814649178617401e-06
or O 0 9.86624471011055e-08
channels O 0 1.700901634649199e-06
. O 0 1.5809939668542938e-07

A O 0 1.9835844796034507e-05
polyclonal O 0 0.00021641544299200177
rabbit O 0 4.141604949836619e-05
antiserum O 0 3.053357431781478e-05
against O 0 2.462444399498054e-07
emerin O 0 5.799065547762439e-06
did O 0 2.657060633737274e-07
recognize O 0 1.0138354156197238e-07
both O 0 4.032113309904162e-08
nuclear O 0 2.26923998525308e-06
membrane O 0 2.408879709037137e-07
and O 0 1.8652972499921816e-08
intercalated O 0 1.5756805282762798e-07
discs O 0 7.86049167800229e-06
but O 0 1.118915733400172e-07
, O 0 1.1067251559637725e-09
after O 0 1.9208290513716975e-09
affinity O 0 5.749924092413039e-09
purification O 0 2.0455788174444933e-08
against O 0 1.2763993417763686e-08
a O 0 1.6858049178836154e-08
pure O 0 1.330283225797757e-07
- O 0 1.8944703697343357e-05
emerin O 0 1.3227806448412593e-05
band O 0 1.3561081857460522e-07
on O 0 3.5957683497400694e-09
a O 0 8.29392643453275e-09
western O 0 3.6227419286660734e-08
blot O 0 0.00011740151967387646
, O 0 3.1698444757921607e-08
it O 0 6.644659045207391e-09
stained O 0 9.571509872330353e-05
only O 0 2.500398821325689e-08
the O 0 8.991131394964214e-09
nuclear O 0 1.5090237184267608e-06
membrane O 0 6.465278374889749e-07
. O 0 1.8817679858784686e-07

These O 0 1.2283301202842267e-06
results O 0 5.368114557313675e-07
would O 0 2.642116214701673e-08
not O 0 9.274487844379564e-09
be O 0 3.1167488590000403e-09
expected O 0 3.4776082014076337e-09
if O 0 3.590628017136055e-09
immunostaining O 0 3.632051459590002e-07
at O 0 6.312313161060956e-08
intercalated O 0 6.631620408370509e-08
discs O 0 2.4457449399051256e-05
were O 0 2.09612380785984e-06
due O 0 1.7941092167461647e-08
to O 0 2.3899768830659696e-09
a O 0 1.0097765290595362e-08
product O 0 2.3542627403116967e-08
of O 0 2.3470955734516963e-10
the O 0 8.906484438853113e-10
emerin O 0 2.610680667203269e-07
gene O 0 6.846607902843971e-08
and O 0 2.199660542601123e-08
, O 0 3.6336880171461416e-09
therefore O 0 7.617106945190244e-09
, O 0 4.889015858822177e-10
cast O 0 5.19242711050083e-08
some O 0 1.2405282356908742e-09
doubt O 0 1.2199178556215884e-08
upon O 0 5.508528633235699e-10
the O 0 1.0200394973125526e-09
hypothesis O 0 7.131074397648263e-08
that O 0 3.016539906752769e-08
cardiac B-Disease 0 0.004368260037153959
defects I-Disease 1 0.9955247640609741
in O 0 2.302628132611062e-07
EDMD B-Disease 1 1.0
are O 0 5.019806849304587e-06
caused O 0 6.700845460727578e-07
by O 0 6.57511689539092e-09
absence O 0 1.375048839236115e-07
of O 0 4.075876081088836e-09
emerin O 0 1.7428705177735537e-05
from O 0 6.839508159828256e-08
intercalated O 0 5.865386810910422e-06
discs O 0 0.0001856085000326857
. O 0 1.249164029104577e-06

Although O 0 3.4526453873695573e-06
emerin O 0 1.6689798940205947e-05
was O 0 1.6351516762824758e-07
abundant O 0 1.9658637384623034e-08
in O 0 1.1371096286794113e-09
the O 0 1.9610053580976228e-09
membranes O 0 2.1368374802932522e-07
of O 0 1.1590461923560724e-09
cardiomyocyte O 0 1.48172205172159e-06
nuclei O 0 1.8174060301134887e-07
, O 0 6.819431686011512e-09
it O 0 4.371976114470044e-09
was O 0 2.0652204568705201e-07
absent O 0 3.139769688687011e-08
from O 0 6.268730534664257e-10
many O 0 2.0801900202371826e-09
non O 0 9.239766995960963e-07
- O 0 1.0121250852535013e-05
myocyte O 0 1.2258456081326585e-05
cells O 0 1.3922581842962245e-07
in O 0 4.312478374401962e-09
the O 0 2.5696683891851535e-08
heart O 0 2.2376539163815323e-06
. O 0 6.469898750083303e-08

This O 0 8.19242629290784e-08
distribution O 0 2.8453564837604972e-08
of O 0 2.532111187392161e-09
emerin O 0 1.3760525234829402e-06
was O 0 2.583753833107494e-08
similar O 0 1.5221723881353455e-09
to O 0 1.4290816308104581e-09
that O 0 9.69827995689343e-10
of O 0 1.2441678798325029e-09
lamin O 0 3.596189571908326e-06
A O 0 2.44155529571799e-07
, O 0 1.5498869965213657e-09
a O 0 1.3259744413574026e-09
candidate O 0 2.3007615368442202e-08
gene O 0 2.7624205145571068e-08
for O 0 3.305336282455329e-10
an O 0 3.2529205995501798e-09
autosomal O 0 6.366458546835929e-05
form O 0 1.660694010752195e-06
of O 0 4.906695494355517e-07
EDMD B-Disease 1 1.0
. O 0 2.45015371547197e-06

In O 0 7.205258043541107e-07
contrast O 0 4.448915262855735e-07
, O 0 3.942963999747917e-08
lamin O 0 0.00011855033517349511
B1 O 0 0.15249989926815033
was O 0 1.1471394145701197e-06
absent O 0 3.5774368711827265e-07
from O 0 5.510065292924082e-09
cardiomyocyte O 0 1.1027852906408953e-06
nuclei O 0 1.5531318808825745e-07
, O 0 5.139277448051871e-09
showing O 0 1.9600460632318573e-07
that O 0 3.260958836293071e-09
lamin O 0 1.416062059433898e-05
B1 O 0 0.0009486113558523357
is O 0 5.56154944320042e-09
not O 0 2.556960199129321e-09
essential O 0 3.6189828911403765e-09
for O 0 3.795235792303231e-10
localization O 0 8.576571275398237e-08
of O 0 1.882882960657639e-09
emerin O 0 9.932610964824562e-07
to O 0 1.037325247921217e-08
the O 0 3.443380691692255e-08
nuclear O 0 1.4588917110813782e-05
lamina O 0 7.385759545286419e-06
. O 0 1.6688100856754318e-07

Lamin O 0 0.11007923632860184
B1 O 1 0.9644238948822021
is O 0 8.326397846758482e-07
also O 0 9.972458769880177e-08
almost O 0 1.5277642262390145e-07
completely O 0 1.8320320123166312e-06
absent O 0 2.646509926762519e-07
from O 0 1.006563365990587e-08
skeletal O 0 1.5623943909304217e-05
muscle O 0 1.1990740858891513e-05
nuclei O 0 4.921363597532036e-06
. O 0 2.975154131945601e-07

In O 0 6.5668054958223365e-06
EDMD B-Disease 1 0.9999997615814209
, O 0 2.1296431285122708e-08
the O 0 1.0886985757352363e-09
additional O 0 3.5055385261273386e-09
absence O 0 2.9657538647143156e-08
of O 0 1.968883278635758e-09
lamin O 0 9.387372119817883e-05
B1 O 0 0.12793822586536407
from O 0 3.991695152194552e-08
heart O 0 1.2757745935232379e-06
and O 0 3.684989025032337e-08
skeletal O 0 3.764448410947807e-05
muscle O 0 3.933450443582842e-06
nuclei O 0 3.094260137004312e-07
which O 0 2.2882975514448844e-08
already O 0 3.511567285841011e-07
lack O 0 1.8729107864601247e-07
emerin O 0 1.473951488151215e-05
may O 0 1.7235220184375066e-07
offer O 0 2.6250612794598283e-09
an O 0 7.644917476845592e-10
alternative O 0 2.2304595503896962e-08
explanation O 0 7.991785011540742e-09
of O 0 7.831542636616007e-10
why O 0 1.4875645604206511e-08
these O 0 6.655236806096809e-09
tissues O 0 9.210980920215661e-07
are O 0 1.1630063134759894e-08
particularly O 0 3.526584535507027e-08
affected O 0 1.4139726545181475e-07
. O 0 7.076899510849444e-09
. O 0 4.0134839451866355e-08

Genetic O 0 1.742644417390693e-05
mapping O 0 3.1136960387811996e-06
of O 0 3.46843549436926e-08
the O 0 1.0451007170786397e-07
copper B-Disease 0 4.8132056690519676e-05
toxicosis I-Disease 0 0.00011992861254839227
locus O 0 3.526525460983976e-06
in O 0 4.2726327365016914e-08
Bedlington O 0 7.080343948473455e-06
terriers O 0 7.390938208118314e-06
to O 0 1.732345644711586e-08
dog O 0 6.607482646359131e-05
chromosome O 0 0.0011770708952099085
10 O 0 1.907879294549275e-07
, O 0 2.9763151943029698e-09
in O 0 7.72875097254655e-10
a O 0 9.59612567186241e-09
region O 0 9.04010875046879e-08
syntenic O 0 1.4281362155088573e-06
to O 0 7.0719745615122065e-09
human O 0 4.329045211193261e-08
chromosome O 0 1.4724174434377346e-05
region O 0 5.820130013489688e-07
2p13 O 0 1.3413947272056248e-05
- O 0 2.862529618141707e-05
p16 O 0 2.322977343283128e-05
. O 0 8.786070111455047e-07

Abnormal O 1 0.9999464750289917
hepatic B-Disease 1 0.9998121857643127
copper I-Disease 0 0.0051580979488790035
accumulation I-Disease 0 3.536575150064891e-06
is O 0 9.17637343889055e-09
recognized O 0 1.3306901358589585e-08
as O 0 7.1960544190119435e-09
an O 0 9.432481817839289e-08
inherited B-Disease 1 1.0
disorder I-Disease 1 1.0
in O 0 1.804401073002282e-08
man O 0 7.043559548947087e-07
, O 0 1.7184308420681305e-09
mouse O 0 2.361760778057942e-07
, O 0 5.44603784291553e-09
rat O 0 1.676675992712262e-06
and O 0 5.1392998301480475e-08
dog O 0 5.714975850423798e-05
. O 0 3.344474635014194e-07

The O 0 1.709380654801862e-07
major O 0 1.2386827563659608e-07
cause O 0 2.8517737860056513e-07
of O 0 7.301558468952862e-09
hepatic B-Disease 0 0.002736200112849474
copper I-Disease 0 0.004690972622483969
accumulation I-Disease 0 1.9768276615650393e-06
in O 0 1.1288380896701256e-08
man O 0 6.401245968845615e-07
is O 0 9.285492930111161e-10
a O 0 6.538586116988654e-09
dysfunctional O 0 3.860749529849272e-06
ATP7B O 0 5.120106379763456e-06
gene O 0 1.0345806913392153e-06
, O 0 1.739839028402912e-08
causing O 0 1.5694223520767991e-06
Wilson B-Disease 0 0.0001647856697672978
disease I-Disease 0 0.009164316579699516
( O 0 5.995216412202353e-08
WD B-Disease 0 0.00269419071264565
) O 0 1.915872616109482e-07
. O 0 1.9249455363024026e-07

Mutations O 0 0.0004405527433846146
in O 0 2.667434095826593e-08
the O 0 6.801791130328638e-09
ATP7B O 0 1.2186573030703585e-06
genes O 0 2.2711488156801352e-07
have O 0 2.452775760275472e-08
also O 0 9.310858750666284e-09
been O 0 2.211447913680331e-08
demonstrated O 0 3.1530311694893953e-09
in O 0 6.820625175762984e-10
mouse O 0 2.931138283202017e-07
and O 0 1.4818617444234405e-07
rat O 0 1.9664767023641616e-05
. O 0 1.69361797475176e-07

The O 0 8.970714020506421e-07
ATP7B O 0 1.3315668184077367e-05
gene O 0 1.1955286254305975e-06
has O 0 3.3893815754026946e-08
been O 0 3.7553046894345243e-08
excluded O 0 7.188703676774821e-08
in O 0 5.297601246567751e-10
the O 0 6.13471440313873e-10
much O 0 2.760412343150165e-09
rarer O 0 3.638284624685184e-07
human O 0 1.4215999044608907e-07
copper B-Disease 0 0.002300191204994917
overload I-Disease 0 0.09723987430334091
disease O 0 0.020614197477698326
non B-Disease 0 1.0368395123805385e-05
- I-Disease 0 4.156120849074796e-05
Indian I-Disease 0 6.871326831969782e-07
childhood I-Disease 0 0.3239075243473053
cirrhosis I-Disease 1 0.8056212663650513
, O 0 3.155120253950372e-08
indicating O 0 3.1631091133021982e-06
genetic O 0 2.360622602282092e-05
heterogeneity O 0 1.8750244635157287e-05
. O 0 8.920346772356424e-07

By O 0 2.1310822262421425e-07
investigating O 0 1.7260336448998714e-07
the O 0 1.33544215685788e-08
common O 0 4.3809856720145035e-07
autosomal O 1 0.5270996689796448
recessive O 1 0.9973750114440918
copper B-Disease 0 0.002016952959820628
toxicosis I-Disease 0 0.001722161308862269
( O 0 8.253751815345822e-08
CT B-Disease 0 4.1261435399064794e-05
) O 0 8.956658525960393e-09
in O 0 2.8151896369621454e-09
Bedlington O 0 4.812214228877565e-06
terriers O 0 7.526435365434736e-05
, O 0 2.6138762265759397e-08
we O 0 6.647246664215345e-08
have O 0 5.6991744656897936e-09
identified O 0 1.0744732215073327e-08
a O 0 5.578353334811936e-10
new O 0 5.613018938532832e-10
locus O 0 2.063830351062279e-07
involved O 0 4.4193139814296956e-08
in O 0 9.800300659890127e-08
progressive O 1 0.9999657869338989
liver B-Disease 1 1.0
disease I-Disease 1 1.0
. O 0 1.1270007007624372e-06

We O 0 3.8059361031628214e-06
examined O 0 1.5990979136404349e-06
whether O 0 4.768166661506257e-08
the O 0 1.665272009176988e-08
WD B-Disease 0 0.0001458888582419604
gene O 0 4.34491357736988e-06
ATP7B O 0 2.2062564312363975e-05
was O 0 2.049207239451789e-07
also O 0 5.419551474261652e-09
causative O 0 2.1606818734198896e-07
for O 0 1.6591776841323735e-09
CT B-Disease 0 9.288800356443971e-06
by O 0 7.112420874477721e-09
investigating O 0 4.031544165172818e-08
the O 0 1.565760499033786e-08
chromosomal O 0 0.0004229148617014289
co O 0 5.033157140132971e-05
- O 0 1.4471509075519862e-06
localization O 0 1.5366557590823504e-06
of O 0 1.7641964333847682e-08
ATP7B O 0 4.493972483032849e-06
and O 0 2.5310697537861415e-08
C04107 O 0 1.9454456889889116e-07
, O 0 8.024513831195179e-10
using O 0 2.3639716850709647e-09
fluorescence O 0 3.085772704025658e-08
in O 0 2.0542068046580653e-09
situ O 0 2.838445993802452e-07
hybridization O 0 6.766519788925507e-08
( O 0 3.099233225611897e-08
FISH O 0 1.5898874039521615e-07
) O 0 3.001566284410728e-08
. O 0 9.671281731016279e-08

C04107 O 0 0.00046778307296335697
is O 0 5.063108119429671e-07
an O 0 3.91108549990804e-08
anonymous O 0 1.210918298966135e-06
microsatellite O 0 2.6090054234373383e-05
marker O 0 1.725623951642774e-05
closely O 0 1.6823123587528244e-06
linked O 0 6.147754902485758e-06
to O 0 8.291130626503218e-08
CT B-Disease 0 0.042828746140003204
. O 0 2.622305999011587e-07

However O 0 6.7534333538787905e-06
, O 0 2.594265424704645e-07
BAC O 0 8.583915769122541e-05
clones O 0 4.884332156507298e-06
containing O 0 3.4982070928890607e-07
ATP7B O 0 9.552485607855488e-06
and O 0 5.140456593721865e-08
C04107 O 0 6.501356324406515e-07
mapped O 0 1.1013516996172257e-06
to O 0 1.5182992640916382e-08
the O 0 1.4911494261582448e-08
canine O 0 0.00010268140613334253
chromosome O 0 0.0006351506453938782
regions O 0 1.9371011603652732e-06
CFA22q11 O 0 4.762929165735841e-05
and O 0 2.0389069277371163e-07
CFA10q26 O 0 5.168010829947889e-06
, O 0 6.0452438610525405e-09
respectively O 0 5.1753811902699454e-08
, O 0 1.0244166626094398e-09
demonstrating O 0 5.636495714611556e-09
that O 0 3.0978901666145475e-09
WD B-Disease 0 0.00013912294525653124
cannot O 0 3.5246083029960573e-07
be O 0 3.5023040023673957e-09
homologous O 0 8.65421441176295e-08
to O 0 6.995601609105506e-08
CT B-Disease 0 0.007708937861025333
. O 0 1.1443399898780626e-06

The O 0 1.220924445988203e-06
copper O 0 4.719137450592825e-06
transport O 0 7.685142691116198e-07
genes O 0 9.405943615092838e-07
CTR1 O 0 4.045443347422406e-06
and O 0 2.99670936954044e-08
CTR2 O 0 1.5424055163748562e-05
were O 0 6.475281111306685e-07
also O 0 1.1509926345354415e-08
excluded O 0 1.0112727011346578e-07
as O 0 1.920730019477901e-09
candidate O 0 3.958079020094374e-08
genes O 0 3.443708962436176e-08
for O 0 2.992287084779832e-09
CT B-Disease 0 7.142364484025165e-05
since O 0 3.4069049092977366e-07
they O 0 3.126073977455235e-08
both O 0 3.144143168043456e-09
mapped O 0 8.018872676984756e-07
to O 0 4.2288920809596675e-08
canine O 0 0.00514491181820631
chromosome O 0 0.022600669413805008
region O 0 3.8816001506347675e-06
CFA11q22 O 0 0.00010101062071043998
. O 0 4.419988783865847e-07

2 O 0 0.00010438080789754167
- O 0 0.0002652032417245209
22 O 0 3.472332309684134e-06
. O 0 2.733557380452112e-07

5 O 0 5.5417378462152556e-05
. O 0 2.921863142546499e-06

A O 0 1.7867689621198224e-06
transcribed O 0 3.929824742954224e-06
sequence O 0 5.144905230736185e-07
identified O 0 1.7855242617770273e-07
from O 0 2.780916608102757e-09
the O 0 5.35134692114525e-09
C04107 O 0 1.492161572969053e-06
- O 0 1.5861507563386112e-05
containing O 0 8.51766799314646e-07
BAC O 0 2.1678864868590608e-05
was O 0 1.286565378677551e-07
found O 0 3.748132915148972e-09
to O 0 5.768705513276018e-10
be O 0 1.5274714826318814e-09
homologous O 0 8.953891850183027e-09
to O 0 1.8479937580195838e-09
a O 0 4.162516997752164e-09
gene O 0 9.30322840986264e-08
expressed O 0 3.363176848125704e-09
from O 0 3.016527028165683e-09
human O 0 7.343107899515644e-09
chromosome O 0 3.3040712423826335e-06
2p13 O 0 8.621688607490796e-07
- O 0 1.8594292896523257e-06
p16 O 0 4.984026986676326e-07
, O 0 5.752249343515814e-09
a O 0 5.883900477954285e-09
region O 0 4.8740673719294136e-08
devoid O 0 1.0461696575703172e-07
of O 0 6.95686119822625e-10
any O 0 7.856546524465102e-09
positional O 0 5.358716407499742e-06
candidate O 0 2.0490388124017045e-05
genes O 0 8.314698789035901e-06
. O 0 5.508570097845222e-07

Molecular O 0 1.6222054455283796e-06
analysis O 0 1.705705159338322e-07
of O 0 3.1533919919723985e-09
the O 0 8.026002085159689e-09
APC B-Disease 0 1.3912838880969502e-07
gene O 0 6.855049861087537e-08
in O 0 1.9602950374064676e-09
205 O 0 2.6659693119768235e-08
families O 0 1.5954396914708013e-08
: O 0 2.9626088249301574e-09
extended O 0 9.757252428244101e-08
genotype O 0 7.68274039728567e-05
- O 0 7.72195835452294e-06
phenotype O 0 1.617148313926009e-06
correlations O 0 3.349463497670513e-07
in O 0 5.847829331884213e-09
FAP B-Disease 0 1.3762846151621488e-07
and O 0 6.10178574333986e-09
evidence O 0 5.606174635630623e-09
for O 0 4.074848236612638e-10
the O 0 1.1652172560161489e-09
role O 0 1.4869177888954255e-08
of O 0 1.5960934796055426e-09
APC B-Disease 0 4.396521831040445e-07
amino O 0 1.4842831319583638e-07
acid O 0 1.4633884859449608e-07
changes O 0 1.6411210879141436e-07
in O 0 2.0598969058482908e-05
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
predisposition O 0 0.13989003002643585
. O 0 9.048731044458691e-07

BACKGROUND O 0 0.00013357121497392654
/ O 0 2.686513471417129e-05
AIMS O 0 5.64251593004883e-07
The O 0 3.767197220838625e-09
development O 0 1.72972729473031e-08
of O 0 3.648476194939576e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
and O 0 6.24887164235588e-08
a O 0 1.2224265155680314e-08
variable O 0 2.834902375070669e-07
range O 0 2.0394863042838551e-07
of O 0 1.2147262751227572e-08
extracolonic O 0 0.0003405859461054206
manifestations O 0 5.142563531990163e-05
in O 0 2.735742555159959e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
( O 0 4.906769845547387e-06
FAP B-Disease 0 4.1166563278238755e-06
) O 0 2.0506140785414573e-08
is O 0 2.0241190945569087e-09
the O 0 1.2927481307656308e-09
result O 0 9.335611395044907e-09
of O 0 4.976521972288594e-10
the O 0 1.1736335459033853e-08
dominant O 0 0.00016658444656059146
inheritance O 0 1.300898838962894e-05
of O 0 6.609583920180739e-07
adenomatous B-Disease 1 1.0
polyposis I-Disease 1 0.9999990463256836
coli I-Disease 1 0.9999998807907104
( O 0 3.527352419041563e-07
APC B-Disease 0 2.191059365941328e-06
) O 0 4.34360174494941e-08
gene O 0 2.2245194486458786e-06
mutations O 0 1.6406938811996952e-05
. O 0 3.561607684332557e-07

In O 0 1.2981469410533464e-07
this O 0 3.1747495743417176e-09
study O 0 4.159461663988395e-09
, O 0 6.383304995694061e-10
direct O 0 6.525044060623486e-09
mutation O 0 1.361012067491174e-07
analysis O 0 7.844956684266435e-09
of O 0 5.391854740466329e-10
the O 0 7.114700384391881e-09
APC B-Disease 0 1.2332559151673195e-07
gene O 0 2.0788807830740552e-07
was O 0 9.38284969720371e-08
performed O 0 1.1102612518243404e-07
to O 0 7.9391870855261e-09
determine O 0 1.194935862258717e-06
genotype O 0 0.0001591545296832919
- O 0 2.8948543331352994e-05
phenotype O 0 1.374089492856001e-06
correlations O 0 3.388817049199133e-07
for O 0 6.1190115197007344e-09
nine O 0 1.873471973112828e-07
extracolonic O 0 1.5933497934383922e-06
manifestations O 0 1.302806538205914e-07
and O 0 4.924779251069822e-09
to O 0 2.4129520603821675e-09
investigate O 0 2.8918295313928866e-08
the O 0 9.07347885714671e-09
incidence O 0 1.2356436855043285e-05
of O 0 3.353901156799566e-09
APC B-Disease 0 4.1062756395149336e-07
mutations O 0 1.1539092383827665e-06
in O 0 4.1026620323236784e-08
non O 0 0.07438372075557709
- O 1 0.9999991655349731
FAP O 1 0.9999964237213135
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.1913368780369638e-06

METHODS O 0 1.2184934348624665e-05
The O 0 2.5938024350580235e-07
APC B-Disease 0 1.7918849835041328e-06
gene O 0 8.866650773597939e-07
was O 0 8.218500369139292e-08
analysed O 0 1.682426642446444e-07
in O 0 1.8641865828783466e-09
190 O 0 2.3268080795446622e-08
unrelated O 0 1.1670632460436536e-07
FAP B-Disease 0 2.907182761191507e-07
and O 0 1.2450800390695349e-08
15 O 0 1.320142359872989e-07
non O 0 0.001109714969061315
- O 1 0.9999938011169434
FAP O 1 0.9999958276748657
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 6.183329242048785e-05
using O 0 2.47284134502479e-07
denaturing O 0 0.0006646696128882468
gradient O 0 7.538675708929077e-05
gel O 0 0.0016378095606341958
electrophoresis O 0 1.5324922060244717e-05
, O 0 7.867373419401247e-09
the O 0 1.3088401473737576e-09
protein O 0 1.795707937901625e-08
truncation O 0 2.5484877141934703e-07
test O 0 5.2647565098595805e-06
, O 0 3.925223257539301e-09
and O 0 2.4013593336036365e-09
direct O 0 3.6701187866583496e-08
sequencing O 0 1.0516289421502734e-06
. O 0 4.404188871376391e-07

RESULTS O 0 0.00012316700303927064
Chain O 0 8.599045031587593e-06
terminating O 0 5.6729268180788495e-06
signals O 0 1.6526869330846239e-06
were O 0 2.9701985226893157e-07
only O 0 3.0440616693994116e-09
identified O 0 2.823202827073601e-08
in O 0 1.8208499152905233e-09
patients O 0 1.7411105446285546e-08
belonging O 0 1.2047400410608589e-08
to O 0 1.06992448234422e-09
the O 0 5.845186112907186e-09
FAP B-Disease 0 2.477611928952683e-07
group O 0 1.4008267434917343e-08
( O 0 4.4264489851286726e-09
105 O 0 6.989493073206177e-08
patients O 0 5.162604566066875e-07
) O 0 1.9897690606285323e-08
. O 0 8.159133102481064e-08

Amino O 0 3.462966196821071e-05
acid O 0 3.114756054856116e-06
changes O 0 8.787112193431312e-08
were O 0 4.358739502663411e-08
identified O 0 3.701027750935282e-08
in O 0 1.079237810230893e-09
four O 0 1.0044157505717521e-07
patients O 0 1.2804963489543297e-07
, O 0 3.999373054952571e-10
three O 0 6.696846965859038e-10
of O 0 2.7328289631256553e-10
whom O 0 3.776076340500367e-08
belonged O 0 4.0683907798211294e-08
to O 0 1.1179484005197082e-09
the O 0 1.116785242061269e-08
non O 0 4.335347966843983e-06
- O 0 1.1446498319855891e-05
FAP O 0 1.7570489490026375e-06
group O 0 1.6833733695875708e-07
of O 0 3.1168360692390706e-06
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.008980453945696354
. O 0 2.966529848436039e-07

Genotype O 0 0.010781331919133663
- O 0 0.0016447986708953977
phenotype O 0 2.663485793164e-05
correlations O 0 7.47261947253719e-06
identified O 0 3.973248567490373e-06
significant O 0 3.079135169059555e-08
differences O 0 1.7315185232291697e-06
in O 0 4.517076934718034e-09
the O 0 2.9475035745463174e-09
nature O 0 3.945625159929023e-09
of O 0 2.1576646025422974e-10
certain O 0 9.705019898831324e-09
extracolonic O 0 4.108256234758301e-06
manifestations O 0 2.1735576183345984e-07
in O 0 4.112547191681415e-09
FAP B-Disease 0 1.3048746723143267e-06
patients O 0 3.389444032109168e-07
belonging O 0 3.652520774721779e-08
to O 0 5.395170088462464e-09
three O 0 1.3923111907843122e-07
mutation O 0 1.303504359384533e-05
subgroups O 0 2.3805982891644817e-06
. O 0 1.9289700503577478e-07

CONCLUSIONS O 0 7.416841253871098e-05
Extended O 0 1.1561472092580516e-05
genotype O 0 0.0001994575432036072
- O 0 2.0434852558537386e-05
phenotype O 0 3.7242516555124894e-06
correlations O 0 9.351919061373337e-07
made O 0 8.243021909493109e-08
in O 0 1.6633888710870792e-09
this O 0 6.17158935067863e-10
study O 0 3.612128374186341e-09
may O 0 2.070860887215531e-07
have O 0 4.7450474660593045e-09
the O 0 4.2641204456295156e-10
potential O 0 9.813722057216978e-10
to O 0 1.5795758034897744e-09
determine O 0 2.9131765444390112e-08
the O 0 4.19173862287181e-10
most O 0 2.385467101628791e-10
appropriate O 0 9.57918633304189e-10
surveillance O 0 9.607208539819112e-08
and O 0 8.803312745442327e-09
prophylactic O 0 2.347014060433139e-06
treatment O 0 2.462496127009217e-07
regimens O 0 2.0560783298151364e-07
for O 0 1.4835966899440223e-09
those O 0 6.380523132065719e-08
patients O 0 1.211972744386003e-07
with O 0 6.3249654402852684e-09
mutations O 0 3.549722896423191e-05
associated O 0 1.0496274427396202e-07
with O 0 2.6919673601355498e-08
life O 0 7.792279461682483e-07
threatening O 0 0.0004308164934627712
conditions O 0 6.44183746771887e-05
. O 0 1.774096034523609e-07

This O 0 6.619715264832848e-08
study O 0 2.3558124340183895e-08
also O 0 7.592491968466675e-09
provided O 0 5.037683603603682e-09
evidence O 0 3.390369318623243e-09
for O 0 4.2921580178933993e-10
the O 0 1.2000608284878922e-09
pathological O 0 6.767939453311556e-08
nature O 0 8.235946147294726e-09
of O 0 9.817204826845227e-10
amino O 0 2.6386521767562954e-07
acid O 0 2.6456866919488675e-08
changes O 0 3.1684885826166465e-09
in O 0 7.407701674289058e-10
APC O 0 4.012106202821997e-08
associated O 0 4.530485320231037e-09
with O 0 7.311588556824233e-10
both O 0 9.77804059942855e-09
FAP B-Disease 0 2.1857636056665797e-07
and O 0 7.110239863550305e-08
non O 0 0.003989432938396931
- O 1 0.9999971389770508
FAP O 1 0.9999889135360718
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
patients O 0 0.032847363501787186
. O 0 2.936338638903635e-08
. O 0 1.1860739590474623e-07

Inherited B-Disease 1 0.9999967813491821
colorectal I-Disease 1 1.0
polyposis I-Disease 1 0.9999988079071045
and O 0 0.029388299211859703
cancer B-Disease 1 0.9991583824157715
risk O 0 2.534707346057985e-05
of O 0 2.7394322366092183e-09
the O 0 2.6055039015204784e-08
APC O 0 1.2718204516204423e-06
I1307K O 0 4.096577868040185e-06
polymorphism O 0 1.727568633214105e-05
. O 0 5.590111982201051e-07

Germ O 0 0.007845723070204258
- O 0 0.00468011200428009
line O 0 1.0632355042616837e-05
and O 0 3.04863050359927e-08
somatic O 0 8.812453984319291e-07
truncating O 0 2.4721839508856647e-06
mutations O 0 8.543970579921734e-07
of O 0 1.0956646701032469e-09
the O 0 3.1320046556260195e-09
APC B-Disease 0 6.709202438059947e-08
gene O 0 2.5617550747369933e-08
are O 0 3.516387181434766e-09
thought O 0 1.514562342208592e-08
to O 0 9.236075015905953e-09
initiate O 0 0.014237937517464161
colorectal B-Disease 1 1.0
tumor I-Disease 1 0.9891631603240967
formation O 0 1.1883074876095634e-05
in O 0 3.611407919379417e-06
familial B-Disease 1 1.0
adenomatous I-Disease 1 1.0
polyposis I-Disease 1 1.0
syndrome I-Disease 1 1.0
and O 0 1.5126392099773511e-05
sporadic O 1 0.9999561309814453
colorectal O 1 1.0
carcinogenesis O 1 0.9962032437324524
, O 0 7.285673859769304e-07
respectively O 0 3.21467064168246e-06
. O 0 1.258659523273309e-07

Recently O 0 2.5377428755746223e-05
, O 0 1.1287222179134915e-07
an O 0 3.484421995381126e-08
isoleucine O 0 0.000470865226816386
- O 0 2.84176021523308e-05
- O 0 5.7304391702928115e-06
> O 0 4.369706800844142e-07
lysine O 0 5.624512482427235e-07
polymorphism O 0 3.1428728561877506e-06
at O 0 1.9610219226251502e-07
codon O 0 2.3031868749967543e-06
1307 O 0 1.3425482165985159e-06
( O 0 1.6844005301663856e-08
I1307K O 0 9.40723836606594e-08
) O 0 1.310063946213802e-09
of O 0 1.64949914838175e-10
the O 0 1.659000381515341e-09
APC B-Disease 0 5.7436139400124375e-08
gene O 0 3.4128390780097106e-08
has O 0 5.420482285245498e-09
been O 0 1.424347306766549e-08
identified O 0 2.2794894860567183e-08
in O 0 8.732385370358031e-10
6 O 0 2.211030469823072e-08
% O 0 1.4979683271576505e-08
- O 0 1.1656933338599629e-06
7 O 0 4.064923686541988e-08
% O 0 6.7393015612537965e-09
of O 0 6.533982799261651e-10
the O 0 1.0391927318664784e-08
Ashkenazi O 0 2.18316040445643e-06
Jewish O 0 1.5720962665000116e-07
population O 0 3.1754964879837644e-08
. O 0 7.721391170889547e-08

To O 0 4.740911094813782e-07
assess O 0 1.8149946754419943e-06
the O 0 1.603781285552941e-08
risk O 0 2.9192460715421475e-07
of O 0 1.9879688173407573e-10
this O 0 2.4241098017796503e-10
common O 0 1.6219559029195807e-08
APC B-Disease 0 2.0726153593386698e-07
allelic O 0 1.2516802598838694e-06
variant O 0 1.1688922313624062e-05
in O 0 4.2998811977668083e-07
colorectal O 1 1.0
carcinogenesis O 0 0.024028848856687546
, O 0 7.487982998100051e-07
we O 0 1.4162225170366582e-06
have O 0 3.264059245111639e-08
analyzed O 0 7.462789852752394e-08
a O 0 2.638408380661872e-09
large O 0 3.686217553422466e-09
cohort O 0 1.58720297349646e-07
of O 0 1.3359791051215097e-09
unselected O 0 4.988794898963533e-06
Ashkenazi O 0 5.0562157412059605e-06
Jewish O 0 1.9030601094982558e-07
subjects O 0 3.133392851850658e-07
with O 0 6.31383088034454e-08
adenomatous B-Disease 0 0.0006888305651955307
polyps I-Disease 0 0.00046082661719992757
and O 0 8.88004834109779e-08
. O 0 4.4102954177560605e-08
or O 1 0.9996845722198486
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
, I-Disease 0 2.263597309593024e-08
for O 0 1.6014358728000389e-09
the O 0 1.952996164789056e-08
APC O 0 1.5080123603183893e-06
I1307K O 0 2.4642467906232923e-06
polymorphism O 0 9.627644431020599e-06
. O 0 6.254105642256036e-07

The O 0 6.667423235739989e-07
APC O 0 4.264598828740418e-06
I1307K O 0 1.6249784948740853e-06
allele O 0 7.473172445315868e-07
was O 0 9.756954710837817e-08
identified O 0 3.292145578370764e-08
in O 0 1.2967339424463376e-09
48 O 0 2.92964781323235e-08
( O 0 1.1354668316698735e-09
10 O 0 2.157151346438013e-09
. O 0 2.770538520824317e-10
1 O 0 1.6084644727243358e-09
% O 0 2.336920879031368e-09
) O 0 3.016444871661861e-10
of O 0 9.157869462761425e-10
476 O 0 3.5364300288165396e-07
patients O 0 1.4569510540241026e-06
. O 0 8.31509154863852e-08

Compared O 0 8.691400580573827e-06
with O 0 2.401571030929972e-08
the O 0 2.401464360701766e-09
frequency O 0 2.3179296704256558e-07
in O 0 2.1193899968352525e-09
two O 0 5.579665174337833e-09
separate O 0 1.70009659683501e-08
population O 0 4.209904869156844e-09
control O 0 6.263381635562837e-08
groups O 0 6.656265316706822e-09
, O 0 1.04469721762257e-09
the O 0 1.7151857711894536e-09
APC O 0 7.168029725335145e-08
I1307K O 0 7.055365358610288e-08
allele O 0 7.126791246037101e-08
is O 0 8.612281443554082e-10
associated O 0 1.6198372643216885e-09
with O 0 5.035375449935486e-10
an O 0 1.3525782716072854e-09
estimated O 0 3.096828038451349e-08
relative O 0 9.672569376562024e-07
risk O 0 5.972048029434518e-07
of O 0 1.7440012767266921e-09
1 O 0 8.14490590528294e-08
. O 0 1.489782732733147e-07

5 O 0 7.376944995485246e-05
- O 0 6.392270734068006e-05
1 O 0 1.7913432657223893e-06
. O 0 3.3171693303302163e-07

7 O 0 2.8896085495944135e-05
for O 0 1.9484680251480313e-06
colorectal B-Disease 1 1.0
neoplasia I-Disease 0 0.37098902463912964
( O 0 6.184321819091565e-07
both O 0 9.43739223657758e-07
P O 1 0.5966709852218628
= O 0 0.00013141619274392724
. O 0 1.9010860441426303e-08
01 O 0 9.37307868298376e-06
) O 0 1.5778843120983765e-08
. O 0 5.012804038528884e-08

Furthermore O 0 2.854346348613035e-05
, O 0 3.5090130268145003e-07
compared O 0 1.682879116060576e-07
with O 0 1.5990408996913175e-08
noncarriers O 0 4.118934157304466e-06
, O 0 1.0341604905761415e-08
APC O 0 2.354029930984325e-07
I1307K O 0 4.7408252612513024e-07
carriers O 0 3.069027059154905e-07
had O 0 4.655953489418607e-08
increased O 0 1.7005572061634666e-08
numbers O 0 2.6049224999269427e-08
of O 0 4.337655568065202e-09
adenomas B-Disease 0 0.00014088256284594536
and O 0 0.0009709232253953815
colorectal B-Disease 1 1.0
cancers I-Disease 1 0.9999996423721313
per O 0 4.180364339845255e-05
patient O 0 0.0051642172038555145
( O 0 8.763579018022938e-08
P O 0 0.23519937694072723
= O 0 0.00024051556829363108
. O 0 1.6519944523452068e-08
03 O 0 6.9057705331943e-06
) O 0 2.50791543088269e-09
, O 0 3.578381480018322e-10
as O 0 1.435156549156602e-09
well O 0 2.6266189223633774e-09
as O 0 1.160886942130901e-09
a O 0 5.1289363867113025e-09
younger O 0 3.578412588467472e-07
age O 0 9.536918099684044e-08
at O 0 5.992883700400853e-08
diagnosis O 0 0.00022305981838144362
. O 0 1.8187688510806765e-07

We O 0 4.829352747037774e-06
conclude O 0 4.78808431125799e-07
that O 0 4.955893473379547e-09
the O 0 3.1202462835722145e-09
APC O 0 2.2708846358909796e-07
I1307K O 0 2.3980473429219273e-07
variant O 0 4.508712834194739e-07
leads O 0 1.040518071704355e-07
to O 0 2.3577767294113983e-08
increased O 0 4.0591552533442155e-05
adenoma B-Disease 1 1.0
formation O 0 1.365121420349169e-06
and O 0 9.295987979385245e-09
directly O 0 1.2288060347032115e-08
contributes O 0 9.217948182538294e-09
to O 0 2.900290452245713e-09
3 O 0 4.891343152735317e-08
% O 0 1.5793176544320886e-08
- O 0 7.56215797537152e-07
4 O 0 1.5478848425232172e-08
% O 0 2.1420183404785575e-09
of O 0 2.707587765105046e-10
all O 0 2.0377708409569095e-08
Ashkenazi O 0 0.00227660802192986
Jewish O 1 0.8928150534629822
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
. O 0 1.2994305507163517e-06

The O 0 6.903511575728771e-07
estimated O 0 3.3164954515996214e-07
relative O 0 4.675005698118184e-07
risk O 0 1.1858776360895718e-06
for O 0 5.8133209357436044e-09
carriers O 0 7.295199679901998e-07
may O 0 4.1248515714187306e-08
justify O 0 5.444440986934751e-08
specific O 0 1.17508278663081e-08
clinical O 0 1.0559829632939e-07
screening O 0 5.9403298280358285e-08
for O 0 1.6225460974794714e-09
the O 0 1.875070321233352e-09
360 O 0 4.599952418971043e-09
, O 0 8.249824712258658e-10
000 O 0 2.661501907752495e-09
Americans O 0 7.104556942749696e-09
expected O 0 2.9214044516834292e-09
to O 0 2.4460562464412305e-09
harbor O 0 4.1480312518160645e-08
this O 0 5.331874386449442e-10
allele O 0 2.4899144079881808e-08
, O 0 5.983010753496387e-10
and O 0 2.608147475768874e-09
genetic O 0 3.5076914173259865e-07
testing O 0 1.0107314665219747e-06
in O 0 1.9834929254614053e-09
the O 0 2.4680448795777465e-09
setting O 0 5.36532098749376e-08
of O 0 1.3534970921824652e-09
long O 0 1.939877847689786e-06
- O 0 0.000255767343332991
term O 0 1.8830327462637797e-05
- O 0 4.660165359382518e-06
outcome O 0 3.046805119311102e-08
studies O 0 1.3225979422770706e-08
may O 0 1.2328157161789477e-08
impact O 0 3.339552989700678e-08
significantly O 0 5.717408839700511e-06
on O 1 0.9435465335845947
colorectal B-Disease 1 1.0
cancer I-Disease 1 1.0
prevention O 0 9.27512337511871e-06
in O 0 2.241632435229235e-09
this O 0 1.1451694037489801e-09
population O 0 1.1624253559716635e-08
. O 0 2.3983027119811595e-08

Localization O 0 1.95264055946609e-05
of O 0 6.131421059762943e-08
human O 0 1.0704193442734322e-07
BRCA1 O 0 1.400858582201181e-05
and O 0 8.986813782030367e-08
its O 0 3.214362109815738e-08
loss O 0 2.194326782500866e-07
in O 0 4.176561763102882e-09
high O 0 3.110111038040486e-06
- O 0 0.001684775808826089
grade O 0 0.0036282541695982218
, O 0 3.9232340043326985e-08
non B-Disease 0 4.9744267016649246e-05
- I-Disease 1 0.9720022678375244
inherited I-Disease 1 0.9999617338180542
breast I-Disease 1 0.9999973773956299
carcinomas I-Disease 1 1.0
. O 0 3.6323706353869056e-06

Although O 0 9.9651924756472e-07
the O 0 1.3245570862352452e-08
link O 0 1.5485439064377715e-07
between O 0 1.432154750347081e-08
the O 0 1.1538769939534177e-07
BRCA1 O 1 0.9835455417633057
tumour B-Disease 1 0.9999998807907104
- O 0 3.85788598578074e-06
suppressor O 0 1.6299778735628934e-06
gene O 0 8.781387919043482e-07
and O 0 3.955091472107597e-07
hereditary B-Disease 1 0.9999994039535522
breast I-Disease 1 1.0
and I-Disease 1 1.0
ovarian I-Disease 1 1.0
cancer I-Disease 1 1.0
is O 0 2.6047089818348468e-08
established O 0 2.7398726842875476e-08
, O 0 1.3150459610145049e-09
the O 0 5.788213242041707e-10
role O 0 2.0100390685229286e-08
, O 0 2.039208579773799e-09
if O 0 6.252609541235188e-10
any O 0 5.58152524199329e-10
, O 0 2.415801447774868e-10
of O 0 4.378917506375757e-10
BRCA1 O 0 3.699493618114502e-06
in O 0 1.7500200399922505e-08
non B-Disease 0 0.004405982326716185
- I-Disease 1 0.9898819327354431
familial I-Disease 1 0.9999978542327881
cancers I-Disease 1 0.9999996423721313
is O 0 7.640420562893269e-08
unclear O 0 7.486912068088714e-07
. O 0 1.4050216634586832e-07

BRCA1 O 1 0.5960153341293335
mutations O 0 0.0004841445479542017
are O 0 7.796197820653106e-08
rare O 0 1.4722487229335002e-08
in O 0 1.0776133763101825e-08
sporadic B-Disease 1 0.946583092212677
cancers I-Disease 1 0.9999998807907104
, O 0 1.252203816193287e-07
but O 0 3.560106165423349e-08
loss O 0 4.185607238582634e-08
of O 0 1.6532797353363549e-09
BRCA1 O 0 0.00020890180894639343
resulting O 0 2.6882352699431067e-07
from O 0 9.83668435594609e-09
reduced O 0 3.220278586013592e-07
expression O 0 2.7794447987616877e-07
or O 0 5.988907787468634e-07
incorrect O 0 2.2790911316405982e-05
subcellular O 0 7.971145532792434e-05
localization O 0 9.099459020944778e-06
is O 0 1.6845611128246674e-08
postulated O 0 5.026533145269241e-08
to O 0 3.76623443543167e-09
be O 0 7.960339054591259e-09
important O 0 3.4947100768789596e-09
in O 0 2.8304425470082606e-09
non B-Disease 0 2.2178101062308997e-05
- I-Disease 1 0.6141067743301392
familial I-Disease 1 0.9999974966049194
breast I-Disease 1 1.0
and I-Disease 1 0.9999966621398926
ovarian I-Disease 1 1.0
cancers I-Disease 1 1.0
. O 0 2.9383804758253973e-06

Epigenetic O 0 0.0001395655272062868
loss O 0 0.00011256990546826273
, O 0 3.6229078403948733e-08
however O 0 6.477996361553551e-09
, O 0 6.383207296067894e-10
has O 0 1.212674627382171e-09
not O 0 1.6393378876600195e-09
received O 0 7.796577272678462e-10
general O 0 1.1923583231876478e-09
acceptance O 0 2.6848089973441347e-08
due O 0 1.9172867737893284e-08
to O 0 3.529813108471558e-09
controversy O 0 1.4741875276058636e-08
regarding O 0 1.2231938129048103e-08
the O 0 3.401082082632456e-09
subcellular O 0 7.254889169416856e-07
localization O 0 2.3968539153429447e-07
of O 0 2.5068871423172823e-09
BRCA1 O 0 2.1895264126214897e-06
proteins O 0 2.4552564426016943e-08
, O 0 2.4995676639605335e-09
reports O 0 7.440018379156754e-09
of O 0 3.910201606949215e-10
which O 0 1.6040198502764724e-08
have O 0 5.34941051455462e-08
ranged O 0 6.020862883815425e-07
from O 0 4.376581319576189e-09
exclusively O 0 5.040329398298127e-08
nuclear O 0 3.6953434801034746e-07
, O 0 8.504059123559671e-10
to O 0 7.598746631920505e-10
conditionally O 0 2.5942867409867176e-08
nuclear O 0 5.023197857667583e-08
, O 0 2.0542176293325554e-10
to O 0 2.7292454407579214e-10
the O 0 5.008347958579407e-09
ER O 0 5.401533144322457e-06
/ O 0 2.552148146151012e-07
golgi O 0 7.029661333035619e-07
, O 0 3.317597530028138e-09
to O 0 5.630113264487591e-09
cytoplasmic O 0 1.6466613033117028e-06
invaginations O 0 3.853301222989103e-06
into O 0 2.2897733487070582e-08
the O 0 2.9432243309202022e-08
nucleus O 0 5.804138822895766e-07
. O 0 1.02864284201587e-07

In O 0 1.7088296999645536e-07
an O 0 6.231919869037483e-09
attempt O 0 5.3827562851438415e-08
to O 0 1.0623988799807194e-08
resolve O 0 3.264290171500761e-07
this O 0 1.3448890889833365e-09
issue O 0 9.247762555730787e-09
, O 0 2.0378398968290412e-09
we O 0 2.3772937396415728e-08
have O 0 1.2736876442431821e-08
comprehensively O 0 3.2952350466075586e-06
characterized O 0 1.5000331643477693e-07
19 O 0 8.867388601174753e-08
anti O 0 3.5043419757130323e-06
- O 0 0.0002902942069340497
BRCA1 O 0 0.0006287830765359104
antibodies O 0 1.8232602087664418e-05
. O 0 2.705214114939736e-07

These O 0 1.6388281665058457e-06
reagents O 0 2.4171026780095417e-06
detect O 0 1.4889496924297418e-05
a O 0 7.23308701822134e-08
220 O 0 7.604074880873668e-08
- O 0 3.806618735779921e-07
kD O 0 8.566088922634663e-07
protein O 0 1.6871406671725708e-07
localized O 0 5.170931558495795e-07
in O 0 6.312840472588732e-09
discrete O 0 1.4441590678870853e-07
nuclear O 0 2.348236421312322e-06
foci O 0 1.4622238495576312e-06
in O 0 9.161927216894128e-09
all O 0 1.0658960825082886e-08
epithelial O 0 4.972352485310694e-07
cell O 0 1.0449752153363079e-05
lines O 0 4.8571848310530186e-05
, O 0 1.6720791418123326e-09
including O 0 1.1947349776164629e-09
those O 0 4.1345931123260016e-09
derived O 0 3.234633538795606e-08
from O 0 8.76585275477737e-08
breast B-Disease 1 0.8321553468704224
malignancies I-Disease 0 0.0017298093298450112
. O 0 9.351776952826185e-07

Immunohistochemical O 0 0.0008154432871378958
staining O 0 0.000126932849525474
of O 0 1.0582594001107282e-07
human O 0 4.985790269529389e-07
breast O 0 0.16348300874233246
specimens O 0 4.250783263159974e-07
also O 0 1.4124954361705022e-07
revealed O 0 1.0696336175897159e-05
BRCA1 O 0 0.001206856919452548
nuclear O 0 8.811547559162136e-06
foci O 0 2.578497151262127e-05
in O 0 1.2969157126008213e-07
benign O 1 0.8347103595733643
breast O 1 0.9906710386276245
, O 0 7.062447338057609e-08
invasive B-Disease 0 0.02627067267894745
lobular I-Disease 1 0.9999854564666748
cancers I-Disease 1 0.9999998807907104
and O 0 6.781469437555643e-06
low B-Disease 1 0.9998477697372437
- I-Disease 1 0.9999489784240723
grade I-Disease 1 0.9997037053108215
ductal I-Disease 1 0.9998841285705566
carcinomas I-Disease 1 1.0
. O 0 5.620723641186487e-06

Conversely O 0 5.6602068070787936e-05
, O 0 4.479764754705684e-07
BRCA1 O 0 4.277389234630391e-05
expression O 0 1.0964471357510774e-06
was O 0 4.835168851968774e-07
reduced O 0 3.0618033974860737e-07
or O 0 7.806128223819542e-07
undetectable O 0 1.8673157683224417e-05
in O 0 1.3947712984574423e-09
the O 0 1.7727294077118927e-09
majority O 0 5.98988769695552e-09
of O 0 7.177462513219268e-10
high O 0 1.1005948181264102e-05
- O 0 0.025707442313432693
grade O 0 0.001647268538363278
, O 0 5.311508033400969e-08
ductal B-Disease 0 0.00018505132175050676
carcinomas I-Disease 1 1.0
, O 0 4.2938655298030426e-08
suggesting O 0 1.1727478010925552e-07
that O 0 1.263958271380261e-09
absence O 0 1.6587987872185295e-08
of O 0 1.3747275540154646e-09
BRCA1 O 0 7.428421668009833e-05
may O 0 1.9230078862619848e-07
contribute O 0 8.802305551114387e-09
to O 0 2.121784525854764e-09
the O 0 4.190717550756062e-09
pathogenesis O 0 2.2346412720253284e-08
of O 0 3.0523511496127753e-10
a O 0 1.9562087505420322e-09
significant O 0 4.9583612771186836e-09
percentage O 0 1.4043359897186747e-06
of O 0 1.4033780360023229e-08
sporadic B-Disease 1 0.9999592304229736
breast I-Disease 1 1.0
cancers I-Disease 1 0.9999992847442627
. O 0 9.892324470683889e-08
. O 0 2.0041306925122626e-07

